Economic Evaluation Applied to Health Policy in New Zealand by Scott, William Guy
ECONOMIC EVALUATIOI{
APPLIED TO HEALTH POLICY N'I
I\E\ry Z,EALAND
by
William Guy Scott
A thesis
submitted to Victoria University of Wellington
in fulfilment of the
requirements for the degree of
Doctor of Philosophy in Public Policy
Victoria University of Wellington
2001
Fconowic Evaluation Applied To Health Poliq'In New Zealand i
ACKNOWLEDGEMENTS
The support and help of Robert Stephens and Claudia Scott at Victoria University,
and the wann support and encouragement of family and close friends is
acknowledged.
I wish to thank the editors of the journals (Journal of Medical Economics, New
Zealand Medical Journal, PharmacoEconomics, WP Press) in which copyright
subsists, for permission to include the flull text of the published papers as an
appendix.
ll Guy Scott (2001)
Economic Eroluotion Applird To Heol
Victoria University of Wellington
Important Disclaimer
l: Victoria University of Wellington and its Council, its members, staff, employees,
students and agents undertake no duty oF care in contract, tort, or otherwise, to users
(whether direct or indirect) of this "Economic Evaluation Applied To Health Policy In New
Zealand",and make no warranties or representations of any kind whatsoever in relation to
any of its contents.
2: Tlre "6cononric Et,oluation Appliet! To Ileulth Policy In New Zeuland", is only
made available on the basis that all users of it, rvhether direct or indirect, must take
appropriate legal or other expert advice in relation to their own circumstances and must rely
solely on their orvn judgement and such legal or other expe( advice.
3: Under no circumstances will Victoria University of Wellington and its Council, its
nlembers, staff, employees, students or agents be liable in any way whatsoever, whether in
contract, tort (including negligence), for breach of arry statutory or regulatory duty (to the
fullest extent penrrissible by law), or otherwise, to any user (rvhether direct or indirect) of
tlris "Ecr;rro tnic Erttlutttiott Applied To I-!ealth Polict' In Nev' Zealantl" for any loss or
danrage rvhatsoevet'arising clirectly or irrdirectly as a result of the use in anYwayof this
"Econontic Eruluutiort ApplietlTo Ilnlth Polic'.t' /rt Nerl Zeuluni'.
W Gay Scott Q0AI)
Eaonomlc Evaluori
CONTENTS
ABSTM,CT,,. ,
CJ{APTER l: INTRODUCTION TO ECONOMIC EVALUATION APPLIED TO
HEALTHPOLICY .....
[.] TNTRODUCTION ,.,......,,..,2
I.2P'TIBLICPOLICYEVALUATIONS. .t..I....2
1.2.1 PolicyCyclesandProblem Solving .... r ... - r. i. 3
l.2.2 Deter,minants of Health Policy
I.3 SCOFE AND IVIETHOD . i . . ,
1,3.1 Scope
l.3.2 Techniques Reviewed , . .
l.3,3 Cases ...... i...
I.4 OUTLINE
[,5 REFERENCES I " ' I
CHAPTER 2: CONCEPTUAL FRAMEWORK F,OR ECONOMIC EVALUATION OF
HEALTHCARE !i!I}
2.T INTRODUCTION ! a. i, r,. ' 14
?.2DETEWINANTSOFHEALTH... .....i.. L4
2.3 tsACKGROLIND TO THE NEW ZEALAND HEALTH SYSTEM i . . . . 17
2.4POLrcYGOALSA,NDTRADE-OFFS ..!.. '".., 19
Z,4.lEfficiency i...; 2A
2.4.2Evaluatir,lgWelfare ..... ,.,', "'.' 21
2,4.3 Equity ., , 25
2.4,4EquityEfficiencyTrade-otf .-.'. 29
2.5 \I,{RKETS ANDGOV:ERNMENTINTERVENTION I i r J r r r-. 3I
2,5.1 TheRoleoftheMarket ,'r.. ....i.."r'r 32
2.5.2 Market Failure and the Second Best .
2,5..3Gor:errtfh,e'ratFailure i!.i' 35
W Guy Sear QA(il)
Economic Evaluation Applied To Health Policy In New Zealand lv
2.5.4 Tcchnical and Policv Evaluations of Health Care . 36
2.6 CONCLUSIONS 38
2.7 REFERENCES 40
CHAPTER 3: VALUING HEALTH OUTCOMES 45
3.I INTRODUCTION 45
3.I .l What is Health? 45
3.1.2 Why We Need to Quantify Changes in Health Outcomes 46
3.1.3 Differences in the Valuations of Health and Health Outcomes . 46
3.2 WAYS OFVALUING CHANGES IN HEALTH OUTCOMES . . . . . . . 48
3.2.1 Cost-benefit Analysis 48
3.2.2 Cost-Effectiveness and Cost-Utility Analysis 53
3.3HEALTHINDICES.... .......54
3.3.1 Health Indices as a Subset of Social Indicators 54
3.3.2ObjectivesofHealthlndices ...'.'.55
3.3.3Validatedlnstruments. .......56
3.3.4 Classification of Health Indices 56
3.3.5 Health Related Quality of Life Indices 57
3.4 VALUING HEALTH STATES 73
3.4,1 Utility Methods 73
3.4.2 Psychological Scaling 77
3.5 QUALITY ADJUSTED LtrE YEARS (QALYs or QUALYs) 77
3.6 NEW ZEALAND INITIATIVES . . . 82
3.6.1 Introcluction 82
3.6.2 Surgical Priority Scoring Systenr 82
3.6.3 Healtlr Furrding Authority Health Related Quality of Life Instrument
3.(r.;l Conclusion
83
87
88
9l
3.7 CONCLUSIONS AND POLICY POINTS
J.8 REFERENCES
ll/ Guy Scoa (2001)
Economic Evaluation Apolied To Health Polic], In New Zealand v
CHAPTER4: COSTS 96
4.I INTRODUCTION 96
4.2 HISTORICAL PERSPECTIVE . 97
4.3 CLASSIFICATION OF COSTS ADOPTED IO2
4.3.1 Direct Costs 104
4.3.2 lndirect Costs 106
4.3.3 Intangible Costs 109
4.3.4 Externalities 109
4.4 INCREMENTAL, MARGINAL, AVERAGE AND SLINK COSTS . . . I IO
4.5 AVOTDING DOUBLE COUNTTNG OF COSTS I I I
4.5.1 Productivity and Health Relared Quality of Life ll2
4.5.2 TransferPayments.... 113
4.5.3 Cost Shifting I 13
4.5.4 Capital Costs 113
4.5.5 Co-morbidity 114
4.6 COSTING PROCESS . 1I4
4.TSENSITIVITYANALYSIS.... II5
4.8 DATA PROBLEMS I 16
4.9 PERSPECTIVE AND COSTS I 17
4.IO CONCLUSION I 18
4.I I REFERENCES I2O
CHAPTER 5: DISCOUNTING 125
5.I INTRODUCTION IZ5
5.2 MECHANICS OF DISCOUNTING I28
5.3 APPROACHES TO DISCOUNTING . 129
5,3.1 Social Ratrg of Tinre Preferencc (SRTP) 130
5,3.2 Opportunity Cost or Social Opportunity Cost (SOC) 130
5.3.3 Shado*'-Price-of Capital (SAC) 131
5.3,4 Dinrinishing Marginal Utility 132
5.3.5 Uncerlainty and Risk . 132
5.4 LOOKING BACK AT PAST INVESTMENT DECISIONS 132
W Guy Scott (2001)
Economic Evaluation Apolied ro Health Policy In New zealond vi
5.s DrscouNTrNG cosTs AND CONSEQUENCES . . . I33
5.6 REAL AND NOMINAL RATES 134
5.7 DISCOUNT RATES IN USE 136
5.8 CONCLUSIONS AND RECOMMENDATIONS I38
5.9 REFERENCES I4O
CHAPTER 6: ECONOMIC EVALUATION t43
6.I INTRODUCTION 143
6.2 ECONOMIC EVALUATION AND HEALTH T44
6.3 TYPES OF ECONOMIC EVALUATION 146
6.3.I Cost-Benefit Analysis (CBA) 148
6.3.2 Economic Evaluations Other Than CBA 154
6.4 THE PROBLEM OF CLASSIFYING ECONOMIC EVALUATIONS . 163
6.5 CONCLUSION . 164
6.6 REFERENCES 167
CHAPTER 7: MODELS
7.I INTRODUCTION
7.2 BACKGROUND
7.2.1 History and Developmenr . . .
7 .2.2 Puryose of Modelling .
7.2.3 Criticisms of Modelling
7.3 TYPES OF N,{ODELS
7.4 WHY MODELS ARE USEFUL . .
7.4.1 Why Use Models . . . .
7.4.2 Situatiorrs Where Models Are Useful
7,5 THE N,IODELLING PROCESS .
7.5. I Forrester's lvlodelling Steps
7.5.2 Generalised Modelling Steps
7.6 CONCLUSION
7.7 REFERENC'ES
170
170
170
170
t7l
t72
r72
174
t74
t74
178
178
178
183
185
W Guy Scott (2001)
Economic Evaluation Applied ro Health Polic.t, In New zealand vii
CHAPTER 8: CARE WITH DATA 186
8.I SUMMARY AND INTRODUCTION 186
8,2 BACKGROUND I87
8.3 CASE ONE: HEART FAILLIRE 189
8.4 CASE TWO: BENIGN PROSTATIC HYPERPLASIA (BpH) l9l
8.5 DISCUSSION I95
8.6 POLICY POINTS 197
8.7 REFERENCES I98
CHAPTER 9: ANTIBIOTIC COSTINC 20r
9.I SLJMMARY AND INTRODUCTION 2OI
9.2 METHOD , 202
9.2.1 Target Population, Perspective and Overall Method 202
9.2.2 Investigative Steps 203
9.3 RESULTS AND DISCUSSION 206
9.4 POLICY POTNTS . 2A9
9,5 DATA COLLECTION INSTRTIN,IENTS 2II
9.6 REFERENCES 215
CHAPTER IO: BENIGN PROSTATIC HYPERPLASTA 217
I O.I SUMMARY AND INTRODUCTION 217
10.2 METHOD 218
IO.-1 RESULTS . 221
10.4 DISCUSSION 224
IO.5 POLICY POINTS 228
10.6 IiEFEREn-CES 231
CIIAPTER l l: HYSTERECTOMY 233
I I.I SUMMARY AND INTRODUCTION 233
II.2 I\.IETHOD 234
I I.3 RESULTS 235
I I.4 DISCUSSION 236
ll Guy Scott (2001)
Economic Evaluation Applied To Health Policy In New Zealand viii
I I.5 CONCLUSIONS 239
I I.6 POLICY POINTS 240
I I.7 REFERENCES , 242
CHAPTER 12: LOWER RESPIRATORY TRACT INFECTION . . . 243
I2.I SUMMARY AND INTRODUCTION 243
12.2 METHOD 244
I2.3 RESULTS 244
I2.4 DISCUSSION 246
t2.s CONCLUSTONS 249
12.6 POLICY POINTS 249
l2'7 REFERENCES 252
CHAPTER 13: INFLUENZA 253
I3.I SLMMARY AND TNTRODUCTION 253
l3'2 METHOD 254
13.2.1 Vaccine Cost . . 256
13.2.2 Utilisation of Health Care Resources If No Vaccination Given
13.2.3 Medical Costs Avoided
13.2.4 Health Care Resource Unit Costs
I3.3 RESULTS
I3.4 DISCUSSION
13.5 CONCLUSION
I3.6 POLICY POINTS
I3.7 REFERENCES
CHAPTER I4: CRITICAL LEG ISCHAEIV{IA
14. I SUNI|v1ARY AND INTRODUCTION
I4.2 METHOD
I4,3 RESULTS
256
257
257
258
260
264
264
266
269
269
270
272
274I4.4 DISCUSSION
ll Guy Scon (2001)
Fconontic Evaluatiort Applied To Health Policl In New Zealand ix
I4,5 CONCLUSIONS , 276
14.6 POLICY POINTS 277
I4.7 REFERENCES 279
CHAPTER 15: HEART FAILURE 281
I5.I SUMMARY AND INTRODUCTION 281
15.2 METHOD 282
I5.3 RESULTS 285
I5.4 DISCUSSION 287
I5.5 POLICY POINTS 288
15.6 REFERENCES . 291
CHAPTER 16: ISCHAEMIC STROKE 293
16, I SUMMARY AND INTRODUCTION 293
16.2 COST OF ISCHAEMIC STROKE 294
16.2.1 Introduction and Objectives 294
16.2.2 Method 295
16.2.3 Results 298
16.2.4 Discussion/Conclusions .... 301
I6.3 COST-EFFECTTVENESS OF ALTERNATTVE METHODS OF ISCHAEMIC
STROKE PREVENTION . 302
16.3.1 Introduction and Ohjectives 302
16.3.2 Method 302
16.3.1 Results 304
16.3.4 Discussior/Conclusions.... 306
16.4 COMPARISONS BETWEEN ALTERNATIVE METHODS OF
EVAI-UATION (CEA, CUA AND CBA) . . 308
l(r.4,1 Introduction and Obiectives 308
10.-1.2 l\lethod 308
16.4.3 Rcsults 308
16.4.4 Discussion/Cortclusions... 309
16,5 POLICY IMPLICATIONS 3IO
l{ Guy Scon (2001)
Economic Evaluation Annlied To Health Policv In New Zealand x
16.6 REFERENCES 3I4
CHAPTER l7: ASTHMA ...
I 7.I SUMMARY AND TNTRODUCTION
I7.2 BACKGROLTND AND OVERALL OBJECTTVES . .
I7.3 COST-OF-ILLNESS . .
17.3.1 Background and Specific Objectives
17 .3.2 Methods and Results
17 ,3.3 Discussion/ Conclusion
I7.4 COST OF ALTERNATIVE TREATMENT STRATEGIES
17 .4.1 Background and Objectives
17 .4.2 Method
17.4.3 Results
17.4.4 Discussion and Conclusion .
I7.5 DECISION ANALYTIC MODEL
I 7.5.1 Background and Objectives
17 .5.2 Method
17.5.3 Results and Discussion
I7.6 POLICY POTNTS
I7.7 REFERENCES
CHAFTER I8: DISCUSSION AND CONCLUSIONS
I8. I INTRODUCTION
I8.2 ECONOMIC EVALUATION PROCESS .
I 8.2. I Prolrlent Dcfinition
18.2.2 Pcrspective
I 8.2.3 Target Population
I 8.2.4 Altematives/ Comparators
1E.2.5 Tinte Horizorr
18.2.6 Tcchnical Evidencc Chcck
I 8,2.7 Constraints to Inrplenrcntation
18.2.8 Identify an Appropriate Methodology
315
315
316
3t7
3t7
3t7
322
323
323
324
325
327
329
329
329
331
331
336
340
340
340
341
342
344
344
345
346
346
347
W Guy Scon (2001)
Ecouoniic Evalaation Applied To Heallh Folicy In New Zealand, xi
18.2,9 ldentification of Costs eurd Outconres (or Benefits) 348
ls,.2.l0EvaluatingCostsandOutcom€$ ;.. ., i. r ..,, 351
18.2.1 I Choice Criterion 352
18.2.12 Sensitiv,ity Analysis 352
18.2"ll3EquityConsequences.. 352
IS.2.l4 Evaluate the Resulls . . . i .
lS,.2.15 Monitor the Decision Taken
IS.3CCINCLUSION ,.....i 354
I8,4 REFERENCES 356
APPENDIX: FULL TEXT OF THE ORIGINAL PAPERS DISEUSS.ED IN THE CASES
CASE l: CARE WITH DATA
CASE 2]: ANTIBIOTIC COSTING
CASE 3: BENIGN FROSTATIC HYPERPLASIA
CASE 4: HYSTERE€TOMY
CASE 5: LOWER RESP,TRATORY TRACT INFECTICIN
CASE 6: INFLUENZA
CASE 7: CRITICAL LEG ISCHAEMIA
CASE 8: HEA.RT FAILURE
CASE 9: ISCHAEIv IC STROKE
CASE IO: ASTHMA
ll Guy Scon (2001)
ealand I
ABSTRACT
Backgrounrl: Nert'Zc'aland health rcfonrrs inrplcnrented in the 1990,s split the purchaser
front the proYidcr and placc<l grcater enrphasis on contracting and cornpetitiol. This was
not sufficielrl in itself to solve thc t*'in problcrrrs of achicving society's goals of equity and
efliciency 
"r'ithilr thc health scctor. To irnprove decision nraking at an operational level
ttticroecottorrric studies are required to highlight potential changes in both efficiency and
equity' Furthernlore, the analyical process nrust be easily understood and applied,
transparent and theoretically grounded if these studies are to be used widely in the health
sector often by non-economists.
Problem: How can economic theory be applied to health care to improve decision making
with respect to the efficiency of resource use iri New Zearand?
obiectives: To: (l) provi<le poticy decision nrakcrs lvith the criteria and techniques by
which the decision-ntaking process in relation lo resource allocation within rhe health
sector can be improl'ed to achieve greater efficiency and more equitable outcomes; and (2)
present a range of practical exantples that illustrate appropriate methodologies and provide
suggested solutiotrs to a range of problerns that may be encountered by decision makers in
health care.
Method: Tlte underlying theory to economic evaluation of health policy options is
discussed and a series ofdifferent types of econonric and policyevaluations (cases) relating
to a rill'lgc of hcalth care rcsourcc'allocation questions are used to ilh"rstrate the application
of thc thc.ory ro uctual hcaltrr policy issue's irr N.,r. Zcalunci,
Results uttil c'ottclusitttt: Tlte cases presentctJ intJicatc-cl that although a conrmon overall
apllroaclr tttav bc allplic'd to tl'le policl'qur-stions no one re-cipe could be applied in all
cnscs' Thc'policl'qrlestioll artd tltc'clata available clictatecl thc methodology. Usipg these
findings' I checklist uas tlc'r'elopecl as a guide for conducting policy evaluations and
assessing eflrciency qains in thc. healrh care.
W Guy Scon (2001)
CHAPTER l: IhITRODUCTION TO ECONOMIC
EVALUATION APPLIED TO HEALTH POLICY
I.I INTRODUCTION
This chapter outlincs the objectives, background and scope of the study. public policy
evaluations, determinants of health policy, policy questions, types of evaluation, the
rationale for public policy intervention and the need for policy evaluation are discussed.
The focus of the study is encapsulated in the following questioni"How can economic
theorv be applied to health care lo intprove clecision making with respect to the efficiency
of resource use in Netr'Zeaktnd? " The specific objectives of the investigation were to;
( I ) provide policy decision makers with the criteria and techniques by which the decision-
making process in relation to resource allocation *,ithin the health sector can be improved
to achieve greatcr efliciency and more equitable outcomes; and (2) present a range of
practical exalllpL's that illustrate appropriatc nrethodologies and provide suggested
solutions to a range of issues that may be encountered by policy decision makers in health
care.
1.2 PUBLIC POLICY EVALUATIONS
Itt tnost developcd countries health care is predonrinantly funded by the stater which means
that govcnlnL.nts ntust nrake policy decisions on s'lrat to fund, how it shoutd be provided,
attcl u lto should rcce ive tlrc funded scrviccs. Inrproving efficiency and equity of resource
use tlrus rc'r}rirr's cvaluartion of e'xisting and futurc public policies.
In 1995 OECD publically funded expenditure as a percentage of total health
experrditurc ranged fronr over 90o./o u"r Lurenrbourg to just under 50% in the US
(n-.2. Nlinistry of Health, 1998: 3 I ).
W Guy Scou (2001)
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I.2.1 Policl'C1'cles and Problem Solving
All policy decision makers are faced rvith an array of policy problems and policy
instntnrents. Policy instntnrents in a mixed nrarket economy range from the voluntary (little
or no state intervention) to the compulsory (high tevel of state intervention). A mix of
instruments will normally be used. Government intervention is necessary to conect for
market failure, but even where markets are efficient, state involvement may be necessary
to achieve society's equity goals. Where the state is subsidising or providing a service,
economic evaluation should be applied to investigate the efficiency consequences of
policies.
Economic evaluation provides one set of infonlation for policy formulation, decision
making, and ntonitoring but it cannot set the policy agenda, make poticy decisions or
intplenrent policy. Figure l.l shorvs the relationship that economic evaluation has within
the policy cycle. Sinrilar ideas have been presented by Howlett and Ramesh (1995) and
Bardach (l995).
Figure l.l: Economic Evaluation and the policv Cvcle
Policy
evaluation
Agenda setting
Economic
evaluation
Policy
formulation
Policr' Decision
makingimplementation
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TIte cycle docs ttot ltave a fixed beginning or end as a policy may evotve and re-enter the
cycle. In practice policy evaluations nrly not cotrlonrr exactly to the steps outlined, and
the process is nrore likely to be iterative rather tlian sequentiar.
Econontic evaluatiott as applied to public policy cvaluation of health care is a systematic
approach to gathering and analysing infornration about costs and consequences (orbenefits)
of different health care programmes, policy changes or treatment options. It is concerned
with providing decision makers with knowledge about potential improvements in resource
usage. In essence, the evaluation procedure involves the identification and measurement
of all relevant costs and health related outcomes connected with the options under
investigation.
1.2.2 Determinants of Health Policv
Policy deterntinants fall into trvo categories; environmental factors that cannot be
influenced by health policy, and those lactors over which health policy has some control.
' Environmental fuctors that heulth policl, cannot change: Power and political
structure, budget and funding constraints.
, Faclors which health policy mq, influence: Society's values and beliefs, available
supply of resources, rationing methods and systems, health care delivery systems,
demand and need for health care and the population to be provided with health care.
All of thesc' dctenttinants of health policy (slrorvn diagrarnmatically in Figure 1.2) are
relevant and should be taken into account il public policies are to be successful and
objectit'es achievcd. The diagranr is sinrplified in that not all the interactions are shown.
Enyi ronntantul Fuc'tors Thut l-leulth Polic.t' Cannot Change
In n r,lctttocriltic socicty'tlrc po*er and political structures are exogenous to public policy
but rvill deternrine the acceptability and success of policies. Social policies are not
indellendertt of economic policies as they cannot be irnplemented without resources and
fundirrg. Although funding allocations to various government expenditure options are a
It Guy Scott (2001)
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part of fiscal policy, they are erogenous to health policy.
Factors I'Wrich Health Policy L,lay Influencc
A key element of public health policy is to alter the values, attitudes and beliefs within
society toward a nlore healthy lifestyle. Exanrples of public health initiatives designed to
change values and beliefs include campaigns to convince the public that smoking is
unhealthy, and education programmes designed to limit the spread of AlDs.
The available supply of health care resources, (such as labour and capital), both influence
and are altered by health policy. The population to be provided with health care is under the
control of health policy but the characteristics of this population are not. Delivery systems,
and rationing methods are a part of government health policy. Rationing may be achieved
by the price systeur or by adrninistrative means such as waiting and booking lists and/ or
criteria based on assessed need or bv a cornbination of these.
Figure 1.2: Determinants of Health Policy
Power/ politrcal
Budget and funding
constraints
Available supply
of resources
Rationing nrethods
and svstenrs
Health policy Demands 
and needs
for health care
Health care
delivery systems1l
Population to be
provided with health Direction of causation
Perccivecl ncetis b1 consunrcrs nta),bc quitc diflcrerrt fronr assessments of need made by
fiealtft care prol'essionals and policy rnakers. Cullis and West ( 1979) isolate three types of
need: ( I ) nonlarive neecl, tfte mininrunr stantlarcl of health care assessed by experts, (2) felt
need, reflecting ipdividuals views of their orvn wants, and (3) expressed need, felt need
Society's values
and beliefs
ll/ Guy scott (2001)
Chapter I : Introductiott
corrveflcd into dernand for healtlt ciire.
Tlte Crossrnan ( I 97 2: 224) nrodel argucs that denrand for health care (perceived need) by
collsumers is derived from the demand for good health. People desire good health rather
than health care. Demand for good health is derived fiom the desire to reduce pain and
suffering and achieve a higher quality of life (consumption component) and to have more
time for work and recreational activities (investment component). Demand in this context
is not the economic concept of willingness and ability to pay for a service but rather the
actual seeking of health care from, for example, the public health systenl.
I.3 SCOPE AND METHOD
1.3.1 Scope
This thesis is concerned with providing evidence on the economic consequences of health
care decisions. The study is intended to improve decision making in health by providing
sonre basic guidelines for econonric evaluation of health together with examples illustrating
the application of economic evaluation nrethods to real New Zealand situations.
A cornprehensive review of the current literature relating to economic evaluation as it
applies to health and health policy was undeftaken. A series of cases relating to original
researclt is presented to illustrate the conrnton economic evaluation techniques. The cases
were prepared as a part of thesis developmenl. and sent to journals for peer review and
publishing prior to conrpletion of tlre thesis. The tlresis was conceived as combining these
pieces of original rescarch into an integratcd rvholc. An overview of each case is presented
and policf inrplicatiorrs, methodological issues and new and original findings highlighted.
Thr'process fronr research proposal to final publication of each case ranged between 2 and
4 1'ears.
Althouglr a u'ide ranqe of nrethods and corrccpts are discussed, the focus is on practical
application oIthc'crry relating to econonric evaluation. Policy analysts and managers in the
ll/ Guy Scott (2001)
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health scctor face a rvide range of diflcrent resource allocation problenrs. No one
nrcthodology or lheorr-tical concept can be uniforlrly and universally applied. To answer
lhe rL'search qucstion, "tlott c(rn econornic thcory he appticd to heulth cere to improve
decisiott nmking v'ilh respect to the qff cienc.t' of resourcc use in New Zealanrl.2" it was
necessary to discuss a wide range of techniques, and show in a series of cases, how
econonric evaluation may be applied in a variety of situations. No one case, technique, or
segment of economic theory is discussed in minute detail.
I.3.2 Techniques Reviewed
The analytical techniques reviewed include:
' Cost-benefit anulysis where costs ofthe programme and consequences or intended
benefits are nreasured in nroney units.
' Cos t-utilit-t'unulS'sis u'here costs are nteasured in money units and consequences in
utility values.
' Cost-efectiveness crnal;srs rvhere costs are quantified in money units and
consequences in natural or clinical units.
' Cosl-minimisalion anttlT'srs where costs are measured in money units and the
consequences are assumed to be identical.
' Cos t-of-tllness (burden of illness) unalvsis and cost-of-treatment analysis where as
n'lany as possible of the costs of an illness or its treatment are measured in money
ternls (and those that cannot be nreasured in money terms are quantified or
described in some othcr rvay).
' Cotttpulcr based dcci,sion unul.t'tit' nrctlelling lvhich incorporates elenrents of many
of tlrc' abovc tccltrticlucs into arr interactivc tllanagenlent and policy analysis
frarrrcrvork.
1.3.3 Cases
Tlte cases illustratc ccononric evaluations of health policy. Each case is discussed in a
nlatlner tltat dc'ntorlstrates the application of the technique/s to different problems
encountered in health policy analysis. Most of the cases described are concemed with
W Guy Scott (2001)
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ntedical inten'entions (for example, a surgical technique or a drug). The underlying
principles are cqually applicable to diagnostic tests, equipment, accidept prevention and
rehabilitation progranlntcs, hcalth pronrotion, illness prevention and protection
progranlnles.
All the cases presented are extended sumnraries of published papers. It was considered that
for clarity and focus a synopsis of each paper should be included in the body of the thesis
and full text versions in an appendix. Because sulficient detail needed to be supplied,
portions of the text and sonre of tables in the body of the thesis are similar to the published
papers.
All cases discuss how a policy maker could use or has used the results. Some of the
examples relate to orrly one perspective or decision maker, but others consider the policy
implications fronr a number of viewpoints.
I.4 OUTLINE
This section outlines the content chapter by chapter. Chapter 2: Conceptual Framework
for Econontic Ewtluation of Hculth Care,sets the scene for the thesis and discusses a range
of issues relating to public policy in general and government health policy in particular.
Econonric evaluations involving resource allocation decisions in health care require reliable
outconle (output) and cost (input) measures. Health, ill-health and health related quality
of lilt are cot.lccpls tltat are difficult to define and quantily with the precision required for
ecottotrtic e'r'aluittiort. 'l-ltc next t*'o chaptcrs discuss the quantification of outputs and
irtputs.
Cltalttr-ri: Iirlrrrrre llt'ulthOutcotttcs,co\crsdcfinitionsofhealth,waysofvaluinghealth
otltcot'llL's. ltc-itltlt indiccs, rrluing hcnlth states, quality adjusted life years, r,alidated
instrutttcttts attd cuncttt Nerv Zealand initiatives. Cost concepts and measurement
techrtiqucs are discussed in Chapter 4: Cbs/s. Costs involving money outlays (explicit
ll Guy Scott (2001)
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costs) arc fi'equently rccorded for accounting purposes and may often be isolated and
nteasured rc'lati'v'ely casily. But as econonric costs include both implicit (do not involve
nloney paytlcttts) and explicit costs, adjustnrcnts to accounting costs will frequentlybe
necessary to estimate econonric costs.
Costs and consequences that occur at different tinres must be adjusted to a common base
before comparisons are nrade. Chapter 5: Discounting, discusses why discounting is
necessary and examines the selection of an appropriate discount rate. A theoretical
discussion of the various economic evaluation techniques is to be found in Chapter 6:
Economic Evulttation. The specific evaluation technique is determined by the policy
question, the nature of the data, and the tinre and budget available for the analysis. Chapter
7: Ir'lotlels, discusses the historical and theoretical foundations of models and their use in
health and public policy analysis. Different types of model are outlined and the modelling
process discusscd. Models assist in integrating data from a number of sources and in the
consideration and testing of a range of scenarios.
The cases illustrating different techniques and problenls are summarised in Chapters 8 to
I 7. The general approach to discussing these cases is as follows. The background, research
question, health and policy issues are first addressed and then the anatytical methods and
data, results, conclusions and the pubtic policy points illustrated and/ or identified by the
case are covered.
Chapter 8: Cure ll'ith Datu, uses tr.vo cases (Heart Fuilure and Benign Prostatic
II.t'perplu.sia) to illustrate a nunrber oI problenrs associated with aggregating and using
secondary data. lt prcseltts a strategy to avoid such problenis. New and previously
uttknos'n evidc-ttce on tlte differences bctu'ecrr Maori ancl non-Maori hospital admission
ratcs for benisn prostittic hrpcrplasia rras found. Paracloxical and previously unexplained
diflc'rc'nc,-'s bc'tucc-tr atlgrcs.nted gc-rrdcr spccific lrcart failure prevalence rates and age
spe-cilrc scrrder riltcs \\,crc isolatcd and erplairrcd.
Clrapter 9: Antibiotic Costitrg, uses nricro costing techniques to quantify costs associated
with antibiotic regittrens for serious infections in three Nerv Zealand public hospitals. A
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dccision analllic nrodcl suitable for costing arry antibiotic regimen rvas constructed and
tested. Thc costing datA rverc'based on obscn'ation ratlrer than the ntore usual self recorded
diary erttries, Thc nrodcl developc'd irr this sludl' provided a new tool for hospital
adnrinistrators and clinicians to ntore accurately contpare the full costs of antibiotic
reginrens.
Chapter l0: Benign Prostatic Llvperplasia, describes a cost-of-treatment study that
integrated data from a wide range of sources; surgical treatment audits, hospital discharges,
and prices. New information on the economic costs of treated benign prostatic hyperplasia
was published. The research highlighted the hitherto hidden intangible costs of the side
effects of surgery and was instrunrental in prornpting clinicians to investigate the
differences in treatment rates betu'een Miori and non-Maori. The research used hospital
discharge unit record data (with patietlt identifiers renroved) which enabled filteringand
dctailed analysis. This rvas the first published Nc.r.v Zealand study that used newly available
unit record discharge data for econonric policy analysis. Earlier research could access
aggregated data only, rvhich did not permit filtering and detailed analysis.
Chapter I l'. H.v'sterec!o,tryt, discusses a cost-of-illness study and highlights issues of equity
and efficiency. For the first time in New Zealand, incidence rates and costs ofhysterectomy
were isolated for women between the ages of l5 and 55 years undergoing hysterectomy for
non-ntalignant conditiorts. Unit record hospital discharge data were filtered and used to
estintate incidence rates and costs. This study was one ofthose cited by the National Health
Conttttittee ( 1998) in tlreir Guideline-s for the n'lanagentent of heavy menstrual bleeding.
Chapter l2: Lou'o' Rc'sJtirutor.t'Truc't Infectiott, prescnts a cost-effectiveness analysis that
rvas conducted alongside a clinical trial in a general practice setting. This was the first such
Netv Zealartd cconornic stLrd1,. It *'as particularlv significant because the clinical results
u'crc publishcd only' in thc ecorrorrric paper. ThL. results provided evidence on cost-
eflbctivcrtess erublirtg bcttc-r inl-onrred lunding dccisions to be made relating to general
practitioner antibiotic prcscribing.
l0
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Clrapter 13: Infttctt:rr, conrbined overseas clinical findings with New Zealand cost
infonttation to cvaluate the cost-effectiveness of vaccinating the 65 years and older age
group in Nerv Zealand. The published rcsults of this study provided essential cost-
effectiveness evidence and rvas used by the N.Z. Ministry of Health (Letter, 1996) to
evaluate and design their subsidised vaccination programme.
Chapter l4: Critical Leg Ischaerria, describes a cost-eft'ectiveness analysis that compared
surgery with a pharmaceutical intervention. Application of breakeven analysis was used
to evaluate the situations in which the hospital cost of drug treatment would be cost-
effective compared with surgery.
Chapter 15: Hearl Failure, uses a decision analytic model to integrate New Zealand cost
data with clinical evidence l'rom an international randomly controlled trial. The model
assessed the cost-effectiveness of altenrative drug treatment options. Application of the
results provided new cost-effectiveness infornration vital for government decision making
when negotiating prices and in preparing treatment guidelines.
Chapter | 6: Ischucmic Srrokc, uses the findings of a cost-of-illness study and evidence from
an international clinical trial to conduct a cost-effectiveness analysis of stroke prevention.
The cost-effectiveness analysis of two drug treatment options would not have been
possible without the cost-of-illness study results. This case has been used to illustrate the
differences bctween cost-effectiveness analysis, cost-utility analysis and cost-benefit
arralysis.
Clrapter 17'..4sthntu, illustrated the use of an adntirristrative database to provide information
for cost-of-illness and cost-effectiveness studies and for a decision analytic model. This
studl'anllysed gcrreral practicc records to invcstigatc differences in direct costs between
different nsthnra nrcclicatiorr dclivery dcviccs. Tlrc published results oIthe cost analysis
study u'crc uscd to corrstruct a contputcr-based dt.cision analytic model. This nrodel was
used s,ith general practice fund holders and Regional Healtlr policy makers to demonstrate
cost differences betn'een altemative asthnra treatnrents and permitted users to assess the
budgetary inrpact of different asthnra treatnrent policy options.
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Chaptcr I 8: Discrrss ion and Conclusiotts, prescnts a suggested procedure and checklist for
policy and econontic evalualion as applied to healtlr. Econonric evaluation tends to be
poorly understoorJ and applied by non-econonrist polic;'makers, ntanagers and clinicians.
A rvorkable econonric evaluation checklisl was developed to provide policy decision
makers and rnanagers rvith thc criteria and techniqucs by which the decision-making
process in relation to resource allocation rvithin the health sector can be improved.
Figure 1.3 summarises the structure of the thesis and shows how the chapters relate to each
other.
Figure 1.3: Thesis Structure
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Chapter 2 discusses the conceptual framework for the study.
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CHAPTER 2: CONCEPTUAL FRAMEWORK FOR
ECOI{OMIC EVALUATION OF HEALTH CARE
2.I INTRODUCTION
The purpose of this chapter is to discuss (he rationale for public policy interventions in the
New Zealand health care market. The determinants of health are first considered.
Technical and policy evaluation methods are considered as are the concepts of efficiency,
welfare and equity. Health care market shortcomings are reviewed to establish the need
for govemment intervention in the market to achieve society's goals of equity and
efficiency.
2,2 DETERMINANTS OF HEALTH
Health care is but one of the nrany determinants of the health status of individuals and
populations. Wildavsky (1977) notes that the medical system (doctors, drugs, hospitals) is
responsible for about l0% of a nation's health status. "More available medical care does
notequal betterhealth."(Wildavsky,1977:105). Anow(1963:491)observedthat"...the
causal factors in hcalth are many, and the provision of rnedical care is only one.
Parlicularly at lovr' levels oIincome, other comnrodities such as nutrition, shelter, clothing,
and sariitatiorr nrity be nruch nrore significant."
Grosstttan (1q72) dcscribed inputs into a production function for an individual's stock of
health rr'ith att or.ttput of healthy tinre. Productiorr of health was dependent upon many
environntental variables (includirrg;health care, education, housing, inconre, employment
status. arrd nrrtritiorr). thc nrost inrporlant of lvhiclr u'as education. It was assunred that
higher levels ol'etlucalion u'ould inrprovc the efficicncy of health production. Figure 2.1
is a clirtgranrrttatic rcprcsentaliorr of Grossrrriur's urodel based on Donaldson and Gerard
(1993: lE0). Evans and Stoddart (1990: 1359)also presented a similarmodelshowingthe
causal re lationships betu'een, social cnvironnlcnt, physical environment, genetic
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enclorr'nrcrrt, individual response, belraviorrr, biology, diseases, health care, health and
function, prospcrity and *'ell-bcing.
Figure 2.1: The Grossnran lllodel
Inputs Outputs
Heahh care
Education
Houing
Inconrc
Enploynrnt stahrs
Nutrition
----+ Individual's
stock of health
Heah'hy tinn
-}
The detenlinants of good health, or lack of it, are discussed under the following groupings:
. l:actors that cdttnot he controlletl ht'puhlic policy'. Genetic endowment.
. Fuctors thot are dfficult for public polict' to influence: Values and beliefs,
lifestyle, diseases, demographics and the physical environment.
. Factors that are controllable b1' public policl:: Health care resources, access to
health care and health promotion.
Figure 2.2 surnnrarise the main cleternrinarrts of hcalth and to show the dorninant directions
of causatiorr. The cliagrant is a sinrplification of rcality in that not all the interactions
betrveu-n tltc exogettous variables attd healtlr stattls arc shou'n.
Fttclot's'fhat Cunnot Bt' Cttnlrolletl h.r Ptthlic Prslicv
Thc gcrrctic crrclorvrrrctrt of inclir,idual citizcrts irtllttcttces hcalth and the need for health
carc, but cannot bc- changed by public policy.
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Fuctors Thut Are Difficult for Puh[ic Polict' to Influence
Valucs, bclicfs and lif'cstylc affcct health status. Disease prevalence and incidence, and
dentographics both influence and are nrodified by health status. (ln this context
denrograplrics enrbrace a wide range of factors, including age, gender, nrarital status,
education, occupation. religion, ethnicity, lamily size, income, employment status and
geographiclocation.)Aspectsofthe physicalenvironnrent,includingcleanwaterandclean
air, rubbish disposal, good drainage and servage, satisfactory living and working
conditions, and diseases, may be affected by public policy.
Figure 2.2: Determinants of Health
Genetic endorvrnent
Lifestyh
Health status
Diseases
Heahh pronntion
Phvsical environnrent
Fuctors Thut Are Controllahle by Puhlic Policy
Spc'cilic hcalth policics can change tlre lcvc'ls of lrc-alth carc resources and access to health
carc for sonle poptrlatiorr groups. lnrproved health status may influence health care
resourcL-s tlrrough irrcreased productivill,. I{-alth pronlotiorl policies tnay have sonre
succL-ss in ulterirrg bchlviour. lvlrich in turrr nray alter health status. For example,
advr-.rtisin{ cutrrptrigrrs and llxcs ainrctl a[ rr-ducing the prevalence of smoking may lower
thc irrcillc-ncc and prevalencr,' crl'lung canccr arrd heart disease.
>r
*
I
+
Direction of carcation
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2.3 BACKGROUND TO THE NEW ZEALAND HEALTH SYSTEM
This section looks at the historical devclopnrcnt ot- the Nerv Zealand health system and
places the discussion o[ efficiency and equity in perspective within the current policy
setLings and trade-offs.
Altltough there was sorne public provision ofhealth care in New Zealand prior to the Social
Security Act of 1938, the Act heralded the birth of the modem day New Zealand public
health system. Benefits (ranging from hospital care to pharmaceuticals and artificial aids)
were progressively introduced from April 1939 (New Zealand Royal Commission on
Social Policy, 1988). Although the intenlion of the lcgislation was that all New Zealanders
should have access to health care regardlcss of tlreir ability to pay, the system that
developed was never entirely publically funded.
The Report of the Health Benefits Review (1986: l) comments: "Despite these good
intentions, a fair distribution of health care may not have been realised. Access to health
care is easier for the affluent than for the disadvantaged, and there is a tendency for a
proportionately greater share of services to go to those people who have less need." The
report pror,'ides a number of exanrples (ranging fronr general practitioner services to
phanrraceuticals) to support these claims.
In the 1980s public funding of health care came under financial pressure for a number of
reasons including; slou' econorrric grow'th, an agirrg population requiring nrore health care,
nerv technologyl rrhich \\ras cxpanding trcatrlerrt optiorrs, and growing consumer
e\pectatiolrs lor hr'alth carc'. Irr addition, the health system's structure altd management
st1,le had not evolved rapidly enough to kcell pace u'ith changes in technology, society's
\\'ants, autl thc c'cononric and political r-nvironurcnLs.
Neu' tc-chnolog;, is a double ed-sed srvorcl, in that it provides benefits by opening up
ncw trcatntcnt options (u hich add to cost) but may rcduce treatment time (which
lorvcrs costs) and inrprove health outcornes.
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Thc Reporl of thc'Hospital arrd Rclatcd Scn'ices Taskforce (Gibbs, 1988) corrsidered that
tltcrc ucrc problL-nts of acccss to public lrospital clre and that hospitals u'ere incfficient.
This Report concludcd that tlrc' ntitin problerrr facing public hospitals was poor
nlanagentertt. There was a lack of accurate and reler,ant information, and no incentive to
obtain and use suclt infonration. As lrospitals tvere bulk funded, the value of their specific
outputs was unknown to managers.
A recommendation of the "Gibbs" report was to separate govemment's role of purchaser
and provider of hospital services and create a market in which prices would be set by
modified competition between hospitals. It was considered that this limited market could
achieve a30o/o to 50% increase irr technical efficiency (Gibbs, 1988: 26). The intention was
that Regional Health Authorities (RHAs) rvould purchase hospital services from Area
Health Boards, private hospitals, and voluntary organisations. Some of these ideas in the
Cibbs repon ( l9SS) s'ere also discusscd in thc "Crl.cn and White Paper" (Upton, l99l) and
inrplenrented in part.
The nrain health sector problenrs perceived at the time of the "Green and White Paper"
(Uptorr, I 991 ) included; growing health expenditure, inefficiencies, lack of accountability,
Iack of choice and responsiveness of services for consumers, fragmented funding, and lack
of integration betrveen prinrary and secondary care. In essence these rnay be summarised
as problents in achieving the implicit societal targets of efficient allocation ofresources and
equity.
The Nerv Zcalarrrl health refonns inrplenrented the purchaser/ provider split and
corrtrlctirrg, but hrvc rrot achicved the clflcierrcy guins quoted in the "Gibbs" report. As
Nerl Zealand health care is still predonrinantly qovL'rnn'rent funded (77.3% oIall funding
in 199(r,'97 (N.2. N'linistry of Heulth, 1998: 25)) public policy influences both the demand
arrd supph' sidr-s ol- tlre rlarkc-|.
The initial post refomrs funding of thc Regional l{ealth Authorities and Crown Health
Entcrprises (CHEs) *'as "...based on unrealistic cxpectations about how fast and to what
dcgrec CHEs could reduce costs through efliciency gains, and about how much growth in
ll Guy Scott (2001)
Economic Evaluation Applied To Health Policy In New Zealand 19
open-cndedexpe.nditurs'couldbecontrollc'd."(N.Z.MinistryofHealth, 1996:5). Although
the rcfonrrs shaqrened tlre focus on evidence-based practice, infomration rvithin the health
systenr, and inrproveti accourrtability and integration of services, public concem about the
healtlr systenl continucd (N.2. Ministry of Health, I 996: 5).
Stated goals of the New Zealand's public health policy are to; improve people's health and
independence (improving the quality of life, not just its length), protect consumer rights
and safety, and ensure access to services based on need and ability to benefit (N,2. Ministry
of Health, 1996: 9). To achieve these goals public policy decisions should be directed
towards improving allocative efficiency and the distribution of output. As these two goals
may conflict with each other, there will be a need to consider potential trade-offs between
them.
The National Advisory Committee on Core Health and Disability Support Services (1994:
l0) advanced tlre following criteria as a guide to specifying health and disability support
services that are publically funded:
. "the treatnlent or service provides benefit
. the treatnlent or service is value for rnoney
. the treatment or service is fair use of public funding
. the treatment or service is consistent with communities' values"
The first two criteria concern aspects of economic efficiency while the next two criteria
relate to equity and judgements of fairness and worth. Where there are multiple and
conflictirrg policy'goals trade-offs rvill be necessary.
2.4 POLICY GOALS AND TRADE.OFFS
Inrportant goals of public policy arc to increase social s'elfare by improving efficiency and
achievc an cquitatrlc distribution of inconrc. This inevitably involves trade-off between
e fficiencl' and equity objcctives. Although tlre corrcepts of efficiency and welfare are
irltert\\'irled it is convenient to discuss thenr under discrete headings.
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2.4.1 Efficiencl'
This sectiort discusses production efficicncy, consunrcrefficiencyand allocative efficiency.
Production Efficiencv
The terms; production efficiency, technical efficiency and x-efficiency are frequently used
synonymously. Production efficiency is achieved when the output from each combination
of inputs is maximised, that is, there is not an input cornbination which could produce the
same output at a lower input cost (Gravelle and Rees, 1985). Maximum output is realized
only when the "best" possible use is made of existing technology, and all resources are fully
employed. Pointsontheproductionpossibilitieslrontier(definingdifferentoutputmixes)
are efficient while points within the lrontier are inefficient.
Consumer Efficiency
Consumer efficierrcy (enrbracing both exchangc and product mix) is the efficient
distribution of comnrodities betweerr consumers to maximise their utility. Exchange
efficiency occurs when for a given basket of goods (not necessarily produced efficiently)
it is not possible by reallocating the goods between people to make anyone better off
without nraking someone worse otf. AII consurners have equal marginal rates of
substitutionl lfor any pair of goods). No one can be nade better off through trade and
excharrge. (Stiglitz, 1999). Product nri.x efficiency ensures that the basket contains the mix
of goods most desired by consumers, that is, producers' marginal rate of transformationa
Tlre marginal rrte ol'suirstitution (NIRS) is tlr,.' ratio of the marginal utilities oItwo goods
and is nreasured hy thc slope of thr'consunrcr's rndill'erence curve between the two goods.
Utrlitl ltrraconsumcrisnrarimiscdsheuthr-'ratrotrfthcmarginalutilitiesisequatedwith
tlrc pricc'rltit'rs. At this pornt, tlrc- bcnefits a consurncr gains from purchastngone more
ulllt ol't procluct areJust r.'c1ual to tlrt- bcncljts tbregone from purchasing one less unit of
thc' othcr prodircl.
Thc nrarginal rate ol'translbrnrarion (MRT) is the ratio of the marginal costs of producing
tuo goods and is nreasured by the slope oIthc production possibilities frontier (PPF). The
PI'Ii for ts,o goods dellnes the rate at *'hich thc production of one good may be transferred
into the production of the other.
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is equal to cottsutrrer's trtarginal rate of substitutiort.
Allocative Efficiencr'
Allocative efficiency is a general equilibrium concept relating to the entire economy and
all markets. Resources are allocated efficiently between different uses if the greatest
output of the mix ofwanted goods is produced from available resources and technologyand
margilal benefits of all goods and services are equal to their marginal costs of production.
For allocative efficiency, there nrust be simultaneous efficiency in production, and
consunrption.
An allocation ol'resources generated as a result of general equilibrium of a perfectly
conrpetitive econonty is Pareto efficient (rJiscussed in section 2.4.2) and anyPareto efficient
allocation of resources can be achievett by the solution to a general equilibrium in a
competitive economy (Boadway and Bruce 1984: 3). If the conditions for perfect
competition are broken market failure occurs (discussed in section 2.5).
Different types of econonric evaluation are concerned with different aspects of efficiency.
Cost-benefit analysis is concerned with allocative efFrciency while cost-minimisation, cost-
effectiveness and cost-utility analysis are concemed rvith production efficiency. If we had
a utility measure that rvould pemrit comparisons anrong all goods and services (including
leisure) then cosr-utility analysis could be used to assess allocative efficiency. Chapter 6:
Economic Etulutttiott discttsses these cotrcepts.
2.4.2 Evaluating Welfare
\\'lrat is \\'elfarel
As ecorrorlic policy, airrrs to nraxinrisc social nclfare subject to constraints of tastes,
techrrology apd resources (Barr, 1987: 70, 73), evaltration of rvelfare changes is important'
Tlre q'ellarc oI society represetlts the aggregatecl sntislaction of all its members and
..wellare comparisons $,ould be simple if it were possible to aggregate the utilities of
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individuals into a single utility function." (Henderson and Quandt, 1958: 201)' However,
crcatiol'r of suclr a socir-'tal qtility function n'ould rc-quire- cardinal utility and cotttparability
among household utilities (BoarJw'ay and BrucelgE4: 6l). Pareto provided a rvorkable,
albc'it paaial, solution to this questiorr.
Pareto Concept
The basic premise underlying welfare economics is the Pareto principle (Pareto, 1927)
which states that a change will result in an improvement in community welfare if the
change increases the utility of at least one individual (in their opinion) but does not
decrease the utility of another (Price 1977, Baumol 1965).
There are two fuldaniental theorenrs of welfare ecotromics which provide some guidance
in assessipg welfare according to the Pareto criteria. First (the direct theorem) maybe stated
as; "Upder certain assunrptions, a state (allocation of goods and factors) resulting from a
conrpetitive general equilibriunr is Pareto optimal." Second (the converse theorem) says
t5at; "Under certain assunrptions, every Pareto optinrum state (allocation of goods and
factors) can be realized as the outcome of a competitive equilibrium given the distributional
claims on income." (Boadway and Bruce, 1984: 64). Underlying assumptions are; that
markets are efficient, households aim to maximise utility, and firms are profit maximising,
In practicc l'tlost resource allocation ciranges nrake some individuals better off and others
worseoff. PearcealdNash(1981:2)nraintainthatinraginingapolicychangethatwillnot
hanrr sonrcone is difficult, particularly as econontic evaluations consider costs and benefits
ovcr tintc'.
T5c conrpcnsatiol'l principal (potential Pareto or Kaldor-Hicks Criterion) enunciated
separatcly ald irr tiiffercnt fomrs by Kaltlor (1939) and Hicks (1939) is adopted in cost-
bclc.llt alirlysis. Urrdcr the Kaldor version of thc contpensation principal, if it is possible
fcrr thc- guipers to contpcnsatc the losers lor their loss, the project is desirable. Baumol
( 1965: 378) states the Kalclor criterion as "A changc is an improvement if those who gain
el,aluate their gairrs at a higher figure than the value the losers set upon their losses'". The
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Hicks vcrsiott of thc con'rpensation prilrciple requires that the potential losers be able to
bribe the gaitters to rttairttain the status quo. Tlrus, if the benefits exceed the costs of a
project and if corlpeltsatiorr is costless thcn the projcct is desirable. A comparison between
the situations with and without the progranrme (courrterfactual) provides a check that the
con'rperlsation test is Ittet (Battiato, 1993:27). This does not mean that the gainers actually
conlpensate the losers. They simply have the potential to do so out of their gains. Thus,
tlre conrpensation criterion tells us nothilrg about equity changes,
Scitovsky ( l94l ; 86) pointed out that changing from one situation to another will generally
affect the distributiorr of welfare by "...shifting relative prices...boosting some industries
and depressing others. ..". In applying the Kaldor criterion it is possible that a change in one
direction could be regarded as an improvement as could a movement back to the original
point. To overcome this paradox Scitovsky proposed a two-paft test: first, apply the Kaldor
criterion to evaluate if a change is an inrproventent, and second, use the Kaldorcriterion
to check that the return back to the original situation is not an improvement. The proposed
change would be an intprovemcnt orrly if both parts of this test were satisfied (Baumol,
1965:379; Scitovsky, l94l). As nrost health carc projects are not large enough to
substantially influence relative prices the Scitovsky reversal criteria has little practical
application in the evaluation of health care prograntn.les.
Potential Pareto itrprovenrents should not be the only criteria considered when evaluating
a ciecision. A frec market is unlikely to ensure that the " winners" will compensate the
"losers" thus policy nrakers ntust consider equity changes. Kaldor ( 1939: 55 I ) commented
that it rvas ",..quite inrpossible to decidc on econonlic grounds rvhat parlicular pattem of
inconrc-distribution nrarinriscs sociul *'clfare." Atkirrson and Stiglitz (1980: 6) conrment
tltat a Pilreto optinra "...does not ensure tlrat tlrc distribution that emerges from the
contpctitivc proccss is in accord rr'ith thc prcvailing cotlccpts of equity (whatever these may
hc) "
Tlrc strc'r'rgtlr of the Pare to critcria is that societal rvellare can be evaluated without the need
for utility conrparisons (or rveightings) betrveen households. However, this is also its
nrajor s'eakness in that it tells us notliing about distributional equity of altemative Pareto
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efficient outconrcs,
There is an infinite nunrber of general equilibriunr possibilities (efficient outcomes), each
retlecting a different distribution of income and there are manypossible Pareto efficient
outconlcs given any particular distribution of incomc. We cannot tell which Pareto efficient
outconle (equivalent to allocative efficiency) is the "best" for society because this would
involve changing the income distribution as well as the relative quantities of each good and
service.
Provided a social welfare function could be constmcted, it would be possible to define a
situation that reflects "... simuttaneous determination of the efficient output mix and its
distribution among consumers." Musgrave and Mttsgrave (1982: 67). This may be
illustrated by figure 2.3, where the verlical axis rcprcscnts the welfare or utility of Y while
the X axis denotes X's utility. Social indifference curves are plotted. These curves identify
combinations of utility of two individuals, Y and X, which leld equal levels of utility to
society (as defined by the social rvelfare function) and describe how society would evaluate
utility trade-offs between Y and X. Finally a utility possibilities frontier that traces the
maxinrunt utility that Y can obtain for a given level of utility of X (and vice versa) is
constnrcted. Society's preferred poirrt "bliss point", is where the highest indifference curve
is rangential to the utility possibilities frontier. Both points A and B are allocatively
efficient. ln practice, policy makers cannot usc such a modet to evaluate utility trade-offs
bets,een individuals because they are unable to assigr relative weights to levels of wellare
o f each nt ertt bc r o f soc icty.
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Figure 2.3: Distribution Choices
U = utility
Sl = cocialindiffercnce
cut yg
UPF s uilllty
posribllitler
frontlcr
Ys lndlvldual Y
X 
= 
Indlvldual X
B (Bliss point)
Pareto provided us with the criteria to guide us to the utility possibility frontier but policy
makers must decide horv to trade-off utilityof different individuals in society, This leads
to a discussion of equity.
2.4.3 Equity
This section is not intended to be a philosophical discussion ofdistributive justice or ethics
but to introduce some of the issues underlying equity concepts. A more detailed discussion
of social justice in econonrics may be found in Schokkaert (1992) and a discussion of
equity in health care in Wagstaff and Van Doorslaer(2000) and Williams and Cookson
(2000).
Equitf is corrcenreci *'ith lainress anci justice and involves the distribution of income or
*'ealth. antl ncce.ss to goods ancl sen'ices. Dcfirring cquity rvith precision is difficult, as it
is r-oncu.rncd rvith valuc jur.lgcrnents, and valucs differ between individuals, groups and
socicti,..s. arrtl rua_\' \'arv over tinrc. Economic tlreory provides no guidance in evaluating
nroral or cthical issues.
Utility
ofY
Utility
ofX
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AII corrccllts of cquity arc cot'lccntetl s'ith cqualising sonrething and because nlany things
of re levalce to fiealtlr could be equalised. tlris lc"acls to l]rany possible definitions of equity'
The ilrplicatiorrs ald interpretation of equity dcperrd upotr what is being equalised' Equity
is evaluated by cornparing a specific leature of onc citizen with the identical aspect of
otlrers. Sep allurjc's to tfie rvide range of variables upon which equity could be judged. ""'
the judgenrerrt and nteasurentent oIinequality is thorouglily dependent on the choice of the
variable (income, wealth, happiness, etc.) in terms of which comparisons are made..'" (Sen,
1992:2).
Le Grand (1982: 14) identifies five criteria that have been used as objectives for the
distribution of government expenditure. These are, equalizing: (l) public expenditure, (2)
final inconre, (3) use, (4) cost,/ access, and (5) outcome. Public expenditure on a particular
scn'ice or good coulcl be allocatcd equally to all relevant citizens. Expenditure could be
allocatcd so that tftc same quantunt of sen'ice is used by all relevant individuals'
Goverrurent furrds could be spent so that their final incomes, private earnings plus
transfers, are the sapte. Equalizing cost or access rvas described as all individuals facing the
same out of pockct cost. However, equal acccss could be regarded as a separate category'
lndividuals nray face equat cost, but access to scrvices may be quite different, as other
factors such as education and knowledge of how to obtain the service may differ'
Equalizing outcome refers to final results of the service which could be an equal state of
health.
.,Equity i1 Sealth care is the subject of much dcbate...most health care systems seem to
definr,- their cqurtv goals in ternts of equal access, nonually equal access for equal need'.,"
(N{ooncy,, 1996: 100). culyer and s'agstaff (1993: 431) considered four equity
propositiorrs of- rclevarrcc lo lrcalth ancl lrealrh cirrc. Tltese propositions related to;
equaliz-ing utilization. clistribution according to rtcct!, eqttal access attd equalizing health'
Tlrt'l'assc-rtc'tl tltat tltcsc fottl collcepts u'erc itrcot'trpatible' Equity, it was suggested' should
lre trrscd o1 cqurlizing liealth. Thus. equity in hcalth care should involve "."distributing
carc in sucS a \\.ay as to get as close as feasible to att equal distribution of health"'"'
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It is corrvenicnt to consider t\\,o tlJ)cs of cquity, tltat is, horizontal equity and vertical equity.
Horizorrtal cquity is flre idcntical treatmcnt of idc'ntical people, that is, equal access for
equal need. For r-"xaprple, tfte provision of uttiversal bcnefits for all elderly, or for all people
under a specified income level. The provision of nrinimunr standards of, or equality of
access to health care for all citizens are also exanrples of horizontal equity' Most health
care systenls are primarily concenred lvith horizontal equity.
Vertical equity is the different treatment of unequals to reduce the differences between them
(Atkinson and Stiglitz, 1980). Exarnples of vertical equity include; targeted benefits'
redistribution of income from rich households to poor households, the provision of wheel
chairs to some disabled and walking sticks to others (depending upon need). Policies aimed
at closing the gap between Mdori and non-Mdori health status also have a vertical equity
focus.
Mooney discusses vertical equity in relation to Aboriginal health in Australia and suggests
that if vertical equity principals are to be applietl to health care, then community
preflerences to s,eight the health gains of different groups in society (with different health
starus) nrust be eslablished (Mooney, 1996: 102). Findings from a survey of Australian
heatth care decision makers suggested that Australians value health gains differently for
different groups that have different health states ( Mooney et al. 1995). The survey also
discovered that people were prepared to express preferences relating to the allocation of
health gains.
Other concepts rclating to equity and clistributive justice are discussed because they are of
rr'lg'lpce to plblic policl,dccision rrraking in hcaltlr care. Tltese ideas are; utilitarianism'
Ral'ls'tSeory of justice, Sen's capaciry to achie'r'c, Willianrs "fair innings" notion, the
invcrse carc rttle arttl thc rttlc of rcsctlL-.
Ljtilitrriarrisrn cl,--flnr'd societal n,elflre as the sunr of the welfare of all citizens. "The
urilitlrian olrjecrive is to nraxirrrize the surl-total of utility irrespective of distribution, but
tlrat retltrireslhe etltrulity of the mttrginnl utility of everyone'.." (Sen, 1982: 354)' Sen
( I 99i) trssefls rhat utilitarianism is unconcerned rvith irrequalities in individual utilities "All
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that rnattcrs in thc utilitarian vieu' is tlrc surtt total oI these utilitics representing the
respcctive individual advantagcs, indepcndently of their distribution." Tlris approach
"...takes po accoult of tfic rolal utility enjoyed by a persotr - only the inrpact orr utility at the
nrargin, so that a person wlro is nruch worse off in temts of overall well-being or utility
receives no particular consideration for that reason." (Sen, 1997:110). The inability to
focus on total rvell being of individuals makes practicat application ofthis criterion socially
unacceptable as a means of evaluating societal equity.
Rawls (lg7Z) accepts inequality provided that it is inrpossible to improve the situation for
the worse ofL He argues that if individuals make decisions behind a "veil of ignorance"
they will automatically ctroose (if they are risk averse) to improve the situation ofthe worst
off bccause they fcar that the circuntstanccs could apply to thenr.
An alternative vierv rvas tendered by Sen ( 1992: I 48) who argues that a person's relative
situation should be judged in terms of capacity to achieve rather than actual achievements.
people are diverse. Variations in factors such as age, gender and genetic makeup mean that
different individuals have very different capacities to beneht from an intervention'
Williarns (1997a, 1997b, 1997c), discusses the notion of the "fair innings" as a way of
considering intergenerational equity and rationing lrealth care by age. Rationing using the
.'fair innings" approach implies "... that healthcare resources should be allocated so as to
redrrce the inequalities in people's lifetime experience ofhealth'.'" (Williams ,1997a:l499)'
Everyone s6osld be "...entitled to sonre 'nomal' span of healtlt..." (Williams, 1997b: I l7)'
T5e " ...prcferrcd coltccpt n,ould be tlrc rrunrber of quality adjusted life years a person had
errjoyed..." rathcr tharr a specific age in years (Willianrs, I 997 c:822). Tl"rus a "fair innings"
for a persop expcricncing a lo*'quality of life *'ould be a greater length of time than for
sonreone elsc living a healthy life lree of pain or suffering'
Thc invcrsc- curc- r'uL- statcs "...the availability of gootl nredical care tends to vary inversely
s it5 thc nr.cd of tlrc population sen,cd. ...The force rhat crcates and maintains the inverse
care larv is t5e- opcrltiop olthe nrarket..." Hart ( l97l:412). In other lvords, those with
greatest need are least able to access health care in a market driven health system' Hart
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ad'r.,ocates renroving as rnuclr of health care as possible from the market.
The nrle of rescue, (Luce, 1994; Moneint, 1994; Hadom, l99l) that conrpels people to
ignore the cost and lrelp those in irnnrediate need, creates a dilemma. It is argued that "To
rescue sotneone rvith interventions beyond his health care package thwarts the democratic
process and cheats all other citizens whose care renrains within the designated limits, or
whose entitled care nrust norv be abridged to acconrmodate the drain on resources..'"
(Moneim, 1994:466).
While ethics or justice criteria do not bound utilitarianism, Rawls' "veil of ignorance"
makes certain that any application ofjustice is impartial. Williams"'fair innings" idea, and
Sen's "capacity to achievc" conccpt are both cortstrained by a sense of justice. Both
Williams and Sen attempt to address inequalities irr health over a lifetime or period of time
rather than inequalities at one specific time. The rule of rescue is strongly based on ethical
criteria. While the inverse care rule is a lactual statenrent about income, burden of illness
and access to health care, its ethical underpinning could be derived from those who believe
that the market distribution of income is fair.
Because defrnitions of different types of equity nray be interpreted differently by different
people, and equity values dil'fer between individuals, clear explanations and descriptions
of equity goals and consequences of a policy are essential.
2.4.4 Equitv Efficiencli' Trade-off
Movipg fronr otrc allocativc efficient solution to another is not costless. Arow ( 1963: 943)
statcs "...if the allocation nrechanisnr in the rcal rvorld satisfies the conditions for a
contpetitive rlodu-I, then social policy cart confinc itself to steps taken to alter the
disrributiol of purchasing porvcr...". FIon'ever, in a footnote (Anow (1963: 943, note 2)
col.lll1epts, "....in practice, it is vir.tualll,inrpossihlc to find a set of taxes and subsidies that
q'ill pot lrave an aclr,ersc effect on tlte achieventettt of an optimal state'..". lf the allocative
and distributional effects of a policy cannot bc separated "... the traditional economic
method, in rvhiclr conrpetitii'e forces are allorvcd to prevail and distribution is only done
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aftenvard, is nol necessarily appropriate,.." (Ricc', 1998:37),
The efficiency equity trade-of[ rlay be denronstrated by use of a utilities possibilities
frontier and social indifference curvcs. In figure 2.4 point A is not efficient but is more
equitable rvhile point B is efficient but less equitable. If there is a shift fronr point B to
point A, sonre societal utility is lost, equity is enhanced, individual Y gains utility and
individual X experiences a reduction in utility.
Figure 2.4: Equity Efficiency Trade-off
Utilaty
ofY
U = utlllty
Sl = soclal
lndiffcrcnce
cut Yo
UPF = utllityposslbllltlcs
frontlcr
Y= lndlvldual Y
X = indlvidual X
Uyz
UYr B (Bliss point)
Two examples of efficiency and equity trade-off are as follow. Taxation and redistribution
of income (except lump-sum taxes and transfers rvhich are not feasible) to redress squity
ntay cause ineftlciencies; "... any practicable system of taxation may restrict factor supply,
reduce outpr.rt aurl cause inefficiency in production and/or product mix." Ban (1987:77).
If a rurtl hospital is closed, productive efficiency nray be increased at the expense of equity
of access to lrospital services for rural citizens.
Efllcienn I cquin' tradr-off in public policy ciccision nrakirig can be avoided only if:
. Agglc-galcd ltL'r bcnefits of rhe policy arc positive and the poor are net gainers and
tlre *'ealtlty arc I'tct losers, or
. Ir is possible- ro ascribe u,eighting factors to the net benefits of different groups in
society apd thus obtain a weighted societal net benefit for the policy. A social
Ai
""""""j
:
:
i
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n'cllarc functiorr ri'ould bc ncccssarv for suclt an analvsis.
The policy nraker rvill often be forcecl to tradc" off sonte efficiency to achieve a policy
outconre in accord rvith society's equity values. Accordingly, equity and efficiency
consequences should be considered in parallel rvhen evaluatirrg public policies. Contmunity
preferences to rveiglit healtlr gains of different groups in society are necessary if equity
goals are to be addressed (Mooney ( 1996: 102). Research is required to derive such usable
societal preference weights for defined population groups.
2.5 MARKETS AND GOVERNMENT INTERVENTION
Most policy objectives may be accomplished using a range of policy instruments (Howlett
and Ranresh, 1995) which have varying degrees of government involvenrent. Voluntary
policy instnrnrents involve little or no governme nt intervention and include private markets,
fanrily,andvoluntaryandconrnrunityorganisations. Attheotherendofthespectrumthere
are computsory instruments such as direct govenrnrerlt provision of goods and services'
Evans (1997: 428-9) provides sonte nlatlagenlent advice and a set of social objectives
relevant to healtl'r care. "Market like mechanisrrrs within publically funded health care
systems constitute a particular set of management tools that might be used along with other
more established mechanisms to promote the following generally accepted social
objectives:
a Effective hcalrh care, efficiently provided and equitably distributed across the
populaticrn irccordirtg to need;
b Fair but uot crccssive re intbttrsement of prol'iders; and
c Equitable clistributiol of tlrc burderr of contributiolls according to ability to pay;
s ithirr
d Arr overlll cr pcncl iture cn vclope that is cortsistcttt rvith the carrying capac ity of the
Ecpc-rill ccolont\', or rathcr its rlcrnbers' collcctive u'illingness to pay"'
Figure 2,5 shoivs horv the interaction of supply, dcntand (market forces) and govemment
spending on health influences resource utilization. This is a simplified diagram in which
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lagged fccdback loops are not sho*,n (for exanrplc', utilization ofresources that are intended
to alter health status nray irr tunr alter needs).
As the Ne*' Zealand health care systenr is predominantly government funded, public
policies havc a nrajor inrpact on utilization of health care resources. Succeeding sections
discuss the role of the nrarket and failure of the markets and governments.
Figure 2.5: Utilization of Health Care and the Interaction of
Supply and Demand
2.5.1 The Role of the lVlarket
Although the application of economic evaluation teclrniques is of value in both free and
urrregulated ntarkets a discussion of nrarkets and rlarket failure is provided because many
public policies arr. introduced either to correct for nrarkct failure or to address equity issues.
Thesc public lrealtlr inten'entions lrequently cornplicate economic evaluatiorr. Prices
clrargcd ntay no longcr be an accurate reflection of production costs. Regulation may
irrrpose linrited diru-ct explicit (or I-rnancial) costs but require substantial conrpliance and
get'lerulc consiclcrlblc'inrplicit costs. In both cases, tlte ccononric evaluation nrust ensure
tlrat nll cosls arrd bcncllts itrc citpturL-d w'itlr the truc economic value irrcorporated.
Accr:r'dingll', policv dr.cision nrakers should understand nrarkets; what they can and cannot
aclrievc, lrorr'they'tirnction, and n'herr they lail.
f*h II Status I
+t;;I
t-p**.i'"d I
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\\rlterc tlrcrc is nrarkel efficienclf (in all nrarkcts) and il'nrarkets exist lor all goods
(including leisure tinre), thc- "irri'isible hand" oI tlrc rnarket place ensures that rttarginal
social benefit arrd nrarginal social cost are cquatcd. The price systenr functions
autonraticallv. Every individual in pursuing her/his selfish interests is led as if by an
"invisiblc hand" to achieve the best good forall of society(Snrith, 1776). Sellers cannot
sell goods or services the nrarket does not wat'lt nor can they charge more tllan their
competitors for identical goods. Perfectly competitive markets produce the goods and
services that society wants at the lowest cost.
Evans (1977:428) notes "There is in health care no "private, competitive market" of the
form described in the economics textbooks, anywlrere in the world. There never has been,
and inherent characteristics of health and heailth care make it impossible that there ever
could be. Public and private action have alrvays bcerr interwoven." Enthoven (1988)
conrnrents that health care nrarkets are not naturally compctitive and "deregulation" will
not make them so. Rice (1997) also notes tliat although nrarket forces may have a
prominent role in allocating resources in health care, economic theory does not show them
to be necessarily a superior approach to health care policy.
Uncontrolled and unregulated free markets may lail to produce the optimal outcome for
society (rvith respect to society's goals of efficiency and equity). That is, the market
solution nray not result in outconres that arc in accord rvith society's goals.
lVherr tlrcre is rnarkcl lailurc, or if tlrc- nrarket solution is not congruent witli society's equity
goals gol'entntcnt nray *'ish to inten'ene and atterlrpt to correct for these shortconlings.
Gibbs ( lgSS: 5)notccltlrat "Orrc of the ccntralreasons forgovernnrents becoming involved
in hcalth cirrc is tlrc concr-'nr lor fairlcss lnd the possiblc outcon'les that would otherwise
rcsul t. "
Fot rnarkct ct'ficierrcy a nurlbcr of critcria must be met. Consumers and sellers
havc pcrfect and certain krrorvledge of the market, there are no externalities or
public goods, tlrere are large nrrnrbers of sellers and consumers with no powerto
influence the nrarket. Market failure occurs *'hen any of these efficiency criteria are
violated. (Boadway and Bruce, 1984: I 3- I 5).
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Registration of nredicirres and health care providcrs is necessary because most consumers
rvould have insufl'icient infomrarion (rlarket failure) to enable them to make informed
decisiops ou thc salety of nreclicincs and conrpetencc of providers. An example of a policy
to address arr equity issue is the provision of atlditional health subsidies to welfare
bencficiaries and tltose on lorv ittconres.
2.5.2 Market Failure and the Second Best
Public policy interventions aiming to maximise social welfare are often concerned with
attempting lo comect lor market failure by enrleavouring to fulfill as many of the Pareto
efficiency conditions as possible. Given the difficulties of determining when a Pareto
efficiency is attained, and of satisfying all tlre contlitions for Pareto efhciency (first choice
or first besr) thc concept of second best is inrportartt. If a Pareto efficient outconre cannot
be attained, is it bcst to satisfy as nlany of thc Pareto conditions as possible or would the
second best be attained in sonre other way'i
The theory of tlre seconcl best, first6 describerJ by Lipsey and Lancaster (1956), contends
that, if in aly gil'cn situation, it is rrot possible (or not desirable) to achieve a first best
solution it may be better to diverge equally lrorn all the efficiency conditions than to
attempt to satisly as ntany as possible of the efficiency conditions.
For exanrple, it nray be better to counter monopoly porver of sellers with nlonopsony power
of cossunrers r:rther than attempt to shift tlte ntarket conditions and structure towards
perltcr coptpL-ritiot'I. Ir could be argued thrr this is the situatiott relating to the
grhtrnraccuticitl tttarkct itr N5r' Zealilnd rt'lterc nronopoly power of the pharmaceutical
iptiustry is plrtclrr.-d by, thc nlonopsony po\\ er of thc Phanrraceutical Managentent Agency
(PI{ARi\1AC)
The concept of tlie second best was first fonnalised by Lipsey and Lancaster but the
ideas had been cliscussed in the literature earlier (McKee & West, 1981 and
Streissler & Neudeck, 1986)
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It is irnporlant to rrote tlte follow'ing:
. In gcneral, notlring can be said about thc direction or the nragrritude of the
secontlary departures lronr optinrunr efl'iciency conditions made necessary by the
original non-fulfilnrent of one condition (Lipsey and Lancaster, 1956: l2).
. There is no way of detennining if one second best outcome is better or worse than
another.
. 'nsecond-best policy recommendations typically require some knowledge of where
on the utility possibility frontier rve want to be or in what direction we want to go.
In this sense, policy reconrmendations cannot be distribution free and one cannot
divorce efficiency from equity to the degree that one might have thought possible
after studying fi rst-best envirolrntents." (Blackorby 1990: 7 49)'
. ln man)' situatiorrs the sccond best solution rvould be so complex that they would
not be usable or able to be translated into u'orkable policies.
. The theory of the second best provides little practical guidance of how to achieve
the second best (Price,1977).
Although the theory of the second best is a useful concept, it raises as many questions as
it alrswers. ln practice, policy makers are virtually atrvays attempting to reach the second
best or some other "best" clroice.
2.5.3 Government Failure
Market irrelficiency or inequity does not nrean that governnlent intervention will improve
thc outconre (Atkinson and Stiglitz-,1980 and Price,1977). Govemment intervention to
correct for hilure to achieve socicty's goals of cfficiency and equity may not always be
desirable , Cor',-.nt1rrcnts ntay also fail to nraxirrtise social wellare (Weimer and Vining,
1989) alti sorrrc rtrarket lailures and distributiorral goals are too costly to correct. Stiglitz
(1999) iclcntil-rr-'s four causcs of golc.rnrlelrt failure; lirnited information, limited control
oyer privatc rrlrrkct rcslloltscs. linritcd control ovcr bttreattcracy and limitations imposed
Lry pol i tical processL-s.
|/ GuSt Scott (2001)
Framework E co tt o nt i c Eval u atio tt Health Care
2.5.4 Technical and Polio' Evaluations of Health Care
IJai,irrg discussctl policy apalysis irr general, this sectiorr (argets policies relating specifically
to health. Policies for investigation nray enter the policy agenda in a number of ways; by
evolution from existing policies, by transptantation from other countries, from
developments in clinical and business ntanagentent, and from scientific discoveries.
Although the focus is on how new health related public policy strategies that emerge from
basic scientific research are evaluated, the procedure is generic in that it may be applied to
any new technology or policY,
Basic scientific research may suggest possible neu' interventions and policies. Applied
research must then be employed, to ask, in an ideal silttation, does the science work
(efficacy) and, if so, could it improve economic efficiency? If the answers to these
questions are yes, then a second set of questions follorv; does it work in the real world, will
it be cost-effective, is it equitable and ethicalty acceptable? If the programme is to be
introduced, horv rvill the patients waiting for treatnrent be selected? Selection or rationing
options could inclu<Je the price system, various assessed needs based methods (normative
need, or the mininrum standard of health care as assessed by experts), or by assessing
quality of life gain. Finatly, once a new policy is introduced, it should be monitored to
check that it continues to work in a technical sense, and to satisfy equity, ethical, and
efficiency criteria.
Table 2.1 illustrates tfte sequence in *,hich new or existing health care interventions are
evaluatetl fi-ont basic scientific researclr to final application in society. The evaluations
listcd f ill rarcly provide a definitive "acccpt/ reject" resutt. More conrmonly, changes in
efficielcy ancl equity rr,ill bc indicatecl rvith yaryitrg tlegrees of confidence' The central
tlienre of rlris thc'sis is economic evaluation in the real rvorld as highlighted by the italic text
in Tll'rL' 2.1 .
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Table 2.1: Technical and Poliq' Evaluations of Health Care
Technical Technical evaluation Policy question Policy evaluation
question method
Y
Is it oossible?
Y
Does it work in an
ideaI setting?
v
Does it work in
everyday practice
in the real world'l
Dor's it c0ntilluc
to u'ork'l
Basic research
v
Aoolied research
Y
Efficacy: The extent to which a
health care intervention achieves
beneficial health outcomes in an
ideal situation. Eg Therapeutic
outcomes determined in a
randomrsed clinical trial.
Y
'fechnrcrl urollllollttg
Could it improve
economic
efficiency?
v
Is it cost-effective?
Y
lJoes it remaln
cost-cfl'ective /
uitable'l
Economic evaluation
an ideal siruation or
setting.
Y
Economic evalustion
in s redl world sening
= Cost-effectiveness.
V
Evaluation of equitY
changes and ethical
issues and analysis of
rationing oPtlons.
V
Monitoring of
economic and equitY
e ffects.
YY
El'fectiveness: The extent to
rvhich a health care intervention
achieves bene flcial health
outconles in a real u'orld
situation. Eg Therapeutic
outcomes determined bY a
controlled clinical trial in a real
*'ord setti
V
Is it fair, where do
the costs and
benefrts fall'l Is it
ethically
acceptable? lfthe
programme is
introduced, who
u'ill receive the
treatlnent'l
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2.6 CONCLUSIONS
The health refbmrs of the 1990s (Upton I 991) that scparated the funder frorn the purchaser
and incrcased conrpetition vvere insufficient on thcir own to deliver the efficiency and
equity goals of our society. Public policies are necessary adjuncts to the market process.
A variety of resource allocatiorr decisions must be ntade at many levels within society and
within the health sector. These decisions relate to efficiency and equity, and the trade-off
between these two objectives. Government, for example, must apportion budgets between
Votes, rationing funds between Vote: health, education, or social welfare' Within the
health budget, services to fund from the public purse must be selected. The range and level
of this publicly provided health care or "core health scfviccs" are matters ofpolitical debate
apd decisiorrs u,ill be different in dilferent societies and will change over time' Resource
allocatiorr decisiorrs may also need to be made betrvccn different diseases, such as, coronary
artery bypass grafts conrpared rvith hip replacentettts, Finally, a choice may need to be
made of the most cost-effective treatment option for a particular patient.
Public sector policy analysts and nranagers in health care enterprises make day to day
resource allocation decisions and prepare long term plans and budgets that have spillover
effects on the rest of society (externalities). Not only do their decisions impact on their
otvn orgarrisation, but they have efficiency and cquity inrplications for society as a whole'
Econonric er,aluution (frorrr a societal perspectivc) assists in the policy decision making
process by proviiting infonnation on efliciency. Tlrc tcchnique considers all costs and
bcnc'fits irrespcctivc of rr.ficther or not a n'ronetary paynrent is involved or rvho pays or
bc.1cfits. Ho*'ever. cthical itrrplicatiorrs and salcty issues must be considered separately
(trcforc. cluring o1 altcr the ecorronric investigatiotr). The prrblic policy decisiort making
proccss nrust bc lnrrsl)arelrt, and ri'lrcrc cfficicncl'cqtrity trade-offs are recommended, the
c o n sL'rl u r- n c e.s o l" t ltr,' c lt o i c es slt o tr I d b t- c- x p I i c i t
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Although nruch of the theory urrderlying health econonries and resouree al,location from a
public po.licy perspective is tr:ell developed lhere are a number of practical difllrculties in
applying eeonontic theory arnd techniques tsactual problems. Succeeding chapters o,fthis
thesis focus o,n the pra.ctical applieation of economic theory to weryday policl pro loms.
Chapter 3 eonsiders ways in which healtlr outcomes may be valued.
lA Gay Seott PAU)
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CHAPTER 3: VALUING HEALTH OUTCOMES
3.I INTRODUCTION
To evaluate econonric efficiency, it is necessary to quantify both inputs and outputs.
Econonric evaluation in health care focuses on the relationship between clranges in resource
usage and changes in health status and it is therefore necessary to measure clranges in both
resource cost and health outcomes.
This chapter discusses the problems of valuing health and the methods used to quantiff
health related outcomes (the measurement of inputs is covered in Chapter 4: Costs.) A
brief history of quality of life measurenlents with respect to health is outlined, and some
exanrples of the instnrnrents that are in use are described. There is a large and increasing
array oIsuch nreasures which are continually evolving. Individual instruments will not be
discussed in detail as tlris chapter is interrded to provide an overview of developments in
tlre measurement of health outcontes. However the Rosser index, because of its historical
significance, and the EuroQol and Short Form 36, because of their wide use, have been
discussed in greater depth.
3.1.1 What is Health?
Hcalth and good health are ill-defined and nrulti dimensional concepts. The World Health
Organisation (WHO) defines lrealtlr as "a state of conrplete physical, mental and social
u,ell-being, and not nrcrely atrscncc of cliscase or infirrnity" (World Health Organization,
1948). This cotrccpt of hcalth is ccntral to thc developnrent of methods to ttreastrre patient
rvell-being or health relaterl quality of life (HRQOt-). Bulpitt (1997: 613) defines health
relatc'c'l cpralitl, o i li fc as "... thc dr'grec o f sul1u'ct ivc s'cll-being attributable to or associated
n'ith llck of s,\'tttptrrnrs, llsycltological stale attd activities purstted."
Only rvlrcre problerns of high premature morlality are no longer a pressing social concern
does it become relcvant to think of health in WHO tenns (McDowell and Newell, 1996:
llt Guy Scott (2041)
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ll). Atlon'lo'elsofirrconre,nrortalityislikelytohighlyinfluenced bydeficienciesin
factors such as nutritiorr, slrelte-r, clothing, artd sattitatiott. In developed countries with
grorving irrconres and an aging population, quality of life becomes increasingly important
particularly as the cost of extending the life of an individual with a poor quality life can be
very higtr, Cooper ( 1980: 4) comments "...death is cxtremely cheap and survival often very
expensive as a faulty body has to be maintained until death claims it by the same or another
nleans... ".
3.1.2 Why We Need to Quantify Changes in Health Outcomes
As beneficial health related outcomes (prolonged life or a reduction of pain and suffering)
are not traded on ntarkets, other approaches must be employed to value them. The problem
of valuing non-mal'ket goods and services is not unique to health outcomes, and economists
have developed a nurnber of ways of obtaining inrplicit values. This is equally applicable
to costs. Even where market prices exist it is often necessary to apply non-market valuation
rnethods if there is market failure.
3.1.3 Differences in the Valuations of Health and Health Outcomes
Valuations of health differ, depending upon the perspective taken and the individuals in the
poprrlation group surveyed. This section discusses these differences and the consequences
lor valuing health related outcomes.
The evaluation oIhealth and healtlr relaterJ quality of liie is highly dependent on value
judgenrcnts u'hich rr ill differ according to whose values are considered (patients, clinicians,
hospital nlanaqers, thr-. Minister of Health, the Minister of Finance). Individuals have
cliffercrrt prefcrcnccs anci accordingly they rrtay valtrc health status and quality of life
clifttrcrrtlv. \/ariutiorrs rrray,rcsult fronr clifl'ercttccs itt age, income or cultural background.
Of particulilr coltccnt trc thc potential tlift'crr'nces iu values derived fronr expert opinion
conrparr'd rr'itlt tltose fronr irrdividuals.
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If thc- plrilosophy of corrsurner sovercigntf is follos'cd, then the values and prelcrences of
thc consurrrcrs of hcllth carc should be llararlount. Econorrrists since the rvritings of Adam
Srrritlr irr his 177(r book ll'aolth of Nutiorts lravc recognised the importancc of consumer
sovereignty (Smith. l98l : 155).
Goldetal. (t996: 99)assertthatifasocietal perspectiveisadoptedfordecisionmaking,
the rnost accurate indicator of society's preferences for a particular health state would be
preferences obtained from informed nrembers of the community. As "...a rational public
decides what is the best course of action wlren blind to its own self-interest, aggregating the
utilities of persons who have no vested interest in particular health states seems most
appropriate." (Cold et al., I 996: 100). This is refened to as decision making under a "veil
of ignorance" (Garber et al., 1996: 35).
Horvever, therc arc even problenrs in using prefcrences from infomted ntembers of the
general public or even r.vhat the ternr "infionrled" means. People who are actually
experiencing a particular health state nlay be better able to give a valuation of that state.
Some health states inrpose extenlalities onto lanrily and friends of the sufferer. To
overcon'le this lack of infornratiorr and experience, values may be obtained by expert
opinion frortt clinicians and nurses familiar with the health state,
Another conrplication is that the interests of society are not necessarily the same as those
of tlre individual and the sunr of individual preferences do not necessarily reflect those of
society. Weinslcin ct al. ( 1980) illustrate this by nreans of an exanrple of two individuals
rr'ho each stand to bene fit fronr nredical treatnrerrt. If each acted in their orvn illterests each
s,oulcl sc.ek all hcaltli care fronr s'hich they expect to bcnefit (assuming no tinre or other
costs). Assurrrc patient A stands to gairr one )'car of lil'e front the treatment and patient B
otre and a half ),sxp. trcattnents are nrutually ex c ltrsivc and tltat there are sufficient resources
to provicle trcatntcnl to olle but not troth patients. E,ach individual (without information
about the othcr) rroulil choose treatn'lcnt for thcntselves. However an irrdependent
adjurJicator actirrg on belialf of society (principal agent) and having knorvledge of both
patients nrav allocate treatnlent to thc paticrrt *'itlt thc greatest potential beneht (with
respect to changes in health relatcrl quality of life). This conflict is mirrored in the
lY Guy Scott (2001)
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pcrspectives of policy nrakers (society or budget perspective where patients are not
individually knon,n to thenr) \'ersus clinicians (u'lrere individual patients are known to
therrr).
A sinrilar parado.r relating to individual values and social choice is ernbodied in Arrow's
( 195 I ) inrpossibility theorem, whiclr says that urrder a rrumber of plausible.assunrptions no
aggregation procedure exists that lvill always result in collective choices that are consistent
with choices of the individuals nraking up the group concerned. This implies that (even if
each individual's preferences were known) it may not be possible to ag$egate individual
preferences into a meaningful societal measure.
3.2 WAYS OF VALUING CHANGES IN HEALTH OUTCOMES
Because of the difficulties in measuring chirngc.s in health related outcomes a number of
evaluation techniques have developed, As each of these economic analysis rnethods copes
with the quantification of health outcomes in diflerent ways. With cost-benefit analysis,
both changcs in rcsource usage and in health outconles are measured in dollars. As cost-
effectiveness rncasures the costs in dollars and the health outcome in physical units, it
avoids some of the valuation difficulties, In cost-ntility analysis, costs are measured in
dollars and health outcomes in a utility measure (see section 3.3 Health Indices).
3.2. I Cost-benefit Analvsis
Mauy costs llncl bcnehts arc lroL tracied on nrarkets, and everl rvhere markets exist, market
tailurc nla\: lrcnn thrt prices do rrot providc accurate societal values. In cost-benefit
analysis (C8.4) l lrunrber of rl,.-thods have lrc'cn uscd to assign money values for non
rrrlrkct goorls und scn'ices ancl cstatrlislr non nrlrkct or sltadorv prices. These tcchniques fall
il'lto t\\o rnlrirr groups, tlrat is, non-clcrllnd cun'e or denrand curve methods, and maybe
Irrrthcrclassifictllsshorr'ninFigureS. l((Turncretal., 1994: 115,8ox8.3)providedsome
of the Lrasic icleas for this diaeranr).
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Figurc 3.1: \'aluation of Non-l\larket Goods and Services
Monev Valuation Melhods
Non-market Valuation IlIethods
Although non-denrand curve nrethods are more relevant to environmental economics they
will be briefly discr.rssed. Health economics and environmental economics have many
sinrilar problcnrs and both disciplines can learn from each other. Health economics can
apply the expcrience gained irr cost-benefit analyses of the environment, while
environnrental economists may profit fronr experience with cost-effectiveness and cost-
utility analyses in health. Non-denrand curve niethods discussed are; replacement cost,
opportunity cost and the cost of mitigating adverse effects.
Replucentent Cost for Vuluing Health Iircilities
Tlrc rcpllccnlcnt cost nretlrod considers the cost of replacing or restoring assets that will be
darlagcd bv the projcct be ing inrplcnrentcd. Upgrading hospital facilities could nccessitate
dcstruction or loss of clr parkrng spacc u hich cotrld lrc rcplaced by a parking building. The
loss of thc eristirrg parking space *oulcl be nrcasured by the cost of constructing a parking
lruilding to providc thc s;:rtrc nunrbcr of llarking spaces.
l. ReplacemenU Restoration Cosl
2. 0pportunily Cost of Not lmplementing
3. 0pportunity Cost of Activities Displaced
4. Cost of Mitigating Adverse Effects
l. Hedonic Pricrng
and
2. Travel cost
Not True Welfare Measures
But Still Usetul
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Oppot'turtit.r'Cosl
Opportunity costs of not undertaking the project irrvolve estimating the benefits of the
project to detenline the nragnitude of conrpensation for costs imposed on others. The
building of a hospital nray inrpose negative externalities of noise and dust on adjacent
homes and businesses and potential compensation costs could be calculated. Altematively
the value of the project nray be evaluated by considering the opportunity costs of the
activities displaced. Building a new hospital nray result in the closure of a lactory and
opportunity cost of earnings foregone to society could be assessed by estintating the value
of the lost factory output.
Miligutirrg Behaviour
Mitigating behaviour relates to activities dcsigned to mitigate damage or costs imposed by
the programnre. An exanrple of niitigating behaviour would be the installation of sound
insulation in housing adjacent to a city anrbulance base.
Demand Curve Methods
Demand cun,e evaluation methods are discussed in more detail as they have direct
relevance to public policy issues in health. Thcsc rnethods attempt to measure willingness
to pay lor a goocl or service. The econonric basis is that the total willingness to pay (WTP)
for a healtlr outconte is the purchase price (P) nruhiplied by the amount purchased (Q) plus
the consunrcr surplus (s). wTP : P x Q + S (Dasgupra and Pearce, 1980: 45). The idea
behind tlrc consunrcr surplus approach is thirt sorllc consunlers would have been prepared
to ply nrore tharr lhc nrarket price to obtain tlrc goocl. These consun'lers' preferences are
nrcasurcd bi' thc trianglc "S" (if thL- dcnrand cun'e is lirrear) denoted by tl're area under the
rle'nurrrd cru..,'L- anti above- thc nrarkct pricc (Figure 3.2). This assumes that it is a
conrpctitile nrlrket n ith rro extenralitics. Figure- 3.2 illustrates total consumer surplus but
it is rhc chnnge in consuntcr surplus irrducerJ b1'thc project that is more relevant to health
prograrlrrlrcs.
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Figure 3.2: Consuntcr Surplus
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Expressed (Srated) Preference Or Contingeilt Vuluation
Expressed (stated) preference or contingent valuation methods use marketing research
techniques to measure willingness to pay for the good or service in question (or some
related good or service), The willingness to pay nteasure so derived is based on preferences
expressed in hypothetical surveys not on actual decisions made. Many economics studies
have utilised these techniques, but the validity of their apptication to valuing health
outcomes is not universally accepted because the relationship between hypothetical
paynlents and actual moi)ey payments is unclear (Johannesson, 1996). There is a
consicierablc body of literature ( for exanrplc, Zikntund, 2000 and Sekaran, I 992) on survey
nrethods applied to social sciences arrd business research but this will not be reviewed.
Altlrough ir is not tlre purpose of this chapter to cliscuss the ntultitude of rvays in which
corrtirrgcrrt valuatiorr questioris coultl br- cotrstructccl, adntinistered, and analysed, one
criilrplc sill bc n1cl1tioned, Johannesson (1996: 92) describes the use of contingent
r.alyatiorr rvitlr respect ro drug tlrerapy for hypertcnsion. A mail-out survey was conducted'
Contingept yaluation rvas used to estinrate horv much patients would be prepared to pay out
of pocket for their treatment. The rr,illingness to pay question was worded as fbllows:
"Would you choose to continue your treatment for high blood pressure if
(,
CJ
A
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your fees for treatnrent $'cre SEK 500 pcr nionth?
YES, DEFINITELY
YES, PROBABLY
NO, PROBABLY NOT
NO, DEFINITELY NOT
DON'T KNOW''
The bid was varied between SEK 50 and SEK 1500 in l5 subsamples to generate data that
could be used to define a demand curve. Regression analysis (explanatory variables
included gender, age, income, education and household size) was used to estimate a
demand curve.
Rcvealed Prcference
Revealed preference nrethods evatuate rvillingncss to pay by observing actual choices
concerningrisktohealthorlife, Intheireverydayactivitiespeoplemakedecisionsandtake
actions that influence the probability of their dyrng, having an accident, or falling ill. The
additional cost of purchasing and driving a large car compared with a small car will lower
the probability of the driver being seriously injured in an accident. A low animal fat diet
is generally colrsidered to reduce cardio-vascular disease risk factors but may cost more
than a diet high in saturated fats. Protective clothing costs more than everyday street-wear.
Additional remuneration nrust be paid to induce workers to do a risky job. In making these
choices, consun'lcrs and enrployees irrrplicitly'reveal their preferences (subject to income
constrairrts and inrpcrfect nrarkets). T*'o techrriqucs arc used in economics, they are, the
travcl cost ancl hetlorric pricing nretlrods. ln applying these methods, an implicit assumption
is pcrfect irrfonnation and "rationll" behaviour. Data should also be collected on factors
suclr as incornc. gendcr, education and age as thcse rvill also itrfluence the decisions.
Trar.r--l costs havc bccn uscd to definl' the dernand curve for (and hence the value of)
recrcational assets such as lakes or forests. This involves estimating the cost of visiting
the sitc by asking visitors how far they have travelled. To rny knowledge this method has
not been applied to health care but coulil be used to measure some of the benehts of
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nraintaining a rural hospital.
Hedonic or inrplicit pricing involves econometric or slatistical techniques to estimate price
or rvage/ risk trade-offs. Hedonic pricing equations could be used to assess willingness to
pay to avoid risk of death or injury fronr fire by purchasing a smoke detector. The demand
curve (the maximum rvillingness to pay) for safety from the purchase of safety products
could be evaluated by observing the difference in willingness to pay over a sample of
individuals. Johannesson ( 1996) describes the use of hedonic pricing in wage-risk studies
and consumer evaluations of safety. In New Zealand the value of a statistical life has been
estimated for transport decision making (Miller and Guria, l99l) (See Chapter 4: Costs
section 4.3.2: Indirect Costs), Although hedonic pricing analysis is not commonly used,
it could be applied to a rvide range of health care interventions.
Conclusiott
Although these techniques have not been widely used in health economics, contingent
valuation ntethods are likely to be used more lrequently in the future as experience and
knowledge of nrethods used in other branches oI economics, marketing and business is
transfened to health.
3.2.2 Cost-Effectiveness and Cost-Utilitv Analvsis
These melhods are discussed in greater detail in Chapter 6'. Economic Evaluotion.
C os t - Ef[e c tr ycless .4nal.t sr.s (C E A )
Cost-cflcctilcness anall'sis avoids allocating rrrorrctary values to outcomes but if there is
nrorcthanonelrcalthrclatedoutconreoIintercstthisnrethodbecomesdifficulttouse. [f
a sirrgle nrcasure coulcl [re uscd for all healtlr relatcd outcomes, it would then be possible
to relate resourcL'costs to this nreasure. This u'ould involve first identifying, then
quantilying and rveiglrting each outcome indicator to derive a single number to describe and
quantify the health related state.
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Cost - u t i I i t.t' A n u l.t'.s i s (C U/)
Cost-utility analysis relates cost to oulcontes measured by a HRQOL indicator, Utility as
used irt CUA is not necessarily the utility as understood by economists. Utility (as used in
CUA) refers to the preferences individuals or society have for a specified set of health
outcomes or health state. Drumnrond et al. (1987: l5) provide an elegant example
demonstrating that a health outconre is different lrom the utility of a health outcome. Two
twins identical in every way except that one is a sign painter and the other a translator. If
they were asked to rank having a clinically identical broken arrn on a health utility scale of
0 (dead) to I (perfect health) their rankings may well differ because arm use may affect their
occupatiolts d i fl erently.
3.3 HEALTH INDICES
3.3.1 Health Indices as a Subset of Social Indicators
According to Culyer et al. (1972) social indicators are needed to measure the output of
social policies and to indicate how that output could be increased. In this context, health
indices are a subset of social indicators. Culyer classihes health indicators as: state-of-
health, need-for-health and effectiveness indicators. State of health indicators are used to
quantify the output ol'a programnle or policy. Need for health indicators attach social
values to these outputs and thus allorv judgenrents to be nrade as to the social desirability
of increasirrg or dccrcasing this output. Eflectivenu'ss indicators nreasure how effective the
policy hirs bcen at dclivering health care . Table 3. t Iists the type of indicator and the task
it has to perfonrr.
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Table 3.1: Health Indicator Tasks and T1'pes
Task Indicator
. Mcasure quantity of outpLrt ol' . State of health
health policies
. Provide social valuations on thc . Need for health
outpllts of hcalth policies
. Measure tlre technical possibility . Effectiveness
of increasing output
The first documented use of a health index applied to hospital management is attributed to
Florence Nightingale in 1863. She considered the outcome of hospital care should be
classified "dead, relieved or unrelieved" (Rosser, 1983:52). Rosser notes that "this
prinritive classificatiort is a little more sophisticated than those in routine use in our
hospitals today!"
3.3.2 Objectives of Health Indices
The objective o[ health indices or indicators is to quantify health status of a dehned
population group, or an individual rvith a specific disease. Health indices may be used to
track health trends over time, for international comparisons, to investigate determinants of
health status, or to provide infonnation for resource allocation.
Time series analysis of health status is a vital check on theeffectiveness of programmes
suclt as control of inhctious diseases. If the notillcations of water bome disease increased
it cotrld inclicltc- a lailure of u'atcr treatmr:-nt nrethocls. Corrrparisons of disease incidence
itt ir*crv Zclliurd rr ith sinrilar 1:opulltions in othcr countries can indicate horv effective New
Zr'alattd prcr c-ntit-ltt artd trr'atnre nt prttgranlles contplrrc u.ith those in other countries or
thcy could indiclte difl-crences in causal lactors. Witlrirr Ncrv Zealand, knowledge of health
irtdicrtors rcllting to difl"ererrt populatiorrs (defincd by geographic location, ethnicity, age,
tr'ltdr-'r or socioccorrortric rneasures) could providc a nlealts of allocating health resources
ac'cordins to assessetl nc"ed. Reliable health irrdices rvould thus facilitate public policy
forrrrulatiort, evaluation and monitorirrg. Uhdc, 1983: 1 l0 - I I I comments on the need for
such indices.
l{ Guy Scott (2001)
Chapter 3: l'aluing Hcalth Outcomes
3.3.3 \'alidated Instruments
McDorvcll anci Nervell (1996: 8-9) proviclc a useful checklist of questions to ask when
evaluating a health related quality of lite instntntcnt or method.
. Is the ntcthod suitable fior the intended use and target population?
. Is the mcthod broad enough to capture health changes?
. What is the underlying concept and is the theoretical basis valid and well
established?
. Will there be problems with administration? How longwill thequestionnaire take?
ls the data readily available? What will it cost?
. How can the scoring method be statistically analysed and interpreted?
. What degree of change can be detected, that is, how sensitive is the instruntent?
. Horv strong is the evidence for reliability and validity? How many other
instrunrents has it been compared against?
Bulpitt (1997:616) lrns 6 recomnrendations for using quality of life as a outcome
measurc,"Thc pteasure ntust be relevapt, scientifically sound, have been extensively tried
and testc'd, and include a profile and a sumnlary statistic." These questions and
recommendations nrake a usefut checklist and illustrate the need for careful selection of an
appropriatc index at tlte planning stage of a project.
Policy ntakers rreed to be au,are tlrat considerable effort is needed to test an instrument for
re liability. responsiveless ancl I'alidity. The EuroQol has taken decades to develop and is
still eyolying. It is usually clifllcult to justify the cost of inventing and validating a new
ilclex lbr a spccilied stu{y rvhcn ilrterlationally validated instrunrents cxist. Using a
i.llitlatc-tl incL-s in conlnoll usc also facilitatc-s the comparison of findings rvith other
st ttd ic's.
3.3.-l (lllssification of Healtlt Indices
T5erc are a \,asr and grol,ing number of health indices and as these indices are continually
evolving, only a ferv selected examples only $'ill be discussed' The purpose of this brief
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rcvies'is to higlrlight sonrr-. con'ulotr ferturcs, arrcl applications of such in indices.
Healtlr ipciiccs refcr to a u'idc raltge of indicators ol'health status ranging lront general
nleasurcs such as nrortality and nrorbidity to health related quality of life indices (Hansen,
1991). These nray be broadly classified as either general or health related quality of life
nleasures.
Three classifications are i1 common use; functional, descriptive and methodological
(McDowell and Newell, 1996: l2). The functional classification describes lrow the index
is used, the descriptive classification is based upon the scope of the index, while
methodological classihcations consider technical aspects of the index.
The descriptive classificatiot'l of lrcalth indices presented in Figure 3.3 is for illustrative
purposes, other authors ntay use different classifications.
Each of these types of index rvill bc briellydiscussed in the following sections.
3.3.5 Henlth Rehted Qualitl' of Life Indices
Quality of lite (QOL), health relatcd quality ol'lilb (HRQOL), functional status and health
sti.rtus are frcqueptly usecl interchangcably. Sonte (phannaceutical researchcrs) refer to
qgalitl,of lir as "outconrcs rcscarch" (Srronr iitrd Mclmon, 1994: 450). Parr of this
conlirsir.rr h;rs occtrn'ecJ bccause lrr.alth indices ltale been developed by a number of
di flercnt disciplirtcs.
Attholgh eOL and HRQOL arc often used intcrchangeably they refer to different concepts'
euality of life indicators encontpass all physical, social and emotional aspects (including
Figure 3.3: Descriptive Classification of Health Indices
Health Related Quality of Life lndices
Specific/ Functional
Global Index/ UtilitY ScoreHealth Profile
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itcn:s suclr as housing, educirtion, job satisfactiorr and the environment) oIan individual's
w'ell-being. Hcalth rclatcd cluality of lifc (llRQOL or HRQL) indicators e.xcludc dornains
that arc unlikely to bc influcnced [ry,health status. However this distinction is not always
relevartl. for cxanrple, Guyatt et al. ( 1993: 622) comnrent "Clinicians focus on HRQL,
altlrough *'hen a patient is ill or diseased, alnrost all aspects of life can become health
related."
Bulpitt (1997:614) provides a listing of ".., a rough current consensus on what should be
included under the heading of qualityof life and those areas that are usually not
considered...". As this catalogue is a good illustration of the scope of health related
quafityof lifeithasbeenreproducedasTable3.2(Bulpitt,1997:614). Thehealthrelated
quality of life donrains of irrl.erest have been assembled into three goups; areas that should
be assessed, areas that are not usually nreasured because they are stable in the short term,
and those considercd too difficult to quantify.
Table 3.2: Quality of Life
Areus to he ussessecl
. physical rvell-being nreasured by absence of symptomatic complaints: to include
pain, system functioning (eg, respiratory, digestive, neurological) sleep, sexual
functioning
. psychotogical well being: to include depression, anxiety, cognitive functioning
. activitics: to include rvork, leisure, social functioning, fulfilment of roles (eg,
rnother. carer, etc)
Art,us ttsuull.t'ut'oidcd orllrrg to lov'proluhilit.t of chunge in llte shorl lernr
. financiirl sccurity
. nllrritirl status
a
a
fi-c'edortt
pc-rsonirlity
itrcus tltought to lta di.f.ficult to eutluute
. hupl'lirrcss
. ar'trbitit-rrr. expectation
. aggrcssion. crirninal activitics
. bttrdctt
. rc'ligiotts cxpcrience, shanre
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Itenrs assesscd \\'crc; plrysical s'ell-being (pain, systenr functioning, sleep, sexual
functioning), psyclrological *'ell-be'itrg (dcpression, anxiety, cognitive functioning), and
activities (for exanrple, work, lcisure, social functiorring). These areas are inrportant
indicators of health related qualitl,of life.
Areas usually avoided because they are not expecled to change greatly in the short term
included; financial security, nrarital status, freedonr and personality. This does not
necessarily mean that they have a low correlation with health status, but simply that they
are relatively stable over the short ternr. The third group of factors included the following;
happiness, ambition, expectation, aggression, criminal activities, a burden to others,
religious experience and shame. These are important dimensions of quality of life but are
considered too difficult to evaluate.
Trvo approaches to quality of life assessmenl are used. Generic/ multi-attribute
instruments provide a sumntary oi HRQOL (Guyatt et al., 1993). Specific/ functional
instrunrents focus on problerns associated rvith single diseases, patient groups,
functiorrality or syntptonrs. Each type of instrurrrerrt has its strengths and weaknesses and
n'ray be suitable in differcnt situations.
It is often desirable to use both a disease specific and a generic instrument in combination
so that ( I ) treatment options for specific diseases may be compared and (2) utilityevaluated
across disease states. The EuroQol Group ( 1996: 2) comment that the EuroQol (a generic
instrumcnt) cornplernents conditiorr specific nreasures. Bulpitt (1996) irr comparing the
perfonrrance of gerrc'ric or disense specilic iustnrrnents, notes that, wltett considering a
particular discasc, a spccific irrslrunrent is likely to be more sensitive than a generic index'
Funhr--nlorc Rulpitt (1996: 613) nrlkcs a sinrillr point in recomntending tlrat "-..both a
hcllth prohlc antl u sunturary statistic suclr as a l-lcirlth Status Index should be measured".
Thc global indcx rvill nreasure differenccs in healtlt relatcd quality of life while the profile
u'ill provicic cletail on horv and s,hy' health related quality of life has changed. "The
cliriir'ian and researcher require to sce precisely thc areas of quality of life that are affected,
while thc policl'-rrraker is interested in the cost-effectiveness of the treatment in
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standardiscd uttits." Bulpitt (1996: 6l6). A lreallh status index is a global index using the
tenrrinology in this chapter.
Specifi c/ Functional Indices
These indices focus on specific diseases or disabilities and are used to nreasure health
related quality of Iife changes brought about by health interventions for specific diseases.
Specific indices are more responsive in detecting health related quality of life changes
brought about by treating specific conditions. As they are useful in evaluating alternative
treatments for specific diseases but not for making comparisons across disease states, they
are often used in conjunction with generic measures.
These instntments will not be discussed in detail as they may be viewed as a subset of
generic indices. However, a selected number are listed sinrply to illustrate the range of
specific aspects of health or disease covered.
The 5-Year Survival Rate is concemed rvith survival and cancer, Symptom Free Days
describes disease syntptoms, tlre Functional Living Index-Cancer (FLIC) focuses on quality
of life in relatiorr to every day Iiving oficancer patients, the New York Heart Association
Classification considers various levels of severity of heart disease, the Profile of Mood
States (POMS) is used in mental health, and the McGill Pain Questionnaire (MPQ)
provides a nleatls of quantifying body pain.
Arthritis Intpucl lllcusrtrentell Scrr/c,s: Thcse scales have been isolated for more detailed
disctrssiott to shorv horv this class of indiccs nray be used. The Arthritis Impact
Ivleasttrctttcnt Scules (AIMS) (NIcDo*'ell and Nervell, 1996) is specific to arthritis
s\tttptortts. Tltcs,-. scalr's nlc.lsure plrl'sical, soci:rl. arrtl erlotional well-being and focus on
tltc. outcotttc of citrc for artlrritis llilticrlts. Most of thc questions relate to experiences over
thL'lilst lttonth. tltc irtslrrtrrte'rrt is sclf rdnrinistc'rcd ancl can be completed in l5 minutes.
ll Guy scott (2001)
Economic Evaluation Applied ro Health Polic]'In New zearand 6l
The specific dorttaitrs covered by tlre Arthritis Intpact Measurement Scales are:
Donrain
. Mobility*
' Physical activity*
. Dexterity*
. Household activity*
. Social activity
. Activity of daily Iiving
Nunrber of itenrs per domairr
4
5
5
7
4
4
. Pain* 4
. Depression* 6
. Anxiety 6
A total health score may be obtained by adding the values from 6 of the domains, that
is, mobility, physical and household activities, dexterity, pain, and depression (marked
with an *).
The arthritis impact nteasurement scales may be used to compare the effectiveness of
different artlritis treatntent nlethods and to track the severity of the disease in defined
patients. For example, a nerv analgesic could be tested against aspirin using the total score
fronr the arthritis impact scales as a measure of the elfectiveness of each medicine in each
patient group.
Generic/ l\Iulti-Attribute lndices
Gencric indices arc irttendcd to bc used across a nrultitude ol'disease states and patient
groups ttnd cover a number of health rclated quality of life donrains. A health related
quality of life dontain (also called a tiinrension, attribute or state) refers to an aspect of
health relateti quality of life, behaviour, experience or attribute that the analyst wishes to
quantify. Thcse indicators arc used in a varicty of different situations, for example, to
cottsidcr cltlnge s in healtlr stiltus across discase trpes, to evaluate health care interventions,
attd to contpare cltangcs irr lrcalth stirtes and cluality of life dimensions in defined
populatiorrs.
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Generic indices nray,be further brokerr dos'n into either health profiles or a global index,
and rvill bc discussed under thcse headings, Tlre health status index describes overall
quality of life n'hile thc health profilc focuses on lro*'and whyquality of life has changed
(Bulpitt, 1997). A global index nray indicate that a new arthritis nredicine is more
effectivc ovcrall in treating arthritis but if a cliniciarr rvanted to evaluate which aspect of
quality of lifb had changed then it would be necessary to consider the health profiles of the
patients, dimension by dimension.
Ilealth Prof les
Health profiles are questionnaires made up of a number of domains which are in turn
composed of a number of items or questions. No attempt is made to amalgamate the
scores from each donrain into a sumnlary score. Although they were not designed for use
in cost-utility analysis (becausc a single index nunrber is not possible) they are often used
in parallel rvith genc'ric indices.
Some of the earliest health profiles focussed on disability, scoring a nunrber of activities
(such as feeding, bathing. dressing and walking) by degrees of disability. Examples of
general health profiles are the Nottingham Health Profile, Short Form 36, Sickness lmpact
Profile and the General Heath Questionnaire (GHQ). It is not intended to discuss these in
any detail but as they have been rvidely used in clinical trials as measures of the
eflectiveness profile of a medical inten,ention arrd provide good examples of such profiles
they rr'ill be nrcntioned in brief.
Nottinghtttn IIt,tlth Prolilt-;Thc- Nottinghanr Health Profile was developed in tlie early
1980s arrd lras bccn used extensivcl),in thc Unitcci Kingdom. It rvas originallydesigned
lor usr. irr pritnary' rncclicnl care but has becn uscd irt sunrcys to assess need or dentand for
hcalth carc in dcfincd populations. Thc instnrnrent is self administered and focuses on the
rcsponderrt's subjectivc cvaluation of their hc'altlt state and takes between l0 and l5
nrinutcsloconrptete(lr'lcDorvellandNei'u'ell, 1996). Thisprohlehasparticularapplication
n itlr nrocleratc to scvere illness but is less sensitive in measuring quality of life in groups
rvith nrild illness severity (Arrderson ct al., 1996).
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TItc profile itr its refined fonrr consists o[ 6 healtlr donrains covering 38 itenrs:
. Ph,vsical rrrobility, 8 itenrs
. Pairr. 8 itenrs
. Slecp, 5 itenrs
. Energy, 3 itenrs
. Social isolation, 5 items
. Enrotional reactions, 9 itenrs
There are also 7 domains of I itenr each relatine to different activities:
. Paid employment
. Looking after the house
. Social life
. Honre life
. Sex life
. Hobbies and interests
. Holidays
Short Form 36 (Sf 3q:The second exanrple is the Short Form 36 health profile developed
in the US and contnrortly used in clinical trials as a measure of effectiveness (McDowell
and Nervell, 1996; Brazier 1995). The SF36 questionnaires have been adapted for use in
Nerv Zealand and Australia (Medical Outcomes Trust, 1994). The profile is constructed
from a sel f-adrni ni stered questionnaire.
Although the SF36 rvas not developed for econonric evaluation it is suitable for use with
cost-nrinitrisation uhere the health outcomes are identical. ln this case preference
s'cighting tvould rrot bc necessoD'br--ciluse all thirt is rcquired is a method of determining
if tlre outcorlrcs rrc thc sarrre betrvcen treatntcnt options. O'Brien et al, (1999) used the
SF36 in tltis l't1, tcr clrcck for difltrcnccs rn qualitl' ot'lilc bctvu'een two drug treatments for
thronttrosis s'hc'rr corrductiurr au cconontic evllrration.
Tlrc qtrestionnairc contains thirry'-sis itcrns tlrat cover the eight dimensions and is self
adnrinistered taking betrvcen 5 and l0 rninutes to complete. The scores from each
dinrension cannot be aggregated because no preference rveights have been developed.
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Horvever the instrunrent is being converted into a preference weighted instruntent (Tobias,
I 998). II'thc- transfornratiorr is successful the SF3(r could become a standard quality of life
rileasurc for cost-utilitv analvsis.
Eight health dirnensions are covered by thc SF36:
' Physical functioning
. Rolc limitations (physical pr:oblems)
. Pain
. General health perceptions
. Virality
. Social functioning
. Role lirnitrtions (emotional problems)
. Mcntal health
In addition there is a question related to changes in health status compared to a year ago,
but this is not counted in tlte scoring for the eight dimensions.
First, each itenr corrtained (within each dimension) is scored on a LikertT scale which has
a range of options. Itenr respoltses are then recorded on to an equal interval scale and scores
conrputed for each dimension. Dimensional scores range from I to 100 (worst health to
best health). Thcse dinrensional scorcs are not rlreasures of utility and are not aggregated
to provide an overall single score of health.
Glohul Inde.r Or Utiliry.Scorcs
Global ilrdiccs rvcight arrd aggregitte scores for each lrealth dinrension to produce a single
scorctodc.scribu'healthrelatedqualityoflifc. Althoughthescoretlpicallyrangesfromone
(lrc"1lthy,) tr) zct'o (tlead), tliere arc statcs considcred to be worse than dead, hence raising the
A Likerl scalc "A ntcasurc of attitudes ranging lrom very positive to very negative
ciesigned to allon, resporrderrts to indicate horv strongly they agree or disagree with
carefulll'constructecl statentcrlts re lating to an attitudinal object." (Zikmund,2000:
GL-8)
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possibilityof ncgative values. Thc eristcncc of states worse than death is suppo(ed by
Rossc'r arrd Kind ( I 978: 348) *'ho notc' tl'rc occurrcncc of suicide, requests to u'ithdraw from
lifc saving proccdrrrc's, and thc euth..urlsia debatc as cvidence of states \\'orsc tlran death.
In constructing health irrdiccs all aspccts (donrains) of health must be addressed and each
nrust be measured. Then each of these domains rnust be weighted to derive one number.
Common steps in constructing a global index are as follows;
. choose the health related quality of life domains and the items within these
domains,
. describe the health related quality of life domains and devise a way of quantifying
them, and
. select or devise a weighting method to errable the domains to be aggregated into a
single sumn'tary score.
The donrains lnust be capable of describing the aspects of health related quality of life of
relevance to the intended use of the instrument. Tlre method of quantifying them must be
capable of identilying differemces across populations and disease states. The weighting
method should reflect the values and preferenccs of consumers of health care.
In practice there are trvo methods of assigning preference weights to health states (Gold et
al., 1996). lndividuals may be asked questions to enable the researcher to locate their
health state on a c lassification nratrix corrtaining preference rveights. The EuroQol uses this
ntethod. The sccorrd rvay is to enrploy techniques such as the standard gamble or time
tradc-off to havc patients rate their healtlr state directly on to a scale suclt as I : perfect
healthto0=clcad.
Trvo cxanrplcs onl1, *'ill be discussed in detail. the Er-rroQol because it is in common use
and the Rosscr irrtlex lor historical rcasorls.
EuroQol: An exanrple of a global or gcrreric index is the EuroQol (The EuroQol Group
199(r). Tlris indc-x has been validatecl in a nunrberof countries and provides information
that is useful for both clinical and ecorronric evaluation, EuroQol complements condition-
lf Guy Scott (2001)
Chapter 3: )laluing Health Outcomes
specific tllcastrres. Originally the EuroQol had si.r health dintensions or donrains, but the
latcsl versiorr, EQ-5D, ltas fir'c donrnins. 'l'lre EQ-5D questionnaire has 2 parts, part I is
a 5 dirrrensional ltcaltlt state classification lnd parl 2 a visual analogue scale in thc fbrm of
a thernronreter.
The 5 dintensiorts (earlier version 6 donrains) evaluated in part I are as follows:
. Mobility
. Self-care
. Main activity
. Family/ leisure activity
. Pain/ disconrfort
. Anxiety, depression
66
)combined to'Usual activities' (EQ-5D)
)
Each of thcse donrains has one itenr u'ith 3 le'cls of severitv:
' No problerrr
. Sonre or nroderate problem/s
. Urrable or extrentc problenr
In the second part of the questionnaire respondents are asked to indicate their current health
state by use of a scale (like a thernrometer) nrruring lrom 0 "worst imaginable health state"
to l00 "the best imaginable health state". The respondent marks a score on this 0 to 100
scale and the score is then converted to a decinral on a 0 to I scale.
The quc'sliottnrire is designed to be self-complcting either in a postal survey, in a clinic or
in face lo lace itrterviovs. Full instrrrctiorrs for respondents are enrbedded within the
questiorlnirircs. Conrllleting the instrunrent takes about 2 rrrinutes.
Infcrrrttatiott dc'r'ivcd frortr lhc. EQ-5D nrry[rt-- uscd in anumberof rvays. Responseson the
5 dirrtensions nta\'lrc prr'senle'd as profilL. or ils a rveighted index (using preferences
establishcd lrottt sun'eys) n'hile'the results flronr the analogue scale can be used to provide
a self-rated vtlue.
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Asaprof le the self reporlc'd hcalth stntcs are prescnted as % numbers ofpatients reporting
problenrs or rcportcd as a dinrension scores. For example, the case study Chapter l0:
Benign Prostrttic ll.t'pcrplusia could lrave evaluated health relatedquatityoflifebeforeand
after prostatectomy using EQ-5D. This rvould lrave provided information on the change
in quality of'life in addition to the change in cost.
The procedure to obtain a health profile based on EQ-5D is as follows:
' Have respondents place a tick in the box that best describes their health state for
each dimension, that is I tick per dimension
. Do this before and three months alter surgery
' Analyse by counting the ticks in each box of the questionnaires to obtain a total for
the survey before and after surgery.
. Present the results as tables and/ or graphs.
The examplc, Table 3.3, relating to changes in self reported health status by domain for
patients before aud after prostatectomy shows the differences in the proportion of patients
recording "any" problcms.
Table 3.3: EQ-SD as a Profile, Change in Health Status for Patients Before and
After Surgery
% of patients reporting "any" problems
Dinrensiorr Beiore surgery 3 months after surgery
Mobility
Self care
Usual activitl'
Pain,/ disconr forl
Arrrictyr
dcprcssion
30
t2
6t
2t)
25
lt
29
4l
l5
Thcse results could hai'e enabled clinical lnanagers to better evaluate resource allocation
options *'ith respect to a particular quality of liie dirnension or dimensions. For example
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if a clinical nranflger s'as particularly concentcd u'ith decreasing the nurnbers ol'elderly
paticttts u.'ho u'c-rc rcliant orr nursirrg staff- for carc, thc percentage of patients reporting
problertrs rvith "self care" rvould be an inrporlant corrsideration when conrparing treatment
options.
If the objective rvas to maxinrise utility (as measured by health related qualityof life a
single score) summarising utility would be of more use. A global index could also have
been calculated and this together with the cost data would have permitted a cost-utility
study to be undertaken to better evaluate cost-effectiveness of hospital expenditure.
Using EQ-5D as a global index involves the following steps:
. Have respondents place a tick in the box that best describes their health state for
each dinrension, that is, one tick per dinre'nsion
. Level I is recorded as l,level 2as2,level 3 as 3
. The questionnaire may then be coded as a 5 digit number, one digit for each
domain, the digits ranging between I and 3. A number such as 13221may result,
fronratickinbox I formobility,3 forsel[-care,2 forusualactivities,2forpain/
disconrfort and a tick in box I for anxiety arrd depression.
. Go to the table of scores and look up tlris number and convert it to a score, for
13221 the score is 0.28
. Conduct a sun/ey before arrd after surgery
. Annlyse all questionnaires in this way
. Calculate rllean scores for thc sun'ey beforc and after surgery
. Prescnt thc results as tables and/ or graphs.
The nrearr rvei-qhtcd score of respondenls nray have fallen from 0.29 before surgery to 0.15
after sunlery indrcatrng that trcatnrclrt was not strcccsshrl in improving quality of life.
Tlrc. "r/rcrnr ontt,lt't:'rnal,tre usc"d to lirst generatc a "tlrermonleter score" which is then used
in thc silnrc nranncr as the *'cighted score. Tlrc "thermometer" score for a patient before
surgcrl, nta1, halc been 0.55 and aftcr sltrgcly 0.65 indicating treatment was successful in
inrprovingqualityoflife. Scoresmaybeaveragedlorpopulationsunderinvestigation.The
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advantage of the thcrrrronrete'r scorc ovcr the s'eiglrted score is that it is easier and faster to
derive and calculate trut it lacks specificity'and prccision. The thermometer score may also
be used as a quick cross clrcck on the weightcd scores derived.
Figure 3.4: Indices Derived From the EuroQol
In summary, the EQ-5D nray be used in clinical trials as an effectiveness measure, for cost-
utility analysis at one tinre (prevalence or cross-section studies), or to compare changes in
health related outcomes over time (longitudinal or time-series). Figure 3.4 (The EuroQol
Group 1996) illustrates the different health related quality of life indices that can be derived
from the EQ-5D and "thermometer".
Rosscl Index: As the Rosser Index is a rvell-knorvn and pioneering example of a global
index it is discussed in nrore detail than the othel irrdices. The Rosser Index was developed
in South Londorr iu the early 1970's by Rosser and Watts (Rosser and Watts, 1972').
Initiallythe index describing statcs of illness was usecl in evaluating if hospital treatment
hacl inrprovetl patient's health status. Subsequently (Rosser and Kind, 1978) developed
a scale of s'cll-bcins fior nrore qeneral ttse.
Rosscr ancl \\'atts ( I 972) developed a nrethodology to nreasure the effectiveness ofltospital
treatn'lcl'lt by comparing disability ancl distress states of patients on admission and then at
discharge frorn hospital. The Rosser and Watts model used eight classes of disability
(ranging fronr (l) rro disability to (8) unconscious) combined with four levels of distress
Weiqhted index I
(Globalor
generic index)
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(ranging fronr (l) no distress to (4) scvcre). Classification was undertakerr byclinicians
sccingthepatients. Resultsrvercreporlc.dasanratrix(Sdisabilitystatesby4distressstates
rvith cells containing the percerrtnge of patients lalling within each cell). One nratrix
represented the rcsults on adnrission and the second nratrix the results on discharge. The
tw'o nratriccs \^:ere conrpared to dctenrrine the effcctiveness of hospital treattnent.
The authors stated tlrat the results rvould be of much greater interest if they could be scaled.
Rosser and Kind (1978) later developed a nrethod of assigning a score for each of the
health states as defined by the matrix. They derived a matrix of 29 "states of illness" by
cornbining the 8 states of "objective disability" with the 4 states of "subjective distress."
Their objective was to value each of these states according to subjects' perceived relative
degree o f undesirabi I i ty.
Rosser descriptions of illness and disability statcs are as follows:
l. No disability,
2. Slight social disability. (Slightly disabled but performance of normal work not
inrpaired.)
3. Severe social disability and/ or slight inrpainrrent of performance at work. Able to
do all houscwork except very heavy tasks.
4. Choiceofu'orkorperformanceatworkveryseverelylimited. Housewivesandold
people able to do light housework only, but able to go out shopping.
5. Unable to undertake any paid employment. Unable to continue any education. Old
people confined to home except for escorted outings and short walks and unable to
do shopping. Houservives able only to pcrlonrt a few simple tasks
6. Conllncd to cfiilir or to \\'l]celchlir or abl" to rilove around the ltotrse only with
suppoll lroril irrr assistant.
7. Cortllrtccl to bc-d.
8. Llrtconsciotts.
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Rosser distress ratirrss are:
A. No distrc'ss
B. Ivlild
C. Moderate
D. Severc
Rosser obtained values on a scale of 0 : death to I : good health, in a detailed interview
lasting between 1.5 and 4.5 hours. Psychonretric scaling, and magnitude estimation
nretlrods, rvere used to produce a set of valuations for each state. The sample was made up
of 70 subjects with different experiences of illness; l0 patients from medical wards, l0
psychiatric in-patients, l0 experienced state registered nurses, l0 experienced state
registered psychiatric nurses, 20 healthy volunteers and 10 experienced specialist doctors
having a nrenrbership or fellorvship in at least one Royal College. This original sample was
not a randorn selection from the general population.
The Research Group on the Managernent and Valuation of Health at the University of York
(Willianrs, 1995) applying a slightly different rnethodology used Rosser's descriptive
systenr and re-estimrated tlre valuation rveights by interviewing 140 nrembers of the general
public, Different *'eights rvere obtained and are rcported in Table 3.4. These re-estimated
weights should better reflect the values ol'the general public and society as a whole and
should accordingly be more appropriate for cost-utility analysis.
The best knon'n use of the Rosser index has bcen irr the calculation of qr.rality adjusted life
years (Qz\LYs). first clescribcd by Willianrs (1985) irr arr evaluation of coronary artery by-
pass surgery. Q.\LYS are cliscusse'cl irr grcater clctail latcr in this chapter. Rosser's index,
and thc applicirtiorr of it by \\'illianrs to calculate Qi\LYS had a nrajor irrpact on the
developrrrcnt of lrealtlr rclatcd qurlitl t-rl- lifc llleasurcs. As thc Rosser index has now been
ovcrtlkcn bl othc'r incliccs. dcrailcd aniilysis of the revised rveights compared with the
originll ri'cithts ri ill not bc' discussc-d.
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Table 3.,4: Rosscr l\lairir Revist'd \\'eights
Fixed poirtts: Hcalthy = I Dead = 0
Distrcss
BDisability
I
2
J
4
6
I
I
1.00
0.89
0.70
0.63
0.44
0.44
0.38
0.01
0.89
0.81
0.63
0.56
0.43
0.44
0.40
0.89
0.78
4.57
0.51
0.44
0.34
0.33
0.67
0.56
0.44
0.40
0.22
0.22
0.20
(QIVB) Qualit.t' of lVell-Being Scale (ormerl.t' the Index of lttell-Beirrgl: This scale
combines nrortality w'ith estimates of the quality ol'life among survivors. A " Well-Year"
is a year of conrpletely rvell lite. The QWB is broad in scope being the only instrument
considering nrorlality, s)mrptoms, and problents togetherwith functional levels (McDowell
and Neu'ell, 1996).
This index classifics patients by use of 3 donrains; niobility (3 itenrs) , physical activity (3
items) social activity (5 itenrs). The analyst also records the presence of syrnptoms or
problern corttplcxes (27 itenrs). Each itern has a preference weight that permits an
aggrt"'ga(cd scrrrc (o bc calculutc-d. l-hc overall scorcs range from one (complete rvell-being)
to zero (du-atlt). altlrough the scorirrg does perlrit values below zero to represent a state
\\'orse than dcatlr.
I[t'ulth L'tilirics Itttlc.r (l{Lll): This indcx tas dr'r'eloped by Torrance and colleagues at
Nlc\laster L:nii crsit)'Canadn ant.l hls been uscrt in economic evaluations, clinical trials and
population hL'altlr surve)'s. As it s,as bascd in part on QWB it is not discussed in detail.
Thc latest vcrsion of this index (HLll:3) has cight domains; vision, hearing, speech,
arrrbulation, dextcrity, emotion, cognition and pain. Each of these domains has five to six
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ln'els of severity (Gold et al., 199(r).
3.4 \/ALUING HEALTH STATES
Methods used to valuc or assign preferorce n,eights to health states have been derived from
expected-utility theory, and psychological scaling techniques (Gold et al., 1996: ll3).
Weights are usually reported as a number on a scale with two fixed anchor points 0 and I
(but negative values are pernritted).
3.4.1 Utility Methods
Utility describes the satislaction derived frbnr the consumption of a product or service. ln
the context of rrreasuring health outcomes, utility, preference, and value are frequently used
interchangeably. When refening to lrealth rc-lated quality of life; von Neumann-
Morgenstcnr utilities, health stiltus, functional slatus and health related quality of life are
used syronynrously in the literature (Gold ct al., 1996).
The trvo nrost conlrlronly applied utility methods are the standard gamble and time trade-
off. These procedures have evolved from economic utility theory. Economists favour the
standard garrrble nrelhod over the tinre trade-off method as it has stronger links to utility
theory (Gold et al., 1996: I l4), Neither method results in utility values as defined in the
economic literature. Utility values in this sense relate only to health related quality of life
rlot to the utility tlcrived fronr tlre corrsumption of any good or service.
A tlrird nlcthod in conrnron use is tlrc applicatiorr of psychological scaling. The three
rlethods ol'assigrrirrg prcfu'rcncr's to hcalth statcs 1n31, yield different results. Where the
tlrrcc tcclrnir'll.lcs hilvc bccn cornplred thc sLantlnrd glnrble scores are consistentlyhigher
thlrr scorcs fronr thc otlrcr trvo nictlrotls n'hich suggests that most respondents are risk
avcrse (Torlencc ct al., 1995: 506). Tlris nreans that the results of studies usingdifferent
scoring rlrcthods cannot be easily conrpared.
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Irr usirrg thcsc indices for policy evatuation the analyst ntakes an implicit assunrption that
individuals' utilities nray be aggregated to rcprescnt societies utility. Btrt this is not so
u'lrcn hcaltlr resources are linrited. see scction 3.1.3 and Weinstein et al. (1980: 230).
Standard gamble
An expected utility index was developed by von Neumann and Morgellstern. Baumol
( I 965) describes the construction of such an index by reference to a lottery. Two necessary
assunrptions in developing such a cardinal index are that consumers have consistent
preferences and nlake rational choices between various qualities of life and death.
But this is not necessarily so. For exanrple, the rule of rescue (Luce, 1994:269) assumes
that society rvill always favour life saving interventions over those that improve quality of
lite, This "nrte" is not necessarily rational and it implies that quality of life cannot be
traded off against dcath.
Baunrol ( I 965 ) describes the use of standard garnble technique in deriving utility values'
Hos,ever, in the example described and in health economics, utility indices for health
states are ntore conectly preference irr<lices ot'health. In valuing healtlr states the standard
ganrble is used to detemrine prelerences belweerl health states, but is not taken to the next
step of detenrrining a utility r,alue oIthc health state. In the context of health indices the
tenn utility is bein-e used interchangeably or instead of preference'
Thc standarrJ ganrble approach nray be applicd to health related outcome states as slrown
in Figurc 3.5
Tltc stcps irtrolvccl in valttittg any hclltlr statc arc as follo"vs:
. Frrsl. copstruct alt allillcial or sttrrrclard lottcry (lottery I ) witli two extreme prizes
full lrcllth H = I problbilitl'p, i.llt(l D tlr.'atlt = 0 probability l-p, This is often
refered to as a stanclrrcl garnble. The probability of winning prize H is p while the
probability of ,uvinning prize D is l-p. If p : I then the outcome is a healthy state
q'ith cer-tainty bur itp : g thcn t|e outcorne is death with certainty. The probability
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is rrot dcfincd and is allos'cd to vary.
' SL'cond. introduce an ordinary Iottery (lottc'ry 2) rvith prize i.
' The' probability p (that relates to n,inning both lotteries) is then varied until the
individual is indifferent between bulng a ticket in lottery I or lottery 2.
Figure 3.5: The Standard Gamble
Hr,'althy
(p)
d (D)
)
Lottery 2
Statc I
(p)
Lottcry I
/\/\/\(H) Dca
(t_p ;-t,
Probability (p) in lottery I is
altcred until there is
indifference between buf ng
ticket in either lottery I or
2. At this point the utility of
statc i is probability p.
The utility ofdifferent health states are
combined to fornr an indcx of health states.
Thc indcx is dcrivcd by this proccss
conductcd for each health state and
rcpeated over a sanrplc ofindividuals from
a dcfined population.
To calculate the utility of any particular outconte it is necessary to either observe or
intervierv respondents to determine the probability at which they are indifferent between
the two lotteries. If the standard lottery has a prize of perfect health with a utility l, or
death with a utility 0, theu the utility of any other lottery may be calculated by varying the
odds of u'inning until the gambler is indifferent between the two lotteries. It is usual, but
rtot csscrtlial, to use dc-ath:0 and perfcct health:l as fixed anchorpoints.
Time Trade-off
'forrcncc and others in 1992 devclclped the time trade-off method as a simple and
convcniclrt n'av to dcrivc scores that n.ould be conrparable to scores based on the standard
garnblc (Dnrnrnrond et al., 1997: I 5.1).
Tinrc trade-off asks subjects to trade-off an existing health state for a specified time period
follorved by death against a shorter tinre in a healthy state followed by death (Zweifel and
| & 2 arc rcpeated lor drffcrent
stltcs in lottcry 2, (Lottery' I
nged). ln this nranncr thc utility of
nt hcirlth stirtcs arc obtaincd.
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Breyer, 1997:46). Tinre trade-ol"f has its origins in clecision theory and as such has a strong
lollorving fi'onr de'cision analysts and opcrational researchers.
Figure 3.6 illustrates that being in health state H, for a time period T, is equivalent to being
in health state H, for a tinre period Tr. The procedure is equivalent to the situation
encountered in QALY analysis rvhere years spent in a health state of less than perfect health
are transformed into quality adjusted life years.
utility
per
penod
u (l-lr
u (FI2
Tr
(neaurmQ
76
T2
(no treafirnrt)
)€ars
Standarcl Ganrble Versus Timc Trade-off
Ziveifcl and Brel,er (1997: 48) conrntent that the standard gamble and time trade-off
nrelhods rvill not necessarily lead to tlte same result. Horvever, they also denronstrate that
if rcspondr,-nts c\pr'ctcd that total utility is a lincar furrctiorr of duration and utilityweights
of hr-alth statcs. tinrr-' traclc'-off antJ starrdard ganrblc rnethods give the same result. In
llractice tlrc trvo lnethods nray lcacl to dill-erent results, if for example, the health states are
not inteqlrctcd by nll resporrdcnts in tlrc sanre u'iiy. The standard gamble approachhas
theoretical support because of its links u'itlr von Neuman-Morgenstem utility theory.
Material to assist researche rs conduct standard ganrble and time trade-off trials to generate
Figure 3.6: Time Trade-off
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preference scores are available (Gude'x, 1994a: Gudex, 1994b). This nraterial is very
useful because it rrol only describcs horv to undertake such studies but also provides the
questionnaires ancl props nceded for cxecutiorr.
3.4.2 Ps1'chological Scaling
Although Williams (1995) provides sonre useful examples of the application of category
rating, pairwise conrparisons and nragnitude estirnation, these valuation methods will not
be discussed in detail as the focus of this study is economic.
Tlrere are three variants of category rating. Subjects are asked to score states by means of
an (i) analogue graphical scale or, a scries of (ii) numbered or (iii) labelled boxes with
descriptions of the quality of life/ health states. Responses may then be converted to a scale
ranging frorn 0 : worst inraginable health state to I the best imaginable health state,
Pairv,ise comparisons involve comparing various health states with each other while in
nrugnitude estimution subjects are required to judge each state in terms of severity against
a benchnrark of no disability and no distress. An cxanrple of the application of magnitude
rating is ttre Rosser index.
3.5 QUALITY ADJUSTED LIFE YEARS (QALYs or QUALYS)
The objcctive of QALYs measurentent is to obtain a single value that summarises all
relevant aspccts of healtlr rclatcd quality of life and conrbines this quality score with the
time spcnt in this hcalth statc. If QALYs arc aggregated for defined poptrlations or patient
groups lnd conrparcd n'ith nct intcrrcrrtion costs they rtray be used to conduct cost-utility
analvsis fr:r policy dccisiotts and clitrical ntattagctttcttt.
Tlrc idca trchind QALYs is that thc utility of a ycar of additional life with reduced health
is rrot as lrigh rs a ycar oi full health, Thut is, individuals would choose to trade-off a
lorrgcr life olrcduced health lor a shorlcr Iifc of supcrior health status. For example, two
ycarsof additional lifen'ithascorcol'0.5 isequivalcntto I yearofhealthylifewithascore
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of l. In both cases tlrere rvould be a gain of I QAL\'.
There is lack of agreenrent on horv to nrcasure and intcrpret QALYs. There are differences
of opinion on the scaling of health related quality otlife states and the weighting of these
states used in the QALY. QALYs rnay be interpreted in terms of individual utility, or
individual utility nray be side stepped and the QALY used directly as a measure of social
value (Nord, 1994).
QALYs may be calculated as follorvs:
. Categorise individuals into the appropriate Rosser category, for example, 2 patients
in cell 2A [score 0.89] and 4 in cell 5C [0.44] each patient spending one year in
that state.
. Multiply the numbers of patients in each cell by the appropriate Rosser score and
by the tirne spent in that state to obtain the number of QALYs, for example
2x0,89x1 = 1.78 and 4x0.44x1 = 1.76.
. QALY gains in future years should be discounted to present values.
. Add thc QALYs to obtain a total nunrber of QALYs for the treatment, for example,
I .78+ | .76 :3.54 or an average gain of 3.5416: 0.59 of QALYs.
In this exanrple Rosser categories and rveights \\'ere used to calculate QALYs, but a variety
of generic health indices may be used to define and rveight the health states. Of the scales
that provide estimates of QALYs, McDorvell and Nervell (1996) consider that the Quality
of Well-Being Scale (fonnerly the Inder of Well-Being (QWB) is the ntost widely used.
Hol'ever other autlrorities (Paul Kind, University of York, pcrsonal communication, July
l99S) considcr thc EuroQol (EQ5D) and the Hcaltlr utilities index (HUI) thetwo most
cornnronly' uscd irtrliccs.
Q.,\l-\'s rn:.ry'bc used to conrprre quality,of lifc gains from treatment across different
tliscirscs arrtl rvithin cliseascs by'usc of cost-utility'anllysis. Applicatiotr of a net resource
c(')st llcr Q.\LY providcs a nrc.tlrod of conrparing the trcatment cost with the health related
qualityolli[c gainccl lrom diflerent interventions w'ithin and across diseases. QALY league
tables result fronr the compilation of the data for these comparisons. Such league tables
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provide'a l'tlcans of cvaluating health carc treatnrorts rvith respect to resourcc allocation
decisiorrs n'itlrin thc hcalrh scctor.
Intplicit irt tlre QALY calculation is that factors other than those measured by the QALY
instnunetrt such as income, are held constatrt. Inconre is a confounding factor as income
levels are highly conelated rvith health and quality of life. This means that increasing
qualityof life could have occurred from factors other than the health care intervention being
assessed.
Comparing costs per QALY calculated in different studies is complicated by variations in
the:
a
a
a
Range of health related quality of life statcs included
Quarrtification and s'cighting of states
Range of costs included and valuatiorrs of those cost items.
The spread of health related quality of life states varies enormously between generic
instrurneltts, and different prcference rveiglrts rnean that all QALYs are not equal.
Including a different range of costs and measuring costs differently adds to the problems.
Thus, rvhen conrparing different studies that have used QALYs, it is important to check that
the satne generic instrument has been enrployed and that costs have been identified and
quantified in thc sanle nranner. Comparisons canrlot be made unless all costs and QALYs
are calculated in the sanre wav.
Gcrarcl altd lvloone1'( 1993) consider tlrat s'hcn calcullting the cost pcr QALY only those
costs l'alling on thc health sector should bc considcrcd. They argue that if a societal
pcrspcctivc is takcn costs should be valued in te rrls of all benefits foregone of rvhich health
rc-latccl bL-ltefits arc nrcrcly a subsct. This inrplics that QALYs can be used to evaluate
Itellth scctor r-csorrrcr- allocatiorrs n'itlr r fired hcalth budget but not to evaluate resource
itllocittitrrts across rll socictl,. Anothcr point is that if irrdircctcosts are included in costsand
if tltc health rclated quality of life includr-'s a dirnensiorr that relates to ability to work then
thcre *'ill bL'an elentent of double counting.
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A partial solutiort to the problenr of conrparability and the range of costs to include when
calculating co5t5 pr'p QALY nral,trc resolved as follows:
. Usc irtcrernental nct direct nrc'dical resourcc costs to calculate thc cost per QALY
for league tables, for decisiorrs relating to a health sector perspectivc.
. Use a rvider definition of costs if direct nredical and /or, indirect costs are inrportant
and the decision maker rvishes to consider a wider perspective.
Druntnrond (1997:268) notes that "...it has beconre fashionable..." to use QALY league
tables as an aid to prioritising resource allocations within a health budget. There are two
ways in rvhich they may be used. First, if a qualiflng price per QALY could be
established then all programmes that had a cost per QALY less than this price should be
implentented. Second, provided all relevant health care interventions have been ranked
in tenns olcost pcr QALY, then progralnrnes could be implemented sequentially until the
budget is exhausted.
A problenr rvith both tlrese approaches is that cost per QALY wilt differ between patient
sub groups bccause the characteristics of the individuals making up the group may differ.
Tlris nreans that a vast and potentially unmanageable number of defined populations by
inten'ention rvould need to be evaluated.
QALYs are not necessarily equivalent to utilities and it is not necessarily valid to sum
utilities or QALYs for different individuals or indeed for the same indtvrdual at different
tirrrcs. Econorrists generally agree tlrat il'a socir'tal perspective is adopted, health states
slrc'rultl tre valuc'd by rrrernbc.rs of the public. Horrcver, health stales are frequenLly scored
bi,diflcrcntgroupsofindii'iduulsonbchnlfofthel)aticntorpublic(Weirrsteinetal., 1980).
Q.\LYs lre inrplicitly'assunted to be equivalcnt ilcross all demographic groups. Health
Slltr'S nr0\' tr.-' r lrlur-d b1'hcalth proftssiorrals, plticnts u'ith the condition or ntembers of the
rtcrrcrirl putrlic. rtnti cach nrny providc clifferent prc-ference values. Hadorn and Uebersax
(1995: 608; rrotc-d that thc.re \\'As sonte eviderrcc tlrrt preferences for a specific health state
t1'lil1,1'r1'n' based on people's experience u'ith those states. Some authorities argue that as
thc general public do not lrar.e sufficicnt know'ledge, clinicians or nurses with a clear
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underslandirrg of the' diseases and hcalth stntes involved should do the scoring.
Accordingly, tt ltc-tt QALYs lronr individuals arc aggregated for policy decision ntaking
purltosr-s tltc prcfcrcnccs nra),not rcflcct those of socicty as a whole (Weinstein et al., I980:
230).
Policy analysts prefer to use increnrental data and utility nreasures that reflect societal
values. Cliniciarrs are not prinrarily concemed with costs and would probably prefer to use
changes in utility values that relate 1o the particular patient they are treating. Decision
makers should use inlormation that is either, already available, can be obtained in sufficient
tinte for the decision to be made, and at a cost that does not exceed the expected benefits
of the information. In practice this means that average cost and QALY data and utilities
measured in a varietyofways will probablybe used. This is not a serious or insurmountable
problem if CUA is used in parallel rvith other criteria as a guide for decision making, and
users understand horv the estimates have beerr derived.
Overthelifetinreofanindividualqualityoflifedoesnotremainconstant. Typically,health
relatedqualityoflifedeclinesuntil avalucof0isrcachedatdeath. Thenraximumvalue
may not be I (optinral health) and tlre nraxinrunr value may not be recorded at birth. If a
graph (Figurc 3,7) is plotted with health related qualityof life on the vertical axis and time
on the horizontal axis the area under the cun-e represents the number of quality adjusted
life years for that indir,idual.
Becnuse QALYs are calculated in the sanre nteurner for all ages two equity (and ethical)
issues arisc. First. the lifetinrc QALY gairrs arc qreater for interventions relating to the
)'oung rrthcr tlrlrr thc old, lavourirrg decisions that clirect resources to tlte young. As a
QALY cnconrpasscs both qualitv of'life and lengtlr of life, large quality of life gains in the
cldcrlv coulcl clorlinatc interventions thilt savc livcs but do little to improve quality of life.
Sccorrtl. tlris is cor.urtcr to tlrc nrlc ol'rcscur'(l-uce, 1994 269) that assumes society will
als uvs luvorrr lili' s.rr ing intcrvr.t'ttiolrs ovL-r thosc thlt inrprove quality of life.
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F[gu,re 3.71 Qu,alilv of Life Adjusted Years of
Life for an lndividual
Healtlr related qunlity of lifcI'
Heatthy year equivalents (HYE) is an altprna,tive to the QALY and has b.een debated
extensively in tlre literature (Drrurnnrond et al." 1997) bu! will not be diseussed in this
thesis,.
3.6 I\E}V ZEALAND INITIATIVES
3.6.1 Introduclion
Two New Zealand approaches to valuling outconrcs; the surgical priority scoring system
and the suggested Health Funding Authority healrh related quality of life instrument uritl
be briefly discussed.
3,5,2 Surglcal Prioriit-v Scoring SSstem
t1 u ,g,t,gical pr'iority sc,oring systefft w'as introduced to the New Zealand pubtie hospital
s)'flenl ro rr'placcr n,aiting lists w'itb a booking system as a rationing device. The generio
sr.ugicalpriorill'criteria (GSPC) rvere introduced firs,t into Afickland F{ospital inJune 1997-
Surgeons plaeing patient$ on wai'ting lists had to complrte a GSFC fonn.
Quality of life years
Duration of tife in years
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Thc scoring systcnr enconrpassed fir'e lrealth dinrcnsions; suffering, disability, clinical cost
ofdc'lay, dcgrec of ittrprovcnrcnt anticipaled ancl likclihood o[improventent. Tlre first three
dirtrensiorts dcscribc clinical sevcritl, and adcl to a nraxin'lum score of 20. The last two
dintensions (nraxintunt score of five) describe the capacity to benefit fronr the surgery. The
total score is found by rnultiplying thc score for clinical severity by the score for capacity
to benefit, hence a nraxinrum possiblc score for a patient is 100 (20*5:100).
This method, although crude, is theoretically better than the waiting list system it replaces
as it is transparent and attempts to conrbine clinical severity with capacity to benefit across
a range of surgical procedures. However, the final result may well be identical because the
sanle resources are available and decision makers who prioritised the waiting list will be
scoring patients for the booking systent.
Thc scoring s)'stenl can only bc applied to conditions requiring surgery and is not as
objective as it appcars. Experiencc in using a prioritisation scoring systenl specifically
designed for cataract surgery found lhat scores arvarded to the same subjects by different
clinicians varied as nruch as 26 points out of 100 points (Halliwell, 1998).
3.6.3 Health Funding Authority Health Related Quality of Life Instrument
The l{ealth Funding Authority (HFA) and the Phamraceutical Management Agency Ltd
(PHARMAC, a u'holly o*'ned subsidiary of the HFA that manages pharmaceutical
strbsidic's), are considering applying cost-utility analysis using QALYs. Each agency has
issur-'d discussiort papcrs (PHARMAC. 1998; Prioritisation Team, 1998). The focus of the
HFA papc'ris rrrore gerreral tharr PHARMAC's paper rvhicl'r is specific to drugs. As the
nrcthodologics prr'setrtcd in both of these papers are essentially the same, the HFA paper
hits bccrr chose'rr for rlore dctailed contrncnt.
Tltc llFA atlvocatc applying cost-utility arrall'sis to the evaluation of services with
"...aqsregate costs exceeding $l nrillion or rvith major social or political implications"
(Prioritisation Tcanr, Appendix A, 1998: 2). The stated goals of the paper were "... to
providc- a rigorous, explicit, ethical and transparent process based on an agrecd set of
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principles to gtride the setting of prioritic"s and resources." (Prioritisation Teanr, 1998: l0).
Fttrtltcr, this process was to relatc to "...prioritisation for publically lunded health and
disability sen'ices rvhich is applicable to all levels of the health system..." (prioritisation
Teanr, 1998: l).
The HFA acknorvledges the difficulties in defining health and heatth outcomes, reject the
WHO definition of health (and thus changes in health based on this measure) as being too
broad. They define "health gain" as "...improvements in suffering, limits on activities, and
life-expectancy produced by services or programmes for defined kinds of patients."
(Prioritisation Team, 1998: 6). Important considerations of the group were that
prioritisation should be explicit, transparent, and the public (to date the public have not
been involved) should be involved (prioritisation Team, 1998: 8-9).
The report recomtnends that five factors be considered when "...setting health care
priorities:
. Effectiveness
' Cost
. Equity
. Mdori lrealth
' Acceptability"(PrioritisationTeam, 1998:24)
A disturbing aspect (from a public policy viewpoint) of the HFA stated objectives is the
limitation of perspective to publically tunded services. If the HFA is an agent lor the New
Zealand govemnlent and iIgovenrment is an agent rcpreserrting the interests of its citizens
therr a societal perspectivc should bc taken.
Altlrouglr the criteria erlploycd to select a suitable generic health index (Table 3.5
ll'c'sct'ltr..d n itlrout conrnrcnt) rcprcsent an acceptable rvay of selecting and designing a
-qcrtL-ric lt.'altlr rclatcd elualityof lil'c irrstrunrcnt, tlre IIFA do notexplain in anydetailhow
thcir sr'lcctc.d instrunrent rneets these criteria.
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Table 3.5: Health Funding Authoritv Selection Criteria for A Generic Health
Related Quality of Life Instrument
"ln selecting a generic health stale nreasurc, a nunrber of a priori features can be
considered necessary to nleet the HFA's needs for prioritising services, including:
l. a manageable nunrber of nrutually exclusive, collectively exhaustive health
states;
2. the dimensions tneasured nrust be relevant to aspects of life that health services
can be expected to inrprove;
3. low interdependence/ correlation between dimensions to prevent double counting
and unnecessary conlplexity;
4. sensitivity to change within dinrensions;
5. health states calibrated by ernpirically-dcrivcd values;
6. use of socielal pre ferences to enrpirically dcrive health states' r'alues;
7. respoltse ntethods (ie lrorv values/preferences are elicited) are conceptually
robust,preferablyusingchoice-basednrethodsratherthandirectscaling. Choice-
based methods include paired conrparison, time trade-off and person trade-off
approaches;
8. response methods are intuitive, easily understandable by the average citizen.
This conrprises pairwise comparison and direct scaling rating methods;
9. face validity, i.e. results ntust scem to be intuitively plausible;
10. good construct validity (both convergent and discriminant validity), ie the
nteasure "behaves" as it is expected or hypothesised to behave with respect to
othernrcasures. Constructvalidityshouldbedemonstratedbyacceptedmethods
such as thc nrultitrait nrultirrrethod (MTMM) technique or Cronbach's alpha; )
I l. good intcr-ratcr and test-rctest reliability;
12. sinrplicitl, of use (feasibility); and
13. use and acceptance elservherr-, as an indicator both of reliability/validity and to
airJ artv corlparison s'itlr otlrc'r health s1'sten1s."
(Prioritisalion J'L-mr, 1998 Appendir A: 6),
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Thc proposed health relatcd quality of life instnrnrent consists of 2 domains; "suffering
(physicalandiorpsychological)"arrd"linritstoirrdepcndentdailyactivities". Eachofthese
dorttaitts has I itenr *'ith I I levels of severity (rangirrg from 0 to l0). This instrument is
based on the Quality of Life and Health Questionnaire (QLHQ) developed by Hadom and
Uebersax (Hadonr and Uebersax, 1995).
Hadorn and Uebersax wished to develop ".,.a standard, very briefl generic quality-of-life
questionnaire that is calibrated according to empirically derived public preferences."
(Hadorn and Uebersax, 1995: 608), The questionnaire tested consisted of three domains;
physical suffering, entotional/ outlook on life, and daily activities each with 4 levels of
severity; none, mild, nroderate and severe. In addition, participants were asked to score
their overall quality of life on a numeric scale from 0, worst possible quality-of-life to 10,
best possible qual i ty.of- li fc.
The HFA have used the Hadorn and Uebersax questionnaire and collapsed the three
domains into 2 and expanded the levels of severity from 4 to I l. The HFA paper does not
ntake it clear horv these nrodified scores fronr the Quality of Life and Health Questionnaire
rvere developed.
PHARMAC ( I 998 ) advocated using the same dinrensions or domains but instead of scoring
levels of severity on a 0 to l0 scale they propose using a 4level scale. The preference
ratings for this itrstrunrent are described in Table 3.6.
The Ll FA (and PH ARNIACs rrrodificatiorr) sche-nrc has thc attributes of simplicity and there
is rttirtirttal drrtgcr of doublc countirrg but it is difllcult to envisage how it willcapture all
relevant aspccts of hcalth related quality of life. Irr addition, there are dangers in using an
unvalidated and Nen'Zcaland spe cific inslrunrerrt. e specially since there are rvell tested and
fi'c,-'ly altilablc gcncric instrunrents. For exanrple, the EuroQol is freely available with
rnirrrulls lrrd qLrcstionrraires, is used itr nrany countries, and in a rvide range of health
econornic cvaluations and clinical trials. Developirrg a new instrument is costly, takes a
longtinrc'and thcrc is no guarantee that it u'ill perfonn satisfactorily.
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Horvever, afier cortsultation rvitlr a u'idc rangc of iltterested parties and those with expertise
irr hu-alth ecottontics, PHARIvIAC (1999) reconrnrended using the EuroQol to evaluate
health related quality o I life.
Dimension: Lirnitations to dailv activities
mild moderat severe
e
Dintension:
Suffering
(physical and
nrental)
none
mild
moderate
severe
dead
1.00
0.85
0.66
0.41
0.85
0.74
0.58
0.38
0.66
0.59
0.49
0.33
0.41
0.38
0,33
0.l8
0.00
PHARMAC (1998: 2l)
Quite appropriatcly (fi'onr a public policy perspective) the HFA state that where significant
externalitics exist, tlre preferences ol thc inrmediate family/ care givers should be
considered but do not explain hon'this s,ill be achieved. Tlre proposed method of
assigning patients to lrealth states using "...rvhatever information is available to decision
makers." (Prioritisation Team, 1998 Appendix A: 3) is low cost but has dangers in that
dccision makers could manipulate the instrunrent to suit their own objectives. This cuts
across thc rr-'quirenrenl for transparcncy, nlay not be ethically sound, and may not
sntislactorily evaluatc cfficiency and cquity consequcnces of decision.
3.6.4 Conclusion
Thu-orcticall-r'tlrc nroposctl tru'* HFA irrstrunrcnt could rcplace the surgicalpriority scoring
s)'stcltl and n'oultl br'ntorc aprpropriatr-- as a hcaltlr rcsource rationing device because all
lrc'alth carc interverrtious s'ould be considerctl,
Table 3.6: Quality of Life and l{ealth Questionnaire Preference Scores
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Both thc tlookirrg s)'stenr and thc HFA's cost-utilit)'approach have inherent dan-gers in their
application. Thesr' dangcrs are: sole reliance on eithcr orre for decision nraking, a uniform
ntetltodology is ltot suitable for all situations. and the perspective taken is rrot that of
society. With rcspect to the booking systcrrr, thcre is no distinction between whether the
delay in surgcry w'ill lead to disability or death, for example, both nralign and malignant
conditions are equally likely to score the sanre rruntber of points (Dennett and Parry, 1998).
The nrajor potential advantages ofthe system arc an increased transparency and uniform
treatnlent across all hospitals and patients. This uniformity has ethical and equity
advantages but uniformity can only be achieved if the system does not involve judgement
(the issue raised earlier). As the booking systenr is based on an absolute score and does not
cortside r cost it catrnot be used in cost-eflectiveness or cost-utility studies as these cotnpiu'e
changes in the utility score with changcs in cost.
3.7 CONCLUSTONS AND POLICY POINTS
Cost per QALY gaincd was oncc seen as the ultinrate answer to health resource allocation
problerns. Horvevcr, QALYs have a nurnber of potential difficulties. They do not
discriltrinate by age of patient, for example, a onL. QALY gain for a 90 year old would be
identical to that of a one QALY gain for a 20 year old mother of a young child. There is
no standard agreed international generic health state classification systenl and method of
eliciting prcferences. While QALYs assist ll'ith decisions relating to resource allocation
rr'itltin the hcalth budget they cannot consider resource allocation across the whole
econonly. QALr''s assume that lcngth of lile carr bc traded off against qualityof life, that
individual utilitir-s ntay lre aggrcuated for policy purposes and a gain of 0.2 to 0.3 is
ilSSuntr'd to bc'idcntical to a gain ol'0.8 to 0.9. These trade-offs and aggregations maynot
bc vrlid.
Frottt tlte'rr itlt'iutd corrlirsirtg an-av ol'hcalth inclices, t\\.o appear to dominate (Short Form
36. l hu-llth prolilc' and EQ-5D a glt'rbul or gcrreric index). Both o[ these have been
validated irr il rarrs,e of countries. While the EQ5-D is suitable for CUA, the SF36 is not.
Hon,ever. the SF36 has been used to check that health related outcomes are identical in
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CI\'IA studicsR, and has been used to valuc health statcs in CUA studiese. It is difficult to
justifv ittverttittg I nc-\\'instrurtrcrtt *'hen intcrnirlionally tested and validated instruments
exist. Therc is tto consensus on the bcst singlc nrcasure to use in all studies (Gold et al.,
1996: l2l ).
lt is often valuable to use a health profile as well as a generic and/ or disease specific health
status index as it gives more specific detail on how and why the quality of life as measured
by the summary statistic in the index has changed. From a clinical perspective the
information provided by a health profile rvould be useful but an index is essential for cost-
utility analysis.
Policy rnakers ne'ed to bc au'are of the large ar:rd grorving number of ways of quantifying
chartges in health related outcolnes. The appropriate rvay of rneasuring changes in health
outcon'les rvill be dctemrined by the policy qucstion, the time available for the analysis, the
budget, and the expected value of the infomration. The following points should be helpful
to policy decision nrakers.
. Do not conslruct your orr'n lrealth related quality of life instrument but use an
existing instrunrent.
. If using health related quality of life instnrments, where possible use a validated
instrurrrent rvith an extensive body of literature that enables judgenrents to be made
about its validity, re liability and its use in other studies.
. As hcalth outcolle nreasures do not consider important non health conrponents of
qualitl'ollife they can only bc used to nrirke resource allocatiorr decisions within
thc healtlr sr"ctor.
. For policl'dc'cisiorr nrakirrg, a gcrrcric health related quality of lite instrunrent
should be uscd in conjunction w'itlr eitlrcr a hc'alth profile or a specific index.
For craurplc, irt au ccononric cvaluation ol'trcatnrctrts for thrombosis, (O'Brien et
al., 1999)
For exanrple, in a study of altenratir,e treatntents for arthritis, (Kristiansen et al.,
r e99)
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, Health related quality of life instmnrents should be used in eonjunction with a range
of policy decision rnakirrg tools such as CEA.
Resource allocation decisions require measures of -both the change in health outcsmes'and
cost. Chapter 4 focus.es on cost identification and quandfication.
WGuy Scott (2001)
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CHAPTER 4: COSTS
4.I INTRODUCTION
Economic evaluation of health care requires infonnation on both changes in costs and
changes in health outcomes. In this chapter, the following specific aspects relating to costs
and costing are addressed; the historical perspective, classifications of costs, incremental,
marginal, average and sunk costs, double counting traps, the costing process, sensitivity
analysis, data problems and perspectives.
Health policy rrrakers require inlornration on costs if they are to establish priorities and set
budgcts. Such data n:ay be provided by cost-ol'-illness and cost-of-treatment studies. The
results of cost-of-illness and cost-of-treatnrcnt studies are essential inputs for cost-
effectiveness, cost-utility and cost-benefi t studies.
Tlrere is sonre confusion over the ternrinologl, used to define costs and this has been noted
by Balas et al. (1998: 54) "...the assessment of eff-rciency is confused by diverse and
conflicting interpretations of the temr cost...". lt is important that costs and costing
methods be described in sufficient detail to penlit users to assess the validity of the
estinral.es (Rice, I 99-t).
Progriurure or illtr'rvcntion costs are nrore con'ectly tcrmed net costs, that is, costs incurred
lc-ss costs avoidcd or savcd. Costs nrav bc either positive or negative. A cost avoided is
a negative. cost and could bc rcgardcd as a benefit. Outcortres of medical interventions are
intetrdr-d to bc [r,..trcficial, accordingly. they rre oftc'rr regarded as benefits. As there is no
runivcrsnlll'acccptcd rulc that detc'nlines il- an itcttt should be classified as a cost or a
rregative bcnc.l'it c;.rrr-' is nr-'edcd rvhur irrterprc-tirrs cost/ benefit ratios oIdifferent studies.
(Scc Clraptcr' 6'. Ilconontic EtuIuutitsttl.
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Hc'alth outcon'rcs arrd resourcc usc changes causcd by medical intervention nray be
evaluatr.-d explicitll'by'thc nrarket or inrplicitly b;,nreans of the opportunity cost of the
rr.'source. Markct valuations rvill not rcflect thc true value to society if market failure is
present, or tlrere is no rnarket for thc health outconre produced by the intervention.
4.2 HISTORICAL PERSPECTIVE
Confusion arises from the use of different systems of categorising costs and from
temrinology being interpreted differently by different disciplines. Accounting and
economic definitions of costs maydiffer. Explicit or financial costs ( also refened to as
accounting costs.) are those costs identified by money transactions. Implicit costs do not
involve ntoney payulents. Econonric costs include all costs, both implicit and explicit. Tltis
section outlincs conl'non cost classification s)'stenrs and dehnes sorne conunonly used
nomenclature. Thc tenrrinology uscd to describc and classify costs in health economics may
be traced back to thc lanquaee of cost-benefit anall'sis from which it evolved.
Historically, cost-benefit analysis (CBA) distinguislred three cost types; direct, indirect, and
intangible costs. Direct (primary) costs represented resources directly consumed by a
project (for exanrple, one-time fixed costs, investment costs and recurring or operating
costs). Indirect (secondary, spillover or extenral) costs fell upon third parties not directly
involved with the project. (Other definitiorrs and approaches to measurement of indirect
costs specifically used in health econonrics are discussed later in this section.) Intangible
costs are either inrpossiblc. or very difficult to quantily in nroney terms. Dasgupta and
Pcarce ( I 980). Dunn ( I 98 I ) ancl Hil'enran and Wcisbrod (1977) provide an overview of
CBA.
Cullis arrr.l \\/csr (1979: 172) classihed hcalrlr care costs (and benefits) in a trvo by two
lratrix (l'ablc .l.l). This classiltcation stenrs clirectly from cost-benefit analysis
noprencllturc. Costs serc classific'd as dircct or irtdirect, and as tangible or intangible.
Dircct costs are' those that are closcly related to the objectives (for example, medical
ex1:enses) of tlre project u'hile indirect costs are rrot closely related to the project objectives
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(for exarnplc, loss of leisurc tinre). Tangibl.- costs can be valued by the market and
intaneiblc costs cannot.
Table 4.1: Classification of Health Care Costs and Benefits (After Cullis and
West, 1979:172)
Tangible Intangible
Direct Closely related to the project objective
Can be valued in the market Not valued in the market
Indirect Not closely related to the project objective
Can be valued in the market Not valued in the market
Dnrmmond et al. (1987: 22) defined costs as (a) direct (organising and operating costs
rvithin the health sector and costs borne by patients and their families), (b) indirect (time
lost lronr u,ork, (c) psychic costs) and (d) costs external to the health sector and their
families (Table 4.2).
Tabte 4.2: Classification of Heatth Care Costs (After Drummond et al., 1987:
22\
Orgunizing ond operating costs tv,ithin the health sector (Health
(a) Direct 
.professionals tinte, supplies, cquipment, power' capital)
Costs hornc b.t,putienrs und tlrcirrttnrilies (excluding time lost from
n'ork and psycliic costs *'hich is recorded in indirect costs)
(b) lldirect Tirrte losr 
.ft'otrt tvork (also bontc by paticnts and their families)
(c) Ps1'chic costs (also bontc by paticnts and their laniilics)
(cl) Costs lrontc extc-nralll'to the healtlr sector. paticnts, and their families
Ip alorlrcr secriol'l of tftcir book, Dnrnrnroncl et al. ( 1987: 2) define costs as C I direct costs,
c2 inclircct costs (production loss) and c3 intangible costs.
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Dortaldson(1990: 345)classified costsinasinrilarrvaytothesecondmethoddescribed
in Drunrnrond et al. (1987), but excludcd intarrgible costs. Direct costs related to health
care resources (staffirrg, consunrablcs, ovcrheads, capital), other related services
(conrntunity sen,ices, anrbulance sen,ices, voluntary services, patients and family
caregivers) and costs incurred by clients and their fanrilies (inputs to treatment, out-of-
pocket expenses). Indirect costs were time lost from work. Costs borne externally by
health and welfare services were included as a third category. Donaldson comments that
these extemal costs should be mentioned for completeness but are rarely included in health
economicevaluations(Table4.3). TheextemalitiesaredifficulttoisolateandquantiSand
frequently the perspective adopted is that of a purchaser or provider in which case they are
not relevant.
Table 4.3: Classification of Health Care Costs (After Donaldson' 1990: 345)
Direct Health care resources: staffing, cor'rsttnlables, overheads, capital
Other related services: conrnrunity, ambulance, voluntary
Indirect Time lost fronr rvork
Costs bome externallv bv the health and welfare services
Both Drummond et al. (1987) and Donaldson (1990) classifications typify those found in
the health econonrics literature at that tinre, and exhibit a strong link with traditional CBA
ternrinology.
Balas ct al. (1998: 56) anentpt to fit all cost items into an accounting or financial
frarneu,ork lronr the perspective of a provider (Table 4.4). This management accounting
classification is helpful (for non accounti.utts) irr that it lists accounting expense categories
rvhere data nral' lre obtaincd fronr rvhich to estinrate econonric costs. It is not useful as a
standurcl lbr rccording arrcl reporting ccorrornic costs because the focus is on sources ofdata
rathr-'r tlurrr lrrr outpul or sector classi{icittiorr. [iurtltent]orL-, accollnting costs include only
tlrosc- costs rccortled in rnoney valucs arrd excludc inrplicit costs (except for depreciation).
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Table 4,4: An Accounting or Financint Classification of Costs
Staft.rtp costs
Labour, personnel
D eve lorpnnertt, programmi ng
Hiring; lraining
New equipr'nent and spaqi
Consulting services
Olher cos-ts
Operattng expgnses
Direct eost of intet"\iontion
Labour
Cliniccl personnel
Nron-clinical support
SuPp,ly
Commu,nicati on ex,paues
Othsr
General overhead
Adminisration
Oceup,ancy (rent, uti,lit'ies, and telephone)
Total co'st
The ourrent standard American text (Luce, B, R. et aL, 1996) claseifies resource cosB aE
direct or productivity (Table 4.5).
Table 4.5: Arnerican "Slandardo
Dliect epsts
Direct lrealth ccre Changes in use of health care resources
Dtreet nau 'liealtli eare
Clranges in use of non health,care [e.sources
ln fornlal caregit'er tifl e
Patient titue for treatmerit
Prodtrc.tiviti' (recornmend c.ap.turing in QALY rather than recording as acost)
IL'Iorbiditl'
Mortatriq'
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Dircct lrealth care costs represcnt tlre clrangcs in hcalth care resources brought about by the
itttervcntion, for exarnple, drtrgs, hospital costs and diagnostic tests.
Direct non health care costs includc' transport, special foods, clothing, or furnishings.
Infornral carcgiver tinre irrcludes, fanrily, friends or volunteers time costs in providing care
such as lronre nursing. Patient timc cost is the tinre a patient spends seeking care or
participating in or undergoing treatment, recuperation and convalescence.
Productivity costs (loss ofproduction, also called indirect costs) relate to changes in the use
of patient time associated with the ability to work or engage in leisure tirne activities
because of morbidity or loss of output from premature death. Luce et al. (1996)
reconrnrend measuring productivity in the QALY rather than a cost. If it is considered
important to isolate productivity costs, these nray be measured in money values and
reported separately but not included in the cost-effcctiveness ratio.
This classification requires that treatnlent tinre be separated from morbidity time.
Treatnrent, recuperatiolt and convalescence time rvill be captured under patient treatment
tinre while morbidity time will be found in the QALY. The separation of such time will
of necessity be sonrewhat arbitrary. "As a general rule, when time could be categorized
equally rvell as treatment time or as nrorbidity time we suggest that analysts consider it to
be morbidity tirne and incorporate it in the denominator..." Luce et al. (1996 182). The
denominator is a quality of lifc nleasure. Under this system, productivitycosts (morbidity
and nrortality, that is charrgcs irr life cxpectancy) are more often captured in the QALY. If,
hos'cver thc qullitl'ol'lilc nreasure spe'cificalll,excluclcs the effects of time, productivity
changcs should bc included as a cost. Both altcrnativcs are technically correct but shifting
costs fronl the nuruerator to thr. denonrinator (or vicc versa) of a C/E ratio will alter the
valuc of tlrc ratio, lntlngiblc costs arr. not irrcludcd as it is assumed these costs will be
capturcd in thc' hcalth rclatcd outconlL' nrcasure .
Drtrnrnrond et al, ( 1997:32) in their latest book present yet another classihcation of costs.
Costs are defined according to sector, health care, patient and family, and other sectors
(Table 4.6).
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Table 4.6: Sector Classification of Costs
Health care sector
Patient arrd family
Other sectors
This systenr is easy to apply and functions rvell when one perspective (health care, patient
or fanrily or other sectors) only is considered. If however an analyst wishes to set up a
matrix and cross-tabulate cost categories by perspective she/ he will encounter trouble
because in this system the categories are in fact perspectives. For example, some health
sector costs rvill be bome by the patient and family but the Drummond et al. (1997)
classification does not allow for this. Other comrnonly used categorisations of costs avoid
this problenr,
As the language describing costs is evolving differently in Europe and America analysts
should clearly dcfine the cost categories used in their reporting.
4.3 CLASSIFICATION OF COSTS ADOPTED
Although there are slight differences, the ntost common breakdown of costs in the health
econonrics literature is; direct (direct medical arrd direct nonmedical), indirect and
intangible. Luce and Elixhauser (1990) use three cate-Hories; direct, indirect and intangible,
*'lrile Eise.nberg et al, (1994) categorise costs as direct medical, direct nonmedical,
intlirect and intangiblc. Table 4.7 presents the breakdou'n of costs used in this thesis. The
rangc of costs and the ir valuatiorrs s ill depend upon thc perspective adopted.
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Table 4.7: Current Gcnerallp' Accepted Classification of Costs (or Benefits) in
Health Economics
Direct: Thcsc ut't, tha opportunitt'cosl.s ussot'iutrtl with goods and sen,iccs cortsumed
or alterei h.t' thc hculth carc interyentiott uni its edverse events.
Direct medical: Thcse costs reldte to mctlicol goods und sen,ices. Theyfall
tlirectlt on the health sector hut nmy be ftnded from a nuntber of different
sourccs. Erantples include;
Comnrunity: Medical professionals' time, drugs, diagnostic laboratory tests and
imaging.
Hospital: These costs ore usually capturetl in aggregate as d DRG cost
Ward nursing, nredical, pathology, inraging, theatre, drugs, critical care, allied
health and pharmacy, medical and surgical supplies, catering, allocated
overhead, other cost centres.
Direct nonmedical: Thesc (osts are gcuerulls'borne by the patient,fumiiy and
f icnils and relote lo non htnlth core or nonnrcdical goods and services.
E.rantplcs includcl
Transporl: Anrbulance, private motor vehicle, taxi, public transport.
Other: Special foods, clothing, alterations to house, additional housekeeping
costs, hotel costs if patierrt travels arvay fronr home for treatment.
Indirect, productivitl' or time: lnlirect costs are concerned with the opportunity cost
of patients' ttnil irtfornwl curegivers' tinrc. Time costs relule to paid work, unpaitl work
und leisnre-titrtc uctit,ities. The potients'tinte nru.t'eilher be estimated as a cosl or
cnptured in u lrculth reluted quulitr of l{e outcot,e measure.
Morbidity: Lost or reduccd ability to work or engage in leisure-time activities.
Morlality: Lost production because of deatlr.
Unpaicl or infomtal carcgivers: Lost rvork or reduced ability to work or engage
i n lr.'isurc-tinrc acti vities.
Intangibfe: Intungihlc,s do nat intoh'e opportunitl'cosls hut people muS'be willing to
puy to tn'oid disc'on1fort. Thel' nru.t' he utluecl rr.silg willingness Io pa.t' crileria or
cttptrtred in u hutltlt relutcd quulit.t'of ltfc outcontc nte(Isltre. E.rumples include:
Quality oi life. pain and suffering.
Erternalities: I/rc.rc costs fire not hornc bt'the hculth scctor, the putient orfamily.
('osl.s to thr'-fttoil or hospitulil.t'inltr.str.t'itt ltrct'ctrlingfood honte diseuse'
Incrcust'tl cost o.f sor,'tt linther ht'cttttse o.f u xt.ft'l.t'Programtnefor vtorkers.
(-osrs t^'oitletl i,t tt'iltcr trL'iltttt(ttt fi'am the eliminutiort r{aler borne cliseases-
Alonitot'ittg ttnd testittgfootl tnd \'ulcr sumples.
Enforcenent of ltcal t h lcgis lut iort.
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4.3.1 Direct Costs
Direct cosls are related to treating or preventing a specific illness and the side effects of
such treatment or prevention. These costs are lrequently broken down still further into
direct ntedical, and direct nonnredical costs. Direct rrredicalcosts maybe eithercommunity
and/ or hospital based.
Direct medical costs are those associated with medical treatment and include medicines,
general practice consultations and hospital stays. These costs fall directly within the health
sector but may be funded from a range of sources. Adopting different analytic perspectives
tuay result in different valuations. As services providcd by voluntary organizations have
an opportunity cost tlrey should be irrcludcd. Contmunity costs could include medical
professionals' (clinician, nurse, physiotherapist, chiropractor) time, diagnostic imaging and
laboratory tests.
For convenience and cornparability, hospital costs are normally recorded as diagnosis-
related group (DRG ) costs or in Australia and New Zealand an Australian DRG (AN-
DRG) cost. This aggregate DRG cost rnay be broken down into sub groupings such as:
ward nursing, nredical, pathology, imaging, theatre, drugs, critical care, allied health and
pharntacy, rrtcdical and surgical supplies, catering. allocated overhead and other cost
centres (Casenrix Developnrent Program. I 995).
Capital costs rrc rclcvant to both conrnrunity and hospital service providers. Capital items
includc; lirnd, buildings, fixlurcs, fittirrgs, r'ehiclcs, rrrachinery and equipmcnt. If new
equiprrre-nt is to be sct up in a hosllital l'hcre land, buildings and other infrastructures
alrc-ady'exist arrd if those lacilitiu-s arc currently r'rot in use, they should not be included in
tlrr.. cosl of'tlrr.- pro1t"ct. Where eristirrs, buildirrgs are cumently in use ([or example,
lalronrtorl', r'ccL'l:)tion,tof llcc or \trd)and ri'ould ncc-d to be moved, the costs of such re
estlblislrrrrents arc a pan of the projcct cost.
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Calculatirrg total arrrrual costs of a project lacilitates nranagenlent understanding and the
conrparisonofaltcnrativeshavingdifl'erentcconortriclivcs(RichardsonandGafini, 1983).
Provisiorr carr bc. rrradc lorcapitalbya rrotional"rcnt" tocoverthecostofbcnefits foregone
(opportunily costs) of the usc of existirrg buildings. A one-time capital cost may be
cotl\'erted into an annual equivalerrt, Subtracting the present value of the salvage (or scrap)
value of tlre asset at thc end of its econonric life from the purchase price and dividing the
result by the appropriate annuity factor produces an annual equivalent cost. The annuity
factor is dependellt upon the nunrber of years the asset is to be used and the discount rate.
Alternatively, the appropriate spreadsheet financial function may be used by inputting the
discount rate, the economic life, the acquisition cost, and the expected salvage value.
Richardson and Gafini (1983) note that the literature abounds with incorrect methods
adopted to evaluate annual equivalcrrt costs. Incorrect methods include the straight line
deprcciation and dc-preciation opportunity cost ntethods. The straight line depreciation
r:rethod sets the annual costs equal to the yearly straight-line depreciation cost (purchase
cost less the salvage value divirled by the nunrbcr of years). If the discount rate is greater
than zero thc nrcrlrod unrJercstinrates the annual equivalent cost as no account is taken of
rhe tinre value of rnoney. The secontj nrcthod calculates the annual straight line depreciation
cost and adds to this an opportunitycost calculated as the product of an interest rate and the
purchase cost. This nrethod overestimates the annual equivalent cost of capital.
Direct norrnreclical costs are tlrose costs incurred as a result of the illness or the need to seek
health caru' alrd are generally bonre by patients and their friends and families. These costs
rclate to non ftcalth care or nonnrc-dical goods artd services and may includc; transport
(rurrtlrlancc. privatc lnotol' r'chiclc., taris ancl pulllic transport) and other additional costs
as I rr-.sult of t|c illrrcss or intervcntiorr (specinl foocls, clothing, wheel chairs, walking
sticks. hc-arin5l iritls. glasscs, prostl'lcses, housckccping, nrodificatiotts to honre or motor
vchiclc-. nnrl hotcl costs if the ptticnt lltust trilvel ns'ay fronr home fortreatment),
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4.3.2 Indirect Costs
lndirect costs are concerned with time costs as a result of reduced capacity to work or
engage in leisure-tinre activities arising from illrress, or lost production to society through
death. They are external to the health sector and fall on patients and the rest of society.
Production loss relates to those in paid and unpaid enrployment. Excluding these costs
front analyses undertaken from a societat perspective will cause a systematic bias towards
interventions and programmes that have the greatest inrpact on the health sector and a
discrimination against those that have productivity implications.
It is convenient to divide indirect cosls into the following categories; morbidity, unpaid or
infomral caregivers' time, and mortality costs. These are the opportunity costs of lost or
reduced ability to rvork or engage in leisure-tinre activities. Mortality costs are concerned
with lost production as a result of death fronr the illness (years of production lost).
Rice (1994: 1520) reconrnrends calculating nrorbiditycosts as "...(a) mean earnings an
individual ,uvotrld har,e accrued had he or she not been affected bythe disease, disaggregated
by age and gender; and (b) the number of days lost lrom work for the employed population
ordayslostirrperformingtheirnrainactivityforthosekeepinghouse....Mortalitycostsare
the product of the nunrber of deaths from the disease and the expected value of an
indivi<luals's future eantings with gender and age taken into account,"
lndirect costs of patients and iufonrral caregivers nray be quantified by using average
eanring mtes ls a pro\).for thc value of productiott and leisure-time loss. Ifdifferent rates
are appliccl to clifferent ltopulation groups (erlplol'ed, trtremployed, age, gender, ethnic
groqps, apd high vcrsus los'canrers), it carr result in differing levels of importancebeing
placccl orr spccilic populatioti groups. Tlris has intportant consequences for evaluation of
policl,oprions rhrrt art- gerrder tnd agc spccilic. lithc objective of the economic analysis
is to prov idc. irr forrnal iop for 1>olic1' dtc isions tltat arc itttcnded to be gender and age neutral,
ilp ccononry-n'idc a\'erage u'age rate should be applied to all time related costs (Weinstein
1996: 1255; Scott and Scott, 1993; Scott, McKerrdry and Scott, 1992)'
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Unlil thc early 1990s ruost cost-of-illrress and cost-effectiveness studies estinrated the
potc'rttinl productivityct'rst charrgcs. Koopnranschap and van Ineveld (1992) introduced the
frictiorral cost nrcthod of nreasuring the value of production lost to society as a result of
disease. Using this nrethod, production losses are confined to the period needed to replace
the sick n'orker. The length of this intcrval, the friction period, depends on the conditions
in the labour nrarket and level of unemployntent. In a later study (Koopmanschap and
Rutten, 1994) investigated eight health care progranrmes. They found, (not unexpectedly),
that the inrpact of indirect costs as nreasured by the friction cost method varied considerably
across programmes and were greater if absence from work was a major effect of the
programnre, and if a high proportion of the target population was employed when they
bene{ited from the prograntme.
The idea behind the friction cost mcthod is that in the short-run, losses in production as a
result of an absent rvorkcr can be nrade up by colleagues working harder and unimportant
tasks not being undertaken. In the long-run tlrc sick worker will be replaced from the
unemployed. Thus, the production loss should be confined to the period required for the
enterprisetoreorganiseproductionbyhiringandtrainingareplacement. Thepotentialcost
metlrod and the tiictional cost method nray give rvidely divergent results and should be
investigated irr sensitivity analysis.
Trvo nrethods (hunran capital and willingness to pay) nray be used to measure mortality
costs. The hurlan capital approach, the earliest nrethod used, calculates the value of an
individual's life hv discounting expectc'd future earnings (Rice, Hodgson, and Kopstein
1985 ). Ricc. and Hodgson ( 1982: 5-1(r) note tlrat rvhile the human capital nrethod provides
reliatrlc and corrsistcnt vatues for futurc eanrings lost, it urtderestimates the inrpact of death
becausc it excludes norr-market activitics and pain and suffcring.
Ricc (lq9l) ntlvocatcs using rnarkct eanrings (including an imputed value for
Irousr'kcepin-e, scrr iccs), togetlrcr rr'ith. lifc cxpectancy, and specific labour force
participutiolt riltes for dift'crerlt age and gender groups. If the perspective taken is that of
society, the individual's lifetime consun'lption should not be deducted from the present
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value of futurc earnings as it is thc totirl contritrution to national output tlrat is relevant
(Sorkin. l9E4: ll(r).
A rveakness of th,-" hunran capital approach is that it places a lower value on the lives of
children (il'future canrings are not corrsidered), older people, and those unemployed or not
in the workforce and nray also discriminate against gender and ethnic groups. The method
gives no consideration to the well-being of the individual or to the individual's family and
friends. A good example of the consequences of gender differences in paid labour
participation and different wage rates may be found in (Rice, 1967:433).
The second method uses s'illingness to pry criteria and values life according to the amount
that an individual rvould be willing to pay to reduce the risk of illness or death by a given
anoultt. \\rillingness to pay estinlates provide higher values for life than the human capital
approach (Rice, t994). Statistical lives rather than particular lives are used, as the value
placed on a particular identified life is likely to be higher than a statistical life (Viscusi,
I986: 194). In addirion, a wealthy individual would probably be willing to pay more to
save his/her life than a poor individual.
Rice (1994) an<l colleagues relined the human capital approach while the
willingness-to-pay method, was first proposed by Schelling (1968) and Mishan (1971).
Willingness to pay techniques may be used in public policy to value health and life and the
avoiclance of pairr and suffering. Thc ivlrnistry of Transporl. and Transit NZ (Miller and
Curia. l99l)fiavcvlluedalifcatS2nrilliorr(in 1989/g0doltars). Thisvalue wasarrived
at by asking peoplc rilrat tlrey u'oultl bc prcparccl to pay to reduce the risk that they would
die o1 tlie roacls. Tlrc questiolt \\'ils posctl for both larrrily members arrd strangers.
\/cr), lcs.cosr-Lrcncllt arraly'sis hcaltlr public policl'studies have been conducted using
u,illingrr..ss to plv vtlues lor hunrln liie. If cost-bcrrcllt analysis is to be applied and used
u'ith conllclence lry policl'rlccision nrakers nrore tcttablc values and nrethods will need to
bc- ctcvc.lopcd lbr rhc health sector. C'onjoirrt analysis, a tccltnique derived from marketing
research, rrray offer scope for obtainirrg credible valuations of healthcare benefits. The
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technique has bccn used in ntarketing lo evaluate the inrporlance of specific features of a
product on consunrer pre lererrces (Cattin and Wittink, I 982; McDaniel, I 996; Davis, 1999)'
If cost is included ns an attribute of a health outcome, willingness to pay can be evaluated
using conjoint analysis without having to ask a direct open ended question (Ryan, 1996).
4.3.3 Intangible Costs
Intangible costs are concemed with reduced quality of life as a result of the illness. These
intangible costs do not involve opportunity costs of resources used and some economists
working in the non health sector would not regard these as true economic costs. Never-the-
less it would be expected that people rvould be willing to pay to avoid them. These costs
are relevant if a cost-benefit analysis is heing undeflaken and are captured in the health
related outcome ntcasure in a cost-utility analysis.
4.3.4 Externalities
Extenral costs are rrot bonre by the health sector, the patient or family and they are not
usually nreasured irr tr cost-of-itlness study. I{o*'cver, if a societal perspective is adopted
there is no valid reason for exctuding extemalities provided they can be clearly identified
and quantified. Examples of externalities include; costs to the food or hospitality industry
incurred in preventing food and water borne diseases. Johannesson ( 1994: 676) refers to
two types of extemality; consumption extemality, and caring extemality. Consumption
extemalities are thc inrpact on consunlption by tltose other than the recipients of health
care. Caring extenralitics do not involve resourcc opportunity costs and are defined as
"...the altlristic valuc of clranges in other people's health status...". Johamesson (1994:
681) notc-s thcre is an argunterrt againsf inclucling cariltg externalities ttnder some
circunrstlrrccs. for eranrplc, "...if altruisnt conccn'ls thc utility of other individuals' tlrese
altruistic vltlucs tvottltl catrccl orlt at the rr'cllitrc optitttttttt.,."
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As l5ere is some corrfusion (by non econonrists) between incremental, marginal, average
and sunk costs, tfuese are defined antl the situatiorrs in which they are used are discussed'
Marginat cost (MC) is the addition to total cost resulting from the production of one more
unit of output. Variable Costs (VC) are related to the volume of output, they increase as
output rises a1d are zero at zero output. Fixed Costs (FC), do not change as output changes
and are incuned even at zero output. Total Cost(TC), is tlte sum of variable cost plus fixed
cost. Average total cost is total cost divided by the units of output. Sunk costs (Sloan
1996: 65) are costs that have already been inctrned.
The increnrental cost of a decision is the additional cost incuned less the costs avoided'
If a cost ,,vill bc altered by a decision (rvithin the time horizon of the programme) it is
relevant but if t5e cost item rvill not be altered, or has already been incuned, it is not
releyant. For exanrple, the historical cost of building a hospital is a sunk cost that will be
unchanged by the activity or decision uncler irrvestigation and is therefore not relevant' In
the lorrg-nrn, decisiols should be based upon long-ntn marginal or increntental costs but
in the shorl-run, sltort-run costs are applicable.
All costs ancl benefits slrould be ci,lci:lated incrcmentally. Incremental analysis takes into
account crnly thc diflerences in costs and the diffcrences in benefits between the alternatives
being colsitlcred, u'ithin the time horizon of the project. Altematives could include various
trcatrnenr oprlol.ls anc'l could enconlpass such valid options as doing nothing (nraintaining
the status quo or tltc cotttrtcrlacttrll).
Ecplopric cfllcir-lcy iprplir--s that niarginal socialcost e(iuals marginal socialbenefit' A real
pr.jr.ct is uplikr-.lv to operatc at tlris rlalgin. Pt'rtctrtial itttprovenrents in economic eff rciency
(rritlt rcspcct to thc ctistriburiorr of rcsources) irrrplies incrctrrental changes not marginal
cStpges irr costs ancl benefits. Oftcn Lhc ternrs ntarginal and incremental are used
ilterchangeably. Horvever, increnrental costs ntay relate to both the sho(-run or long-run
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(depcrrdilg ot'l titllc lrorizorrs atrd plalrt capacit)') attd are defined as the change in total cost
rcsultirrg fi'o1r a decisiorr. Ir{arginal cost is a sltort-rrttt col'lcept and excludes fixed cost'
Alflroug6 a\,crage costs (total costs pcr unit of output) and marginal costs ntay not be
appropriate for calculating dilfercnces in costs bctrveen options, analysts lvill be forced to
use thenr if it is impossiblc to obtain nrore appropriate incremental cost data. I f this is likely
to bias the results sonle comn'lent should be made'
For example, trvo additional hospital patients will not add to the overhead costs of a
l-rospital but 500 more patients may necessitate the hiring of additional staff and the
building of additional facitities. Where marginal costs do not change markedly, they may
be used tcr cyaluate c5nrrges that involve a small number of additional patients. Average
cost (whicfi include overheads) rnay provide a better guide in evaluating larger changes
(such as a tle\\r ltospital s'ard) bttt not rvhen therc is unused capacity or where the change
in the nunrber of patients is snrall'
4.5 AVOIDING DOUBLE COUNTING OF COSTS
lf costs are counted ntore than once or counted rvhen they should have been excluded a
prograt'nnte's costs rvill be overestinlated ancl the programme may be rejected when it
shoglcl have bectt accepted. Prodtrctivity costs arld transfer payments are frequently
counted nrore thiur ollce or counterj ilappropriately. It is irrrportant that policy nrakers and
r1r iu'la gL-r's be l$'irrc o I tltese poten t i irl problertts'
In this scctiott tlrc follorving rvill bc tlisctrsscd:
. Productivity' costs attd qtrality oI lifc
' Trallsfcr pavnlctlts
. Cost shiftirrg
' Crtpitul costs
. Co-rtrorbiclity
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4.5.1 Productivitl' and Heatth Related Quality of Life
cost-utilityanalysis(chapter 6:Ecortonrit-Evtltmtiorr)cornparesthecost-of-treatmentwith
a hcalth related quality of lif-e nlc:lstlre. Doublc counting can occur as cltanges in
productivity nlay be captured in both the health rclatcd quality of life measure and in the
cost rneasure. This confusion can also lead to changes in productivity not being captured
in either costs or effects. A solution suggested to this problem is that when quality of 
life
values are being obtained from subjects, respondents be told to assume that all health care
costs anrl income losses are fully reinrbursed (Johannesson, 1997)' Productivity (output)
losses may also be overestimated if a money paynlent fronr loss of earnings' insurance' 
and
lost eantiltgs are coutited as costs,
There is uo generally accepted convc'ntion of rvhere to record productivity' The
Washington Panc-l on Cost-effectivcness in Health and Medicine consider that 
productivity
losses should be cxcluded fronr the costs of cost-utility analyses and included in 
the utility
nleasure(Garberetal., 1996). TheParrel notcthatifproductionlossfortheindividualis
capturctl in thc uf ilit)' lueasltre tlterr orrly tltose productivity costs external to the individual
should be include<J as a cost. Exantples of these externalities are the frictional 
costs to an
enrployer. Il, horvever, respondents to the utility questionnaire are specifically 
asked to
exclude loss of inconre in their evaluation of health related quality of life states 
then
productivity loss should be evaluated as a cost'
Thc Waslrington Panel (Garber cl al., 1996: 39) state that.'." under corrditions of perfect
r':.rrke ts. thr.'cost-c l'[ecti\ er]ess l1'lctlrod lcads to the sittttc decision rrrles for allocating health
fesoul'cr:-s..." llo l'lli,IttL'r rvhctltc'r tinic costs irrc capttll'L-cl irr tltc cost colnponcllt 
or in the
cfle.cti'c'css ,.rcilsurc. Brou*cr'. Kooprrranschitp atrd Rrrtten (1997: 253) argue that
"...trrrly,rlircct [cllltfi related effccts ort cltralify'of life that cannot be meaningfully
'tot.tL.tar.izcd 
5llqruld lrc co'sidcr-ed iis lrr,-altl cl'l'ccts." Brourver et al', note that tlre 
patient's
pL'rspcctivc is uscttrl for qtrality'ot" liie ttssessnlettt but rtot lor cvaluating productivity 
from
a soc ie'tal perspcctive.
lA Gay Scott (2001)
, In Ncw Zealand
4.5.2 Transfer Pa1'ments
As trattsfct'pay't'lents irtvolvc the redistribution of lllollcy they do not represcnt real costs
front tltc perspcctivc of society (Ltrce et al., 1996). In Nerv Zealand, the goods and services
tax (CST) is a cost fi'orrt the perspective of an individual patient but is a transfer payment
if the perspective of all society is taken. Sinrilarly, trrtenrployment benefits are relevant if
the perspective is that of the govemnlcnt budget buf are irrelevant from the perspective 
of
society as a rvhole. The costs of collecting taxes, distributing benefits and any costs
resulting fronr reduced market efficiency are relevant but would be very difficult to
neasure. Govenrmetrt rvelfare benefit payments used to pay for medical treatment 
could
be counted both as a medical subsidy and as a medical cost. Taxes could be multiple
counted if inccme tax losses to goyenrntcnt Were adcled to losses of earnings of individuals
and agairr il-the tax rcvenues Nere then trscd for public health care which had been counted
as a lrealth cost (Rice, 1967:429).
4.5.3 Cost Shifting
Cost shiftillg. occurs \ten a budget holtler shifts costs out of their budget itrto another
budget, lf rricntally ill patielts w'ere discharged from hospital to be treated in the
comnrunity. but funding for conrnrunity care not increased, cost shiftingwould occur' with
a societal perspective, all costs are captured and cannot be shifted elsewhere'
4.5.4 Capital Costs
6tcrcst o^ bon.orr.cd tirpcls is incler,arrt if a societal pcrspective is a<lopted, but is relevant
if tlre pcrspcctir.c taken is that of an incliVicltlal cllte4)rise. However, for att cnterprise'
dc-tlucting int,-'rcst costs fronr u cash ilorv antl tltcrt tliscounting to a present value 
will
t t tt tl c rc s I i tlr lr t L' l1 l' L- s t' l'l L I il I t t r-- s'
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4.5.5 Co-nrorbiditr'
Tlre presence of nrultiple diseases creates difficulties in isolating the costs and
consequences of each coltdition may result irr prultiple counting or onrissions (Rice'
1976:429:Sorkin, 1984:l l5). The probleni ofjoint or shared costs is well understood in
economics but easy solutions remain elusive'
4.6 COSTING PROCESS
The costing process may be described in the sante way irrespective of the type of economic
evaluation in N,hich the costs rvill be used. The first step in estimating costs is to prepare
an itcnrised list of resotlrces thar rvillbc alterc<l by thc illness or iutervention' A unit cost
for caclr resource itcm should be obtained. Hoyever, unit costs and shadow 
prices
frequently ueed to be irnputed u'here there is nrarket failure and where policies 
have been
intro{uced to correct for inequity. Prices pai<l by purchasers may not necessarily reflect
econonric costs, differerrt priccs nray be cfiarged to different consumers for the same
product, anrl a nrarkct price for the product or sen'ice may not exist because it nray not be
traded on a nrarket. Rcsource costs in money units may tlren be derived by multiplying 
each
resource utilisation by its respective unit cost. Finally, where shadow prices and other
uncertititttics are involVed sensitivity analysis is reqtrired'
lr is dcsirable to report all resource costs both in volume units and money values to
lacilif atc serrsitiVity analysis and allorv rrpdating if unit costs change' Provided trnit 
costs
and total costs in nlollr'y Valucs arc presettted, rcsource rrtilisations (voluntes) nray be
calculated.
N,ticro-costing is thc nrost accurute rnetlrod of costing and involves deriving a 
unit cost for
crclr rr..sourcc c(rst corllpoucr"lt. For crlnrplc, a urrit cost could be derived for imaging'
dfirgrrostrc tL.sts iil'ld rvard stlys. Activity'-based costing involves breaking a process down
into I scrics of actir.itics and rlicro-costing cach of these activities' For exanrple, antibiotic
treattltent ntly bc brokcn dorvn into preparatiotr of drug' administration of the drug' and
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nlonitoring. Resource utilisations (for exattrple, drugs, nurse time) for each of these
actir.itics trray tltep bc nreasurcd. Otfier cosLing nretltods are tess accurate' Urrit costs 
per
diagnosis related group, or hospital average daily costs nray be used to cost hospital
adnrissions. Drummond et al. (lgg7) cliscttss costing methods in detail'
4.7 SENSITIVITY ANALYSIS
Sensitivity analysis allows the soundpess of economic models to be examined through
changes in variables of these models (Agro et al., lggT\' Effects of uncertainty in costs
and other estimates may be investigated and taken into account. The degree of influence
that each factor has on the outcomes of a nrodel may also be evaluated using sensitivity
analysis. It is recommended in guidelines (for example, Ontario Ministry of Health'
Canadian Coordinating Office for Health Technology Assessment' Australian
Conrnroprvealth Department of Hcalt[ Horrsing and Conrnrunity Sewices) for conducting
such studies, but llo set ntethod is outlined'
Sensitivity anllysis may bc either; single paranleter (univariate, one way) or various forms
of multiple paranreter analysis. The latter include scenario analysis such as best and 
worst
cases and platrsible future scenarios.
In single paranteter analysis variables or parameters are examined one at a time and 
the
impact on the final results rec6r<Jed. Variables are often changed plus or minus the same
set pcrceutagc. This approaclr is quite usefirl as it that allorvs the critical parameters 
in a
rrroclel to be dc-ten1]inctl. Sirrglc parall'lctcr analysis slrould be conducted alongside some
sort of scen:rrio arrirlysis as ipycsf igatirrg lt only orte paranleter at a tinte can provide an
incotlplc.te and optinristic estintatc of total ttncertaittty.
N{ultiplc ptlral]lctcr Sellsitiyit}' anill)'SiS, p'lterc trtorc tfian one variable is changed' can
providc a ltlorc cotrrplc-tc tttr,lerstatttlipg of uncertainty' Best and rvorst-case scenario
analysis conrbines thc loiv or high range of variables to detennine the worst or best 
case'
,.ln rilost cases, nrultiple sotlrces of uncenainty rvill generate a less "certain" result 
than a
orre-at-a-titrte, single parameter sensitivity analysis would indicate' "'combining the
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extrc'e 
'ar'cs 
of parameters to gain an "o'erail" best or rvorst estimate can overstate the
uncertainty. Ignoripg tfie con'elatiops anlottg tentts or the presence of interactions 
could
have the sanre effect" (Mattning, Fryback' and Weinstein' 1996: 252)'
In tftreshold analysis, a parameter (such as a dnrg price) is altered over a range to determine
when major changes in corrclusions are warranted' This arralysis estimates the values 
of
a parameter or nunrber of parameters to isolate the point at which a different 
decision
should be nrade. Breakeven analysis is a simple example of threshold 
analysis' Threshold
analysis becomes difhcult to use with nrultiple variable changes (Agro et al', 1997\'
sonietimes the cliverse range ancl quality of the c'tata preclude using the 
standard statistical
tests. sensitiyity alalysis may theu be used as an altemative means 
of testing the
robustness of the data. As it is possibre for a varue to be statistically 
different from zero yet
so close to zero to be of little consequence for policy or clinical decision 
nraking (o'Brien
and Drunrmopd, 1994), sensitivity analysis may also be required in addition 
to statistical
tests of significance'
The following rexts provide valuable discussion of sensitivity analysis; 
(Gold et al" 1996;
Haddix et al., 1996; Sloan 
'1996)'
4.8 DATA PROBLEMS
Frl.qr'rcntly, policl,atrall,sts har,e linritetl cotrtrol oVer thcir Statistical 
data. Tirne and budget
construints ruean that infornration nlust oftell be dr:rrvn from secondary 
sources' Data may
co'sist of ad'iinistrirtir.e rccords, *,itlr thc variables det'i'ed by other 
people, and with the
rcco*ls collccr,-'cl in tiiffcr,--rrt situatiorts for differcnt purposes' 
Data available in the public
tlor'uirr ilrc fl.L.(l.cl1tly, aggre gatcd to plcscla e cortl'idc'tiality (for commercial' ethical 
and
lcgltlrcits.'lrts)lrrrtltt]Icdtlccadataluseto0lllatlllgcablcsize.Itisessentialthataclear
defirrition antl dc.scriptiorr be obtained for cach variable and a clear 
understanding of how
thc data have becn collectecl recorcled and aggregated'
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Researchers slogld study thc tiata-set irr the rnost disaggregated fomr availablc and check
horv data have beerr clefincd, collcctetl ancl rccortiecl, belorc preparing sunlnlary tables and
graphs. Additional rcsearch or data lronr another soLlrce tlay be needed to clarily findings'
Unit record data may not be available, and it nray be necessary to use tabulations provided
by others. Data should be analysed using cross-tabulations which involve disaggregation
to the lorvest possible level. Variables that are found not to influence the outcomes may
be aggregated to produce tables that hightight the important determinants. Increasing
avaitability of unit-record data sets, and software tools to nlanage and analyse them, makes
such detailed analysis practicable. For example data available from PC INFOS (Statistics
New Zealapd) have already been aggregated but Health Statistics New Zealand hospital
discharge data are available as unit records. Software packages such as SPSS (Norusis,
lggT) permit data exploration, aggregatiop an,J analysis. Chapter 8: Care lVith Data
discusses these data problents iu ntore depth.
Where costing 6ata have been derived fronr clinical trials, adjustments may be required to
take account of "protocol driven costs" (Coyle and Lee, 1998). Protocol driven costs arise
because the trill dcsign nray require certain diagnostic tests that would not normally be
required. This results in clinical rnanagemcnt oI the illness that differs lrom everyday
practice. Problems of this sort nlay be overcome by nrodelling (chapterT) and sensitivity
analysis.
4.9 PERSPECTIVE AND COSTS
The analytic perspectivc is the view'point fronr rvhich a study is conducted' Most policies
may,bc r.ie\\'ecl diftcrently,by diflerent groups in society and inrplenrentation of policies
$,ill nffcctcliffcrr"rrtsectorsofsocictyirrdiffcrcnt\\'itys. Perspectil'eisusedintrvoways;
(l) to irrdicare r5c scopc orbourrclary'of thc costs, and (2) to indicate the viewpoint from
u.lrrclr costs drc nlcilsufc-d. Dircct nrctlical costs borrtrdcd rvithiI the health sector may be
ntr'asured ll"or1 t5c pcrspcctive of a privatc lrousclrold (patient) or from the perspective of
a healtlr carc pttrcltaser.
Different cost iten'ls'uvill be relevant to tlifferent perspectives and the same cost item may
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bc nec-d to Valuccl diffcrentll'for difhrcnt vie$' poilrfs' For exanrple' GST is a transfer
paynlent fronr tfic pcrspectivc of socicf y or a httsitrc'ss enterprise but is a cost from the
perspective of a sirrgle hotrsehold.
It is vital for policy ntakers to consider the inrpact of decisions from a number of 
different
angles and failure to do so may result in failure ofthe policy to achieve its objectives' The
perspectives analysed should be wide enough to pemlit all stakeholders' interests to 
be
considered. The widest possible perspective is that of society' A societal perspective
encompasses the broadest possible range of costs and measures them with respect 
to their
impact on societY as a whole.
A central goven.lntent clecision ntaker, if acting as an agent on behalf of society' should 
be
interestetl in a societal perspective. A nratrager in a lrospital rvould be primarily 
concemed
witlr costs releva't to the hospital perspective, that is, explicit costs rather than implicit
costsro rvill be relevant to the hospital manager' Some policies may shift costs 
from one
sector of societY to another.
4.10 CONCLUSION
cost categories and ternrinology describing costs should be clearly defined 
and explained
as tenlls nray bc interpreted dil-feiwlly by different disciplines and there are different
sysrctlls of cli:rssify,itlg costs. If thc anirll'sis is irltcnded to providc infornration 
for gender
arrcl lgc pcutlal llolicy nraking. illl ccollollly-f icle ilverage rvage rate shouldbe 
appliedto
all ti're rclatcd costs. Carc should lrc take. not to cotll'lt costs more than once' to 
include
all costs relcvirttr to tltc- perspt'ctlvt's acloptecl, and to recognise the consequences 
ofjoint
costs nncl co-rrrorbiditics, Tlre perspectives chosctr slrotrld be witle enough 
to enable the
effc'cts of lt prtlgral'lllllL- oll all stakeholders to be asscssed'
Accotttttittg costs lllay providc a basis for estinratiug ecortomic costs 
where the bulk of
Explicit costs ipvolye ll1one)' payletits, u'hile implicit costs do not relate to money
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i'puts arrd products produced are tnaded on eflircient competitive rnarkets; in situ'ations lilce
these nrarket prices *'ill refleet unit costs. flo$:ever, accounting costs are measured from
the perspectir.e ofa frnaneial en ity\\'hereas pUbllc policy make'rs shouldbe csncemed 
with
a socielal perspectife. Prices charg.etl for goods and ser"viees do not neeessarily reflect
econontic c,Ost$ atxl in ntany caScs unit costs atrrj sltadorv prices must be inrputed for USe
in the ecottonrig evaluations-
The following points are reiterated:
r The perspeotive should dictate the relevant range of costs and how they should be
valued.
. Clearty defline all'cost categories used'
. Estirnbte cosls incrementally asthis rvill help to avoid [raps of inelusiorrt (sunk eosts'
double counting) and exclusion (ovcrlreads that $'ill change)'
. Value the costs 'in a lvay tltat is relevanl to: the research question arld the
pertpectives adoPted,
. P ,esent as rvide a range of costs as possible
. Consider c-onvertiirrg a One-time capital cost into an annual equivalent
. Present costs in resource units and in dollars'
. Apply sensitivitY analYsis'
This ehapter bas focussed on cssts in isolatisn. succeeding,cha,pters discuss how cost 
data
are used in eombination rvlith e,ff.ectivene.ss measures to forrnul'ate policy advic'e' Chapter
5 considers discorrnting of future costs and effects'
W Guy Scott (2001)
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Economic Evaluation
CHAPTER 5: DISCOUNTING
5.I INTRODUCTION
This chapter discusses methods for setting the discount rate with a particular focus on
public policy evaluatiorrs of health care in New Zealand. The mechanics of and rationale
for discounting and the appropriate magnitude of the rate are discussed. Discount rates are
examined with respect to the study perspective. curtent thinking on the discounting of
outcomes or effects measured in non-uroney units is reflected upon' Real versus nominal
rates are described, as are discount rates that have been or are cunently being used in the
public sector. Suggestions and recomnrendations for New Zealand policy evaluations of
health care are outlined.
There are two relevant questions. ( l ) what is tlte ntost appropriate rationale for discounting
and hence the most appropriate method of choosing the discount rate' and (2) given the
method, wlrat magnitucle or nrtmeric value shotrld be selected for the discount rate?
Although there has been ntuch argunletlt by policy analysts over discounting, the debate has
focusetl on the rnost appropriate numeric value of the rate to use rather than the underlying
rationale for discounting (Goodin, 1982).
Discounting is used in econonric evaluation to adjust costs and benefits that occur in
diff-crent tirne periotls to :r conlt1'tol1 basc. Freqtrently costs are incuned before benefits
accnle lrom a prograr'nlIe. Esscntially discounting nleans tltat costs and benefits occuning
in the futurc arc assignccl a snraller u'eight than those closer to the present' The weighting
appliecl to a luture cost or benefit to convert it into a prcsc'nt value is the discount factor'
The rrragpitude of the s'c-ight dc"pencls upon the discor.rttt rate and the timing rvhen the cost
or bcttcfit occtlrs.
Discountiug is tlcr-'t'ssilrv bccausc socicty placcs a higher value on goods and services
receir.ed carlicr rathe-r llran latcr. A clolllr today nray bc invested to earn interest in the
futirre, Accordingly, societal discount ratcs lllay bc basecl on the social rate of time
preference or the social opportunity cost of capital. Goodin (1982) outlines four reasons forll GuY Scott (2000)
discou,rting: ( l) psl,clrological or ptrre tinre, (2) ttttcertainty and risk, (3) dinrinishing
niarginal utility. and ('1) oppotltlnit)' costs'
Often discounting is not necessary as nlany health policy investigations are 
prevalencerr or
cross-Sectional studies and consider incremental or total costs during one time 
period
(usually ope year). Discounting will usualty be required if the costs and benefits or health
related outcontes are derived from longitudinal or time series studies that follow 
events
over a number of time Periods.
While there is general agreement on the need to discount future costs and consequences
(health related outconres), the selection of an appropriate method of determining the
discount rate for public sector investnrents is open to debate' The choice of different 
ways
of estinrating the discount rate can lead to different rates and thus different 
present values
ofcosts and benefits.
The choice of the rveighted cost of capital or cost of bonowing as an appropriate 
private
sector discount rate is less contentious. As it is appropriate to take a societal perspective
when evaluating public policy optiotls, the social rJiscount rate should be used 
to discount
costs and benefits occurring in the furure. Other perspectives may require 
the use of
alternative discount rates. For exarriple, a private hospital capital budgeting 
evaluation
could use the cost of capital lor that prolect, whilc a government deparlment 
with a budget
perspective rrray allply the capital citarge rate'
Ba[nrol (196E: 78E) conrnrcnts thttt tlrc social rate of tliscount should measure: 
"The
oppor.turrir;,cost o|.postpol.lement of rccr-.ipt oIarry bcrrefit yielrJed by a public 
investment.''
Furtrrer hc asserts thar thc opportunity cost rcprcserts trrc rr,clfare foregone 
by not receiving
t'c bcncrrts inr.r.-.diatc-1y,. Trrc disco*rlt rate used to c'aluate p*blic projects 
should
accur.ulu-lY rcflcct rhis oPportttntry cost. Alrhotrgh this concept elucidated 
by Baumol ( 1968)
,, T'c pre'ale*ce of l,., illness is tlre nunrber of cases in^a population at 
one point in
timc rvlrilc the inciderrce ol'a tlisease is the number of new cases 
occurTlng over a
spccilied tinre period. That is,.a still photograph or snapshot 
compared with a
ntovie. For example, most or trr. .ut.r discirssed in this thesis 
were prevalence
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nta), appear clear and straiglrt fonvard thr,'rc is cotrsiderable ntisunderstanding and 
debate
about the ntethod of sclecting tlre rate, rts nragnitudr-', flr1d thc application 
of tlrc discount
ratc itr Practice.
The social ratc of discottnt cloes not necessarily ecltratc either with the cost 
of funds to the
goven.lntent or to the private sector. The weighted cost of capital to an entity 
(public or
private) is appropriate solely to that entity. lf there is rnarket failure in any market then the
social rate of discount will not equate with the marginal rate of return on investment' 
In all
(or vir-tually all) societies there are varying degrees of market lailure'
Arrow (1985: 382-3) isolates five problems in usirrg market rates as proxies for social
discount rates in a mired economy. (l ) There is a spcctrum of market rates rather than one
single rate. (2) Price anticipatiorls are not necessnrily accurate' (3) The future is 
risky' (4)
Govemnrent itl\'estlnertt is often cotrcented $'itlr tltc provision of public goods' 
(5)
Govemments have a responsibility for the future above and beyond 
private individuals or
hrnrs. Tlree of Anorv's problerns are impoftant. (l) There is a range of market rates
posing a problern of choice. (2) Govemnlent inve stnient is often undertaken to 
correct for
nrarket failtrre in $,hich case ntarket discount rates are not necessarily be valid' 
and (3)
govemnlent has additional respotrsibilities for the future' Thus the choice 
of public sector
discourrt rates is often more involved than the selection of a discount 
rate for private sector
investments'
pri'ate sector discoutrt rirles arc cottrnrottly based oll the *'eighted average 
cost of capital
ro rhe llnL Public scctor discotrtrl ratcs cliffer frour tltose applicable to individuals 
and the
prir.ate scctor for a nunrbcrof rsasotrs. (l) Httnratt cntitics have a limited lifespan' while
society is rtrirtle up of rIan1, in<lividuals atld contitlucs indcfinitely' 
Because of this' society
lurs * nrore distarrt tinte ltorizon for rctttnts ott in'estnlt-llts 
than i'dividuals' Accordingly'
an i'dir idual r'ould place less 
'alrtc 
otr benefits occttring in t'e future than would society
asarr.lrolu..(2)Tlrercisaltargrttrlcllt|brusirrgirlorr.ertliscountrateforsocietythanfor
irrdir.iduals as the lo$'cr the discotrut rate tlte ntore inrpt>rtauce is 
placed on future returns'
Horr.er.erthereisadatrgertlratifthcrcisalorvcrpublicSectordiscountratethantheprivate
sector,inferiorprojectsinthepublicsectorcoulddivcrtinvestnrentawayfromsuperior
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private sector projects. (3) Another inrpprtant factor for consideration is the lorver cost of
bon'o$,ing by goventrttcnt cotrtpared rvif h the priVaf e Sector' The private sector pays a risk
prCrliupr oyer that of gOventntent, because 1vitlr goyelTtnlent there is less risk of default in
debt repaylent than iryit[ t[e privatc sector. Goycnttttcttts also have a greater opportunity
to sprctd risk oycr a u'ider rallge of projects thalr the private sector'
5.2 MECHANICS OF DISCOUNTING
Although spreadsheet software and financial calculators have taken the drudgery out 
of
discounting it is useful to review the underlying nrethodology.
The net present 
'e,lue 
(Npv) of each altenrative may be calculated by applying the
follos'ing fortrrula:
Bn-Cu
NPI" = (l +r)o
Where NPV is tfie net present value, B, thc expected benefit of the programme in 
period t'
C, the cxpected cost oIthe progranrtlte itr period t, n the total number of time periods' 
and
r the discount rate. If the values of the costs and bcnefits are known, this fomrula 
can be
evaluated easily using Spreadsheets, business calctllators or tables' The formula 
assumes
costs and benefits for period t occur at the end period t'
Present values are inVersely proportional to the magnitude of the discount rate 
and the time
Iroriz_orr of the costs a'd benefits. For exanrp'le, S 100 irt one year's time discounted 
at l0olo
has a present Valuc ots90.9l (that is s90.91 cotrld be irrvested at l0% and yield $100 
in a
1,ear,s tirlc) s'hilc Sl00 in a )'ear's tirtte cliscorrnted by 57o rvould have apresent 
value of
s95.l.l lrr arrotlrcrcsanrplc.sl00in l0years'rirttcdiscountedatl0%hasapresentvalue
ol-S jS.55 rr.lrilc. S 100 i' fir,c years' tilrc discountcd b1' I {) lzh yields a present value of $62'09
(scc'fablc' 5.I ).
Tlre prcrgranl-llcs clc.scribed in Table 5. I all have identical total present 
values if discounted
at 0'/o (urtdiscotrrttcd). Progralllme A records a presetrt value of S72'170 
(Ar) when a
discount rate of 5% is adopted but shows a negative present value 
of $85'540 (At) when
lY Guy scott (2000)
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discountcd at 10?i,. Tlre cffect of clifferc't titttc pattcnls of net berrefits is dentonstrated 
by
progranlnles B arrd C. Pragrarrtttte C fias a highcr total prcsent value tharr progran]me B
because positive llt-t bcllefits occur earlic'r'
Table 5.1: Effect of Different Discount Rates and Different Time Patterns 
of A
Programme's Net Benefits on the Net Present Value (NPV)
PeriodPrograntmeA,ProgranrnreA,ProgranrmeBProgrammeC
Net benefit $(000) Net benefir $(000) Net benefit 5(000) Net benelrt $(000)
:.-, p*-, Cr-' Ptr Ctr PV CV PV
-700J0)(-700.00x700.00)(700.00)t7oo.oo)(700.00)(700.00)(700.00)
Atc 1l0 (700.00) (700.00) (iuu.uu) (/uu'uu, \/uv'vv/ \''
1100.0095.241 0. 090'911.000.95489.00465. |
2 100.00 90.70 100'00 8?'64 2'00 I '81 2s6'00 232'20
3100.0086.38100.0075.134.003,46128.00110.57
4 100.00 82.27 100.00 68'30 8'00 6'58 64'00 57'65
5 100.00 78'35 100.00 62'09 16'00 17'54 32'00 25'07
6 100.00 74.62 100.00 56'45 32'00 23'88 16'00 I l'94
7 t00.00 7l .07 100'00 5 I '32 64'00 45'48 8'00 s'69
8 100.00 67.68 100.00 46'6s 128'00 86'64 4'00 2'71
9100.0064.46100'0042,4|25(1.00165.022.001I.29
10100.00(11.39100'0038.55a89.00300.201.000.61tv
Discouttt rate Pcr
FO/J/O 109/o svo 5%
5.3 APPROACHES TO DISCOUNTING
Lisconrlr et al. (199(r: 2lE) assert that thrce approachcs to discountingcosts and 
benefits
frorl tltc pcrspc-clivc- of socictv havc gailccl protttinettce in recent 
years' These are: ( I ) the
social ratc of'tittt,-- prcfct'clcc (SRTP). (l) thc social oppofltrrrity cost (SOC)' and (3) the
sltaclol -pricc-ol:clpital (SPC)'
An.rr* c..sirrt,rcd tlrc rliscou'l ratc to bc- cretcr'riuctr b1'the 
i.teraction of tinre preferences
and clinrinishirrg triarginal utility. Ilc clescribed the relationship 
as follows:
(l ) utiliti, tinre preference * (2) growth-of-cottsttnrptiotr decrease 
in marginal utility
url,J," 
,oo.oo ,r.,r roo.oo,rr.ro, roo.oo,rr.oo'' roo.oo ,or.*t
( ) denotes a negatile benefit = a cost, cv :u.r.nt or nominal value' 
PV = present value
= time preference in goods = interest rate (Arrow ' 1976: 123)
W Cuy Scon (2000)
5.3.1 Social Rate of Time Preference (SRTP)
SRTP is the rate at u,hich society is prepared to trade off present consumption for future
consunrption. Accordingly, tlre social discount rate should reflect the opportunity cost to
society of alternative benefits forgone. lt is assumed that individuals in society would
rather have a beneht now, while putting off a cost as far into the future as possible' Time
preference is the marginal rate at which individuals within society are prepared to forego
present consumption for future consumption. Goodin ( 1982) argues that human psychology
should not necessarily be applied to public policy'
This rate will not necessarily coirrcicle with goventment bonowing rates, private sector
discount rates or t|e nrarginal rate of return ort capiral (unless perfect competition exists in
all markets). tv{ethods used to select the SRTP range from the real rate of return on safe
investrrrents (govenrment stock) to market interest rates' These estimation procedures are
outside the rnain foctrs of this study and accordingly will not be discussed'
5.3.2 Opportunitl'Cost or Social Opportunity Cost (SOC)
Displacing Private Sector Investment
Thc ratiorralc ulderlyipg SOC is that if too lorv a rate is used' public investment could
..cro$,d out" or displace more "profitable" privatc iltt'estnrent. The Soc is equivalent to the
private sector lrargilal beforerl tax rettlrn ott invcstntent' This rate is a tneasure of the
opportuliit), cost of resourcr.'s collstlnled by tlrc project rtnder investigation' It is the
*,eightcd a'crage rntc of retum tlut could 5a'e trectt achicyed from the projects displaced
by,tlrc- in|estntcut. Bauntol (l()17:163) statcs' ""' the correct discount rate for the
evitlultion ol- I qovcnlnlcllt projcct is thc pcrccntage rate of return that the resources
tutilize-tl rr ttttltl otllcr\\'isc proViclc in the prir.atc sr--ctor'"
Taxcs are a transfer pa).ntent fronr a socictal perspective. Jh" before tax return 
is
appropriate because this is a meastlre of the output accruingto society' Part 
of a
firm's earnings goes to society as taxes and part in the form of profits 
(Arrow'
1976 t27).
ll/ Guy Scott (2000)
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SOC involt'es cllcrtlatirrg tlrc rveighted averagc rate of return on all investtttents'
Horvet'cr, the n'eightcd average rate of rctunl on all investments is unknown and 
for all
practical purposcs not possible to estinlatc rvith accuracy. It rvould only be valid 
to equate
govemnlcnt discottttt rates with the private sector if all the government funding came from
tlre sanre sources as corporate funding (Anow, 1976: 125)' Some governnlent funds are
derived from taxation and the opportuntty cost of this funding is more corectly related 
to
private consumption and investment opportunities foregone and the deadweight 
loss of
taxation. Many investments avaitable to individual small savers yield lower returns 
than
those from corporate investment opportunities'
Opportunitl' cost of future consumption
A variant oI the opporttrpity cost argument is cxplained by Johannesson 
( 1996: 127) who
notes that a reason lor cliscouttting is that resources col'lsulned in the present 
could instead
be used to increase future oulput, that is, the discount rate should relate to the 
real return
on invcstrne'ts. Goodin ( l gg2) contends that the opportunity cost argument only applies
to investments and not collsulllption. However, in nry opinion' this argunrent 
fails to
recognise the link between investment and output in terms of goods and services 
available
for consunrption nrade possible by the investntent'
5.3.3 Shadorv-Price-of Capital (SAC)
Liscorrrb ct al.( I 996: 2l 8) asscrt that thc opporttrnity cost nlcthod has been transcended 
by
the shirdorr'-pricc-of-capital tccltttitlttc. This proccdttre firsr couverts 
programme costs into
consunrptiorr losses caused try thc ittvesttrtcnt. Progratrtttre bctrefits 
are then converted into
cot.ts'tltption gai.s ge'crittcd lry t5c project. TScsc cortsttntptiou losseS and 
gains are then
discrruntccl to pfL-scnt valucs using tltc socill ratc of tinre preference' 
SAC in effect means
thar rhc social rarc of tirile prcl'cretrce (SRTA) is prefierred as the discount rate because 
the
ainr of all investnrent irctivity shotrld be increased consumption for society' 
while this may
hrrr.e a sound theoretical basis, clifficulties irt underlaking the appropriate 
estimates make
its practical application diffictrlt (or impossiblc) for nrost policy makers and analysts'
ll Guy Scon (2000)
5.3.4 Dinrinishing I\targin al Utilitl'
This argurrrcnt rclies on tfie prerrrise tltat ecotlonties corttintle to expand and consumption
contirrues to increase. The larv of decreasing nrarginal utility means that a unit of
consuntption will yield nrore uf ility in the present than in tlre future (as total consumption
rvill bc higher in the furure). As not all economies grorv and as the rate of growth maybe
variabte over tinre the discount rate tteed not be positive or constant over tinre (Goodin'
1982:57).
5.3.5 UncertaintY and Risk
Frequently discount rates are increased to providc a matgin to cover risk' Goodin (1982:
56) agrees that expecterj values sfiould be adjusted for risk but points out that this is
technically and philosophically different front cliscounting' Risk does not necessarily
increase ovcr tinle attd even if it did rvhy slrould it ittcrease at a constant rate?
5.4 LOOKING BACK AT PAST INVESTMENT DECISIONS
Policy managers sftould be aware that the discount rate used to appraise an investment 
in
the planning stages need not necessarily be identical rvith the rate used to value 
the
investment in hindsight. One could argue that a rate used before the investment is
undcnaken may include a margin to take account of possible over-optimism or risk'
Horvever, $,herr evaluating the perlomrance of already implemented investment
progranllltcs a ntore appropriate rate migfit be thc actual growth in real output in the
econonty ovcr the periocl as this is tlre opponullily cost or tlte retttm that could have 
been
achier.,cd by tfte resoulccs displacecl by tftc progran]n1e or project (Wells ( 1985: I I )' When
lookirrg [rack ilnrl r.\'illunting tltc pcrfortrtatrcc oIpast illvcstnlerrt decisions processes 
(as
opPoscd tr.t invcstnrcnls tltctrtselves) it is inrportattt to cottsider the infonnation that was
nvarllblc at lltr' titrtc dc'cisiotls \\crc bcirrg ttiittlc'
ll Guy scott (2000)
5'5DISCOUNT|NGCOSTSANDCONSEQUENCES
Non-tradable goods such as huntan lives introdttce trade-off problems' This does not
necessarily mean tlrat a policy that costs lives catrnot be justified (Goodin' 1982: 63)'
Trading one life for another can be justificcl rvithin a progranlme (for example' closing a
rural hospital may cost lives but this could be traded off against lives saved through
expansion of an entergency flying doctor service). It is possible to justify trading lives for
lives, but it is difficult to justify trading lives lor more of sonre unrelated good such as new
carpet in govemment buildings. Atthough one cannot necessarily say that all lives are
equivalent, the use of such measures as quality adjusted life years or healthy year
equivalents, are useful ways of comparing outcomes or effects induced by health care
interventions or programmes. These topics were discussed more fully in Chapter 3:
Valuing Health Outcomes.
There is general (btrt not universal) agreement that future costs and consequences
(outcomes or effects) nreasured in non-money units should be discounted at the same rate'
viscusi(1996: 144)notcsthathealthcffectsshouldbcdiscountedbut""'Becausethereare
no nrarkets for explicitly trading health status across tinre, the choice of the appropriate
discount rate for health status has renrained a substantial subject of debate." Drummond'
Stoddart and ronance (1987: 8l-82), Drummond et al. (1997: 107-109), Gold et al''
(1996), Weinstein (1996) and Weinstein and Stason (1977) discuss this concept and
generally agree tltat costs and elfects slrould be discounted using the same rate 
for both'
For example. cffccts such as QALYs (quality ndjustecl life years) gained as a result of a
ficalth prograptn]c shotrl{ be tliscourited in the satrte \\'ay as nloney-quantified costs and
benefits.
\\,einstcirr and Stasolt (1q77.720) srrrtc thtt they hirie not ussumed a year of life in the
future is $orth less tltatr ottc itt thc llrt'scttt, or that it is possible to invest a life year in the
prcscnt to obtlin nrorc lifc. lears in tlrc fittttrc. Tlrcy lrgtre that if a cost-elfectiveness
arrrrly,sis is copductetl lifc years arc bt'ittg yaluetJ relative to flollars' Dollars can 
be invested
to yicld nrore clollitrs in thc future thus a lifc ycar in the future should be discounted'
W Guy Scott (2000)
However, Goodin (1992:60) argues that unless everything is tradable in terms of something
else then the argument for discounting all costs and consequences by the same rate is
weakened.
Some studies in cost-effectiveness analysis and cost-utility analysis have used lower
discount rates for effects or have not discounted effects at all. Keeler and cretin (1983:
300) discuss the issue ofdiscounting nonmonetary effects in cost-effectiveness analysis and
comment .....if the ability to produce the nonmonetary effect does not diminish too 
quickly
over time, failure to discount benefits implies that programmes are always improved by
delay.,, Although this statement lacks precision it nevertheless highlights a potential 
issue
in a number of public policy areas in addition to health' If the sfream of future costs is
discounted at a higher rate than the flows of future benefits then the net present benefit 
of
the programme will be increased' As an example, the present value of a $100 cost in ten
years time discounted at l0 percent is $38.55, while the present value of abenefit of $100
occuring at the same point in time without discounting is still $ 100' This gives a net 
present
benefit of $61.45 ($ 100 - $38.55), while if the time period was halved the net present value
would be lower ($100- 562.09: $37'91)'
Most studies employ a uniform rate over all time periods and categories of goods'
Although Goodin (1982: 67) challenged this practice and states that there is no reason to
assume that the same discount rate is appropriate over all time periods or to all categories
of goods, he advanced no practical alternative'
These issues are equally relevant to other areas of public policy analysis' for example' 
an
engineering project may save lives or work place legislation may increase safety and
reduce accident rates.
5.6 REAL AND NOMINAL RATES
Discounting has nothing to do with inflation. (Discounting future benefits and costs
accounts for the opportunity cost of not incurring those costs or receiving the 
benefits in
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the prcsent). costs arrd bencfits nlaybc adjusted 
for inflation and discounted using a 
real
rate, or they r]1ay be evaluated in rronrinal 
tenrts and discounted using a nominal 
rate'
Consistency is vital. lf nominal costs al'ld bctrefits 
are discoutrted by real rates or if real
costs and berrefits are discounted by rro'rinar 
rates, irrcorrect results will be obtained
(Florio, 1990: 109 antl Sugderr and Wil|ianrs' 1978: 36-39). 
N.Z. Treasury (1996: 4)
reconrmend trrat 
..rf future costs are estirnated in nonrinal dollars 
then they need to be
converted into real dollars before being 
discounted by a real discount rate'" N'Z' 
Treasury
alsonotetlratthisprocedurerequiresanestimateofexpectedinflation.
In practice most evaruations are conducted 
using real or inflation adjusted values 
with a real
discount rate. It is important to note that if 
a real rate is used to discount' with 
costs and
bc'efits nreasurecl i, cunent prices a'd u.it costs, 
trrerc is an i'rplicit assumption that the
variotrs cor.'po.cnts of costs and conseq*e*ces 
*ill inflate at the same rate in the future'
This is not neccssarily so, but u'less there 
is clear *'idence to the contrary it is usually 
a
reasonable assunrption to nrake. N'Z' Treasury 
( 1997: 8) indicate that the consumer price
irrdex rnay be used as tlte expected rate 
of inflation' Tlre GDP deflator may in 
some cases
be better.than tlre constlll]cr price in<icx as it covers 
a 
"vider 
range of goods and services'
Frequently a nonrinal rate rvill need to be converted 
into a real rate to use with future costs
and benefits in real dollars'
The folloNirrg formula lrlay be used to convert 
a nonrinal rate to a real rate (NZ Treasury'
1997:8):
Where:
r, = l'clll discottttt Llltr-'
f,, = tlol1lil'lill disctrttttt rate
i = espccted ratc of irtflatiort
I +l'
-nt
r=
' l ni
r -itl
I *t
An nppt.r-.rxirrlatiott cottrtrrottll'used in llnirnce 
is to sinrply subtract the inflation rate 
from
t'e 
'ourinal 
rrtr_, to deri'e a real disco.rlt or interest rate 
. This is a good approxinration at
low ratcs of i.fratiorr but *.ill introduce increasi.g 
enors as the price inflation rises 
(see
Sugden ancl Willianis' 1978: 37)'
@s"ott (2ooo)
5.7 DISCOUNT RATES ln- USE
Viscusi (1996: 144) reconrnteuds that though itt nrost situatiorrs nredical decisions will not
be sensitive to rcasot'lable variatiotts in thc discount ratc. sensitivity analysis 
should be
conducte{ using real tliscount rates rapgirtg fron l o/o to 7n/o.
Although tfie cost of funding to governn]ent etrterprises for invesl'ment purposes is not
usually equivalent to tlte cost to society it is never-the-less uselul to consider 
government
capital charging costs and rates.
Thc Ne*, Zealand Treasury i' a guide on cstintating thc cost of capital for Cro*'n e'tities
(N.2. Trcasury, 1997, Appendix I : 29) conrnlent orl tfic rvide divergence of practices
intentatio'ally for discount rates for capital charging ancl capital budgetirrg' The 
UK
governn.lent uses a risk free rate for public health capital charging to the National 
Health
System. The US Cerrtral Budgeting office also appll'a risk free rate' Both the UK 
and US
rates are equiva[.'rtt to a private sector rate adjtlsted to a risk lree rate' The Australian
Govetnntettt Departntc'trt of Finatrce apply a private scctor rate with an allowance 
for risk'
In the past, in Neu, Zealand, a comnton real discourrt rate lvas used for all public 
sector
investment (lrom the perspective of the entity) and economic evaluations from the
perspectiye of society, Departments are now required to pay a return on capital to 
the
Govenrmenr, *,hich is called a capital charge. In a N.Z. Trcasury guide book 
(1991: 32) it
is stirtccl..Dr.partt.ltcnts slroulcl rl1akc irrvestnlcnt clecisions $'hich generate sr'rfficient retltrn
for tlrcr. trr pa), c l'etu't ott capit*l lo tltc Co'crtttltctrt"' Trcasttry state that 
"While the
capital clrilrgc for clclt dr'pllfll1]cl]t tttnv bc ttsccl ls fltc tliscotruL rate wlren evaluating
investrtretrt, tjift-crcnt rlltes llla)'hc ttrorc appropriAtc ftlr s1'tccific investments' The rate
chosen $'itl tlepend on tlrc'rlskitress of tlrc ittVcstttrctrt " Tltc capital charge rate reflects
so\.crt'.tc't llru'ciul cL)sts ol'capital not tlrr'econoll'lic cost to society which is tleasured
by thc social rste of discount. Tltc capital cltrrgirrg and social rnte of discount 
may rvell be
diffcrent.
W Guy Scott (2004)
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ln t|re nrid 1960,s tlrc Nr--rr.Zcaland public sector rcal discottnt rates in conrnton 
use \\'ere
arotr'd 50zt arrd rising ro 70hin trru- ratc r g60,s. Trrc'sc rates $,ere comparabre 
to therr current
go\,en11eltt borrog'ittg rates. I1 l97l 1-rcasutl ittstructed departments to use 
a real
discourrt rate ol- l0%o. T[e selection of rhis l0% lnts wts probably influenced byUS
official pubtic sector rates iu the late 1960's' (See Copeland and Rose' 
1975: l5; Wilkinson'
1982: l).
The UK and US govemmetlts encouraged the use of a public sector 
real discount rate of
I0%inthemid I960s(Goodin, I982:59). Anorv(l976: I26)consideredthatthe I0%rate
reflected the high rate of technological change in the previous 
two decades and maintained
tlrat as the rate of change in technology had fallen a lower rate of 
6 - 7% (Arrow' 1976:
139) would be more aPProPriate'
N.Z. Treasury (1996: 4) note that while a real cliscourlt rate of 10% should 
be used in N'Z'
Treasury econonric eyaluations, the capital charge rate (then ll '5% nominal) should 
be
used for financial ar"ralysis. Fttture costs in nonlinal dollars should 
be converted into real
dollars before being discounted by the real rate'
Lisconrb et al. ( 1996: 231-2) nrake the foIlowing cotllparisons of recommendations 
|or and
usage ofdiscount rates by a range oforganisations'
. The US office of Management and Brrclget guidelines for cost-effectiveness
a'alysis reconrnrend using the real rreasury borrorving rate 
applicable to the time
horiz-on of rhe proj ect being cvaluated ' Rcccrrt rates range between 
2'lo/o for a 3
ycar tenll to 2.8% for 30 ye:lrs. The Oflrcc rcconrtnends using 
a real rateof 7oh
(redttccdfr.ottrl0%inoctobc'r1992)lorcost.bctrcfitanalysis.
.TlrcUSCcrrtc-rforDiscascCorrrrolatldPrcr,etttiorr(CDC)suggestusingabaseline
rl.irlratcoi5%rr'ithsensitir,itl,anirlysisbctrr.ectt0%and8%'
. 
'l-hr. LIK Nntionlll Health Serr icc (NI{S) ativisc ttsittg a real rate of 6%'
. 
'l-lrt \\'t-rrltl lllrrk in l99J clu-cirle'r-l to ttsc a rt'rll r;ltc of3% fordiscotrrrtingoutcome
lllcilsllrcs irt cost-eftbctivctrcss stttdies in hcalth'
. A srlrvcy oI thc' illtcnlatiollirl literattrre reportirrg economic 
evaluation studies in
hcalrh i'ciicates that 5% is a cornnronly used real discount 
rate'
W CuY Scott (2000)
Lisconrb ct al., ( 1996: 213) lttlr'ocatc usillg riltes of 3'll and 5% rvith sensitivity 
analysis in
thc rangc of 0,)ir to 7ozir. Thcl' colrtcnd tlrat cltrent cvirlencc of real econontic 
growth
supports a basc real riskless rate of 3% btrt intemational contparisons 
require 5% to be
used.(Sce-a|so.5.4LookittgBuckAtPrlstllt'c's|ntailDecisions)
Turning now to the health sector. Dt'umnrond et al' (l 997:73) offer the follorving advice;
(a) costs and consequellces should be presented undiscounted and in a form 
that allows
others to evaluate the impact of applyng different discount rates' 
(b) use for the base case
either the locally accepted discount rate or real rates of 3Yoand 570, 
(c) perform sensitivity
analysis at rates of 0,3 and 5olo, and (d) highlight the discount rate used where 
it has an
major influerrce on the results. Drunrntond et al' (1997: 107-109) also note that 
although
there is somc diyergence of opinion as to rvhetficr future health effects 
should be
discounted,tltcu'eightofrhe:rrgumelltisfordiscottnting'
Althougfi Treasttry advocate using a discount ratc of l0% for economic 
evaluations' the
nrost conrnloll rare usecl intenrationally and in published health 
economic evaluations is
5%. Accordingly. it is rccontnrended tlrat 5Yobe used as the base case and 
sensitivity
analysis be performed using discount rates ranging fronr 0% to 
l0%'
5.8 CONCLUSIONS AND RECOMMENDATIONS
Although therc is a lnrge body of litcrature otr tlre social discottnt 
rate much of it is
contrarJictorl,i.urcl 
,or 
ol-litth-, practical valuc to thc policv analyst and public sector 
nlanager
\,hcn nrlking actull dccisiotrs. A rcvicN ol thc rclc\attt literature atrd current 
practice
irrdicates trrirt trrc [ollo*.ing practical rcco.rnrencrutiorrs *.urd be appropriate 
for public
polic5,cr,altrlttiotrso|.lrcaltlrcareintltccurrc.trtNerr,Zcalalldcontext.
Discoupl all crlrectctl futurc cosls altd bcncfits ($'ltether nrcasured in 
money terms
or irr sonrc othcr Nay) to present valttes using a collnlon rate of discount 
for all
lV Guy Scott (2000)
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eategories of gpods and for all tinre periods (discounting is not 
required when all
eosts and berlglits occur in tlre'salnc time period')'
. pf€sen,t all costs and benefil,s in nr,anner tllat allowsreaderfi to apply 
discount rates
of th'cir orvn choice'
rUsearealdiscountflare.withrealr:aluesofcostsandbEnefitstosimplifyanalysis.
.Useabasecascrealdi'scountratethatreflectsthel'oclallyacceptedrateorratesgf
3 and 5% with sensitivity analysis ranging from 
no di'scotrnting (0)% to l0%' that
is, (0, 3, 5 and l0o4 are suggestions see pago 135)'
.Iinternationalcompar.iso'ngwouldbefacilitatedbyusingO".3and.5or6asrealdigoount
rates.
,r Be awale of the,coRseguences of theselection of a discount 
rate' If' fbr exarlrple'
a high rate ( I 0.9/o rather than 5%) is chosen this will reduee tho 
number of potential
projectsabletobeulrdertakenandlvil|alsodecneasetheviabilityofprojectswi.th
lottg.temr rather tha'n sJrorl'ternr benefrts'
This chaprer has discrussed dis-cour,r ing of cssts and 
effects' health outcomes'the next
Ctrapteleovers.lherang€of,econoflrlcevaluationteclrni'quesofrelev&Dcetopolic 
arralysis.
ffiGoy Suotl (2000)
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Economic Evaluation Applied To Health Poliq'In Nery Zealand
CHAPTER 6: ECONOMIC EVALUATIOI\
6.I INTRODUCTION
This chapter discusses the theory underlying economic evaluation and different techniques
(cost-minimisation (CMA), cost-effectiveness (CEA), cost-utility (CUA) and cost-benefit
analysis (CBA)) used in health policy analysis.
Table 6.1 presents a classification systenr for health policy evaluations and illustrates how
econonric evaluation fits into this scheme. Econonric evaluations consider both costs and
health related outcomes and/or compare two or more health care interventions, programmes
or policy altenratives. The objective of econonric evaluation is to assist u'ith policy
decisions relating to resource allocation. Partial evalrtations consider either costs or health
related outconres in isolation or do not conlpare options (see Drummond et al., 1987: 8;
Drummond et al., 1997: l0)'
Table 6.1: T1'pes of Health care tntervention/ Policy Evaluations
Type of ,4nalysis Ohjective/ use
143
Cost-oFillness
Outconre analysis
Cost-o t'-trcrtntcrtt
ldenti[y and quanti[y costs ofan rlltress.
ldentiti' and quantily hc"lth related outconles'
Itlt-'ntil'v and quantify cosls of trcating an illness'
.\llocrrion ol rcsotrrccs bctrvccn lreatlllents l'or the same condilion'
Orrtconres are identlcal in all respccts'
Allocatron of resourccs b(:t\\'Ccn trciltrllenls [br the same condition.
L)trtcqnres arc ln Silntc dirrrensirltr btrt acfiievu'tl to differing degrees'
r\llt)clltlorl oIl-.'sourccs ilcross dll'lcrcl)t trcrtlllt'nts for over a range of
cl)|ldrtlor'ls $ itltrn thc he:lllh scct()r'
Allocation ol'resourcc.s bet\\'ccn different u5es across a whole economy.
-!
q)
q
AJ
.n\,
\
o(J
{
Cost-trttninristtton
Cost-c l-li'ctrr'cncss
('ost - trt rl tt r'
Cost-bcrtcht
ta
o
I
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Econonric cvaluatiorr is rrorv considcrecl in nrore dctail. Hcalth related outconte analysis
rvas discussccl irr Chapter 3: Italtting l-laulth Outcotnes antJ costs of relevance to an illness
or its treattlcnt were covered in Chaptcr 4: (bst'r'
6.2 ECONOMIC EVALUATION AND HEALTH
The purpose of economic evaluation of health care is to assess the economic efficiency
consequences of health care progEmmes or interventions' Economic evaluation may be
simplified by regarding all changes in resource usage as costs or the causes' and all changes
in health related outcomes as benefits or effects of the irrtervention (see Donaldson, 1990)'
If this approach is adopted. a health care intervention or programme may be likened to a
production process rvhere outputs and healtlt relatc'd otltcomes are generated lrom inputs'
T[e inten,entiop cor"tsunrcs inputs of resources to produce outputs of health care goods and
services intendccl to alter healtfi otltcomes. This is shorvn in Figure 6'l '
Figure 6.1: Health Interl'ention or Programme As a Production Process
Inputs
= Costs
= Cattses
lrurcnveruTloN
OR
PRocnnuue
Outpttts
: Health
goods and
services
Health related
outcomes =
Health
consequences
Health effects
{{-+
Direction oI causatiotr {
I'puts or opg.r6rtur.lit), costs altcred bv rlrc irrtcrvctrtioll rcprt-scnt the changes itt resource
tutilisatiol crrrsetl b1'tlre lrealt[ carc illtt-n't'nttott or policy' T[at is, the intervention may
col'lsLltlt!'or crcilte l'csr.lilfcr-'s. 1'he opportttttitV cost of rcsottrces used is the value of those
rcsourc!-s ip tfieir ltcxt best alternatiye rlse or tlte yalue of tfic gtrods and services they coUld
W Gny Scott (2001)
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have protlucr..d, (Costs are discussed in chapter 4). As rcsource opportunity costs ntay be
either itrcurred or avoiclecl, thcy should [rc- ntorc corectly termed netl] costs'
Outputs are tlte goods and services produced which are intended to' but may not' cause
changes in health related outconles. Health relatcd outconres represent the consequences
or effects o I the intervention on health status. Although the changes in healtlr status are
intended to be beneficial or positive, interventions nlay also have adverse or negative
effects.
As an intervention results in changes in resource usage and is intended to alter health
related outconles economic analysis may be further sinrplified as shown in Figure 6'2'
Figure 6.2: Interv
HnnlrH cARE
INTERVENTION
entions Change Costs and Outcomes
I{ | Cllongcs in resource opportunity costs I
{
Econontic gnalysis oI treatnrent options involves comparing these changes in resource
opporturrity costs rvith the changes in health related outcomes produced by the treatment
or intervention.
Incremental analysrs is used to isolate and measure opportunity costs and health outcomes
tlrat are cftanged by the inter"*etltion, A cost or a health outcome unchanged by the
intcn'cntion. policy. or illtlcss, is in'clevarlt. Costs alrcacly incuned (sunk costs) are not
applicablc ils lhr-!'ci,lltl'lot be alterccl tr1'any'dc-cisiott nladc in the future' See Chapter 
4:
Co.st.r.
Additional costs or costs incufferl /css costs avoided or saved.
ll Guy Scott (2001)
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Dillcrenccsrr bctr\.e c-n costs and ltcalf h rclatccl otttcontes are conrparecl bctrveen
contparators; illness versus tto illness, ollc treatnlL-l]t option versus another' treatment
compared rvith no treatntent. Adverse effects of lreatntent nrust be set off against positive
health outconles,
6.3 TYPES OF ECONOMIC EVALUATION
Different techniques of economic evaluation will be appropriate for different situations'
The methodology chosen will be determined by;
. the research question,
. the arralytic perspcctive,
. relevant costs and outcontes,
. availability of data,
, the methods used to measure costs aud hcaltlr related outcomes,
. the research budget, and
. the tinte available for thc study and rvhen tlte results are required'
The research question or problent to be addressed dictates the perspective/s that should be
adopted. For exanrple, does the problem relate to resource allocation decisions within the
health sector or across the whole of society?
Pcrspectives ntay include one or ntore ol thc follo$'ingl society, health care provider'
health care pttrcltascr, privatc inclividual. The analyic perspective deternrines the range of
resource cosrs (sec Clraptcr 4: Costs) and hcalth relatecl outcontes that should be
considerecl. lf vie$etl as a cotrtinuunr. CBA is at one enci (widest perspective' most
corrrprelrerrsir.e) and cost-rTininrisation is at tltc ofher end (narrorvest perspective' least
contprcltcusivc ).
rr Changc itt costs = costs ittcttrrecl /ess costs avoided; change in benefits/ outcomes
: benefits/ otttcotrres gained /ess outcotnes/ benefits foregone'
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Data ayailatriliti,ll.lll cletcrnrinc *'hich costs and hcalth outconles can be measured and their
nterhod of qualtificatiorr. Stutly'clcsigrr nral'also trc ittflttenced by the size of the research
budget. For exaprl.rlc-, r,cr1,fes'cost-utility studics (cliscussed later in this cltapter) have
been undertakerr in Nerv Zealand. T[ey are more conrplex and costly to conduct than cost-
eflectiveness stuclies (discussed latcr in tlris chaptcr) and cost-effectiveness studies may
yiekl sufficient ittfonrtation for decision makers' purposes'
As the aim of a health care inten,ention is to alter health-related outcomes, efficiency is
more usefully evatuated by comparing net resource cost against net health outcomes rather
than against outputs of health care goods and services (Weinstein and Stason, 1977)' One
treatnrent option is rrrore efficient than another if nrore of the beneficial health-related
outcomes of interest can be produced u'ith thc silme quantity of inputs or if the same
quantity of health outcon'les can be achieved using lcss inputs.
The u.ays in u,hich health related outconres(discussed fully in Chapter 3: Valttittg Health
Outcotrtes.)are t"neasured or taken into account provides a means of classifying economic
evaluations. Table (r.2 sho$,s that for alt techniqucs costs are measured in money values'
Cost-ntininrisarion assutnes health related oulconlcs of comparators are identical' Cost-
effectiveness analysis considers alternatives that produce the same health effect but to
varying clegrees. For example, two alternative treatments may both reduce blood pressure'
but they rnay differ in effectiyeness. With cost-tltility analysis, the outcomes are measured
in utility values. Cost-benefit analysis measures both costs and health related outcomes in
nloney uttits.
W Guy Scou (2001)
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Table 6.2: Economic Evaluations I\ta1'Be Classified According to the Method of
IVteasuring Health Outcomes (Effects)
Technique Cost Health related
nreasurement outcome
Perspective
measurement
Cost-nrinimisation Moneyvalues
Cost-effectiveness
Cost-utility
Cost-benefit
Money values
Money values
Money values
Assunred to be
identical
Clinical/ phYsical
measures
Utility nteasures
Money values
Decision maker
Decision maker
Societal
Societal
6.3.1 Cost-Benefit Anall'sis (CBA)
The discusslon contntences $'ith CBA because (in nry opinion)' all other types of evaluation
may bc regarded as subsets of CBA. Marry of thc ideas and concepts embodied in CBA
underpin all other economic evaluation types considered in this chapter'
As cost-benefit analysis (CBA) takes a full societal perspective the widest possible
inrplications of the use of resottrces is considered. All relevant societal costs and benefits
are takel ipto accoult apcl rleasured in nrorrey values. A benefrt may be gained or lost 
(a
negativc bcrrefit is a cost) and a cost nliry be ittcurred or avoided (a negative cost is a
benelit). CBA is also refemcd to as social CBA or as BCA'
The qoals of public policies cirtr be grouped itrto trvo broad categories; allocative
cfllcir.rrcr,. aptl ciistribtttiprtal ccltritl" As Cost-bcncfit analysis focuses on allocative
cflicictrcf it could br.- rc$artlcd i15 n 11sdcl tbr public sector decisions that would be made
if priVate nrarkc'ts firnctioned satisfactorily (Havenian and Weisbrod, 1977 136-7\'
Dasgupta et al. ( 1972)considerecl thc nrain reasoll for undertaking cBA was to ensure that
W Guy Scott (2001)
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a consistcnt set of rulcs \\'ere used to evnlttate ptrblic projccts. Fu(her they stated that CBA
is rrot a teclutique bttt an allproach to cvalttatitrg social choices'
Because CBA is concerned with the potential inrprovement in the efficient allocation of
society's resources it can cornpare a ronge of diverse outcolTles' For example' costs and
benefits of rnedical treatntents can be compared with costs and benefits of protecting the
environment or extending an airporl runway (provided all costs and benefits can be isolated
and valued and that equity changes are also considered)'
Succinct summaries oI the historical evotution of cost-benefit analysis are provided in
Pearce (1971) and Pearce and Nash (1981). The underpipning theory of cost-benefit
analysis can be linked to nineteenth cetttury welfare economic theory' French economist
Dupuit (1844) is regarded as the first to describe the maximisation of a project's net
benefits (cost-benefits) in rernrs of the nraxinrisation of societal welfare or utility'
The first practical application of cost-benefit analysis was concerned with US water
resources in the 1930's. Pearce (1971) notes tlrat the US Flood Control Act of 1936
enrbodied "the principle of corrtparing benefits to whomsoever they may accnle with the
estimated costs". However according to Pearce ( l97l ) t|e precise meaning of benefrt was
unclear and different US government agencies applied different interpretations of the cost-
benefit criteria. Attempts to standardise the methodology were made by the Federal lnter-
Agency River Basin Committee in their Green Book of 1950 and in a Bureau of Budget's
Budget Circrrlar A-47 in 1952 (Pe'arcc' l97l)'
Cost-benefit anitly'sis in the UK began to be uscd in tfie 1950's to evalttate transport
investnrerrt but it \\.as not until tlre 1970's that the nrethodology was extended to water
resourcr.s. A l9(r? UK goycrttntent q'hitc papcr rcliervipg the economic and financial
ob.jcctir.cs ol' latiopllised inciLrstrics u'as the first acknorvledgement that cost-benefit
analSsis hurl r,..[,..r.ancL- to tlrc cvaluirtiorr oIthc'sc indtrstries. The first conrprehensivetext
orr cost-trcnclrr arrtlvsis $'as publishcd in l97l by thc UK cconomist Mishan (1988' lst
edirion lgTl)itrrti ip l97l thc Llnircrj Narions published a set' of guidelines for project
evaluatiott (Dasgrrpta ct al., 1972).
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Cost-bene fit arralysis is ofterr criticised as lacking objcctivity because valuc judgtnents
cannot be avoided. "Cost-benefit analysis can ncver replace the need for sheer political
decision."(self, 1970: 9). Self also collllllel'lts that the logic of cBA requires social or
politicaljudgements at every stage of CBA. He expresses an extreme view that cost-benefit
analysis is "nonsense on stilts" and " ... its use is blocking nlore prosaic but more ratiOnal
planning methods." He states many values and estimates are notional, cannot be adequately
validated by actual exchanges and are arbitrary in that a ""'very wide range of values can
be plausibly predicted, depending upoll innumerable opinions and assumptions"' In
addition, Self was concerned about the possibility that important items may have been
excluded.
Drunrnrond (1993: 108) in discussirrg CBA in hcalth and health care comments that
analysts should consider other social objectives besides efficiency. The analysis becomes
more of an interchange betrveen the analyst and the social decision maker, and a forum 
for
making the decision nraker's values explicit." Druntmond calls this the decision-making
approach to CBA. Pearce and Nash ( I 981 : 9 ) comnrent that "... a CBA will be sensitive
to the value judgeurents underlying it." All value judgements and assumptions should be
transparent and the irnplications of changing them should be provided'
Shadow prices are used rvhen market prices do not reflect the social value of the inputs 
and
outpLtrs of a project, or u'lten no nrarket price exists. Consumer sovereignty dictates that
shadorv prices stlould be bascd on *'illingness to pay criteria' Where an output or an input
can.ot be quantified thc itcrls shoultj bc listetl ancl dcscribed. Many health-related
outcontcs do not h;rvc nrnrket prices artd it is oftcrl diillcult to estimate values on a
willingness to Pal' basis.
If *,illinc,ness to pr!,criteria are usecl to cvaluatc trc-nefits thcn it is likely that decisions 
will
favour lrigS i'co're and *'ealthy inclil'i6uals at t5e expellse of low income and poor
ildir.idurls. T[e prarginal utility of pronef is higher for lot' income individuals' Thus' low
inconie inclividuals $,ould not be rvilling to pay as much for a particular benefit as a high
lI'Guy Scott (2001)
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inconre indiviilual, Hicks (1939: 700) discusses lhc difiference in marginal utilities of
money betrveett rich and Poor.
Another kind of equity change can result from irrdividuals having divergent tastes and
preferences for the sanre change in health effect arrd thus valuing the same health effect
differenrly. A sirnilar situation ariscs rvhere diffcrent people place different values on
different dimensions of health-relaterj qtrality of life. This would result in different
rankings and trade-offs for health care interventions when different aspects ofqualityoflife
are affected. Pauly ( I 996: 107-9) discusses consequences arising from individuals having
different incomes, tastes and preferences.
For the practical application of cost-benefit analysis the basic choice criterion is the
potential improvemeni in allocative efficierrcy (the potcrrtialPareto improvement' Kaldor-
Hicks or contpct'lsatiort criterion). Iisocial bencfits exceed social costs, the gainers lrom
the progranrnre could (but need not do so) cotltpetlsate the losers, and there would still be
net gains to society. This nrle can be applied by calculating the present value of the net
benefits usittg atl appropriate discopnt rate and cfioosing those programmes which have the
highest nct prcsent value. Equity and ethical conscquences shotrld also be considered'
ln practice, decision-nrakers face different choices. Where there is a set of independent
options. the decision-ntaker must decide rvhich' if any, ought to be undertaken' If there are
no constraints on the number of prograntrttes which nray be undertaken all programmes 
that
have net present benefits greater tlran zero should be inrplerttented. However, if a specific
input is scarce, thc fcasible progranlnles shoulcl be inrplcnlented in the conrbination which
exhausts the irrput $'lriclr is scarcc lnd yiclds thc highest total NPV' The process of
ecorrorrric cvalulf iott is cliscttssed iti Cluptcr l8: /Jiscrrssirtns anrl Conclusions'
lf sonrc optiorrs lrc rilutullll,cxclusivc (that iS, trndc-rtaking olle prevents implementation
ofonc- or ntore ol-thc othr-rs). the decision-nrlker trttrst cltoosc between them' Where there
are rL-soltrcc constriritlls Or sltere progralllnles are mtlttrally cxcluSive' SOnle analyStS
advocate applyilrg fhc' berrefit-cost ratio. Thc project n'hich has the greatest ratio of
discounted bcnefits to discouuted cosl.s is chosett' Hor'vcver, this can lead to wrong choices
l5l
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being lladc as the nunteric valuc' of the ratio dcperlds ott ltow Costs and benefits are
classified in each project. Is a cost treate d as a benefit forgotte or a benefit treated as a cost
avoided? If the fonler, the berrefit-cosr ratio is reduced; if the latter, it is increased'
Interpretation of t5e cost-benefit ratio rvhere there are cost offsets requires care' Consider
a prograntnre with a present value of B-c+K and a ciB ratio of either c/(B+K) or (c-K)iB'
wherec = costs, B = benefits and K = acostoflset or a negativecost' shiftingKbetween
denominator and numerator will not rer.'erse the sign olthe ratio but the relative rankings
will alter. Evans (1984: 244 and Culyer (1989: 218) discuss this problem' Table 6'3
illustrates how the cost/benefit ratio may be altere<l by changing the classification of costs
and benefits.
Table 6.3: Costs and Benefits antl the cost/ Bcnefit Ratio of A Health
ramme
$Million Method B $MillionMethod A
Additional costs incurrcd
Less costs avoidcd
= lncremental costs
Additional benefits
Less benefils foregone
= lncrertletrtal bertefi ts
Net bcnefits =
increnrental benefirts
Addi tiorral costs incured
Plus lrcnefits foregone
= Progranrtne costs
Additional benefits
Plus costs avoided
: Programttre benefits
Nct bertefits =
Progranttrte bcncllts
100
55
45
200
60
140
95
100
60
160
200
55
255
95
Less incrctlcutnl costs L-ess proqrtrt'llll1c costs
Cosl't'rcttcfi[ rittio 0.31ll.l Cost/bcnclltratio 0.6?745
Thc rrct bu'ne.fits rr.ill bc idr.ntical urriicr lroth ntcthods olcalculation but a cosUbeneltt
ralio calculrttcd trsittg nlclhod A cliilcrs li'orn tlr.rt calctrlnted using method B'
ffirtrtrrall1'crclttsirc.n.ll.'a'.tl.'esanleliI.c(iitheydidnothavetlresame
life, proccc-tls ll.onr thc project rvith tlrc shoficr lit"e coulcl be reitrvested in anotherproject
tl-rat las diflerest c5aracteristics from the original projecr) but are of different scale in terms
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of cost (if the net prescnt valttc oItlre costs is identical there is no conflict between the two
criteria), the cost-berrefit ratio selects project A, rvhereas the net present value criterion
selects project B. Use of the intenral rate o[return (llR) to compare mutuallyexclusive
projects results in the same dilenrnra'
The project with the smallest cost-benefit ratio may not have the greatest NPV' Table 6'4
illustrates this problenr. Project A has the lowest c/B ratio and also the lowest NPV' The
C/B ratio criteria would choose project A but the NPV criteria would select project B'
Tabte 6.4: The Selection Criteria NPV and C/B Ratio May Result in Different
Choices Being Made
Cost-benefit ratio Net Present
value
Present value of
costs
Present value of
tlenefits
A
B
C
100
600
900
615
| 200
r 150
0.44
0.50
0.67
375
600
450
The choice criteria for CBA may be summarised as follows (Pearce and Nash' l98l: 46-7):
. AccePt or reject for u single Project: Accept the project if the net present value
(NPV)isgreaterthanzero,andrejectiflessthanorequaltozero.
. Rarrking:lfanentityhas unlimitedfundsallprojectswithaNPVgreaterthanzero
sSould be imptemented. If rvorking within a finite investment budget, projects
should be ranked in order of tlesirability and selected in order of this list until the
budget is csfiattsted. It is importattt to rank projects in order of desirability (another
value jtrd*uenlent) rtot on the NPVs'
. lrlrrtrtttll.t' rsc/lt.sit'r' pro"iects:Select the project u'ith the highest NPV'
Alrlrough CBA is not perfect, it is not so bad cotrrparccl $'ith the alterative (Williams'
1977: 5.14). willianis notes that CBA is itrtperfcct, prolre to misunderstanding and
nrisapplication bv the trninitiated and ullscrupulotrs' CBA should not be abandoned on the
grounds thirr ir is inrperfect. costl-,-, tliltrcult to apply and could be misused or
rurisunderstood. CBA pror.icles a logical framcrvork for public policy analysis, and 
if
assumptiol.ls and estintatioll procedures are transparent and clearly stated will provide
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val uable in fomrati on about potenti al econont i c effi c i errcy.
making, it cannot nlake the decisions. Equity and ethical
policy decision process.
At best, CBA assists in decision
issues must also enter the Public
In summary, the following should be discussed by analysts when presenting results of CBA
studies; the alternatives or comparators evaluated, the costs and benefits included or and
excluded and the reasons for inclusion or exclusion, the valuation methods' the discount
rate, and distributional changes'
Difficulty in assigning money values to all health-related outcomes led to the development
of cost-effectiveness analysis (which avoids this problem), and contingent valuation
techniques to measure willingness to pay for inrproved health (Johannesson' 1996: 2)' In
the health sector cost-effectiveness analysis (various types) has dominated CBA'
6.3.2 Economic Evaluations Other Than CBA
These economic evaluation techniques compare changes in costs in money values with
changes in health related outcomes. Health related effects or outcomes are assumed 
to be
identical, quantified in clinical or physical units, or measured in utility or quality of life
terms. These techniques focus on potential improvenrents in efficiency of resource use
within the healrh care sector or within a fixed budget. They cannot be used to compare
resource atlocatiops belrveen health and other non health uses' For example' the use 
of
resources for hip replacenrent Surgery cannot be compared with the use of resources for
nrotot1\'aY collstructlotl.
Unlike cBA, \'hcre the perspectiVe slrould ahvays be that of society, the perspective taken
in other econonric evaluations may range fronr that of society to narrower perspectives
such as that of the purcSaser or provider of health care sen'ices' Frequently, the objective
is given arrci the decision nraker $ishcs to detcnline the nlost cost effective way of
achier,ing that goal. Sonretimes economic evaluations other than cBA are referred to as
decision maker approaches. A rnajor danger rvith tliese forms of evaluation is that the
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health related outcomes of different programmes beipg considered may not be directly
contparable.
Mishan (1988: I l0) comnrents that, "... the analysis of cost-effectiveness can be described
as a truncated foml of cost-benefit analysiS:..'", "."while it is true that a knowledge of
cost-benefit techniques more than suffices for any cost-eflfectiveness calculation' it is
important to make explicit the difference in political constraints involved in the latter and'
therefore, their prescriptive significance ." Further, Misham contends that although CEA is
useful, CBA is theoretically superior. Because CEA focuses on one objective' the
technique may provide misleading information for public policy decision making'
Cost-minimisation analysis (CMA), cost-effectiveness analysis (CEA), and cost-utility
analysis (CUA) can consider only resource allocation questions for a particular disease or
at most across different diseases encountered within the health sectorbecause the full range
ofsocietal costs are not assessed.
The terminology relating to CEA and CUA in the US is different from that used in UK/
Canada. Tlre current US approach categorises CUA as a sub-set of CEA and avoids using
rhe term cUA (Gold er al.,l9g6) but in the uK and carrada a distinction is drawn between
CEA and cUA (Drummond et al., 1997). I have chosen to follow the UK and Canadian
approach as this is more clearly understood by Nerv Zealanders.
Cost-l\'tinimisation Analvsis (CMA)
Cost-nrinintisatiort alalysis (CMA) is tlte nanowest t)?e of economic evaluation where
costs alone are usc-d to conlpare hcalth care treattrrcllt or policy options' cMA is also called
cost-itle.tificatiorr s.hich is rrot arr iclcal tenn els ir ntay be confused with the cost
identification or cost eltunteratioll stL'ps in the ecotrottric evaluation process (Chapter l8:
Di.sctrs.s iotr .,1 n d C o n cltt'riotrs).
Because costs are not compared rvith outcomes. r'alid corlparisons are possible only if the
treatrnents result in identical (or almost identical)outcomes. Problems in interpretingthe
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rc'sults of CMA inr.cstigation occur if tlre outcontcs are not identical. The resttlts of CMA
are prescnted as cost per unit Of health care scn'ice suclt as, the cost per patient treated' or
the cost per patient treatnrent day.
For exanrple, the case, critical limb ischaemia, coltsidered costs per amputation with costs
per patient treated with the drug Iloprost (Chapter l4: Critical Leg Ischaenia\' ln this case
the patient outconre measure was lives saved by the treatment which would classify the
apalysis as CMA. However consideration of a different set of health related outcomes such
as quality adjusted years would reclassify the study as cost-utility analysis'
Cost-Effectiveness Analysis (CEA)
CMA apd CEA are tlre n'tost comnlonly used type of study for health and policy evaluation'
In his early text on CBA Mishan ( 1988: 6) says CEA nray be used to evaluate the costs of
altemative politically desirable proglammes and provides an example of costs averted by
eliminating a disease (expenditures on medical care, production loss and pain and
discomfort).
In health care, CEA allows comparisons to be nrade between different ways of treating or
preventing a particular disease, for example, heart failure. CEA cannot provide robust
infon-nation on resource allocation betrveen different diseases unless there "' "is a common
effect of interest (eg lives saved)" (Drunrmond, O'Brietr, et al' 1997:97)' For example' it
rvould pot help irr dctemrining u,hether resources should be clirected away from treating
hcafl failrrrc to thiit of lrip rcplacentetlt srrrgcry'
Costs are nleasured in nroney values and health oulcolllcs are quantified in clinical
r.lteasgl-cs or pfiy,sical urtits (for exanrplc, cost pcr clipical ctlre or deaths avoided)' CEA is
appropriilte rvlrcrr oulcoll1L-s rre in the sante clintettsiotl (for cxample, lives saved) but are
acltic-rcc1 to ditl-crinq cxtcllts' Corrtparisons arc tladc- betrveen identical treatment
obicctivcs but thc'('rutcol'l'lcs ttray bc acltic'rccl to yarying degrees' Examples of outcome
t]]c'surcs arc-; li'es sar.ed, life years gained, aciverse cycnts avoided, patients successfully
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treated, symptom free days or pain-free days' The treatments may be more or less effective
in achieving these outconles. The outconre could also be an internrediate clinical n'leasure
such as, percentage cliolesferol or blood pressure reduction, or cost per patient treated'
Unless the economic evaluation is being conducted alongside a clinical trial, the clinical
outcomes are determinecl from the literature or from surveys of expert opinion'
The cost-effectiveness ratio is the change in cost resulting from the intervention divided by
the change in the health-related outcome of interest. The outcome of interest is the
effectiveness measure.
Changes in resource opportunity costs
$ (AC)
Cost-effectiveness ratio
(C/E ratio)
Changes in health related outcome
(effectiveness measure)
(AE)
As an example of cEA, the net cost of medical treatment for hypertension might be
compared with millimetres of mercury reduction in blood pressure achieved' Hypertension
may be treated by two different medicines with the objective of lowering blood pressure
but one medicine may reduce blood pressure to a gleater extent' ln another example the
results of a comparison between two antibiotics with differing clinical efficacycould be
reported as a cost pcr clinical success.
Cases rclating to lorver respiratory tract infection (Chapter l2), influenza (Chapter l3) and
critical linrb iscfiaenria (Chapter l4), {o not satisfy all the criteria for CEA' However they
illustrate a range of possible outcome measures and thus extend beyond CMA and also
illustrate the difficulty of measuring health related outcomes'
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Both CMA and CEA freql'rently consider:
o Direcr medical costs from tlre perspective of the health sector
. Direci medical costs pftrs direcj nonnledical fronr the perspective of the health
sector
. Dir,Ect medical costs p/rts direct nonnredical from the ptrspeetiv€ o:f the health
sectorpllr indireet costs from the perspective of soeiety.
The decisiort eriteria and,rules for CEA
Fon allproerammgs:
Prog"ramme eoslS and,effects shouldberneasured incrementallycompared'with"do
nothing'"or placebo. Costsand eff,ectSare relevant only if theywould be churged
b-y ttne programme,
For-indeBendent p ro grarn nres :
. Rank according to the average clE. ratios and implernent them in order of c/E ratio
until the budget is exhausted-
. If there is a maxirnum aeceptabte or cutoff price per e'ffectiveness unit then all
programme$ with a c/E ratio below or equal to the cutoff priee should be
implemented,
For mutuallv exc lusive Dro gramilxesj
Rank in order of effectir''eness.
Calculata incre-mrental C/E rati s.
Exclude donrinated programnlcs and recaLeulate increm:ental C/E ratios'
Contitrtre tlti s Process-
trf tfi,ere are only lrvo options, increnrental C/E rati65 do nOt need to be calcul'ated
as the aterage CIE ratios qan be used to select the rnsst cost effective option'
a
a
!
a
W Gult SaottPALD
Economic Evaluatiort To Health In New Zealand 159
Tlre i'crenrental C/E ratio is the difference in cost between two alternatives divided by the
diflercnce in elfects. Forcxatttplc, (Costs oIprogratttntc A - costs of progranln]e B)divided
by (Effccrs of prograntntc A - effects of prograrllre B). A progranrme is said to be
dominated if the incremental C/E falls for the next (ranked in order of effectiveness)
programnte with higher effectiveness. Provided there are constant returns to scale more
units of effectiveness are always gained by excluding the dominated programme'
There is offen a distinction drawn between average and incremental cost-effectiveness
ratios. Confusion may arise because the costS are always nreasured incrementally from
either no treatment or a comparator treatment. The following definitions will clarify this
point:
. The average cost of a programme is the cost of the programme compared with the
cost of the placebo or of doing nothing'
. The average effect of a programme is the effect of the programme compared with
the effect of the placebo or of doing nothing'
. The cost-effectiveness ratio is the net change in cost [C] resulting from the
intervention divided by the net change in the health-related outcome (health related
effect) [E] of interest, CE ratio : C/E'
. The average cost-effectiveness ratio is the C/E of the programme compared with no
inten,ention or the "do nothing" or placebo option' The average ratio can be used
to rank indeperrdent progranlnles'
. The increnrental cost-effective ratio is thc (net costs of progranrme A less net costs
of programnre B) divided by (net effects of programme A less net effects of
progranrntc B)
Table 6.5 sunrrrarises the results of a cost-effectiveness analysis of two antibiotics' Direct
arrcl indirect costs are considered fronr thc perspcctive of society. Costs that rvere identical
for botlr trcatnrerrts rr.cre not evaluated. Cosrs that are itlentical between options disappear
*.hc-rr diflclct'lccs bets cctt options arc t'.rke tt. [:xlrrrlplcs of such identical costs are medical
co.sultarions ancl cliagnostic tests thtt rvould be uncJertakcn lor both antibiotics' Because
tlie outconres (clinical success rates) for eaclt niedicitte are different, this is a CEA study'
but had the clirrical sttccess rates proved to bc identical the analysis would have been
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classifiecl as ClvlA. Horr.ever, tlrerc s'ould lravc bccn absolutcly no difference itt tlte way
irr rvhich tltc' ccotlonric evaltratiol'l \\'as cottdttcted'
Table 6.5: Direct lVledical Costs of Antibiotic A Compared with Antibiotic B: An
Example of costs and outcomes in A Cost-effectiveness Analysis.
Cost IltedicineA MedicineB Incremental
costs of
medicine A less
medicine B
Cost$ N Cost$ N Cost$ N
Antibiotic acquisition cost 3,300 100 2,500 100 800 0
Medicines to treat adverse 500 20 700 30 -200 -10
events of the antibiotic
Diagnostic tests for atlverse 50 ? 75 3 -25 -l
events or treatn'lent failure
.-9lll'-'-*::::-':::--- - -- -----?9 ----91---- --ll----
Total Direct medical cost 3,850 3,215 575
Total direclneclical cost per 3g'2g 37 '64 52'27
- 
-.-ti ryl! -tf-c-ejs- - - - - -
Indirect costs (production 200 I 500 7'5 -300 -l'5
loss) week weeks weeks
Total cost 4,050 3,775 275
Total cost pcr clirrical 4l .33 43 39 25'00
success
Note: A negrttiYe cost is a berrcfit. N = ttttnrber of patients
Mcdicinr. A costs nlore per clinical success than rttcdicine B in terms of direct
medical costs, but if indirect costs arc considered, uredicine A is the most cost-
effect ive al tcrttati vc.
Tabrc 6.5 slro*-s trrrt on rrrc basis of tre.ting 100 patic-nts, the incremental cost of antibiotic
A $as sS00 higlrcr rhan antibiotic B. l\{edicinc A gcnerated ferver adverse events and
ar.oidcrj s225 irr related costs cotl]parc'ti with uredicine B. Total direct rnedical cost was
5575 [ig[cr lbrnreclicine A. I1{irect c6sr of tinte off rvork rvas $300 lower formedicine
A. Total cost (direct 5575 plus indirect 5-300) rvas 5275 more per 100 patients treated for
l( Guy Scott (2001)
E co tt o nt ic Eval u al io tt To Health Policl'In New Zeg!4!!4
nredicirre A. TSc clilical success rate \\'as g8 paf ients per l00 treated for nredicine A and
87 yrcr 100 for tttc'dicine B, a diffcrcncc of I l'
Average cost-effecriveness ratios ($ per clinical success) u'ere calculated by dividing total
direct apd total costs by the number of successfully treated patients. Direct cost per clinical
successrvere s39.29(3,850198)fornredicineAands3T.64 (3,275187)fornredicineBwhile
totalcost-effectiveness ratios were $41 .33 (4,050/98)formedicine A and $43'39 (3'775187)
for medicine B. Incremental cost-effectiveness ratios were calculated by dividing the
incremental costs by the incremental effects. The direct incremental cost-effectiveness
ratio was S5Z.Z1(575/l I ) rvhile the ratio using total incremental costs was $25 (275lll)'
Luce et al. (1996: 209) describe a health care intervention as altering costs and health
effects, but exclude prorJuctivity changes conferreti on the recipients of health care' Their
rationale for this opinion is that if t[e nleasurcnlent of changes irr health effects is
comprehensive enough, it r.r'ill capture these changes in productive output' Luce et al'
(1996) are forced into this stance because they do not draw a distinction between cost-
effectiveness analysis and cost-utility analysis (defined and discussed later in this chapter)'
Double counting of productivity changes and utility changes as a result of a change in
health related status would occur in a CUA study'
Dnrmnrond et al. (1997) suggest that a way out of this impass is to report productivity
changes separately. users of the study nray then nrake their own decisions as to 
whether
or uol tr'r irrclucle thetrr. This $'ould sccnt to bc a rvorkable solution to the different
opirriops he|J. Druttrnrond et al. (1997) also clrarv attel'ltioll to the possibility of double
counting protluctrVitv cltanges itr cost-trtility studics. Double counting traps are discussed
in Chaptr."r 4: Co.sls.
Cost-Utilitl' Analr sis (CUA)
Cost-utility attall'sis (CUA) is oftep rcgarded as a subsct oiCEA (for example' Gold'et al''
1996) or as a fialfu'a,v ltottse bettyeen CEA anti CBA' Unlike CBA' CUA avoids the
necessity,ofplacilgtt'noneyyalueotrhuntanlifeandthequalityoflife' Outcomesare
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nrcasured as utility (satislaction, pleasure, \'cll-being)' The costs of alternative medical
procedures ntay be conrpared s'ith increased qtrality adjusted life years (QALYs) resulting
from treatment given. Whereas CEA can nreasure only one dimension of outputs (for
exaprple, lir.es sayed), CUA can cotrtbinc outcol1lc catcgories (for example, lives saved and
synlptonl free days) by assigning utility values to each output category.
cUAs are usually conducted fron'r a societal perspective. costs evaluated may range from
direct medical alone, through to direct nredical plus direct nonmedical plus indirect costs'
It is common to use direct treatment costs less indirect benefits of gained production to
derive a net resource cost per QALY or healthy year equivalents ( HYE) gained as a result
oftreatment. Accordingly, the treatment of different medical conditions may be compared'
Quality of life measures have been discussed nrore fully in Chapter 4: Cosls'
A major obstacle faced by a researcher conductittg this type of analysis is that of obtaining
suitable utiliry values for various health states being evaluated' Utility values for health
states may be deriyed lrom the health econonlics and medical literature, calculated from
surveys of patients rvitli the disease state. or by asking healthy respondents to imagine 
they
had a particular health sratus and describe their utility for that state. Gold et al' (1996)
considerthatirrdirectcostsshouldbeexcludedasthequalityoflifemeasure shouldcapture
the impact on lost productivity. Chapter 1: Vttluing Health Oulcontes' discusses disease
specific and general or generic quality of life specitlc instruments in more detail'
Ideally the influcttza and critical lirl]b ischaeuria cases (Chapters l3 and i4) should have
beerr evirlultr,'rj in tcnrls o[cost per trfrlity nlcasure because quality of life was different'
Trris *.as rror 
'ossibre 
be causc of rack of readily a'ailable crata and budget constraints that
did not alloN, thc rcscarchers to applt'quality of lil"e itrstruments'
Cost-con se(luence Anall'sis
Cosr-consequetlce:nalysis is (in nry opinion) a variant of CEA and CUA where sensitivity
analysis is condttcted ald a number of dillerent perspectives and associated costs and
l{ Guy Scon (2001)
E co rt o ttt ic Eval u a t io rt ied To Healtlt In New Zealand
outcor'cs are consiclercd. Ir is arr extensiorr of trrc icrc. co'cred rvhen the dcsirabilityof
adopting a rangc of pcrspccliyr-'s ri'as clisctrsserl. I5 tftis type of analysis costs and
conscqlences are pot aggregated apd ratios of cost-cflcctiyeness are not calculated' 
costs
and outconres are risted and it is reft to the user of sucrr studies to calculate the aggregates
and ratios that interest thent. For cxample, instead of calculating a cost per QALY' a vector
of all clinical outcopres and relevant costs nray be given. (Tonance et al', 1996:59; Detsky'
1994:284)
6,4 THE PROBLEM
EVALUATIONS
OF CLASSIFYING ECONOMIC
In real life, it ntay be difficult to classify an economic evaluation technique into a particular
type as the categories grade into each other. It is often not possible or sensible to classify
an investigation until it is completed because the analyst will not necessarily know exactly
which costs and outcomes are relevant and how they can be quantified' If the economic
evaluation is being conducted alongside a clinical trial, the results of the clinical 
trial will
detemrine rvhether or not the outcomes of lrvo treatments are different'
The appropriate type of analysis will be deternrined by the problem under investigation' 
the
availability of data and the research budget. The decision maker should be more 
concerned
with obtaining the n'lost appropriate inflornration and analysis for their purposes than 
the
classification of the sturJy. Classifying methodologies into different types is however
conyenient to discuss the concepts of econotnic el'aluation'
If the cost of tw,o antibiotic treatnrent reginrens is bcing compared, a suitable way of
reporting fhc results ol'such a StudY cotrld be cost pcr patiertt successfully treated' 
Cost-
ltininrisation is lppropriate if fhc patierlt otltcollles arc ideptical' However' if 
one regimen
hiis a greatcr l'iltc- of atlverse events tltcn tltc paticrtt otltcomes are not identical' 
These
advcrsr- cvL-nts crrttld ranse front rlte ntinor such as a temporary skin rash 
to non life
tlreatcrrirrg bur scrious ciisabilities such rs deafncss or life threatening kidney 
failure' If all
the cosf s (clirecl, irrdirect and intangible) of prinlary Ircatnlent and the treatment of adverse
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e'crlts \\.e[e cnuprerated and quantificd in nroncy valttes tltcn tlte study could be classif,red
as cost-betlefit analysis. Depending upol"l tlre tJefiniriou oIsuccess and the range of 
costs
evaluated tlic study could eitfier be classified as cost-minimisation or cost-effectiveness'
Health related outconres are frequently identical or similar in the clinical sense but 
the
quality of life aspects nray differ. For exanrple, a patient could be treated either by surgery
or by drugs at homc to produce the sanre clinical outcome, but for the patient the pain 
and
suffering, the treatment setting, time off work, and leisure time activities could be very
different. This problem is highlighted in the critical limb ischaemia case study (Chapter
l4). Pain and/ or gangrene of a leg or foot could either be prevented by drug therapy to
increase the blood supply to the limb or the amputation of the limb' In both treatment
options the individual's life nray be saved and pain relieved but quality of life for the
patient rvould be diff'erent rulder each treatnrent option. Successful drug treatment would
avoid the loss of a lirrrb or part tltercoIand ttre quality of the patient's life would be higher
compared with the surgical option. It could be argued that both studies were cost-
minimisations, because the clinical outcomes as defined (avoidance of death) were
identical, but there are differences in quality of lile' These outcomes were discussed
although not quantifi ed.
6.5 CONCLUSION
This chapter 53s discrrssed tfie yariotts types of ccononric evaluation' Although 
policy
decision nrakers are likely ro be most concented ivith cEA ancl cUA they need to be aware
of the full range of cconontic evalttatiott techttiqtrcs' thcir strengtlts and weaknesses 
and
wSere they carr *.d canuot be used. cost-bcnefit a.alysis has not been widely applied 
in
lrcalth polict arralvsis n.lrcre vnrianrs of cost-cffcctivcttess analysis (including;cost-utility'
cost-pripinrisltron ald cost-cor.rsequences apalysis) fiaye rJotninated. As experience with'
arrcl tlcr.cloplllcllt of hellth outcollle tTlcasures progresses, cost-utility analysis 
is likely to
grorv itr itrtporllucc.
ll Guy Scott (2001)
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Table 6.6 sunutarises tlte distinguishing
evaluation discussed in this chapter.
featurcs of the different types of economic
The follorving points are reiterated:
' Tlre study design (type of ei'aluation) shoukJ be driven by thc policy analysis
objectives, data, time, research budget and expected benefits of the research'
Accordingly, a range of techniques are likely to be applied in public policy analysis
of healtli.
' It may not be possible to categorise the type of evaluation until the study 
is
comPleted.
Table 6.6: Economic Evaluation Categories: Distinguishing Features
tleatth Perspeclite Choice UseType of Range
anrll'sis of costs crileriaoutcomc
measure
Cost- Cl or Assumed
minimisation C2 or idcntical
Ct\,tA Cl
Cl & C2 Cosr pcr Conrparing treatment options rvherc
t{calth outcotllc outcomes are identieal and a given
scctor'; guantity ofresourccs or cxpcnditurc
C3 Soclcty
C I & C2 Cost pr'r Conlparing trcatment options for thc samc
Hca|thoutcomcdiseaseandagivenquantityofresources
sector'; or cxPcnditurc
C3 Society
C I & C2 Cost pcr Conrparing treatment options for thc same
Healrh utrlity discasc and rcsource allocation across
sectorri mcasure differcnt diseases ftom a given quantity of
C3 Socrcty resources or expenditurc
Cost- C I or
effectivcncss C2 or
CEA C]
Cost-utility Cl or
CUA C2 or
c-l
( Possiblc
doublc
counting
tf C3)
Cost-bcnclt C{
CI]A
Clrnrcal
or
physical
units
Utility
l\ loncr
r ulucs
Socr(l) Nct
PrcsL-nt
tlIttcr
Rqsourcc allocatron lor thc rvholc of
soclctV
Cl = Drrcct llcdrcal Costs
C'l = Dtr,.'ct \lcdrcirl Cosrs /'/rr-r' Dttt'ct Nonnrcdrcirl C'osts
C-1=Drrccr\lr'drc.rlCosts/)itr-rDrrcctNonntcdrculCostsl'/rrslntlrrcctCosts
('-l = llrrcct \lcJrcll Costs l)/rr.r Dtrcct Nonntcdrcll Costs /'/rr's Indtrccr Costs /)/rrs Intangible Costs
I -Ihr. hc-;rltlr scct.r nlil).bc drssr..cfctl lnt. lund.rs' purchasc'rS (eg go'crnnlcnt' insurance companies and 
patients)
und pro\ ldr'rs 1r.-g hosprtrls' gcncr:rl Pruclltloncrs)'
! Both fh,.. intcrnrl riltc of rcturn and thc cost bt'ncfil rutto hlvc- bccn Omitfcd becausc 
whcrc the options arc
murual|1,crclusir.c thL.sc t\\.o crirr..ria cln Icad to tncorrcct cholccs bcing nradc
Nolcs: A negativc cost= abcncfit' A negativc bcnefit= acosl
LIt Guy Scott (2001)
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Chapter 6: F,conamlc Evaktafion' '
The r"lext cLrapterco,n:siders,nrod.etlingand its application t'o'publicpolicyevaluations 
in the
health s€cto(. of particular importanoe is rhe ability of rnodellingtechniques to integrato
data f.rorn a r:ariety of diverse sourcesr cornpare eosts with ogteomes and to conduct
sensitivity and scenarjo analysis.
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CHAPTER 7: MODELS
7,1 INTRODUCTION
Models describe and ntinlic relevant aspects o[ reality and may be used to simulate real
situations. A dehnition by a group of rnodelling pioneers described models as ""' an
ordered set of assuntptions about a complex systetn'" (Meadows et al'' 1972:20)' This
modelling definition is still relevant today'
All econonric analyses and policy studies involve a model of some sort' This chapter
discusses a nrore formal approach to nrodels that ttse computers and computer software'
Policyanalysts can nrake useoftrtotlcllingbut nlotlu'ls are equallyuseful forpolicymakers
who ntay rvislr to test oPtions.
This chapter discusses the use of models and nrodclling methodology, with application 
to
health care policy, A history of models and thcir recent use in the health sector' types of
models, horv nrodels are used, and the modellirtg processes are presented' A growing
number of studies in healtlr economics that have trsed models and modelling are being
publishedrs.
7.2 BACKGROUND
?.2.1 Historl' and DeveloPment
The origins of coniputcr-bascd nrodcllirrg fordecision rtlaking and forecasting purposes 
can
be traced lrack to the *,ork by F-orrcstcr anrj Meado*'s in the 1960's and 1970's (Forrester'
A \,1EDLI\E (l lcnlth$'orld. 1999) scarclt of irrticles published lor the years 1990
to 1997 inclusivc rrsing the kcpvor'd, "ttroclel'?" Ioun<J 148,767 articles' 
using the
key *.ords" r'odel'1" nird "cost?" 1,702 articlcs, and "model?" and "economic?"
154 articlcs. Trencls trsing tlrc kcy rvord "ntodel?" were as follows:1980-84'
39.(179; 1985-89, 54,169; 1990-92, 50,446; I 993-95' 69'085 and 1996-97
(i ncorlplc'te year) 29,23(t artic les'
li
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l96l;Meado$,s et al., lg77). Fonester and Meado\\rs modelled world population and
resources 1o investigate tlre linrits to growtlr. Meaclorvs et al' ( 1972:Z3)concluded "lf the
present trencls in rvorld poputation, industrializatiotr, pollution' food production' and
resource depletion continue unchanged, the linrits to growth on this planet will be reached
witlrin the next one hundred years. Thc nrost probable result will be a ratlrer sudden and
uncontrollable decline in both population and industrial capacity'"
Although models can be constructed and used without reference to computers the 
process
would be considerably slower and prone to mistakes. Models designed for use with 
digital
computers were originally created using a general programming language such as Fortran
and may still be constructed in this way. However, specific modelling software has been
developed and spreadsheets are now more sophisticated with the ability to create multiple
work sheets. These changes have altowed models to be more widely used in disciplines
such as health econonrics and private arrd public sector management' Application 
of
modelling was in the past restricted by lack of conlputing power' high cost of computers
and conrplex mathematical procedures involved' Hardware and software have both
improved in perfontratrce and lallen (in real temrs) in price'
7.2.2 Purpose of Modelling
The primary purpose o[ modelling is to enhance our understanding of the real world and
facilitate simulated experinrentation and scenario analysis' Models and the 
process of
model constnrction and testing assist in analysirrg anrl interpreting the real world' 
Simulated
experinrents n13y be conducted that coulcl ltot be undertaken on real systems 
because of
cost, tinle or ctltical cottstraitrts.
All c-cononric or trrolicv researclt inrolVes sorlc kind of modelling to integrate 
data from
ditt-ercnt sourccs urrtl use tlrr.- clatir to clrinv inl'erences. Even tl're collection 
of information
in cirsc trotcs iplolycs abstractiott, sittrplificatiol arrd categorisation of complex reality
(Sheldon. 1996: l).
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Modelling is increasingly being usctl as a tool for decision nraking in business and its
application to health policy is no exception to this trerrd' Models and niodelling assist in
the decision nraking process by helping to assetublc arrd analyse relevant infonnation 
but
cannot make decisiols for clinicians, n'ranagers and policy makers. This helps in clarifying
the problent. and in contparing and evaltratir,g options in a simulated environment' For
effective use, the policy decision maker must have some uttderstanding of the structure 
and
operation of the model and be aware of its limitations'
Econonric evaluation requires infomration on costs and health related outcomes' Models
assist i' integrating this infomration and in the calculation of net benefrts and other decision
criteria such as cost-effectiveness ratios. This infomration must then be used to develop
workable policies. Models allow policy ntakers to test and evaluate policy options by
simulating situations in a model rather than in the rcal world.
7.2.3 Criticisms of l\Iodelling
Conrnron criticisnrs of models and nrodelling are that they are imperfect, oversimplify
actual situations, or are incomplete and unfinishecl. However, many decisions cannot be
postponed until perfect models are developed and a full understanding of the problem is
achieved (Meadows et al., 1972:21-2). Some researchers who are familiar and skilled at
data acquisition flrom controlled trials, experiments and observation feel uneasy 
with the
fact that models ntay drls' data frorn a variety of sources and may use estirnates and
assunrptions. Horvever, this is a strengtfi as a prodcl can integrate data from a number 
of
actual experinrents s'it| obsen'ations, estinlates and data on file or in databases'
7.3 TYPES OF i\IODELS
NlotJc.ls nonttalll' ltave a n'lathcl]lilticll basis and may be split into two nrain tlpes;
dctcrrtripistic or srtrr'ltastic. Each ol thesc tttaitt tlivisiops nlay be further subdivided' 
In
prilcticc, a ;lirrttcttlar tltode'l ttrll' ltavc' leaturcs of a number ol' varieties' making 
precise
cl:rssihcation difticult. The types oi nrodels of relevance to health policy and health
economics include the following non-mutually exclusive categories:
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' Detemriuistic
. Stocltastic
. Decision analYtic
. Longitudinal cohort or incidence
. Cross-sectional population or prevalence'
Deterministic and Stochastic models
Deterministic models give the same result each time the model is run provided 
the same
input data are used. tnputs and outputs are point estimates' stochastic models are 
based
on probability distributions and the same inputs will not give identical results for each run
(if replicated and nrn many times a distribution of results is obtained)' outputs are
probability distributions rather than point estintates'
Decision AnalYtic Models
Decision anttl,ticmodels based on decision trees track a sequence of events and 
branching
options over tinre (Drumnrond et al., 1997:242). Each pathway up through the branches
of tlre tree represents one sequence of events' Clrapter 15: Heartfailure andChapter 
l7:
Asrltma provides examples of models that are in part decision analytic deterministic
models. However, both these models mentioned also have features of some of 
the model
types that follorv.
Longitudinal and Prevalence lVlodels
Longitudinal cohort or incidence modcls considu-r expected outcomes for 
groups of people
over tinrc. A subse't of this ntodel classification is the Markov or state transition 
model'
These rrroclels allot ntcnrbers or groups of tlre study population to distinct states 
or
categoriL's ovr'r til'!'lc. Poptrlatiol ttnits trtay ss itclt fronr one category 
to another as time
progrr.sscs. An exanrple of a lritarkov model was ttsed to evaluate alternative 
lvays of
treating hcarr failure (Chapter l5: Henrt Fuilurc)'
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Cross-sectiopal population or prevalence ntode ls consider a population at one point in time'
Chapter 17: Astlttrta considers tfte costs of treating astltntatics over the cotlrse of one 
year'
Detenlinistic prcvalence-based nrorjels arc valuable for assessing the annual costs and
berrefits of various policy options.
(See also Drummond et al., 1997:242-6; Keeler; 1996; Mandelblatt et al'' 1996: l5l-6;
and Sheldon, 1996)
7.4 WHY MODELS ARE USEFUL
7.4.1 Why Use Models
Models can make the process of integration of data from a variety of primary and secondary
sources expticit and transparent. Modelling of costs and health outcomes enables the
assessment of nrany factors simultaneously. Users are able to evaluate the effects of
changing data and assumptions about uttit costs. risks, prevalence, and treatment options'
Models may be based on actual clinical practice ratlrer than randomised controlled clinical
trials. Thus, models are tools to be used in evidence-based medicine and management
decisions relating to actual health policy and treatment protocols.
7.4.2 Situations Where Models Are Useful
Models are useful in the follorving situations:
. lntcgrating diflcrcnt types of data fronl a variety of sources
. Cotlpirring costs u'itlt lrealtlr relnted outconlcs
. Translating and applyirrg clinical trial results to actual clinical practice
. Scertario and sensitivity anall'sis
. Apllliing thc finclings front one setting to another
. Linkitrg intr-rnretliate cnclpoinrs vn'itlr llnal healtlr related outcomes
. Extending the tinte horizon of a study
W Guy Scott (2000)
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Integrating Different T1'pes of Data From A Variety of Sources
obtaining antl integrating data rvith different characteristics and fronr a plethora of sources
isoftenoneoIthemostdifficultprocessesinpolicyanalysis' Usuallydataforaneconomic
or policy analysis must be obtained fronr a variety of diverse sources' Examples of these
include; clipical trials, surveyst administrative data bases and literature searches' Clinical
trials provide effectiveness data ol1 new treatment options' Surveys of various kinds'
interviews, expert panels, focus groups and Delphi groups are frequently necessary 
to frll
information gaps where data are unavailable from secondary sources' Often information
collected for administrative purposes nray be accessed and processed' For example'
reimbursement and accounting data relating to government subsidised prescription
medicines may be useful in estimating the volume of prescriptions for different 
illnesses'
Patient record data could be used to obtain informatiorr on disease prevalence and
incidence. Literature searches provide data in a rvide range of forms both qualitative 
and
quantitative.
Often these data rvill be presented in a variety of fornrs including; frequency distributions'
index numbers, sumurarised tables, rates and percentages, unit record and verbal
statenrents. For example in public policy evaluations in the health sector' clinical
effectiveness evidence may be presented as frequency distributions, prices as 
index
nunlbers, a'd prevalence as rates and sumnrarised tables. Without some sort of integfating
device nruch of this information callnot be analysed and interpreted by policy analysts'
Comparing Costs rvith Health Related Outcomes
Tlic changcs in costs of resottrces cotrstrtttcd [ry lttt irttcrventiot't orpolicy mustbecompared
r,,,ith thc ch:rngcs irr healtlr relatctl outcott'tcs prodrrcccl' A model facilitates both the
integratio' r.r I all cosr lncl hcalth rclatccl ourcr)n'lc data and in thc calculation of appropriate
surllutilrv stltistics. Lrttit costs oIrt-sottrc,-'s itcttt by itenr (dollars)' changes in resource
utilisatiorrs (rolunre) antl changes in hcalth r.-lated outc0tlles must be integrated and
cotttparcd.
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policy nrakers arrd rlanlgers are rllore lllterested in tltc operational iniplications of new
cli'ical evidence than the evidence itselr'. Infonrration dc-rived from artificial and controlled
situations are ltot lrvithout furtlter analysis and/ or research) sufficient for developing and
implenrenting workable policies. Clinical trials that are designed to evaluate the efficacy
of treatment options are highly controlled and participants are carefully selected according
to the trial protocol. Additional clinical monitoring and diagnostic procedures will usually
be undertaken than in normal clinical practice. Accordingly, trials will probably not reflect
actual practice in temrs of patients selected, treatment protocols, patient conrpliance 
with
treatment prescribed, monitoring and follow up. A model provides a means of taking 
these
differences into account through inclusion of a range of assumptions and different 
data'
Scenario And Sensitivitl' Analysis
It is useful to sir'ulate policy and treatment protocol options and conduct "what if 
analysis"
by changing input dara and nrodel assumptions. Tinre is often a critical constraint 
and
undertaking a new and separate analysis to evaluate another set of different policy options
is often nor pracricable. Running a validated model rvith different input data and
assumptions facilitates this type of analysis. Inrplenrenting a new and untested 
public
health policy fias a greater probability of firiltrre than one that has been tested in a
sinrulatiotr rrtodcl.
Applving the Findings Front One Setting to Another
Res'lts fro'r u Sospital-Lrased stutly nral'bc applied lo a gelleral practice setting' 
A multi-
ccntrc' intentrtionul stttdl' Or a trial contlucted in one coutltry can be transported 
to other
cotrntric-s. (Drut.llrlrorrd et al., 1997:275-80). Rcplicatillg an itrternational study in New
Zcalantl or irr arroth..r sctting is not rtstt:tllV cost cf'lccf ive and may nOt be an 
option because
of firI,-, antl hurlget constraints. Carc t1rrtst Lre cxercised to take account of differences 
in
clenrogt-aphics, hcalth sVstelt'lS, treatnlcllt protocols and unit cOsts rvhen transfening 
findings
fronr orre Setting to anotfier. It is not possible to translate findings from one country 
to
Translating and Applf ing clinical Trial Results to Actual clinical Practice
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another sinrply by adjusting only for exchattge rates and populatiorr differences as this
\\'ould lot adjust for all ttpit costs, {iffcrertccs bctl'een health Systen'ls' arrd other factors
suclt as denrographic profilcs and incottte lcvels'
Clrapter l5: Haurt Fuilurediscusses a cost-effectiveness alalysis using a decision analytic
model based on clata derived fronr an overseos clinical trial. New Zealandspecific 
unit costs
and epidenriological data were used in the model to investigate the cost-effectiveness 
of
introducing the new drug into the New zealand health system.
Linking Intermediate Endpoints rvith Final Health Related outcomes
Irrtcnletjiate errdpoints are of littlited valtre for policy anatysis. It is more valuable to have
infornration on tlrc final health-related outcome. Population nrodels link intennediate
endpoirrts detennined from clinical trials r'vith health outcomes of a population' For
example, the effccts of altering blood pressure nray be related to changes in final outcomes
such as death or ischaemic heart attack (Drunrtttortd et al., 1997:244-5)' Disease specihC
ourcomes as measLrrecl in a clipical trial may also be extrapolated into utility scales 
(see
Clrapter 3: Vttluing Health Ottlconrcs).
Extending the Time Horizon of A Studl'
Most clinical rrials have a short duration compared with the life expectancy of a 
patient or
the nomralprogressionof adisease. Extrapolation models projectbeyondthetimehorizon
of a clinical triirl, for cxanrple 30 days, to pcrhaps a trunrber ol'years (Drummond et al"
1997: 24.1). A policy anall',st $'lto $isltes to track the policy conseqtrences of an
iltterlr.tltion to redttcc lteafl attacks oycl'a ttttntbcr oIyc-ars but rvho has only actual 
cliniCal
trial rlata relating to sir ntotttlts, ntay lle able to ttsc a Markov nrodel to extend the time
horizott.
W Guy Scott (2000)
7.5 THE MODELLING PROCESS
7.5.1 Forrester's Nlodelling Steps
Many of the steps and processes of modem nrodelling techniques for business and industry
stenr firom Forrester ( l96l ). His book 'lndustrial Dynamics' has survived the test of time
and is still relevant. Forrester listed and elaboraled on the following modelling steps:
. "ldentify a problem.
. Isolate the factors that appear to interact to create the observed symptoms'
. Trace the cause-and-effect information-feedback loops that link decisions to action
toresultinginformationchangesandtonewdecisions.
. Formulate acceptable formal decision policies that describe how decisions result
front available infornration streams'
. Construct a nrathematical modelof the decision policies, information sources' and
interactions of the systenl components'
. Generate the behaviour through time of the system as described by the model
(usually rvith a digital conlputer to execute the lengthy calculations)'
. Compare results against all pertinent available knowledge about the system'
. Revise the model until it is acceptable as a representation of the actual system'
. Redesign, within the model, the organizational relationships and policies that can
be altered in the actual system to fincl the changes that improve system behaviour'
. Alter the real system in the directions that model experimentation has shown will
lead to intproved performance'" (Forrester' l96l: l3)
7.5.2 Generrlised Nlodelling Steps
Builcling I nrodcl is a cyclical proccss irntl tltc stcps presented are not intended to be
clcfinitir.c,. bur rilrhcr indic'.rtive of thc ke1, clenrcrrts. Some of these steps overlap 
or are
s'r1Lrll\'tous u itlt tltc c'cottotttic cvalttaf ioll stcps clcscribcd in Chapter l8: Drscrlss ion 
and
Conc'lttsiotrs.
Althoueh there is a commoll thread, the steps considered relevant by different 
practitioners
|V Guy Scott (2000)
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depend on the atralyst's perspective and specific purposc of tlie model' For exarnple' 
Snider
et al. (1996) clcscribe tfie basic steps in decision alalysis u'ith a focus on prcvention
effectiveness analysis (rvhere decision t.rec nrodels donrinate) as: structuring the problem'
developing a decision tree, estintating probabilities, valuing consequences' calculating
expected values and interpreting results'
The development of the model requires skills of a number of professionals (for example'
economists, clinicians, statisticians) and thus nrirrors tlre multi disciplinary nature ofhealth
economics. It is important these people are involved from the first step of problem
identifrcation to the end if confirjence is to be gained with end users'
The process of modelling is iterative n'ith fecd back loops rather than linear' The
simplified process shorvirrg the circular l)ature attd major links between steps is illustrated
in Figure 7.1. For thc purpose of this discussion on modelling' the process has been
generalised and reduced to the following steps:
. Problenr description and definition
. lsolation of relevant factors
. Structural design
. Cotrstntction
. Testing and validation
. Sensitivity tests and scenario artalysis
. Recommendation for action in the real rvorld
Problenr Description and Definition
A description o[ the problem u'ith a clear problem statement and set of objectives is a
necessary first step. Tlris step $'ill requirc sotlle qtralitative pre-research and literature
scarclr. Structttrittg t[e problepr itrvolvcs deterntining the key issues involved in the
dccision. cleciiling upon tlrc analltic perspcctire ltncl titne horizon and deciding 
upon the
rcll or practicablc altcrrtative cotlrscs of actiort' Unlcss thc problem is clearly delrned
furtlier analYsis is Pointless.
W Cry Scott (2000)
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C larification o f Obj ectives
Figure 7.1: lltodelling Process in the Form of A
Florv Chart rvith Feedback LooPs
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Isolation of Relevant Factors and structural Design
The steps of isolating relevant factors and the structural design of the model are 
closely
linked. and often culminate in a decision tree. Durirrg construction of the model' 
absence
of data to quantify a stnlcture or parameter does not mean that it should be excluded 
from
the nrodel. Sinrulation tests rvill help to regtne the value of a parameter within 
plausible
linrits (Forrester, 1992: 60).
\
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Throug|out thc pro{elling process, sinrplicity, transparerrcy, ability to nrodify and change'
ancl flexibility of use are of underllng itttponancc rvlicn building the model' Other design
critcria are tlrat a model should be able to be used easity with rninimal training' and be able
to run on a rvide range of computing platforms'
Decisiott Trees
A decision tree can form the basis for model construction, and is particularly useful in
health care for showing treatment pathrvays and outcomes' An example of a decision 
tree
can be found in chapter l7: Asthnta. Developing a decision tree involves preparing a
graphical representation of how the possible choices impact on the final outcome' At each
node there are a nunrber of branches representing choices among options (decision node)
or a number of branches representing charrce events (chance node)' Figure 7'2 illustrates
vaccination against influenza choices and outconres. Those at risk may be vaccinated 
or
not, and those vaccinated nray contract influenza or not, and so on.
Estimating probabilities is concerned with assigning probabilities to each chance node
along an event pathrvay in the decision tree. The sum of all the probabilities at each chance
node must equal orre. Valuing consequences is the quantification of the outcomes at 
the
end of each event pathway. The consequences nray be evaluated in money terms' natural
units, clinical values or a health related quality of life measure.
The first step ip calculatirrg expected values using the decision tree involves calculating 
the
nurlbers of patie6ts passing alortg each evetrt pathway' Then the nunrber of patients
reaching thc end of each pathrvay is multiplied by the cxpected cost per patient for 
that path
to obtairr the total cost for tlre path. Tltc satne process is applied to each event 
pathway to
dcrive a total cost.
LJsing tlre "tlo not Vaccinare clo not contract irrtltrenza" branch, the expected cost 
is
(probabilitl: of no r.accination nrultiplied by the cost of no vaccination plus the probability
of not colttracting pneumonia rnultiplied by the cost of not contracting pneumonia 
(0'80 x
$0.00 plus 0.80 x s0.00 = s0.00). Addirrg up the expected values of allbranches gives the
ll/ Guy Scott (2000)
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expected value for tfie tree. (S2.24 + S14.40 + $0-00 + $4'00 = $20'64)' The decision tree
pror,ides tltc cost per at risk populatiott ntctttbcr of a vaccination progranllne rvith the
defined probabilities and costs as illustrated in Figure 7'2'
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Testing and Validation
After the model is constructed, it must be tested and validated, and accuracy of data
ensured. Docurnenration should take place at this stage to facilitate use by parties not
directly involved in the design and construction process. Validation of the model can 
take
many forms. Comnron methods involve comparing model results with historical data
(predictive validity) and evaluation by experts in the study area' Often it is difficult to
validate a nlodel directlybecause if accurate infontration relating specihcally to the model's
outputs rvere available then there rvoulcl have been no need to develop a model' "Thus/ace
yctlirlt tiottof a modcl nray haye to rest solely on evaluating the inherent reasonableness of
model assumptiotls as a representatiol of reality'" (Mandelblatt et al'' 1996: 161)'
Sensitir,itl'TestsandScenarioAnalysistoobtainResults
After r.aliclatiort. sr.ltsiriyit)'and scenarlo anxl)'sis llltlst bc undertaken' This often serves the
dunl purposes of linking back to validation, antl revealing hidden insights and effects 
with
rcgard to tlte problcm itrvcstigated'
Figure 7.2: Decision Tree Diagram
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Interpreting tlte results inclucles rrrtclcrtakirig various types of serrsitivity 
analysis where
nunrerical values of input probabilitics atrd otltcr estintates are clranged and 
the expected
values oIthc rrrodel outcotnes tracked. Threshold analysis involves altering nrodel 
input
values until the point that a different decision should be made is reached' 
Best and worst
case scenario arralysis applies rvorst and bcst estinlates to the model' Sensitivity 
analysis
was discussed in ChaPter 4'. Costs'
Recommendation for Action in the Real World
Finally results found need to be reported and important policy options and 
implications
outlined. The modelling process is not nrechanical or blind' Judgement is vital in
deternrining how to sinlplify the real world, and how far the process of simplification
should proceed. when the model is used to draw conclusious and make 
recommendations
for actiorr, rvisdom and insight are also nceded'
7.6 CONCLUSION
Models in the health sector nray combine data from clinical trials, health databases' 
and
qualitative in[ormation from clinicians involved in treatment' Models are particularly
valuable aids in combining quantitative, and qualitative information' It is 
this wide range
of ilformation sources that necessitates a multi-disciplinary approach' To ensure 
the model
built has the confidertce of all potential rlsers' is realistic, and of value' the 
potential users
should also be involved during the final stcps of resting. Thus it can be 
seen that a model
pernrits a ltolicy nraker to sitlulate and eyalttate pol'cntial policy 
options and thereby
nrininrise the risk of nraking potentially costly nristakes and introducing 
policies that are
likely to fail.
Thc $.ay in $.hich rllodels are used to integrate and aggregate a range of cost data 
from a
r.arict-v- of sourccs is sho$.n by the asthnra case. Chapter 17: Asthntu, presents 
a
spreaclsIee t-based detenrrinistic, prevalence decision-analyic model' 
The model described
in this case allorvs the user to evaluate the full costs of alternative treatments' 
or by
entering ditferent values irr the input screen, to look at asthma treatment 
costs from the
W Cuy Scott (2000)
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viewpoint of a patient, a gerteral practiti.oner, a hospital, or a defined poptllation' 
The
design is Sur.ffioi,entl,y flexible to talce accoutrt ofchangingtreatrnBnt o'ptions 
and gu'idelines'
A user is, abl€ to calcu,late'tota'l costs, eompare data through benoh maraing' undemake
sensitivity,anatysis, or consider a de,fined ptpulation, di'ff'Erent patient Categ€ries' 
or
appropriate rnedication use'
Theheart fairurecase (.ctrapter rs: Heart Faifurc),ilrrstrates theuoe of adecisi'on analytic
tnodel that oombines international cliniqAl trial and cos't data to conduot a cost 
effootive
analyois using New Zealar''rd cost and epidemiological data.
The fsllowir,rg Chapters (8 to 17) present the resultc of cases designed ts illustrate the
methodologies discussed.
lI Guy Seou (200i0)
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CHAPTER 8: CARE WITH DATA
8.I SUMMARY AND INTRODUCTION
Summarl'
Two cases (Heart Ftrilure and Benign Prostatic HS'perplasia) are used to illustrate a
numberof problems associated with aggregatingand usingsecondarydata' The 
chapteralso
presents a strategy to avoid such problems. New apd previously unknown evidence 
on the
differences between Maori and non-Maori hospital admission rates for benign 
prostatic
hyperplasia was found. Paradoxical and previously unexplained differences between
aggregated gender specific heart lailure prevalence rates and age specific 
gender rates were
isolated and exPlained.
Introduction
This chapter discusses problems that ntay occur when data are aggregated 
(Scott' Camden
& Scott, l99S). These problenrs, if unrecoguised, (by either analysts and/ or decision
makers) have the potential to mislead policy makers into making decisions that are not in
accord with their objectives. Economic and policy evaluations often use secondary
processed data from adnrinistrative records, and from experimental and observational
studies. U'it records lor a population or study group may be aggregated to form cross
tabulations of cottttts for subgroups. These cottnts are commonly used to create 
rates
(nunrber observatiotls per total nurnber irr tlte category)' Often the unit record data are not
available to the researchcrs. Problents can arise from the definition of the original 
data'
$,ith aggrcgation into suntnlary tables and rvith the fonuation of rates' Examples of such
probleuts incltrcle confttsion over tfie detjnitiols and meanings of variables' Sinrpson's
prraclos, and the ecological fallacy'
W Guy Scott (2000)
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8.2 BACKGROUND
Denrographic or epiderliological rates or indiccs arc intpodant summary statistics in the
study of colrnrunity health, environntental health, health economics and policy analysis'
Rates are fonned by taking the number of occurrences (incidence or prevalence) of some
event. dividing the nunrber of these events by the population "at risk" and multiplying by
a convenient constant (for exartrple 1000). If the population is divided or "disaggregated"
into groups (for example by age) a set of "specific" rates is derived, which maybehave
differently flronr the aggregated or "crude" rate. Researchers are often forced to use
aggregated data and aggregate data themselves, but are frequently unaware of the possible
consequences of doing so.
Statisticians consider their discipline to be a scientific enquiry process (Pfannkuch, 1996)
which involves care lvith data quality at all stages' The total statistical process (Lipson and
Jones 1996) includes posing the right questions, collecting the right data and examining it
with care and an eye for the unexpected. The exploratory approach, where the data is
examined carefully with an open mind, is recognised as an important alternative to the
"confirmatory" approaclr of statistical inference' When a research project is based on
admirlistrative records, this exploratory approach is almost always the most appropriate'
When using secondary data sources, the definitions and meanings of variables are not
always explicit or clear and this rnay result in confusion and misinterpretation'
Basing policy advice on the results of macro strrdies is recognised as a potential problem
by joumal editors and by some government agencies' The British Medical Journal
(Drunrnrond et al., 1996) has ptrblished a cltecklist for referees and authors of health
econorrric stuclics (Chirpter l8: Discrrss ion artd Cottclusiotrs). British Medical Journal'
ctteckpoint ntturtrcr 32 rclates to aggregation attd states fhat major outcomes should be
presented i1 disaggrcgated as t'ell as in an aggregated fornr' The US Public Health Service
in a rcport on tlte contluct of cost-eflcctil'cness analY'sis (Luce, 1996:710) recommends
(u'[r-rc possiblc) trsitrg nricro-costirrg ilr preferellce to gross costing using aggregated data
(Clraptc-r '1: ( c.r.rts)'
tY Guy Scott (2000)
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Tw,o illustrations frorl published original rcscarch are used to denronstrate a number of
problenrs and thcir resolution. Tlte casrrrs rclatc to Ne$" Zealand health eCOnomics studies:
hearr lailure (Scort and Sco1, 199(:) and bc-nign prostatic hyperplasia (BPH) (Scott and
Scott, 1993). Additional infonration relating to methodology, data' results and conclusions
may be found in these two papers and i1 Chapters l0: Benign Prostatic Hyperplasia 
and
Chapters 15: Heart Foilure'
The first example (Heart Failure)discussed in this chapter illustrates Simpson's paradox'
(Wild and Seber, I996: 561-3 and Simpson, l95l). The paradox involves a three-way
cross-classification table, where one of the three factors is a categorical variable 
(such as
gender or the presence or absence ofdisease) with values presented as percentages or rates'
Collapsing (that is, aggregating) the table and considering only the two (remaining) factors
of interest in isolation can be very rnislcading'
Frazier(1993: 28) discusses Simpson's paradox irr relation to US educational attainment'
In this article Simpson's paradox was described as showing ""' that an average can 
change
in a direction opposite from all subgroups if the proportion of the total represented by 
the
subgroup changes". The educational statistics described revealed that although every 
ethnic
or racial population subgroup maintained or improved its average Scholarship Aptitude
Test (SAT) score, there was a decline in the combined average score' This decline arose
because more students in the lower percentiles in each class were taking the SAT test' 
The
median test taker fell lronr the 79th percentile to the 73rd percentile within a class' 
A more
fitting i.terpretation of this data is that educational attainment was rising ratherthan falling'
Education policy a1d funding decisions based on the macro data may have led 
to
inequitable arrd ittet fi ciettt resottrce al locations'
Anotlter exatrrplc of Sinrpsop's paradox rvas raised by Westbrooke (1996' 1997) when
commenting on a publication by Dunstan ct al. ( 1995). Dunstan and colleagues studied 
the
pool of 2984 pcople rvho reported l"or jury service in New Zealand in a four-week period
of 1993. 10.1,,/u of tlrem $'ere Nlaori, and the poptrlation in the Jury Districts was 9'5%
Maori, $,hich ga\.e a slight ovcr represcntation. Horvever, rvhen the authors calculated
expL-cted trtrnrbers of Maorijurors fot'each of thc l3 Jury Districts separately' the actual
nurrbers u.crc less tSan the cxpected numbers in l2 Districts (and equal in the l3th)'
l{ Guy Scott (2000)
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A further phenonrenon *,ith its orvn body of litcraturc is tlre ecological fallacy 
(Steel and
Holt, 1996). Frcquently, utrit records are aggrcgatecl into groups where the r'rnit record
values of a quarrtitative variable are replaced by tlre nrean values for each group' 
The
ecological fallacy arises rvhen an alalysis based on aggregated or grouped 
data produces
different results fronl an analysis usilg unit level data' Conclusions based on means 
may
..give conclusions very different from those that would be obtained from an analysis 
of unit
level data, if they were available" (Steel and Holt, 1996: 39)' This fallacy is also discussed
by Greenland and Robins (1994)'
The second example discussed in this chapter (Benign Prostatic Hyperplasic) is about
differences between Mdori and non-Mdori hospital admission for benign 
prostatic
hyperplasia. Health care for Maori is an issue that involves public policy' public 
debate and
research. Pomare et al. (1995: 29) claim, "l[ has become apparent during the last two
decades that Maori want to define the threats to wellbeing, as well as the 
possible range of
solutions". To succeed in these aspirations, researchers will need data that is appropriately
defined, collected and analysed. There are also issues of control and ownership 
of data'
research processes, decisiorr praking and delivery of services' Bishop and Glynn 
(1992:
127) assert "Porverful and rapid changes have occurred in areas like Maori women's 
health
... since Maori people have been taking control over their own development 
and resources
in these areas." and they discuss (1992: 130) research as "empowerment"'
8.3 CASE ONE: HEART FAILURE
Heart failure occurs when the heart muscle is danraged, overloaded, or exhausted 
by such
corrditions as hypcflension, corollary artery disease, damage to cardiac valves'
carcliorryopathy, antl anhythmias. The rates for dcaths and hospital admissions 
for heart
failure incrcirsr- rvith age. Table g.l and Figure g.r irl'strate the age and gender specihc
dearlr rarcs forlieart failure in 1992 calculatecl liorl] New Zealand deathcertificatedata'
l{ Guy Scott (2000)
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Table 8.1: I\lortalitl' From Heart Failure in Nerv Zealand lgg2" Numbers' Age 
and
Gender SPecific Rates
Age
Years
Dr'aths
Nurttbcr
Population
Number
l)eaths
Rate per
r 00,000
Male Female
PoPulation
age group asaVo ofthe 59+
total poPulation, bY gender
Male Female
Male Female Male Fenrale
60-64
65-69
70-74
75-79
80-84
84+
3l
34
67
13 l0
53 63
90 203
69,860
61,290
45,270
31,540
17,740
9,710
69,480
66,210
57,320
46,170
31,020
23,420
56
13 12
41 22
299 203
927 867
30% 24%
26% 23%
t9% ?0%
t3% 16%
8% llo/o
4% 8%
Total59+ r68 288 235,410 293.620 71 98 1007o 100%
Using agglegated data, (ages 60 years attd over, and all ages) the statistics 
shorv higher
death rates from heart failure for females than for males' However' different 
patterns
enlerge when five-yearly age-specific rates for 60 years and over are 
used' Age-specific
mortality rates are higher for males than for females. This is a clear example 
of Simpson's
paradox. The opposite conclusions would be drarvn from the two sets of 
data'
FigureS.l:MortalityFromHeartFailure|gg2.RatePer100'000
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Theclata-setupon$,hiclrFigure8.l andTableS.l arebasedhasthreecategoryvariables
relating to thc Ne$, Zealand population of l')91; t$'o ittdependent variables (gender and age
group), and one depcnderlt variablc (nrortality fi'ottt heart failure, or not)' The mortality
variable is strorrgly related to both the gender variable and the age group variable' 
However'
the two independent variables (gender and age group) are strongly related themselves' If
nrortality rates are defined by gender alone (aggregated over all ages), or by age group alone
(aggregated over all ages), we get an incomplete portrayal of the information lrom the data-
set. Defining the mortatity rates by both gender and age group together provides a 
more
complete picture, which reverses the effect of gender' Overall' a male is less likely 
to die
of heart failure than a female (71 per 100,000 compared with 98 per 100'000)' However
a male of a specific age is more likely to die of heart disease than a female of the 
same age
(as shown by higher age specific death rates for males than females)' This explains how
Simpson's paradox arises.
The heart failure example demonstrates tltat researchers need to be very careful 
about what
their data really tllean: the definitions of variables, and the way these defrnitions 
are
interpreted when the data are collected. The main conclusion from this case 
is that health
policy decisions made entirely on data aggregated across all age groups would direct
resources torvards heart disease in females, while decisions made entirely on 
age specific
rates would direct resources torvards heart disease in males' In this case age specific 
rates
give a nlore complete and accurate picture tharr rates aggregated over all ages'
8.4 CASE TWO: BENIGN PROSTATIC HYPERPLASIA (BPH)
Trvo studies of BpH are discussed. Thc first is an analysis of adnrinistrative records
relating to hospital adnrissions. attd the sccond is a conrparative community-based 
study'
BPH is a notuttalignant enlargement of fhe prostate in men that comntonly 
occurs with
ageipg. T[is sttrdy is used to discuss t[e apparent dift-erences in prevalence of BPH
betn'r--etr lr'llrori and tton-Mlori metl'
l9l
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Statistics on adnrissiotts for BPH 1'cre dcrived frorl hospital discharge data for all of New
Zcalapd. Hospitirl disc[arge data includcs in fonrtation on ethnicity' gcnder' age ' diagnosis
and surgical procedures. Table 8.2 and Figurc 8.2 trse this admissions data and 
combine
it with data about the poputatiorr of Nerv Zealand by age and ethnicity' They present 
the
age and ethnicity specil-rc rates for admissiols rvith BPH as the primary diagnosis' All-ages
hospital adprission rate for BPFI for Maori is much lower (0'37 per 1000) conrpared with
non-Maori (2.04 per 1000). For rrrales aged 50 and above, the rate for Mlori is lower (3'37
per 1000) than for non-Maori (8.71 per 1000). When the data for age 50+ is disaggregated
into age groups, the same feature occurs in each age group. The admission numbers are
small (especially outside the 60 - 79 age groups), but the difference in rates is clear and
consistent.
Table 8.2: Hospital Admissions 1988 With Primary DiaEnosis BPH
f,ii,ari Non-MaoriAge Maori'
years Admissions Population Rate Admissions Population
50-54 4 5,220 0'77 87 68',400 l '27
55-59 4 4,360 0'g2 257 68',160 3'77
60-64 I 0 2,940 3.40 459 67', 1 50 6'84
65-69 14 1,770 7 'gl 645 52',370 12'32
70-74 I I 990 1l'l I 603 40',180 15'01
7 5-7s 9 590 I 5 '25 525 28',200 I 8'62
80-84 2 300 6'67 304 l5',l l0 20'12
84+ I 140 7.14 
-146 
7',980 18'30
r ollo :.rz :ozo r+z.sso r'ztTotal 49+ 55 16,3 lU J.J / 'rvzu ',- ', '"-"
Cli'icians, at t5c tilre oIthe study. considered (because they treated very few Maori men
for BPH) that sotllctlting protccted Mlori men tionr BPH' There was a perception that
BPH N'as not ir problcnr for Mlori ntett atrd that health care and health promotion resources
u.ould be br,-tter be dirccted ton'ards otfter lrcalr[ problcnts and conditions'
Horver.er. tlre higler no.-[vlitori hospitalisation ratcs corrld have resulted from differences
in a rtunrber of firctors, including: clisease prevalence as a result of genetic or Iifestyle
differences, cultural attitircles to health and health care, ability to access health services'
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kno$,ledgc about health attcl socioc-cottotttic status. The age profiles oIthe trvo populations
arc quitc differcnt, that is, tltere are proportionally lcs'er Maori in older agc 
groups' As
BpH syl]ptolrrs increase rvith agc, this rvill alfcct thc total numbcrs of adnrissions and all-
ages prevalence and incidence rates but not age specific rates' The disparate 
age prof,rles
explain nrost of the very large differences notecl in the all-ages rates for admissions' 
Use
of these rates alone for policy decisions, even though they point in the same direction 
as the
age specific rates, could be inappropriate as BPH is an age specific condition'
Figure8.2:HospitalAdmissionslgS8withPrimaryDiagnosisBPH.
Rates Per 1000 Male PoPulation
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At the tinre of this econonric study (Scott and Scorr, 1993) a clinical investigation 
(Nacey
et al.. 1993) $,as begun. The Nacey stucly lound that no statistically significant difference
ip prevalence 6f syrttptontatic BPH coul{ be clcmottstrated among European' Maori and
polyresian nrcn agetl 50 years antl ovcr, Thc crtrcial difference between the Nacey 
study
and thc adrrtissiott (liltr 1s anai,v-seti by' Scott alrtJ Scott is that the Nacey study took a
reprcscllrative satnple of Ne$'Zealarrd trlctr, atrcl askcd them about BPH symptoms' 
whereas
the adnrissions dat:r irrvolved ntett who had self-sclected by seeking 
treatment'clearly' in
tfiis case, hospital adtuissions $'cre not a measure of the incidence or prevalence 
of BPH'
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A conclusion fronr thcse t$'o studies considerecl togcther is that Maori and non-Maori
appeared to have different rates of seeking ald obtaining treatment' The most likely
explanation for the differences betrveen Maori and non-Mflori age specific 
treatment rates
are differerrces in access to treatment for econonlic and social reasons rather than 
an
underlfngdifferenceindiseaseprevalence. Durie(1994:201)claimsthat""'thebiological
substrate is only o'e indicator of health. The others include spiritual, psychological,
interpersonal, lamily, economic and environmental dimensions'" P6mare et al' 
(1995: 168)
claim that .....Miori have difficulty in accessing health care services''n, and that mainstream
services need to be....,affordable, accessible, appropriate and acceptable"'
lnterpreting the data at face value could lead to the conclusion that Miori men are 
not
susceptible to cleveloping BPH and that conlparatively fewer health care resources 
should
be directed towards Maori BPH health problenrs than to the treatment of BPH in 
non-
M6ori. A more appropriate policy would suggest that more resources should be directed
towards ensuring that M6ori men have access to and seek treatment forBPH 
problems (for
example, consultation rvitfi Maori gloups and specifically tailored and targeted 
health
promotion). Ponrare et al. ( I 995: 159) note that "Maori use health services differently than
non-Maori. when need for health care is takqr into account. Maori visit a general
practitioner less often tltan non-Mdori'"
The BpH example also raises tlre issue of horv rvell the country's health statistics 
collection
ancl analysis systents nreet thc needs of lr4aori, as the health profiles and needs 
of the two
partner cultures to the Trcaty of Waitangi arc olten very different' In the past much
research rvas designed to meet the needs of the researcher and the dominant 
group (Bishop
and Glynn. 1992: 126). In disctrssing tlte intportirnce of the community perspective'
Raeburn ( I gg4: 3ig-g) cotl]nletlts thar if research into Maori health is to be "emporvering"'
rescarchcrs "...n1itv need to reasSeSS fllcir stancc, cspecially rvith regard tO the 
'community'
artcl to the voices of tlrosc in it'"
l{ Guy Scott (2000)
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8.5 DISCUSSION
Researchers nlay rvish to investigate a problent using data at the individual 
"unit record"
or nricro le,,,el but arc often unable to do so. The degree of aggregation is frequently
inrposed on tlrem by the fornt in which the data are available' lndividual 
or unit data are
often not available because of commerciar sensitivity or conhdentiality with 
respect to
individuals.
Frequently, published data are in tables that have already been aggregated 
across important
variables, and researchers will not have access to less aggfegated forms' However' 
it is
sometimes possibre to obtain the underrying raw data and conduct a more 
disaggregated
analysis. For example, Health Statistics Nerv Zcalald publishes aggregated data' 
but unit
record data, with thc patierrt identifiers removcd. are available in electronic 
form' If an
analysis is based on grouped or aggregated data there should be some analysis 
and
discussion of the grouping procerlure or of the consequences of aggregation 
and/ or' of any
major changes in the structure of the underlying population'
Researchers are often confronted with data sets containing variables which 
they did not
define and for which they did not control the data collection. These variables 
will often not
match the researclr questions precisely. Variables and rates calculated from 
them must be
treated rvith care'
Wlrert rvorking rvith counts of eyents (or conditiorts) from a population with diverse
features thr-rc are t\\'o inrportaut factors that shor.rlcl be considered' Firstly features 
which
appear l,lrep t5e data arc disaggregated (and expressed as rates) by the groups within 
the
populaLion rrray disappear (or evcn be allparentl)' rcversed) when the data are aggregated
too nruch or lnappropriately. Sccondly, rates dcpcnrl on trvo sets of numbers; 
the counts of
tltc e\,e llts (b1, group) and the coullts for thc total trutnbers in the population (by 
group)' The
countirrg by group of both events ancl population nray be subject to errors' varying
interpretations and di tl'erent defi rritions'
W Guy Scott (2000)
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Anot|er iprportartt point tvfierl analysing rvi',I sutr-erotrps is that there is a greater probability
of a significant rcsult bcing found b1'chance aloltc, u itlt increasing nutnbcrs of 
subgroups
analysed. In the nredical area, subgroups are cortectly formed when these groups 
are
defined according to nrutually exclusive categories rhat are observed in baseline 
attributes'
It is difficult, if rtot inlpossiblc, to interpret accurately subgroup treatment differences 
that
nray be found when subgroups are defined by characteristics measured after 
randomization
as they are potentially influenced by treatment (Abramson, Kelsey, Safar and Sutton-
Tyrrell, 1992\.
This chapterhas not discussed the important problems of confounding and multicollinearity
in detail because it was considered that these are well understood by researchers 
and that
information is readily available in epidemiology and econometric texts' Both 
confounding
and multicollinearity result in sinrilar problems of interpretation'
Confounding occurs when an independent variable not included in the study 
is related
independently to both an independent variable ip the study and the dependent 
variables'
For exarnple a study of risk factors for deafiress corrld hnd a strong association 
between
developing deafness and being a successful business leader. This is not a causal 
association
but an indirect association, confounded by age as most successful business leaders 
tended
to be older,
Multicollinearity occurs rvhen some or all independent variables in a study are 
highly
correlated. It then becomes difficult to isolate tlte separate influences of the variables' 
For
example, multicollinearity could occur if in a nrultiple linear regression using 
time series
data, hospitirl ad'rissiorrs (as t5e clependent variablc) rvere regressed on both educational
attainnrent atrd incotrre (as irldependetrt variables)' Educational attainment and income are
higlrly con'elatc'tl.
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8.6 POLICY POINTS
Occasiolally clear examples of paradoxes, fallacies and nrisinterpretation of data 
will arise
and be recognised. More often the underlying problems will be present and will cause
problerns, but rvill not make thenrselves evident. This has serious implications in that
policy decisions made on faulty infomration will be flawed'
In health economics and in other disciplines, researchers often have limited control 
over
their statisticar data. These data may consist of adnrinistrative records, with the 
variables
defined by other people, and rvith the records collected in different situations' 
unit record
data may not be available, and the researchers may need to work with cross-tabulations
provided by other people. Accordingly, researcltcrs need to take great care at all 
stages in
their analyses, choositrg the level of aggregation at rvhich they analyse data 
with care' and
investi gating unexpected results.
The follorving points are presented as a summary' The research question and each 
variable
in the data set nrust be clearly defined and described' Subgroups of a human population
may have different structures, behaviours and tleeds, and investigators should be 
aware of
these differences. Data involving Maori health should be analysed and controlled in 
ways
tl.rat meet the needs of Mdori and in partnership with the affected group. Data 
should be
analyserJ using cross-tabulations which involve disaggregation to the lowest 
possible level'
If sopre variables are found not to influence the outcomes, these variables can 
be aggregated
toprodttcctablesthatlrighlighttheinlportantinfltrencing
of unit-record data sets, attd soltware tools to nlanage
detai led anall'sis Practicable.
factors. Increasing availability
and analyse them, makes such
t97
ll Guy Scott (2000)
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CHAPTER 9: ANTIBIOTIC COSTING
9.I SUMMARY AND INTRODUCTION
Summarl'
Micro costing techniques were used to quantify costs associated with antibiotic 
regimens
for serious inflections in three Nerv Zealand public hospitals' A decision analytic 
model
suitable for costing any antibiotic regimen was constructed and tested' The costing 
data
were based on observation ratfter than the more itsual self recorded diary entries' 
The
model developed in this study provided a new tool for hospital administrators 
and clinicians
to more accurately compare the full costs of antibiotic regimens'
I
Introduction
This chapter discusses and illustrates a cosr-of-trearnrent analysis (see Chapter 4: Costs) 
in
rhe evaluation of antibiotic treatments used within New Zealand hospitals (Scott et al''
1999). Tightening budgets within the New Zealandhealth system have increased the 
need
for clinicians and Inanagers in hospitals to consider the cost-of-treatment regimens 
as well
as clinical efficacy and safety when selecting treatment options'
Objectives of the study were to identify and quantify the cost components of antibiotic
regintens used itt hospitals ip the treatnrent of patients with severe infections' 
This
inforrttatiotl \\'aS ttsed to constnlct a dccisiotl analytic nrodel' Tlie model would 
enable
hospital clipicians attcl ttratragel'S to colllpare the cost o[ nerv and current antibiotic
reglnlclls.
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9.2 METHOD
9.2.1 Target Population, Perspective and Overall lltethod
This study rvas cotlaborative, multicentre and multidisciplinary involving rnedical 
and
economic elenrents. The target population was hospitalpatients with severe 
polynicrobial
infections in intensive care or febrile neutropenia in immunoconrpromised 
patients in
haematology departments. Patients were eligible for inclusion in the study if they 
were
treated with a particular monotherapy, or could have potentially been treated 
with this
regime. The analytical perspective adopted was tftat of a hospital rather than 
society as a
whole because the policy question related to the hospital management of serious 
infections'
Approvals for tlre study were obtained from the relevant ethics committees 
of the three
hospitals. As the study was observational and non-intrusive it did not alter treatment 
or
clinical decision making.
Researcl.r was conducted in intensive/ critical care units of three hospitals 
(Auckland'
christchurch and Palmerston North). and in the haenratology departments of two hospitals
(Christchurch and Palmerston North). Both Aucktand and christchurch hospitals were
major hospitals in a main city in tlie North and south Islands respectively, and Palmerston
North hospital was representative of a large hospital in a provincial city' christchurch 
was
used as a pilot centre to del'elop the study protocol and data collection methods' 
Data
collection fonrrs were designed in constrltatiorr rvif h hospital staff in each 
centre' tested in
christchurch then nrodified. Infornration rvas gatltered sequentially from each 
centre
conrrrrencing in latc Nor.ember 1995 and cnding in March 1997'
Datir \.erc acquircd fronr a prospective time antl nrotion study (to quantify time taken 
and
nrarcrials corrsuntctl in r,ArioUS stagc-s of t'e trclltlllcllt process)' ancl from a retrospective
studl,of hospititl rr'cords (cltart rcricrvs lrtd laboratory files)' Treatment processes were
s1:1ir into a uunrber of actiVities nrtti tlte conlponellt costs of each activity 
identified' A
crinicaily qualified obsen,er rccorded srar.f ri're. crrugs and nraterials used 
for each activity'
A sinrilar approaclr $.as used by (N4alek et al., 1992; Atkinson et al', 1989)'
lA Guy Scott (2000)
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Rcsource utilisation obsen,ations fol the stutly $'erc patient treatnrent days' Data 
were
collected only for contplete hospifal deparlntent day stays per patient' That 
is' the patient
had to be in the department for a complete day of treatment' [t was not possible to use 
data
relating ro part ota day because the exact lractiort could not be determined 
from patient
records.
Labour rate information was derived from the literature (Norton' 1997)' and from
consultation with health sector managers' All unit costs and prices were in 1997 
New
Zealand dollars'
9.2.2 Investigative StePs
The investigation took the following steps:
. Project setup
oDefinitionoftheresearchquestionandoverallapproach
o StudY Protocols established
o Ethical aPProval
. Costing method develoPed
o Antibiotic treatment protocols defined
o Resources identified
o Data collection instrtrments designed
. Data collection method trialed
' Data collcctiorr nrethod and fonls reviscd
. ResollrcL'volumes and unit costs data collected
. Data artalysis
. Decision arralyic rnodcl designed and constructed
. Scttsitivitl' arralysis contpleted
ll Guy Scott (2000)
9: Antibiotic C'
Setup
A considerable arnourrt of qualitative research was required to clarify the policy 
question'
the research objectives and general approach. The health care staff of the hospitals were
fanriliar with clinical research, but not rvith econonric and policy analysis' while 
the
economist team members were not farniliar with the clinical treatment processes' 
Before
the nrethodology could be developed it was necessary to embark on a process of 
discovery
and find out about the complex treatment processes involved' This process was not
unidirectional. The policy question, research objectives and an overyiew of economic
costing methodologies were discussed with the clinical staff who would be collecting 
the
data. Establishing the study design and protocol required detailed interviews with 
hospital
medical, nursing and pharmacy staff'
Because the research involved observing and recording the resources used in treating
hospital patients it was necessary to prepare a research proposal for approval by 
the ethics
committees of the three hospitals.
Costing method
A micro-costing analysis of antibiotic treatment regimes used for serious infections 
was
undertaken. Micro-costing is the most precise and detailed method of hospital costing 
(see
Dnrmmond, O'Brien, Stoddart, et al., 1997; Luce et al', 1996, and Chapter 4: Cosfs)' The
follow,ing lisf from Kerr, Barr, Snryth, et al. (1992) is an example of the activities that can
be costed in such a study; insertion of intravetrorts canttttla, drug delivery, drawing 
ofblood'
sharps disposal, and delivery of bloorj to tlte laboratory' The following were costed; drug
preparatiorr, adntinistration and monitoring in detail' Similar listings of cost items 
can be
found irr Davis and Bryson (199a) and Atkinsotr et nl. (1989).
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Drug trcatprelt rcqintclts were definerj first by clinicians and subsequently verified by a
retrospcctivc attalysis of paticpt records' Trealtucnt processes were broken down into 
a
scries of distinct activities, (l) preparatiorr and atjnrinistration and (2) monitoring, that
could be observed and costed.
Relevant resources specifically required or altered by a treatment regimen were 
identifred
and listed. Costs incurred, in'espective of the antinricrobial treatment regime used' 
or costs
that woutd not be changed by the selected treatment, were not applicable to the study' 
For
example, the insertion of a central intravenous line would not be relevant if all patients
inespective of the treatment received required such a line'
when the various activities and resources were identified, the data collection instruments
for obtaining resource utilisations and unit costs were developed' trialed and refined' 
Drug
preparation and adnrinistration used two instrunrents; one for obtaining information 
on the
antibiotic and cor"rsurnables (Figure 9.1 : Antibiotic and Consumables) and another for
measuring staff labour (Figure 9.2: Drug Adntinistratiott Time). Monitoring resource
utilisations and unit costs required a funher two instruments' one for consumables 
(Figure
9.3: Co[srr ntuhlcs artd LuborntoT' Chttrges), and another for labour (Figure 9'4: Drug
I,[onitoring Titrte). Unit costs rvere obtained front each of the hospitals involved in the
study.
Data analYsis
Resource 
'olunres 
measured by the nticro-costing method and unit costs applicable to each
[ospital ryere ttsed to coll\'ert resorlrce utilisations into costs measured in monetary values'
Volunre aud urrit cost data rvere recorded separately for each centre. An implicit 
price per
rcsource u.ir *.as calculatcd by dir,iding the avcrage cost per patient day data by the
a\.er1gc volutrtc ller paticllt clay lbr eac| cliffcrellt typc of rrnit used' This gave a weighted
a\.crirgr, ol'pricr-.s or.c'r thc three gcographic ccrltrcs itlrd rvas used in the decision 
analytic
rrtodr'1.
20s
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Adrrrinistration artd prcparatiotl titttcs $'erc cotrtbitted because of the dilficulties
encountcrcd $'ith oVcrlap atr<1 ntergitrg of tlrcse actiVities' lnfusion times derived from
protocols were not nreasured by the tinre apd nrotiotr study' Analysis was conducted 
on
groups of itcms; for exanrple, syringe sizes fronr 5 to 20 mlwere summed and analysed 
in
aggregate to derive mean resourcc cost and resource volumes used' However' 
within these
aggregates the actual price for each syripge size was used' Accordingly' iniplicit 
unit costs
for syringes differ between the different drugs analysed because different mixes 
of types
of syringes were usecl. This was also done for fluid additives' needles (sharps and 
non-
sharps), and fluid bags. This analysis produced weighted average costs and volumes of
items unique to each drug reginre'
one drug only was nronitored and the rate of morritoring was obtained from 
a ehart and
laboratory recortl revierv within each of the study hospitals. Monitoring rate was 
the total
nunrber of monitoring events divided by the total nr:mber of patient treatment 
days for the
drug. A micro-costing sttrdy determined labour ancl consumables required 
per monitoring
event. The resource units per monitoring from the micro-costing study were multiplied 
by
the rate of nronitoring to derive the monitoring resource utilisation per patient 
treatment
day.
A deterministic decision analytical model (Chapter 7: Models')was constructed and used
for single and multiple parameter sensitivity and scenario analysis (chapter 4: costs)' This
nrodelling approach pemritted the costs of treatnretrt using any antibiotic to 
be evaluated'
Irrputs to the ntodel w ere ttnit cosls ancl volttmes of rcsottrces per patient treatnrent 
day' The
output screen providCd infomratiorr on total treatlnctlt cost.
9.3 RESULTS AND DISCUSSION
A total of -l I I pltir.nt da1's for drtrg prepat'atiott atttl adntinistration were collected 
from 94
hospitnl admissions for treatnrent. Finnl analysis of aggregated drug data was conhned 
to
tftosc drLrgs lor n'fiiclt 20 or tlore obscn'atior]s or patient days were recorded' Thus' 
the
Study anitlysed 83 patients lor rvlrotl a total of ]60 treatment days rvere recorded'
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The study focus rvas on cvaluatittg trcatnrent costs' Ncither tlte severity 
of the infection'
nor patiept outcotltes conceming efficacy or adverse events were considered' 
A full
econonric study (Chapter 6: Econottric Evlttotiorrl woutd require the evaluation of 
patient
outcot.nes, drug acquisition, preparation and adnrinistration costs' nronitoring' 
Iength of
hospital stay, and the cost of adverse events (sce Beringer et al'' 1998; Birmingham 
et al"
l 997).
while the cost of adverse events is acknowledged as important in the treatment 
of such
patients, the evaluation of these events is difficult for the following reasons' 
Very large
nunrbers of patients are required to detect irrfrequeltly occurring adverse events' 
There are
obvious ethical impediments to setting up traditional randomised placebo 
controlled
clinical trials to collect such information. It is also difficult to attribute an adverse 
event to
a particular drug rvhere a conrbinatiorr of drugs is used, or in a situation in 
which regimens
are continually changing. As most patients u'ere seriously ill there would have been
difficulties in deternrinilg if an adverse event was a result of the treatment or the
underlf ng condition of the patient. other investigators have also omitted 
evaluating the
cost of adverse effects (Ken et al', 1992; Malek et al'' 1992)'
Although there were differences between the three hospitals in the prices 
of antibiotics and
other materials used, most of this could be explained by differences in timing 
of purchases
and negotiatecl price. commercial scnsitivity precluded disclosing price data from
individual hosllitals. Tlris problent is not peculiar to Nerv Zealand' other 
investigators
(Malck. Lyrclt, Wells, et 11., 1992) fiaye ellcotllltcrcd sinrilar problenrs with cornmercially
sensitivc data in thc UK.
Adnrinistratiorr lrrd prcplratiol'l tinres rverc cotttbirtcd in thc analysis because 
it was difficult
fo diflercntiate bct\\'ecu tlie t$'o tasks. Therc rvas little variation in preparation and
adnrirristration tinres bctr.r'ectr hospitlls ancl departnlents and the differences 
that did occur
may be cxplairred by sonre staff not being as fantiliar rvith routine 
procedures as other more
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experienced stalTor by difficulties g'ith a partictrlar patient' For exarnple' 
a child who may
require coaxing before a nredication is given'
A hospital's hnancial costs (nrotretary outlays) rvith respect to nursing staff 
will not
normally be lorvered by reducing the tabour cotllpopent in the administration 
of drugs
because these patients frequently require one-to-one nursing' There 
is however' an
opportunity cost as the nurse could be providing other care to the 
patient (Atkinson'
chambers, McGinlay, 1989). Another point is that advances in technology could alter 
the
one-to-one nursi ng requirement'
wastage of antibiotics, defined as the unused portion from a pack' occurred 
with only two
dnrgs. while wastage may indicate that an inappropriate pack size has been 
selected or that
the appropriate pack size was unavailable, wastage n'lay not necessarily 
add to costs' For
example, it nray be more time consuming for staff to use a number of 
smaller packs' and/or
a combination of smaller pack sizes may be more expensive than one 
larger pack'
Dnrg protocols are continually evolving and during the course of the study there 
was a
move to once-a-day administration and a greatly reduced frequency of monitoring'
However, the model was designed so that protocol changes such as 
this could be taken into
account.
The dnrg reginren chosen is detenlined by knorvn adverse reactions' 
drug resistance and
tlre patient,s severity of illness, Tlre study did not take into account the 
spectrum of cover
of the various antibiotics and the susceptibility of nricro-organisms 
to specific antibiotics'
Marry oItlte recently introdtrced antibiotics havc a broader spectrum of 
cover than the older
protlucts. N-ilrro\,-spectruln anfibiotics are oftcti cotrrbined (for exarrrple' triple
conrbination thcrapy) to provide the satttu'spcctrum of col'er provided by a single 
broad-
spcctrul't'l agr-tl1, WIe1 corttparittg costs of arrtibioric conibinations offering 
the same
coverage, the aclditive costs of a contbination sfiottld be taken into 
account and compared
u'ith the cost of the single agent'
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9.4 POLICY POINTS
The study was multicentred $'hich in itself created issues for data collection' consistency
and quality control. Clear protocols for the study had to be set up and efforts 
made to
ensure the protocols were interpreted in the sanle nlanner and uniform data 
collection
methods used. Each centre was monitored and the data carefully checked 
to assure
accuracy and consistencY'
The multicentre nature of the study and that fact the data was collected by 
persons in
addition to their normar work meant the data coilection period took longer 
than planned'
when antibiotics in a hospital are being administered there is much activity' 
and recording
consumables used posed some problems. These were resolved by collecting 
ail packaging
of cottsunrables in a container to be recorded later'
Recording labour times raised issues of staff management as people 
were not comfortable
in being nrouitored in their work. Staff were very suspicious of any time 
and motion study
and carelul explarratiop had to be given that this was not a cost cutting 
management
exercise.
The information gained from this observational study can be considered 
superior to that
gained from a self-recording diary approach. Staff are busy and would not 
be able to
accurately record activities in a diary ttrrtil after the event' Micro-costing 
is iu essence a
tinre and ntotion stucly $,ith a nc\\'nanle, but it has iu recent times been neglected 
by policy
a'alysts rvSo 6irr.c tended to gse data recorded prinrarily lor other 
purposes or from diary
records.
Ahhough the str.rcly results ancl ntodcl could be usetl lbr henchmarking 
and comparlsons
bL-t\\'eclt 66spi6ls corlnrcrcial sensitiviti, precltr<ie<l tlris' Commercial 
sensitivity is a major
barricr ro tlrr-. glthcrirrg of data llecessary for irtfonneti policy evaluation 
by people other
t'un the firttrtciirl officers of a lrospital. This cor:ld be overcome 
by a data warehousing
approach *'lrere data is passed to a ccltral sotlrce and reicased to userS 
in an anOnymOUS
fomt.
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Sonrc costs, such as nurse labour altlrough fixed in the shorl run could be variable as
protocols and technology change over the long run. Altlrough administrators may not in
the short run have the ability to control sonre fixed costs, knowledge of these costs is vital
forlongtenn planningand policyanalysis. Thepatients inourstudyhad serious infections
and protocols dictated that each patient have a nurse allotted to them exclusively; the nurse
was thus unable to undertake other duties.
The Gibbs Report (1988) considered that the main cause of technical inefficiency within
the public hospital system was the lack of good quality management inlormation and the
lack of incentives to usc and acquire suclr infonnation. This study has shown that the
nretlrods cleveloped nray be used to estinrnte the full costs of an antibiotic regimen. The
nrodel developed enables managers rvithin public hospitals to be better informed on total
treatment costs (not just drug purchase prices).
Different policy decision makers could use the results of this study in different ways.
Business unit nranagers and clinicians could jointly use such a model to evaluate and design
new antibiotic treatnrent protocols and nronitor the costs of existing policies. Drug
purchasing nranagers and health funding agencies could use the cost comparisons between
different antibiotics as a means of obtaining better information for negotiating prices with
suppliers. Hospital general management could use the model in benchmarking to compare
costs calculated in a unilorm mar]ner betrveen differcnt business units within a hospital and
betw'cen hospitals.
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9.5 DATA COLLECTION INSTRUMENTS
Figure 9.1: Antibiotic and Consumables
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Figure 9'2: Drug Administration Time
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Figure 9.3: Consunrables and l.aboratory Charges
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Figure 9.4: Drug l\lonitoring Time
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CHAPTER 10: BENIGI\ PROSTATIC
HYPERPLASIA
IO.I SUMMARY AND INTRODUCTION
Summary
This cost-of-treatment study integrated data from a wide range of sources; surgical
treatment audits, hospital discharges, and prices. New information on the economic costs
of treated benign prostatic hyperplasia was published. The research highlighted the hitherto
hidden intangible costs of the side effects of surgery and was instrumental in prompting
clinicians to investigate the differences in treatmcrrt rates between Maori and non-Maori.
The research used hospital discharge unit record data (with patient iderrtifiers removed)
which errabled filtering and detailed analysis. To nry knowledge this was the first New
Zealand study that uscd newly available unit record discharge data for economic policy
analysis. Earlier research rvork could access only published aggregated data which did not
pernrit filtering and detailed analysis.
lntroduction
The objective of the cost-of-illness analysis, which had a societal perspeciive, was to
estitrrate the econorrric cost of treated benign prostatic hyperplasia (BPH). Little attention
has ber'n fcrcussr--d on the cosl of BPH hecause it has been regarded as part of the normal
aging proL-css in rlales. Hos'evcr if attitudcs s,c-re changed by a health education or health
pronrt'rtiorr progmnlnc, and nrore nrcn sought treatnrcnt, tlemands on the public health
Lrudgc't n crultl irrcrclsc. Aspects of this study u,erc discussed in Chapter 8: Cure lltith Data.
Dr'tlilcd infornration on thc nrcthodoloev ancl firrdinqs can be found in Scott and Scott,
( l9()-11.
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BPH is a nonnralignant enlargenrent of tlre prostate that commonly occurs with aging
(Barry. 1990), Enlargenrentoftheprostaternaycauseavarietyofurinaryproblentsranging
lrom acutc urinary retention to recurrent urinary tract infections (Christensen and
Bnrskewitz, 1990). BPH frequelrcy of occurrence increases with age, 70% of men by 80
years of age rvill have significant syntptonrs of BPH (Cockett, 1992). It is uncommon in
nren under the age of 50 but nrost nren of over 60 years will have some symptoms of
prostate enlargement (Gri ffi ths, 1 992).
BPH manifests itself in the following syntptoms; the sensation of incomplete bladder
enrptf ng, a hesitant urinary stream, slou, urinary florv, urgency, a need to push or strain to
begin urinating, and nocturia (McConnell, 1992). Over a period of several years one-third
of patients rvill spontaneously inrprove, one-tlrird will remain stable u'hile one-third will
deteriorate. Appropriate treaturent options are rvatchful waiting, surgery or ntedicines
(Denis, 1992).
A patient in New Zealand rvith symptomatic BPH u,ill usually consult a general practitibner
who will normally refer the patient to a specialist urologist in a public hospital or in private
practice. If assesscd as needing surgery (scoring enough points, see Chapter 3: Valuing
Health Outcontes) the patient rvould be given a booking forpublic hospital surgery. If not
booked for surgery in a public hospital the patient would either be referred back to their
general practitioner for rvatchful rvaiting or booked for surgery in a private hospital.
IO.2 METHOD
Range of Relevant Costs
The costs ol- BPH frorn tlre perspcctive of Nn'", Zealand society may be classified as
follorvs:
Dircct nredical costs
Anrbulance
Hospital rvard
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Operations
Outpatient and specialist coltsultatiotts
Ancillary hospital stalT(e.g. district nurse)
General practitioner consultations
Medicine prescribed (hospital and community) and associated markups and
dispensing charges
Diagnostic procedures and laboratory tests (hospital and community based)
Medical research
o Direct nonmedical
Transport costs of patient, family and friends
Community and volunl.ary organisations
Additional laurrdrl' costs lnd protr-'ction aids
Additional costs associatcd rr'ith premature entry into residential care
. lndirect costs (time related)
Production loss by patients
Production loss by unpaid care-givers
Leisure time loss by patients
Leisure time loss by unpaid care-givers
. Intangible costs
Quality of life of patient, family and friends
Ideally for a cost-of-illness study all of these costs should be evaluated but data covering
the full set s,ere not available. For lhose costs that could be quantified, the latest available
resource utilisttion (r'olurne) data (at the time of data arralysis) were combined with March
quarter 1992 prices to calculate total econonric costs. All unit costs were net of GST which
is a transfer payuent lrom the societal perspective adopted in this study.
Hospital \\'ard and Surgerl'Costs
Putrlic arrcl private hospital adnrissions and nunrbers of operations performed for the year
eriding Dccernber 1988 u'ere obtained as unit records on computer diskette from Health
Statistics Sen'iccs (HSS) of the Depaflment of Health.
ll Guy Scott (2001)
Chapter I0: Benign Prostatic Hvperplasia 220
Lacking reliable public sector costs, prices fronr the private sector were used for direct
nredical costs. At tlre tirnc of the study', reliable arrd detailed public sector costing data in
Nerv Zealand rvere not readily available for ecorronric research, and in many instances the
datadidnotexist. Suchdata,iftheyexisted,rvercregardedbymosthospitalsandRegional
Health Authori ties as commerc ial I v sensi ti i,e.
Competition between hospitals means that supemormal profits in the private sector are
likely to be small, and offset by higher costs in the public sector, where hospitals may have
a teaching component and be more likely to treat "at risk" and therefore more costly ciuies.
Public hospitals usually have more back-up facilities such as intensive care units.
The Southenr Cross schedule of fees for surgical and anaesthetic procedures culrent in the
March 1992 quarter, was used for prices in relation to preoperative consultation fees,
surgeryand anaesthetics. Wakelreld Hospital in Wellington provided theatre and ward unit
costs.
Medical Consultations and Prescriptions
Without any national data at general practitioner or specialist level it was assumed that
each patient admitted to hospital would require two specialist consultations and these were
valued using the Southern Cross Medical Care Society schedule of specialist fees. Survey
data relating to gencral practitiorrer consultations for primary diagnosis BPH rvere obtained
frorn IMS ( 1992). These data togcther rvith an aver&ge consultation fee of $27.56 (Health
Benefits Letter 4, l99l) rverc uscd lo calculatc the cost of consultations.
Medicincs prescribcd for BPIJ at gcncral practitiorlcr level were derived lrom lMS survey
data (llvlS. l99lt. Wlrolesalc and retail nrarkups (Pricing Schedules l99l) were added to
thc cost at nrtnuftrcturc.r selling pricc (ll\'ls 199?) and the number of prescriptions was
niultiplicd by the average dispensing fee and container allowance (Pricing Schedules,l99i ).
No data were available on rrredicines prescribed by specialists or at hospital level.
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Production and Leisure-time Foregone
The corlbirre'd value of leisure-tirrre and productiorr (both paid and unpaid) was calculated
using the a\.'erage hourly earnings for nrales and an estirnated two weeks for patients
undergoing surgery and one week for hospital patients not requiring surgery. This time lost
from nomral act ivities was estimated fronr in-depth interviews with a number of urologists.
Average hourly earnings for nrales rvas used as a proxy for the value of all leisure and work
tinre.
Quality of life
The study attemptetl to collect information on aspects of the quality of lifb of patients with
BPH. A literature search was undertaken to see if there were any patient support groups
within Nerv Zealand and find studies (both published and unpublished).
10.3 RESULTS
Estinrates of the total direct medical costs of BPH in New Zealand were $14 million, and
production loss and leisure time loss by patients $4 million (Table l0.l ). Direct medical
costs accounted for almost 80% of total quantified costs.
In Nerv Zealand tlre nrost important operation done for BPH is transureth;al prostatectomy
(TLIRP). If this operatiorr u,as perfonled in a public hospital, patients on average stayed
8.5 days, rvhilc those in private hospitals staycd 4.3 days. The mean age of these public
hospital patients u'as 7l years conrptrred with 67 years for those in private hospitals.
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Table l0.l : Summarl' O[ Quantified Costs For BPH
Cost (1991 resotrrcr'\'oluntes in 1992 dtrllars) Low
$
million
Base case High$$
million million
Direct medical costs
Ilospital rvard
Operations
Outpatients and specialists
General practitioners
Medicines, dispensing fees and container
allowances
Laboratory tests
Diagnostic procedures
Total direct nredical costs
lndirect costs
Production loss by patients under 65 years
(unadjustec{ lor labour participation and
unemploynrc'nt)
Lcisure time lost by patients 65 years and over
Total Indirect cosls
Total quantified costs
6.5 l0
4.742
0.285
0.234
0.1 52
0.1 89
0.144
12.256
1.082
2.566
3.648
r5.904
7.ssz 8.760
5.50 r 5.501
0.33 r 0.496
0.234 0.234
0.152 0.152
0.219 0.219
0.167 0.167
14.156 15.529
l .255 1.255
2.977 2.977
4.232 4.232
l 8.388 19.761
Note: Because of rounding individual items may not add exactly to the totals shown
HSS data reveal an overall 16.2% increase in adnrissions for BPH during the period 1988
to l99l'0. Public lrospitals recorded a 14o/o increase and private hospitals recorded an
increase of 20o/' ilr adnrissiorrs. Accordirrgly, all 1988 volumes that were dependent upon
hospital adnrissiorrs iverc irrcreased by l60,/o to olrtairr a l99l volume estintate - the base
case estinrate of S I E.3EE rnillion. (Direct costs of S l4.l 56 nrillion, indirect costs of $4.232
million).
A high estintnt!- s'as obtainc-d by incrcasing tlrc basc case estimate of hospital ward costs
Belu'een 1988 (hospital unit record data used to estimate costs) and l99l (latest
published volunre data on hospital adnrissions available at time of finalising the
paper) tlre voluure oI admissions for principal diagnosis BPH to all hospitals
increased bv l6%.
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by l6% (to tnkc- accor.urt of lrigher daily *'ard costs as indicated by Wellington and
Clrristchurch data), arrd outpatient and specialist consultations by 50% (based on survey
data), to give a total of $19.761 milUon. (Direct costs of $15.529 million, indirect $4.232
ntillion).
Hospital admission infornration in New Zealand are recorded at time of discharge or death.
ln 1988 there were 1.9 BPH patients per thousand males of all ages admitted to all
hospitals. The equivalent rates for males 50 years and over were; Maori 3.4, non-Maori
8.7, and all males 8.5. The data indicate that the prevalence of BPH among the Mdori
population could be lower than that for non-Maori. Chapter 8: Care With Data for a
discussion of the observed differences between Maori and non-Maori.
Admission data (BPH Diagnosis A) for public hospitals were analysed with respect to type
of adn:ission and source (comparable data \\,ere unavailable from private hospitals). Fifty-
nine percent of admissions canre from waiting Iists, ZTYowere acute admissions and l4Yo
were arranged (by general practitioners, specialists or outpatient departments). Some
patients with acute urinary retention present directly at accident and emergencydepartments
of public hospitals. Most hospitals admit directly to the appropriate ward but as some
major hospitals admit all patients through the accident and emergency departnrent very little
can be read into this rnanner of admission.
Thirty-seven percent of patients u';rc referred for admission by specialists, 32% by
outpatient departnrent s,23o/o by general practitioners,5o/o by accident and entergency, and
2o/olty othcr hospitals. Analysis of irt'lrrrission data sr-rggested a greater degree ol'monitoring
by gencral practitionc.rs irr snrall centres and rural areas at some distance from a urologist.
Arralysis of adrnission and dischargc dates for BPH Diagnosis A (all types of surgery not
orrly TURP) shoucd that thc nrean days stav \\'as higher for public hospital patients;
(public) 8.9 dl1's cr)r'nl)arL'd rvith (;lrirltc) -1.6 dl1's (for all ages).
Fronr a total of 79 patients (sun'ey of urologists in both private practice and public hospitals
undertaken by the authors) 33 patients presented with perioperative complications (within
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30 days of surgery) arrd 25 patients presented rvith latc postoperative complications (over
30 days). Tlre cornplication rate for pcrioperativc conrplications was 42o/o and 32oh for
postoperative conrplications. All 79 patic'nts had a TURP.
The survey also indicated that the following laboratory tests were routinely undertaken for
all patients in both public and private settings; urine culture, prostatic acid phosphatase,
prostate specific antigen, complete blood count, electrolytes, group and hold blood (halfof
the patients), and post-discharge urine culture (half of the patients). The total cost of these
tests was $0.189 million.
Although the survey showed that the following diagnostic procedures were undertaken the
data were insufficient to extrapolate for all specialist consultations. The procedures
undertaken were; intravenous polygranr, plain abdominal X-ray, chest X-ray, abdominal
ultrasound, urinary flow rate, and electrocardiogranr. It was clear that virtually all patients
had an X-ray of some sort.
The following costs rvere either unquantified or not isolated because of inadequate data;
ambulance, ancillary hospital staff, medicine prescribed at hospital and specialist levels,
production loss and loss of leisure time by unpaid care-givers, transport costs of patient,
family and friends, services provided by community and voluntary organisations, medical
research, additional laundry costs and protection aids, premature entry into residential care,
additional home help rvhen a patient is partially incapacitated, pain and suffering for the
patient and their effects on the family, quality adjusted life years lost.
I O.4 DISCUSSION
A corrrplicatiort rate ol 2.02o/' u'as recorded for TURP in public hospitals but surveys
(conducted by tlre rcscarchc:rs) in both public and private settings suggested that the
corlplication ratc is substantially under-recordcd. This could have a major impact on
reducrng tlic quality of life status oIpatients undergoing surgery but this could not be
quanti ficd.
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The direct nredical costs of BPH account for alnrost 8096 of the total quantified costs'
Hospital warcl and operation costs account forjust over907o of thedirect nredicalcosts.
Horvever. ward costs are underestinrated in the study as BPH diagnoses B, C, and D were
excluded (it u,as irnpossible to isolate u'ard costs attributed solely to BPH where admission
was prinrarily for another condition, (see joint costs in Chapter 4: Cosls). As most BPH
patients in Nerv Zealand are over 65 years of age, paid production loss is relatively
uninrportant in relation to total costs.
Hospital ward stays and operations are the 2 areas where savings would have maximum
impact on total costs. A substantial reduction in costs could be achieved if the length of
stay in hospitals could be reduced. Public hospital patients stay on average 8.9 days
compared rvith 4.6 days for private hospital patients (all types of surgery for BPH). If the
public hospital average rvard stay could bc reduccd to that of private hospitals then total
ward costs would fall by 37olo, total direct costs would fall by 2lo/o and total quantified
costs by l6%. This *'oul<l implicitty assume that the patient outcomes and patient profiles
are sintilar. Not u'ithstanding these qualifications, the differences in length of stay are
worthy of i nvesti gation.
Reasons were sought for the disparity in the length of stay between public and private
hospital patients. The case mix of public and private hospitals is likely to differ in that
older, at risk, and emergency patients are more tikcly to be admitted to public hospitals
rvhich arc ntore able to cope n'ith conrplications, ttnd have a more intensive level of care
and morritoring.
Factc'rrs *'ere invcstigatctl that could possibly' aflcct lengtlr of stay and that could be
crnrrrinctl usirrg HSS clata. Age and discharge typc (covering classihcations of dead,
1outilc. sclf clisclrlrgc, and Lrarrslcrs to olhcr tlpes of institutional care) were analysed. The
average lerrgth of stay'for all age cohorts in private hospitals was about half that of public
hospirals. Thcre s'as little difference in discharge type rvith 97% of patients in public
hospitals and 99% of all patierrts in privatc hospitals recorded as routine discharges. It was
thought that had Lhere been substantially more patients in the public system returning to
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nursing hornes or other hospitals this could cxpluin a longer hospital stay as presumably
such patierrts u'ould require a ntorL' intcnsive level ofcare. As the private hospital database
covers only the principal diagnosis and principal operation it was impossible to determine
if there rvas a difference in lrcalth status betrveen the public and private hospital patients by
reference to nrultiple diagnoses and operations. The identified differences in case mix do
not fully explain why patients stay trvicc as long in public hospitals as patients in private
hospitals.
Surgery was the most common treatment option for most patients with symptomatic BPH.
Watchful waiting and/or treatment with medicines was relatively unimportant at the time
of the study but should either of these two options assume greater importance there will be
follow-on costs in areas of laboratory and diagnostic investigations, specialist consultations
and nredicine prescribed. But if treatment rvith rrredicine could avoid the need for surgery
or lessen the hospital stay this treatnrent option could substantially reduce costs. Il
however, surgery is merely postponed rather than avoided, surgery costs are simply moved
forward in tinre, and the medicine costs becon're an additional cost. Moving the cost on in
tinre reduces the ne-t present cost. Howevcr, thc patient may enjoy an improved quality of
life and older patients nray die fronr urtrelated causes before surgery is needed.
Laboratory tests and diagnostic procedures were under-reported in this study as data at
general practitioner level were unavailable. In addition, although the urologist audits
recorded tests undertaken, the sample sizes were considered to be too small to allow rates
to be applicd to all patients except fcrr the nrajor tests carried out on most patients. Both
the tcsts and tlie procedures were consen'ative estirnates of the true costs.
Laboratory tcsts and diagnostic proccdurcs arc areas in ri'hich changes are occurring and
o ntr,-lSurr3 ol'tlrc inrplct of ltotcntial clurnges cun hc gained by corlsideration of possible
additions or cleletions to the tests costcd. Thc prostate specific antigen test is likely to
replncc- tlre che.apc'r'prostxtic acid phosphatase tcst as it is regarded as being more sensitive
as a lullour rlarker for carrcerof the llrostate. Both tests rvere included in the study, but
if rhe phosphatase test is delctcd thc nrcasurcd costs *'ould fall byonly $0.019 million.
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Changes in tcsts and procedurcs u'itlr thc introduction of new technology could increase
costs but nray have little irnpact orr thc overall cost of nredical treatnrent as this area forms
only a sntall percentage of the total dircct nrcdical costs. It is realistic to assume that each
patient may in the future receive an abdominal ultrasound rvhich would increase the cost
of diagnostic procedures by 157%. While this rvould more than double the total cost of
diagnostic procedures it would only increase the direct medical costs by 1.7%. Conversely,
confining chest X-raysrT to only those patients over 65 years would lower the cost of
diagnostic procedures by 23% and lower total direct medical costs by 0.3%. However, as
the current cost of diagnostic procedures is l% of direct medical costs none of these
changes will make a nreaningful difference to the costs of BPH.
Complications recorded for surgery in this study came from three different sources, each
at a different stage of treatnrent for BPH. Hospital data recorded complications within the
duration of the patients'hospital stay, the survey collected data within 30 days of surgery,
and after 30 days of surgery, and Gilling's study (1988) interviewed patients at a minimum
of 6 months following surgery (sexual dysfunction only was studied).
Hospital staff nray regard some problems/complications associated with surgery as normal
occurrences and therefore may not record them as the survey indicated a higher
complication rate. Recording compliance is likely to be higher in a survey, and as the
survey covered a post-discharge period a liigher conrplication rate would also be expected
but the difference betrveen the hospita! data and the audits was sufficiently large to assume
tlrat under-rcporting is occurring rvithin hospitals. (Under-reporting of complications will
not have resulted iu an underestinrate of hospital rvard costs as these rvere fullycaptured
if the paticnt rvas adnritted under BPH diagnosis A).
Therc nray also be an inadequate appreciation of postoperative problems facing BPH
patients in Ncs' Zcallnd if patients do not volulttecr information on what they may regard
as a scrrsitir c subiect. Althoush rrrost ol-thc cornplications of the treatment for BPH are not
r7 Required to check for underlying corrditions that could increase the risks from
surgery.
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life threatening and add littlc to dirc'ct nredical costs they are inrportant in terms of quality
of life, Society nray rtot fully appreciatc tlre rnagnitude of the reduced quality of life
resulting lront sytrptonratic BPH and its possiblc' lrcaunent conrplications for the patient.
As inlorntation ort this topic werc not a'"'ailable lronr other sources, more research would
be required to quantily the quality oi lilb cosrs.
A possible lower prevalence of BPH among Maori may be explained by the fact that the
MSori age cohort for those 50 years and over has a lower ratio of older people than the
same age group in the non-Maori population. Furthermore, as small numbers are involved
this apparent difference in rates should be interpreted with caution. A reluctance to use the
health system for social and economic reasons nray in part explain the lower number of
Maori presenting for treatment. A clinical investigation (Nacey, Morum and Delahunt,
1993) found that rro statistical difference in rates could be demonstrated betu'een European,
Maori or Polyresian nrales aged 50 and over. (Scc. Chapter 8: Care w,ith Data)
Papers presented at the International Consultation on BPH (1992) produced evidence that
suggested that the rate of BPH in the community is under-reported. Many people consider
BPH to bc part of the normal aging process of nrales and tend to accept attendant problems.
If these attitudes change and BPH symptoms become less acceptable, more focus will be
placed on intangible costs. Society may be prepared to accept higher direct medical costs
to achieve inrproved quality of life. As the New Zealand population ages the prevalence
of BPH w'ill increasc.
IO.5 POLICY POINTS
Ward costs \\,ere undcreslinrated in the- study as cliagnoses B, C, D were excluded as costs
cotrld not bc isolatcd ll'ortr tlrc prirnary diagnosis. This is a conlmon problem when
attentlrtinu to apportion slrared or joirrt costs, typically overheads. (Chapter 4: Costs
discusscs ioint costs and rclated co-nrorbidities).
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This study used nrlle *'age ratcs to evaluate production and leisure tinre foregone but lower
cost estinral.cs u'ould lrar,'e been obtained had the rnale and fentale conrbined rate been used.
Using the conrbined rate is ir:rportant if policy nrakers are to allocate funds in a gender
ncutral nlanrlL'r. This nreans that published results in the Iiterature may need to be adjusted
to take this into account as the publication nlay not be targeting policy makers. (See
Clrapter 4: Costs)
Under-reporting of complications nlay have arisen as some clinical conditions were
regarded as nomral occurrences and therefore may not have been recorded as
complications. Because the complications of surgery have the potential to greatly reduce
the quality of life of patients, they are important when making policy choices from a
societalperspective. Furtherresearchrvouldbedcsirabletoquantifyqualityoflifechanges
as this could have a nrajor impact on policy reconrnrendations.
Apparent dilferences in disease prevalence between Mdori and non-Maori were probably
a result of Maori rrot accessing health services. Data on hospital admissions needs to be
interpreted with care if inferences are to be nrade about disease prevalence and allocation
of resources. See Chapter 8: Cure lVith Dattt.
If societal attitudes change from a condition considered to be normal to a disease that is
not acceptable, provision of nrore nredical inten'ention may be needed. Although this
rvould increase health care resource utilisation and impose greater pressure on health
budgcts it nrust be rveighed up against qualityof life gains. As the population ages this
particular discase rr'ill assunre greater importance. The cost of increased health resource
tutilisation should be fully accounted for rvhen considcring the costs and benehts of a health
cducatiorr or pronrot ior) prograrnnlc.
Tlris casc studv illustratetl the neecl to assenrble arrd integrate data from a wide range of
sol.n'ces. 'l'lrc 1:t'ocess of integrating daia rcqurrc-s trar)sparent careful reporting so that
ltolicy,rnakcrs rnay nrake fully infbrnretl decisions. This is a particular problem rvhen the
results of such a sludy are presented to decision rnakers with clinical or accounting
backgrounds where data is usually derived frorn a single source (clinical trials or financial
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records),
Farticularprob,llenrs arisitrg out offhis study rvere the diffrculties ofo-btaining any dataother
tlran hospital ad,nrissions and surg::::::::::::::::sry eosts and the need to cross-cheek data.using different
,soqrc€s and studies. Policy makers eould use the results of the study to estirnate the costs
sf'hidden'" lllnerss in thecomrnunity. Thi,s'hidden" illness wsuldsw aceifgovernment,
support group.s, cl,inicians orprivate finne embarked on educational andhealti promotior,r
policies and c'ampaigns,
In summary the results of this study could be used in the following ways by'
. Ministry of He€tth policy makets to assess the potential cost conssqueflces of an
educational earnpaign that provides infornration about BPH and treatrnent options,
. hospital health funding agoncies in setting u{, contraots with hospitals.
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CHAPTER II : HYSTERECTOMY
I I.I SUMMARY AND INTRODUCTION
Summary
Tlris chapter discusses another cost-ol-illness study and issues of equity and efficiency. For
the first time in New Zealand, incidencc rates and costs of hystersctomy were isolated for
wonlen between the ages of l5 and 55 years undergoing hysterectomy for non malignant
conditions. Prior to this study, published data related to total hysterectomies. ln this study
unit record hospital discharge data were filtered and used to estimate incidence rates and
costs.
Introduction
This chapter presents the results fronr a cost-of-illness study (Scott and Scott, 1995) (see
also Chapter 4: Cosrs). The analysis sought to establish the annual hospital and indirect
costs to New Zealand society of hysterectomy for nonmalignant nrenstrual conditions. The
target population was women between puberty and menopause. Comparison of New
Zealand's rates of hysterectonry with those of other developed countries within the OECD
was also undertaken.
Accurate cost data is essential if alternative inten,enl.ions that could reduce the need for, or
the ccononric cost of surgical proccdures, arc to bc conrpared with existing surgical
treatnleltts. Policy options evaluated could include altcrnatives to surgery and different
hospital rllanasenlcnt systents. Econornic evaluations lbr policy analysis require both cost
and hcrlth rclated outcolre data. Cost-of-illness sl.udics provide the costing data required
for policr. lrr;.r11'sis. This infonlatiolt rr.ould also lssist both flunders and providers to
nL'rtoti lltc cOrltract priccs.
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I I .2 II{ ETHOD
Costs \\'cre nleasured incrc.rrrentally ll'orn thc pcrspcctive of society. Public hospital costs
rvere cstinrated by nrultiplying the public hospital Diagnostic Related Groups (DRG) unit
cost by the number of patients for each operation. A similar calculation was made for
private hospitals using private hospital cost data.
The combined total of production and leisure-time loss was calculated by multiplying the
average number of weeks incapacitated by surgery by the average weekly earnings (as a
proxy for the value of production and leisure tinre forgone). Discussions with nurses and
patients suggested that a conservative estinlate of tlre time apatient was incapacitated could
be nradu'by using threc tirles the hospital stay.(a lite rature review did not uncover any more
definitive data). Nurnbers of surgical proccdurcs for I 991 were estimated front unit record
data in electronic fonrrat (N.2. Departntent of Health, 1993). This data encompassed all
New Zealand hospitals, both public and private
Data were sorted and a subset made rvhich excluded patients with indications of
malignancy, infections, and congenital abnormalities. Patients under the age of l5 years
and over the age of 54 years were also excluded from the subset. This was done because
the focus of the study was hysterectomy for nonnralignant conditions in women between
the ages of l5 and 54 years.
The public lrospital unit cost of 54,736 rvas dcrived lronr DRG 359 uterine and adnexa
procedurcs lbr non-nralignlncy age lcss than 70 rvithout co-nrorbidities and/ or
conrplications (Natiorral Advisory Conrnrittee on Core Health and Disability Support
Sen'ices, 1992). Private hospital unit costs from the Southern Cross Medical Care Society
( I 991 ), and Wakeficld Hospital, Wellington ( 1992) s,ere also used as an alternative method
forcvrlultirrgcrtstsirrtlrcprivatesector. Costsol'the surgeonandtheanaesthetistwere
tlkcn lrotn tlrt-'Socir'l1'. and thc rrrtrd arrcl theatrc costs rvere provided by Wakefield
Hospital, Wcllington.
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Public hospital costs rvere estirnated by nrultiply'ing the public hospital DRG unit cost by
tlre nunrber of paticrrts for each operation. Private' hospital costs were calculated using
privlte hospital cost datt. Dnily s'ard cost nrultiplied by the total nunrber of days in the
hospital rvas added to tlre unit cost of the operation (excluding ward costs) nrultiplied by
the nunrber o I operations.
I I.3 RESULTS
The all ages all conditions hysterectomy rate per 100,000 women was 365 in New Zealand
in l99l compared rvith 431 in 1980. This rate for New Zealand is similar to that of
Australia, lower than Canada and the US but is much higher than in Japan and some
European countries. Time series data shorved that ratcs in most OECD countries (including
Nerv Zealand) have been falling since thc latc 1970's (OECD, 1993; Olfice of Health
Econonrics, 1992).
In 1991,6,331 hysterectonries (for all diagnoses, all operations and all ages) were
undertaken in Nerv Zealand (50.5% of these opcrations were carried out in public hospitals,
and 49.5Yo in privrte hospitals). Both the nunrbers of all hysterectomies in public and
private hospitals and the rate per 100,000 females are shown in Table I I .1. Hysterectomies
for rronmalignant menstrual conditions (4,390) rcpresent 69% of the total hysterectomies
undertaken in Nerv Zealand in l99l . The hysterectomy rate per 100,000 females ( 15 to 54
years) rvas 446.
Table ll.l: Hvstercctomies l99l
Opc'ratiorr Public Privitte All Female Rate/
hospitals hospitals hospitals ppprde!i-qll-19-9p99-
All hysterectornics, all ages
Flystcrc-ctorttie's, I 5 to 5;l years.
for norrrnll i srrarrt cortd itiorts
9u of all [lvstu't'cctontics
3,199 l.l 32 6,331 I ,733,700 365
I ,9S I 2,409 4,390 984,120 446
61.99/o 169% 69.3%
Note: Bccause of roundine individual items nrav not add exactly to the totals shown.
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Tablc I 1.2 shorvs that public hospital patients are about I year younger than private
hospital patients, and stay otl average onc day longer in a hospital. Privatc hospitals
conduct 55% of [lrc. liysterecton]y opcrations for this group olwonten, but generate 45o/o
of the cost.
Table I1.2: Hospital Cost of H1'sterectomies for Nonmalignant Conditions Patients
Aged l5 to 54 Years: l99l
Public Private All hospitals
Number
Yo of all hospital number
Age in years
Days stay
Total cost $ (000)
% of all hospital total cost
Total cost per hvsterectonv $
l,g8l
4s%
4t.5
6.5
9382
5s%
4,390
r00%
2,409
ss%
42.3
5.3
7,601 16,983
4s% 100%
4,736 3,t 55 3-868
Table 11.3 sumrnarises the cost of hysterectomies for nonmalignant conditions by cost
category. Annual hospital costs of $17 million accounted for 73o/o of total cost while
production and leisure time foregone was estinrated to be $6 million or27o/oof total costs.
Hospital cost per hysterectonty \^'as 54,390 while u,ork and leisure time costs were $ I ,400.
Table I 1.3: Summary of l99l NZCost of Hysterectomies for Nonmalignant Disorders
Cost Number/$ $Million "/o
Hospital cost
Production/lei sure cost
Total cost
Nunrircr of hl,stercctornies (N)
Hospital cost per hvsterectonrv
Production/leisure cost per
l'otal cost per hysterector'rly
t7
6
23
73
27
100
4,390
3,868
I,400
5.268
I I.4 DISCLISSION
This study selccted patients lrctrveen puberty and rrtertopause experiencing menstrual
prolrlenrs of a nonnralignant nature. It drd not include women of 55 years and older as it
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\\'as assunred that nrost $'onren rvotrld lrc post-nrenopausal at that age. Although most
\\'onrcrl bcgin n'rcnslruating lre forc I 5 ycars of agc- it nray be several ycars, and as a last
resort. before a [)aticnt 
"",itlr 
nrenstrual problr-nrs undcrgoes a hysterectonry.
Average total rveekly eaniings for nrales and females conrbined, as at June l99l (Statistics
New Zealand, 1993 ), were used as a proxy for the value of production and leisure-time loss.
Eanring rates relating specifically to women were rejected because it was considered that
health decisions should be gender neutral. If a lower rate is used for valuing women's
output and leisure, it can result in less importance being placed on women's health when
comparing the costs of different diseases and the benefits to society of treating them (See
Chapter 4: Costs). This has important consequences for evaluation of policy options that
are gender and age specific. If the objective of ttre economic and policy analysis is to
provide infornration for decisions where the outcome is intended to be gender and age
neutral tlren an econonty-wide average wage rate should be applied to all time related costs.
Deductions rvere not made for unemployment in the paid workforce as it was considered
that unpaid work and leisure-time were as relevant as paid work for this age group. This
also takes accout'lt of the situation where, if a nrother of a family is incapacitated, her
partner may lose some time in paid employment or may have to employ home help to run
the household (discussed in Chapter: 4 Costs in the section covering the frictional method
oI estinrating productivity loss).
The total Nr'rv ZealantJ rate for hysterectonry for all ages is lower than comparable rates in
USA and Canada. sinrilar to rates in Australia and the Netherlands, but higher than rates
in England and \\'alcs, and Ireland. lt is unlike ly that any physiological difference between
\\'onlelt in diffcrerrt countries could account for the variation in rates. The differences are
nrore likell,to rt'sult front differerit health systenls, rnedical trends, income levels, and
social pilltcnts [r,-.lrr.ccrr countrics. Possible cxplanations for the discrepancies include,
dill'crctrccs irr thu- prcparedness to put up *'ith a rerluced quality of life, an increase in
\\ot'l'lcll's krro*lcdgc'of thenrselves and diseases, treatntent options, a higher rate of
tuterinc/pc-lvic discirsc. a sterilisiltion procedure that catt be legitimised as medically
neccssur), and thc availability and access to surgeons and hospital facilities.
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Thc recent declirre irr tlre rrunrtrer of hystcrectonry procedures in some developed countries
nrly bc explaincd lry controversy ovcr unnccessary' opcrations, patient pressure to avoid
hysterectonry, a\r'arelless of nen' treatnlents (for example endometrial ablation,
phrnlacothcrapy), arrd the costly nature of a long cottvalescence.
Lower numbers of hysterectomies undertaken in wonren of the younger age groups will
partially reflect a desire by both the patient and the clinician to avoid or delay surgery until
the patient no longer wishes to have children. Up to this time it is considered that watchful
waiting and the treatment with medicines and/ or ablative surgery will be preferred to a
hysterectomy (Sessiorr conducted at RACOC Annual Scientific Meeting, 1994).
The 4,390 hysterectornies for nonnralignant conditions in New Zealandrepresented 690lo
of the total hystercctonries conducted (62% of the public andTTYo of the private hospital
hysterectomies). In private hospitals sonre hysterectonries for malignant conditions maynot
have been recorded under a specific diagnoses but in the more general ICD 621 disorders
of utenrs, not elses'here classified, and therelorc nray not have been filtered from the data.
The age ofpatients was similar in both public and private hospitals. Public hospital patients
were on average 41.5 years and private hospital patients were 42.3 years. Public hospital
unit cost was higher ($4,736 public unit cost, $3,155 private unit cost), there were fewer
patients, and these patients stayed on average a day longer compared with private hospitals.
Actual fees for the surgeon and anaestlretist are often higher than those derived from the
Southerrr Cross Schcdute ( l99l ) lvhich u,ould irtcrease the estimates ofprivate hospital unit
costs. The higlrer cost arrr.l longer stay,s in public hospitals contpared with private hospitals
may not indic:rte that public hospitals are less efficic-nt. Public hospitals' casc mix may be
biascd torr'arrJs paticnts likely to re cpire a greatcr degrce of care and whose stay is therefore
likely'to bc lorrgcr.
For thc age coltort studied and the conditions analysed, private hospitals recorded a greater
numberofhysterectomiesthanpubliclrospitals. Apossibleexplanationforthismaybethat
ntalty wonten in rhis u,orking age group ( t 5-54 years) may have health insurance and prefer
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to plarr surgcry to suit business and lanrily conrrnitrttents. Surgery in a public hospital is
usually sclreduled by a rvaiting listibooking systenl over rvhich the patient has little control.
If New Zealand women are opting for private surgery for the above reasons then such
surgery is likely to be price and inconre sensitive. For example, if women in the working
age group have less disposable inconre or lower rates of insurance cover there may be a
drop in the number of hysterectomies in private hospitals, and a corresporrding increase in
the number of hysterectomies in public hospitals. The decision made to have a
hysterectomy in a private hospital at a time convenient to the patient maybe the best option
for these patients if the cost oItreatnrent is traded off against lost production and reduced
quality of life.
Some important costs, such as, rnedical costs after discharge, voluntary and community
care, care provicled by family and friends, and intangible costs relating to qualityof life
could not be evaluated because oIa lack of robust data. Costs of treatment and production
and leisure time lost before surgery for hysterectomy were not quantified as the intention
of the study rvas to nleasure only those costs incurred following the decision to operate.
I I.5 CONCLUSIONS
Further reduction in the rate of hysterectomy in New Zealand may save hospital costs but
these savings should be offset against the costs of any other treatment options chosen' For
exanrple, rvatch fu I rvaiting cou ld incur continu ing costs relating to general practitioner and/
or specialist consultations, analgesics. protective tarnpons and pads, loss of output and
reduced quality'ol'life. Although it s,as found that unit costs of public hospitals were higher
than tlrosc of private hospitals the case rnix for the tu'o tlpes of hospital may differ and
public lrospitirl cost rcdttctiotts ttrav rtot be possiblc.
At t[t rinrr. of this studl,rhc urrit costs oIpublic hospitals \\/ere higherthan those of private
hospitals. Accordingly, if the public hospital unit costs fell to that of the private hospitals
a reducriorr of l8 % in total hospital costs could occur. Subsequent changes to the New
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Zcaland health sy'stenr ul'ldr.r ulriclr hospitals nrr.rst compete for funding nray make cost
reductions of this order possiblc. Bur if tlrc casc rnix is different, rvith public hospitals
trcating ltlore coltll)licated cases, this rlay not bc possible. Further research on tlre case mix
of public and prir.ate hospital patients would be needed to obtain the data with which to
evaluate relative effi ciency.
Data for decision making would be enhanced if research were undertaken to detect the
reasons why New Zealand women elect to have hysterectomies, and why most choose a
private hospital. Information should also be collected before and after hysterectomy to
evaluate changes in productivity, out ofpocket expenses (such as analgesics and protective
clothing), and quality of life for these patients.
I I.6 POLICY POINTS
Although most policy issues have alreadybeen discussed in the bodyof this chapter, the
key issues are highlighted below.
Hysterectonry is an intervention for a gender and age specific condition. Valuing
productivity losses using the lower female wage rates would provide misleading
infomration to policy makers (Ministry of Health) if the objective is to implement gender
and age neutral policies.
Public hospital costs were higher than private hospital costs implying that if ltospital stays
could be shortL'ltcd in public hospitals considcrablc savings could be nrade. This may not
be possible if case rlix is different.
\\tonren rvith grcatu.r disposable inconrc and/ or u'ith liealth insurance may opt for private
surgcry to circunrvent public lrospital rvaiting lists. Furrher research would be needed to
establish tlris.
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Quality of life is arr irnportant elcnrerrt in this condition but was not taken into account
because sufficiently robust data did rrot exist and could not be obtained within the research
budget. Econorrric evaluation of altenrative treatnrent options (from a societal perspective)
rvould be inrproved if all relevant costs (direct, indirect and intangible) were known.
A similar conrparison betrveen public and private hospitals would be more difficult now
because private hospitals can tender for publicly funded surgery and there is a more intense
focus on costs within the public hospital sector.
This was another study in which data other than hospital admissions and surgery were
unavailable. Ifeffective public policy evaluations are to be undertaken, communitycare and
morbidity data need to be collected and made available for policy analysis. Evaluation of
indirect costs is particularly difficult as there are no national surveys of lost production and
leisure tinre as a result of specific illnesses.
Health funders for the first time had infomtation on l,olume and cost of hysterectomies for
nonmalignant conditiorrs arrd could consider separate funding options and policies for
nralignant arrd nonnralignant corrditions. This paper was one of those used and cited by
the National Health Committee (1998) in their Guidelines for the management of heavy
menstrual bleeding.
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CHAPTER 12: LOWER RESPIRATORY TRACT
INFECTION
I2.I SUMMARY AND INTRODUCTION
Summary
This chapter presents a cost-effectiveness analysis that was conducted alongside a clinical
trial in a general practice setting. This study was (to the author's knowledge) the frrst
published economic analysis conducted along side a clinical trial that attempted to mirror
actual general practice treatnrent in New Zcaland. It was particularly signihcant because
the clinical results were published only in tlre cconornic paper. The results provided hard
data on cost-effectiveness to enable infornred decisions to be made with respect to the
fund i ng o f di fferent arrtibiot ics for general pract i ti oner prescribing.
Introduction
The study that is summarised and discussed considers the policy implications of an
economic anatysis undertaken to compare the effectiveness and the direct medicalcosts of
two antibiotics used in the treatment of lorvcr respiratory tract infection (LRTI). Additional
detail can bc found in Scott et al., (lc)93).
LRTIs accoullt for betn'ecn 1.59,i, and 2.6'% of general practice consultations in New
Zealand, ancl lrrtibiotics arc prcscribc"d in tlrc nrajority of cases, Roxithromycin was
conrparecl rrith cchclor, Roxitlrrorlycin t'as l nc\\'orirl nracrolide antibiotic with an
inrprovecl phtnnacokinc"tic profile over carlier gcrteratiott macrolides, a broad spectrum of
antibioric activitl'and a long half life (Acar, l99l). Cefaclor, is one of the antibiotics most
cornrrrorrly uscd for lrcating LRTIs and as such represents a standard against which other
trcatnrerrts should bc- evaluated,
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I2.2 METHOD
A nrulticcntre, rerndonrised, double-blind corrtrolled clinical trial, comparing the efficacy,
tolerance and cost-effectiveness of roxithromycin l5Omg twice dailywith celaclor 25Omg
3 tintes per day for the treatnrent of LRTI, was undertaken in 8 centres throughout New
Zealand. 240 patients with a diagnosis of LRTI were enrolled. Ethical approval was
obtained to conduct the trial. The sample size was chosen to reliably detect a difference of
l5% between the two medicines, with 807o power, 57o risk and assumingg}Yo efficacy for
roxithromycin. Dataforeconomicevaluationwasobtainedfor238patients(roxithromycin
120 patients, cefaclor I l8 patients) with 2 patients being lost to follow-up.
Diagnosis was based on community practice standards and treatment was for a minimum
of 7 days, rvith provision for a further 7 days tlrerapy if clinically indicated. Clinical
assessment rvas nrade at baseline and at withdra',val or completion of treatment. Patients
were eligible for selection if they were clinically diagnosed as suffering from lower
respiratory tract infection.
The economic evaluation considered only the direct medical costs, and all prices relate to
the last quarter of l99l . General practitioners were given forms on which to record details
of resource utilisations. The data collected are detailed in the results section.
I2.J RESULTS
The t*'o randontly selected treatntcnt groLlps wcre conlparable at commencement of the
trial rvith respect to age (niean 5 I 1'ears), gender and underlying disease. Results of clinical
effcctiteness (arc sho*n in Table l2.l).
Thcrc \\'as iI statisticllly signihcant differe-nce- irr side-effects, withdrawal rates and extra
courscs of trcatrnent in lavour of rorithronrycin conrpared rvith cefaclor. In otherwords,
thc Rorithronrycin group of patients experienced ferver withdrawals (usually for
untolerated side-efl'ects effects) and required fewer extended courses of treatment (for
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unrcsponsii'e treatntent). Treltnrcnt lailurcs, rr'ithdrarvals or side-effects incurred additional
costs for ll/120 (9?6) patients on rosithronrycirr arrd l9ll l8 (16%) paticnts on cefaclor.
Additional antibiotics and general practitioner visits (for treatment failures, rvithdrawals,
side-el'fects) were required more often and cost nrore for cefaclor treated patients than for
Lhose receiving rox ithromycin.
Table l2.l: Results of Clinical Effectiveness
Roxithromycin Cefaclor Significance
Effectiveness
Number of patients requiring extended
coursc of treatnrent
Average trcatnrcrlt duration
Number patients n'ithdrawn from study
Side-eft'ects considered to be related to
tTeatment
Number of patients gcnerating additional
costs (based on treatnrent failure.
treatment withdrawal or adverse effects)
I l5/120
(9s.8%)
33
8 9 days
6
IJ
r r/120
(e%)
110/il8
(93.2%)
50
9.7 days
l5
?4
l9ll I 8
(l60/,)
No sig dif
p < 0.05
p < 0.05
p < 0,05
The econonric analysis of this study assessed prinrary medicine cost, the cost of additional
medicirre to treat side-effects and therapeutic failures, additional general practitioner
consultations and additional diagnostic tests required, cver and above that reqtrired as part
of the strrdy protocol.
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Table | 2.2: Summary of Direct l\ledical Costs of Roxithromycin Over Cefaclor
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Dircct increnre ntal mcdical costs/ (bcnefits) of
rorithronrvcin over ccfaclor
Per patient in the
trial
$
Pcr 70,000
patients
$ 1,000
Add i tronal pri mary nre'd r c i nc' acqu ist I ton cost
Less: Other nredicines acquisition cost avoided
Less: Dispensing & container costs avoided
Less: General practitioner consultation costs
avoided
Less: Diagnostic test costs avoided
= Net Cosr (Benefit) (9.37) (656)
Table 12.2 sumnrarises the difference in cost betu'een the two antibiotics. Although the
nredicine acquisition cost rvas greater flor roxithrornycin tharr for celaclor additional drugs,
general practitioner corrsultations and diagnostic tests for the treatment of LRTI and the
side-effects of treatnrent $'ere less for rorithromycirr. Total direct medical cost per patient
treated with roxithromycin rvas 59.37 lorver than for the cefaclor treated group despite a
higher primary rrredicine cost. An estimate ol 50.656 million per year in total savings in
direct medical costs could be made in New Zealand if roxithromycin was to replace all
cefaclor prescriptions in the treatment of LRTI.
12.4 DISCUSSION
In contrast rvitlr rnarry trials, tlrc stucly on which this economic analysis was based was
spccilically designcrl to cnrulate gencral practicc diagnostic and assessnrent nrethodsrs.
Hos'cver. thc r ariatiorr in treatnrent lerrgth betrveen thc protocol of this trial and day-to-day
clinical espcriencc should lre noted.
A literature search using MEDLINE at the tirne of the studydid not reveal anyother
such trials. Other studies rvere either rrot designed to emulate actual practice or
rverc irr a difl'erent scttins.
0.61
( r .e8)
(0.44)
(s.42)
(2.14)
43
(l3e)
(3l )
(37e)
(150)
l( Guy Scott (2000)
Ecouomic Evaluation In New Zealand
Direct medical cost savings to the country n'ere based on the actual trial usage of the
prinrary alttibiotics by gerreral pracritioners but thc ttuntbers of additional nredications and
consultations antl tlirgnostic tests nray have bcctt higher in the trial than in day to day
nredical practice. Tlris is a coinnlon difficulty in applying economic analysis to clinical trial
data. Bias is mininrised by the use of incremental analysis as most of the additional costs
are comnlon to both the studied and control groups attd cancel out when comparisons are
nrade. The economic analysis took into considcration only those additional diagnostic tests.
general practitioner visits, and pharnraceutical costs rvhich resulted front inadequate
treatment of the initial infection.
It would have been desirable to have included indirect and intangible costs and benefits in
this study but information on such costs and benefits (non-medical and intangible costs and
benefits, such as travel costs, increased production, and the effect of treatment on quality
of life) were pot available. The savings calcutated therefore represent an underestimate to
society as there were fewer side-effects and treatment failures at seven days with
roxithronrycin than rvith cefaclor.
In the trial, a ntininrum treatntent duration of 7 days rvas set to ensure that cases of acute
on chronic bronchitis and pneumonia would receive an appropriate treatment length
(Mandell, Douglas and Bennett. 1990; Conte and Barriere, 1988). In actual practice
prescribing length would have been shorter.
A nrininrunr of 2 general practitioner visits were required for evaluation of each case
rvlereas ip routilc clinical practicc a patient rvould nrost likely only retum if treatment
lailed or if thcrc lerc- signilicant side-effects. 'l'he 2 haematological and biochemistry
ipyestigatiorrs cnrricd out as an assessnrent of cotrtparative safety would not normally
contribute to thc routine nralrirsen'lcnt of LRTI irr general practice. Chest X-rays and
rlicrobiological rcsrs * erc unclcflakcn s,henever possible and the fact of the study bearing
thc cost of-thr-sc irrr',.'stigations rloultl hrtve cncouraged greater use than normal' All of
tSese- cr-rsts, hol cvcr. n'c.re incun'c-t1 equally for paticnts on roxithromycin and cefaclor and
therefore cancel out in an economic contparisotr of treatments.
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By calculating prinrarl nredicine costs blscd on tltc national average treatment duration for
etch antibiotic lbr thc inclicatiorr of LRTI, a faircr assessnlellt of the ovcrall contparative
costs, nalionally, of the 2 trcatnrents w'ould bc achic-r'ed. This rvas not undertaken bccause
data op prescribing practice tt'as utlat'ailable to thc rcsearchers'
It could be argued that cases of acute bronchitis (which represent a significant proportion
of the study patients) are viral in aetiology and do not require antibiotic therapy (Billas'
1990). Three percent of the cases included in the intent to treat analysis of clinical efficacy
in the study were deemed viral in origin by serology. On the other hand, others (Dunlay et
al., 1987) have demonstrated a benefit from antibiotic therapy for acute bronchitis, and in
this study practitioners selected patients whom they believed clinically to have a bacterial
LRTI which would benefit from antibiotic therapy. Results are thus representative of actual
general practice usage pattems as contpared to restrictive analyses based on infection
proven by sputunr culture, a tool rvidely regarded to lack sensitivity and specificity in this
setting (Lentino and Lucks 1987).
The reconrmended dose of cefaclor for general practice LRTI varies internationally ranging
fronr 250ntg twice daily to 500mg 3 times per day for mild to moderate infections.
Holvever, as with most antibiotics there has been a trend to reduce the dosage to the lowest
effective level associated with the most favourable side-effect profile. The dose of 250mg
3 tinres per clay is that recommended for mild to moderate infections in the official New
Zealand prescribing information for cefaclor. It is possible that a small number of patients
lray huve bcen nrore effectively treated with a higher dose of cefaclor, however, efficacy
u as alreacl1,93ol, and onc-lralf of the trcalnrent lailures observed with cefaclor were due to
early 11itlrclrarval lcccssitated by'intolerable si,le-c-ffccts, ratlter than insuflrcient efficacy'
A1y sprall increrse in efficacy would therefore be oflset by substantially increased direct
ntedicirte cost. alld in all probabilitir increased othcr ntedicine costs' consultations and
diagnostic tcsts rcquircd to trcat and assess an ittcrease in side-effects and resultant
treiltl'l'tcnt rv i t ltclran ltl s,
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I2.5 CONCLUSIONS
The observed statistically significant clifference in sidc--effects, withdrawal rates and extra
trealmcnt courscs irr lhvour of roxitlrronrycin in this study is translated into actual cost
savings. Theorctically, if roxithronrycin rvere to be used in place of cefaclor for the
estinlated 70,000 prescriptions for cefaclor filled each year in New Zealand for LRTI,
savings in excess of $0.656 nrillion could result, in spite of roxithromycin having a greater
unit cost. This analysis demonstrates that econonric data can and should be obtained from
clinical trials and used to evaluate costs and benefits. If the an economic component is not
included in a clinical trial then decisions that effect the efficiency of resource use will
continue to be made without robust cost data.
I2.6 POLICY POINTS
Most clinical trials take place in an artificial setting and the results are therefore diffrcult
to apply to everyday usage. This trial rvas desigrred to emulate the general practice
environment and actual treatment as far as possible. Policy analysts and managers must
make decisions in the real world and for this they need real world data.
A common but often flawed criticism of applying economic evaluation based on clinical
trial data is that this is an artificial situation and costs evaluated using trial resource
utilisations rvill be biased uprvards. Although the trial setting and protocols were as close
to reality as possible, there was ntore intense nronitoring and diagnostic evaluation of
pittients than in actual practice. The study protocol applied the same ntles and conditions
to Lroth rlrc clrug undcr irrl'estigatiorr arrtl tlre cornparatot'. lttcremental analysis was used to
rliltiltise the bias irrtrociuced by the trial. Thus, u'lierr differences between tcst drug and
coptparatol' \\'erL' c:rlculated all tlre cost increases resulting from the trial protocol will
clnccl out. ln ltlditiotr. general practitionr'rs \\'ere spccifrcally asked to record and note any
prcscribing. consultatiorrs antl diagnostic tests ovcr and above that set down in the trial
protocol.
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Econonrists arc usually forced into using published clinical trial results to conduct an
expost evaluatiorr. In this instance, thc ccorrorrric data rvas collected alongside the clinical
data. Evcn So Sontc' dcsirable data could not lre oblairred. Data collected relating to direct
non rrredical or indirect costs u'cre considered to be too unreliable for analysis as general
practitioners were unable to question patients in sufficient detail on non rledical aspects
of tlreir illness. Attenrpts to obtain such infonnation using nurse research assistants may
be more successful as the nurses would be able to devote more time and may be more
interested in collecting the non clinical data required for economic analysis. It was not
possible to calculate levels of statistical confidence for the economic differences observed
because the sanrple size was set to achieve sufficient statistical power to detect clinical
differences rather than economic differences. See Chapter 4: Cosls where risk, uncertainty
and sensitivity analysis is discussed
As the clinical results for these trials had not pro'iously been published in a specialised
peer revierved clinicaljournal it u'as necessary to describe thenr in more detail than is usual
in an econontic paper. The study u,as interesting in that although there was no significant
difference betrveen the effectiveness of lhc trvo drugs and while cefaclor had a lower
acquisition cost, r.r'hen the average length of treatment and the side-effects were taken into
account roxithromycin was more cost-effective.
There is no set formula that can be mechanically applied to all economic evaluations and
it is usually not possible to classify a study until it has been completed. Although the
origirral intention rvas to conduct a standard cost-effectiveness analysis, no significant
diflcrenccs w'erc dr-tectcd irr the clirrical outconres measured. The results were thus
prcsented ns increrrrental cost diflcrcnccs rathcr tltatt cost-eflective ratios because this was
corrsidcred to bc of morc usc for policy evaluation and budgct cost management decisions.
As thc.re \\'r-rc- dil'lcrc-rrccs in tlrc. sidc eff'cct profilc bL-t$'cen tlre drugs tested it would have
bcen possiblc to coltduct n cost-utilitl' stutl5, (trld thc btrdget allowed for the collection of
this additiorral intbnlation). Tlrc irrlbnnatior.l collccted and the type of analysis was
fiorvevcr quitc sufficient for the intended use. A cost-utility analysis would not have added
to the uselulness lront a decision nraker pcrspective,
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The study: firrdings allow policy analysts to better conrpare the net costs differenoec
between tu'o treaJnrent options and to evaluale the budgetary irnpact of the polieies" Wheu
a goverruuent agency sueh as PHARMAC is ne,goliating prices and seleetingdrugs to fund
the flull treatrn€nt cost o,f each drug should be taken i,ntb ascount and notjust the drug pr:iee
in isolati.on. lt is possible that a l w priced drug, in cornparison with a higfuer priced drug
csuld generate higher health spend,ing because it may have more side effects and treatrnert
failu es necessitating additional patient consultations, drugs and diagnostic tests.
Sirnilar nnethodologies as used in this study cquld be applied to the evraluatio-n of a w,ide
range of policies involving new or existing technology. Undertaking an eoonomic
evaluation alongside a clinical trial is expensive and probably necessary only for high
expenditure med i'cines,
F,/ Guy Saott (2000)
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CHAPTER 13: INFLUENZA
I3.I SUMMARY AND INTRODUCTION
Summarl'
This case combined overseas clinical findings with New Zealand cost information to
evaluate the cost-effectiveness of vaccinating the 65 years and older age Sroup in New
Zealand. The published results of this study provided essential cost-effectiveness evidence
and was used by the Ministryof Health to evaluate and design their subsidised vaccination
programme (Ministry of Health letter l8 June 1996).
Introduction
The objective of this cost-benefit analysis was to evaluate the costs and benefiG of
influenza vaccination for the population aged 65 years and over, from the perspectives of
individuals, health iusurers, government, and socicty. This chapter uses a study (Scott and
Scotr, 1996) that had some influence on public health policy changes. At the time of the
study, influenza vaccinations tvere not subsidised by government. Since publication
government policy has been changed and influenza vaccinations are now paid for by
governn'lent for those 65 years and over.
Influenza is regardetl *'orld rvide as an important and highly infectious viral illness and is
nlosr sevcrc for thc vcry young antl tlre elderly. The likelihood of being hospitalised or
tlying fronr influenz-a increascs rvith agc ancl tlre number of underlf ng medicalconditions
prescnt in the patient (Wiselka. 1991). Tlie benefits of influenza vaccination are dependent
upolt agc, health status, the rate of vaccirr:ltion, attcl the efficacy of the vaccine. Although
influenza vaccirration is consideretl to lre slfc. cl-fcctivc vaccination rates are low inNew
Zcallncl anrj vaccilation is rcgardcrl as being under-utilised (Tobias M, l99l; Jennings,
r 991).
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Tlrcre are four grolps Largcted for influcrtza vaccination in New Zealand. The first group
are those at high risk of corrrplicatiorrs, for exantplc, adults and children with chronic
debilitating diseases, persons aged over 65 years, residents of rest homes, geriatric hospitals
and other chronic care lacilities, and immune compromised individuals' Group two are
those irrdividuals who nray spread infection to those at high risk, and group three are those
engaged in essential community services, The fourttr group covers childrerr with specific
health conditions (N.2. Department of Health, 1993).
I3.2 METHOD
The incremental direct medical costs and benefits of influenza vaccination were evaluated
using New Zealand health care resource usage and unit cost data for 1992 applied to
clinical trial results reported in the literature (Niclrol et al., 1994).
Direct medical costs are those involved in providirrg treatment and include the purchase of
vaccines, medical practitioner consultations and hospital costs, Direct nonmedical costs
incurred by the illness alrd treatnrent could include transport to receive treatment and the
cost of special food as a result of thc illness. lndirect costs encompass work output lost as
a result of morbidity and nrortalitywhile intangible costs are concerned with loss ofquality
of life, pain and suffering rather than changes in resource opportunity costs (Eisenberg,
Schulnran, Click and Koffer, 1994).
The net benefit/ net cost of vaccination rvas compared against no vaccination. At risk
adults unclu'r 65 years of agc and children rvith chronic debilitating diseases are evaluated
as an adjurlct to the sensitivitv analysis. Togetltcr tlrese trvo at risk groups account for
about 20or',, of the total r.Nerv Zcaland population (Tobias. l99l). If vaccination were to be
extenrled to thc lrousclrolcl colltacts and carc gircrs of these people the nunlbers would
double (Tobiits. l99l). but insufficicnt tlata cxist to allorv quantification of the costs and
bc'nellts for tltcse pcople.
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lrrentational Classificatiol of Diseases (lCD) diagnosis codes relating to influenza and
pneun.ronia, other rcspiratory conditiorrs, artcl ltcarl failure as described by Nichol et al.
( 1991) rvere uscd as the basis for calculating hcalth carc resource volumes in New Zealand,
As all costs related to one year (prevalence study) discounting to present values was not
necessary. All unit prices and costs used in the study were in 1992 dollars and net of goods
and sen'ices tax (GST).
Table l3.l summarises the steps followed to estimate the incremental net costs of
vaccinating the 65 year and over age group.
Table 13.1: Steps in Estimating the Incremental Costs and Benefits of Influenza
\/accination
I Estinlate the cost of I'accination (C)
2 Estimate utilisation of health care resources if no vaccination given (Up)
3 Calculate the change in volume of resources (increased vaccinations and reductions
ip other health care resources utilisations) iIvaccination given (Uc)
4 Apply unit costs (P) to the change the volunre of resources used (Uc) to estimate the
costs avoided (benefits) of vaccination (B)' (B = Uc x P)
5 Calculate the increntental net costs or beneltts (NC)' (NC : C - B)
6 Corrduct sertsitivity analysis
T[e curclt yaccipation rate of 20?b (Tobias, l99l) for the 65 years and over, (together
tvith tfic base case values lor hcalth rcsource utilisation rcductions) were used in the base
case. Sensitiviry analysis *,as usc'tl to evaluatc tlte intpact of changes to thekeyvariables.
T5c pcr yaccipation cost rclating to thc older group (cxcluding the costs of heart failure and
adjusting t[c- lrospital costs to take accour.rt ot'difl'crcnt Diagnostic Related Group (DRG)
6ospital costs fcrr t|osc under (r5 ycrrs) s'as ap1:lictl to the younger group as no specific data
on hcalth rcsourcc utilisation cltanges rr,ere availltrlc.
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13.2.t Vaccine Cost
The potential nuruber of vaccinations u'as based orr tltc nunrber of people rvho fell within
the age group 65 years and older (Statistics New Zealand INFOS) who accounted for ll5%
of the total population in 1992, Those under 65 1'ears at risk (for the sensitivity analysis)
accounted for 9.3o/o of the total population (Tobias, l99l). Influenza vaccine acquisition
cost to general practitioners was $ I 2.96 (infomration supplied by Rhdne-Poulenc Rorer NZ
Ltd, and CSL NZ Ltd). General practitioners charged a total fee of $17.78 (fee plus
vaccine) for an influenza vaccination (nrean charge from an informal telephone survey of
Wellington general practitioners). This fee was unchanged lrom that reported in l99l
(Tobias, l99l).
13.2,2 Utilisation of Health Care Resources If No Vaccination Given
Tobias ( l99l ) considered that based on influenza vaccine sales in New Zealand, about 20olo
of the elderly population and l0% of the younger at risk groups were currently being
vaccinated. A nunrber of researchers (Karalus et al., l99l; Nichol et al., 1994; Fedson et
a1.,1993) have found that vaccinated individuals utilise fewer health care resources than
unvaccinated individuals. Accordingly, to establish the counterfactual, it was necessary
to rate upwards the actual recorded utilisation data to take accountof the estimated 20%
rate of influenza vaccination and for the consequent reduction in utilisation of health
resources per vaccination for this group. This procedure was necessary to establish the
counterlactual casc so that contnarisorrs could lre ttrade.
l'1t =
I | 7r crt,:
L:p = It()tL'nttttl ttliltstrliort vtlunr' (trr/ttltr'
I-(li'rL'c')
hutl tht'rt b(t'tr trr) t'ttt'cinulions)
L'u = ottrtul rtttltsutiort tvlttmt'
l'r -- vtt't'ittttlitttt ntl( tts u tlL'<'itttttl('( = fropo,'tionul radttction ns n rlLtt'irnol fttr rttilisttlion volume us a resull d vuccinalion
Data (broken clorvn by ICD code) on the nunrbers of general practitioner consultations and
prescription itenrs dispensect were avr-raged overtheyears 1991, 1992 and 1993. These
data rvere obtained from lntenrational Medical Statistics (NZ) Ltd. The number of
L'tt
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prescriptions for those aged 65 years and over *'as cstintated lront the ratio ofprescription
itcnrs rvritten per general practitioner consultation for all ages nrultiplied by the nunrber of
consultations for those aged 65 years and over. Hospital admissions by ICD code were
deriverJ lronr public hospital separatiorr data averaged over the three years 1990, l99l and
1992 (the latest three years available at the tinre of study, N.Z.Ministryof Health, 1993)'
13.2.3 Medical Costs Avoided
The potential reduction in the volunre of health care resource use was the mean of the
percentage reductions in hospitalisations over three influenza seasons for patients aged 65
years and overwho were vaccinated compared with unvaccinated individuals (Nichol et al.,
1994). These percentage reductions were obtairred for pneumonia and influenza, other
acute and chronic respiratory conditions (all chronic and acute respiratory conditions less
pneuntonia and influenza), and congestive heart failure. The comparisons between
vaccinated and unvaccinated groups were adjusted for differences in patients' baseline
characteristics rvhich could alter outcome variables (Nichol et al., 1994). In the absence
of resource specific data from randonrised clinical trials orcase controlled studies these
percentage reductions rvere employed to calculate the potential reductions in all health care
resource utilizations in our studv.
Base case savings in the volume of health care resources used were: influenza and
pneunronia 527u, other respiratory conditions 2870, and heart failure24Yo. The incremental
cost of influenza vaccination in volunre terms r,vas the percentage reduction in utilisation
of Nerv Zealand health care resources multipliect by the volunre of resources used assuming
no vaccination. The increnrental resourcc utilisations volume, nrultiplied by Nerv Zealand
unit costs gave the irrcrenrentatl cost in dollars.
13.2..1 Henlth Care Rcsource Unit Costs
Ccneral pfactitioner consultatiorr costs used in the study'were based on the mean fee
acrually chargcd oi S23.20 (W Guy Scott and Associates Ltd, 1992), inclusive of the
general practitioner subsirJy [(general nredical services benefit (GMS)] but exclusive of
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GST. The GMS used s'as thc'rate applicablc'to bcncficiaries, $13.33 as at February1992
(McKendry arrd Muthurrrala, 199-l). Thc avcrage governnrent subsidised cost of a medical
prcscription used for tlrc calculations \\'as S3l.l6 applicable to the elderly at June 1992
(Health Benefits Ltd., Health Benefits Centre,l993). The patient co-payment was $4.44,
applicable to beneficiaries, and clrrorrically ill and high user groups at February 1992
(Health Benefits Ltd., Health Benefits Ccntre,l993).
Hospital costs were based on DRG costs (National Advisory Committee on Core Health
and Disability Support Services, l99Z). The DRG codes most closely relating to the
specilic age group concemed and to the diagnoses codes were used. A weighted average
(by volume) rvas derived forpneumonia and influenza ($5,501) and forother acute and
chronic respiratory conditions ($4,700). Weighted average hospital unit costs for the at risk
age group under 65 years of age rvere sinrilarly cstinrated ($1,787). For Heart failure the
DRG unit cosl r,,'as 54.963.
I3.3 RESULTS
Costs and benehts to society as a result of vaccinations (at the current ral,e of 20o/o) for the
65 years and older age group were estimated to be; the additional direct medical costs of
vaccination $ l .42 million, ($17.7S per vaccination) direct medical costs avoided of $5.35
nritlion (567.18 pcr vaccinatiorr) and net benchts ol'53.93 million ($49.40 per vaccination).
Direct nredical costs avoided per clollar cost of vaccination were; $1.04 for individuals,
5.1.69 t'or the govenl'trent buclget perspective and 53.78 ficr society as a whole. If the
vaccination uptake for this group is irrcrcased in 20')t increnrents, the net benefit to society
increaserJ by a furthcr 53.93 rrrillion at eaclr step. If tltc economic evaluatiorr is extended
to include vaccinltion of those at risk indivicluals urrdcr 65 years of age net benefits to
socictv incrcrse bi' l5orb.
Corrsidr-'rirrg the adtlitiorral costs fi'orrr a socictal pcrspcctive. Additional direct medical
costsofr.accinirtiorrarnounted toSl.42rnillion(SlT.TSpervaccination),directmedical
costs avoiclcd u'crc S5.35 rrrillion (567.18 pcr vaccination) rvith net benefits of $3.93
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nrillion (549.40 per vaccination). Becausc thc" nrajority of costs fall on the individual (out
of pockct) antj nrost of f he costs avoided accruc to govemntent, there is a srnall net benefit
to ipdividlals of S0.19 per vaccirration and a conlparatively much larger net benefit to
goventnte nt of S49.22 per r,accination. Direct nrcdical costs avoided per dollar vaccination
cost rverc; $1.04 for each dollar spent by individuals, $4.69 for eaclr dollar spent by
government and $3.78 for societY,
Turning now to benefits from a societal perspective. The medical costs avoided as a result
of reduced calls on health resources for various diagnoses were estimated to be $1.43
million($lS.00pervaccination)forpneumoniaandinfluenza, otherrespiratoryconditions,
$2.40 million ($30.13 per individual), and heart failure $1.52 million ($19.05 per
individual),
Sensitivity analysis was undcflaken for the societal net costs/benefits for the 65 years and
over age group. The analysis considered the percent vaccinaterl, and the maximum and
minimum reported changes in health care resource utilizations. Changing the vaccination
cost and subsidy rates could not be effectively evatuated as the price elasticity of demand
for vaccinations rvith respect to out of pocket payments was unknown' If the percentage
of tlrose vaccilated (in the age group 65 years and over) was increased in steps of 20Yothe
net benefit rose in increments of $3.93 million. The ratio of costs avoided per dollar cost
of vaccination indicates that the vaccination cost (r'accine plus administration) could rise
by a multiple of 3.78 before net benefits fall to zero.
T5c" 1t risk populirtion under 65 ycars of age *'as also considered as an additional adjunct
to tlc'sensitivit.v analysis. If this youuger at risk population is considered, tlte societal net
bcnellts incrc-asc by S0,58 trrillion or l5')ri, ovct'tlte base case. The ratio of costs avoided
pc'r clollar cost of vaccination for the younger at risk group rvas 607o lower than the older
age group ( l.5l conrpared n'ith 3.78).
Artal1,5i5 using the reporled mininrlrnr reductions in health
vaccination (pneuntonia and influenza l9% (Karalus et
resource usage as a result of
al., l99l), other resPiratory
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conditions 20o,6 (Nichol et al., 1994) reduceci thc net benefit to society by 8l% and the
direct nredical costs saved per dollar of vaccination cost by $2.24 to $1.54. Using the
nraxinrunr reported resource savings (Nichol et al., 1994) of 57o/o for pneumonia and
influerrza, 34o/oforotherrespiratoryconditions,and 38% forheart failure, increasedthenet
benefits to society by 42%and tlre direct rnedical costs saved per dollar of vaccination cost
by $ I .18 to $4.96. The results of the sensitivity analysis from the perspective of society(65
years and over) are presented in Table 13.2, while the sensitivity analysis for those under
65 years of age is presented in Table I 3.3.
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Table 13.2: Sensitivity Analysis From the Perspective of Society. Net Cost (Benefit)
7o of population
vaccinated
lation 65 Years and Over
Change in health care resource usage
Base case High Low
Base case = 20
40
60
80
100
Cosls uvoicled ner dollur cosl of vaccitttttion
-3.93
-7.87
-l 1.8
-t5.7 4
-r9.67
3.78
-5.6 -0.76
-t 1.2 -1.52
-16.8 -2.27
-22.4 -3.03
-28 -3.79
4.96 1.54
Table 13.3: Sensitivitv Analvsis At Risk Group Under 65 Years of Ase
Cost Perspectiv
Personal out Government SocietY
of pocket /
insurance
Total costs
Net cosl [( ) = net beneft)]
$ million $ million $ million
0.08 -0.66 -0.58
Costs at'oidel pcr rlollrtr cost of tutccinttrion 0.71 1.77 I '51
I3.4 DISCUSSION
Ipfluenza laccination for thc o|Jer age group is cost-e ffective from the perspective of
sociL-tyandgovenrnrerrtanrlforindivitluals. Ifthevaccinationrateforthe65yearsand
over population irr Nelv Zealand could be incrcased from 2Qoh to 60% the net benefits
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rcporlccl irr this paper s'orrld incrcase by 200')'i,, ltorvet'er, the costs oI prorrtotion and
cducation to aclrieve this w'ould neccl to be dcducled lront the net benefits. Stratcgies to
incrcasc the r,accination rate include altering thc cost of vaccinations to the individual,
irrtensilying education and protnotior.l programnres, and changing the mode of delivery.
EacS of these strategies has a resource cost whiclt rvould need to be offset against the
benefits.
Sensitivity analysis indicated that although there is considerable variation when upper and
lower ranges in resource savings are applied, the direct medical costs avoided remain
greater than the ad<iitional costs of vaccination. From a societal perspective changing the
co-payment or subsidy rates altered the division of costs that individuals or govemment
paid. Altering the GMS subsidy is also likely to alter the rates of vaccination as the price
to the patent rvould change but rhis could not be quantified. Sensitivity analysis also
indicated that as the uptake of vaccinations rose by increments of 20% there would be an
incremeptal net societal benefrt of $3.93 miltion. To achieve a higher vaccination rate
additional costs of education and promotion (targeting at risk groups and health care
professionals) rvould be incurred by either the suppliers of the vaccine, by govemment, or
by botlr. TSis adtlitional cost has not been taken into account in our analysis but the results
provide the information required to set an upper limit on an educational/ promotional
budget.
It u,as found that there was a difference in the breakdown of cost savings by disease
caregory betrvec'rr rhis study and th:rt reported by Nichol et al. ( 1994) because the underlying
hospitaladnrissionratcs forpneunroniaanrlinflucnz-ainthcUnitedStateswerehigherthan
tlose recordcd i1 Nerv Zealand and corrversely, the Nerv Zealand hospitalisation rate for
hcart failure was higher tfian the Unitcd Statcs' study. (Although it is beyond the scope of
tlris study to cyllulte lhc rcasons for ciil'fcrerrt hospitalisalion rates a possible explanation
is r5lrt t5c prcyalclce:urcl nrode ol'trcatnrcul of the discases considered could be different)
Altlrous,h thc absolutc volunrcs n'ere clifferent it rvas considered that it was valid to apply
thc US pL.rcentage recluctions in utilizations of hcalth care resotlrces to Nerv Zealand base
resource uti I isat ion volutttc-s.
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Tlris arralysis uscd lvcragc rathcr tharr rrrarginal uttit costs. Policy decisions relating to
influcnza vaccinatiorr n'ould involt'e incrcrrtcnts of hundreds or thousands rather than a
silglc individual. N,tultiplying thc nrarginal rtct cost of one additional vaccination by the
nurrrber of vaccinations rr'ould providc a lalse estinrate ofthe incremental net costs/benefits
of thc progran'une. The shon nrrr nrargirral net cost of one additional vaccination would
igpore overSead costs but the long nrn incrcntctttal net cost of large numbers of additional
vaccinations should ipclude those overhead costs that would change if the vaccination rate
altered.
As health authorities consider that influenza vaccinations should also be given to at risk
groups under 65 years of age the authors applied a similar methodology to estimate the
costs and benefits of such vaccinations. The costs of hearl failure rvere excluded from this
group. and in the absence of ntore specific information, the reduction in costs for
pneunronia and irrfluenza. and other respiratory conditions were those applicable to the 65
years and over group. Although the percentagc recluctions in resource utilisation for the
under 65 years of age group are unlikely to be i<lentical and the results obtained for this
group cannot be accepted rvith the sanre confidence as those pertaining to the older age
group it u,as considered that policy nrakers would lrnd this information useful. It was found
tSar the ratio of net costs avoided per dollar of vaccination cost was substantially less for
the younger at risk group than the ratio appticable to the older group. The nrain reason for
this difference was the lower incidence and unit costs for hospitalisations for the younger
age group (tlre average length of hospital stav \\ras less for this age group).
As nr.-r s;rccific d1t1r rverc available orr general practiriorrer ancl prescription utilizations the
autSors applic<l tlrc pcrcentage reducriorrs in hospital rcsource use to general practitioner
consultatiorrs and prcscriptions. lt could be argucd tltat in['luenza vaccination is more
efllcicrrt irr prcvctrring hospitalisations than in avoidirtg general practitioner consultations
anr.l prcscrilttiorrs. As lcss tharr onc-third of thc total nredical costs avoided were non-
6ospital costs. inaccurlcies in estinrates of rron-lrospital resottrce utilizations would not
intposc a scrious bias to our total cost savillg estinratc'
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Subsets of the targct groups studied could also be researched. For exanrple, in 1992 there
were 20,962 becls in rest honres arrd approrirnatcly 20,000 full and part-tinre employees
(Rest Hopres Association Inc. Lerter I I January 1995). If it is assumed that the net benefit
of vaccinating 20,000 patients is the sanle as that estimated in this study (rest home
residelts are a sub set of t[is), the nct benefit to society of vaccinating these full and part-
tinre enrployces rvould be $1.34 nrillion.
For an individual of working age, the cost of a vaccination would be offset by additional
production gains. Riddiough et al. ( 1983) found that 0.03 rvork days per vaccination could
be gained for an individual aged between 45 and 54 years. In a study of Canterbury Health
Laboratory staff it was found that absenteeism from influenza was39.5o/o in the vaccinated
group compared u'ith 66.7?i, in the unvaccinated group (Sclrousboe , 1993). It is sorttetimes
argued that short term absence fronr work is rtot a cost because there is slack in the
econonty (unemployment and rvorkers able to cover for absentees) or that work set aside
is actioned on tfte retunt of the rvorker (Kooprtranshap and Rutten, 1993)' Potential
production loss, both paid and unpaid, should be estimated on the understanding that actual
production loss may be somervhat less. However, irt many situations in New Zealand if a
worker beconrcs ill there is no surplus capacity and the output of the absentee worker will
be losr. A production loss may also occur when parents or guardians take time from work
to care for children who are ill with influenza.
The cost of adverse events relating to the vaccine were not evaluated in this study. Modern
influelza r,accipes are copsidered to lrave ferv adverse events, and nredical practitioners are
adyiserl agailst vaccitrating those patients rvith a knorvn or possible anaphylactoid
hyperserrsitir.ir,"-to lrens'cggs (N.2. Dcprurtnrerrt of lJcalth, 1993). Although intangiblecosts
*.ere ltot craluaterJ, quality of lile aspects arc oIintpoflance for potential sufferers, their
fiutri l1' and ft'icrrtls.
Jr*cl.Zclllpcl dart for 1992 recortlc'd ll32 ch--alhs fi'otti pneumonia and influenza, (N.Z'
Nlipistrl,ol-Helltfi, 1994) ancl for nrales and fentalc's ovcr 75 years of age it was the fourth
antt third leaclitrg cause of cleath respectively,. Hos'ever. it is considered that influenza is
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respopsible for prany deaths recorde<J urrder categoric's other than influenza and pneumonta
(Fedson et al., 1993;Nicholsotr, 1990; Sprengcr attd Van Naetten, 1989)' The Manitoba
study by FerJsort (1991) (covering itrfluenza outbreak periods 1982 to 1983 and 1985 to
1986), lound thal vaccination rvas 43o/olo 65% elltctive in preventing hospital deaths of
patients atlnritted with pneumonia, influenza or other respiratory conditions' and27o/oto
30% effective in preventing deaths fronr all causes'
Vaccination, where an infectious disease is involved, confers external benefits to
unvaccinated individuals in a commupity by limiting epidemics' The protection' or herd
immunity, afforded to the unvaccinated when others around them are vaccinated has been
estimated by Tobias ( l99l ) to be achieved by vaccinating70%to 7 5o/o of residents in a rest
home or 80% in open communities. The U.S. Deparlment of Health and Human Services
(1991) have rccomnrendetJ a vaccitre coverage of 80% for institutionalised at risk
individuals and 60% for those at risk in the contntunity'
Research into the inrpact of vaccination on the uLilisation of non-hospital resources for the
65 and older age group rvould be useful, but not essential, as most cost savings relate to
hospital costs. In order to formulate a vaccination policy and recommendations for the at
risk group of working age further infornration is rcquired on all costs'
I3.5 CONCLUSION
The results ol this paper dentonstrated the ecouotlic bencfits of vaccination of at risk
groups in society. lrr particular considerablc hcalth sector costs could be avoided by
increasing t5e yaccination rate to tlre over 65 ycars agc group. For those in the working age
group thc ttet benefits rvere less cleitr.
I3.6 POLICY POINTS
The vaccinarion rare in Nerv Zealand is less than is medically desirable (Tobias, l99l) and
a higher rate 5as been dcntonstrated in this paper to be justifiable in economic terms'
l( Guy Scott (2000)
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Public policiy oprtiols to increasc. the vaccination rate irtclrrde; subsidising vaccinations to
rcducc tltc cost to thc individual, cftapgirrg tlte ntocle of delivery, and education and
promotiorr prograllntes. The N.Z. Ministry of Healtlt chose to increase the vaccination rate
for the 65 years and over by providing "free" subsidiscd vaccinations and running a health
pron.rotiot't canrpaign front Fc.bnr ary 1997. These cftbrrs raised the vaccination rate in all
lriglr risk groups from an estinlated 29olt irt 199(r to 44o/o in 1997 and 46% in 1998
(Kennedy, 1999) rvhich is still less than optirnal.
There are a number of policy initiatives the Ministry of Health can take to increase the
vaccilatiort rates. Suggestions include; investigating the reasons why high risk individuals
do not seek vaccination, investigating how general practitioners notify their high risk
patielts tSat a vaccine is available and woukl bcncfit tltent, and determining what and how
effectivc are their recall systems. A policy ntakcr *'ould then be able to determine where
the problenr/s lay and perhaps design better irllbrmation and follow up systems and
inrplentent a ntore focussed health infornration cantpaign'
This paper has conrbined published overseas finclings rvith New Zealand volume and unit
cost data. Because of the need to use health care resources efficiently suitable overseas
studies should, rvhere appropriate, be applied to New Zealand to evaluate treatment and
health policy options forNew Zealand. The resources required to replicate overseas studies
and generate equivalent New Zealand clinical data nray be better devoted to evaluating and
appf ying overseas srudies to Nerv Zealand and in providing health care'
Avcragc rat6cr tftlrr margirral unit cost data $u-re uSCr-l lbr estimating cost changes because
policy clc.cisions relating to influenza vaccination sould involve incremcnts of hundreds
or thousillr(ls rathc-r than a single irrdiviclual arrd it is intportant from a policy perspective
to cr-rnside't'tltc- lotlg-rlttr rathcr thrrrt thc slrort-rutr.
'I1c argunrcltt lbl'goventnlent funding of the vaccinrtiott programme is strengthened as
r.accirration against influenza, confers cxternill benefits to unvaccinated individuals in a
colrpiunity b1, linriting epidenrics. Prii'atc provisiolt oIvaccinations would result in a sub
optirrral allocatiop of resources from a societal pcrspective.
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CHAPTER 14: CRITICAL LEG ISCHAEMIA
I4.I SUMMARY AND INTRODUCTION
Summary
Chapter l4: Critical Leg Ischaerria, describes a cost-effectiveness analysis that compared
surgery with a pharmaceutical intervention. A variant of breakeven analysis was used to
evaluate the situatiorrs in which the hospital cost of drug treatment would be cost-effective
compared with surgery. Prior to this study the full cost of surgical intervention was
unknown and therefore public hospital adrninistrators and clinicians were unable to
compare the cost of alternative treatments.
lntroduction
The econorrric analysis set out to establish the inciclence of surgical amputation for critical
leg ischaerrria in Nerv Zealand. Standard therapeutic altematives (surgery plus prostheses)
were compared, ip economic temls, with a new pharntacetttical treatment option,lloprost'
Backgroul<l infonnation and rnore detail ntaybe found in (Scottand Scott, 1994)'
lloprost is a prostacyctin analogue with a half life of 30 minutes (Crant and Goa, 1992')
(natgral prosracyclin 5as a half life of 2 to 3 nrinutes). The analogue inhibits platelet
aggregatiotr and induces vasoclilation. This provides a non surgical treatment option for
patierrts rvitlr criticnl leg ischaenria whcre revascularisation is not possible or has failed and
thc next procedttrc s'ould be amptttation'
Criricitl lr-g iscftirctliii is ischacntia linadc-quatc llou' of blood) that endangers the leg or part
of a lr-g. [:ristirrg darir orr tlrc prevalcncc of critical lcg ischaenria lrave been based on a
propontolt of thc lr--g arrrputltiorr procertures undertakctr or on the numbers of referrals to
lintb-[rttipg cL-t]trr-s. The inforrlation available indicates that the prevalence of peripheral
arterial discase is 5% in ntalcs oyer 50 years of age, but fewer than l0% of these will
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devclop critical leg isclracnria (Dornrandy arrd Stock, 1990). Incidence rates fronr studies
in We.stcnr Europe and USA, have bccn cstin'ratcd to fall between 500 and 1000 nerv cases
pcr year per rrrilliorr population (Europcan \lrorking Group on Critical Leg Ischaenria l99l )'
Patients p'it[ diabetes are five t.inres ntore tikely to develop critical leg ischaemia than non-
diabctic patielrrs (Etrropearr Working Group on Critical Leg Ischaemia l99l )'
For patiepts with critical leg ischaemia who present with rest pain and/or ischaernic ulcers
the first choice of treatment is revascularisation by surgical bypass or percutaneous
angioplasty but alnrost 40%o of such patients are not suitable for reconstructive surgery
(U.K. Severe Limb Ischaenria Study Group, l99l ), The last resorl is amputation (Norgren
et al., 1990) rvhich is regarded as a high risk procedure.
I4.2 METHOD
The study rvas retrospective, using unit record patient admission data for l99l forboth
public and private hospitals. Unit costs for l99l were applied to the volume data of
patients and procedurcs to derive total costs. A societal perspective was adopted and costs
were estirnated increnrentally, The incremental analysis measured costs that would change
as the result of the decision to anputate or to use a pharmaceutical treatment' It was
assumed that the costs up to the point oIamputation would be identical forboth treatment
alternatives stuclied. The option of no treatrnent rvas not evaluated as the authors
considered t6is *,oultl be cthically and socially unacceptable in present day New Zealand
soc icty.
Prticnts sho utrdcnrettt
included in thc attalvsis
disclrlrg,-- rl:.rtl lc-ltti Itg to
r.[scular rcconstntctir,c surgcry lbllowed by anlputatlon were
but costs rvere cvaluatcd for the anrputatiorl only' Hospital
DRGr') cotlcs ll3 a'd 285 and ICD procedure code 841 were
DRGs (Ditgnosis Rc'latecl Groups) are a classification schetne relating the type of
patients thaia hospital treats (caie mix) to tlre costs incurred by the hospital in their
trearnlent. That is, DRCs are groupings of cliagrioses according to both their clinical
sinrilarritics and treatnrent costs. DRG ll3 Amputation for circulatory system
rJisorclers except upper limb and toe, DRG 285 Amputation of lower limb for
lri
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obtained for all Nerv Zealand public and privare hospitals (N.2. Department of Health,
l99l). Data are recorded at the time of discharge or death. Any patient readmitted for the
same condition within the period studied was recorded as a separate admission which could
have resulted in the annual costs per patient undergoing surgery to be underestimated' Data
rvere analysed with respect to age and gerrder groupings'
Two methods were used to isolate patients undergoing leg amputations; the first method
selected records by ICD procedure code (the procedure code method, and the second
method selected records by DRG code the DRG method). The two methods were used as
a cross-check on data extracted.
Amputation data, were also used to calculate the cost of providing patients with artificial
limbs (unit costs were supplied by the Artificial Limb Board, Wellington, 1993) after below
knee, the knee and above knee procedures. It was assumed that halfof these patients would
be fitted with artificial limbs (European Working Group on Critical Leg Ischaemia, t99l ).
Production loss was evaluated using the total average weekly eamings for males and
females combined (15 to 64 years inclusive), (N.2. Depanment of Statistics, 1991) and
assumed a week off work for every day in hospital (informal survey of physiotherapists
and surgeons).
The standard treatment with the pharmaceutical, iloprost was for the patient with critical
leg ischaemia to be hospitalised and the medicine administered intravenously for 6 hours
per day for 20 days at a cost ofSl 85 per day'
All unit costs relate to the l99l vear and are exclusive of goods and services tax (a societal
transter payttc'nt).
endocrine. nutritional, and metabolic disorders. ICD : lntemational Classification
of Diseases, ICD 841 Anrputation of lower limb.
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I4.3 RESULTS
The data analysed using ICD procedure codes resulted in a total of 688 records (628
records in the public hospital file, and 60 in the private hospital file). These records were
used to estimate hospital costs and calculate incidence rates. The incidence of amputations
for critical leg ischaemia was 202 per million.
Major amputations (involving more than digits only) were almost exclusively undertaken
in public hospitals. The analysis of the data with respect to gender and age found fewer
female patients, both in total and in the working age group, but found little variation in the
mean age between males and females. A third of ICD 841 patients in public hospitals were
classified as having been readmitted for the same condition but not necessarily within the
same year which may mean that annual costs per surgical patient were underestimated.
The total cost of prostheses was $0.370 million when estimated by the ICD procedure
method, and $0.341 when estimated by the DRG method. Production loss for those of
working age amounted ro 52.764 million. Using the procedure method, 218 patients fell
within the working age group ( I 5-64 years inclusive), that is, 32Yo of the total number of
amputations for critical leg ischaemia. Males nrade up 67Vo (145) and females 33% (73)
of this working age $oup. Under the DRG method, 90 patients (or 25%) of the total
number of critical leg ischaemia amputees were of working age. Males made up72%(65)
and females 28Yo (25) of this group and together incurred a production loss of $l'901
million.
Theprocedurecostestinlatesrvere: hospitalcostsofsl2.Tmillion,prosthesis$0'4million,
a11d lost pro<luction of S2.8 rlillion; rvhile the DRG estimates were: hospital costs of $6'3
nrillion, prosrhesis s0.3 million, and lost prodrrction of $ 1 .9 million (Table l4' l )'
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Table t 4.1 : Summarl': Costs of Amputations for Critical Leg Ischaemia
Tolal and avcrase costs Procedure
nrctlrod
DRG
method
Total costs $ million $ million
Hospital (all costs)
Prostheses
Subtotal (quantified direct medical
costs)
Production loss
Total quantified costs
t2.716
0.370
I 3.086
2.764
r 5,850
6.267
0.34r
6.608
1.901
8.509
Number of procedures 688 353
Average cost per procedure
Quantified direct medical costs
Production loss
Total cost
19,020
4,017
23,038
18,720
5,385
24,105
If Iloprost is adnrinistered for 20 days at a pharmaceutical cost o [$ I 85 per day in a hospital
setting at a rvard cost of $330 per day (Scott and Scott, 1993) the total medical cost per
patient would be $ 10,300 compared with a cost of $ 19,020 (procedure method) per critical
leg ischaenria patient undergoing an amputation. Medical cost savings per amputation
avoided were $8,720. If the medical treatment fails (lloprost) then this pharmacotherapy
cost of $ 10,300 becomes an additional cost. There need to be 1.2 amputations avoided, that
is, successful iloprost treatnlents to pay for I failure. In other words, for every l0 treatment
failures s,ith the drug there have to be l2 successes of the drug treatnrent. Thus the
sr.rcccss ratc rlrust bc 0.55 (12/(12+10) to break*'en on costs
If lloprost is adnrinistered for 24 days (an average of the treatment length reported in
Europt-arr srurlies) thc treatrnent cost riscs to S12,360 and the savings fall to $6,660 per
antputation avoidcd. There have to tle 1.9 anrputations avoided, that is, successful
treatrltcltts to pl1'for I lailurc (for cvery l0 trelttnent failures there have to be 19
succc.sses). ThLrs the success ratL- ntust be 0.(16 (19/(19+10) to breakeven on costs.
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I4.4 DISCUSSION
This study presented nerv information, hitherto unal'ailable, on the incidence and annual
economic cost of arnputations for critical leg ischaemia in New Zealand. Although the
study focussed on lrospital costs for amputations, artificial limb costs, lloprost costs, and
production loss lor amputees of working age, other costs are important in evaluatingthe
cost-of-illness but could not be quantified using the data available' Such costs include the
quality of life, reduced mortality, community care costs, and production loss of those not
in the work force.
The estimates of loss of production of those in the working age group would have been
higher had a separate rate been used for inales and femates, as the male earning rate is
higher and there were nlore males in the study. However, the estimates of lost production
would have been lou,er had adjustments been ntade for unemployment and labour force
non-participatiotr. Lost productiorr of those not irr the paid workforce (although of no less
importance to sociely) was not evaluated.
The procedure ntethod of selecting patient records gave higher numbers than the DRG
method. This was not unexpected as DRC code I l3 related specifically to amputations for
circulatory disorders, but if a patient had an additional and more costly procedure they
rvould have been categorised under the more expensive DRG code relating to that
procedure (a1d thus lost to DRG code 1 l3). It was considered that the procedure method
gave llie best estinrate of incidence and costs but thc DRG method provided an absolute
mininrunr estinrate and rvas calculatccl as a cross-check antl for sensitivity analysis'
Hospital unit costs used in tlrc papcr u'ere tltc averages of 4 Area Health Boards' The
greatest sipgle group of rccorcls rcnroled liortt thc data base related to amputations as a
resulr of acciclerrts of all tlpes including rrtetlical tttisatlvcnttrre (23%). Thus measuring the
incitielc.- of critical lcg ischaenria fi-onr total anrprrtation cleta would result in an over-
estintation of costs.
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The inciderrce of anlputatiolts for critical lcg ischaenria estimated in this studywas 202
(proce<lure rrrethod)per nrillion people. Il it is assunted lhat25o/oof critical leg ischaemia
patients have amputations (European Working Group on Critical Leg Ischaemia, l99l ), the
estinrate of the incidence of critical leg ischaemia in New Zealand is 808 per million
people. Rates in other developed countries ranged between 500 and 1,000 per million
people (European working Group on critical Leg Ischaemia, l99l).
As one third of patients are readmissions, the prevalence of critical leg ischaemia if
derived from amputations and/or adnrissions will be overestimated (as some but not all
patients with readprission indicators will be readmitted during the course of a year)'
However, this will not result in costs being overestimated as costs were calculated using
all admissions over the period of one year.
There were ferver female patients and little variation in average age between males and
females but fenrales had longer average hospital stays which may indicate possible
inadequate early treatment of female patients, or if the condition develops in females, it is
more severe.
The costs per amputation represent a weighted mean taking into account the mix of
different types of amputation and requirenrents for artihcial limbs, and as such, allow true
comparisons to be made between treatment options. To compare the treatment costs of
Iloprost rvith surgery it was assumed that the only difference in usage of medical resources
betw,een each nrode of treatment was the hospital, surgery, prosthesis and lloprost cost'
In otSer u,ortjs, costs Ltp to the time of inten'ention either by amputation or treatment with
Iloprost. rvould have becn identical.
Treatrlcnt ir it5 Iloprost has lreen shorvn 1s ]es'cr nrortality, reduce amputation rates (U'K'
S*,erc- Lirnb Ischacnria Study Croup. I 991 ), heal ischaemic ulcers and to relieve rest pain
(Donrrand1,, I 991 ), B)' avoiding or postpotlirlg anlputation (Grant and Goa, 1992) lloprost
improves qualiry of life for thc patient and reduces amputation costs. If amputation is
sinrply postporrcd the patient nray still havc an improved quality of life and the present
value of amputation costs rvill be reduced as the costs will have been moved forward in
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tir1c. T6ese belcfits rlust bc oflset against the additional cost of the pharmacothcrapeutic
treatnrclrt.
If Iloprost is adrninistered for 20 days there have to be 1.2 arnputations avoided, that is,
successful treatntents ro pay for I failure. The success rate must be 55%to breakeven on
costs. However, if lloprost is administered for 24 days there have to be l'9 anrputations
avoided, that is, successful treatments to pay for I lailure. The success rate must be 660/o
to breakeven on costs.
Iloprost has the potential to either reduce hospital costs if amputation can be avoided, or
increase them if drug treatment fails and amputation is subsequently canied out' This is
dependent upon the patients chosen for drug treatntent, but at the time of the study clear
selection criteria were not available. Iloprost as an alternative to amputation would also
become more cost effective if it was able to be adrninistered orally or in a lower cost
hospital setting such as a day clinic (Dormandy and Stock, 1990) or at a time convenient
to the patient thqs minimising disruption to work and loss of production. Additional cost
savings for successful phamracotherapy would accrue if production loss avoided was
included as a benefit.
I4.5 CONCLUSIONS
Amputation for critical leg ischaemia is costly and has a high mortality. If it is possible
to target those patients ntost likely to benefit from lloprost (that is, avoidance of
amputation and rerluction of rcst pain) the maxirlum benefit rvould be obtained from this
pharnracotherapeutic option. For Iloprost treatnlent to be cost effective in a New Zealand
hospital setting patiertts ttrust be targcted and a success rate of 55% achieved'
Hospital policy nrakers wcrc presentu'tl *,ith tu'o cltoices, remove a limb or part or a limb
ancl sar.e rhc patient's life. or attentpt to save thc linrb and the patient's life with expensive
drug trearnrent with the chance tlrat this rrray firil arrd the patient rvould stilI require surgery
and lose the linrb. T5c cost of using tlre drug w'ts S 10,300 rvhich became an additional cost
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if the treatrnent lailerl and thc lirnb subsequerttly hacl to be amputated, Horvever, as the
socictal valuc for a linrb or portion of a linrb, or precise information ott incremental
effectiyeness of the t\\,o trealntent options was rlol available, the results were presented as
breakeven ratios.
I4.6 POLICY POINTS
The study may be regarded as a form of cost-effectiveness analysis in that both treatments
are intended to save lives, but wifh surgery a limb or portion of a limb is amputated while
drug treatment nray save the limb. Outcomes rvith respect to quality of life are quite
di fferelt, thus the preferred technique would be a cost-utility analysis but sufficiently robust
data were not available for this to be undeftaken.
The study used intlividual hospital records lronr a national database rather than data in
aggregated or sunlmarised fornr. This nreant that the researchers had control over the
methods used to summarise and analyse the data (see Chapter 8: Care With Data)'
Two methods of estimating hospital resource utilisations were used as a cross-check' Both
methods produced similar results and differences were in accord with expectations'
Hospital unit costs were also authenticated from two different sources. Obtaining data from
a number of sources and estimating results in different ways is a useful check on reliability
and accuracy.
As clinical e ffectir,crress ilrfomration rvas unccrtlin, a breakeven technique was applied
rarSer than the rronntl CBA approaclr. This ntethod cstimated a breakevcn effectiveness
ratio q.hich r.r'as uscful for selectirrg target groups rathcr tltan calculating costs per unit of
e[fc'ctiycpc-ss. egalitl,of lifc, althouglr inrpor-tlutt tbr this corrrlition, could not be evaluated
bccirusc of lllucitv oIrJata. Be fore robust polici'gtritlclines for treatment can be developed
nroreclinicalarrdcpalitl,oflifeoutconreevirJertceisttecessary. Thisstudypresentedpolicy
nrakc'rs g.it5 nerv policy inputs that s,ould enable thenr to develop treatment policy
guiclclirres. If fhe surgeon colsidered that there was a better than 55% success for a
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partiqular patient ttrep i,t \lifts cost effecti, :e to use the drug treatmenlt If the hospital Bolicy
makers cousidered that it was \r"orth spending $10,300 in an attempt to save a linrb then
drug treatnrent shopld be used for all such patients. The Health Funding Authority should
take these facto:rs into raccount when setting funding lwels and contrasting service volumes'
In this ca$e contracts should b:e set on the basis of achieving a desired outeome" leaving
hospitals and medieat staffto nrake choices as to ths m:ost appropriate treatment which may
be either surgery or dnrg theraPY.
W Guy Scott QALI)
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CHAPTER 15: HEART FAILURE
I5,I SUMMARY AND INTRODUCTION
Summary
A decision analytic modet was used to combine New Zealand cost data with clinical
evidence fronr an international randomly controlled trial. The model assessed the cost-
effectiveness of altemative drug treatment options. Paradoxical and previously unexplained
differences between aggregated gender specific heart failure prevalence rates and age
specific gender rates were isolated and explairred. Application of the results provided new
cost-effectiveness information vital for governnrent decision making when negotiating
prices and in preparing treatment guidelines'
Introduction
A cost-effectiveness analysis using a decision analytic model (Scott and Scott, 1996)
evaluated t5e changes in direct medical costs, and life years gained or lost by adding the
pharmaceutical. enalapril, to conventional treatnrent for heart failure using the drugs
digoxin and diuretics.
Heart failure occurs rvhen the hearl musclc is damaged, overloaded, or exhausted by such
corr{itions aS ltypertensiotl. corollary artery disease. damage to cartiiac valves'
cardionyoptSy, and arrhythnrias. Thc rates oI hospitalization and mortality among such
patients are higlr, About one-third of those sulfering from congestive heart failure are
hospitalised each vear (The SOLVD lnvestigators, 1991). The one-year mortality ranges
frorl 159'u antong relatively uttselected paticnts to 50% among those in New York Heart
Associariorr furrctionirl class 1V (The CONSENSUS Trial Study Group, 1987)'
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In 1992 tlrere rvere 456 people aged 60 years and over (168 males and 288 fernales) who
died of hearr faiture. That is, a rate of 86 pcr 100,000 (71 for males, 98 for females)'
Morrality age spccific rates risc s'ith incrcasirtg age. Alrlost all (88.3%) of thc total heart
failure deaths occur in those agect 80 years and over, with only I .SYo of deaths occurring
in people under 60 years of age, As therc arc nlore fentales than males aged 80 years and
over tlrere are more deaths recorded for females than for males (65.0% of all heart lailure
deaths were females). Chapte r 8: Cure With Data discusses these differences with respect
to Simpson's paradox.
Heart failure is a high cost generator, incurring direct costs of primary medical care,
hospitalisation, pharnraceutical treatment, indirect costs of lost production (lost output or
productit'ity), ancl intangible costs of a reduced quality of life, and death' As the
population ages and survival rates for cardiovascular events continue to improve increasing
numbers of people will suffer frornr hearr failure and as a result, medical costs fronr this
condition rvill increase.
I5.2 METHOD
The study did not evaluate indirect and intangible costs. A societal perspective was
adopted and transfer paynrents were excluded fronr the analysis. All unit costs and prices
were in 1993 dollars (either as recorded, or adj usted to I 993 using a health sector cost index
developed for the study). As there were no reliable New Zealand data on age specific rates
for lrean lhilgre. age specific rates fronr the US s erc applied to the New Zealandpopulation
to estipratc punrbers of helrt lailure patients. A dccision arraly4ic modeldeveloped in the
US anct dcscribed i1 Scotr and Scott (1996) u'as used to integrate data frorn different
sources attcl to cottcluct setrsitivitl'analy'sis on key inputs and assumptions'
Costs altl bc-1cfits \\'crc cstinrarecl inclenrenrally. It n'as assumed that as enalapril was
a,Jclitiopal to cxisting trettnlellt thcre \\ ould bc rro extra rrledical practitioner consultations'
Ho11,er.cr, ap additiopal dispensing fee and contairrer charge arnounting to $2.60 per three
nroltSs or S0.87 per month rvas allocatetl lor c-nalapril (Pricing schedules, 1993)' It was
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also considcred that as heart lailure patients rr'ould bc consulting the ir medical practitioners
regularly no additional rnonitoring u'ould bc required. This prentise was supported by the
publishcd results of SOLVD in rvhich no acltlitional monitoring was reported' The
treatnrent altered the hospital admission rates for rlyocardial infarction, arrhythmia, and
srroke in additios to heart failure and these changes rvere evaluated with respect to hospital
costs.
However, as patients treated with enalapril lived on average two months longer than those
patients treated with conventional medicines the incremental routine care costs incurred
by enalapril patients during the additional two months were incorporated in to the model
(SOLVD Investigators, l99l). It rvas estinrated (from discussions with pharmacists) and
subsequently verified (Taylor Nelson Healthcarc, 1993) that New Zealand heart failure
patients routirrely visit their medical practitioner on average once every three months.
Consultations are for nrolitoring and to obtain a new prescription for a further three
months supply of conventional nredicine. Thus, trvo-thirds of the 3-month cost (60 days
supply)ofthelollorvingwereallocatedtogive; rledicalpractitionerconsultation($16.09)'
convenrional therapy (digoxin 52.91, furosenride $2.04), and dispensing charges for each
item of convenlional therapy ($3.47) (Pricing Schedules, 1993). The total of these
additional non-cnalapril drug costs or routine care costs was $24.51. These costs were
incorporated in to the model as a per rnonthly cost by dividing by the total undiscounted
monrhs of enalapril survival (38 months) to give a value of $0.65. Medical costs for
treatment of conditions other than for heart lailure were not evaluated for these surviving
patients.
It q as considc-rc-d tlrat if a deatft occurred outsidc hospital, either an ambulance or a general
practitiolter or troth uould have been callecl to attend to the patient. Thus' the cost of an
anrbulance and tlre cost of I nrcdical practitioner call-otrt r,vere used for the estimate of the
cost of clr..ar5s ogrsidc hospital. During thc 1'ear cnding March 1992 the average total cost
per p:rtir-r'11 lor tlrc Nes'Zc'lllnil Arnbullncc Bourd rr'as S 159.74 (Nerv Zealand Ambr'rlance
Board, Lerter 3l August 1993) ancl uas adjusted (using the health sector cost index) to
S 162 pcr call-out. A typical call-out fee for ceniflcation of death by a general practitioner
as at Scptenrber 1993 rvas around S50. Rates varied considerably depending on the day
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(holiday, q,eekerril, *,eck rJa1,), tlrc tinre of clay artd geographic location (lronr a telephone
survcy of a snrall rrunrhcr of general practiriotrcrs in Aucklarrd and Wellington). The base
case yalue q,as 52l2 (consistipg of thc anrbulancc cost of $162 plus the typical general
practitioner call-out fee of $50).
Data were unavailable in sufficient detail to enable separate costs to be calculated for fatal
and nol-fatal hospitalisations. It was therefore assumed that the costs for the hospital stay
would be identical whether or not a patient was discharged alive or dead. However it is
possible that those dytng in hospital may have stayed a shorter time and thus incurred lower
hospital costs. The limited range of DRG unit cost data available from Core Health
(National Advisory Committee on Core Health and Disability Support Services, 1992) were
supplcmentccl by ICD unit cost data lronr indivi<lual cost-of-illness studies. As 95% of all
hospital inpatients a6mitted for heart failure during 1992 were admitted to public hospitals
(N.2. Minisrry of Health, l98l-93)the unir costs applicable to public hospitals were used
for patients in both public and private hospitals.
With the exception of costs for stroke, the DRG and ICD unit costs fully capture the
hospital costs. The possibility that some institutional costs associated with stroke have not
been captured rvas taken into account by using data from a cost-of-illness analysis (Scott
and Scott, 1994) in the sensitivity analysis'
Average lengrh of stay in a public hospital in 1992 for acute myocardial inlarction (lCD
410) 1,as 8.(r days for nrales and 8.5 days for fentales (N,2. Ministryof Health, 1981-93)'
An ipplticrrt rvith nryocardial inlarction w'ill spcnd on average trvo days in a coronary care
urrit and t5e renrainder of thc'ir hospitalisation in a cardiology rvard (Scott, White and Scott,
1993). The cost lbr a patient's toral tinre in hospital rvas the weighted average of a stay of
tu,o days in a coronary care unit at S1,053 pcr cliry, and 6.5 days in a cardiology ward at a
rJlily, rare of S59l usirrg priccs relevant to I Jrnuary 1994 (Nonresident prices. Green Lane
l-lospitlll. Aucklanri, Lcttcr22 Februarl lgg4). Applyingthisnrethodologytheunitcostper
triyocardial infarctiorr paticnt for their liospital stay rvas S5,954' This cost was deflated
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rusirrg tlre HSCI (He:"rlth scctor cost irrdex constructcd specifically for this studf0 (Scott and
Scort, 1996)) ro cstablis[ a basr-. case valuc of S5,9-{8 in September 1993 dollars' lt was
t.leccssflry to adjust unit cost iterls occurring at dif'l'crcnt times to a common base period
with the health sector index.
The pubtic hospital unit costs for cardiac arrhyhnria for the year ending June l99l
(National Advisory Committee on Core Health and Disability Support Services, 1992)
were divided into DRG 138 age over 69 andy'or complicating condition and DRG 139 age
under 70 without complicating conditions. A weighted average (by patient numbers) of the
unit costs applicable to each of these DRGs was calculated and adjusted (using the price
index constructed) to give a base case value of $2,666. The public hospital DRG 127 unit
cost for helrt failurc and sfiock (Nntional Adyisory Committee on Core Health and
Disability Support Services, lgg}) 1r'as adjusted to give a base case value of $5,030'
I5.3 RESULTS
Applying overseas disease incidence rates to the New Zealandpopulation provided a base
case estimate of 10,000 (rounded to the nearest 1000) for the numbers of people suffering
from heart failure (Scott and Scott, 1996),
Potential net cost savings per patient treated over a 4-year period were $652 plus an
adr3irional rrvo nronths of life gained. If enalapril therapywas extended to 100% (10,000
peoplc.) of the population rvith heirfl failure u'ho are untreated with ACE inhibitors there
could be rliscourrrccl (59ir) costs of 56.517 million avoidcd (over4 years), and in addition
1.58i urrtJiscotttttcd lifc ycars gainccl (19,000 rllonths of life gained)' A total of 3'465
hospiralisatioris could be ayoi{e'd, ancl 476 deaths could be postponed beyond the 4-year
periocl 6f the srudy. \rirtually all thc glin in lives saved *'as made in the ltrst two years of
lrL-iltlt'lL-l1t (5,car onc: 690lo, year trro: 2lo..t. 'd cttmulative total of 90%)' 86% of
lospiralisarions ai'oidecl, occuned w'ithin ycar I . ovcr the 4-year period, if 1000 individuals
The consutners price index relates to costs facing the average household and was
not considered appropriate for cleflating health sector prices and expenditure'
ll/ Guy Scott (2001)
286I5: Heart Failnre
rvere treated g,itlr elalapril, 343 s'oulcl die, u'hile if I 000 individuals were treated only with
cortvcntional rncdicincs 390 sould die. In otlter rvords, there were 48 fewer deaths for
epalapril patients treated over the four year period (because of rounding individual items
do not add to tlre total shorvn). The model showed that totalhospitalisations were reduced
by 3a7 per 1000 individuals o\/er a 4 year period of treatment with enalapril'
The additional costs ($1,064) incurred by a patient treated with enalapril were more than
offset by hospital costs avoided and medical costs of death outside hospital avoided
($ 1,7 l6). Base case estimates for an individual and for the population to whom enalapril
treatment could be extended (New Zealand total) are summarised in Table 15'1.
Table 15.1: Base Case Estimates
Estimate Per individual treated New Zealand
Population treated "
Undiscounted months of life gained
Deaths avoided
Hospitalisations avoided
Costs
Hospital costs avoided and medical cost of
death outside hospital avoided
Less Additional drug. dispensing, and medical
practitioner costs
= l'otal nct costs avoidcd
I
1.9
0.0476
0.3465
s
I ,7 16.16
1,064.51
65 r.65
10,000
19,000
476
3,465
s (oo0)
l7,162
10,645
6.517
" 1'he population to n'honr cnalapril trcatment could be cxtended
As a result o{'roundtng indivitJual itents may not add exactly to the totals shown
All costs drscountcd to present yalucs (Scptc'rnber 199.1 clollars)
Sensitiyity analysis slio*'ed that the results rvcrc robust *'itlt respect to changes in the input
yariables. Four factors in particular s'ere found to be major determinants of the potential
pet cost savings; the populatiorr rvith lrc'art lailure to rvhom treatment could be extended,
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t5e percentage of tlris population treatcd *'itlt cnalapril, tlte price of enalapril, and the non-
fatal hospital costs.
If either of the first trvo detemrinants above is changed by a given percentage from the base
case estimates then the total net costs avoided alter by the same percentage. If the enalapril
price is alrered by 2O% (holding all other input values at their base case levels) then the
total costs saverj change by 32%. Enalapril price could be increasedby 63% before the
total net costs avoided fall to zero. if the non-fatal unit cost for treating patients in hospital
is altered by 20% then the total net costs saved change by 47o/o.
Altering the discount rate makes very little difference to the results as most of the impact
on costs occurs in the first year. It might be argued that a death outside the hospital is cost-
effective for a healrh care systern and if all deaths (100%) occur outside hospital the net
savings in the nroclel reduce by 25%. Horvever, this situation would not occur as there will
always be sotne patients adnlitted to hospital who clie of heart failure'
I5.4 DISCUSSION
The study dentonstrated that the addition of
conventional treatment of heart failure was
conventional nredical therapy alone.
the ACE inhibitor, enalaPril, to the
cost effective when comPared with
The poterrtiat cost savings achieved by adding enalapril to conventional treatment for heart
failure tlo not inclutle tlte value to society of lives saved, productivity gains, or the increase
in quality oilile of tltose patients treatcd. Charrges in productivitycould be considered to
be relatively unimportant as rnost patients rvitlt heart failure are not of working age' The
bepclrt of r'nalapril s as also undercstirnated as rlre SOLVD Treatment Trial did not take
into irccoutrt thc adtlitional cost lor thc gfcater numbcr of patients in the placebo grouP
,t.ho requircd additional therapf in thc fonrt of vasodilators to treat worsening congestive
ftcarf lailgrc. Frorn thc trarrorv perspectiye of governttrent btrdgets, prolonging life could
inrpose'adclitionll costs rvith respect to rvclfare payments'
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It is unlikely that cnalapril treatnrcnt could bc applietl to all patients untreated witlr an ACE
inhibitor because, as rvith any inten,ention, a cenaitr proportion of patients will suffer side
effects and rvill have to be placed on an attenrative trcatment regimen. In addition not all
patiepts (anti this nray include some patients experiencing side effects) will comply with
the treatment regimen. The study was unable to evaluate the costs and benefits for males
and females separately, or beyond a time horizon of 4 years as these factors were not
evaluated in the original trial. Beyond the four year trial period the surviving patients will
incur medical costs thereby lowering the net benefits of enalapril treatment.
Application of the model to 3 other countries has also been reported in the literature and
average net cosl savings per patient were; Australia $A I 100, Canada $Can 57 4, and France
FF8076 (Witde, Bryson and Goa, 1994). tf converted into N.Z. dollars usingexchange
rates these cost savings rvould differ because of differing health care costs. Although ACE
inhibitors slow the progression oIthe disease ancl treated patients will stay longer in less
severe heart failure categories requiring less hospitalisation (van Hout, Wielink, Bonsel,
et al., 1993) the economic benefits of treating asymptomatic patients with enalapril have
not yet been assessed.
15.5 POLICY POINTS
The statistics on the prevalence of heart failure are interesting and a challenge to interpret'
There are highcr age specific death ratcs fronl hcart failure for older males tlran for older
fenrales btrt tlc all ages and aggregatcd 60 years irncl over prevalence rates are higher for
ferlales. Tlis parador has inrportarlr. coltsequeltces for policy analysis and is discussed in
Chapter 8: Crll'c l!'ith Dutu.
Decision apalyric nroclelling of the costs and benefits of treatment options is a valuable aid
i1 tlrc Sclltlr sector for policy, nrakers, hospital nranagers and clinicians' These models
Sirye r5c poteptial to provide valuablc cost-effcctive ittformation for policy analysis and
decision ntakirrg and shoulcl be used tttore oftetr. (Sce Chapter 7: lv'loclels)
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Ofterr decisiop nlakers rvant to apply the results of research in one country to another'
Applying t5e results of a single study to differcnt seltings by converting costs arrd health
effects estintated ilt one countryby n'leans of exchange rates and crude population numbers
is inappropriate. Application of the SOLVD ntodcl in dit'ferent countries will contribute
to the global knowledge of the costs of treating hearl lailure however, country-specific unit
costs and epidemiological data should be used as inputs to such health economic models'
Because prices and unit costs related to different time periods, a health sector price index
needed to be constructed to standardise allcosts to a common base' Commonly, because
a speciflrc price index does not exist analysts rvill resort to using the consumers price index
or the GDp deflator. However it is sonretimes possible to construct a more suitable index
tusing a suitably rveighted set of available indices.
This case illustrated the importance of public policy nrakers (if they are acting as agents for
society) in taking a societat perspective rather than a nalrow goverrlment budget holder
perspective. There is a danger that a budget holder perspective may show that extending
tlre lives of nrore people may add to social welfare costs' See Chapter 4: Costs where
perspective is covered.
The results of this cost-effectiveness analysis were unusual in that costs were saved and
lives extended. Most nerv treatments incur adriitional costs to achieve additional health
gains, In tlrese cascs the policy nraker faces an ethical dilenrma, not choosing the least cost
optiorr means that sonte patients $'ith other diseasc's nray be denied care because budgets
haye been spclt q)n leart llrilurc pittictrts, yet choositrg the least cost option will mean that
nrorr' paticnts n'ill dic fronr ltcirrt lailtrre.
Clraptcr 3: l'ttluirrg l{coltlt Ortlcotrtcs discttsse's the concept of QALY league tables where
(if cost per QLTALy arc ktrorr'tr for all diseases antl popularion groups) resources could be
allocaled using rhc criteria of cost per QALY gain. The policy decision makers
(pHARMAC and tlre Ministry of Hcalth) using the results of such a study would have no
ll Guy Scott (2001)
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such ethi,cal dilenrnra as the findings clearly demonstrate both a saving in health resources
andreducedmortalityand improvedquatityoflifebychangingthed.rugtreatrnentofheart
failure patients. In situations such as this. ttre Ministry of Health (if it accepted lhe results)
could advise thc medical profession on the best prescribing policy to achieve the greatest
health gains from available re'sources.
W Gay Scott (2001)
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CHAPTER 16: ISCHAEMIC STROKE
16.I SUMMARY AND INTRODUCTION
Summarl'
This chapter discusses trvo studies and how the in[onrration from two econontic studies was
integrated and used for policy evaluation. First a cost-of-illness analysis (Scott and Scott,
1994) was used to estimate the societal costs of ischaemic stroke. Second, the cost data
generated from the cost-of-illness analysis were updated and used in combination with
effectiveness data from a clinical trial clata to conduct a cost-effectiveness analysis (Scott
and Scott, I 997). The cost-effcctivencss analysis of two drug treatment options for stroke
prevention rvould not have been possible without the cost-of-illness study results. Finally,
a conrparisou of CEA, CUA and CBA rvas ntade.
Introduction
Strokes are caused by an intemrption of the florv o f blood to the brain. They can occur with
the rupture of an artery wall (cerebral haemorrhage: haemorrhagic stroke), blood clotting
(thrornbus: ischaentic stroke), or when a clot lodges in an artery (embolus: ischaemic
stroke). A more fomral definition of stroke is that of the World Health Organisation
(WHO). WHO describe stroke as a rapicl onset of disturbances of cerebral function leading
to dcatS or llstirrg lbr longcr than 2.1 hours rvith no apparent cause other than vascular
(Hatano. l97l).
Eigpty-eight percenr of all strokc cascs of tl'rosc- agccl60 ancl above admitted to hospital in
Nr-rr.Zcullprl 1'cre isc5acnric (Frictlnr;.rrr. 1992) . For policy evaluation of treatment and
prer.cltiorr olttiorrs lbr strokc. it is irnpcrrtant to dilfcrentiate between thcse two classes of
strokc' (ischaertric altd ltactttorrhagic) as thcir treatment differ' For example' if a
hacnrorr6agic stroke \\,ere treaterJ as if it rvcre an ischaenlic stroke the patients condition
llr Guy Scott (2000)
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u'ould \\'orsell. Tltc cost-c'ffc'ctiveness attalysis cottsidcrs treatment options for ischaemic
stroke onll'.
In New Zealand (and in most other dcvelopcd countries) stroke is the third most common
cause of death and the incidence of stroke increases with age. lntemationally, age adjusted
incidence rates lor "first in a lifetinre" stroke range between 2 and 7 per thousand people
for the age groups 55-64 and 65-74 years. If recurrent strokes (people who have had a
stroke) are included, the incidelce rates (new strokes per year) rise by between 20Yo and
307o. prevalence rates (all stroke sufferers) are about 4 to 5 times the incidence rates
(Dunbabin , 1992).
Stroke patients are high users of hospital resources, and stroke often results in disablement
rvhich has important consequences for rehabilitation, and for long{erm and comnrunitycare
costs. Patients rvith cerebrovascular disease (of rvhich stroke is a subset) account for the
greatest bed day usage in public hospitals (1.5% of patients and 8.9% of bed days, (Scott
and Scott 1994)). As many of stroke patients when discharged from hospital require costly
community support or continuing care, strokes are important generators of direct and
indirect costs.
16.2 COST OF ISCHAEMIC STROKE
16.2.1 Introduction and Objectives
This cost-of-illrress stucly (see Chapter 4: Costs for the theoretical basis of cost analysis)
estinrated t5e- costs of isclraenric strokc in 1992 or1 a prevalence basis. (Prevalence of a
diseasc is the punrber of cases irr the population for the period studied. lncidence of a
diseasc is rhc rruurber of rre*, cases that occur u'itlrirt a given time period.) Both those
pnticrrts lur.ing str(rkc L'\'ellts tlrrring tlre current year and sun'ivors fronr past events (who
still rc.cluire tt'ci'ltlleltt or strppofl) contribttte to costs, and are covered in the prevalenCe
estintatcs. The objectives \\'ere to quantify and describe the annual cost of ischaemic stroke
to Nerv Zealand society during 1992.
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16.2.21\lethod
The prevalerlce or cross sectional analysis cstintated incremental costs lrom a societal
perspcctivc. All identifiable transfer paylnel'lts, fronr the perspective of society, were
excluded. Costs were neasured in 1992 dollars. The nrethodology, data sources and
estimation procedures are described fully in Scott and Scott (1994).
Unit recor{ discharge clata for all hospitals in botfu public and private sectors for the year
ended 1992, and mortality data lor the year ended 1990 were investigated' Some longer
stay stroke patients coulil be trarrsferrcd to atlotltcr hospital and be recorded as a
rcadnrissiorr litlrrrr tlrc srrurc- y'ear. -l.o rrrrrlinrisc Illc Potr'ttti]l tirr doribl'-'coLllltillg' ilil
hospital stroke patients rsith stays of nrorc than 90 days were excluded from the hospital
data. Hou,ever, thcse patients n.ere not lost to the sttrdy as they were captured in the rest
home estimates (but at a lower day rate tlratr acttte hospital patients)'
The number of ischaenric stroke events occurring annually was estimated from New
Zealand hospital admissions and the assumption that 70% of strokes or 4,707 ischaemic
stroke cases were admitted to hospital. This was based on a New Zealand study that found
that tn,o-thirds of all stroke patients etrtered hospital, and UK findings thatl5o/oof patients
with acute stroke are aclmitted to hospital (Scott and Scott, 1994)' From this it was deduced
that 2.017 rvere treated in the conrnlunity and that there were 6,724 ischeamic strokes in
total in 1992. This ntctltod of estimating total strokes \\'ns necessary as hospital admissions
are tlre onlV dati.r rccortled. Thesc rcstrlts ilre prcscl'lted in Figtrre l6't'
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Figure l6.l : tncidence of Ischaemic stroke in New Zealand and
Treatment PathrvaYs
100%)
Information from whiclr to construct event pathrvays was obtained from a number of
ditferent sources. Although the data was the best available from international sources the
information sfiould be regarded as indicative ratlter tltan conclusive' Figure 16'2 is a flow
chart of event pathrvays for stroke assuming a 5}o/o survival rate and that 50% of the
survivors would require continuing support. Of the 6,724 ischaemic stroke cases' after 3
to 5 years, 3,36|will die and of the survivors 1,681 will require continuing support thus
generating ongoing costs.
The number of patients requiring continuing care or support was based on stroke events'
surv.ival rate s of 50% (at 3 to 5 years after an actlte stroke event, most dying within the first
month), artd tlte perccntages of srtn'irors permanently disabled or needing community
support. LIS data indicated that about half of stroke sttn'ivors had major motor problems
and up to 109,,0 of stroke sun'ivors ntly be penrtanently disabled.
Fort\,-eight pcrcr-t.lt of all ischaenric stroke patients (60 years and over) surviving a stroke
rvere clischarged to rest honres or gcriatric hospitals (Friedman, 1997)' This percentage
(rounded ro 50%), rvith hospital discharge data (live discharges of patients over 60 years)
Treatment or Death
Hospital (4,707;10%')
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*,ere used to estinrate thc nurrrber of patients dischargcd to rest homes or geriatric hospitals
during 1992 (see Figrrre I (r.2).
Figure 16.2: Treatment Pathrval's for Ischaemic stroke Patients
After 3-5 Years
Dead (3,362; 50%)
The total cost o[ general practitioner consultations rvas estimated from the number of
consultations and the average fee charged. The value of medicine prescribed by general
practitioners had the appropriate dispensing costs and markups added to the manufacturers
selling price to obtain the cost to society. Transport costs of all ischaemic stroke 
patients
admitted to hospital were evaluated using the average cost of an ambulance trip' Hospital
costs were estinlated, using trvo nrethods. The DRG (diagnosis related group) unit cost was
multiplied b1, the numbcr of patients. hl the secon<j nlethod hospital patierrt days were
nrultiplied by the daily ratc lor ptrblic hospitals (5300'00)' and for private hospitals
(s284.41).
As the costs of continuing care \\'erc not available, trvo cstirnation techniques were 
used'
The firsr ,.,tcthocl crraluatcd rhe annual cost of a caregiver (either unpaid or paid) using total
a\,cr.ge s.eckly ear.nirrgs fcrr nrales and lemales corlbirrccl. The second method used as a
rveekly cost, the average of Stage I and Stage 2 rest home subsidy (in general' the subsidy
met thc ftrll costs).
6,724 strokes: After 3 to 5 Years
Survive (3,362; 50%)
Support required (1'681; 25o/o)
I tnO.pendent (1,681 ;25'/o)
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Data liorl Fiplarrd (Rissancl. l99l) allo*'cd c-stitttatcs to bc ntade for the rtut]ibcr of stroke
patients deperrdent orr outside help, pemranently instirutioltalised as a result of the stroke,
and requircnrcnts for physiotherapy and spcech therapy sessions within the first year after
stroke.
Loss of production was valued at the total average weekly earnings for males and females
combined. This valuation was made for rhose in the working age group l5 to 64 years
inclusive. A lower bound of I 2 weeks off work, and an upper bound of 26 weeks off work
was used, (as there was no national infornration available, these bounds were chosen after
discussions with health professionals involved in rehabilitation of stroke). No deduction
was made for non-labour force participation or unelllploynlent' It was considered that non-
paid output arrd leisure time had a value to societl'and lacking nrore precise alternatives
could be valued in tlte same manner as paid output'
16.2.3 Results
In 1992 there rvere 6,724 ischaemic stroke patients of whom 4,707 were admitted to
hospitals (70o ),and 2,017 rvere treated in the community (30%) in New Zealand' Almost
all (98% ) of ischaemic stroke admissions were to public hospitals' There were l8'000
general practitioner consultations lor stroke at a total cost of $0.49 million' General
pracririoners prcscribccl merJicinc valued at $0.46 ntillion for stroke patients' Transport for
patients is a reltrivell, inrportant aspect of this diseasc bccause of the large nunrber of acute
adprissions requircrJ for pltients, nlost of rvlront rverc elderly. Acute adnrissions to public
hospitals accounred lbr 3,959 or 8(:94 of all adrlissions for ischaemic stroke' For the
purposcs of this stud,v all adrlissions to hospital for ischae ntic stroke patients rvere allotted
an anrbulittrce trip cstit'ttatcd to lrc Sl nrillion in total'
Ischilenric strokc patie-nrs'hospital costs al'rlounted to 528 nrillion. Calculation of hospital
costs usil'tg tlrc DRG ttnit cost gave el highcr cost of S47 million' The total cost of
rchabiliration, that is, ph1'siotherapl' ancl spcech therapy for each stroke patient was
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calculirted to trc Sl rnilliorr. lt u'as estinratcd tlrat 2,95S iscltacnric stroke sttn'ivors required
cor.ltir.tping cArL' n'l a rcst honre as a result oItlrc strokc. Tlte annual cost of tlris corttinuing
care w,hen,,'aluetl using the average scekly wage \\'as estinrated to be $90 nrillion, and
rvhen valued using thc rest honre subsicly ratc u'as estintated to be $62 million'
Lost prodrrction for the 9 I2 hospital patients o f rvorking age ( I 5 and under 65 years) who
had an ischaernic stroke was valued at $6 million (using l2 weeks off work), and $14
million (using 26 u'eeks off work).
Direct medical costs ranged from $93 million to $140 million and loss of production was
between $6 million and $14 million, Totalquantified costs were estimated to lie between
$99 rnillion and Sl54 rnilliorr. Hospital and continuing care costs when combined make
up90%of all quantifiedcosts.Table l6.l presentsasummaryofthecostsforischaemic
stroke in Ncrv Zealattd for 1992.
Table l6.l : Cost Sttnrnrary - Ischaentic Stroke 1992
Cost Lorv
$ million % of total $ million % of total
High
General practitioner
GP prescribed medicines
Transport to hospital
Hospital
Rr'habilitatiorr
Contirtuingittstitutiottiilisedcare 61.94
0.49 0.49 0.32
0.46 0.46 0.30
0.76 0.75 0.49
28.22 47.43 30.82
l .l I 1.50 0.97
61.48 89.50 58.16
93.59 140.1 3 9l .06
6.41 13.75 8.94
100.00 153.88 100.00
0.49
0.46
0.75
27.97
I l?
l.l /
Total direct ntc-dical
Loss o f ltrodttctiott
'l'otll dire'ct arrd itrdiru-ct costs
e2.7I
6.15
99.1 1
ffitrrrdirlg'indir,idtralitentsnraVrrotadd exactly to the totals shown'
$l million.Resglts ciuotc.d ip tlt,-. te\t haye been rottnded to tlte nearest
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Sorne tinre after publication of thc studl,the authors rvere asked to conduct a cost-
eftcctiverress analysis of ischaenric strokc prcvention drug treatment. As numbers of
hospital adnrissions for stroke had not changecl greatly. resource utilisation (volume) data
from scott and Scott ( 1994) w,as used in conjunction with the latest available unit cost data
to update the cost-of-illness study. This was necessary because prices had altered in the
intervenirrg period. Table 16.2 shorvs the horv the volunres obtained from the 1992 study
were updated using 1996 unit costs. These updated data were used in the cost-effective
analysis reported in section 16.3.
Table 16.2: Ischaemic Stroke - 1992 Volumes, Unit Costs Updated to 1996 Dollars
Event /Cost Item Volume+ Unit cost Total cost Cost per
stroke
te92 1996 1996 1996
NZ$ NZ$ NZ$
Nunrber of strokes in 1992 6,724
Generalpractitionerconsultations Number 18,000
GP prescribed medicines
Primarv carr-'
29 520,000 77.33
460,000 68.41
980.000 145.75
4,701 5,943 27,974,000 4,160.32
3,694 318 1,174,692 174.70
2.958 26.217 7',1,549,393 tt.s33.22
4.707 160 75 1,896 I I L82
108.429.981 t6.12s.82
Hospital #
Rehabilrtation #
Continuing institutional care
Transport to hospital #
Direct medical costs
Loss of production
Number
Sessions
Number
Nunrber
Weeks I 0.944 627 6,861,560 I ,020'46
rotat airect mearc XSZ9.!la! !-Ll-+0.22
tlnit cost sourcc$
Gencral practitioncr consultations: What do you pay your doctor'i Consumer 1996; (April) p2a'
i Hospitat. rc'hatrilitltion and trans;rort to hospital: [-ow'cstimates from (Tablc 4, Scott and Scott,
199-l)
Continuing inslitutional crrr.: l\'cragc- of stage 2 and stage 3 rcst home care. (Purchasing for your
hcalth 199-l 95. tirblc 5.3. pll6)
Prodrrctitrn: .l'tltll avcrage rrc-ckl1'carntngs lirr tttrlc's and lenrales combined, Mar 96. N.Z.
Dcpartmcnt ttl'Statrstrcs. lNl"OS l 2 rr ccks per patlcnl
* (Scott irrrcl Scott. 199-l)
Tlre nrajor cost conrponerrt rvas continuing institutional care (12o/o of direct medical costs)
follorved by hospital in patient stays (26%).
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| 6.2.4 Discussion/ Conclusions
Ischaemic stroke affects nlairrly older people, nratty of whom are discharged into the
comnrunity apd require costly comnrunity suppor-t or continuing care. The level of disability
for patients after stroke is dependenr upon the severity of the stroke. Disability nranifests
itself as epilepsy, depression, and cognitive losses (for example, in language and
perception). Studies of surviving stroke patients have shown reduced socialcontact with
those outside immediate family and diminished leisure activity' Some of the costs
associated with these disabilities have been captured in rehabilitation and continuing care
costs but none of the reduction in quality of life has been quantified'
As Diaglosis A (the primary diagnosis for *'hich the patient was admitted) was used to
select patient recorcls from the hospital unit data hoth the numbers of ischaemic stroke
patients and Sospital costs are conservative. Patients admitted to a public hospital for an
unrelated Diagr"rosis A but additionally diagnosecl ischaemic stroke in Diagnoses B, C or
D were not included in the analysis as it was inrpossible to separate the additional stroke
cost component from the cost of the primary diagnosis using the data available (see Chapter
4: Cosls where joint costs and co-morbidities are discussed). Private hospital data are
recorded for prirnary diagnosis only. Patients adnlitted to one hospital and subsequently
transferred to anotfter are recorded as separate records and as sueh all the hospital costs
have been captured but nunrbers may haye been double counted as discussed in section
16.2.2: lr,lcthott.
It u,as calculatcd tlrat itt 1992 t[r--re \\'crc apprL]xinratcly 1,557 patients 60 years and over
disclrargecl lir.c to rest homes or ge rintric hospitals, but as it'uvas not known how long these
paticlls staycd i:r c:rre. tSis estinratc coulcl not bc uscd to obtain total costs' Continuing
care is att itttportilllt conlpotlertt of rhe cost of ischacmic stroke to society'
Nery Ze1l11d rest home/continuing carc total costs \\'cre tltree times the acute hospital total
costs. LISA data (Adelnran, l98l ) indicated that rtursing home costs were equivalent in
W Guy Scott (2000)
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rrragnitude to75g'ool'inpatient lrospital care total costs. This differencebetween the ratios
of corttinuinq carL' to acute hospital costs betrveen USA and New Zealand ntay be a result
of our decision to exclude long stay patients from the Ncrv Zealand hospital data and to
capture these costs uptler rest honles. As this is a ntajor cost (which is "hidden" from
policy ntakers because of dilficulty in obtaining data on costs paid for by patients and their
families), further research should be underlaken to obtain estimates of the case mix and
numbers of patients resident in rest homes and those requiring similar care in private
honres. Policy analysts concerned with decisions involving stroke and rest home costs need
this data for infomred decision nraking'
16.3 COST-EFFECTIVENESS OF ALTERNATIVE MBTHODS OF
ISCHAEMIC STROKE PREVENTION
16.3.1 Introduction and Objectives
The cost-effcctiverress analysis (see Chapt er 6: Economic Evaluatiort for the theory
undertying CEA) used the resttlts fronr the cost-of-illness study to evaluate cost offsets
(costs avoided) as a result of stroke prevention treatment reported by the European stroke
Prevention Study 2 (ESPS-]) (Diener et al., 1996). ESPS-2 compared a new preventative
treattrrent against the statrdard cunently used'
The ESpS-2 trial considered e ffectiveness but not cost or cost-effectiveness' Accordingly'
the ainr of this cost-effectiveness arralysis study was to compare the cost-effectiveness 
of
altenratir.c dlrg regiructts in tlte sccotldary pre'erttion of ischaemic strokes in New Zealand'
16.3.2 Nlethod
Coprpurisotls \\'crc tttttlc bctl'c'u-tt thc costs of lol'-dose acetylsalicylic acid monotherapy
arrcl u crrrl[rirratiol thcrnpl'of rrrodifietl-release dipytidanrole and low-dose acetylsalicylic
acid. Differenccs in undiscor-rrrted tlirect nreclical costs \\'ere calculated over 
a 2-yearperiod'
Nerv Zealand costs pcr stroke event (Scott and Scott lgg4)rvere multiplied by the ESPS-2
ll/ Guy Scott (2000)
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increrrrcntal reductions in strokc cvents to derive the costs of strokes avoided'
As the focus of the paper was oll direct nredical costs tlte primary perspective adopted was
that of a hcalth care provider or [under, brtt a societat perspective was also considered when
irrdirect costs $'ere evaluated.
The clinical effectiveness evidence rvas derived from the European Stroke Prevention Study
2 (ESPS-2) (Diener et al., 1996). The two-year trial (the largest to date) involved 6,602
patients who had experienced either a transient ischaemic attack (TIA) (23'1Vo) or an
ischaenric stroke (76.3%) within the previous three months' ESPS-2 patients were
randomised to the following treatnrent reginrens: (1) rnodified-release dipyridamole 200mg
twice a day conrbinetl ivith low-dose acetylsalicylic acid 25 mg twice a day' (2) modifred-
release dipyridamole 200 mg twice a day, (3) lo\\'-dose acetylsalicylic acid 25 mg twice a
day, or (4) matched placebo twice a day.
The ESPS-2 study assessed the effects of the treatntent regimens in the prevention of
ischaemic cerebro-vascular events in those patients who have already had a cerebral
ischaemic event. Tlrese patients were selected because they were highest risk population
group and would derive the most benefit from preventative treatment'
The absolute risk of stroke (fatal or non-fatal events) per 1000 patients treated was reduced
in each treatnlettt reginren (compared 11 ith placebo): by 26 events for those receiving
modified-release dipyridantole, by 29 evetrts for the acetylsalicylic acid group, and by 58
eyerlts for tSose rc'cciving the combinarion therapy of nrodified-release dipyridamole and
acetylsal icy'lic ac id.
Ttrere \\,as qreater belefit to lhe pltient (in risk reduction of a stroke) if a combination
tlrcrapv(rrrodi|lecl-releascdipl,ritlanroleandacetylsalicylicacid)wasgivenratherthan
eitlrcr rrrcclicipc altlnr-. Although each rrredicine r.vas in itself effective in reducing stroke
risk, u.hen gil,cn in cor-nbination thcir effccts rvere additive. The analysis compared only
tlre combination t|erapy against acr-tylsalicylic acid rvhich rvas chosen as the comparator
|l/ Guy Scott (2000)
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as ir is the clrug regintcn nrost likely to be rcplacect by the combination therapy being the
torvest. cost and ntost \t irjr-ly used altentatiVc. Tablc 1 6.3 sunrmarises tl'rese resulls which
provicled the effectivetrcss cvidencc lor tlte cost-effectivetress analysis'
The focus oIthe paper was on incremental costs, thus all resource utilisations (for example,
general practitioner consultations) prior to drug acquisition were irrelevant and not
evaluated. Differences in undiscounted costs were calculated over a Z-yeat period from a
societal perspective. Cost of stroke data were obtained from a New Zealand cost-oFillness
study (scott and Scort, 1994) updated to 1996 New Zealand dollars.
Table 16.3:
Analysis
Results of the European Stroke Prevention study 2 Relevant to the cost
Strategy Srroke events avoided per 1000 patients
(relative to Placebo)
DYP + ASP
ASP
Difference ((DYP + ASP) - ASP)
Abbret,iations.' ASP = lorv-dosage aspirin (acetylsalicylic acid); DYP : modified-release
dipyridamole.
As very lorv dose (25 nrg) acetylsalicylic acid (as uscd in ESPS-2) was unavailable in New
Zealand, unit costs rvere based on half a 300 rng tablet. The costs per stroke event were
calculated by dividing tfie total costs by thc nlnrber of stroke events estimated in the cost-
of-illncss paper (Scott and Scott, 1991). Nc'rv Zealand costs per stroke event were
nrultipliccl by the ESPS-2 itrcretttetrtal reductiorrs in strokc events to derive the costs of
strokes avoided,
16.3.3 Results
For every 1000 at-risk patierrts treateci for iscliaenric stroke prevention over two 
years with
nrodified-release dipyridanrole corlbined s'ith lorv-dose acetylsalicylic acid replacing
acetylsalicylic acid on its orvn the following differences rvould occur' Twenty-nine stroke
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eve'ts s'oukJ be avoiclecl, direct costs of S18,223 uottltl be avoided and in total, $40,963
direct and indircct costs $.ould be saved. Individually, each treatment regimetl resulted in
direct nredical cost savin-{s whetr conrparerJ r.vith tfte placebo but what is imporlant is the
difference between the treatments. Table 16.4, colurrtn 3, summarises the costs on a per
1000 patient basis for a 2-year period.
Table 16.4: Two-year costs Per Patient Treated for Ischaemic stroke Prevention:
Modified-release Dipyridamole/ Lorv-dose Acetylsalicylic Acid Combination
Comoared with [,ow-dose Acetylsalicylic @
Effect/ Cost
ASP
Ischaemic stroke events
Preventative treatment cost: all patents ln
treatment arm
Drug acquisition
Costs qenerated by ischaemic stroke
0.058 0.029
NZS NZ$
0.029
NZS
965.43 I I .91 953.52
events
Primary care (16'91) (8'45) (8'45)
Hospital (482'60) (241 '30) (241 '30)
Rehabilrtatron Q0.27) (10'13) (10'13)
Continuing institutional care ( 1,337'85) (668'93) (668'93)
sub total: Direct medical cost (892.20) |z16.90) 24'71
Trrrsporr to hospital 02.91) (6'49) (6'49)
Sub total: Drrcct cost (905'16) (923'39) 18'22
Loss of production ( 1 I 8'37) (59' l 9) (59' | 9)
rotar direct nre.li LL*Q?ll4l (2821-7) (a0'96)
Notes:
Loss of production rvas cvaluatecl for $ orking age hospital patients' tinre off work' loss as
a result of prenratrtre death \\as not cvaluated
( ) : ncgativc virlucs, a ucgatiVe cost : tl cost avoidcd or a benefit
Incrernctrtal strokc evcnts and costs: DP\'/ASP less ASP
DP\,/ASp = rrrodilletl-rclcase diprridanrolc'/ lol'-dose acetylsalicylic acid combination
ASP : lol-dosc ace-tylsalicylic acid
Bccause of rouriding 1116if i6s"l itertts ntiry not adcl exactlV to the totals Shown
W Guy Scott (2000)
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lncremental cost effective ratios, the difference in cost divided by the difference in
effectiveness (strokes avoided), were calculated, To avoid one additional stroke event by
changing therapy, $1,413 total net direct and indirect costs would be avoided
($40.96/0.029 strokes), $628 additional net direct costs would be incurred ($18.2210.029
strokes) and $852 additional net direct medical costs would be incuned ($24.7I/0.029
strokes). Figure 16.3, shows the incremental cost-effectiveness NZ$ per stroke event that
is avoided.
Figure 16.3: Incremental Cost-Effectiveness NZ$ per Stroke Event Avoided
El Co6t 0 hlegtire cost = ban€fit
1,m0
fln
0
aNz {m
-1,m
-1,5m
16,3.4 Discussion/ Conclusions
The combination therapy was more cost-effective (with respect to total societal costs)
compared with acetylsalicylic acid (the comparator). Sensitivity analysis revealed that the
main cost drivers were hospital and continuing institutional care volumes and unit costs
(Scott and Scott, 1997)'
In the ESPS-2 trial Z2o/oof the placebo Soup, 22o/o of the acetylsalicylic acid group and
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2ggboftSosereceivirrgthcconrbinationtherapy discontinttedtreatmentformedicalornon-
rrredical reasolts. Thus, it s'as concluclccl that 7E% ol'thc potentialcandidates forsccondary
stroke prer.entiorr could be trcatctl n'ith acctylsalicylic acicJ arrd 7l% could be treatcd with
the coprbination therapy of modihcd-releasc dipytidanrole and acetylsalicylic acid' This
would inrply that 9l ,/o of parients cunently trcated w'ith acetylsalicylic acid alone could be
changed to the cornbination therapy.
ESPS-2 demonstrated that with the combination therapy, (although the number of deaths
remain unchanged), the number of stroke events are reduced. This means that the number
of patients progressing to a state where either continuing care' or more intense care is
required rvould be reduced. However, this assumes that the distribution of severity of
stroke evcnts rvas identical for all treatnrent groups. but if the stroke events of one group
are more disabling rltatl those of another grotlp the costs per stroke event would be
different.
The weighted ayerage costs for srrokes used (Scott ald Scott, 1994) covered the costs of
all stroke patients, (tatal and nop-fatal ancl those rvho recovered with varying degrees of
incapacity and dependence) rather than just those patients admitted to hospital'
The analysis demonstrated thar changing patients lront acetylsalicylic acid to a combination
therapy of nrodified-release dipyridamole and acetylsalicylic acid would result in a small
rise in incremenlat direct costs (using our conseryative assumptions relating to hospital and
continuir.tg instituti6nal care costs). If less corrservativc unit cost assumptions were adopted
(g.6ich is a ntorc likcly sccnario) tltcrc s'ould bc greatcr savings in incremental costs'
Altlrough tlrc sturll' focuscd on tlrc cost conrparisons bcts'een the combination regimen
versus acctl'lsalic5'lic acid, tlte cottrbination rcgimen could replace both single drug
therapies.
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I6.4 COIIIPARISONS BETWEEN ALTERNATIVE METHODS OF
E\/ALUATION (CEA, CUA AND CBA)
16.4.1 lntroduction and Obiectives
The findilgs front the cost-effectiveness analysis of ischaenric stroke prevention are used
to denronstrate the rlifferences betrveen CEA, CUA and CBA. (Chapter 6: Economic
Eyaluation discusses the theory underlying CEA, CUA and CBA).
16.4.2 Method
The results fronr the cost-effectiveness analysis arrd assumptions relating to QALY gain and
the value of a QALY [o Neq,Zealand society proyided the information used to develop the
conrparisons betw,een the three economic evalual.ion methods.
Increnrental costs and effects rvere derived from table l6'4' For the purposes of these two
illustrative examples it rvas assumed that 5 QALYs would be gained per stroke avoided'
and that the value of a QALY was $10,000.
16.4.3 Results
In rhe CUA example, the 0.029 strokes avoided translated into 0.1450 QALYs gained (5
QALYS pcr stroke avoided x 0.029 strokes avoided = 0.450 QALYs)' The additional direct
cosr pcr QALY gainecl rr,as sl16 (s18.22 + 0.1450 = s125.66).
For tfie CBA study, t|c QALY gain per stroke iryoidcd was converted into an intangible
benctlt in dollars of Sl,450 per strokc avoided (0.1450 QALYs x $10'000: $1'450'00)'
\\'lrcrr rhc i'crc-11ct'lrll il'ltrngible costs \\'erL- addc(l to thc itrcremental direct and indirect
costs il l.rr.t illcrentental cost savirtg of Sl,49l per patient treated was obtained' In this
exanrple. negative costs represent bcnefits'
The results of this analysis are presented in table l6'5'
|/ Guy Scoa (2000)
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Table 16.5: Two-year Incremental Gosts Per Patient Treated for
lschaemic Stroke Prevention: Modified-release Dipyridamole/ Low-
dose Acetylsalicylic Acid Gombination Gompared with Lowdose
Acetylsalicylic Acid in 1996 Dollars: CEA, GUA, CBA: all Costs and
Effects Measured lncrementally DPY/ASP Less ASP
a) CEA
Incremental costs (C) and health outcomes (E)
Direct costs
lndirect costs
Direct and indirect costs
lschaemic stroke events avoided (E)
lncremental cost effectiveness ratio C/E
Direct costs per stroke avoided
$18.22
-$59.19
-$40.96
0.029
$628
Total direct and indirect costs per stroke avoided -$1 ,413
b) CUA
Incremental costs (C) and QALYs (U)
Dlrect costs $18.22
QALY gain (U) '
Incremental cost-utility (C/U) ratio: direct costs per QALY
oained
0.1450
$125.66
(1) Assumed 5 QALYs gained per stroke avoided
c) CBA
lncremental costsDirect $18.22
lndirect -$59'19
lntangible 2 -$1,450.00
Total incremental c 0.97
(2) Assumed $10,000 per QALY
16.4.4 Discussion/ Conclusions
Although the original research for the cases did not encompass examples ofCUA and CBA
it was considered that this case could be used as a hlpothetical example to illustrate
concisely and clearly the similarity and differences in the data input requirements and
output measures between CEA, CUA and CBA studies. Detail on the conduct of CUA and
CBA was discussed in chapter 3: Valuing health outcomes and in chapter 6: Economic
evaluation. As the CUA and CBA examples are partially based on assumptions, the
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finrJilgs qgotc'd ryere' rtot arrd s|ould not lre uscd for actual policy decision nraking'
Resutts fronr tlrc CUA denronstrated rhat if thc health sector cut-off price per QALY was
$ 126 (of direct costs) or higfter, thc treatrnent should obtain funding approval' The CBA
study showed that if society valued a QALY at $10,000 then the net benefit to society
would be $1,491 per additional parient treated. These results suggest that (l) resources
within the health sector that are nor delivering one QALY per $126 should be transferred
towards stroke prevention, and (2) that additional funding be directed into the health budget
to altow this treatment to proceed. CBA is used to assist in allocating overall funding
levels to health while CUA and CEA assist in allocating resources within the health budget.
Both rhe CLIA ancl CBA lscd lrlpotlretical ,u'rlucs for the number of QALYs gained per
stroke avoided and for the dollar value per QALY gained. The conclusions would be
different had different values been used. Further research or literature reviews would be
necessary to establish the QALY gain per stroke avoided'
I6.5 POLICY INIPLICATIONS
Costs oIstroke are a nrajor component of total health costs. Stroke prevention is important
both in ternls of health related outconles and in the direct and indirect costs generated'
Because of the coltbination of an ageing poptrlation and increasing survival rates with
constant incidence rates, there rvill be a substantial rise in the costs of continuing care and
comntunity support. Nlost of these costs are at present obScured because much of the care
proyicled tlocs rrot involve mot'ley paynrents and/or data are not recorded and collated on
a natiorltl basis.
Inappropriatc policy decisions rrray be rlade if the non-ltospital costs of stroke are not taken
ipto uccourrt. polic-v nrakcrs frccluerrtly'base their clccisions entirely on the financial impact
orr rlrcirll.dqcts. T5e rcsults of this could lre cost shifting from the public sector to private
indir.iduals. priVatesectorcoststhatnrayincreaseinclude;paidandunpaidcaregivercosts,
possible nroclificlrions to private honres, loss of quality of life of the patient's family'
lV Guy Scon (2000)
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T5c. inrportarrcc oI ignoring costs that u'oulti bc irtcurred inespective of the occurrence of
stroke g,as illustrated by tfic cctst of stroke analy,'sis. Tlris shorved that approxinrately 25"/o
of srroke patients in institutional carc rvould rtccrl rlris care irrespective of their stroke,
although they rvould probably requirc a higlrer tcvel of care as aresultof the stroke (see
increnrental costs, Chapter 4: Co.lls)'
The danger of nrultiple counting of hospital costs is demonstrated (see the dangers of
multiple counting, Chapter 4: Cosls). Longer stay stroke patients may be transferred to
another hospital and thus be recorded as a readmission within the same year' To minimise
the potential for double counting, all hospital stroke patients with stays of more than 90
days were excluded fronr the hospital data but not lost to the study as they were captured
under contitrtti ttg care.
Accurate cost and prevalcnce data are essential for the economic evaluation of treatment
options, policy changes, and the nlanner in which an ageing population may affect health
costs in hospitals and the community. Thc cost-of-illness study provided the
epidemiological and cost of stroke data necessary for the cost-effectiveness study'
New Zealand national data were non existent or very sparse and posed serious problems
which were overcome by obtaining ipformation from panels of experts and from
intemational literature. Rcsults fronr intemational rnulti centre clinical trials and overseas
prevalence atld resource utilisation studies rvere combined with New Zealand data to
conduct both the cost-of-illness antl tlre cost-e [l-ectivcness analyses. Lack ofa complete data
set is a protrlerl alnost invariabl5,encountcrr-d s'hert conducting health policy analysis in
Nerv Zr-allld but t6is shoulti not prc-clude an analysis being undertaken. Problems with
data are discusscd in Chapter 8: Crrrc ll'ith Dutu'
Nc$. Zcaland doc-s not have cotrtprchettsiVe and rcady to use cost and effectiveness data'
Policl. arruly,sts rlust eitltcr cle riye their orvn primary cost and effeetiveness data or use the
best sccondary data available. Tlre qtrestions that need to be asked are; will the additional
costs of settipg up their o1,n stuclies jlstiiy the erpected benefits of tfte data acquisition,
ll Guy Scott (2000)
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and rvill there be tirne availablc to obtain thc data bcfore the decision must bc made?
Usually the ansg,cr to one of thesc qucstions rr'ill be "no" and the use of secondary data will
bc preferred to that of getteratiug prinrnry data'
Cost-of-illless stutlies pror.'ide; (l) essential data lor a gencral overview of the economic
inrportance of a disease, (2) a ready source of costing data for cost-effectiveness analysis
and (3) highlight those costs that are of nrajor importance. If a cost-of-illness study needs
to be updated it may not be necessary to quantify costs of nrinor importance'
The results of cost-of-illness evaluations (resource utilisations, unit costs and total costs)
should all be reported separately. This facilitates updating and the use of the study findings
in nrodelling (for example, use of the findings in other settings and in other population
grouPs).
The choice of conrparator in the cost-effectiveness study was important as both treatments
under consideratiop resulted in cost savings if corrlpared against placebo, but the
conrbination tSerapy provided a lower cost effective ratio (see Chapter I 8: Dr'scus sion and
Conclusions for a discussion of the selection of comparators).
It could be argued that for an economy with less than full employment, a proportion of the
potential loss of output of those of rvorking age should be omitted froru the analysis as this
rvould not reduce the economy's measured GDP. However, this approach ignores the
opporturnity cost of lost unpaid outpttt and the value of leisure time (see chapter 4: Costs
rvlrere the frictiorral cost mcthod is discussed)'
Loss of lifecould lravcbcu-r'revaluated using$'illirlgnessto paycriteriaorthehumancapital
approach but Lrecause of thc agc- of strokc pilticllts trcitltcr method yields satisfactory nor
platrsiblc rcsults. Thc hurrtau capital (scc clraptcr 3: I'rrlrring Health outcomes where
estinrati'g 5ealt5 related outcorl'res is discusscd) nrethod rttttJervalues the lives lost because
of thc lou' trunrber of potenl.ial rvorking years lost' Given the average age of the patients
(73 years, and 77 ycars, for public and private patients respectively) the willingness to pay
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r.,alucof$2 ltilliolperlile(MillrrandGuria, l99l) n'ottldresultinatotal costthatmay
be considered by sottlc readers to be too high. Age specific values for statistical lives
would facilitate analysis of this type.
Hospital and continuing care costs could be saved by reducing the incidence of stroke by
using a more cost effective drug regimen. To nraxinlise society's benefits, the decision
makers must have infornration spanning public hospitals, phannaceuticals, rehabilitation,
community care and support, and be prepared to act upon this information'
This published CEA study was used as evidence in negotiations between the government
drug buying agency and drug suppliers. Neither a CUA nor a CBA analysis would have
have provided any additional information that rvould have been considered by policy
nrakers.
CEA studies predonrinate in the health economic evaluation literature because they provide
adequate inforntation for decision making within most present policy environments' CBA
and cUA are rarely used for health sector policy evaluation because (l) the required data
is difficult and costly to obtain and (2) the current decision making processes could not
effectively use the results of such studies.
CUA provides information that could potentially bc used to compare costs per QALY
gained across all health care inten'entiot,s. Horvever, neither a set of QALY league tables
nor a cut-off price per QALY (that the health sector was prepared to pay) was available'
CBA penrrits cornparisons of the net bcnefits to socicty liorn the intplenlentation of any
policy or pro.lect. T[e CBA resttlts s'ould not havc provided any additional usable
inforrrratio. lor clecision uraking bccausc Nerv Zealancl, uovemment budgeting decisions
across Vorcs arc tlot ntirdc trsing tlte rcsttlts of CBA'
Valuc.s for t5e cul off price per QALY for tlre health sector, and the societal value of a
eALy could be estinratecl by sun,eyirrg the Neu'Zealancl communitybutthe final decisions
rr'ould ltavc to bc Political.
lA Guy Scott (2000)
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CHAPTER 17: ASTHMA
I7.I SUNIMARY AND INTRODUCTION
Summary
This chapter discusses a research project that was made up of three parts' These
components were integrated and published in two papers and in the form of a CD-ROM'
An administrative database (general practice records) was used to provide some of the
infonnation required for a cost-of-illness study and to irrvestigate differences in direct costs
bet*,een altenrative asthnra nredication delivery d,:-r'ices. The cost-of-illness analysis and
the cost of altemati\,e lreatments analysis providcd the data used to design and validate the
decision alalyic rnodel. This model rvas used rvith general practice fund holders.and
Regional Health Autlrority policy makers to denronstrate cost differences between
altematiye asthnra treatntents. The nrorlel permirtcd users to assess the budgetary impact
of different asthtrta treatnlent policy options.
Introduction
Three policy evalultion techniques; cost-ot-illness analysis (Chapter4: Costs)' an economic
er.alrration oltreatprent options (Chapter 6'. Ecotrotrtic Et'ttluttlion) and decision analytic
nrodclling (Clrapter 7: Llodels) arc adclressed in this chaptcr. The techniques are applied
to asthnra. The cost-ol'-illrress arrd thr' asthma inhalcr cost conlparison analyses provided
thc datr used to desigrr arrci validatc- the decisiort analltic nrodel (Figure l7'l) The
discussiott dt'l$s upoll t\\'o ptrblishcd papers (Scott ct al', 1997, Scott et al" 1998)'
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Figure l7.l: Sources of Data for the Asthma
Cost I\lodel
Data for construction and validation
of the decision analYtic model
17,2 BACKGROUND AND OVERALL OBJECTIVES
Asthnra is a chronic inflamntatory disease causing airflorv obstruction of varying severity
anrl difficulty in brcathing. It is an inrportant clisease for New Zealand because of the
number of people atTected and the econonric costs, both direct and indirect. It is generally
regarded iis a cltronic disease requiring continuitrg treatment to prevent symptoms' As
such, asthnra has considerablc associate'd nrorbitlity and on-going treatment costs which
include the exacerbation of existing and other acute illnesses. Accordingly treatment
decisions have both important health and cost consequences.
The overall airn of the threc integrated studies was to develop a policy and management
tool (a clecision analyric rriodel) that ivould enable tlte costs of altemative asthma treatments
to bc asscssed.
Tlrr-. objectir',.-s of eaclr cogrpopent ol'this research *'crc: ( l) Cosl-of-il/rless: to idcntify and
evaltr.rtc. thc costs of asthnra to Nc-rr Zcalurd frorrr a societal perspective, (2) Cost oI
ttltt'r.ttttrit't: tr(,(ttDt('ilt.r1,.(t/cgrcs: to cotl'll)trc the tlircct rrrcdical costs of treating asthmatics
trsilg altcr6ulir.c corticosteroicl inhllcr optiorls in I gctteral practice setting' (3) Decision
tttttrl.t-ric ttrotlt,l..to tlcn usc this infonn:rtion to dcvelop att asthnta treatment cost model that
rvould allorv nranagcrs and clitrical decision nrakers to evaluate economic costs of treating
astfipta usiltg different treattlent strategies. Each of tfiese objectives are covered in more
Asthama inhaler
cost comparison studY
using general Practitioner
administrative records
Cost of illness study
using New Zealand
ional epidemiological
economic data
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dctail ivltc-tt etclt of tfic tfirce fucets of tfte t'cscarclt project are discussed'
I7.3 COST.OF.ILLNESS
17.3.1 Background and Specific Objectives
Although asthnta is an important disease in New Zealand the information on prevalence and
costs are fragmented and incomplete. The objectives of the cost-of-illness study (Scott et
al., 1997) were to; (l) demonstrate horv data must be gathered from a variety of sources
both New Zealandand international, (2) identify and estimate from a societal perspective
as nlany as possible of the costs of asthl11a to New Zealand and (3) measure resource
rutilisalion volutnes and costs in monetary units'
17.3.2 Methods and Results
Steps in Estimating Costs
The follo$,ing steps were involved. Prevalence of the illness was first estimated to provide
infomration on tlte numbers of asthmatics in the population' Resource utilisations' unit
costs were detemrined and finally resource costs calculated'
Prel'alence of Asthma in Nerv Zealand
No recordc{ statistics on astltnta preyalencc exist but estintates of the prevalence of
diagnosecl asthnla tn Nes' Zealarrd n'as between l3% and 14% of the population' and of
treatcd astl'llt'Iil bct\\.een 9% to I l%. PreValettce rates multiplied by total population
(StatisricsNcu'Zcrland 1997)inclicart-thatjtrsttrl'ldt-I500,000peoplehavebeendiagnosed
as ilsthr.ltiltics. utrout j50,000 arc trcatcd s'itI ast[1ra clrugs, an<J there are abot'tt 150,000
trr-:rrctl ,sth.riltrcs irr rhc- s'orkforcc. Talrlc' l7.l details the prevalence of asthma in New
Zealand in l996 based on this irrfomtation. The prevalcnce estimates were derived from
Crane et al. (1994) and A Picture of Health (1993); NRB (1996)'
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Table 17.1: Prevalence of Asthma in New Zealand 1996
Rate % Total Number in the
number of emPloYed
Low 13% 473'2oo 218'855
Hish 14% 509'600 2s5'690
Treated asthmatics
Low
High
g% 327,600 151 ,515
11% 400,400 185,185
Total population (mean year ending Dec 1996) 3'640'000
Total workforce (June 1996) 1 '683'500
Drug Acquisition
Asthnra medicines and devices accounted ior $ 104 rnillion (asthma preventive medicines
$72 nrillion, bronchodilators $30 million, and respiratory devices $2 million) or l7o/o of
total Phamraceutical Schedule expenditure on government subsidised medicines
(PHARMAC 1996). A high estimate of $ 153 million for drug cost was obtained by taking
lioh of total public and private expenditure on medicaments (N'2. Ministry of Health
lggT). This includes patient co-paynlents and premiums (patient out-of-pocket payments
where the government subsidy does not cover all of the nredicine cost) and over-the-counter
(orc)
medicines. (As different therapeutic groups have different price structures and co-payment
antoullts ancl OTC nrcclicirre optiorts t[is estinratc nlusl be interpreted with caution')
General Practitioner
Astlmra is a li-ecluent rr"ason paticllts consrtlt general practitioners' Studies indicate that
asllrrrra accolt'lts lbr 6et1'cer t ?.4',6(Tilyard ct al', 1995) and 4'5% (McAvoy et al'' 1994)
ol'gcncltl prilcticL'L'llcor.rllters. Ilfornratiott lrortr (lMS (NZ) Ltd) showed that consultations
lbr asthnta rc-prcscrrted "1.0% of the total number of consultations'
ll Guy Scott (2001)
Ecott orttic Eva I u ation To Health PolicY Iil Netc Zeglqn4
Durirrg thc ycar cpding Sclltenrber 1996,7gl ,000 general practitioner consultations were
rc'corcled for astlttrtn (li\'ls (NZ) Ltd) at a cost of $24 trtilliorr'2r A low estimate of $18
nrilliorr for experrditure on general practitioncr consultations was estinlated by rnultipllng
total expendirure on gcleral practitioner consultations (N.Z' Ministry of Health 1997) by
3.5% (the average of the high ald lorv estitlate of encounters).
Specialist Consultations
The low and base case estimate for specialist consultations was $3 million in 1996 (data
all specialist consulrations $ 136 million (N.2. Ministry of Health 1997) multiplied by2'0%
(usilg the propo(ion of specialist refenals from general practitioners for asthma) (McAvoy
et al., 1994). A high estimate of $6 million was obtained ($136 million multiplied by
4.5oh, using the proporlion of general practitioner consultations as a proxy for the
proportion of specialist copsultations) (McAvoy et al., 1994)' A range22 of fees from $60
to $100 was used to calculate the consultatiort nunrbers from total expenditure' giving
nunrbers of between 45,000 to 61,000 consultations (rounded to the nearest thousand)'
Diagnostic lmaging and Laboratory Tests
Diagnostic imaging anrd tests associated with diagnosis and monitoring could not to be
evaluated because of lack of information. However, discussions with clinicians indicated
that resource utilisation in this area was I'ery small'
7l 't[c total cost \\'as deriyed by nrultiplyilg tlrc number of consultations by the
average ailult cotrsqltation fee of S30 (rounded to the nearest whole dollar) obtained
tio'r t5e consunrers pricc Ildex (Consumers Price Index 1996) (November t?-q0l
arrd cltecked agaipst a constlnl!'r stln'ey that gave sinrilar results (Consumer 1996)'
lf it is assunred that a specialist consultation fee is double that of a general
practitioner, a fee of 560 is obtaine,J but if relativity with accident and emergency
consultations is assumed a fee of $100 would result'
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Entergencl' l\Iedical Treatment
As Neiv Zealald national data on entergency treatntent was not available data from a UK
study (National Asrhma Campaign 1996) was used. They found that l3% of asthnratics had
atterrded a hospital accident and emergerrcy department in the last l2 nronths. Applying
this finding to the lunrber of treated and diagnosed asthmatics, and assuming a unit cost
of $100 per visir (Asthma and Respiratory Foundation of New Zealand (lnc) 1997)' the
following costs were obtained. Base case and low estimate (base case treated asthmatics
x l3o/o x $100) $4 million, and high estimate (base case diagnosed asthmatics x l3o/o x
$100) $6 million.
Hospital InPatient Treatment
In 1994 there were 10,558 (5,171 male and 5,387 female, ICD (lnternational Disease
Caregory) 493) asthma inpatient discharges from publicly funded hospitals representing
38,009 days stay in hospital (N.2. Ministry of Health 1996a). The estimated cost of these
hospital discharges rvas Sl3 nrillion (calculated by applying 1994195 DRG (diagnosis
related group) unit prices, DRG codes bronchitis and asthma 096, 097 and 098) (N'Z'
Ministry of Healt6 1996b) to the number of asthma inpatients). Asthma accounted for l '7o/o
of all inpatient discharges or 0.8% of all public hospital patient days in 1994' A high
estimare of $16 rnillion for hospital cosrs was nratlc using 1990/91 DRG prices paid to
hospitals (Natiorral Adyisory Committee on Core Health and Disability Support Services
1993) (27% higher than unit costs in 1994/95) to provide a high estimate of inpatient
hospital costs.
Transport Cost
Transport cosls \\'cl'e estilnated to lirll lrct.1'ectr Sl4 apd Sl8 million with a base case
estinutc of S lE rrrillion. This cvaluation, uscd a cottscrvative unit cost of $20 a round trip,
on thc basis of one rourrd trip per consuitation and hospital visit or admission' An informal
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sun,et'r of anrbula'ce sen'ice pro'i6ers indicated a unit cost of about $100 rvould be
justified if all anrtrtrlatlce \\'as ttsed fcrr trilllsport'
Indirect Costs
Indirect costs attributable to lost prodtrctivity of those in the paid workforce 
was estimated
to be $95 millionzt. The assumptions were; each trealed asthmatic in the workforce 
will
lose 5 days or one week of work through asthma (Mellis et al', l99l)' the total employed
workforce was 1,683,500 (June 1996) (Statistics New Zealand 1997)' and the average
weekly wage was $628 (June 1996) (Statistics New Zealand 1997)' If the average weekly
wage is applied to the high estimate of enrployed treated asthmatics a high value 
of $ I l6
million is obtained. Travel and rvaiting time (at lc'ast one hour per consultation) to attend
consultatiot"ls was assunred to be included in the 5 days lost output'
If productivity loss was evaluated on the basis of thc total labour force (employed and
unemployed) the cost u,ould be 6.3% higher than our estimates' Calculations made using
the workirlg age population (enrployed, unemployed and those not seeking paid
employnrent) would be 62.0o/ogreater. Reduced productivity of asthmatics while at work'
or asthmatics unable to work, rvas not evaluated because of insufficient data' 
similarly'
productivity loss by ulpaid caregivers or family menrbers unable to work because 
theywere
caringforaclrildorotherfami|ymenlberwasnotevaluated.
I\Iortalitl'
In 1993 thcre $'erc- 126 deaths attribrrtcd to astltma $'hiclr accounted for 0'5% of all
recorded cleaths (N.2. Ministry ol't{calth l995)' Tficsc lives would be valued at $252
nrillion usilg a rrillingriess to pav for a statistical lifc (Miller and Guria' l99l)' but
corrsidcral-r11, less tharr this if valued ttsitrg a htttr]an capital and lost productivity approach'
Telephorre sun,ey rn Auckland and wellington corrducted by the author
This calculation takes no account oI lost school days, unpaid work 
or leisure time
foregone
2_l
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Tahlc I 7.2 sunrrnarises thc costs of asthnra to N$r' Zcaland society as a total cost, and cost
per treated astlrnratic. Total costs range,J fronr $251 nrillion to $340 million, direct rnedical
$142 nrillion to 5205 nrillion, direct non-medical Sl4 nrillion to $18 million' and
productivity loss of $95 nrillion to Sll6 nrillion (Sec'Table 3 in (Scott et al', 1997))'
Table 17.2: Summary of the Base Case Annual Costs of Asthma From the Perspective of
New Zealand SocieW 1996
Gost Total cost Cost Per
treated
asthmatic
Plus Primary caregiver (GP and specialist consultations) 26 81
Plus secondary care (hospital inpatient and accident and emergency) 17 52
= Direct medical 148 451
Plus Direct non medical (transport) 18 54
= Total Direct 166 505
Plus Indirect (Lost productivity) 95 291261 796
= Total Direct and indirect
ffoles
Because of rounding individual items may not add exactly to the totals shown
Goods and services tax (GST) of 12.5o/o (a transfer payment from the perspective of society)
in 1996 New d dol clusive
I 7.3.3 Discussion/ Conclusion
The Asthma and Respiratory Foun<lation of Nerv Zealand (lnc.) (Asthma and Respiratory
Foundation of nNcrv Zealand (lnc), 1997) have higher estimates than the study results (see
Tablc l?.2)l direct costs were Sl60 rrrillion, irrdirect costs $216 million an<l total societal
cosrs 53?6 nrillion pcr al'lltunl in 1996 (Crarre, 19g7)' J'hc Foundation did not exclude
transl-er pavnlcnts (scc chaptcr 4: ('o.srs scctioll 4.5.2) front costs. and their drug cost data
u,as frotn atr c-lrlir-'r p.'riod rvhctt dntg prices u crc ltighc-r' They used diagnosed rather 
than
lrcatcd lstSpratrcs lbr tlre'ir prcvalcttce cstilllstcs; this uoulcl overestimate the number 
of
asthntiltics ils lt'lalt)'pr-oplc nlay ltayc Lrccl cliagnoscd as asthmatic at Some stage in their
livcs but tttr longcr be astltttratic'
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I7.4 COST OF ALTERNATIVE TREATI\!ENT STRATEGIES
17.4.1 Background and Objectives
Treatnre't rvith a corticosteroid inhaler is considered the primary or first litte treatment of
asthma (The British Guidelines on Asthma Management 1995 Review and Position
Statement, 1997). The delivery system (inhaler device) is an important factor influencing
the efficacy of irrhaled steroids (Barnes et al-, 1995)' In New Zealand the general
practitioner is regarded as the gate-keeper to the healt[ care system, and hence the decisions
they make are major health care cost drivers. lncreasingly, the emphasis is on evidence-
based nredicine rvhich encompasses both the economic and health effects of clinical
practice.
Accordingly this study (Scott et al., 1998) focussctJ on differences in cost outconles of a
choice ofcorticosteroid inhalerby general practitioners' The objectives were to detemiine
the cost conseqrlences of a general practitioner's cltoice of inhaler device for the delivery
of corlicosteroid preventer medication for asthnla'
There are two main types of inhalerdevicers: aerosol (AUTO, MDI), and drypowder(DISK
and TURB) inftalers. Dry powder iphalers (DISK, TURB) deliver active ingredient as a
powder and reqttire inspiratory effort lor drug delivcry' Aerosol inhalers may be breath or
manually actiVared. Breath actuated inhaler devices such as AuTo overcome coordination
problerns conrpronly associated 11'ith MDI use, elimitrate the need for spacers' and 
provide
improved ntedicltiott delivery to thc lutrgs attd inrprovccl cfficacy for patients unable to
correctly usr-- lvlDls (lvlcFadderr, 1995; Nervnlarn et al., l99l)'
Inhaler types: Autohaler"' lAuTo], Diskhaler'' [DISK], metered dose inhaler
tMDII ancl Tr.rrbuhaler^' ITURBI
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Data $,erc analysccl by,prescribecl corticostcroicl irtlrrler. The setting for thc study was
gencral practice, and the analyic pcrspectil'e takctt rvas that of the funderof health care'
Treatnrent options inVestigated rvere treatntent ol'asthnta with four corticosteroid inhaler
drug delivery systenrs (Autohaler'" [AUTO], Diskhaler* [DISK], metered dose inhaler
tMDI] and Turbuhaler^' ITURB]) in a general practice setting.
As the research was retrospective and observational it recorded (without altering or
influencing) actual general practitioner prescribirrg practice, and because it used an
extensive data-base a large population rvas ablc to bc studied. Utilisation of health care
resource l,oluntes (drugs, general practitioner colsttltations and numbers of prescriptions
for tfte ],ear ettditrg 30 Jtrne 1995 rvere obtainccl frottr the Royal New Zealand College 
of
General Practirioners Research Unit, University of Otago (RNZCGP)'
Data rvere obtai.cd fronr coprputerised clinical records of 28 general practices covering
128,585 consulting patients (Figure l7 .2).Thc data set is of a standard suitable for research
and aclministrative purposes and is considered to be representative of the nature of 
general
practice (Tilyard et al., 1995) in New Zealand and a valid research tool (Dovey and
Tilyard, 1996).
Figure 17.2: SamPle Breakdown
All consulting Patients
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All prescribing records (frorn the I 28,585 consulting patients) were electronically searched
to identily those paticnts ttsing AUTO, DISK, MDI or TURB as the sole inhaler device for
corricosteroicls (5,70-l patients) oyer tfie l2 lrotlth study period (Figure I 7'2)' Tlrese records
for patients prescribed inhaled corticosteroids ,uvere further examined to identify all beta
agonist and oral steroid prescriptiorts and consultations'
Prices for thc dmgs prescribed, retail and wholesale markups, and dispensing fees and
charges were obtained from the New zearand pharmaceutical Schedule (1996)'
(Respiratory system and allergies, Dispensing fee plus container charge $2'60, wholesale
nrarkup 107o, retail markup I L28%.). Ceneralpractitionerconsultation feeswereobtained
as described in section 17.3.2. All unit costs and prices were exclusive of Goods and
Scn,ices Tax (GST). The average daily dose of inhaled corticosteroids was calculated from
the prescription in fonnation.
17.4.3 Results
Tlre results of the cost-of-treatnlent study are presented in the form of Tables; l7 '3' 17 '4'
and 17.5. More in depth commentary on the results can be found in (Scott et al" 1998)'
along with statistical analysis of the data and conhdence intervals' As the data did not
confomr with the nomral distribution, the Kruskat-wallis method was applied to calculate
confidence intervals (Siegel S and Castellan, 1988)'
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r Conicosterotd inhaler derice: AL'TO = Autohillcr; DISK ' drsl tnhalcr; MDI = mctcrcd dose inhaler: 
TURB = Tu6uhaler
At'1'o Total 
samPlc
Table 17.4: General Practitioner Consultations (Mean Number Per Year Per Patient)
bv Corticosteroid Inhaler Device
Asthma
All consultattons
1.59 41 50,o
8.lo 100 0"6
l.')o il5.8ouo
8.t'5 100-016
t.]7 45.0%
t.12 100.00/"
4.05 40.67o 4.15 41.9/o
q.97 t00.0% 9-46 100-ff/.
a Corticosterord inhaler devlce: AUTO = Autohaler; DISK = drsk Inhaler; MOI = metered 
dose inhaler; TURB = Turbuhaler
Table 17.5: Yearly Resource Utilisation and Cost Per Patient Treated for
Asthma SummarY
Resource/ cost tlenr Corlicosteroid inhaler device
Re source utiltsations (volumes) Cost (exclusive of GST)
AUTO DISK MDI TURB AUTO DISK MDI
Urrits Units Units Units $NZ $NZ $NZ
TURB
$NZ
1.12 5.86 6,45 5.2-{ 349
3,59 3.96 4.17 4.05 10"1
45-l
409 265 490
Prc'scriptrons lbr
astlrnla
Cenc'ral prarltitiol)cr
consultall()lls
'l'()tal 
Prt tlut't' lllcd lcrl
clrc
ll5 121 ll7
5?4 392 608
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17.4.4 Discussion and Conclusiolt
The largest singlc. cosr itent identilled in this study rvas that of corticosteroid inhalers 
which
ranged from 4lo,/o of total primarycarecost forMDI LoS}YofortheTURB group' Total
dnrg acquisitiop cost (inclgsive of dispensing costs and rvholesale and retail markups) was
highesr for TURB at $490 and lowest for MDI at $265, a difference of 85%' There was less
variation in general practitioner consultations for asthma with total costs ranging from $ 104
for AUTO to $127 for DISK. Total primary care costs were lowest for MDI at $392 per
annum and highest for TURB at $608, a difference of 55%. conclusions relating to cost
differences betrveen tfte treatment groups were robust, in all but one instance TURB
remains the highest cost grouP.
Not all records in the data-base rrsed allowed clear identitrcation of the reason for the
consultation and thus some asthnra-related consultations may not have been counted' As
data were actual general practitioner prescribing records and not pharmacy dispensing
records, failurc to present or collect a prescription from the pharmacist was not measured'
Estimates for non-dispensing varybut Gardner et al' in a recent study (1996) found that the
non-dispensing rate for both bronchodilators and corticosteroids was l0'5%'
A number of factors n'lay cause wastage of asthma dnrgs; some patients do not complywith
treatment. and inhaler deliverl'devices may be test fired and used inconectly' Estimates 
of
paticnt nonconrpliatrcc u'ith prescribed medication vary widely' Noncompliance depends
upon the ildividual patient, the natrtre of the disease being treated' and the type of
nredicationprescritre<j. Thcstudydidnotattenrpttotrtcasurenoncompliancebutnever-the-
less the irnpact on prescriptions and general practitioner consultations has been 
accounted
for i' rhc study. O'cr-use *'ould 5a'c been measured in additional prescriptions and
gcneral practitioner corrsultations. Utrtler-ttsc rl'otrltJ lrilve been accounted for by
subscqur-.tly lts cr pre-scriptions anci fes'er gencral practitioner corrsultations' If under-use
rcsultcd in art astlttttn attack, ar1{itiolal prcscriptiolls and additional cotlsultations mayhave
been gencratccl an<l nreasttred in the strrdy'
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Wlstagc as a rcsttlt of test firing, ittcon'cct activatiotr (poor co-ordination) or incorrect
usage was t.rot specifically tlleasurcd in the study btrt is accounted for as it is included 
in the
volurrrcsofnredicationprescribed. Gebbic(1971)repoAedfromasurveyofasthnraticsthat
test firing \\,as an inrponant cause of rvastage of bronchodilator aerosols in pressurised
containers (MDls). Test firing is usually a problem associated with MDIs and is considered
to be less of a problettt for breath-actuated inhalers'
King et al. (1991) found that 68% of patients were unable to use their MDI inhalers
successfully. Enors in use fell into two main categories; failure to sytchronise 
deep
inspiration with depressing the canister (a problem of co-ordination), and failure to hold the
breath after inspiration. In a review of asthma literature Shrestha et al' 
(1996) reported that
approximately,20?b to 409t, of astltma patients used MDIs conectly and this 
has important
inrplications for rcsottrce usage, morbidity and ntortality' McFadden (1995) reviewed 
the
Englislr langr.rage literature (20 papers) an<J found that the error rate per patient in the use
of MDIs ranged from l 7'/o to 89% with an average of 38%' The proporlion of 
patients
misusing MDIs in tlris review rvas 367o. A French study of the literature 
came to similar
conclusions (Chinet and Huchon, 1994)'
Faulty inhaler technique has both clinical and econotnic consequences in 
the treatment of
asthma. Cost-effectiveness of the treatment decreases as costs rise and 
effectiveness falls'
Costs rise because of the additiona'l volume of nleclication used, and because 
asthma is not
as well controlled there is an increase in general practitioner and hospital'
As explanatory r,ariablcs for asthtna severity ancl risk rvcre not sufficiently 
documented in
the clatabasc, lirrtSer i'vestigatiott suclt as nrttltivariate analysis was 
not considered
appropri;rte. llorveyer. colllnlellt ltas bcctl tllade on differcnces in age 
between treatment
grouPS.
Trris sr.cly rJifferr,rj fro'r'rost randorrrisecr controlrccJ clinicar trials in that it 
involved a
large study population arrd recorcletl (ivithout altering or influencing) actual 
general
practiriolter prescribing practice' Clinical trial protocols are frequently 
difflerent from
actual practice and patients tend to be carefirlly selected to meet specific 
criteria'
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I7.5 DECISION ANALYTIC I\IODEL
17.5.1 Background and Objectives
Asthma treatment is cornplex and clinicians and hcalttr sector managers make 
decisions
with irnportant cost and health care consequences. As data for decision making are
fragmented, and decision makers are frequently under considerable time 
constraints' a
method of both integrating data and allorving scenario analysis is urgently required'
The objectives of tfue study were to design and evaluate a model capable of; (l ) integrating
data from a wide variety of sources, (2) allowing a health sector administrator or clinician
to evaluate the cconomic costs of trcating asthnra using different therapeutic strategies 
and
(3) pernrittilg decision nrakers to cfiange data inptrts assunrptions and analyic perspective'
17.5.2 Method
A deterministic decision analytic spreatlsheet based model was designed and evaluated 
the
following healthcare costs:
. Drug acquisition cost (ingredients, markup and dispensing charge)
, Plus Generalpractitioner, specialist and otherhealth care professional consultations
. Plus Diagnostic tests (e g' x-ray)
. Plus Secondary care cost (hospital)
: Direct nredical (health sector costs)
p/rrs Dirccr no. mctJical cost (rron hcaltlr sector costs: transport to seek treatment
apd otfier lrquseholtl costs [e.g. special bedtlingl of treating or preventing asthma)
Tottl direct cost
p/rrs lrrdirect cost (Lost productivity and leistrre time activities ofpatierrt family and
friends. That is, tinre costs of thc illrrcss or its treatment)
Total direct and indirect cost
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Ncw, Zealand cgridcntiological, resource utilisatiorrs arrcl unit cost data (as discussed in the
previous sectiorrs) $,erc used to construct and test thc nrodel. Where New Zealand data was
unavailablc a literatttre search yielded Australian and UK information that could be
adapted for New Zealarrd. This rvas possiblc as treatnlent guidelines for asthma are 
similar
in these countries.
The modet was constnrcted using a series of different screens or pages' Welcoming 
pages
contained instructions for running the programme, highlighted cells in which data 
could be
entered, background on asthma prevalence and information about the pre-loaded 
base case
values and assunrptions underlying the model. There was a section for inputs another 
page
for, calculations. The outputs were in the form of tables and charts' All pre-loaded 
values'
assuptptions and Sogrces ,ryere docutlentcd q'itftin tlte rrrodel'
The florv otthe model was as follows:
Pathways the model follows to assign the nuntber of asthmatics to each corticosteroid
inhaler device are as shown in Figure 17.3, The model calculates the number of 
asthmatics
and assigns thern to treatment groups. Resource costs are calculated by multiplying
numbers of patients by the input unit costs and by the resotlrce volumes for 
each treatment
option.
The inplts to tlte tlodcl are slrou'n in Table l7'(r' Output costs are presented (in both
tabular and grapfi lonl) bi' iltraler dc'r'ice' Costs arc described in terms of dollars per
trearcd parictlt. pcr 1000 paticnts. and per srtrdy poptrlation (Table 17'7: is a schematic
listing o l' tlre cost or'ltpl'tt's)'
Inputs +Calculations'-
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Figure 17.3: NIodel Pathtval's
17.5.3 Results and Discussion
The base case preloaded values yeld identical results to those presented in the earlier
sections of this chapter (cost-of-illness and cost-of-treatment studies)' Medicine prices and
volunres were described in monetary units per milligram rather than price per 
pack' This
was done to enable thc model to cope rvith changing prescribing patterns and 
so that it
coultl be usecl in other countries. lvlarragers and policy makers can use the 
model to
erraluate different price scenarios, srvitching paticnts fronr one delivery device 
to another'
Differenr perspectivcs can be considercd by changing tlte inptrt unit costs'
I7.6 POLICY POINTS
Therc rfe sevc'rol policy rclaterj issttes illustraterj b5r this case; thedifficultyof obtaining
clatir for policr.anal5'sis, clifferences in data cstitrtation methods, and 
the use of a model to
intcglittr. rlata tj.oril tlil'terc.nt sotlrccs ttttd cottdrtct scenario analysis frotrr a nunrber 
of
di fl ercnt pcrspL-cti\ cs'
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Obtaining Data for Policl' Analp'sis
Lack olcourrtrystrrc.cific data oftcn ncccssitates thc irttcgration ofdata fronr a range ofNew
Zealand and intenrational sourcL's; the cost-of-illrress study illustrated this process.
Absence of prinrary data on eflectivencss and resource utilisations of different treatment
options rrray often be overcome by obtaining and processing secondary data that has been
collected for other purposes such as clinical and adnrinistrative records. The use of an
administrative data-base of general practitioner patient records is an example of an
alternative data source that can be used instead ol'data from a randomised trial to estimate
the cost-o f-treatment,
Differenccs in Estimation ll!cthods
The study highlighted the inrportarrce of investigating differences in estimation methods
and rhe leed to adjust the findings to take account of this when using secondary data from
differentsources. Ifthisstepisnotundertakeninappropriatepoliciesmaybeirnplemented.
For exanrple, the inrplications of overestirrrating the cost oI asthma compared with other
illnesses are that health resources may be nrisdirected towards asthma and away from other
priorities within the health system. Policy makers rvill often be presented with conflicting
informatiort such as this and must decide horv to use such data.
Use of A l\todel to Integrate Data and Conduct Scenario Analysis From A
Nunrber of Different Perspectives
The nrodel arrcl its construction antl tcsting clcmonstrated the practical application of
intcgrating clata lronr a cost-of-illrrc'ss arrall'sis and a cost-of-treatment analysis. It was
designed as a ntanagentent arrcl policl, tool to bc usr-cl by any manager rvlto is able to
nlr.igatc. fi-orrr s5cr.t to shcc't ancl lr-orn cc'll to ccll in a spreadsheet and insert data into
clcsigplted cclls. D,-'cision nlelkr-rs arc able to corrsider a range of costs from any
perspective sinrply by entering tlre apllropriate resource trtilisations and unit costs'
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A he,altlr purchaser sftould be nraking decisions based on the total direct medical costs of
an interrention str irtegy and not sirtlrtply orl the price of the primary med'icine' A lower
priced inhalernray generate lrigher lotal direct nedical eosts than a higher priced inhaler'
Policy makers wlthin funder aud purchasing organisations could use such infonnation 
in
negotiating prices rvith suppliers of aslhma inhalers. It would be possible for tlre funder 
to
calculate breakeven prices for inhalers s.uch that total direst medical reosts were equal'
As data for the model'were derived frorn actual genetal practice (everyday community
trea,nnent) it provides a realistie way. of making evidenee based deeisions' Policy makers
within fundholdEr health care provider organlsatisns could usethi's information to select
the most csst €ffective asthma treatment regirnens and olinigal guidelines' to design
tr€atr,nent strategies, and to,more effectively negotiate contracts With funders 
to maximise
their profitts.
The model ha.s been used.,rvith generatr practice fund holders and health sector 
fundors to
demonstratecogldifferengesbetweenatternativeastlrnratreatm€ntsandhas.pe,rmittedusers
to assess the budgetary im,pact of different asthma trestrnent poli'cy options'
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Table | 7.6: Asthma Treatment Cost l\Iodel lnputs
Cost itents by arrnull volunres and unit costs
Drugs
, Corticosteroid inhalers (assuming no wastage)
. Bcta-agonist inhalers (assuming no wastage)
' SPacers
. Other drug I
. Other drug 2
. corticosteroid inhaler over/ under use and test-firing
. Beta-agonists over/ under use and test firing
. Wholesale/ retail markups and dispensing fees
Primut),care
. General practitioner consultations
. Retraining:additionalgeneralpractitionerconsultations
. Specialist cottsttltations
. Physiotherapist consttltations
. Nurse cotrsultations
. Retraining: additional ntlrse consultations
. Diagnostic tests
Secondurt cut'c
. Entergelrcy nredical treatment
. Hospital outpatient specialist corrsultations
. Hospital admissions for inpatient treatment
Direct non medicul cosls
. Transport to seek treatment
. Household costs
Indirect cosls
. Paid and unpaid Productiort
. Eclttcatiotr
. Leisure tinte activities
Epitlemiologicul and dantogruphic duttt
. PoPttlaticrtr at risk / study poptrlation
urt, oItreat,.'d astltma prtientsa
I
'7o of trcrttecl paliertts on eaclr inhrtler dcvtce
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Table | 7.7: Asthma Treatnrent Cost I\lodel Outputs
Corticosteroid i nhalers
Beta-agonist inhalers
Spacers
Other eg Prednisone
Sub total Ingredients
Wholesale and retail markuP
Dispensing
Total Drug acquisition (A)
General practitioner consultations
Specialist consultations
PhysiotheraPist consultations
Nurse consultations
Diagnostic tests
Tota|Primarycareconsultationsplusdiagnostictests(B)
Total PrimarY care (C = A + B)
Emergency medical care
Hospital inpatient
Total Secondary care (D)
Total Direct medical (E = C + D)
Transport to seek treatment
Household costs
Total Direct non medical (F)
Total Direct medical and non medical (G = E + F)
Lost paid and unPaid Prodttction
Lost edtrcation
Lost lcistrre tinre activities
Total Indirect (II)
Total Direct and indirect (l = G + H)
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CHAPTER I8: DISCUSSION AI{D CONCLUSIONS
I8.I INTRODUCTION
Although ntat]y of the points ltave bcen coverccl in previous chapters it is useful 
to
integrate the ideas cliscussed and outlirle ttle ecottonric evaluation 
procedure as a series of
steps that anyone who works in a public policy position may follow and 
use' Many policy
makers do not have the skills or background knorvledge to apply and interpret 
the results
of economic evaluations, or detemline the econottric consequences 
of policy interventions'
18.2 ECONOMIC EVALUATION PROCESS
This sectiorr discrrssc.s an cr,aluation procedurc thirt nraybe followed irrespective 
ofthetype
of econopric evalttatiop being conducted. Tlre procc{ure was developed jointly flront the
chapters on methodologies and the cases researched in this thesis, 
and fronr procedures and
check lists createcl by othcr authors and agencies including; Australia 
Commonwealth
Department ol-Hurnatt Sen'ices and Health (1995), Gold (1996)' Canadian Coordinating
officeforHealthTechnologyAssesment(1997), Dnrmmondetal''(1996)andDrummond
et al., (1997).
These checklists rvere developed becatlse nlally health economic studies 
are used and
conducterl by 
'o. 
ccononrists. Help is required r*hcn e'aluating the quality of 
published
research rcporls and *.hen rrncrertaking cco'orrric cr.aruatio'rs. Journal 
editors considered
tlrat guidclirrr-s s,oukl itr..prove thc qtrality of sttbnlitted articles and improve 
the peer
revie$, proccss. RcgulatoD, autl ftrntlittg agcrrcies rvattted tecl-rnically sound 
reports in a
rurritonu lbrrltlt to fircilitlte cottlpnrisotts stttdy by sttrtly' Dangers 
in adopting such a
chccklrst .rc t6i.rr c!iffr--rcnt rescarclr cprcstions urnl rcquire different 
nrethodologies and if
tlrc proccss is totr prcscriptive it tuaV iprpcdc tttctltotlological development'
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Thc folorvi'g steps are rere'ant to ail typcs of cco'onric evaruation but they should not
necc-ssariry bc appricd in exactly thc sanrc r.ra.r1er in ail situatiorrs arid nray bc iterative
rathL-r tlrart lincar.
Table l8.l: Economic Evaluation Steps and Checklist
ion and define the objective/s
2. Decide uPon the PersPective/s
3. Identify the target population
4. Identify all relevant altemative/s and select comparators for analysis
5 Decide uPon the time horizon
6. Check the clinical and technical evidence
7. Identify atly constraints to inrplententation
8. Identil'y arl appropriate nrethodology
9. Identify relevant costs and health relatc-d otltcomes for each comparator
l0 Value the costs and outcomes
I l. Apply the choice criterion for determinin-e the most efficient option/s
I 2. Condrrct sensitil'ity analysis
13. Investigate equity consequences
14. Evaluate the results, drarv conclusions and make recommendations
15. Monitor the decision taken
18.2.1 Problem Definition
The problelrl nlust be clearly identificd and dcfirrecl' More often than 
not the health policy
arralyst is prcscnt..d rvith a Yague artcl $ oolly problern arrcl asked to undertake 
an cconomic
evaluation and nrake precise rccomnteurjatiorrs. It is inrportanl' to establish 
the background
of the problc.rl attcl cltcck that ffic problent cxists ancl that a decision 
needs to be taken'
This u,ill often inr olVe sonle irrvestigltive and qualitative research' 
The research question
rrrust tre lo''ulirte.cl anrl tlc spr'cific objcctires of the analysis sharply 
derrned' The
rcsearc' qrestio. sets the o'r-rail air.us but these o'er'll airns can usually 
be broken down
into a rrunrber olnrore specific objectiVes' These objectives must be precisely 
stated in
ternls that rvill allorv them to be nteasured. Some examples 
from the case studies will
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illustrate the need for prectston'
Clrapter 9: Attrihiotic Costitrghad trvo aims. The first, rvas to identify 
and detemtine the
econonric costs oI tfie reginrens currently usetl irt three New Zealand 
hospitals in the
treatrnent of scrious bacterial infections itt haettrarology patients 
with febrile neutropenia
and in intensi'e care patients with severe infections. The second 
aim was to develop a
decision analytic model for use by hospital decision makers as 
an aid in evaluating the
comparative cost of drug regimes. chapter l0: Benign Prostatic 
Hyperplasia and chapter
ll: Hysterecloml,cases aimed to determine the annual costs of treating the conditions 
in
New Zealand so that future new treatments (not at that time in current use) could 
be easily
evaluated' Chapter 72: Lotuer Respirarory Tracl Infecrion and Chapter 
14" Critical Leg
Ischaentiacases aims were to determine the cost difference 
between two alternative
treatnrents. The aim of chapter 13: Irfltrcn:rt was to evaluate the differences 
in costs and
outconres of a policy of increasing the rates of vaccination against 
influenza for at-risk
populations. Chapter l6: Iscltaentic strokecase had two aims' First to evaluate 
the annual
cost of ischaemic stroke in Nerv zealandand second to use these 
costs in combination with
the results oI a randorrrised clinical rrial to evaluate the cost-effectiveness 
of stroke
prevention treatnlents.
18.2.2 PersPective
Perspectiye is used in two ways; to indicate the scope or boundary 
that captures the costs'
and to i'rlicate the r.ierr,point frorrr rvlrich costs are measured. 
It is important to determine
andstatetlier,icrr'lroitttortltepcrspectir'eoftlresttldyasthisdeternrinestherelevantcosts
anrl lrerrcfits a.tl 6or' thcy slrould lrc r.llucd, The perspecti'e 
could be that of an individual
patieut, a lrgspitirl. a rcgional 5calth autl'lolity or society as a 
whole' A full societal
perspcctiVc etlcolllpilss!-s tl"lc broadest possiblc rallge of costs 
and benefits and measures
thcnt rr itlr rcspcct to their irlpact ot.t societl' as a n'ltole'
Dctining the target audiences arrd stakeholders rvill dictate the 
analytic perspectives'
Diffcrc"nt dc-cisiott nrakers triay havc distinct vicrvpoints' 
Those who may use the study
couldbeseveraloftliefollowing;thepatientorpatientadvocates'healthauthorities'
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general practitio'crs, phannacists, clinicians and hospital administrators' Most user groups
can be catered for w'ith citlrer onc or ntore oIthe follorvipg three perspectives:
. Private individuals/ patients/ health insurer
. Health sector or governn"lent as a funder/ purchaser (Vote: Health)
. SocietY as a r'vhole
Failure to take account of the appropriate perspectives is a serious shortcoming 
in many
economic i.vestigations. Most evaluations should try to include a societal perspective 
or
discuss the findings with respect to society. The danger of not including the societal
perspective is that some impoflant costs and benefits may be omitted from the analysis 
or
inconectly valued. Subsequent policy changes may be made on the basis of a 
partial
understanding of tfie problem. Decision makers (even in a financial analysis) should be
encouraged to colsider the impact of their actions on society in addition to their 
own
viewpoirtt.
For policy purposes both a societal perspective and the perspective of the agency
concemed are nrininrunr requirements. A govemment agency may want only its 
own
perspective taken into account because it normally has a responsibility to keep within 
a
fixed budget. However, it (government agency) also acts as an agent for New zealand
citizens and it is therefore essential that the societal perspective is included 
for full and
open advice. If serious externalities are identified then the appropriate decision 
makers
affected by the spillover should be informed and given the opportunity to 
contribute to the
funding of tfie project, or ensure that other economic instntments are employed to align 
the
agency's perspcctive $'ith that of society. Unfortunately agcncies may refuse 
to take any
cogpisance oI an1' ot|er perspective but tlteir oq'n bttdgct' This may indicate that their
tenls of relerencc slrould be changecl to rellcct thc objcctives of society'
Clrrrpter 9: .,ltttilriotic Co.slirrg, rvas considered ll'ottt the viewpoint of a 
hospital
adrrrinistrator conccnle,J $ ith miuilrtising lrospital costs' A health sector 
perspective was
adopted in Chapter l0: Betrigrt Prostrttic I-l.t'perplasirt, Chapter ll: Hysterecton'y'Chapter
12.. Lower Respiratory Tract lrtfectian,chapter 14: Critical Leg Ischaemia' 
chapter l5:
Heart Failureand Chapte r 11: Asrhnrn' A societal perspective was considered 
in Chapter
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16: Iscltuetttic Stroke. Chapter 13: IttJluert::a considered the costs and benefits of
vaccinatiort fronr tltree separate perspcctivcs: an irrdividual, the Govemnrent and of society
as a rvlrole. Three perspectives \\,ere evaluate'd because the costs and benefits 
were different
when viervcd fronr each these perspectives and because some policy options would 
shift
costs fronr one groltp to another.
ln each case there was either a single objective or the objectives were sequential' This gave
a precise focus to each study and determined the perspective/s.
18.2.3 Target PoPulation
The problem to be investigated may be more sharply focussed by clearly identifying 
the
target population. A challenge encountered i1 defining the problem for chapter 9:
Arttihiotic Costingwas the vast nunrber ofpotential treatment combinations and 
infections'
It was therefore decided that the target populations were those patients in 
haematology and
intensive care with se\.ere infections rvrro were or could have been treated with 
a specific
drug.
I 8.2.4 Alternatives/ Comparators
Econonric evaluation is concerned rvith comparing one option with another' 
All possible
options including the option of doing rrothing or keeping the status quo should be
considered. lt is irrrportant to iderrtify and list all possible alternatives even if not 
all
altenratives rviil be evaruated. From trre ristcd optiorrs, select the comparators 
for study'
In evaluatit'lg a lle\\' therapy thc tttain colllparator slrould be the most 
commonly used
altenratir c trr-crt'llcnt tlrat $'otrlcJ bc rcplucecl by the trcrv thcrapy' The 
results of studies can
bc. birrsctl ,' or clo*.' bi, selcctipg tlc 6rost or least costly or the least effective 
or most
cflcctir.c ulrcn1lltrVc trr'iltll'lL-nt. For a brcaktltrotrglt therapy the comparator 
could be 'no
treat'rcnt, or co'tinuirg carr,. Therc is also a case for considering additional 
comparators
such as the lorve.st cost treattlletlt, 110 treatment or treatmellt 
as recommended in clinical
guidelines' lt is possible for a neu' therap)'to be cost effective against the most common
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trcatnrent, but neitlrcr the nrost conrrnorrly used treatnrent nor the nerv treatnrent may be
cost e ffectivc w'lren cornpared against continuing cafc or no treatnrent.
Chapter 9: Antihiotic costing isolated all main treatnlcnt options and compared their costs.
Chapter 10. Benign Prostutic H1'perplusia and Chapter I l: I{T,sterectomy comp^red costs
oftreatnrent versus no treatment. Chapter 12: Lov,er Respirotory Tract Infection compated
the treatment costs of a new antibiotic against one in most common use in New Zealand.
Chapter l4: Critical Leg Ischaemia studied the options of amputation versus intravenous
medication as a treatment for critical leg ischemia. For ethical reasons the no treatment
option was not considered. Chapter 13: Influenzat measured the costs and benehts of
vaccinating or not vaccinating different proportions of the at-risk populations. Chapter l5:
Heart Failure and Chapter l6: Ischaemic Stoke compared a new drug treatment against
treatments that u'ould be displaced. Chapter 17 Asthma compared the costs of treatment
using four dilferent inhaler devices that rvere all capable of delivering the same drug.
18.2.5 Time Horizon
Prevalence based studies consider all cases and costs in a one year time period while
incidence or lorrgitudinal studies isolate new cases and track costs and outcomes over time'
Prevalence studies do not require discounting but costs and outcomes in longitudinal
analyses occur over a rrunrber of years. All of the cases discussed are either prevalence
baseti or costs lrave beerr converted itrl,-r annual equivalents. From a policy and budgeting
perspective it is usrially of nrore valuc to considcr a "steady state" situation and consider
the arrnual equivalerrts. Prcvalcncc studics are useful in assessing the total costs of a
disease or its treatrnent in one year, rvhile incidcnce studies are valuable when considering
the treatn'rent of ne*'ly'diagnosed pttients over titrtc.
Thc tinrc horizon is important irr clecidirrg upon the costs that rvill be altered by a decision-
In tlrc long- nrrr all costs are variahlc and thus relevant but as the time horizon shoilens
sot1'tc costs beconre fixed ancl thus not relevant to the decision. Setting too shorl a time
horizon has tlrr. potential to cxcludc'nerv technology that may not be cost-effective in the
shoil-run but could be cost-effective in the long-run.
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18.2.6 Technical Evidence Check
It may seenr obvious, but it is important to check that the clinical and technical evidence
for detemrining the lrealth effects/ outcontes of thc treatnrent options are sound before the
econonric evaluation is conducted. Sonre treatnlents may be clinically unproven or cause
more harm than good to patients.
I 8.2.7 Constraints to Implementation
Irrespective of the economic worth of a programme or new treatment, there maybe factors
that rvill inrpede or prevent successful implenrentation. These constraints must be
identified and appraised. It is a waste of resources to conduct an economic evaluation of
options that cannot or should not be inrplemented
Some of the factors which could be of irnportance are technical feasibility, legal issues,
ethical considerations and social aspects. It would be inappropriate to evaluate an option
for treating patients that rvas so hazardous that it would not be implemented on ethical
grounds. Exclusion of some groups of the population from treatment, may be regarded as
unethical and ereate such a political fallout that it would be impossible to implement the
policy. Certain forms of health promotion may be inappropriate for the Polynesian or
lv{ioripopulationinNervZealand. Differentwaysofcontnrunicatingmayneedt<.,befound
for differenl groups.
No technical. cthical or legal cotlslraints s'ere identified in any of the cascs discussed.
Hos cver ethical consitle rntions constrairicd the choice o f cotrrparators that were considered.
For csanrplc, a policv of no trcatrllcnt \\'as l'rot rn etlrically acccptable optioll for most of the
cascs iuutlvsctl antl *'ns lltcrcforc not cvalultcd.
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I 8.2.8 ldentifl' an Appropriate l\lethodologl'
As discussed in Clrapte r 6'. Et'orrotrtic Evu[uutiorr tltc appropriate method of analysing costs
and outconrcs is dictaterj by a number of lactors outside the control of the analyst, for
example, tlre rescarch question, data, and availablc tirne. It is often not possible to classify
an analysis into an economic evaluation category until it has been completed.
Table 18.2: of EvaluationType
Choice criteriaEconomic
evaluation
technique
Type of
efficiency
evaluated
Obj ective, to investigate:Perspective
Lowest: Costs /
outcome
ratio
Cost-
minimisation
Productive
(fechnical)
Allocation of resources
betu,eeu treatments for the
sanre condition s'here
outcomcs are identical in all
respects
Clinical
nlanager,
practicc
manager or
hospital
manager
Lowest: Costs/
effectiveness
ratio
Cost-
effectiveness
Productive
(Technical)
A llocation ol' resources
bet*'ecn lreatnlcnts for thc
same condition. Outconres an"
in the same dimension but
achiered to differing degrees
Clinical
manager.
practice
manager or
hospital
manager
Lorvest: Costs/
utilily
ratio
Cost-utiliryPartly
productive
(Tcchnical)
and panly
allocat tr.e
cflicicncy
Allocation of resources across
t'lrflerr-'nt treatnlenls ovcr a
rlngc of conditirrns nitltirt the
Iru'll th scc tor. i\laritntsc'
Irealtlr benellt lor a dcfincd
pt.rpulatrort frorrt a gtt'ctt
buduct
Herlth lunder'
purcltasc'r and
lrlinrstry ot'
I {u'rlth
Highest Net
present value
Cost-bcne fit
analysis
Allocutilc
efficrcncy
A Iloc:.rtion ol' rcsottrccs
bet\\'r-crl dr l'lcrcnt tlscs across
tlrc rvltole cconontv to
rnrxinilse societrl s'ellare
(irt" crtttttettt
('abrnct
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Tablc 18.2 slrou's horr'pcrspc'ctivc, objectivcs. cflrcicncy and the type of evaluation are
linkcd. This w,as done to assist policy arralysts clroosc an appropriate technique. For
cxarnplc, a hcaltlr purchascr may n'ish to conduct a cost-utility analysis because this
provides the best infomration for tlre decisions lhcy lrrve to make but they n'ray be forced
to rrrake do with a cost-eflectiverress antlysis if thc appropriate qualityof life data are not
availablc or not obtainable within the tinre and budget constraints lor the analysis.
Sinrilarly, a clinical manager may wish to undertake a cost-effectiveness analysis but is
restricted to a cost-minimisation studv because effectiveness data is unobtainable.
18,2.9ldentification of Costs and Outcomes (or Benefits)
All relevant costs and outcomes should be identified, listed and described. This may be
facilitated by constnrcting treatment and outconre trees (Chapter 7: Models\. The tree
diagranrs rnay sinrply be a device to assist thinking through the options and making certain
all possible outconles and costs are notcd, or it nray form an integral part of the model used
to estinrate cost-eff-ectit,eness. Chaptcr l7: Asthnm used diagranrs to clarify the method
used to isolate and nreasure costs but this diagrarrt did not form part of a model'
Direct nredical costs arc those associated rvith nrl-dical treatment and include medicines,
general practicc consultations and hospital stays. Thcse costs fatl directly within the health
sector. Direct norrmedical costs are those costs incurred as a result of the illness or the need
to seek health care and are generally borne by patients and their friends and families' They
could include the cost of transport to seek nredical care, the need for special food or
clothing or nrodifications to one's honre as the result of illness. Indirect costs relate to
production loss ns a result of death or rcduced capacity to work. Indirect costs are external
to the lrealth sector and fall on patienrs ancl thc rcst of society. Production loss relates to
botfi tlrosc in paid ernploylcnt and unpaid entploynlcnt. Intangible costs are concerned
rvith reclucetl quirlity of life as a rcsult oIthc illncss. 'l.lrese intangible costs do not involve
opportunitl,costs of rcsources but ltcoplc nray be *'illing to pay to avoid pain and suffering.
N{ost oItltc cascs atrtlvsecl considcred dircct costs ottlt"
Costs rlry bc cithcr positir.e or ncgative. For exanrplc, a cost avoided is a negative cost and
coultl bc' r-cqlrticrl ls a bencfit. Outconrcs of nrcdicll irrterventions are nomrally positive,
t6us t5c1 arc rL-gardetl as benefits. Trarrs[r-'r payllcttts shotrld be identified and excluded
lrorl llte arraly'sis (Chapter 4: ('o.sl.s).
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Table 18.3 lras trcen developed to shorvs the rclationship between the type of cost,
technique, pefspective and boundary. This tablc rlay bc used to determine which types of
cost nray bc nreasured by each type of analysis and it shows where the costs fall by each
perspective. A societal perspective may be adopted to measure costs but only some of
society's costs nlay be selected. A cost-mininrisation study rrtay value costs from a societal
perspcctive lrut nray only inclutle clirect nrcclical costs. In this case costs are quantified
using societal values but the boundary used to capture the costs is the health sector.
Chapter l0: Benign Prostatic Hl,perplusirr, evaluated the impact on costs of the wider use
of nerv diagnostic tests and found that this did not alter the conclusions' Chapter 14:
Critical Leg Ischaenia used a break even analysis as the effectiveness of medication for
all patients was uncertain. It was found that there would have to be 1.2 successful
treatments to pay for one treatment failure. In other words the success rate had to be 55%
to break even on the nredical costs of dnrg therapy.
Cost-benefit analysis is the only techniquc that is capable of capturing all of society's costs
apd benefits. Cost-nrinimisation is the narrowest range of costs and the narrowest
perspective. Table 18.3 mns from the narrorvest perspective and boundary(cell A3, health
sector perspective anrJ bounclary, cost-rrrirrinrisation) to the rvidest perspective and boundary
(cell C30, full societal perspective, cost-bcnefit arralysis). Row 6 indicatesthat inacost-
benefit arralysis that although the perspectivc adopted is always that of society, the
boundary could be set such that health sector costs only are captured.
Cost-minimisations and cost-effectiveness studies almost always consider direct medical
costs valued from a health sector perspective but may also value these sanre costs from the
patient and fiurrily and from a societal perspective. Usually the boundary r,vill be set at the
healtlr scctor but nray extend beyoncl this. Cost-utility analyses usually set their boundaries
to capturc putiellt. lanrily arrtl societul costs. Cost-rrtility studies should not evaluate
irrtarrgiblc- costs ns rhc.sc rvill bc incoqloratcrl in the trtility nlcasure. If indirect costs are
capturc-d [rv tltc utilir5' t'llcilstlre tltcsc too shottld bt- cxcluded'
W Guy Scon (2001)
Chapter I8: Discussion and Cortclusiort 350
Table | 8.3: Tvpe of Cost and Technique bv Perspective
Perspective
BoundarT', tcchnique ancl type of cost Health
sector
(Notc I )
Patient
friends
family
Society
Colunrn rel-crence A B C Row
ref
F,
€
(u
tr
a,q,
.,^
6lq,
Cl = Direct Medical Costs
()
(J
0.)F
Cost-of-il lness analysts
Cost-of-treatment anal ysis ,
Cost-minimisation analysis 3
Cost-effectiveness analvsr s 4
Cost-utility analysis 5
Cost-benefit analysis n( n( 6
C2 = Direct Medical Costs P/rrs Dtrect Nonmedica Costs
C'ost-of-illnr'ss analvsrs I X 7
0.) Cost-of-treatment analvsis I I 8
Cost-nrininrsatron analvsis | )( 9
Cost-effectr\eness analvsis I X l0
F Cost-utrlrtv analYsis | )()( lt
C.
lnd
Cost-benel'it analysis | )()(
= Direct Medrcal Costs P/r.i Dtrect Nonmed
'ect costs
n(l
cal Costs Pr t/J
l2
OJ
()
0.)I-
Cost-o f-rI lness analvsts x/ l3
Cost-ol'-treatment analvsis xx l4
Cost-minimrsation analvsis xx t5
Cost-e ffectiveness analvsi s )$ l6
Cost-utilitv analvsis l( )( )( )( l7
Cost-benefit analvsis )( )( )$ l8
ffi/rrs Direct NonmedicalCosts P/rs Indirect
Costs Plrrs Intangible Costs
a)
c.)
CJl-
Cost-of-il lness analvsis xx l9
('ost-ol--treatmcnt analysrs x)( 20
('osl-rrriurntisatiorr aualvsls I XX x x 2l
C'trst-cfli'ctrven!'ss lnllvsis I XX x )( 22
('ost-utrlitv analvsis I XX xx p( 23
('osl 
-bcncli t lnalysrs xx )l 1{LA(:i = t,tr,"'cr Nl.'drc, o.sts P/rr.r f)rrcct Nonmcdtcal Costs P/rr.s Indtrect
('tlsts P/rrs lntrngiblc (-trsts /)/tr.r crtcmal rttcs
t-
(irsi-ot'-illrrcss anallsis | )(X xx xx 25
('rrst-ol'-lrcaLnrcnt anallsts I XX xx xr 26
('ost-nrrninlsatlon analr,'sts xx n( xx 21
Cost-c l'fec t i vencss analvsts xx xx x)( 28
Cost-utrlrtv analvsis xx xx xx 29
('ost-bc-nellt anal 1,st s xx xx 30
//--Type of'cost almost als'lys includcd. /= lv{ay bc included, rt S eldom, I'{ = Never
A saling: a cost ofl.set = a negative cost = a bertct-rt
Norc l: Thc realth sector is often brokt'n dourr into health providcrs and health purchasers
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18.2.10 Evaluating Costs and Outcontes
Quantifl,irrgcosts ancloutcontes \\'as cliscussed in Chapter 3: Vuluing Health Outcontes and
Chapter 4: Costs. As econoniic evaluation looks at dift-erences between comparators,
increntental analysis (Chapter 4: Cos/s) should be used to evaluate costs and outcomes.
This simply n'leans that costs and outcomes that are identical between treatment options
within the relevant time horizon may be ignored. Only those costs and outcomes that differ
between comparators need be measured. Costs and outcomes that were identical for each
option would cancel out when conrparisons were made between the options. Chapter l4:
Critical Leg Ischaelria was designed to provide inforntation that would allow drug versus
surgical treatment options to be evaluated. It was assumed that the costs up to the point of
deciding to amputate or treat with clrugs rvoulcJ be identical but would differ after this point.
Resources used or avoideti should be valued in temrs of their opporlunity cost. The floor
space used by the administration in a hospital could be valued by using the rental that office
space could eam on the real estate market. Health related outcomes if valued in money
terms should be evaluated using willingness to pay criteria (Chapter 3: Valuing Health
Outcomes). Where a nrarket does not exist or rvhere there is market failure, contingent
valuation methods may be needed to establish shadow prices'
Costs and outconres that occur at different tirne periods should be adjusted to present values
by means of a discount rate to take account of tinring differences. Prevalence based studies
that. relatc to one tinrc period rvill not invoh'e discouriting. Costs and outcomes estimated
fronr lolgitudinal srutlics that trlck cvr-nts ovcr tinrc lvill reqtrire discounting to the base
year.
lnflation nrust bc takcn account of in sonte consistetlt \\'ay (Chapter 5'. Discounlurg)' Costs
and br-nefits arc ct'rnrnronll, c-ithcr valuccl in base period unit costs and prices and
discotrptccl usitrs I pc:tl cliscount rate. or valucd irr clollars of the day and discounted with
a nonrinal discount ratc. If sonrc input prices changc by diflerent amounts than others, then
additiorral adjustments rr'ill have to be made to the future values of these inputs before
discounting by a contmon rate .
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Health ecorronric evaluation is usually undertaken assuming partialequilibriunr conditions.
The evaluator assumes that the irnpact oIthe progranrnres being evaluated will not alter unit
costs and prices. Ii horvever, the changes advocated rvill alter prices and unit costs, then
this nrust be taken into account rvhen these costs are valued. When evaluating the impact
of increasing influenza vaccination (Chapter l3 : Influenza) it was assumed that the
increased denrand for vaccipations would not alter unit costs of general practice
consultations or the prices of other drugs.
18.2.1 I Choice Criterion
In sinrple terms the best option can be selected by choosing the alternative that provides the
highest level of net present benefits or the lowest net present cost per outcome or the lowest
cost-effectit,eness ratio. Chap ter 6'. Econontic Etuluuriol discussed the appropriate criteria
to use rvith various types of economic evaluations.
I 8.2.12 Sensitivity Analysis
Sensitivity analysis and uncertainty were discussed in detail in Chapter 7: Models.
Sensitivity analysis allows us to evaluate the robustness of the estimates, to determine
worst case and best case scenarios and to analyse changes in key estimates. Uncertainty in
some of the estimates of costs and outconteb can be taken into account by considering upper
and lorvcr bor.rnds for each estinrate. Sensitivity anarlysis of all of these factors should be
conducted in all studies.
I 8.2.1 3 Equitv Consequences
Econonric evnluations provide infomrlrion orr efllcicncy of resolrrce allocations but do not
cvaluate equifl, chanqcs. Sonre solutions tltat are ntore efficient may not be desirable
choicr-s if unacccptable cquity changes occur. lt rvill often be necessary to make trade-offs
betn,een efficrency ancl equity. Clrapter 2: Conceptuctl Framework for Economic
Ewtltuttiort of Ileultlt Crtre provides a more detailecl discussion of the concept of equity.
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Chapter ll: Ifi.stcrectop4'and Chapter l0: Bcnign Prostutic Hyperplasia are both gender
specific conditions and directing resources lrom one condition to the other would result in
gender specific equity changes. Chapter 16: [schuemic stroke provides but one example
of a disease that falls nrore heavily on the elderly. Shifting resources lrom asthma
treatment (chapter 17: Asthnra) to stroke preventiotl could cause inter-generational equity
changes.
The manner in which indirect costs are valued may have a major impact on inter-
generational and gender equity where econonric evaluation is applied to gender or age
specific illnesses. There are usually dift-erences in employment status and market wage
rates betu,een genders and ages. Applying gendcr specific market wage rates to value
productivity rvill not be desirable if policy decisions are intended to be age and gender
neutral.
In general the analyst should make explicit all potential winners and losers resulting from
a policy change. If equity changes are a concern then a policy maker should clearly speciff
these concems in the brief to the analyst.
18.2.14 Evaluate the Results
The results ot'econornic evaluation provide inlbrnration on costs and outconres and the
process provicles a logical franre*'ork for decisiorr rnaking but cannot make the decisions'
Economic evaluation focuses on changes in econonric cfficiency and is only one of the
pieces oIinfonlation required for decision making. Eqtrity, ethics and other issues must
also be cottsidcru'd.
18.2.15 i\lonitor the Decision Taken
lf a nerr policy, progranltl'le, or trcatntent option is introdttced, the change should be
nronitorccl to check liftether the econorlic iincl policy attalysis has provided accurate
infornration. By nronitoring the introduction of nerv policy it can be evaluated and
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inlonrration can be- ilccur'nLllerled tlnt u'ill help futurc- policy decision making.
I8.3 CONCLUSION
Many costs are obscured fronr policy nrakcrs because they do not involve money payments
and very little non-hospital cost and ntorbidity data are collected. The continuous
collection of and access to a wide range of data in as dis-aggregated a state as possible is
necessary for quality policy analysis. The New Zealand health "reforms" with their
emphasis on the commercial model have created difficulties in accessing "commercially
sensitive" data, and some loss of continuity in collection coverage. This could be overcome
by making mandatory the provision of data to a central data warehouse to be released to
users in an anonyntous and dis-aggregated fonn.
Although econorrric analysis is an integral corrrponent in public policy decision nraking26
the theory underlying economic evaluation of health is complex and is not well understood
or correctly applied by non economists. The practical cases illustrate the application of the
methodologies to a ranqe of policy problems that rrray be encountered and indicated that
although a commotl overall approach may be applied to the policy questions no one recipe
could be applied in all cases. The policy question and the data available dictated the
methodology.
Tite econopric eyaluation checklist (Table I 8.1 ) that has been developed and the theoretical
reyic*, (cSaptcrs 2 to 8 irrclusivc) are intendecl to provicle non economist health policy
managers s,ith thc critcria and tcchniqucs by n'hich thc dccision-makingprocess in resource
allocatiop cnp bc intproved. lf this chccklist is uscd, ttli1tly of the common errors in
econorrtic evaluatiott ntay bc avoidetJ.
The ecorrc'rnric clc-sign slroukl rrot bc predetenttitrecl but should be driven by the policy
qucstiolt. pcrspecti\.c, data, tirle, rescarclr budget and espected net benefits of the research'
Altlrotrgh it has yet to be dcternrincd exactly horv Nerv Zealand policy decision
makers use ecoltomic data.
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Accordingly, a range of techniques is likely to be applied in public policy analysis of health
and it may be inrpossible to categorisc the type of evaluation until the study is completed.
It is more important to clearly describe the method used than aftach a label.
Public sector policy health managers makc day to day resource allocation decisions and
prepare long term plans and budgets for their organisations that have spillovers with
efficiency and equity inrplications for society as a whole. Public sector decision makers
should be encouraged to consider the impact of a programme on all stakeholders in addition
to their own viewpoint. The perspectives chosen should be wide enough to enable this to
be done. Where efficiency equity trade-offs are recommended, the consequences of the
choices on different interest groups should be explicit.
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Abstract
Dau available irr the public domain are frequently aggregared
to preserve conftdentialiry and ro reduce a database to a
manageable size. D,rawing csnclusisns frorn s-uch data rnary lead
to inapgrropriate policy advice.
The airus of this paper ar€ to Ehow how the aggegarion of
dara ro form rates rna.y obscure important inforrnation and lead
to misinterprerad,on of results. Suggestions a,re offered on wayt
in which this problem rnay be addressed" Ve also hichliglt the
need to seek additlonal inforrnation in order to clarify findings.
We used a case study approaeh by drawing on illustrctirre
examples to higtrligit some problerns eneountered when using
aggregated data abput popularioru..The focus is on health
policy.,
li"o ry-po of problenr were discuesed in the cases chosen, but
a'comme.n tesolu.don was appropriate. In the first case policies
based on the assugrg4lon that hospiral adrnissions eqtrate with
dis,ease incidence would be differenr from Bolicies framed on
achal inc:idenee data. In thesecond, ineidenceftiteS changed
when they we,re disaggregated ro gender and age.speciff.c rates.
Policies f.oruT ulated &om analysis of aggregated data would be
different from those based sn disaggregated data.
In the cases,studied, the var'iables,of, ger,rder, age and ethnieity
influence incidence rates and must not be ignored. REsearchers
are recomrnsnded to study the,dab-set in the most
disaggregared fornr availab-le, and to check how data have be.en
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deftned, collected and recorded, before preparing sumrnery
tables and graphs. Additional resqsgsh ot data fiom another
.source rnay be needed to clarify findings.
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Introduction and Aims
Economic and policy evaluations often use secondary processed
data from administrative records, and from experimental and
observational studies. Unit records for a population or study
group may be aggregated to form cross tabulatioru of counts for
subgroups. These counts are commonly used to create rates.
Often the unit record data are not available to the researchers.
Problems can arise with the definition of the original dara, with
aggregation into summary tables and with the formation of
rates.
This paper aims to highlight these problems, suggest some
resolutions and show how a closer investigation of the original
information may change or even reverse policy conclusions
drawn from processed data. The incention is ro show how the
aggregation o,f data to form rates may obscure important
information and lead ro misinterpretation of results.
Demographic or epidemiological rates or indexes are
important summary srrtistics in rhe srudy of communiry health,
environmental health, health economics and policy analysis.
Rates are formed by taking the number of occurrences
(incidence or prevalence) of some event, dividing the number
of these events by the population "a[ risk" and mulriplying by a
convenient constant (for example 1000). If the populadon is
divided or "disaggregared" into groups (for example by age) a
set of "specific" rares is derived, which may behave differently
from the aggregated or "crude" rate. Researchers are ofren
forced to use aggregaced data but are frequently unaware of the
possible consequences of doing so.
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Data Care and the Literature
When a situation is analysed with less detail than it could be,
several problems can arise. These include confusion over the
definitions and meanings of variables, Simpson's paradox, and
the ecological fallacy.
Statisticians consider their discipline to be a scientific enquiry
process (Pfannkuch 1996) which involves care with data
qualiry at all stages. The total sradsdcal process (Lipson &
Jones 1996) includes posing che righr questions, collecting the
right data and examining it wirh care and an eye for the
unexpected. The exploratory approach, where the data is
examined carefully with an open mind, is recognised as an
important altemative to the "confirmatory" approach of
statistical inference. When a research project is based on
administrative records, this exploratory approach is often the
most appropriate. Vhen using secondary data sources, the
definicions and meanings of variables are not always explicit or
clear and this may result in confusion and misinterpretation.
Wild and Seber (1996) illusrare Simpsons paradox (Simpson,
1951). The paradox involves a three-way cross-classification table,
where one of the three factors is a yes/ no variable presenred
using percentages or rates, "ln situacions like this, collapsing
(that is, aggregating) the table and looking at the two (remaining)
factors of interest in isolation can be very misleading."
Frazier (1993) discusses Simpson's paradox in relation to US
educational attainment. In this article Simpsons paradox was
described as showing "... that an average can change in a
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direction opposite from all subgroups if the proportion of rhe
total represented by the subgroup changes". The educational
statistics described revealed that although every ethnic or racial
population sub-group maintained or improved irs average
Scholarship Aptitude Test (SAT) score, there was a dedine in the
combined average score. This decline arose because more srudents
in the lower percentiles in each class were taking rhe SAT test,
The median test taker fell from the 79th percentile to the 73rd
percentile within a class. A more fiming interpretarion of this
data is that educational attainment was rising rather than falling.
Education policy and funding decisions based on the macro data
may have led to inequitable and inefticient resource allocations.
Another example of Simpson's paradox was raised by
Westbrooke (1996, 1997) when commenring on a publication
by Dunstan et al (1995). Dunstan and colleagues studied the
pool of 2984 people who reported for jury service in New
Zealand in a four-week period of 1993. 10.1olo of them were
Maori, and the populacion in the Jury Districts was 9.57o
Maori, which gave a slight over-representarion. However, when
the authors calculated expected numbers of Maori jurors for
each of the ll Jury Districts separately, the actual numbers
were less than the expected numbers in 12 Disrricts (and equal
in the llth). Westbrooke recommended that researchers should
mke care in choosing the level of aggregation at which they
analyse data, and investigate unexpected results.
A further phenomenon with its own body of lirerature is rhe
ecological fallacy (Sreel and Holt, 1995). Frequently, unit
records are aggregated into groups where the unit record values
of a quancitative variable are replaced by the mean values for
each group. The ecological fallacy arises when an analysis based
on aggregared or grouped data produces different results from
an analysis using unit level data. Conclusions based on means
may "give concLr5i6n5 very differenr from those that would be
obrained from an analysis of unit level data, if chey were
available" (Steel and Holt, 1996: 19). This fallacy is also
discussed by Greenland and Robins (1994).
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Our second case is about differences between Maori and non-
Maori hospiral admission for a certain condition. Health care
for Maori is an issue that involves public policy, public debate
and research. Pomare et al (1995: 29) claim, "lt has become
apparent during the last rwo decades that Maori want to define
rhe threar to wellbeing, as well as the possible range of
solutions". To succeed in these aspirations, researchers will
need dara that are appropriately defined, collected and
analysed. There are also issues of control and ownership of
data, research processes, decision making and delivery of
services. Bishop and Glynn (1992 127) assert "Powerful and
rapid changes have occurred in areas like Maori women's
health... since Maori people have been taking control over
their own development and resources in these areas." and they
discuss (1997: 130) research as "empowerment".
Basing policy advice on the results of macro srudies is
recognised as a potential problem by journal editors and by
some government agencies. The British Medical Joumal
(Drummond et al 1996) has published a checklist for referees
and authors of health economic studies. Checkpoint number J2
relates to aggregation and states that major outcomes should be
presented in disaggregated as well as in an aggregated form'
The US Public Health Service in a report on the conducr of
cost effectiveness analysis (Cold 1996) recommends (where
possible) using micro-costing in preference to gross costing
using aggregated dara.
TheTwo Cases
Two cases drawn from published original research are used to
illustrate a number of problems and their resolution. The cases
relate to New Zealand health economics srudies: heart failure
(Scott and Scott, 1996) and benign prosratic hyperplasia (BPH)
(Scott and Scott, 1993). Additional information reladng to
methodology, data, results and conclusions may be found in
these rwo papers.
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Case One: He.art Failure
Fleart fiilureoeeurs when rhe'heart nruscle is darnaged,
overloaded, or exhausted by such conditions as hypemension"
coron'ary aff€ry diseaseo damage to cardiae valvcls,
cardiornyopathy, and a,rrhythmias. The rates for deaths and
hospit"al,admissions fol hean failu're incr,ease wirh age. Ta:ble I
and chart I illusma,re the age and gender speeiftc deadr rates for
heart failure in t 9e calculated frora New Zealand death
cetiftcare data. Using aggregared data, (ages 60 years and oler,
and all ages) the statistics show higher deatlr rates frorn treart
failure for females then for rnales. HoweveS different Par-@rn$
sfllerge when ftve-vearly age-specific rates for 60 years and over
arc us€d. Age"sBecif.ic mortality rates are higher for males rlran.
for female. This is a clear case of Simpsonis Baradox-
The dam"set upon which chart I and table I are based has
three category varBbl,es re,lating rc the New Zealand pop.ulation
of 1992: rwo independent variables (gender and age group),
and one dependent variable (mormlity from'heart failure, ot
not). The moreliry varbble i! strongly related to both the
gender variable and the ag€ gr.oup variable, Ftroweveq the two
independent variables fuender and age group) ar.e strongly
related trhemse,lves'
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Tabte 1: Mortality from heart failure in New Zealand 1992:
numbers, age and gender specific rates
\ge
fears
Deaths
Number
Population
Number
Deaths
Rate per
100,000
Population
age group as a
% of the 60+
total population,
by gender
60-64
65-69
70-7 4
75-79
80-84
84+
Male Female
5I
34
67
t3 10
53 63
90 203
Male Female
59,850 69,480
6l,290 66,210
45,270 57,320
31,540 46,170
L7 ,7 40 3 1,0209,710 23,420
Vlale Female
1
6
L2
22
203
867
4
5
13
4L
299
927
Male Female
30% ?4%
26% 23%
L9% 20%
13% 16%
8% Ll"/"
4% 8%
fotal 59+ 168 288 235.410 293,620 7t 98 i00% 100%
Chart 1: Mortality from Heart Failure in New Zealand 1992
If mortaliry rates are defined by gender alone, or by age group
alone, we get an incomplete portrayal of the informacion from
the data-set. Defining the mortaliry rates by both gender and
age group together provides a more complete picture, which
reverses the effect of gender. Overall, a male is less likely to die
from heart failure than a female. Horvever a male of a specific
age is more likely to fall victim to heart disease than a female of
the same age.
Rate per 100,000 population
1 000
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0
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Age group
Fleart failure is the end resnlt of a nunnber of eardiovaseular
conditions. Elderly peopli may have a mr,rltitude of health
problerns, a nrrruber of which. could cause r:leath or adrnisslon to
hospirals. Accotd,iqg\r, she nurnbers given for people d;6ng f5om
heart fa:rlure may bc overestirnates. Thi$ e-dse demorssates that
researehersneed to be very careful about whar their data really
mean; rhe definitions sf varbblesi and the way these defrnitions
are interpreted when the data is collected.
The main conclusion from this ease is that health policy
decisions made entirely on data aggregated across all age groups
would dir,ect resorrces toryards hearr disease in fe,rnales, while
decisior,rs rnade entirely on age specific rates would direcr
resources towards heart disease in males.
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GaseTwo: Benign Prostatic Hyperplasia (BPH)
Jrvo studies of BPH are discussed. The first is an analysis of
adminisrrative records relating to hospital admissions, and the
second is a comparative community-based study. BPH is a
nonmalignant enlargement of the prostate in men rhat
commonly occurs with ageing.
Prostate enlargement may cause a variery of urinary problems
ranging from acute urinary retention to recunent urinary tract
infecdons. The prevalence of BPH increases with age.
Symptomatic BPH is uncommon in men under the age of 50
but many men of more than 60 years will have some sr,tmPtoms.
By the rime men reach the age of 80 years, 70olo of them will
have significant symptoms of BPH. \(/e wish to use this study to
discuss the apparent differences in prevalence of BPH between
Maori and non-Maori men.
Statistics on admissions for BPH were derived from hospiral
discharge data for all of New Zealand. Hospitel discharge data
includes information on ethniciry, gender, age, diagnosis and
surgical procedures. Table 2 and chart 2 use this admissions
data and combine it with data about the popularion of New
Zealand by age and ethniciry. They presenl the age and
ethniciry specific rates for admissions with BPH as the primary
diagnosis. All-ages hospital admission rate for BPH for Maori is
much lower (0.37 per 1000) compared with non'Maori (2.04
per 1000). For males aged 50 and above, the rate for Maori is
lower (3.37 per 1000) rhan for non'Maori (8.71 per 1000).
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When the data for age 50+ is disaggregated into age grouPs,
che same feature occurs in each age group' The admission
numbers are small (especially outside the 60 '79 age groups),
but the difference in rates is clear and consistent'
Table 2. Hospital Admissions 1988 With Primary
Diagnosis BPH
Chart 2: Hospital Admissions 1988 With Primary
Diagnosis BPH
Clinicians at the rime of the study considered (because rhey
treated very few Mrori men for BPH) that something prorected
Maori men from BPH. However, the higher non'Maori
hospitalisation rates could have resulted from differences in a
number of factors, including: disease prevalence as a result of
generic or lifesryle differences, cultural attitudes to health and
health care, abiliry to access health services, knowledge abour
Asc Mnori N^n- M t
years Admissions Population Rate
Number Number per 1000
Admissions Population Rate
Number Number per 1000
50-54
55-s9
ou-o+
65-69
70-74
75-79
80-84
84+
4 5,220 0.77
4 4,360 0.92
10 2,940 3.4
L4 1,770 7.91
11 990 11.11
9 590 15.25
2 300 6.67
I 140 7.14
87 68,400 1.27
257 68,160 3.77
459 67,150 6.84
645 52,370 12.32
603 40,180 15.01
52s 28,200 L8.62
304 15,110 20.t2
145 7,980 18.3
btal 49+ 55 15.310 3.37 3026 347,550 8.71
Rates per 1000 male Population
25
20
15
10
Age group
Oao=gttol++T??'?9TT?=?60604060
lho€6FFO
health and socioeconomic status. The age profiles of the two
populations are quite differenr, thar is, there are proportionally
fewer Maori in older age groups. As BPH symptoms increase
with age, this will affect the total numbers of admissions and
all-ages prevalence and incidence rates but not age specific
rates. The disparate age profiles explain most of the very large
differences noted in the all-ages rates for admissions. Use of
these rates alone for policy decisions, even though they point in
the same direction as the age specific rates, could be
inappropriate as BPH is an age specific condition.
At the time of this economic study (Scott and Scott, 1993) a
clinical investigation (Nacey et al, 1993) was begun. The
Nacey study found that no statistically signifrcant difference in
prevalence of symptomatic BPH could be demonstrated among
European, Maori and Polynesian men aged 50 years and over.
The crucial difference between the Nacey srudy and the
admission data as analysed by Scott and Scott is that the Nacey
study took a representative sample of New Zealand men, and
asked them about BPH symptoms, whereas rhe admissions dara
involved men who had self-selected by seeking treatment.
Clearly, in this case, hospital admissions were not a measure of
the incidence or prevalence of BPH.
A conclusion from these two studies considered together is
that Maori and non-Maori appeared ro have different rates of
seeking and obtaining treatment. The most likely explanation
for the differences berween Maori and non-Maori age specific
treacment rates are differences in access ro treatment for
economic and social reasons rather than an underlying
difference in disease prevalence. Durie (1994: 201) claims thar
"...the biologicalsubstrate is only one indicaror of health. The
others include spiritual, psychological, interpersonal, family,
economic and environmental dimensions." Pomare et al. (1995:
168) claim that "...Maori have difficulry in accessing health
care services.", and that mainstream services need to be
"...affordable, accessible, appropriate and acceptable".
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lnterpreting the d.ata at fac:e value could lead ts the
conclusion that Maori tnen are not sus€eptible to deve-loping
tsPH and that cornBaradvely fewer health care resources should
be directed rswards Maori BPH health p,roblems than to the
treatment of BFH in non-Meqri" Arnore apgopriate poltcy
would suggest that more resgur€es'should be dire.crcd towards
ensrrring that Maori men lrave access to and seek treatrnent for
BPH problems (for example, consultation with Masri g'roups
and specifically tailored and targeted health promotion).
Pornare et al (19,951 159) note rhat "Maori use health se.rviceJ
differently than non,Maori. Vhen need for health care is taken
inGo acco-rrnt, Maori visit a general practicionet less often than
non-Meori.t'
This secsnd ease also raises the issue of hour well the
cotrRtry's health statistics eollection and analysis syst€rns meet
the needs of Maori, as the health proftles and needs of the two
partner e.ulrures to the Ti:eaty of'!flaiangi are often very
diftetent. In the past much research was designed to meet the
needs of the researcher and the dominant gloup (Bishop and
Glynn 1997.: 176).In di;scussing the irnportance sf,the
conununity perspective, Raebum ( I 994: 338.9) eomrne.nts that
if research inm Maori health is to be *edtpowering", re$earctrers
o...may need ro treass€ss thcii stancen especially with regard ro
rhe tonrnunit' and ts the voicet of those in it."
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Discussion
Researchers may wish to invesrigate a problem using data at the
individual "unit record" or micro level but are often unable to
do so. The degree of aggregation is frequenrly imposed on them
by the form in which rhe dara are available. Individual or unit
data are often not available because of commercial sensiciviry or
confidentialiry with respect to individuals. Frequently,
published data are in tables that have already been aggregated
across important variables, and researchers will not have access
to less aggregated forms. Howeveq it is sometimes possible to
obtain the underlying raw data and conduct a more
disaggregated analysis. For example, Health Statistics New
Zealand publishes aggregated data, but unit record dam, with
the patient identifiers removed, are available in electronic form.
Ifan analysis is based on grouped or aggregated data there
should be some analysis and discussion of the grouping
procedure or of the consequences of aggregation.
Researchers are often confronted with data sets containing
variables which they did not define and for which they did not
control the data collection. These variables will often not
match the research questions precisely. Variables and rares
calculated from them must be treated with care.
When working with counts of events (or condicions) from a
population with diverse features there are two important factors
that should be considered. Firstly features which appear when
the data are disaggregated (and expressed as rates) by the
groups within the population may disappear (or even be
apparently reversed) when the data are aggregaced Eoo much or
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inapprop,riarcly. Seeo.ndly. ra.tes depend on two sets of numberc:
the counts of the events (by grcup) and the counts for the total
nurnbers in the populacion (by goup). The counting by group
of both ev€nts and population rnay be sublect to enorq varying:
interpretations and different definitions.
There is cornpu-tet software currently available and under
development chat will assipr in'these proeedures. General-
purpose srarlsdcal packages (for exantple Data Desk, Minitab
and SYSTAT) enable reEearchen ts wsrk from unit record
data-sets (if they are available) to cros$-tabulationp w,ith rnahy
dirnensions or factors. Recent r,eleases of these pac-kages
facilirare analysis by groups. Spreadsheet softtrare (for example:
Excel) rnakes it very easy for researchers to aggrcgare tables
wifh rnany dimensions into simpler'ones, and to forur rates;
The paekage Supercross (being developed for Statistics New
Zealand)" and similar tools will allow,clicnts, to qpec-ify
cabulasions from pr.oprietary dara-sets (initially the Census
data) which are stoled in confidential u,nit record fonn. A wide
range of cusrornised cross-tabulations may be specified for
Statbtics New Zealand to run on their behali Checks are built
into,rhe sy€tem to ensure that confidentialiry will not be
viiolated.
This paper has not discussed the importantprotlems of
confounding and multicsllinearicy because it was eonsidered
that these are well understood by researohers and that
information is readily available in epidemiology and
eaono.rnetric texts-
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rconclusion
Oecasionally clear exatnples of paradoxes, fallacies and
mioioterptetatisnof daa will arise and be recognised, Nlore
of'tenthe underlyiag protlegrs w{ll be present and will catrse
problems, but will nor qgke tlernselves ev,lden't
ln health econorrrics and in other discip[inesn researchers
often have lirrite'd c-oorrol over gheirstalistical data. These data
may coruistof administtative reqords, with the variables
deftned by other peoplen and with the records csllected in
differenrsituatisns. Unit record dala may not be available, ar,rd
the resear'chers may need ts work with cross'eabulations
provided by other people- Acco,r.dinglyn re$arehers need w tr'ke
gFeat care at all stages in their analyses.
The followirrg. poirits are presented as a summsry.
. lt is esserrtial that each variable ts clearly deffned and described"
. Subgoups of a human population rnay have different
s'tructures, behaviours and needg and investigarors should
be aware of rhese diffetences-
. Dara involving'lvlao,ri health should be analysed and
eonuolled in ways thar me,et the needs of Maori and in
parrnership wigh the affected group,
. Data should be analysed rtsing cross.mbulations which
ihvo-lve disaggregarion to thp lowest possible level. lf sorne
t ariables are found not to inftuEnce the qutcomes, these
vairiables catr be aggregated ro produce tables that highlight
the irnportant infl uerrciqg faetqrs.
. Inereasingavailabilify of unit record da&eets, and srrftwate
rosls to manage and araalyse them, makes sraeh detailed
analysis pracricable"
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Abslroct Objective: The Frrst aim was to identify and determine the economic costs of the
regimens currently used in 3 New Zealand hospitals in the treatment of bacterial
int'ections in haematology patients with febrile neutropenia and in intensive care
patients with severe int'ections. The second was to develop a spreadsheet-based
decision analytic model for use by hospital decision-makers as an aid in evalua-
ting the comparative cost of drug regimens.
Design and setting: The research utilised time and motion and microcosting
techniques. The analytical perspective adopted fbr the study was that of a hospital
administrator or clinical man:rger.
Patients and interventions: Patients were eligible for inclusion in the study if
either they were treated with the imipenem/cilastatin monotherapy, or could have
been treated with this regimen. The final analysis considered 360 patient-treat-
ment days and 8 antibacterials.
lllain outcome measures and results: Drug acquisition cost ranged tiom 4.52
New Zealand dollars ($NZ: 1997 values) per patient-treatment day for gentamicin
to $NZ 104.81 for imipenem. The cost per patient-treatment day (when other cost
components such as fluid additives. giving sets and needles were added) ranged
from $N28.?5 for gentamicin to $NZl29.l2 tor tazobactam. Drug acquisition
cost. as a percentage of total drug preparation and administration cost, ranged
from 52Vo for gentamicin to 937c for piperacillin.
Civing sers and intravenous (IV) fluids were found to be important cost items
when they were required specifically for the treatment regimen. There was a mean
monitoring rate of 0..t0 at a cost of $NZ6.4l per putie nt-trciltment day tbr genta-
micin. It was estimated that nephrotoxicity could add between $N223 and $N243
per day to the cost of aminoglycoside treatment.
l8{ Scott et al.
Conclusions: Although the small sample sizes of the study mean that results
should be regarded as indicative rather than conclusive, there were sufficient
information to construct a working model and show how the total cost of an
antibacterial regimen could be evaluated in practical terms. The imporrant cost
drivers were found to be drug cost, the use of fluids and giving sets, and moni-
toring.
Tightening budgets within the New Zealand
health system have increased the need for clini-
cians and managers in hospitals to consider the cost
of treatment regimens as well as clinical efficacy
and safety when selecting treatment options. Clin-
ical managers and policy decision-makers require
timely and relevant information, and budget and
time constraints usually preclude the design and
execution of randomised controlled clinical trials
for this purpose. Other methods of gathering appro-
priate information should be considered.
There is often limited cost information and a
lack of 'user friendly' analytical tools to assist in
decision-making. Consequently. many patient
treatment cost decisions and selection of prefened
protocols may have been made on drug acquisition
cost alone rather than on the full direct medical cost
of a treatment regimen. Pharmaceutical acquisition
cost is easily identifiable but is only I component
of the total cost of drug therapy.ttl
The overall aim of this research was to identify
and determine the direct medical costs of the re-
gimens currently used in 3 New Zealand publicly
funded hospitals for the treatment of bacterial in-
fections in immunocompromised haematology pa-
tients with febrile neutropenia and in intensive care
patients with severe infections. The study objec-
tives were to identify and measure the total direct
medical costs of the activities and resources asso-
ciated with each treatment regimen, and to develop
a decision analytic model for use by hospital deci-
sion-makers to evaluate the comparative cost of
drug regimens.
Methods
Study Design ohd Porticiponts
The study was collaborative, multicentred and
O Adis lnlernstionol Limifed. All rights reseN€d.
multidisciplinary, involving both clinicians and
economists. It was not a clinical trial evaluating
sal'ety and efficacy but a costing study utilising
time and motion and microcosting techniques.
The target population was patients with severe
microbial infections in intensive care or immuno-
compromised patients with febrile neutropenia in
haematology departments. Patients were eligible
for inclusion in the study if either they were treated
with the imipenem/cilastatin monotherapy, or
could have been treated with this regimen. It was
implicitly assumed by the clinicians that patients
would have infections that would respond to either
imipenem/cilastatin monotherapy or to the alterna-
tive chosen and that the antibacterials were equally
effective and produced identical patient outcomes.
lmipenem/cilastatin is referred to in this paper as
monotherapy because it cannot be broken into its
constituents; the components cannot be adminis-
tered separately. A combination therapy is one in
which the components are separate entities and can
be administered separately. for example, gentami-
cin plus piperacillin. The analytical perspective of
the study was that of a hospital administrator or
clinical manager.
Research was conducted in intensive/critical
care units of 3 hospitals (Auckland Public Hospi-
tal, Christchurch Public Hospital and Palmerston
North Public Hospital), and in the haematology de-
partments of 2 hospitals (Christchurch Public Hos-
pital and Palmerston North Public Hospital). Both
Auckland and Christchurch hospitals were major
hospitals in the largest cities in the North and South
Islands and Palmerston North hospital was repre-
sentative of a large hospital in a provincial city.
Approvals for the study were obtained from the
Canterbury Ethics Committee of the Southern Re-
gional Health Authority, North Health Ethics Com-
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mittee of the Northern Regional Health Authority.
and the Manawatu Wan-ganui Ethics Committee of
the Central Regional Health Authority. Christ-
church was used as a pilot centre to develop the
study protocol and data collection methods. As the
study was observational and nonintrusive. it did
not alter treatment or clinical decision-making nor
were any drugs or consumables provided.
Resource Utilisotion
Drug treatment regimens were defined by clini-
cians and verified by a retrospective analysis of
patient records. Relevant resources were those spe-
cifically required or altered by administering a spe-
cific drug.
A microcosting analysis of the antibacterial
treatment regimens used for serious infections was
undertaken. Microcosting is the most precise and
detailed method of hospital costing.t:'31 We costed
all activities involved with drug preparation. ad-
ministration and monitoring. All consumables
were itemised [e.g. syringes. needles, giving sets,
drugs, fluid additives and intravenous (tV) fluidsl
and we recorded staff time for preparation, admin-
istration and monitoring. Similar listings of cost
items can be found in the articles by Kerr et al..tll
Davis and Brysonlsl and Atkinson et al.tll
Costs that would not be changed by the treat-
ment were not appliclble to the studl'. Those costs
that would be incurred irrespective of the antimi-
crobial treatment regimen used. were also not in-
cluded. For example, the insertion of a central ve-
nous line would not be relevant if all patients.
irrespective of the treatment received, required
such a line. This incremental costing approach was
essential to avoid multiple counting of resource
items that could occur when the cost of a drug regi-
men (consisting of a combination of drugs), was
calculated by adding together the cost of individual
drugs. For example, a giving set may be required
for drug A and drug B but 2 giving sets may not be
needed for the combination regimen A plus B.
Five data collection instruments (sets of forms)
were designed in consultation with hospital statf.
O Adis Internotionol Limited, All rights reserved.
and were then tested and modified where neces-
sary. These data collection instruments were: ad-
ministration (drugs and consumables) fbrm. drug
administration staff time form. monitoring (con-
sumables and laboratory charges) form, drug mon-
itoring staff time form and a rate of monitoring
form. Information was gathered sequentially from
each centre commencing in late November 1995
and ending in March 1997.
Data to complete these forms rvere acquired
from a prospective time and motion study (to quan-
tity time taken and materials used in various stages
of the treatment process) and a retrospective study
of hospital records (chart reviews and laboratory
files). Treatment processes were split into a num-
ber of activities and the component costs of each
activity were identified. A clinically qualified ob-
server recorded staff time, drugs and materials
used for each activity. Resource utilisation unit re-
cords for the study were patient-treatment days.
Data were collected only for complete hospital de-
partment days; incomplete hospital days were ex-
cluded from the analysis.
Resource volumes measured by the microcost-
ing method and unit costs applicable to each hos-
pital were used to convert resource utilisations into
costs mecsured in monetary values. These were re-
corded separately for each centre.
Administration and preparation times were
combined becuuse of the difficulties encountered
with overlap and merging of these activities. Infu-
sion times derived tiom protocols were not mea-
sured by the time and motion study. Analysis was
conducted on groups of items; e.g., syringe sizes
from 5 to 20ml were summed and analysed in ag-
gregate to derive mean resource cost. and resource
volumes used. However. within these aggregates
the actual price tbr each syringe size was used.
Gentamicin was the only drug in the study that
required monitoring. The rate of monitoring was
obtained from a chart and laboratory record review
within each hospital. The monitoring rate was the
total number of monitoring events divided by the
total number of patient-treatment days for genta-
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micin. The microcosting study determined labour
and consumables required per monitoring event.
The resource units per monitoring event from the
microcosting study were multiplied by the rate of
monitoring to give the resource units used in moni-
toring per patient-treatment day.
Costs
Labour rate information relating to nurses, doc-
tors and pharmacists was derived from the litera-
ture,[6] and from consultation with health sector
members. Commercial sensitivity precluded us
from quoting all of the sources or revealing the
precise details of the rates obtrined. Unit costs for
all drugs and consumables were collected from
each hospital. All unit cosrs were prices or churges
and were exclusive of goods and services tax
(GST) which is a transfer paymenr. Alt unit costs
and prices are in 1997 New Zealand dollars ($NZ;
$NZl = $US0.5925, midrate December L997I7l).
Decision Anolytic Model
A deterministic decision analytical model was
constructed and used for sensitivity and scenario
analysis. This modelling approach permitred the
costs of treatment using any antibacterial or com-
bination of antibacterials to be evaluated. The
model consisted of a series of spreadsheets in
which the resource items used (drugs. nondrug ma-
terials and labour) were analysed. Inputs to the
model were mean unit costs and volumes of re-
sources per patient-treatment day. The output
screen provided information on total treatment
cost.
For the purpose of incorporation into this
model, implicit prices per resource unit were cal-
culated by dividing the average cosr per patienr day
by the average volume per patienr day for each dif-
ferent type of unit used. This gave a weighted aver-
age of prices over the 3 geographical centres.
Univariate sensitivity analysis was undertaken
on the major cost components isolated by the data
analysis. Sensitivity analysis (conducted usin_g rhe
O Adls lnternotlonol Limlted. Att rlghts reserved.
model), considered 0 labour costs and a l}Vc de-
crease in drug cost.
Results
Data from a total of 4l I patienr days for drug
preparation and administration was collected from
94 treatment cycles (an average of 4.4 treatment
days per treatment cycle). Final analysis of aggre-
gated drug data was confined to those drugs for
which 20 or more observations (patient days) were
recorded. Thus, the study analysed data from 83
patients, for whom a total of 360 treatment days
were recorded. 20 observations was considered to
be the minimum number required to provide mean-
ingful information. The sample breakdown of pa-
tient-treatment days by centre was as tollows;
Christchurch 53.6?o, Auckland 29.7Vc and Palmer-
ston North l6.7Vo.
Drugs for which sufficient dara were collected
were; amoxycillin (n = 30 treatment days), cefur-
oxime (n = 32), flucloxacillin (n = 23), gentamicin
(n 
= 92), imipenem/cilastatin (n = 90) [abbreviated
to imipeneml. metronidazole in minibag form (n =
2l ) [abbreviated to metronidazole], piperacillin (n
= 52) and tazobactam/piperacillin (n = 20) [abbre-
viated to tazobactam]. Data relating to 8 drugs were
excluded from the analysis because they did not
achieve the minimum sample size of 20 observa-
tions.
Wastage was recorded only for cefuroxime and
gentamicin. Fluid additives, syringes and needles
were used for all drugs except metronidazole,
while giving sets and [V fluids were nor uniformly
required by all drug regimens. Metronidazole had
the lowest labour cost (2.07 minutes) in terms of
administration and preparation time and pipera-
cillin had the highest labour cost (6,7 minutes).
Resource utilisation for preparation and adminis-
tmtion by drug are presented in table I.
Drug acquisition was the major component of
preparation and administration costs. Drug acqui-
sition cost ranged from $N24.52 per patient-treat-
ment day for gentamicin to $NZl04.8l for im-
ipenem. The cost per patient-treatment day (when
Phormocoeconomics 1999 Aug; l6 (2)
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the other cost components were added) ranged
from $N28.75 for gentamicin to $NZl29.12 for
tazobactam. Drug acquisition cost as a percentage
of total drug preparation and administration cost
ranged from 52Vc for gentamicin to 93Vc for
piperacillin. Giving sets and IV fluids were impor-
tant cost items when they were required specifi-
cally for the treatment regimen. Both tazobactam
and imipenem utilised giving sets and IV fluids to
a greater extent than other regimens. Table II pres-
ents the preparation and administration costs for
each drug regimen.
Imipenem and gentamicin were the 2 drugs used
by all 3 hospitals. [mipenem (imipenem/cilastatin)
was the only drug used almost exclusively as
monotherapy. Centamicin was the drug most often
recorded as part of combinution therapy and could
be considered as a reference regimen, as many cli-
nicians implicitly relate other antibacterial regi-
mens to this drug.
The major cost component of monitoring gen-
tamicin was the laboratory charge (657c of total),
with labour (?8%) and consumables (77c) making
up the balance. Monitoring of gentamicin occurred
I t6 times out of 289 patient-treatment days. This
gave a mean monitoring rate per patient-treatment
day of 0.40. The total cost of monitoring was
$NS6.4l per patient-treatment day. Labour was re-
quired for blood collection. obtaining laboratory
results and interpretation of these results. Although
labour cost data were collected separately for these
tasks they have been presented in aggregate. Blood
was normally collected by nurses, while obtaining
laboratory results and interpretation was primarily
undertaken by a clinician. Table lll presents the
monitoring resource costs for gentamicin (the only
drug for which monitoring was recorded).
Sensitivity/Scenorio Anolyses
Univariate sensitivity analysis showed that
when drug prices were reduced by l07c (holding
all other factors constant), the decrease in total cost
for a drug regimen per patient per day ranged from
3Vo f.or gentamicin to 9Vc for the piperacillin regi-
@ Adis Internotlonol Ljmrted, All rlghts reserved.
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men. As would be expected, the magnirude of
change was greater for those regimens in which the
drug cost constituted the highest proportion of total
cost. Gentamicin included a large cost for monitor-
ing, which is reflected in lower trearment cost
changes in response to changes in drug acquisition
cost.
As some managers consider labour costs to be
fixed. we conducted a sensitivity analysis to deter-
mine the effect of eliminating the labour cost (hold-
ing all other factors constanr). This reduced the to-
tal cost of the tazobactam regimen by lVc and the
gentamicin regimen by 22Vc. These analyses are
presented in figure L
Nondrug consumables of different regimens
were found to be important cost drivers. Drugs ad-
ministered by IV push do not require a dedicated
giving set whereas others do (imipenem, metroni-
dazole and tazobactam). The protocols relating to
the use and replacement of giving sets differed both
between hospitals and between the departments
studied within hospitals with some replacing giv-
ing sets with every infusion and others replacing
Iess frequently, but running saline between infu-
sions. Imipenem and tazobactam regimens had
nondrug materials (giving sets and IV fluids)
amounting to over $NZ l5 per parienr per day.
Some drugs recorded as being used for mono-
therapy (e.g., amoxycillin/clavulanic acid, cefu-
roxime, t'lucloxacillin, gentamicin, imipenem and
piperacillin) were also used in combination (more
frequently in the intensive care departments) and
these combinations included up to 4 antibacterials.
The model (used to analyse the results and conduct
sensitivity analysis) was also developed so that
clinical managers could evaluate the cost of any
drug regimen including combination therapies. Ta-
ble II may also be used to obtain rhe costs of prep-
aration and administration of combinations of
drugs. The combinations that occurred most fre-
quently in the study (and theircosts) were: pipercil-
lin plus gentamicin $NZll7.ll ($N2102.34 +
$NZ 14.77 X tazobactam plus gentamicin $NZ 144. I 4
($N2129.37 + $N214.77): umoxycillin plus met-
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Consumables
Laboratory
charge
Labour
Total
Table lll. Monitoring resource costs for gentamicin per patient-
treatment day
Monitoring occurences (M) 1 16
Patient days (P)
Treatment multiplier (T = M/P) 0.4014
Resoutce costs monitoring
CosVmonitoring Cost of monitoring per
(A) t$NZl patient-treatment day
O x A) [SN4
tial information for policy and management deci-
sions rather than clinical decision-making alone'
This was an observational study, with the infor-
mation recorded at the time of the event by a cli-
nically trained observer. In a busy hospital envi-
ronment, a diary in which data are self-recorded
cannot always be written up at the time events are
taking place as clinicians and nursing staff must be
primarily concerned with the needs of the patient.
Data obtained in this manner may not be as accu-
rate as that derived from observational studies in
combination with chart reviews as used in our
study.
Althou-sh there were differences between the 3
hospitals in the prices of antibacterials and other
materials used. most of the variation could be ex-
plained by the timing of purchases and differences
in negotiated prices. Commercial sensitivity pre-
cluded disclosing price and costing data tiom indi-
vidual hospitals. Other investigatorsl8l have en-
countered similar problen'rs with commercially
sensitive data in the UK.
Data on a greater number of drugs were collec-
ted in intensive care departments than in haemato-
logy departments as patients presented with a
1.16
10.38
4.42
15.96
0.47
4_17
1.77
6.41
SNZ = New Zealand dollars.
ronidazole minibag plus gentamicin $N236.03
($N210.96 + $N210.30 + $N214.77)', and amoxy-
cillin plus metronidazole minibag plus gentamicin
plus flucloxacillin $NZ5 I .01 ($NZ 10.96 +
$N210.30 + $N214.77 + $N214.98).
Discussion
It was intended that the study findings and
model developed would be used by clinical man-
agers as an aid in assembling and evaluating essen-
Amoxycillin
Cefuroxime
Flucloxacillin
Gentamicin
lmipenem/cilastatin
Metronidazole
Piperacillin
Tazobaclam/piperacil lin
tr
EI
10o6 reduclion in drug price
Labour cost = 0
5 10 15 20
Reduction in cost from the base case (o/")
Fig. 1. Sensitivity analysis conducted using a decision analytic model. The model considered 0 labour costs and a 10o/o decrease in
drug cost.
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greater range of conditions requiring a wider vari-
ety of drug treatments. At study outser, the range
of antibacterial regimens was not known with cer-
tainty and the number of eligible drugs expanded
as the study progressed. To achieve our second ob-
jective (that of designing an acriviry costing model
that could be used for any antibacterial), we had to
ensure that we captured the full range of activities
and resources that could be encountered in prepa-
ring, administering and monitoring an antibacterial
regimen. The drugs excluded from the final analy-
sis (because of insufficient sample size) would not
have provided any additional information on acti-
vities or consumables.
Wastage of antibacterials, defined as the unused
portion of a pack. occurred with 2 drugs only.
While wastage may indicate that an inappropriate
pack size has been used or that the appropriate pack
size was unavailable, wastage will not necessarily
add to costs. For example. it may be more time
consuming for staff to use a number of smaller
packs, and/or a combination of smaller pack sizes
may be more expensive than I larger pack.
Administration and preparation times were
combined in the analysis because in many in-
stances, it was difficult to diff'erenriate between the
2 tasks. There was little dift'erence in preparation
and administration times either between hospitals
or between departments and the dit'terences that did
occur may be explained by some staff not being as
familiar with routine procedures as other more ex-
perienced staff or by difficulties with a parient.
Delivery systems such as oral and rectal are less
intensive on staff time than IV push or infused
medications.tll Although infusion was the method
of delivery used in tazobactam, metronidazole and
imipenem regimens. the infusion times were not
included because it would be possible for nursing
staff to perform some other tasks concurrently.
From the protocols of the regimens evaluated. in-
fusion times range between 20 minutes and an
hour. A hospital's financial costs (monetary out-
lays) with respect to nursing staff will not normally
be lowered by reducing the labour componenr in
O Adis Internotionol Umited. All riohrs reserved.
the administration of drugs because these patients
frequently require one to one nursing. There is,
however, an opportunity cost as the nurse could be
providing other care to the patient.tll Norrbytel
comments that unless staff numbers can be reduced
or a hospital ward can be fully or partially closed,
there will not be a financial saving.
Drug protocols are continually evolving and
during the course of the study, an important change
occurred rvith respect to gentamicin. There was a
move towards once daily gentamicin administra-
tion and a reduced frequency of monitoring. Our
study found that monitoring was conducted on
average every second day. From a cost point of
view, this actual practice finding is more important
than a protocol best practice. The model is de-
signed so that protocol changes such as this can be
taken into account.
The dru-e regimen chosen by a clinician is deter-
mined by known adverse reactions, organism sen-
sitivity and the patient's severity of illness. This
study did not take into account the spectrum of
cover of the various antibacterials and the suscep-
tibility of micro-organisms to specific antibacteri-
als. Many of the recently introduced antibacterials
such as imipenem and tazobactam have a broader
spectrum ofcover than the older products and have
been used to treat infections caused by both gram-
positive and gram-ne-cative organisms. Narrow-
spectrum antibacterials are often combined (e.g..
triple combination therapy) to provide the same
spectrum ofcover provided by a single broad-spec-
trum agent. When comparing costs of antibacterial
regimens otfering the same coverage. the additive
costs of a combination regimen should be taken
into account and compared with the cost of a single
agent. The model developed enables these compar-
isons to be made. For example, a piperacillin plus
gentamicin combination would cost $NZll7.ll
compared with $NZl29.l2 for tazobactam mono-
therapy.
A full economic study of a treatment requires
the evaluation of patient outcomes, drug acquisi-
tion cost. preparation and administration costs,
Phormocoeconomrcs 1999 Aug; 16 (2)
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monitoring, length of hospital stay and the cost of
adverse events.il0.lll A limitation of the study was
that it did not consider different patient outcomes.
While the cost of adverse events is acknow-
ledged as important, the evaluation of such events
is difficult for the following reasons. Very large
numbers of patients are required to detect infre-
quently occurring adverse events. It is also difficult
to attribute an adverse event to a particular compo-
nent when a combination of drugs is usedll2l or in
a situation in which regimens are continually
changing. There are also problems in determining
if an event is a result of the treatment or the under-
lying condition of the patient.
It is therefore hardly surprising that t-ew studies
have identified statistically significant differences
in adverse events between antibacterial regimens.
Atkinson et al.tll were unable to evaluate the cost
of adverse effects such as nephrotoxicity, super-
infection and complications of IV lines. Other in-
vestigators,[a'81 have also omitted evaluating the
cost of adverse effects. However, Eisenberg et
al.,[13] using a sample size of 1756 patients infected
with psecudomonas aeruginosa, estimated that
nephrotoxicity added $US 103 ( 1987 values) to the
average cost of each patient receiving aminoglyco-
sides. Using the rate of nephrotoxicitytl:t of 7.3Vc
and New Zealand hospital costs [$NZ1297 for
Australian Diagnosis-Related Group (AN-DRG)
587 
- 
other kidney and urinary tract diagnoses
without complicating conditions - and $NZ2-tS-l
for AN-DRG 586 
- 
other kidney and urinary tract
diagnoses with nonmajor complicating condi-
fisntr+l (199611997 values)1, we estimare rhar rhe
additional cost per patient treated with aminogly-
cosides could range between $N295 and $NZl8l
(or, if based on the average days per treatment cy-
cle for gentamicin in our study of 4. l8 days, neph-
rotoxicity would add between $N223 and $NZ-t3
per patient day). For example, if the cost of adverse
events of $N223 per day is added to the costs of
combination piperacillin plus gentamicin, the cost
per day increases from $NZ I I 7 to $NZ 140.
g Adls Internotlonol Umited. All dghts reservecl.
Univariate sensitivity analysis showed that the
total cost of the regimen was inelastic with respect
to percentage drug price changes, with the total
cost response being less than the percentage
change in price. As would be expected. the percent-
age change in total cost was greatest for those re-
gimens in which the drug cost constituted the high-
est proportion of total cost. Gentamicin was the
only drug requiring monitoring and. as this in-
volves additional labour, the scenario of setting
labour costs to 0 had a major impact of reducing
this regimen's total costby 72Vo.
The nondrug consumables (giving sets and IV
fluids) were important components of the total cost
for both imipenem and tazobactam regimens. As
giving sets and IV fluids made up l4Vc and 20Vc,
respectively, of these regimens, any changes to ei-
ther the unit cost of these consumables or to proto-
cols determining utilisation rates would have im-
portant cost consequences.
Incremental costing was applied to all cost
items; thus, it is possible to add the individual drug
total costs to obtain a total regimen cost. If incre-
mental cost estimation had not been used, there
would be serious multiple counting of costs when
multidrug regimens were evaluated. It is recom-
mended that clinical managers use such a costing
tool at regular intervals or when prices and treat-
n'lent protocols change, but in doing so, be careful
to avoid double counting and being too prescrip-
tive in recommending protocols. As patients differ
in the nature and severity of their illnesses. it is
important to be able to cost a wide range of treat-
ment protocols from the basic cost components.
Although the sample sizes of the study mean
that results should be regarded as indicative rather
than conclusive, the study provided sufficient in-
formation to construct a working model and show
how the full cost of an antibacterial regimen could
be evaluated in practical terms. The results can be
generalised in that treatment for serious infections
is a common occurrence and will be ongoing in the
2 departments studied in all hospitals. The impor-
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tant cost drivers were found to be drug cost, the use
of fluids and giving sets, and monitoring.
Conclusion
The study identified and measured the eco-
nomic costs of the activities and resources associ-
ated with each treatment regimen for serious infec-
tions, and developed a decision analytic model for
use by hospital decision-makers. The model is a
tool to aid in the evaluation of the comparative cost
of regimens involving up to 4 drugs and the asso-
ciated consumables and labour costs for each drug.
A copy of the spreadsheet-based model was given
to each hospital department involved in the study.
The study found that drug acquisition costs were
the most important cost itcm but the use of giving
sets and IV fluids were important cost drivers if
required specifically for an antibacterial treatment.
Lack of information on treatment outcomes meant
that our results, while providing useful costing in-
formation, could not be used for cost-effectiveness
analysis. Ideally, a large multicentre study is re-
quired to provide data on treatment outcomes, par-
ticularly adverse events of treatment regimens used
in New Zealand.
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Annual Costs of Benign Prostatic Hyperplasia in
New Zealand
W. Guy Scott and Helen M. Scott
W. Guy Scott and Associates Ltd, and Wellington Polytechnic, Wellington, New Zealand
Summary Benign prostatic hyperplasia (BPH) has been regarded as part of the normal aging process in
men and little attention has been focused on the cost of the disease in New Zealand. The purpose
of this study was to estimate the direct and indirect costs of treating BPH in both the publiCand
the private sectors in New Zealand. The costs of treatment were estimated from public and private
hospital data on admissions for BPH, obtained from the New Zealand Department of Health,
medical insurance reimbursement schedules, hospital ward costs at one centre, and urology and
general practitioner consultation fees. The length of time spent off work, as a measure of indirect
costs, during urological investigations or treatment was estimated from interviews with urologiss.
The annual 1991 total direct medical costs of treated BPH as primary diagnosis in New Zealand
were estimated at $NZl6 million (the average of the end-month mid-point exchange rate for the
first quarrer of 1992 was $US0.5457 per $NZl ), and the costs of lost production plus loss of leisure
time by patients was estimated at $NZ4 million ( 1992 dollars). Patients with a principal diagnosis
of BPH stayed on average 8.9 days in a public hospital and 4.6 days in a private hospital. Based
on the above costs, if the average length of stay of public hospital patients could be reduced to
that of private hospital patients, then hospital ward costs for BPH could fall by 37Vo and the total
direct medical costs by Zl%o.
The most commonly performed surgical operation for BPH was transurethral prostatectomy
(TURP). For operations performed in a public hospital, patients stayed on average 8.5 days, while
patients whose operations were performed in private hospitals stayed 4.3 days. The mean age of
these public hospital patients was 7l years compared with 67 years for those in private hospitals.
A complication rate of 2.OZVo was recorded for TURP in public hospitals but audits (conducted
by the researchers) in both public and private settings indicated that the complication rate was
substantially under-recorded.
Benign prostatic hyperplasia (BPH) is a non-
malignant enlargement of the prostate that com-
monly occurs with aging (Bany 1990). Enlarge-
ment of the prostate may cause a variety of urinary
problems ranging from acute urinary retention to
recurrent urinary tract infection (Christensen &
Bruskewitz 1990). The frequency of occurrence of
BPH increases with age: by 80 years of age,70Vo
of men will have significant symptoms of BPH
(Cockett 1992). BPH is uncommon in men under
the age of 50 but most men aged over 60 years will
have some symptoms of prostatic enlargement
(Griffiths 1992).
BPH manifests itself in the following symp-
toms: the sensation of incomplete bladder empty-
ing, a hesitant urinary stream, slow urinary flow,
urgency, a need to push or strain to start urine flow,
and nocturia (McConnell 1992). Over a period of
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several years the condition of one-third of patients
will improve spontaneously, that of one-third will
remain stable while that of one-third will deterio-
rate. Appropriate treatment options are watchful
waiting, surgery or pharmacotherapy (Denis 1992).
In New Zealand, a patient with symptomatic
BPH will usually present first to a general practi-
tioner who will normally refer the patient to a spe-
cialist urologist in a public hospital or in private
practice. This treatment profile was established on
the basis of qualitative research involving a small
number of general practitioners and specialists. At
the time of the study the New Zealand population
was 3.4 million (Department of Statistics 1992).
There were approximately 2300 practising general
Table l. Assignment of costs of benign prostatic hyperplasia in
New Zealand
Direct medlcal costs
Ambulance/private transport
Hospital ward
Surgical operations
Outpatient and specialist consultations
Ancillary hospital stafi (e.9. district nurse)
General practitioner consultations
Pharmaceutical prescribed (hospital and community)
Dispensing fees and container allowances
Diagnostic procedures and laboratory tests (hospital and
community based)
lndirect plus nonmedical costs
Production loss by patients
Production loss by unpaid care-givers
Leisure time loss by palients
Leisure time loss by unpaid care-givers
Transport costs of patients'family and friends
Services by community and voluntary organisations
Medical research
Addilional laundry costs and protection aids
Additional costs associated with premature entry into
residential care
lntangible costs
Quality of llfe of patient, family and friends
Loss of life
practitioners who have a 'gatekeeper' role in the
health system and 34 practising urologists based in
the main population centres. Urologists may work
in public or private practice, or both, and may be
involved in teaching and in hospital management.
The New Zealand healthcare system is a mixture
of both public and private sector providers. Public
and private spending on health in New Zealand in
1992 was 7.6Vo of gross domestic product
(McKendry & Muthumala 1993). Most hospital
care is provided free of patient charges, orat a nom-
inal charge, by public hospitals.
The purpose of this study was to estimate the
direct and indirect costs of treated BPH in both the
public and the private sectors in New Zealand.
Methods
Hospital Data
Public and private hospital data and mortality
data for the year ending December 1988 were ob-
tained as unit records from the Health Statistical
Services (HSS) of the Department of Health (see
Appendix). These official statistics cover all hos-
pital patients and all deaths, for the whole of New
Zealand. Subsets of this database were extracted
for detailed analysis. HSS diagnoses A, B, C, D
and operations I ,2, 3 refer to multiple diagnoses
and procedures, respectively, in public hospitals
(see Appendix). HSS data for private hospitals re-
cord data for only I diagnosis and 1 operation per
admission.
Audits
Audits of urology consultations and surgery in
both public and private settings were used to col-
lect information on BPH when this was unavailable
from existing data sources. Audits were undertaken
in the last quarter of l99l by 2 consultant urolo-
gists and support staff in 2 centres and covered
patients in both private and public settings. The
audit of consultations (n = 117) covered: (a) the
place of consultation; (b) the age of the patient; (c)
the type of consultation (e.g. first/postoperative
visit); (d) the referral source; (e) diagnostic proce-
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dures; (f) laboratory tests; (g) medicines pre,
scribed. The audit of surgical procedures covered:
(a) surgical procedures; (b) days in hospital; and
(c) perioperative and late postoperative complica-
tions. The audit information in this study should be
regarded as indicative rather than conclusive, as
the sample size was not sufficiently representative
to enable statistically precise quantitative conclu-
sions to be drawn.
Costs
The costs of BPH from the perspective of New
Zealand society were classified into 2 categories:
direct medical costs and indirect plus nonmedical
costs (table I).The latest available patient volume
data (at the time of data analysis) were combined
with March quarter 1992 prices to calculate total
economic costs on an incremental basis. As the per-
spective taken was that of society, transfer pay-
mentsl such as taxes, subsidies and welfare bene-
fits were excluded. In the absence of reliable public
sector costs,2 prices from the private sector were
used to estimate direct medical costs, but these pri-
vate sector prices included profit which was un-
quantifiable. The impact of including private sec-
tor profit is likely to be offset by higher cosrs in rhe
public sector, where hospitals may have a teaching
component and be more likely to treat patients who
are at risk of death or complications because of
their age and/or health status.
The Southern Cross Medical Care Society3
medical insurance schedule of fees for reimburse-
ment for surgical and anaesthetic procedures cur-
rent in the March 1992 quarter was used to estimate
I [n New Z,e.aland, the goods and services tax (GST) is a
cost from the perspective o[an individual parient or individ-
ual hospital but is a transfer payment ifthe perspective ofall
society is taken.
2 Reliable and detailed public sector costing data in New
Zealand are not readily available for economic research and
in many instances the data do nor exist. Such data, if they
exist, are regarded by most hospitals as commercially sensi-
tive. Available data are difficult to interpret, as some costs
differ by more than 1007o between area health boards, and
different items are included in cost breakdowns from differ-
ent area health boards.
prices of preoperative consultation fees, surgery
and anaesthetics. The first postoperative visit was
included in the surgical fee, but subsequent follow-
up visits were generally charged separately.
Direct Medical Costs
Not all the costs of the resources used by the
healthcare system in caring for BPH patients could
be quantified. The coding categories of the New
Zealand Ambulance Board statistics were too
broad to enable the costs of ambulance transporta-
tion for patients with BPH to be evaluated. Data
on the numbers or costs of visits by ancillary hos-
pital staff, such as district nurses and social work-
ers, to patients after they were discharged from
hospital, were unavailable because of their com-
mercial sensitivity.
Hospital Ward Costs and Operations
A daily ward cost of $N2284.44 was used,
based on data from Wakefield Hospital, Wellington
(personal communication 1992), cross-checked
with the New Zealand Private Hospitals Associa-
tion survey (1991) and Resource Utilisation Sys-
tem (RUS)a data from Christchurch Hospital, New
Zealand. This daily bed rate (which includes the
cost of medicines and other consumables used in
the ward) was applied to all hospitals.
The ward stay cost per patient per day in a sur-
gical ward of Wellington Hospital was estimated
at $N2300 (1989 New Zealand dollars)[Stewart
et al. 19921, This ward stay cost was adjusted to
first quarter 1992 prices (Scott 1990) to obtain a
value of $N2330 which was used for sensitivity
analysis and which represents a l6Vo increase over
$N2284.44 (our baseline estimate of ward costs).
Adjustments were made by using 8O7o of the in-
crease in the Prevailing Weekly Wage Rate Index
for central government, and 2OVo af the change in
3 The Southern Cross Medical Care Society has operated
in New Zealand for over 30 years, owns several hospitals,
and has about 807o of the health insurance market covering
one-third of the total population.
4 The RUS is a manaBement database system that allocates
all costs that make up the total cost of a patient's stay, except
for the cost of buildings and equipment.
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the Producers Price Index for inputs to central gov-
ernment. Weighting factors of 80/20 were used
because in a New Zealand hospital the breakdown
of expenditure on inputs is approxim ately 80Vo
staff costs and 207o purchases of other goods and
services.
Unit prices for BPH operations do not include
the ward costs for the hospital stay. Prices in com-
bination with the number of operations were used
to derive total costs for all surgical operations.
Outpatient and Specialist Consukations
As there were no national data it was presumed
that each patient admitted to hospital would see a
urologist before his admission, in either a private
practice or a public hospital outpatient or accident
and emergency department. This first consultation
was evaluated at $N280 (Southern Cross Medical
Care Society 1991), It was also estimated that every
patient discharged live from hospital would have a
postdischarge consultation valued at $N256
(Southern Cross Medical Care Society 1991).
However, the urology audits indicated that the
number of consultations could be 50Vo higher than
this estimate, and this was taken into account in the
sensitivity analysis.
Ge ne ral P ractition e r Cons ul tations
Survey data relating to consultations for a pri-
mary diagnosis of BPH were obtained from Inter-
continental Medical Statistics (IMS) 1992 (see
Appendix). Thdse data, together with an average con-
sultation fee of $N227.56 (Health Benefits l99lb)
were used to calculate the cost of consultations.
Pharmaceuticals, Dispe ns ing Fee s and
Container Allowances
Total sales volumes of pharmaceuticals pre-
scribed for BPH at general practitioner level were
derived from New Zealand survey data (IMS
1992). New Zealand wholesale and retail markups
(Pricing Schedules l99l) were added to the cost at
the manufacturer selling price (IMS 1992). The to-
tal cost of pharmaceuticals was obtained by multi-
plying the number of prescriptions by the average
dispensing fee plus container allowance5 (Pricing
Schedules l99l ). No data were available for drugs
prescribed by specialists in private practice or in
hospitals.
l-aboratoryt Tests and Diagnostic Procedures
No published national statistics were available
for tests and procedures. Volume data from the con-
sultation audits were combined with the fees which
the government pays for laboratory diagnostic ser-
vices (Health Benefits l99la).
Indirect plus Nonmedical Costs
On the basis of in-depth interviews with a num-
ber of urologists, the loss of production for men of
working age (< 65 years of age) was estimated at
2 weeks inclusive of surgery for surgical patients,
and I week for patients who were admitted to hos-
pital but who did not undergo surgery. The assump-
tion was also made that an equivalent amount of
leisure time would be lost by men aged 65 years
and over. Production and leisure time loss by pa-
tients was valued by multiplying the number of
days of output forgone by the average male gross
weekly earnings for the March quarter 1992
($NZ654.14)[Department of Statistics 1992] as a
proxy for the economic value of lost output.6
The following costs were either unquantified
or not isolated because of inadequate data: ambul-
ance; ancillary hospital staff; transport costs of
patients, family and friends; services provided
by community and voluntary organisations; medi-
cal research; additional laundry costs and protec-
tion aids; premature entry into residential care;
additional home help when a patient is partially
incapacitated.
5 Pharmacists are reimbursed by the New Zealand Govern-
ment for the pharmaceutical ingredients plus markup, plus a
dispensing fee, plus an average allowance for the pharma-
ceutical container.
6 In the absence of more specific information, leisure time
for individuals who are not in paid employment was valued
on the same basis as production loss for those who are in paid
employment. Leisure time for individuals in paid employ-
ment was not evaluated.
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Intangible Costs , .
Our study attempted to collect information on
aspects of the quality of life of patients with BPH.
A search was undertaken to ascertain the existence
or otherwise of patient support groups within New
Zealand and studies on urinary incontinence (both
published and unpublished) that may have been
conducted. Loss of life was not quantified in mon-
etary terms.
Resuhs
Hospital admissions in New Zealand are re-
corded at the time of hospital discharge or death.
Table II shows the age-specific discharge rates
from both public and private hospitals. In 1988, for
every 1000 men of all ages with BPH, 1.9 either
were discharged from, or died in, a hospital. The
equivalent rates for men aged 50 years and over
were: MaoriT 3.4, non-Maori 8.7 and all men 8.5.
These data suggest that the prevalence of BPH
among the Maori population could be lower than
that for non-Maori.
Admission data (BPH Diagnosis A) for public
hospitals were analysed with respect to admission
type (arranged, acute, or waiting list refenal) and
the referral source of admission (general practi-
tioner, specialist, outpatient, accident and emer-
gency department, another hospital). Comparable
data were not available from private hospitals. 597o
of admissions came from waiting lists, 277o were
emergency (acute) admissions and l4%o were ar-
ranged by general practitioners, specialists or hos-
pital outpatient departments. Some patients with
acute urinary retention present directly at accident
and emergency (A & E) departments of public hos-
pitals. Most hospitals admit patients directly to the
7 Maori made up 97o of the population in 1990 (Depart-
ment of Statistics 1992), but had a younger demographic
profile than that of the total population. Maori at all ages have
higher levels of mortality and morbidity, and lower life
expectancy, than do non-Maori citizens. Some of these dif-
ferences may be explained by different genetic charac-
teristics, by cultural practices relating to health and the use
of health services, levels of educational attainment and
socioeconomic status.
Table ll. Admission rates per 1000 of population (1 988) for patients
with benign prostatic hyperplasia as primary diagnosis, assessed
from rates of discharge from public and private hospitals or death
in hospital
Age range (y) All patients Maori Non-Maori
0.003
0.066
0.208
1.236
e too
6.691
12.172
14.914
18.548
19.857
18.421
1.888
8.471
a Individual columns may not add to the totals shown because
of rounding.
appropriate ward, but some major hospitals admit
all patients through their A & E departments.37Vo
of patients were referred for admission by special-
ists,32Vo by outpatient departments,23Vo by gen-
eral practitioners, 5Voby an A & E department, and
2Vo by other hospitals.
Analysis of admission data indicated a greater
degree of monitoring by general practitioners in
small centres and rural areas located at some dis-
tance from a urologist. Cross-tabulations of gen-
eral practitioner (referral source) with waiting list
patients (admission type) and place of residence
showed that all 39 patients thus identified came
from small to medium-size towns, cities and coun-
try areas having no resident urologist. Similar data
cross-tabulations for arranged admissions also
showed that the majority of such patients (77)
came from small towns and rural areas.
Almost all patient discharges were classed as
routine: 97Vo from public hospitals, and99Vo from
private hospitals. LVo of public hospital patients
and 0.4Vo of private hospital patients died in hos-
pital.ZVo of public hospital patients, and almost 17o
0-39
40-44
45-49
50-54
55-59
60-64
65-6S
70-74
75-79
80-84
>85
Totala
>50
<0.001 0.003
<0.001 0.071
0.154 0.212
0.766 1.272
0.917 3.771
3.401 6.835
7.910 12.316
11.111 15.007
15.254 18.617
6.667 20.119
7.143 18.296
0.369 2.042
3.372 8.707
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Public 1982
Private 1128
Alt 3110
Table lll. Hospital ward costs for all patients with benign prostatic
hyperplasia as primary diagnosis (1988 volumes, 1 992 prices)
type patients days length day cost
of stay ($Nz) ($Nz
million)
while the mean age of those in private hospitals
was 67 years.
Table IV describes the breakdown of surgical
operation unit costs (exclusive of ward costs) for
the surgeon, anaesthetist and operating theatre for
each operation. Prices in combination with the
number of operations were used to derive a total
cost for all hospitals of $N24.742 million
($N22.872 million for public hospitals and
$NZl.87l million for private hospitals). Table V
gives the cost by operation for both public and pri-
vate hospitals.
Complications of surgery, as recorded in diag-
nosis B, were extracted from HSS public hospital
data relating to operation l, BPH diagnosis A.
(HSS data were not available for private hospitals.)
Postoperative complications for all TURP proce-
dures (1235 operations), in order of frequency of
occurrence, were: haematuria, pneumonia, myo-
cardial infarction, urethral stricture, septicaemia,
Table lV. Prices for surgical operations ($NZ, March quarter 1 992).
Sources: surgeon and anaesthetist prices from the Southem Cross
Medical Care price schedule, and operating theatre charges from
Wakefield Hospital, Wellington, checked against the New Zealand
Private Hospitals Association survey data. Cystoscopy and ure-
throscopy prices were used to cost procedures for WHO code 601
WHO code and Surgeon Anaesthetist Theatre Total
description
600 lncision of
prostate
601 Diagnostic
proceoures on
prostate
602 TURP
603 Suprapubic
prostatectomy
604 Retropubic
prostatectomy
606 Other prosta-
tectomy
609 Other opera-
tions on the
proslate
Abbreviationsi TURP = transurethral prostatectomyi WHO =
World Health Organization.
17 662 8.91
5 224 4.63
22886 7.36
284
284
284
of private hospital patients, were transferred to
other care-giving institutions such as nursing
homes or other hospitals. Reasons for the transfer-
rals were not recorded.
Hospital Ward
Analysis of admission and discharge dates for
BPH Diagnosis A showed that the mean length of
stay was higher for patients admitted to public than
private hospitals (8.9 compared with 4.6 days, for
patients of all ages; 6.5 days compared with 3.9
days for those patients under 65 years of age). Av-
eraged over all hospitals, the mean length of stay
was 5.2 days for patients under 65 years of age
compared with 7.4 days for patients of all ages. The
total annual hospital ward costs were estimated to
be $NZ6.5l million based on the total number of
days in hospital and the cost per patient per day.
Table III describes ward costs and how these were
calculated.
Surgical Operations
In New Z,e,aland the operation that is most com-
monly performed for BPH is transurethral prosta-
tectomy CIURP). In public hospitals TURPaccounted
for9I.4Vo of all prostatectomies. Retropubic (4.47o)
and suprapubic (3.67o) and other prostatectomies
(0.5Vo) accounted for the balance (diagnosis A, op-
eration l). In private hospitals TURPaccounted for
98.7Vo of all prostatectomies.
The average length of stay for patients having
TURP in a public hospital was 8.5 days compared
with 4.3 days for private hospital patients. The
mean age of public hospital patients was 7l years
5.024
1.486
6.510
516
142
1022
1022
1022
1022
516
93
zot
267
267
267
187
200
444
622
436
1733
19't1
1911
1733
969
4M
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Table V. Cost of surgical operations for benign prostatia hyperplesia in New Zealand (1988 volumes, $NZ, 1992 prices)
601 Diagnostic procedures on prostate
WHO code and
description
600 Incision of prostate
number
cosl per operation
total cosl
number
cost per operation
total cost
602 TURP
number
cost per operation
total cost
cost per operation
total cost
3
969
2907
58
436
2s262
1 457
1 733
2525 462
1 911
110 844
Privateb
't 063
1 733
1 842 530
3
5 733
64
27 876
4367 992
61
116 578
WHO code and Publica
description
604 Retropubic proslatectomy
number 96
cost per operatlon 1 91 1
total cost 183 467
606 Other prostatectomy
number 7
cost per operation 1 733
total cost 12 133
609 Other operations on the prostate
number 12
cost per operationc
total cost
All operations
numDer
lotal cost
969
11 627
1 691
2871 702
Privateb Atl
4
1 911
7 644 191 111
11 627
1 083 2774
1 870654 4742356
603 Suprapubic prostatectomy
number 58
a Diagnosis A-D (primarysecondary etc), operations 1-3 (for benign prostatic hyperplasia).
b Diagnosis A, operation 1.
c Same as 600.
Abbreviations: TURP 
= transurethral prostatectomy; WHO = World Health Organization.
cardiac arrest and urinary retention. The complica-
tion rate for TURP was 2.O2Vo, and for all prosta-
tectomy operations 2.3 | Vo.
From a total of 79 patients in the audits of sur-
gical procedures (in both private practice and pub-
lic hospitals) 33 patients presented with periopera-
tive complications (within 30 days of surgery) and
25 patients presented with late postoperative com-
plications (over 30 days). The rate for periopera-
tive complications was 42Vo and 32Va for postop-
erative complications and surgical failure. All 79
patients had a TURP.
Perioperative complications recorded were: spi-
nal headache (8 patients), clot retention (5), failure
to void (4), haemorrhage requiring a transfusion (4),
transient impotence (3), urgency or urinary fre-
quency (3), electrolyte imbalance (2), sepsis 
- 
uri-
nary infection (l), respiratory insufficiency (l),
myocardial ischaemia (l), and transient inconti-
nence (l). Late postoperative complications re-
corded were: retrograde ejaculation (ll patients),
partial retrograde ejaculation (3), bladder neck
stenosis (3), urethral stricture (2), nocturia (l),
urinary tract infection (l), stress incontinence (l),
and slight post-void urinary dribbling (l). One
patient showed no improvement and one required
reoperation.
Outpatient and Specialist Consultations
The costs of outpatient and specialist consult-
ations were calculated to be $N20.285 million.
Table VI describes how outpatient and specialist
consultations were costed.
General Practitioner Consultations
In l99t there were 8500 consultations for BPH
in New Zealand at a cost of $N20.234 million. All
these consultations were for patients aged 40 years
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Table Vl. Costs of outpatient and specialist con$ultationd for
benign prostalic hyperplasia in New Zealand (1988 volumes, 1992
prices)
Consultation Patient Cost per Total cost
consullations consultation ($NZmillion)
($Nz;
Pre-admission 3110
After discharge 637a
Total
(507o of patients), and postdischarge urine culture
(5OVo of patients). The total cost of these tests to
New Zealand was $N20.189 million. Table VII
itemises the laboratory tests routinely undertaken.
It shows the number, unit cost, and total cost for
each test.
The procedures undertaken were: intravenous
pyelogram, abdominal x-ray, chest x-ray, abdomi-
nal ultrasonography, urinary flow rate and electro-
cardiogram (ECG). It was clear that nearly all
patients had an x-ray. The price of a chest x-ray
($N246.22) [Wakefield Hos pital 1992) was multi-
plied by the 3ll0 patients who received an x-ray,
to give a total cost of $N20.144 million. As the
older and 'at risk'patients were more likely to have
chest x-rays, ECGs, blood tests, the quantified
costs underestimate the cost of diagnostic proce-
dures and laboratory tests. Although the audits
showed that these diagnostic procedures were un-
dertaken, the data were insufficient to extrapolate
for all specialist consultations.
Lost Production and Leisure Time
Loss of production during hospitalisation and
recuperation for all 850 patients under 65 years of
age (BPH Diagnosis A) was estimated to be
$N21.082 million. This estimate was calculated on
the basis of 2 weeks off work per patient undergo-
ing surgery (804 patients) and I week per patient
Table Vll. Laboratory tests (1988 volumes, 1992 prices)
Number Unit cost Total($NZ1 cost
($Nz
million)
80.00
56.00
0.249
0.036
0.285
a These patient numbers are derived from the 3110 patients ad-
mitted with BPH diagnosis A, less the 2467 patients who
had BPH diagnosis A and at least 1 operation for BPH,
less 6 patients who had no operation and died. This adjust-
ment was made because the surgeon's fee normally in-
cludes 'l posloperative visit.
and over, a rate of 14 per thousand men. Over the
same period there were 3612 hospital admissions
for BPH, which indicates that for every l0 consult-
ations for BPH at general practitioner level there
are 4 hospital admissions.
Pharmaceuticals, Dispensing Fees and
Container Allowances
The 3351 prescriptions (written by general
practitioners), when combined with container al-
lowances of $N20.18, a dispensing fee of $NZ2.l6
per prescription and the cost of the drugs at a phar-
macy selling price of $N20.144 million, gave a
total of $N20. 152 million. Audits of urologist con-
sultations indicate very little prescribing at this
level, as the records showed that only 2 pharma-
ceuticals (phenoxybenzamine hydrochloride and
oxybutynin chloride) were dispensed for a total of
I l7 urologist consultations. Costs of drugs pre-
scribed at hospital and specialist levels were not
included because data were unavailable.
Laboratory Tests and Diagnostic Procedures
The audits indicated that the following labora-
tory tests were routinely undertaken for all patients
in both public and private settings: urine culture;
prostatic acid phosphatase; prostate-specific anti-
gen; complete blood count; serum electrolytes;
blood group typing and holding blood in storage
Urine culture
Prostatic acid phosphatase
Proslate-specilic antigen
Complete blood count
Serum electrolytes
Group and hold blood
Urine culture
(postdischarge)
Total
15.11 0.047
6.03 0.019
12.40 0.039
9.99 0.031
6.07 0.019
6.13 0.010
15.'11 0.024
3110
3110
3110
3110
3110
1 555
1 555
0.189
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not having surgery (46 patients) and costed aJ
$N2654.l4 earnings forgone per patient per week.
Leisure time loss for patients 65 years and over
(1663 patients undergoing surgery,597 patients no
surgery) was estimated similarly at $N22.566 mil-
lion. Production loss and loss of leisure time bv
unpaid caregivers were not assessed.
Quality of Life
The New Zealand literature identified only one
relevant article (Gilling et al. 1988). This was a
retrospective study of 62 patients interviewed at a
minimum of 6 months after TURP to investigate
factors associated with sexual dysfunction. Al-
though potency was retainedby 897o of these pa-
tients, 68Vo reported that their sexual potency had
decreased.
There are continence/incontinence clinics for
both men and women in several cities but to date
the focus has been on women. Literature searches
and inquiries found that although the Auckland and
Christchurch clinics had undertaken surveys on
urinary problems, the focus again had been on
women and only the Christchurch survey (Crow-
der 1991) has been published. The pain and suffer-
ing experienced by the patients, and its effects on
the family, could not be quantified.
Summary of Quantified Costs
Total direct medical costs amounted to
$N212.256 million and indirect costs were
$N23.648 million (production and leisure time
lost) giving a total of quantified costs of
$N215.904 million.
Table VIII summarises the quantified costs and
the impact of increased admissions, higher ward
costs, and greater numbers of outpatient and spe-
cialist consultations.
Sensitivity Analysis
HSS data revealed an overalln nonpopulation-
standardised, 16.2%o increase in admissions for
BPH during the period 1988 to 1991.8 Public hos-
pitals recorded a l4vo increase and private hospi-
tals recorded an increase of 20Vo in admissions.
Accordingly, all 1988 patient volumes that were
dependent upon hospital admissions were in-
creased by 16%o to obtain a l99l volume estimate
- 
the baseline estimate of $N218.388 million
(1992 prices)[direct costs $NZl4.l56 million, in-
direct costs $N24,232 millionl. As general practi-
tioner consultations and prescribed medicine costs
related to l99l volumes, it was unnecessary to in-
crease these costs for the sensitivity analysis (table
vlrr).
A high estimate was obtained by increasing the
baseline estimate of hospital ward costs by l6vo (to
take account of higher daily ward costs as indi-
cated by Wellington and Christchurch data), and
outpatient and specialist consultations by 50Vo
(based on audit data), to give a total of $NZl9.76l
million (direct costs $N215.529 million, indirect
costs $NZ'4.232 million).
The production loss would fall by 35Vo if ad-
justed for the labour force participation rate
(73.9Vo) and unemployment rate (ll.5Vo) for the
total male labour force (New Zealand Department
of Statistics 1992), but this fall would be offset by
a corresponding increase in leisure time lost and
would not affect the total indirect costs. The eco-
nomic cost of paid employment may be overesti-
mated, as short periods of time off work may not
result in lower production if co-workers tempo-
rarily increase their output to cover the absent
worker (see Koopmanshap & Rutten 1993 for de-
tailed discussion).
Mortality Rates
In 1988 the total mortality rate for BPH was
0.052 per thousand for men aged 50 years and over
(primary cause of death as recorded on death cer-
tificates). All 19 men with BPH recorded on death
certificates were aged 65 and over, and these deaths
were not quantified in monetary terms.
8 Between 1988 (hospital unit record data used to eslimate
costs) and l99l [the latest published volume data on hospital
admissions available at time of finalising this article (Depart-
ment of Health I 992)l the volume of admissions for principal
diagnosis BPH to all hospitals increased by l6vo.
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Table Vtll. Summary and sensitivity analysis of quahtified costs (1992 $NZ million) for benign prostatic hyperplasiaa
Cost (1988 and 1 991 volumes in March quarter
1992 prices)
Lowb
(o/o of total cost)
Baselinec
(o/o of total cost)
Higho
(% of total cost)
Direct medical costs
hospital ward
operations
outpatients and specialists
general practitionersc
medicines, dispensing fees and container allowancesc
laboratory tests
diagnostic procedures
Total direct medical costs
lndirect costs
production loss by patients under 65 years of agd
leisure time losl by patients >65 years
Total Indlrect costs
Total quantified costs
6.510 (40.9)
4.742 (29.8)
0.285 (1,79)
0.234 (1.47)
0.152 (0.96)
0.18s (1.18)
0.1,14 (0.91)
12.256 (77.O'
1.082 (6.81)
2.s66 (16.1)
3.648 (22.9)
15.904
7,552 (41.1',t.
5.s01 (29.9)
0.331 (1.80)
o.zu (1.27',)
0.1s2 (0.83)
0.21s (1.1e)
0.167 (0.e1)
14.1s6 (76.e)
1.255 (6.83)
2.sn (6.2)
4.232(2S.Ol
18.388
8.760 (44.3)
5.501 (27.8)
0.496 (2.s1)
0.234 (1.18)
0.152 (0.r/)
0.219 (1.10)
0.167 (0.8s)
15.52e (78.6)
1.2ss (6.35)
2.577 (15.11
4.232 (21.41
19.761
a Because of rounding, individual items may not add exactly to the totals shown.
b 1988 unit record data for hospitals, and volumes derived from hospital admissions for benign prostatic hyperplasia on which this study
was based.
c Low 1988 unit record data rated up to 1991 volumes based on the growth In hospilal admissions for BPH, a 167" increase.
d Ward costs increased by 16% and outpatient and specialist cusultations increased by 50o/o.
Discassion
Our study found that the ratio of direct to indi-
rect costs for BPH was 80 : 20, and that patients
with BPH stayed longer in wards of public than of
private hospitals. Our data also suggest that the
complication rate for surgery for BPH was higher
than that recorded by public hospitals.
The sensitivity analysis indicated that total di-
rect costs and total indirect costs of BPH were ro-
bust with respect to variations in key parameters
such as the type of diagnostic test routinely or-
dered, numbers of outpatient and specialist con-
sultations, and changes in labour force participa-
tion and unemployment rates. The best estimate of
1991 costs (measured in 1992 prices) was consid-
ered to be the high estimate which may still be
regarded as conservative, as many costs were not
quantified in monetary terms, and only those costs
relating to treated BPH were measured.
The direct medical costs of BPH accounted for
79Vo of the total quantified costs. Hospital ward
and operation costs accounted for 92Vo ofthe direct
medical costs. However, hospital ward costs were
underestimated in the study as BPH diagnoses B,
C, and D were excluded because it was impossible
to isolate ward costs attributed solely to BPH when
the patient was admitted primarily for another con-
dition. As most patients with BPH in New Zealand
are over 65 years of age, and retired, production
loss was a relatively small component of the total
costs. Part of the explanation for the relatively low
indirect cost is the short time off work and our as-
sumption that there was no Ioss of production be-
fore surgery was performed. The length of stay in
hospital, and the cost of surgical operations (567o
and 35Vo, respectively, of the direct medical costs)
are the 2 areas for which a reduction in costs would
have the maximum impact on total costs.
A substantial reduction in costs could be
achieved if the length of stay in hospitals could be
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reduced. Public hospital patients stay on average
8.9 days compared with 4.6 days for private hospi-
tal patients. If the public hospital average ward stay
could be reduced to that of private hospitals then
total ward costs would fall by 37vo ($NZ3'249 m\l-
lion), total direct costs of BPH would fallby Zlvo
and total quantified costs for BPHby l6Vo.
Reasons were sought for the disparity in the
length of stay between public and private hospital
patients. The case mix of public and private hospi-
tals is likely to differ in that older, at-risk and emer-
gency patients are more likely to be admitted to
public hospitals which are more able to cope with
complications, and which have a more intensive
level of care and monitoring.
We examined factors that could possibly affect
length of stay and that could be examined using
HSS data. Age and discharge type (covering the
classification as dead, routine discharge, self-dis-
charge and transfers to other types of institutional
care) were analysed. The average length of stay for
all age cohorts in private hospitals was about half
that seen in public hospitals. There was little dif-
ference in discharge type: 97Vo of patients in public
hospitals and 99Vo of patients in private hospitals
had discharges recorded as routine. If substantially
more patients in the public system had returned to
nursing homes or other hospitals, this could ex-
plain a longer hospital stay, as presumably such
patients would require a more intensive level of
care. As the private hospital database covers only
the principal diagnosis and principal operation, it
was impossible to determine, by reference to mul-
tiple diagnoses and operations, whether there was
a difference in health status between the public
and private hospital patients. The identified differ-
ences in case mix do not fully explain why patients
treated in public hospitals stay twice as long as
patients treated in private hospitals,
Changes in case management have the potential
to reduce hospital costs, particularly if they result
in fewer inpatient days. For example, in the public
system, patients with acute BPH who require
catheterisation and surgery were at one time cath-
eterised and admitted to await surgery, but may
now be catheterised and returned to the community
until a surgical bed becomes available. However,
the reduced inpatient stay should be offset against
possible increased costs in the community to the
patient and caregivers.
Surgery was the treatment option for most pa-
tients with symptomatic BPH. Watchful waiting
and/or pharmacotherapy was relatively uncommon
at the time of the study, but should either of these
2 options assume greater importance, there will be
follow-on costs in areas of laboratory and diag-
nostic investigations, specialist consultations and
pharmaceuticals prescribed. If drug treatment
could avoid the need for surgery or lessen the hos-
pital stay, it could substantially reduce costs. If,
however, surgery is merely postponed rather than
avoided, surgery costs are simply moved forward
in time, and the pharmaceutical costs become an
additional cost. However, surgery moved forward
in time means a resulting saving via deferral of
cost. Also, the patient may enjoy an improved qual-
ity of life and older patients may die from unrelated
causes before surgery is needed, thus saving the
cost of surgery for BPH.
Laboratory tests and diagnostic procedures
were under-reported in this study, because data at
general practitioner level were unavailable. In ad-
dition, although the urologist audits recorded the
laboratory and diagnostic procedures undertaken,
the sample sizes were considered to be too small to
allow rates to be applied to all patients, except for
the tests carried out on most patients' Total costs
for both the tests and the procedures were conser-
vative estimates of the true costs.
Laboratory tests and diagnostic procedures are
areas in which changes are occurring, and a mea-
sure of the impact of potential changes can be
gained by consideration of possible additions to, or
deletions of, the tests costed. The prostate-specific
antigen test is likely to replace the cheaper pros-
tatic acid phosphatase test, as it is regarded as be-
ing more sensitive as a tumour marker for cancer
of the prostate (Editorial 1988). Both tests were
included in the study, but if the phosphatase test is
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deleted, the measured costs would, fall rby
$N20.019 million annually.
Changes in tests and procedures with the intro-
duction ofnew technology could increase costs but
may have little impact on the overall cost of med-
ical treatment, as fhis area forms only a small per-
centage of the total direct medical costs. It is not
unrealistic to assume that each patient may in the
future receive an abdominal ultrasound scan which
would increase the cost of diagnostic procedures
by L57Vo (3110 patients x $N284.44 per test =
$N20.263 million). Although this would more than
double the total cost of diagnostic procedures, it
would only increase the direct medical costs for
treatment of BPH by 1.7 Vo. Conversely, confining
chest x-rays to only those patients over 65 years of
age would lower the cost of diagnostic procedures
by 23Vo (850 patients x $N246.22 per x-ro) =
$N20.039 million) and lower total direct medical
costs by O.3Vo. However, as the current cost of di-
agnostic procedures is lVo of direct medical costs,
none of these changes will make a meaningful dif-
ference to the costs of BPH. Diagnoses may be
improved for those patients for whom clinical di-
agnoses are not definitive, but the impact on total
costs was not evaluated.
Complications recorded for surgery came from
3 different sources, each at a different stage of
treatment for BPH. Hospital data recorded com-
plications within the duration of the patients'
hospital stay, the audits collected data within 30
days of surgery and more than 30 days after sur-
gery, and the study of Gilling and colleagues
(1988) interviewed patients at a minimum of 6
months following surgery (sexual dysfunction only
was studied).
Hospital staff may regard some problems or
complications associated with surgery as normal
occumences, and therefore may not record them, as
the audits indicated a higher complication rate than
hospital records. Recordingy'compliance is likely
to be higher in an audit than in routine hospital
records, and since the audit data covered a
postdischarge period, a higher complication rate
would also be expected. However, the difference
between the hospital data and the audits was suffi-
ciently large to assume that under-reporting is oc-
curring within hospitals. Under-reporting of com-
plications will not have resulted in an
underestimate of hospital ward costs, as these were
fully captured if the patient was admitted under
BPH diagnosis A.
There may also be an inadequate appreciation
of postoperative problems facing BPH patients in
New Zealand if patients do not volunteer informa-
tion on what they may regard as a sensitive subject.
Although most of the complications of the treat-
ment for BPH are not life threatening, and add little
to direct medical costs, they are important in terms
of quality of life. Society may not fully appreciate
the magnitude of the reduced quality of life result-
ing from symptomatic BPH and its possible treat-
ment complications for the patient. More research
is required to value the cost of changes in quality
of life.
It was a commonly held belief that Maori had
a lower prevalence of BPH because a lower pro-
portion sought treatment for BPH synrptoms than
among the rest of the male population. This possi-
ble lower prevalence of BPH among Maori may be
explained by the fact that mean age of patients in
the cohort aged 50 years and over was lower for
Maori than for non-Maori patients. Furthermore,
as small numbers are involved, this apparent dif-
ference in rates should be interpreted with caution.
A reluctance to use the health system for social and
economic reasons may in part explain the lower
number of Maori presenting for treatment. A recent
clinical investigation (Nacey et al. 1993) found that
no statistical difference in prevalence of BPH
could be demonstrated among European, Maori or
Polynesian men aged 50 and over.
Papers presented at the recent International
Consultation on BPH (1992\ produced evidence
that suggested that the rate of BPH in the commu-
nity is under-reported. Many people consider BPH
to be part of the normal aging process of men, and
tend to accept attendant problems.If these attitudes
change and BPH symptoms become less accept-
able. more focus will be placed on intangible costs.
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Society may be prepared to accept higher direct
medical costs to achieve improved quality of life.
As the New Zealand population ages, the preva-
lence of BPH will increase.
Appendix: Data on Morbidity
and Mortality
l. New Tnaland Department of Health
Both public and private hospital data and mor-
tality data relating to BPH for the whole of New
Zealandand for all patients were obtained on com-
puter diskettes from HSS, Department of Health.
The data supplied related to individual patient re-
cords for all New Zealand, with National Master
Patient Index numbers removed to protect patient
confidentially. At the time of data acquisition (Jan-
uary 1992) the most current data available in this
form were for the year ending December 1988.
Data for 1989, 1990 and 1991 became available
after the analysis for this study was completed. De-
tailed analysis of the latest data in unit record form
was not possible because of cost and time con-
straints. Howeveq published information in tabu-
lar form (Department of Health 1992) was used to
update some of these data for sensitivity analyses.
Diagnostic data were recorded on up to 4 con-
ditions (A, B, C, D). Primary diagnosis (A) is the
diagnosis for which the patient was admitted, and
subsequent diagnoses were recorded in order of se-
verity. Similarly, a patient may have had more than
one surgical operation (1, 2 or 3) and these were
recorded in chronological order during a patient's
hospital stay.
Data collected from private hospitals were not
as extensive as those recorded for public hospitals.
For example, private hospital data recorded only I
surgical operation per patient.
2. Christchurch Hospital, New Zealand
Cost and volume data relating to Christchurch
Hospital were used to validate data from other
sources. Data came from the Resource Utilisation
System (RUS) Unit, and the Urology Service De-
livery Unit publication Basin ess Plan Information
Systems, Christchurch Hospital, 199 I
3.lMS (NZ) Limited
Each calendar quarter the prescribing patterns
of 300 general practitioners (l3%o of general prac-
titioners in New Zealand) are analysed for 7 con-
secutive days and the results are rated up to the
totals for New Zealand.
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study and cover all New Zealand hospitale both public and private.
Unit records relating to Intemational ClassiJication of Diseases(ICD) operation codeg 683 to 686 for all operations wene ertracted
from the data base (683 sub total abdominal hysterectomy, 684
total abdominal hyeterectomy, 685 vaginal hysterectomy, 686
radical abdominal hysterectomy). Subtotsl aud total refers to the
type ofprocedure aud are no! numeric sggregat€s. Private hospital
information covers only the principal diagnosie and principal
operation. Public hospital data provide up to four diagnoses (A, B,
C, D) with primary diagrrosis A being the condition for which the
patient ie admitted.
Data were sorted and a subsel made which excluded patients
with indicatione of malignancy, infectiona, and congenital
abnonnalities. (Patient recorda were identified for removal using
diagnosis A of the private hoapital file and atl four diagnoses
categoriee in the public hospital file.) Patients under the age of 15
years and over the age of 54 yeare were also excluded from the
subset. The data now covered the following ICD codes(International Classification of Diseases. gth R€vision, Clinical
Modification [ICD-9CM]) 218 uterine leiomyoma, 219-221 other
benigrr neoplasm ofuLerus, benign neoplasm ofovary, other female
genital organs, 614-616 inflammatory disease of ovary, fallopian
tube, pelvic cellular tiaeue, peritoneum, uterua, cenvix vagina,
vulva, 617 endometriogia, 620 noninflammatory diseage of ovary of
fallopiao tube broad ligament, 621 diseases of uterus not elsewhere
classified, 622-624 noninflammatory disorders of cerrix, vagina,
vulva, perineum, 625 pain and other aymptoms associated with
female genital orgsng, 626 disordera of menstruation, abnormal
bleeding from female genital tract.
The public hospital unit cost of $4736 waa derived from
diagnostic related groups (DRG) 359 uterine and adnexa
procedures for nonmaligosncy age under 70 without comorbidities
and/or complications.r Private hospital unit costs from the
Southern Croes Medical Care Society,t and Wakefield Hospital,
Wellington 1992 were also used as an alternative method for
evaluating costs in the private sector. The costs of the surgeon and
the anaesthetist were taken from the society, and the ward and
theatre costs were provided by Wakefield Hospital, Wellington.
Public hospital costs were estimated by multiplying the public
hospital DRG unit cost by the number of patients for each operation.
Private hospital costs were calculated using private hoepital cost
data. fire daily ward cost multiplied by the total number of days in
hospital was added to the unit cost of the operation (excluding ward
costs) multiplied by the number of operations.
t ack of robust data precluded the estimation of some important
costs; medical costs after discharge, the value of production and
leisure time forgone, voluntary and ctmrnunity care, carre provided by
fainily and friends, and intangible costs relating to quality of life.
Costs of treatment and production and leisure time lost prior to
hysterectomy were not quantified ae the intention of the study was to
measure only those costs incurred following the decision to operate.
Results
A comparison was made between hysterectomy ratcs in 12
OECD countries. Switzerland, Canada and the United
States had the highest hysterectomy rates per 100 000
females, followed closely by Australia{ and New Zealand
which had substantially higher rates than the lowest group
of countries (Ireland, Japan, Norway, Sweden). Time series
data indicated that rates in most OECD countries have
been falling since Lhe lale 19?0's.5 The New Zealand rate
per 100 000 females in 1980 was 431 and the equivalent
rate in 1991 was 365. Table I shows the rates of
hystcrectomies per 100 000 women in a range of OECD
countries.
Abstract
Aims, fhs niyn of the study was to estimate the annunl
hospital costs to New Zealand society of hysterectomy for
nonmalignant conditions in women between puberty and
menopauae, and to colDpare international rates for all
hysterectomies.
Metho&. The records of patients aged between 15 and 54
years inclusive, who had a hysterectomy for a
nonmalignant menstrual condition, were researched.
Hospital costs were estimated using specific hospital unit
costs and prices.
Regulte. The 4390 hysterectomies for nonmalignant
conditions represent 69Vo of the total hysterectomies
undertaken in New Zealand in 1991. Estimated costs for all
hospitals were $17 million or $3868 per hysterectomy. The
all ages all conditions hysterectomy rate per 100 000
wornen of 365 (368 in 1992) in New Zealand is higher than
in some other developed countries.
Conclusions. Further reduction in the rate of
hysterectomy. in New Zealand may save hospital costs but
these aavingd should be offset against the costs of any olher
treatment options chosen. Although it was found that unit
costs of public hospitale were higher than those of private
hospitals the case mix for the two types of hospital may
differ and public hospital cost reductions may not be
possible. Economic evaluation of alternative treatment
options would be improved if all relevant costs (direct,
indirect and intangible) were known. Further research is
needed to deterrrine the reasons why New Zealand women
elect to have hysterectomies, why most choose a private
hospital, and changes (before and after hysterectomy) in
productivity, out of pocket expenses, and quality of life for
these patients.
ItlZ l{.d J l0e6; 108: l2ll4
Published information in New Zealand on hysterectomy
does not differentiate between hysterect'omy for malignant
or nonmalignanl conditions. This paper sought to establish
the numbers and the direct medical costs of hysterectomy
for nonmalignant menstrual conditions and to compare
New Zealand's rates of hysterectomy with those of other
developed countries within the OECD. Once the costs of
hysterectomy are established it then becomes possible to
evaluate treatmenl and hospital management options in
economic terms.
Costs were estimated from the perspective of society for
those patients (15-54 years inclusive, of menstrual age) who
underwent hysterectomies for nonmalig:nant conditions'
The objective ofthe study was to establish the costs ofthese
hysterectomies from the time of the decision to undergo
surgery. Costs already incurred (prior to surgery) or costs
that would be incurred (regardless of the treatment option
chosen) were thus irrelevant to the study.
Methods
Data for 1991 were obtained in unit record form from Health
Information Sewices, Department of Health.r Such data were the
latest full calendar year available in this format at the time of the
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Country
Austnlia(NSr[)
Caneda
Elenmar*
Eaglaud and Wdes
lreland
Japaa
Net}erlaadr
New Zealaad
Norway
Swedea
Switzerland
United Ststes
Trbb l. - lntrrnrtionel comprriron of hystcrrctomY tatcl maligaancy. Records in the data subset (as described 
-in
meth;ds) were selected on operation 1, 2, and 3 for tbe
public sector and operation 1 for the private 6ector. A total
ir aggo hysterectomies was obtained (45.L% for public
hospitals, and 54.9% for private hospitals). These 4390
hysierectomies represent 69% of the total hysterectomies
performed for all indications. Under the selection criteria
idescribed above) the hysterectomy rate Per 100 000
females (15 to 54 years) was 446'
Table 3 provides details of the hysterectomy cost
calculations for public hospitals for patients 15 to 54 yeare.
82Vo of patients had a total abdominal hysterectomy and as
the sqme unit cost was applied to all hysterectomies in
public hospitals (specific cost data wag unavailable) this
represents 82% of the estimated hospital cost.
Tables 4 and 5 show how private hospital costs were
calculated. Ward, surgeon, anaesthetist and tlreah'e rtnit
costs Jwere used to derive a unit cost for each type of
hysterectomy in Table 5. The weighted average ultt- 
-costpLr hysterectomy in private hospitals was $3155. Table 4
ihows that 73% of all hysterectomies undertaken in private
hospitals were total abdominal hysterectomies and
accounted for 751o of the total hospital cost.
Table 6 draws together information from Tablee 3 and 4
to summarise hospital costs by type of hysterectomy. When
specific public and private unit costs were applied q !!9
respecfive sectors the totd hospital costs were $16'983
million or $3868 per patient.
Year
198iil
1985
1982
r99t
r989
1980
1980
199l
r986
r980
r986
r989
Rate per 100 000 females
376
{83
255
292
1l,t
90
38r
365
145
145
166l
425
Sourcer: OECD fg93f Dichiosou & IIiU r988r (Australia); OHE 1992r'
(Englaad aud Walee).
In 1991 there were in total 6331 hysterectomies (for all
diagnoses, all operations and all ages) undertaken in New
Zealand (50.5Vo of these operations were performed in
public hospitals, and 49.57o, in private hospitalg). This total
number of hysterectomies is equivalent to a rate of 365 per
100 OOO females. Both the numbers of all hystcrectomies in
public and private hospitals and the rate per 100 000
females are shown in Table 2.
The study was ioncerned with hysterectomy within the
age cohort 15 to 54 years, for patients with menstrual
piobleme, and where there was no indicaiion for
Trbb Z 
- 
Hyrfrr.ctombt l99t
All hyrtcrcctomier, ell eger
Operation Public
hospital
3077
100
22
3r99
Private
hospital
3132
3132
Privatc
hospital
2409
2{09
76.9%
Female
population
I 733 ?00
I ?33 ?00
Femaleg
l5 to 54
98.t 120
98{ r20
R8t€/f00 0O0
358
365
R8tP/100 000
. 4.16
6331
All
hospitals
4362
24
4
{390
693%
All
hospitals
6209I
2.
3
Total
Hyrtcrcctomicr, l5 to 5,1 yeara, nonrnaligrrant conditionroPcntioa 
r,P"liltr
1 1953224g4
Total 1981
% of all 61.9%
Sources: Unit record data 1991. Health Informgtion Services, Department of Health. Department of Statistics. INFOS' Population statistics.
Tabb 3. - Pubtb hospitrlr: cost of hystrroctomid for nonmalignrnl condilion3 P!ti.nt3 lgod I 5 to 54 ys!t3: 1991
ICD
code
Operation
Subtotal abdonrinal hysterectomy
Total abdominal hystcrectomy
Vaginal hystrrectomy
Radical aMominal hyst€rectotny
Average
age
years
I
44.5
4l.B
40.3
3{.0
41.5
Unit
co st
$
,1736
{736
{736
4736
Number
of
patrents
B.
l6l6
3{0
t9El
Hospital
cost
$(000)
C=AxB
l14
7653
l6l0
o
9382
Average
stay
days
s
6E3
684
685
686
Total
7.4
6.7
5.D
10.0
6.5
Notec
Because of rounding individual it4mq may not add exactly to the otals shown'{ Operation: operation l(the ftrst opetation coded).
'All operations (1,2 and 3)
Unit cost: rclevant DRG unit cost for the year ending June 1991.
Sourcer
Unit record data 1991. Health Information Services, Department of Health.
National Advisory Com;;1iftee on Core Health and Disability Support Senices. First report f 992 (DRG unit costs)
Tebb f. 
- 
Privrtc hospitclr: cost ol hystcrcctomicr for nonmalignant conditionc pltirntt !g!d 15 lo 54 yrars: 1991
ICD
code
684
684
685
686
Total
Operation
Subtotal abdominal hyst€rectomy
Tolal abdominal hystcrectomy
Vaginal hysterectomy
Radical abdomi nal hyst€rcctomy
Average
age
years
36.0
42.5
41.6
35.3
42.3
Unit
costl
s
A
3306.6
3268.1
2846.1
4317.0
Number
of
patients
B
3
l?{9
65{
3
2409
Hospital
cost
$(000)
C=AxB
10
57 t6
l86r
l3
7601
Average
stay
days
D
6.0
5.5
4.7
7.3
5.3
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3 Trbb 5. - Prlvrt. horphdr: cort of hyrtrrrtomict for nonm.lign.nt condition3 prii.ntr.g.d 15 to 5f yorn: lggl Unit cortt
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ICD Operation
code
Number Average
of staypatients days
AB
6.00
5..r9
{.66
?.33
5.27
Ward cost Totsl Surgeon
per day ward cost unit cost$ $1000) $C D=ArBxC E
Theatre Surgery
unitcost total costt 9000)GH=
(E+F+G)xA{00.00 5{00.00 2985400.00 99,r{00.00 7
3991
Total Unit
hospital cost
cost S
t(0o0) J=VA
I=H+D
r0 3{1075?16 32681861 28.1613 43r?7601 3155
284.44 5281.44 27312E4.44 E67284.41 6
3610
Anaesthetic
unit coEt
s
F
3r 1.1 1
328.89
320.00
108.89
683
6E{
685
686
Totel
Subtotel abdominal hysterectomy 3
Total abdominal hysterectomy 1749
Vaginal hyst€rectomy 654
RadicalaMominalhysterectomy 
2403
888.89
977.78
E00.o0
t422.22
ICD Operation
code
683 Subtotalabdominalhyst€rcctomy
681 Totrl abdominsl hyst€rectomy
685 Vaginalhysterectomy
686 Rsdicel eMominal hystercctomy
Total
Totd coet per hyst€r€ctomy
Hospital
cost
9000)
t24
13 370
3472
IE
t6 983
3868
Noter and souFces: See Tables 3 and 5 ;
Figure 1 shows the age breakdown of the numbers of
hysterectomy patients in public and private hospitals. It
was fould that one third of all such hyst€rectomies were for
patienh aged between 35 and 44. years, and two'thirds
were for patielts aged 35 to 49 years.
90
&
Noter for tables { aDd 5
Because of r,ounding individual it€ms msy not add exactty to the totals shown.
Operation: operatioo I (the first operation coded).
t Unit cost frooc Table 5.
J
Trbb 6. - All horphrlr: co3t of hystrr.ctomicr nonmdignant conditionrptlhnt| rgDd 15 to 5a y.rrr
Sourcas
Unit record data 1991. Health InformatioD S€rvices,
Department of Healti.
Southera Crogc Medical Care Society, 1991.
Wakefield Hospital, 1992.
hospitals whose average stay was 5.3 days. It is a general
belief that public hospitals in New Zealand treat more
patients, and that their case mix is biased towards those
likely to require a greater degree ofcare and whose stay is
therefore likely to be longer. Thus, the unit cost of public
hospitals is likely to be greater than that of private
hospitals. The study found that the public hospital unit cost
was higher ($4736 public unit cost, 93155 priv;te unit cost),
there were fewer patients, and these patients stayed on
average a day longer. Actual fees for the surgeon and
anaesthetist are olten higher than those derived from the
Southern Cross schedules which would increase our
estimates of privatc hospital unit costs.
If the average total weekly earnings combined as at June
19916 were used as a proxy for the value of production and
leisure-time loss and if, for example, a patient was
incapacitatcd to the extent of three times their hospital
stay there would b€ combined loss of production and leisure
time of $6 million or $1400 per patient. As it is important to
measure indirect and intangible costs of illnesses? further
study is necessary to quantify such costs.
The total New Zealand rate for hysterectomy for all ages
is lower than comparable rates in USA and Canada, similar
to rates in Australia and the Netherlands, but higher than
rates in England and Wales, and lreland. The difliculties in
interpreting the geographic di{ferences ih rates of surgery
have been discussed in the international literature..,E'10
Some possible explanations for the discrepancies included;
an increase in women's knowledge of themselves and
diseases, a higher rate of uterine/pelvic disease, a
sterilisation procedure that can be legitimised as medically
necessary, the availability of surgeons and hospital
facilities, differences-in payment and insurance cover for
health care, supplie(\nducid demand, patient preferences,
referral procedures, differences in income levels and social
patterns. The recent decline in the number of hysterectomy
procedures in some developed countries may possibly be
explained by controversy over unnecessary operations and a
desire by both clinicians and patients to avoid hysterectomy
where possible.
Although hatf of all hysterectomies (for all indications
and all ages) in New Zealand were undertaken in private
hospitals, for the age cohort studied and the conditions
analysed, such hospitals recorded a greater number of
hyslerectomies. A possible explanation for this may be that
many women in this working age group (15-54 years) may
have health insurance and prefer to plan surgery to suit
business and family commitments. Surgery in a public
hospital is usually preceded by a waiting list/tooking
system and an inability to make arrangements other than
at short notice, If New Zealand women are opting for
private surgery for the above reasons then such surgery is
likely to be price and income sensitive. For example, if
women in the working age group have less disposable
income or lower rates of insurance cover there may be a
drop in the number of hysterectomies in private hospitals,
and a corresponding increase in the number of
Number
of
patientE
27
3365
99{
4
4390
$;
ao
,q,
o
25.29 g-3. 35-to Ul .5-.9 *54
Agr gep
Figurr 1. 
- 
Numbcr of hyst.rcctomias for nonmalignenl condhlonr In Ncw
Zcrland by cac
Discussion
lhe study select€d patients between puhrty and menopause.
Women of 55 years and older were not included as it was
assumed that most would be post-menopausal ab that age.
Although most women begin menstruating before 15 years of
age it may be several years, and as a last resort, before a
patient with menstrual problems undergoes a hysterectomy.
The 4390 hysterectomies for nonmalignant conditions in
New Zealand represented 69Vo of the total hysterectomies
performed (62Vo of the public and 7770 of the private
hospital hysterectomies). In private hospitals some
hysterectomies for malignant conditions may not have been
recorded under a specific diagnoses but in the more general
ICD 621 disorders of uterus, not elsewhere classified, and
therefore may not have been filtered from the data. Most
public hospital hysterectomies for nonmalignant conditions
were classified under ICD 218 (3t7o) and 626 (457o), while
most such hysterectomies in private hospitals were
classified ICD 621 (667o) and 626 (25Va\.
There was little difference in age between public and
private hospital patients; public hospital patients were on
average 41.5 years and private hospital patients were 42.3
years. Public hospital patients stayed on average 6.5 days,
a day longer in hospital than did patients in private
tt.r9 m-za
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hyst€rectoEies in public hospitals. the decision made to have
a hysterectony in a prinate hospital at a rirne convenient to
the patient may be the best option at present for these
patients if the cost of treabenf lost production and reduced
quslity of life before hpterectomy is taken into account.
Conclusions
Further reductions in the rate of hysterectomy in New
Zealand may save hospital costs but these savings should
be offset against the costs of any other treatment options
chosen. For example, watchful waiting could incur
soagisrring costs relating to general practitioner and or
epecinlisl consultations, analgesics, protective tampons and
pads, Ioss ofoutput and reduced q'rnlity oflife.
At the time of this study the unit costs of public hospitals
were higher than those of private hospitals. If the public
hospital unit costa fell to that of the private hospitals a
reduction of L87o or $3 million in total hospital costs would
occur. However, a8 discussed earlier the case mix for the
two types of hospital is likely to be dillerent and cost
reductions may not be possible.
It is boped that the costs and the additional inforoation
on the number of hysterectomies for nonmalignant
conditions derived in this paper will assist in the economic
evaluation of alternative treatment options. Data for
decision making ivould be enhanced if research was
:
undertaken to determine the reasone why New Zealand
woruen elect to have hysterectomies, and why mogt choose aprivate hospital. Information ehould also betollected before
and after hysterectomy to evaluate changes in productivifi
out-of pock"! exlrerures (such as analgeaica and protcctive
clothing), and quality of life for these patients.
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Hip frabture incidence among older people in Aucktand: a
Abstract
Aim. To determine the incidence of hip fractures among
those aged 60 years or older in the Auckland region.
Metho&. Demographic data were obtained on all older
people hospitalised with a fracture of the femoral neck in
Auckland, between 8 July 1991 and 7 February 1994.
Incidence rates were calculated using the 1991 census data.
Besults. An average incidence of 733 hip fractures or ?10
individuals sustaining hip fractures eacb year was
observed. Age-adjusted incidence rates were 571.5 per 100
000 for women and 318.2 per 100 000 for men. 9?.07o of the
hip fractures were sustained by those identified in the
records as European, with lhe rates for Maori and Pacil'rc
Island populations 25-50Vo lower than for Europeans.
Among Maori and Pacific Island populations, incidence
rates were similar for men and women. Overall, 4l.8Vo of
the hip fractures were sustained by those 2 85 years, with
67.0Vo sustained by those 2 80 years. Incidence rates
increased with age, with the rates continuing to increase in
those 2 85 years.
Conclusion. Among Europeans, hip fracture incidence rates
in Auckland are similar to those found for other caucasian
populations. However, the rates among Maori and Pacific
Island populations are among the lowest internationally and
are similar for men and women. The increase in incidence
rates with age continues in those ) 85 years.
NZ Mcd J lrer; lo8: a2&!
populatio n'based study
lobyn {olgl, PhD, MPH, Director; Meg Butler, ASCT, DPH, Besearch Officer; Rochelle Currie, DipOT,Research Officer; Trevor-Lee-J'o_e, MEn_g, Data Manager,lniury Prevention Research Centre, Univircity of
Auckland; A John Campbell, MD, FRACP, Professor of Geriatric Medicine, Department of Medicine, University
of Otago, Dunedin; lan R Reid, MD, FRACP, Associate Professor, Department of Medicine, University of
Auckland; Auckland; Harley Gray, ChM, MMedSci, FRACS, Clinical Direstor Surgical Services, Middlemore
Hospital and Honorary Professor, University of Auckland, Auckland.
Hip fractures are well recognised as an important cause of
morbidity and disability among older people.r'2 The New
Zealand Health Information Service (NZHIS) routinely
collects and publishes data on hospitalisations for hip
fraciure (ICD code 820) in New Zealand, providing
information on all discharges for hip fractures among those
aged 60 years or over, by five year age groups.s However,
these data include hip fractures that are not attributable to
either falls or osteoporosis and include data on
readmissions for the same hip fracture and transfers
between hospitals. Thus the true incidence of hip fracture
that may be amenable to preventive interventions is
unknown. In addition, in the published data, information
on the numbers ofhip fractures sustained by those aged 85
years or older are combined, despite the fact that hip
fractures sustained by individuals in this age group are
shown to comprise over one third of the hip fractures
among older people.3 Given the preventive, acute and long
terrn management, and cost implications of hip fracture,
particularly among the older old,. there is a need to identi&
the true incidence of hip fracture. This paper, therefore,
reports the descriptive epidemiology of hip fracture
incidence among the elderly in the Auckland region, using
data from a populaLion-based regional surveillance system.
Methods
Between 8 July 1991 and 7 February 1994, all older people (>60
years) hospitalised with a fracture of the femoral neck in Auckland
were identified through the ward registera of Auckland aod
Middlemore hospitah. Almost all individuah who are hoapitalised
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Roxithromycin versus Cefaclor in Lower
Respiratory Tract Infection
A General Practice Pharmacoeconomic Study
W. Guy Scott,t fulurray W'. Tilyard,Z Susan IV. Dove\,,2 Bruce Cooper3'and
Helen M. Scottl
! W GUV Scott and Associates Limited, and Wellington Polyrechnic, Wellington, New Zealand2 Royal New Zealand Coltege of General Practitionirs Reseirch Unit, Depairmenr of General practice,
Otago Medical School. Dunedin. New Zealand
3 Delpharm Limired, Auckland. New Zealand
Summary An economic evaluation comparing roxithromycin l50mg twice daily and cefaclor 250mg
thrice daily in the treatment of lower respiratory tract infections (LRTI) was rindertaken as pan
of a randomised clinical trial in New Zealand general practice. The observed sratistically sig-
nificant difference in adverse eventst withdrawal rates and extra treatment courses in favour of
roxithromycin in the clinical study was translated into medical cost savings. Treatment failures,
withdrawals or adverse events resulted in addirional costs for I I of 120 (9%) patients receiving
roxithromycin and l9 of I l8 ( l6%) patients receiving cefaclor. In these cases (treatment failures,
withdrawals, adverse effects) additional antibiotics and general practitioner visits were required
3 times more often and the cost of additional medication for treating failure or adverse efTects
was 3 times higher for patients treated with cefaclor than for parients receiving roxithromycin.
The total direct medical cost per patient treated with roxithromycin was $N29.37 lower (on an
incremental basis) than for patients treated with cefaclor, despite a higher drug acquisition cost.
An estimate of $N2656 000 per year rn total savings in direct medical costs could be made in
New Zealand if roxithromycin were to replace all cefaclor prescriptions in the lrearment of LRTI.
Recent studies in Australia (Munro 1989; Teng
Liaw l99l) and earlier studies in New Zealand
(Reid & Anyon 1986: Ridley-Smith t 973) confir-m
that lower respiratory tract infections (LRTI) re-
main one of the most common reasons for visits
to the general practirioner (GP). They account for
1.5 to 2.6% of consultations in general practice, and
antibiotics are prescribed in a large proportion of
cases (Tilyard & Dovey 1992). Because the major-
ity of LRTIs are rreated in general practice rather
than in a hospital setting, it is important that new
therapies are tested in circumstances under which
they are intended to be used.
Traditionally, new medications are evaluated
and compared with existing therapies using clinical
trials which provide information on clinical and
bacteriological eflicacy, safety and tolerability.
Clinical trials seldom include suflicient data for
cost-effectiveness analysis. Because of the need to
examine economic factors in the provision of health
care, economic items were included in the trial
evaluation of 2 pharmaceutical treatments. These
treatments were compared for safety and eflicacy
in a randomised double-blind clinical trial.
Roxithromycin is a new oral macrolide antibi-
otic with an improved pharmacokinetic profile
Roxithromycin vs Cefaclor in Lower Respirarory Tract Infecrion t23
compared with earlier generation macrolides, a
broad spectrum of antibiotic activity and a long
half-life which enables once or twice daily admin-
istration (Acar 1992). Clinical studies to date sug-
gest that roxithromycin is at least as effective but
significantly better tolerated than commonly used
antibiotics such as amoxicillin/clavulanic acid
(Dautzenberg et al. 1992), eryrhromycin (Herron
1987) and doxycycline (Marsac et al. 1988).
Worldwidc-, thc oral cephalosporin. cefaclor. is
one of the antibiotics most commonly used for
treating LRTIs. It represents a standard against
which other treatments should be evaluated. Ce-
faclor has been proven as a safe and effective
therapy (Kammer & Short 1979) but as yet has not
been compared with roxithromycin in a controlled
clinical trial. It was therefore neither necessary nor
practicable to evaluate all possible treatment op-
tions. Medical ethics precluded the evaluation of
the no-treatment option.
Methods
A multicentre, randomised, doubledummy
controlled study, comparing the eflicacy and tol-
erability of roxithromycin l50mg twice daily with
cefaclor 250mg thrice daily for the treatment of
LRTI, was undertaken by the Royal New Zealand
College of General Practitioners Research Unit in
general practice clinics at 8 centres throughout New
Zealand. GPs received no payment for taking part
in the study.
It was estimated that a sample size of 230
patients was required to reliably discern a differ-
ence of l5% between antibiotics, with 80% power
(p) and 5% risk (c) assuming 90% eflicacy for rox-
ithromycin. After ethical approval for the trial had
been obtained from the Otago Area Health Board
Ethics Committee, 240 patients with a diagnosis of
LRTI were enrolled between June 1990 and June
1991. Data for economic evaluation were obtained
for 238 patients (roxithromycin 120 patients, ce-
faclor I l8 patients) with 2 patients being lost to
follow-up.
Eligible patients were aged l8 years or older and
all gave written informed consent. A clinical diag-
nosis of bacterial lower respiratory tract infection
was required for entry into the study.
Exclusion criteria were: concurrent or immedi-
ately prior antibiotic therapy; pregnancy, lactation
or inadequate contraception; hypersensitivity to 0-
lactams or macrolides; serious liver or renal dis-
ease; concurrent use of warfarin. Patients with
serious disease, who were likely to require paren-
terally administered antibiotrcs or hospitalisation,
were also cxcluded.
Diflerential diagnoses of acute bronchitis, acute
or chronic bronchitis, and typical and atypical
pneumonia were assisted by serological, microbio-
logical and radiological examinations in the ma-
jority of cases. Diagnosis was based on community
practice standards.
The study was conducted and analysed on the
basis of intention-to-treat. Absence of a suitable
specimen or.examination result did not exclude a
case from the analysis. Haematology and biochem-
istry investigations were made on entry and at
completion of the study or withdrawal from
therapy. Additional testi, outside those required by
the study protocol, were not paid by the study.
Treatment was for a minimum of 7 days, with
provision for a further 7 days therapy if clinically
indicated. This length of therapy was set to ensure
that an adequate minimum course of treatment was
available for patients with pneumonia and exac-
erbations of chronic bronchitis (Mandell et al.
1990). Assessment of clinical signs and symptoms
was made by the general practitioner at baseline
and at withdrawal or completion of therapy. The
'end' of treatment was defined as the time of com-
pletion of all study medication, usually at day 14
or earlier if dicuted by intolerable adverse events
or lack of eflicacy of the study compound. 'Treat-
ment failure' was defined as the requirement for
further antibiotics, whether at 7 days or treatment
end. The trial methods and results of efticacy and
tolerability analyses are described in detail else-
where (Tilyard & Dovey 1992).
In addition, the number of patiens in New Zea-
land with LRTI who required antibiotic prescrip
tions and consulted general practitioners was es-
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timated from a study of general practice activiries.
This data collection was made during February,
March and April of l99l and involved 102 ran-
domly selected general practitioners from through-
out New Zealand. Supporting estimates of LRTI
incidence and treatment were made from analysis
of the total l99l consulution and prescribing data
of 6 general practices (Tilyard et al., unpublished
data). From these data it was estimated that ap-
proximately 70 000 patients would have been
treated with cefaclor during the year ending De-
cember 1991.
The economic analysis of this study assessed
drug acquisition cost, additional support medicine
costs, additional general practitioner consultations
and additional diagnostic tests required, over and
above those required as part of the study protocol.
The principle of incremental analysis was used;
only those costs and benefits that changed or dif-
fered between the treatment options were relevant
to the analysis (Scott et al. 1992). Healthcare costs
and benefits that were common to both treatments
were not included as they cancelled out when com-
parisons were made. Direct medical costs and
benefits were evaluated from the perspective of New
Zealand society, although indirect costs such as
those incurred through lost wages or productivity
were not evaluated. Not all of the direct medical
costs and benefits were captured, because of the
artificial constraints of a clinical trial design. As
patient copayments in New Zealand (the non-
reimbursable portion of government prescription
charges payable by the patient) have a different im-
pact on different income and benefit groups, and
this information was not available from the trial
data it was impossible to split all the costs and
benefits accurately between government and indi-
vidual patients. Indirect taxes (Goods and Services
Tax and copayments) were not included, as these
are transfer payments from the perspective of New
Zealand society.
Where treatment failure, treatment withdrawal
or adverse events occurred, general practitioners
used a standardised form to provide data on any
additional treatments, investigations and consul-
tations. Although attempts were made to evaluate
indirect costs of production loss and the costs of
additional patient travel from the trial data col-
lected and from practitioners' records, the infor-
mation obtained was inadequate (with respect to
both quantity and quality) for analysis. The so-
cially sensitive nature of the data relating to em-
ployment status and earnings precluded a vigorous
questioning by general practitioners to elicit infor-
mation.
Medicine prices, dispensing fees and container
allowance per prescription, and patient premiums
on medicine (the portion of ihe total price of the
medicine paid by the patient) for cefaclor and ad-
ditional therapies were derived from the Depart-
ment of Health Pricing Schedules, I August 1991.
Premiums vary between medicine brands, and are
included in the cost to society. Roxithromycin
pricing negotiations were not finalised at the com-
pletion of this study, thus rhe direct medicine cost
was that agreed to by the Department of Health in
March 1992. Fees payable in resfect of laboratory
diagnostic services were obtained from Health
Benefits Letter 29, number 3 (1991). The price of
a chest x-ray was obtained from Wakefield Spe-
cialist Medical Centre, Wellington, New Zealand,
(November l99l). The charge for a visit to a gen-
eral practitioner was assumed to be $N227.56
(Health Benefirs Letter 17, l99l). Because of un-
availability of cost data, prices were used as a proxy
for unit costs, and as such would contain an un-
quantifiable profit component.
All prices used related to the last quarter of 1991.
An average of mid-point exchange rates for Octo-
ber, November, and December l99l (INFOS) is
appropriate to convert New Zealand values into
US dollars ($N21.0000 = $US0.5541).
1-Square and Fisher's Exact (2-tailed) tesrs were
used for between-treatment comparisons. Fried-
man's test was used for nonparametric data.
Iiesatts
Table I summarises the major findings of the
clinical trial. The 2 treatment groups were com-
parable at baseline for age (mean age 5l years, range
18-90 yean for roxithromycin; 51.6 yean, range 2G
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Patients 
€nrollsd
Trsatment failures at 7
daysg
Treatmont successes al
7 days
Pati€nts reguiring
extended therapy
Mean duration of
treatm€nt (days)
Patients withdrawing
during treatment
Patients with treatment-
relat€cl adv€rse 
€vents
Patients wlth treatmont
failure, aclversg svents
or withdrawalb
Patients tor whom
quantitiable additional
costs w€r€ incurred
Table l. Summary of the clinical findings of the comparison
beh,vgen roxithromycin and cefaclor tor treatment of lower res-
piratory tract intection
Parameter Roxithromycin Cefaclor
nificantly more common among cefaclor-treated
patients (24 patients vs l3 patients, p < 0.05). Four
of the 8 treatment failures observed in the first week
of treatment with cefaclor were due to early with-
drawal necessitated by intolerable adverse events
rather than inadequate eflicacy.
The difference in costs (apart from the drug ac-
quisition cost) between treatment options was
manifest in terms of treatment failure. treatment
withdrawal or adverse events. During the study 6l
patients (29 receiving roxithromycin and 32 re-
ceiving cefaclor) reported adVerse events, treat-
ment failure or therapy withdrawal. which poten-
tially could have resulted in additional cost. Of
these 6l patients, quantifiable additional costs were
actually gcneratcd by 30 patients; I I patients re-
ceiving roxithromycin and l9 receiving cefaclor.
Drug Acquisition Cost
The trial medication cost to New Zealand for
roxithromycin was $N22.38 per patient per day for
8.9 days ($NZ2 |. I 8 total) and $NZ2.l 2 per patient
per day for 9.7 days for cefaclor ($N220.57 to.tal).
The incremental primary medical cost for trial
medication versus control was $NZ0.6l per patient.
Support Medicine Cosr
Four patients receiving roxithromycin required
further antibiotic therapy. Five patients were pre-
scribed additional medication to treat adverse
events (antifungal, antidiarrhoeal therapies). Two
patients required additional medication (antitus-
sive, bronchodilator or decongestant) to treat the
infection.
14 patients treated with cefaclor required ad-
ditional antibiotic therapy. Seven patients required
additional medication to treat adverse events (anti-
fungal pr antiherpetic therapies or topi€l steroids).
Six patients required additional medication to treat
the symptoms, in the form of analgesiB or non-
steroidal anti-inflammatory agents (3 patients), oral
steroid ( I patient) and bronchodilator, antitussive
or decongestant (2 patients).
Table II summarises the costs of additional sup
120.
38
82'
33'
8.9
6't
13',
a
11
118
53
65
50
9.7
15
24
32
r9
, ^ Tha83 patigntc wcre ewilehod le e €laffer€nFsFtibiotio,b Patienb could experience more than I of these outcomes.
' = p < 0.05 (psquare or Fisher's Exact test).
90 years for cefaclor), gendcr and underli'ing dis-
ease. Analysis of clinical efficacy (satisfactory or
improved response) on the basis of intention-to-
treat revealed no significant difference between
treatments in clinical efficacy at study end (p )
0.05), with 95.8 and 93.2% efficacy for roxithro-
mycin (l l5l120) and cefaclor (l l0/l 18) respec-
tively. An extended course of therapy was required
for 50% more patients randomised to cefaclor than
roxithromycin (50 ys 33, p < 0.05).
Roxithromycin was significantly more effective
than cefaclor, with 82 treatment successes com-
pared with 65 treatment successes for cefaclor after
7 days therapy (p < 0.05). The average treatment
duration was 9.7 days for cefaclor and 8.9 days for
roxithromycin (p
patients receiving cefaclor withdrew because of
treatment failure or treatment-related adverse
events (15 vs 6, p ( 0.05). Adverse evenrs deemed
possibly or probably related to treatment were sig-
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port medicines for parients enrolled in the study.
Additional dispensing and container fees were as-
sociated with support medicines prescribed. Ad-
ditional costs of support medicine were $NZl.98
more for cefaclor and additional dispensing fees and
container allowances were $N20.44 more for ce-
faclor on a per-patient basis (table III).
Additional General Practitioner Consultarions
Treatment modifications necessitated by inad-
equate treatment and adverse events generated 47
additional general practitioner consultations ( l2 for
roxithromycin and 35 for cefaclor). On a per-patient
basis, consultation costs were $N25.42 less for those
patients treated with roxithromycin compared with
patients treated with cefaclor.
Costs of Additional Diagnostic Tests
There were 20 additional diagnostic tests or-
dered. For roxithromycin, 3 patients required 7 ad-
ditional tests: 2 sputum cultures, a nasal swab for
culture, a complete blood count (CBC), a liver
function test profile, a serum glucose test, and a
chest x-ray. Of patients receiving cefaclor, 7 re-
quired a total of l3 additional tests: 4 sputum cul-
tures, an oral swab and a skin swab for fungal cul-
ture, a CBC, and 6 chest x-rays.
On a per-patient basis the costs of addirional
diagnostic tests were $NZ2.l4 less for patients
treated with roxithromycin than for patients treated
with cefaclor.
Table ll. Acquisition costs of additional support drugs for patients in th€ sruoy
Tr€atmont No. of
patients
r€cgiving
the drug
Drug
(no. of drugs)
Total cost to NZr lor
patients requiring
adclitional drugo
(r991 $NZ)
Total cost to NZ p€r
pationt sntering th€
studYb'c
(1991 SNZ)
Roxithromycin 36.01
45.97
13.17
1.69
96.83
189.91
78.61
5.10
12.36
4.86
3E.45
sxt.27
-232.4
TotEl
Cefaclor
Tot|l
Incrcmcntrl cort
(rorltfiromycln minur
cctrclod
4
4
2
1
9d
14
5
3
1
2
176
Antibiotic (4)
Antifungal(5)
Bronchodilator/antitussiv€/
decongestant (3)
Antidiarrhoeal (1)
Antibiotic (17)
Antifungal(7)
Analgesics/non-steroidal anti-
lnflammatory (3)
Bronchodilator/antitussive/
decong€stant (4)
Oralstoroid ('l)
Topical steroid/antiviral (3)
0.81
2.7!t
-1.98
a Total q)st to New Zealand is the sum of pati€nt out-of-pock€t payments (premiums plus copayments) ptus govemm€nt payments.b Because of rounding, individual it€ms may not adc, up exactty to the totals shown.
c Roxithromycin 1= 120,cefaclorn = 11g.d More than one drug was prescribed for some pati€nts.
Abbrovieilon: NZ = New Z6aland.
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Overall Cost Effectiveness
Table III summarises the overall cost effective-
ness of roxithromycin over cefaclor. The net bene-
fit (per patient treated) of using roxithromycin in
place of cefaclor was $N29.37. Although roxith-
romycin cost more, the roxithromycin-treated
patients required fewer prescriptions for support
drugs, fewer general practitioner consultations and
fewer diagnostic tests than cefaclor-treated patients.
Extrapolation of Results to New Zealand
General Practicel
Using an estimate of 70 000 patients treated per
year with cefaclor for LRTI, the total net benefit
to New Zealand of roxithromycin replacing cefa-
clor for this indication would be $N2656 000.
We estimate that the net benefit to New Zea-
land for 100 000 patients would be $N2937 000
million, and for 50 000 patients would be
$N2469 000. The reason for applying a smaller es-
timate is that roxithromycin would not replace all
treatments with cefaclor, and the reason for using
a higher estimate is that roxithromycin may re-
place other antibiotic treatment regimens as well
as cefaclor. Thus, since roxithromycin has equiv-
alent eflicacy but better tolerability than other anti-
biotics, a similar net benefit could be expected.
Discussion
In contrast with many trials, the study on which
this economic analysis was based was specifically
designed to emulate general practice diagnostic and
assessment methods. The multicentre, country-
wide nature of the study controlled for regional,
racial. and climatic differences and the study pe-
riod of one year allowed for seasonal aetiological
I The population of New Zealand was estimated to be 3.4 mil-
lion at the end of 1991. The predominantly publicly owned and
funded rystem (government currently funds just over 8096 of dl
healtb expcnditure) hnq constrained the prices of pbarmaceuticals
and medical scrviccs. Spending on health for the year ended June
l99l was 7.396 of gross domeslic producr. Total expendilurc on
hcalth (both private and public) for the fiscal year ended June
l99l was 3N25387 million (McKendry & Muthumala 1993).
Table lll. Summary ot incremental medical costs of roxilhro-
mycin over cefaclor
Incr€mental dirsct medical
costs of roxlthromycin over
cefaclor
Par patient in Per 70 000r
the trial patients
(1se1 $NZ) (1991
sNz. 1000)
Additional primary drug 0.61
acquisition cost
Support drug costs avoided 1.98
Disp€nsing fegs and 0.44
container allowancesb
avoided
General practitioner fees 5.42
avoided
43
1.39
3'l
379
Diagnostic tests avoided
Net co3t avoidance
2.14
9.37
r50
6s6
Estimated number of prescriptions lor cefaclor filled each
year in New Zealand.
A small reimbursement pald by the NZ government to
pharmacists, for the drug container,
differences. In addition the proportions in the study
group of patients with acute bronchitis (80%), ex-
acerbations of chronic bronchitis (15%) and pneu-
monia (5%) are consistent with available local epi-
demiological data on community-acquired LRTI
(Tilyard & Dovey 1992). The results can thus be
reasonably extrapolated to actual general practice
usage, at least in New Zealand- In generalising these
results to other countries it should be noted that
13% of patients in this study were asthmatic and
that New Zealand has a high prevalence of asthma.
For this economic analysis, total direct medical
cost savings to the country were calculated based
on the actual trial usage of the medications by gen-
eral practitioners. However, treatment durations
and the numbers of consultations and diagnostic
tests are often higher in a clinical trial than in day
to day medical practice.
In this study, a minimum treatment duration of
7 day's was set to ensure that patients with acute
or chronic bronchitis and pneumonia would re-
ceive an appropriate duration of treatment (Conte
& Barriere 1988; Mandell et al. 1990). The vari-
ation in treatment length between the artificial
minimum of this trial and day to day clinical ex-
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perience highlights a problem thar must be faced
when undertaking and interpreting an economic
evaluation using clinical trial data. However, this
bias is minimised by the use of incremental analy-
sis because most of the additional costs are com-
mon to both the active treatment and control
groups and cancel out when comparisons are made.
A minimum of 2 general practitioner visits was
required for evaluation of each case whereas in
routine clinical practice a patient would probably
return only if treatment failed or the patients ex-
perienced major adverse events. The 2 haem-
atological and biochemistry investigations per-
formed to assess comparative safety would not
normally contribute to the routine management of
LRTI in general practice. Chest x-rays and micro-
biological tests were undertaken whenever possi-
ble. The fact that the patients were part of a study
bearing the cost of these investigations may havc
encouraged greater use of microbial tests and chest
x-rays than would normally be the case. All of these
costs, however, were incurred equally by patients
receiving roxithromycin and cefaclor, and they
cancel out in the economic comparison of treat-
ments.
The economic analysis takes into consideration
onty those additional diagnostic tests, general prac-
titioner visits, and pharmaceutical costs which re-
sulted either from inadequate treatment of the in-
itial infection at study end or from adverse events
of trial treatments. The study did not subsidise these
costs, so they are therefore representative of costs
which might normally result from the trearments
offered. No attempt was made to assume an ad-
ditional cost for patients who required an extra
week of medication, as this was allowed for in the
protocol design and it is difficult to extrapolate ro
routine practice. However, because significantly
fentr additional one week reatment courses were
required as part of the study for roxithromycin than
for cefaclor, it is possible that the difference in fa-
vour of roxithromycin has been underestimated.
A fairer assessment of the overall comparative
costs, nationally, of the 2 treatments could have
been achieved by calculating primary medicine
costs based on the national average treatment dur-
ation for each antibiotic used to rreat.LRTI. This
calculation was not undertaken because although
data on prescribing practice were available from
commercial sourbes, the researchers were unable to
obtain permission to publish calculations based on
these data.
It would have been preferable to have included
direct nonmedical, indirect and intangible costs and
benefits in this study but these could not be eval-
uated with suffrcient accuracy. The savings calcu-
lated therefore could represent an underestimate to
society, as there were fewer adverse effects and
treatment failures at 7 days with roxithromycin.
Accepting the inherent limitations of extrapo-
lation from a prescribing database of 6 general
practices for one year and 102 practices over 3
months, an estimated 70 000 prescriptions for ce-
faclor are filled each year in New Zealand for treat-
mcnt of LRTI's. Theoretically, if roxithromycin
were to replace cefaclor, savings in excess of
$N2656 000 could resulr, in spite bf roxithromycin
having a greater unit cost.
It could be argued that cases of acute bronchitis
(which represent a significant proportion of the
study patients) are viral in aetiology and do not
require antibiotic therapy (Billas 1990). Indeed, 3%
of the cases included in the intention-to-treat an-
alysis of cliriical efficacy in the study were deemed
by serology to be viral in origin. On the other hand,
others (Dunlay et al. t987) have demonstrated a
benefit from antibiotic therapy in acure bronchitis,
and certainly in this study general practitioners sel-
ected patients whom they believed clinically to have
a bacterial LRTI that would benefit frorn antibiotic
therapy. The study results are thus representative
of actual general practice usage patterns, in con-
trast with restrictive analyses based on infection
proven by sputum culture, a tool widely regarded
to lack sensitivity and specificity in this setting
(I-entino & Lucks 1987).
It'should be noted that this study was under-
taken between epidemic cycles of Mycoplasma
pneumonia infection and no cases were detected.
Given the demonstrated effrcacy of roxithromycin
in treating Mycoplasma pneumonia and other
'atypical' pneumonias (Saito 1990), and the inef-
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ficacy of p-lactam antibiotics such as cefaclor
against such pathogens (Mandell et al. 1990), it
could be reasonably expected that during the ob-
served cyclic epidemics of such pathogens the cost
effectiveness advantage of empirical use of roxith-
romycin over cefaclor would increase even further.
The recommended dose of cefaclor for general
practice LRTI varies internationally from 250mg
twice daily to 500mg thrice daily for mild to mod-
erate infections. However, as with most antibiotics,
there has been a trend to reduce dosage to the low-
est effective level associated with the most favour-
able adverse+ffect profile. The dose of 250mg thrice
daily is that recommended for mild to moderate
infections in the oflicial New Zealand prescribing
information for cefaclor. It is possible that a small
number of patients may have been more effec-
tively treated with a higher dose of cefaclor, how-
ever, eflicacy was already 93% and one-half of the
treatment failures observed with cefaclor were due
to early withdrawal necessitated by intolerable ad-
verse events, rather than inadequate efficacy. Any
marginal increase in efficacy would therefore be
offset by substantially increased drug acquisition
cost, and probably increased support medicine
costs, consultations and diagnostic tests required to
treat and assess an increased frequency ofadverse
events and resultant treatment withdrawals.
Prices were used as a proxy for unit costs in this
study and accordingly there may be an economic
profit component in addition to the unit cost of
production. However, we consider that excess
profits would be minimal because of the compe-
tition between providers in New Zealand and the
dominant role of government in determining prices.
Thus, prices are likely to represent costs.
Therapeutic I mplicat ions
The observed sutistically significant difference
in adverse effects, withdrawal rates and extra treat-
ment courses in favour of roxithromycin in this
study is translated into actual cost savings. Theo-
retically, if roxithromycin were to be used in place
of cefaclor for the estimated 70 000 prescriptions
for cefaclor filled each vear in New Zealand for
LRTI, savings in excess of $NZ[656 000.could re-
sult, in spite of roxithromycin having a greater unit
cost. This analysis demonstrates that economic data
can and should be obtained from clinical trials and
used to evaluate costs and benefits.
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Economic Evaluation of Vaccination
Against Influenzain New Zealand
W. Guy Scott and Helen M. Scott
Wellington Polytechnic, and Independent Health Economists, Wellington, New Zealand
Summory The objective of this study was to evaluate the costs and benefits of influenza
vaccination for the population aged 65 years and over, from the perspectives of
individuals and health insurers, government and society.
The annual incremental direct medical costs and benefits of influenza vacci-
nation (colnpared with the nonvaccination, or 'do nothing', option) were evalu-
ated using New Zealand healthcare resource usage and unit cost data lin 1992
New Zealand dollars ($NZ;; $NZl = $US0.5458, June 19921 applied to cohort
studies reported in the literature.
The costs and benefits to society as a result of vaccination of people aged 65
years and older (209c of people in this age group are currently vaccinated) were
estimated to be: (i) additional direct medical costs of vaccination of $NZl.42
million [$N217.78 per vaccination]; (ii) direct medical costs avoided of $N25.35
million ($N267.18 per vaccination); and (iii) net benefits of $N23.93 million
($N249.40 per vaccination).
The direct medical costs avoided per dollar cost of vaccination were $NZl.04
for individuals, $N24,69 for government and SNZ3.78 for sociery as a whole. If the
vaccination uptake for this group is increased in207o increments, the net benefit
to society increases by a further $N23.93 million per year at each step. If the
economic evaluation is extended to include vaccination of at-risk individuals
under 65 years ofage, net benefits to society increase by 157o.
Influenza vaccination for people aged 65 years and over is cost effective from
the perspective of society, government and the individual. If the vaccination rate
for at-risk individuals in New Zealund could be increased to 60Vo, the net benefits
reported in this study would increase by 200Va. However, the costs of promotion
and education to achieve this vaccination rate would need to be deducted from
the net benefits, Strategies to increase lhe vrccination rate include altering the
cost of vaccinations to the individual. intensifying education and promotion pro-
grcmmes, and changing the mode of delivery.
Influenza is regarded worldwide as an important
and highly infectious viral illness thlt is most severe
in the very young and the elderly. The likelihood of
being hospitalised or dying from influenza increues
with age and the nunrbe r of underlying medical con-
ditions present in the patient.lll The beneflts of influ-
enza vaccination are dependent upon age, health
status, the rate of vaccination, and the efticacy of the
vaccine. Although intluenza vaccinltion is consid-
ered to be srf'e and e[t'ective. vaccination riltes are
low in New Zealand and vaccination is regarded as
being underutilised.lr'll The aim oi this study is to
assess the cost eftectiveness of influenza vaccination
from the perspectives of individuals and health in-
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surers, government and society for the at-risk
group of patients aged 65 years and older.
Four groups are targeted for influenza vaccina-
tion in New Zealand. The first group consists of
people described as being at high risk of complica-
tions:
o adults and children with chronic debilitating
diseases
o persons aged over 65 years
r residents of rest homes, geriatric hospitals and
other chronic care facilities, and
o immunocompromised individuals.
The second group comprises individuals who may
spread infection to those at high risk, and group 3
consists of people engaged in essential community
services. The fourth group covers children with
specific conditions (e.g. children who require long
term salicylate therapy, and those with sickle cell
and other haemoglobinopathies).lll
Melhods ond Doto
The costs incurred and the costs avoided (bene-
fits) in health economic analyses can be classified
as direct medical, direct nonmedical. indirect and
intangible. Direct medical costs are those involved
in providing treatment, and include the purchase of
vaccines, medical practitioner consultations and
hospital costs. Direct nonmedical costs incurred by
the illness and its treatment could include transport
to receive treatment and the cost of special food as
a result of the illness. Indirect costs encompass
work output lost as a result of morbidity and mor-
tality. rvhile intan*sible costs are concerned with
pain. suft'erin-e and loss of quulity of lit'e rcther than
changes in resource opportunity costs.l5l
This study tocuses on thc incrcmentll direct
medicnl costs of intluenz.a r';.tccinll,ion tbr pr'ople
aged 65 years and over. The net cost of vaccinution
was conrpared with that of no vaccination. Vacci-
nction of at-risk adults under 6-5 ycurs of age and
children vu'ith chronic debilituting discascs \ri,rs
evululted as an udjunct to the scnsitivity analysis.
Together, these 2 at-ri.sk groups ilccount tor ubout
209c oI the total (ull agcs) Ner" Zeulitnd popull-
tion.t:l Il'r'accinrtion '*'r're to bc extended to thc
iu Adrs hternohonol Lrmtled All nghts reseNed.
household contacts and caregivers of these people,
the numbers would double.trl but insufficient data
exist to allow quantification of the costs and bene-
fits for these individuals.
Table I lists the International Classification of
Diseases (ICD) diagnosis codes relating to influ-
enza. pneumonia, other respiratory conditions and
hean failure, as described by Nichol et al.tTl These
codes were used to define influenza and its compli-
cations and as the basis for calculating healthcare
resource volumes in New Zealand. The vaccination
cost and the direct medical costs avoided for the at-
risk group studied (i.e. people aged 65 years and over)
were estimated using these diagnosis codes.
Table II summarises the steps followed to esti-
mate the incremental net costs of vaccinating peo-
ple aged 65 years and over.
Costs were estimated from 3 perspectives: that
of the individual (personal, out-of-pocket or health
insurance), government and society. Because all
costs relate to I year (i.e. a prevalence study), dis-
counting to present values was not necessary. AII
unit prices and costs used in the study were in 1992
New Zealand dollars ($NZ) and were exclusive of
l2.5%o goods and services tax (GST), which is a trans-
fer payment from a societal perspective. The mid-
point exchange rate at the end of June 1992 was
$NZl = SUS0.5458.
The current influenza vaccination rate of 2jVcl?l
among people aged 65 years and over, together with
the baseline values for health resource utilisation re-
ductions, were used in the base c:lse analysis. Sen-
sitivity anulysis rvus used to evalulte the impact of
chun_qes to the key variubles in the study. For exam-
ple. the per vrccination cost rel:rting to the older
group (265 yelrs) [excluding the costs of heart fail-
urc' and adjusting the hospitalcosts to tuke account
ot'diflercnt diagnostic related group (DRC) hospi-
trl costs for those under 65 yearsl was applied to
thc youngcr group (<65 vears) because no specific
di.rta on health resourcc utilisation ch;lnges were
avuilablc.
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Table l. Diagnosis codes taken from the ICD-9CM (lnternational Classification ot Diseases. ninth revision, clinical moditication)tel lst 1n11r"n.",
pneumonia, other respiratory diseases and heart failure
Code Diagnosis Code Diagnosis
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Pneumonia and intluenza
480 Viral pneumonia
481 Pneumococcal pneumonia
82 Olher baclenal oneumonia
483 Pneumonia due to other specitied organism
N4 Pneumonia in infectious diseases classified elsewhere
485 Bronchopneumonia,organisrnunspecified
486 Pneumonia,organismunspecified
487 lnfluenza
Acute nasopharyngitis, the common cold
460 Acute nasopharyngitis, the common cold
$2 Acute pharyngilis
465 Acute upper respiratory infections of muhiple and
unspecified sites
466 Acute bronchitis and bronchiolitis
490 Bronchitis, not specilied as acute or chronic
491 Chronic bronchitis
492 Emphysema
493 Asthma
494 Bronchiectasis
495 Exlrinsic allergic alveolitis
496 Chronic airway obstruction, not elsewhere classitied
500 Coalworkers'pneumoconiosis
501 Asbestosis
ffi2 Pneumoconiosis due to other silica. silicates
5Og Pneum@oniosis due to other inorganic dust
504 Pneumonopathy due to inhalation of other dust
505 Pneumoconiosis, unspecified
506 Respiratory conditions due to chemical fumes and
vapours
507 Pneumonitis due to solids and liquids
508 Respiratory conditions due to other and unspecitied
extemal agents
510 Empyema
511 Pleurisy
512 Pneumothorax
513 Abscess of lung and mediastinum
5 14 Puhonary congestion and hypostasis
515 Postinflammatorypulmonaryfibrosis
516 Other alveolar and parieloalveolar pneumonopathy
517 Lung involvement in other conditions classified elsewhere
518 Other diseases of lung
Heart failure
428 Heart failure
a Exdudinq influenza and pneumonia.
Voccine Cost
The potential number oI influenza vaccinations
was based on the number of people aged 65 years
and older.tsl who accounted tor ll.5Vo of the total
population of New Zealand in 1992. Those aged
under 65 years and at risk of intluenza (for the
sensitivity analysis) accounted tbr 9.37c of the total
popularion.tll The influenzl vaccine acquisition
cost to general pructitioncrs (CPs) \t'as SNZl2.96
per annual virccination (intorrnation suPptied by
Rh0ne-Poulenc Rorer NZ Ltd. and CSL NZ Ltdl.
GPs charged a total fcc oi'SNZl7.78 for an intlu-
enza !'accination, being thc costs of their fee plus
that of the vaccine. This tigure tvas the meun charge
culcullted from an inlornrrtl tc'lephone survey of
approximately l0 CPs in Wellington, New Zealand
(own unpublished data). This tee was unchanged
from that reported in l99l.t:l
Utilisotion of Heolthcore Resources if No
Voccinotion is Given
Tobiastll considered that. on the basis of influ-
enza vaccine sales in New Zealand, about 20Vo of
the elderly population (265 years) and l07c of the
Table 11. Steps involved in estimating the incremental costs and
benefits ot rnlluenza vaccination in New Zealand
Steo Calculation
1 Estimate the cost of vaccination (C)
2 Estimate utilisation of healthcare resources il no
vaccination given (Up)
3 Calculate the change in the volume of resources il
vaccination given (Uc)
a Apply unit costs (P) to the change in the volume of
resources used (Uc) to estimate the costs avoided
(benefits; B) of vaccination: B = Uc x P
5 Calculate the incrernental nel costs or benefits (NC):
NC=C-B
6 Conduct sensitivity analyses
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younger (<65 years) at-risk groups are currently be-
ing vaccinated. A number of researcherslT.e. l0l have
found that vaccinated individuals utilise fewer
healthcare resources than unvaccinated individu-
als. Therefore, to calculate healthcare resource
utilisation in the 'no vaccination'scenario, it was
necessary to scale up the actual utilisation data to
account for the 20Vo of the elderly population who
are actually being vaccinated. Thus:
Uat-,P=l-o/.r.u.)
where:
Up = potential utilisation volume (i.e. the volume had
there been no vaccinations)
Ua = actual utilisation volume
Vr = vaccination rate expressed as a decimal
Uc - proportional reduction (expressed as a deci-
mal) for utilisation volume as a result of vaccina-
tion.
Data (broken down by ICD code) on the numbers
of GPconsultations and prescription items dispensed
were averaged over the years l99l, 1992 and 1993.
These data were obtained from IMS (N.2.) Ltd. The
number of prescriptions for those aged 65 years and
over was estimated from the number of prescrip-
tion items written per GP consultation for all ages
multiplied by the number of consultations for those
aged 65 years and over.l Hospital admissions by
ICD code were derived trom public hospital separa-
tion data averaged over the 
-i years 1990, l99l and
1992 (the latest 3 years available at the time of the
studv;.ltt I
MedicolCosts Avoided
The potential reduction in thc volume of heulth-
care resource use was lhe mean o[ the percentaue
reductions in hospitalisctions over 3 influenz-a sea-
sons for vaccinated paticnts aged 65 years and over.
complred with unvuccinuted individuals.lTl Thc'sc
percentuge rcductions $r-rc obtlincd for pncunronia
and intluenza. othcr acutc' i.rnd chronic respiruttlrv
I These dlta prob;rbly untlerestirnutc the number of pre-
scriptions written lirr thosc :rgctl 6-5 ycars and ovcr. Thus, our
costs would bc conrervatire.
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conditions (i.e. all chronic and acute respiratory con-
ditions excluding pneumonia and influenza; see table
l) and congestive heart failure. The comparisons
between vaccinated and unvaccinated groups were
adjusted for differences in patients' baseline charac-
teristics that could alter outcome variables (e.g. had
the patient been diagnosed as having a heart or lung
disease before the study;.tzl
In the absence of resource-specific data from
randomised clinical trials, case-controlled studies
or cohort studies, these percentage reductions were
employed to calculate the potential reductions in
all healthcare resource utilisations in our study. The
baseline savings in the volume of healthcare re-
sources used were: influenza and pneumonia52Vo;
other respiratory conditions 287o; and heart failure
24Vc. Tlte incremental cost of influenza vaccination
in volume terms was the percentage reduction in
utilisation of New Zeiland healthcare resources
multiplied by the volume of resources used assuming
no vaccination. The incremental cost in dollars was
calculated by multiplying the incremental cost in
volume terms by New Zealand unit costs.
Heolthcore Resource Unit Costs
GP consultation costs used in the study were based
on the mean fee actually charged of $N223.20,t121
which is l4Vo lower than the listed fee because GPs
do not charge all patients the full fee. This fi-sure is
inclusive of the GP subsidy Igeneral medical services
benefi t (G M S) I but exclusive of GST at I 2.57c. The
CP subsidy (GMS) used was the rate applicable to
benellciries (i.e. $N213.33 as at Febru:ry 1992;.tt.rt
The average government-subsidised cost o[ u
medical prescription used for the calculations rvas
thc averuge value of SNZ3 l.l6 applicable to elderly
pcople (265 yearsl ar June l992.tl{l The purienr
copavnrcnt was $N24.44, applicable to beneficiur-
ies. and chronically ill and high user groups, at Feb-
ruary | 991.llrl Nledicines avail:rble and sold ro pl-
tients over-the-counter were not evaluated.
Hospital costs were bused on DRG costs.ll-5lThe
DRG codes most closely related ro the specific age
group c<lncemed and to thc diagnosis codcs described
in tablc I were usc'tl. A weighted avcrage (by volume)
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Table lll. Baseline costs of influenza vaccination versus no vaccination, by perspective. These costs are for a population of people aged 65
years and over, and are in 1992 New Zealand dollars ($NZ; $NZt = $US0.5458, June 1992) exclusive of goods and services tax. Calculations
assumed that 20olo of this population are vaccinated. Costs were calculated lrom 3 perspeclives: individual. govemment and societal
Cost type Heafthcare Cost b,y perspective (SNZ)
resourcevolume individual.
change (no.)
govemment society
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Total costs
Additional direct medical costs
vaccination at GP
Direct medical @sts avoided (benefits)
GP consultations
prescriptions
public hospital admissions
Total direct costs avoided (benefits)
Net cosP
Costs avoided per clollar cost of vaccination
Coote per vacclnatlon
Addfional direcl m€dical costs
vaccination at GP
Direct medical costs avoided (benefits)
GP consultations
prescriplions
public hospital admissions
Total direc{ clsts avoided (benefits)
Nel cosP
79 632
24094
29 494
745
350 000
240 000
130 000
370 000
(10 000)
1.04
4.44
2.99
1.65
4.63
(0.19)
1 060 000
320 mo
920 000
3 740 m0
4 980 000
(3 e20 00o)
4.69
13.33
4.03
11.54
46.98
62.55
(49.221
1 420000
560 000
1 oso 000
3 740 000
5 350 000
(3 e3O 000)
3.78
17.78
7.02
13.19
45.9E
67.18
(49.40)
1
0.30
0.37
0.01
a Personal, out-of-pocket or insurance.
b Costs in parentheses indicate a net benefit.
Abbrcviation: GP = Q€neral praclitioner.
was derived for pneumonia and influenza ($NZ550l
for I episode) and for other acute and chronic re-
spiratory conditions ($N24700), Weighted average
hospital unit costs for at-risk people aged under 65
years were similarly estimated ($NZl787). For
heart failure. the DRG unit cost was $NZ-1963.
Resulls
T:rbles III and IV summurise the baseline costs
by diagnosis and from the perspectives of the indi-
vidual. government and :ociety for the age group
65 years and over. CST is not included in the pre-
sentction ot'results bec:lusc it is a tr;rnsfer payment
tiom the perspectives oF government, society as a
whole irnd the citizens thlt mirke up society. How-
ever, tiom the perspective of an individual as opposcd
to the sum of all individuals. GST is an additionrl
cost to be paid. If a health insurance company is
O Aclis Intemotionol Limited. AII fights reserved.
reimbursing that individual, GST will be included
in the payment.
From a societal perspective, additional direct
medical costs of vaccination compared with no vac-
cination amounted to $NZl.42 million ($NZ,17.78
per vaccination); total direct medical costs avoided
were $N25.35 million ($N267.18 per vaccination)
with net benefits of $N23.93 million ($N2.19.40
per vaccination) [table III]. Because the majority
of costs tall on the individual (out-of-pocket) and
most of the costs avoided accrue to government,
there is a small net benetlt to individuals of $NZO.l9
pcr vaccinution and a comparatively much larger net
benefit to government of $N249.22 per vaccina-
tion (table lllt. The direct medical costs avoided per
dollar vuccination cost were: $NZ I .04 for each do[ar
spent by individuals, $N2.t.69 tbr each dollar spent
by government and SNZ3.78 for society (table III).
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Table lV. Basetine costs ot influenza vaccination versus no vaccinalion. by diagnosis. These costs are for a population ol people aged 65
years and over, and are in 1 992 New Zealand dollars ($NZ: $NZt = $US0.5a58, June t 992) exclusive of goods and services tax. Calculations
assumed thal 20% of this population are vaccinated, and costs were calculated from 3 perspectives: individual, govemment and societal
Cost typ€ Cost by perspective (SNZ)
Totsl costs
Direct medical costs avoided
pneumonia and influenza
other respiratory conditions
heart lailure
Total direcl costs avoided
Costs per vaccinalion
Direct medical costs avoided
pneumonia and influenza
other respiratory conditions
hearl tailure
Total direct costs avoided
30 000
22oooo
120 000
370 000
0.43
2.74
1.46
4.63
1 400 000
2 180 000
1 400 000
4 980 000
't7.56
27.40
17.59
62.55
1 430 000
2 400 000
1 520 000
5 350 000
18.00
30.13
19.05
67.18
a Personal, out-otpocket or insurance.
From a societal perspective, the medical costs
avoided as a result of reduced calls on health re-
sources for various diagnoses were estimated to be
$NZl.43 million ($N218.00 per vaccination) for
pneumonia and infl uenza $NZ2'40 million ($N230. I 3
per vaccination) for other respiratory conditions, and
$NZl.52 million ($N2t9.05 per individual) for
heart failure.
Sensitivity analysis was undertaken for the soci-
etal net costs for people aged 65 years and over, and
the results are presented in table V. The analysis
considered the percentage vaccinated. and the maxi-
mum and minimum reported changes in healthcare
resource utilisation. Changing the vaccination cost
and subsidy rates could not be effectively evalu-
ated, because the price elasticity of demund for vac-
cinations with respect to out-of-pocket payments
was unknown. If the percentuge of those vaccinated
(in the age group 65 years and over) was increased
in steps of 207c, the net benetlt increased in incre-
ments of $N23.93 million (table V). The ratio of
costs avoided per dollar cost of vaccination indi-
cates that the vaccination cost (vuccine plus admin-
istration) of the vaccine could increlse b.v a multi-
ple of 3.78 before net benefits tall to zero.
The at-risk populution under 65 years of age was
also considered as an additionaladiunct to the sen-
O Adis hle,noiionol Llmrted. All rights reserved.
sitivity analysis; costs of vaccination in this group
are shown in table VI. If this younger at-risk popula-
tion is considered, the societal net benefits of influ-
enza vaccination increase by $N20.58 million or
l57o over the baseline. The ratio of costs avoided
per dollar cost of vaccination for the younger at-risk
Table V. Results of the first sensitivity analysis. The etfect of varying
the rate of influenza vaccination lkom2O/o (baseline) to 1OO%l on
healthcare resource utilisation in people aged 65 years and over
was studied in this sensitivity analysis. Costs are in 1992 New
Zealand dolhrs ($N4 $NZl = 9959.54*, June 1992), are exclusive
of goods and services tax, and are calculated trom a societal
perspective
Populahon vaccinated
i /o,
Change in healthcare resource usage
(mitlions ot $NZ)a
baseline highb loraf
20
40
OU
80
100
Costs avoided per
dollar cost of
vaccination (SNZ)
(5.60) (0.76)(11.20) (1.52)(16.80) (2.271(22.40) (3.03)(28.00) (3.7s)
4.96 1.54
(3 e3)
\7.87)
(11.80)
(r s.74)
(rs 67)
3.78
a Figures in parentheses andicate net benelits rather than nel
cosls.
b Results assuming that vaccination leads to the maximum
reported reductions in healthcare utilisation,
c Results assuming that vaccination leads to the minimum
reported reductions in healthcare utilisation.
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group was 60Vo lower than the older age group
from a societal perspective (L5l vs 3.78) [tabtes III
and VIl.
Running the analysis using the reported minimum
reductions in healthcare resource usage as a result of
vaccination (i.e. pneumonia and influenza lgvo,lel
other respiratory conditionsZ}Volll and heart fail-
ure 0Vo11\ reduced the net benefit of vaccination to
society by 8l%o, and the direct medical costs saved
per dollar of vaccination cost by $NZ2.24to $NZ t .54
(table V). Using the maximum reported resource
savingstTl (i.e. 57Vo for pneumonia and influenza,
34Vo for other respiratory conditions, and 38Vo for
heart failure) increased the net benefits to society
by 42Vo and the direct medical costs saved per
dollar of vaccination cost by $NZ I . l8 to $N24.96.
Discussion
Influenza vaccination is probably more effective
in preventing severe complications from influenza
than in eliminating minorcomplications. Thus, the
application of the hospital reductions to GP con-
sultations and prescriptions may overestimate this
cost saving. However, as the major costs lie within
the hospital sector, our final results are unlikely to
be seriously biased.
Sensitivity analysis indicated that although there
is considerable variation when upper and lower
ranges in resource savings are applied, the direct
medical costs avoided remain greater than the addi-
tional costs of influenza vaccination. From a soci-
etal perspective, changing the copayment or subsidy
rates altered the division of costs that individuals
or government paid. Altering the GMS subsidy is
also likely to alter the rates of vaccination because
the price to the patient would change, but this could
not be quantified.
Sensitivity analysis also indicated that, for each
207o incremental increase in the uptake of vacci-
nation. there would bc' an incremental net societll
benetlt of $N23.93 million. To achieve a higher vac-
cination rate, additionalcosts of education and pro-
motion (targeting at-risk groups and healthcare
professionals) would be incuned by the suppliers o[
the vaccine, government or both. This additional
@ Adis Internotionol Limited. All righls reserved.
Table Vl. Results of the second sensitivity analysis. The cost of
vaccinating at-risk people under lhe age of 65 years was studied,
from lhe perspeclives of the indiviclual, government and society.
Costs are in 1 992 New Zealand dollars ($NZ: $NZl = $US0.5458,
June 1992) and are exclusive of goods and servicss tax
Cost type Perspective
individuala government society
Net cost (millions ot $NZ)D 0.08
Costs avoided oer dollar 0.71
cost ol vaccination ($NZ)
(0.66)
1.77
(0.s8)
1.51
a Personal, out{tpocket or insurance.
b Figures in parentheses indicale net benefits.
cost was not taken into account in our analysis, but
the results provide the information required to set
an upper limit on an educational/promotional bud-
get.
It was found that there was a difference in the
breakdown of cost savings by disease category be-
tween this study and that reported by Nichol et al.t7l
because the underlying hospital admission rates for
pneumonia and influenza in the US were higher than
those recorded in New Zealand. Conversely, the New
T,ealand hospitalisation rate for heart failure was
higher than that in the US study. (Although it is
beyond the scope of this study to evaluate the rea-
sons for different hospitalisation rates, a possible
explanation is that the prevalence and mode of
treatment of the diseases considered could differ
between the US and New Zealand.) Although the
absolute volumes are different, we consider that it
is valid to apply the US percentage reductions in
utilisations of healthcare resources to New Zealand
base resource utilisation volumes.
In this study, rve used average rather than mar-
ginal unit cost dirta to estimate cost changes as a
result of vrccination. Policy decisions reluting to
intluenza vaccination would involve increments of
hundreds or thousands rather than a single individ-
ual. Multiplying the marginal net cost o[one addi-
tionul vaccination by the number of vaccinations
r.r'ould provide a false estimate of the incremental
net costs ot'the programrne. The marginal net cost
ol'onc additionul vuccination would ignore overhead
costs. but the incremental ne( cost of large nunrbers
of aclditional vaccinations should include those
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overhead costs that would change if the vaccination
rate altered. The actual costs associated with policy
changes would be greater than marginal costs, but
probably less than average costs.
Because health authorities consider that influenza
vaccination should also be given to at-risk groups
under65 years of age, we applied a similar method-
ology to estimate the costs and benefits of such
vaccination. The costs of heart tailure were excluded
from this group. In addition, because more specific
information was not available, the reduction in
resource volu;nes for pneumonia, influenza and
other respiratory conditions applicable to the 65
years and over group was used in the younger age
group.
The percentage reductions in resource utilisa-
tion for people under 65 years of age are unlikely
to be identical to those for older people. Moreover,
the results obtained for people aged <65 years can-
not be accepted with the same confidence as those
pertaining to the older age group. Despite these 2
points, it was considered that policy makers would
find this information useful. It was found that the
ratio of net costs avoided per dollar of vaccination
cost was substantially less for the younger at-risk
group than the ratio applicable to the older group.
The main reason for this difference was the lower
incidence and unit cost for hospitalisation in the
younger age group (the average length of hospital
stay was shorter for this age group).
As no specific data were available on GP and
prescription utilisation, we applied the percentage
reductions in hospital resource use to GP consult-
ations and prescriptions. Horvever. it could be argued
that int'luenza vaccination is more efficient in pre-
venting hospitalisations than in avoiding GP con-
sultations and prc'scriptions. As less than one-third
of the total medicalcosts avoided were nonhospital
costs. inaccuracies in estimirtes of nonhospitll
resource utilisations w'ould not impose r serious bias
on our estimlte ot'total cost savings. Omissittn ot'
nonhospital costs would detract from the study's
value as a policy analysis tool.
Subsets of the target groups studied could also b','
resenrched. For examplc, in 1992 there were 20 961
O Actis Inlernononol Umr?ed. All rights reserved.
beds in rest homes and approximately 20 000 full
and part-time employees.tl6l If it is assumed that
the net benefit of vaccinating 20 000 patients is the
same as that estimated in this study (rest home res-
idents are a subset of this), the net benefit to society
of vaccinating these full and part-time employees
would be $NZl.34 million.
For an individual of working age, the cost of a
vaccination would be offset by additional produc-
tion gains. Riddiough s1nl.tr7l found that 0.03 work
days per vaccination could be gained for an individ-
ual aged between 45 and 54 years. In a study ofstaff
in a New Zealand health laboratory, it was found
that absenteeism from influenza was 39.59o in the
vaccinated group and 66.7Vo in the unvaccinated
group.tl8l [t is sometimes argued that short term
absence from work is not a cost, because there is
slack in the economy (unemployment and workers
able to cover for absentees), or that work set aside
is actioned on the return of the worker.flel Potential
production loss, both paid and unpaid, should be
estimated on the understanding that actual produc-
tion loss may be somewhat less. However, in many
situations in New Zealand, if a worker becomes ill
there is no surplus capacity and the output of the
absentee worker will be lost. A production loss may
also occur when parents or guardians take time from
work to care for children who are ill with influenza.
The cost of adverse events relating to the vac-
cine were not evaluated in this study. Modern in-
fluenza vaccines are considered to have few adverse
eft'ects, and medical practitioners are advised against
vaccinating patients with a known or possible ana-
phylactoid hypersensitivity to hens' eggs.trl Although
intangible costs were not evaluated. quulity-o[-life
aspects are important for potential intluenza patients
and their l'amilie s and friends.
New Zealand duta for 1992 recorded I132 deaths
fronr pneumonia and intluenza (as a wholel.tltll nn4
for men and wonren over 75 years of age it rvas the
tburth and third lcading cause o[ death. respectively.
However. it is considered that intluenza is respon-
sible for nrany de aths recorded under categories other
than intluenza and pneumoniu.ll().ll.lll Fedson et
ol.ttttl (which covered the intluenza outbreaks oI
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1982-3 and 1985-6 in the Canadian province of
Manitoba) found that vaccination was 43 to 65Vo
effective in preventing hospital deaths in patients
admitted with pneumonia, influenza or other respi-
ratory conditions, and 27 to 30Vo effective in pre-
venting deaths from all causes.
Vaccination, where an infectious disease is in-
volved, confers external benefits to unvaccinated
individuals in a community by limiting epidemics.
The protection, or herd immunity, afforded to un-
vaccinated people when others around them are vac-
cinated has been estimated by Tobiastsl to be achieved
by vaccinating 70 to75Vo of residents in a rest home
or807o in open communities. The US Department of
Health and Human Servicesflllhave recommended a
vaccine coverage of 80Vo for institutionalised at-risk
individuals and 60Vc for at-risk community resi-
dents. If the vaccination rate for at-risk individuals
in New Zealandcould be increased to6OVo then the
net benefits reported in this study would increase
by 20AVo. As discussed earlier, the costs of promo-
tion and education to achieve this would need to be
deducted from the net benefits. In a study of healthy
working adults, Nichol .1 u1.t]rl found that vaccina-
tion against influenza resulted in substantial health-
related and economic benefits. There was a reduc-
tion in days off work and medical costs resulting in
net savings (direct and indirect costs) of $US46.85
per person (1994 dollars).
The results of this study have demonstrated the
economic benefits of vaccination of at-risk groups
in society. The current vaccination rlte in New Zea-
land (207c) is less than is nredically desirable.lrl
and a higher rate hils been dernonstrlted in this
study to be justitiablc in econontic terms. Strategies
to increase the vaccinution rtte include subsidising
vaccinations to reducc' the cost to the individual.
changing the mode of dc'lirery'. and education and
promotion progrilnlnlcs.
Research into the inrprrct ot'r'lccinat.ion on thc
utilis:rtion of nonhospitll rcstlurcc's lor pc'ople aged
65 years and oldcr would bc. usel'ul. but not essen-
tial. becausc most cost stvin,gs relate to hospiti-rl
costs. To formulate a vaccination policy and recom-
O Adis Internotionol Limited. All rights reservecl
mendations for at-risk individuals of working age,
further information is required on all costs.
This study has combined published overseas
findings with New Zealand volume and unit cost
data. Because of the need to use healthcare resources
efficiently, suitable overseas studies should, where
appropriate, be applied to New Zealand to evaluate
treatment and health policy options for New Zea-
land. The resources required to replicate overseas
studies and generate equivalent New Zealand clin-
ical data may be better devoted to evaluating and
applying overseas studies to New Zealand, and in
providing healthcare.
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Critical L.g Ischaemia in New Zealand
Economic Cost of Amputation versus Intravenous Iloprost
Helen M. Scottr and W. Guy Scott2
I W. Guy Scott and Associates Ltd, Wellington, Nerv Zealand
2 Wellington Polytechnic, Wellington, New Zealand
Summory The purpose of this study was to establish the incidence of surgical amputation
for critical leg ischaemia in New Zealand, and estimate the hospital, prostheses
and indirect costs of this intervention. The cost of amputations was then compared
with the cost of treating such patients with iloprost.
The study was retrospective. Individual patient records relating to l99l for
both public and private hospitals were analysed. Unit costs relevant to 199 I were
applied to the volume data of patients and procedures to derive total costs. Costs
were estimated on an incremental basis taking a societal perspective.
Conservative estimates were obtained for hospital costs" prostheses and for
production loss (loss of output or productivitl't. Total cost was SNZl5.9 million
(hospital and prosthesis cost SNZl3.l million. production loss SNZ2.8 mitlion).
The total quantified cost per amputation rvas SNZ23 038 (hospital and prosthesis
cost SNZI9 020, production loss $NZ.{017).3JVc of patients requiring amputa-
tions efrvere in the working a_se 
-sroup. The theoretical avoidance of amputation
by treatment with iloprost resulted in net savings of hospital and prosthetic costs
of betrveen SNZ6660 and SNZ8720 per patient.
Amputation for critical leg ischaemia is costly and has a high mortality, but
for iloprost treatment to be cost effective in a New Zealand hospital setting,
patients must be tar_eeted and a success rate of at least 557c achieved in avoidance
of amputarion and reduction of pain while at rest.
Critical leg ischaemia is ischaemia that endan-
the leg or part of a leg. Patients with diabetes
5 times more likely to develop critical leg isch-
mia than nondiabetic patients.I ll
Existing data on the prevalence of critical leg
ischaemia have been based on all leg amputation
procedures undertaken or on all referrals to limb-
fitting centres. The European Working Group on
Critical Leg lschaenlioll I assumed that virtually alt
leg amputations were undertaken for ischaemia
and that 25Vo of patients with critical leg ischaemia
would eventually require an amputation. Referrals
to limb fitting centres gave an estimate of amputa-
tions on the assumption that half of the patients
requirin-e amputation rvould be referred for a limb
fitting, The available information from Western Eur-
ope and the US indicates that the prevalence of
peripheral arterial disease is 5Vo in males over 50
years old, but ferver than 107o of these will develop
critical leg ischaemia.[]l Incidence rates, similarly
based on studies in Western Europe and the US, have
been estimated to ran-ee between 500 and 1000 nerv
cases per million population per year.fl I
For patients rvith critical leg ischaemia who
present with rest pain (i.e. incurring pain while at
rest) and/or ischaemic ulcers, the first choice of
treatment is revascularisation by surgical bypass or
percutaneous angioplasty. However, almost 407o
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of such patients are not suitable for reconstructive
surgery because of the distribution of arterial dis-
ease, other rnedical or anaesthetic considerations,
or because prcviclirs rcvtscularisiltion was ullsuc-
cessful.l'jlThc lasr rcsort is anrputation,14l which is
regarded as a high risk procedurc.
This study sought to cstablish the incidence and
costs to New Zeallnd society of critical leg isch-
aemia patients u'ho had lower Iimb amputatiorrs
and to use these costs to evaluate the cost or benefit
of treating selectc'd numbers of such patients with
iloprost. Thus, both pharmacoeconomic and cost-
of-illness aspects ri,ere assessed.
Iloprost is a prostacyclin analogue with an elim-
ination half-lil'c ol' 30 rninutcs.l-51 Natural prosta-
cyclin has a hall'-lil'c ol'2 to 3 minutcs. Thc alra-
loguc inhibits plltclct uggrcgation and induccs
vasodilatiou, providing a nonsurgical treatment
option for patients with critical leg ischaertria irr
cases when revascularisation is not possible, or has
failed, and the next option would be anrputation.
Information on both the economic cost and clin-
ical efficacy of treatnrent options are essential for
cost-effecti ve deci s ion- making relati ng to indi vid-
ualpatients and to hospital management. Accurate
clinical and costing data are the starting point for
policy analysis and formulation.
Methods
A retrospective study incorporating incremental
analysis was used to estimate costs for critical leg
ischaemia patients who had amputations. Incre-
mental analysis is concerned with the measurelrrent
of costs that wouid change as the result of a deci-
sion rnade (in this ilaper the dccision to amputate a
limb or to use drug treatrnent).
Since the objecrir,cs of the study were to provide
data that rvould allori, drug vs surgical treatntent op-
tions to be evaluate d in cconomic terms. it was nec-
essary to estimate only those costs and benefits that
would ditfer betw'een these treatments. Costs and
benefits that were identical would cancel each other
when differences in costs and benefits between
treatment options u'ere calculated. It was assumed
o Adis Internoiionol Umilec All rights reserved.
that the costs up to the point of amputation would
be identical for both treatment options studied.
Diagnosis Related Groups (DRGs) is a classifi-
cation schcrrie relating the type of patients that a
hospital trcats (case mix) to the costs incurred by
the hospital in their treatment. That is, DRGs are
groupings of diagnoses according to their clinical
similarities and treatment costs. International Clas-
sification of Diseases (ICD) is a classification sys-
tern (published by the World Health Organization)
of diseases, each with a unique code number. Pa-
tients who underwent vascular reconstructive sur-
gery followed by amputation were included in the
analysis, but costs were evaluated for the amputa-
tion only. Individual l99l paticnt rccords (unit rc-
cord data) rcluting to (DI{G) codes ll3 (anrputa-
tion lbr circulatory systcur disordcrs cxccpt uppcr
lirnb and toe) and 285 (amputation of lower limb
for endocrine, nutritional and nretabolic disorders),
and ICD procedure code 841 (arnputation of lower
limb) were obtained for all New Zealand public and
private hospitals.l6lThese data related to all hospi-
tal admissions, the details of which are recorded at
the time of discharge or death. Any patient readmit-
ted for the same condition within the period studied
was recorded as a separate admission. Data were
analysed with respect to age and gender groupings.
Records with the following ICD codes were ex-
cluded from the analysis: all accidcnt codes, all
codes rclating to nralignant and bcnign ncoplasrns
likely to result in surgery to the lirnbs (lCD codes
170 to 173, 198,2A2,213,215,237,238), late ef-
fects of injuries to the limbs (lCD codes 905, 906),
unspecified disorders of the joint (lCD 719), other
disorders of the bone and cartilage (ICD 733), and
congenital :uomalies of lirnbs and musculoskeletal
defornrities (lCD 754 to757).
Two alternative rnethods were used to isolate
patients undergoing leg arnputations. The first
method selected records by ICD procedure code
(the ICD procedure code method) and the second
method selected records by DRG code (the DRG
method). The 2 methods were used as a cross check
on data sorted. ICD procedure code 841 (amputa-
tion of the lower lirnb) was costed using DRG code
PhormocoEconomics 6 (D 1994
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113.tzJ The DRG method selected records under within the range of iloprost 0.5 to 2nglkglmin over
DRG codes 113 and 285 (relating to limb amputa- 6 hours daily. For the first 2 to 3 days, treatment
tions), and also those records in DRG codes I10, should be started at an infusion rate of l0 mlft. The
I I t and I l2 relating to reconsrructive vascular pro- dose is then increased at intervals of 30 minutes in
cedures where a limb amputation was recorded. steps of l0 mlftr, up to 40 ml/h. Current clinical
The amputation data, as derived above, were practice in New Zealand is to administer iloprost
also used to calculate the cost of providing patients for 20 days, although European studies indicate
with artificial limbs (unit costs were supplied by that best results were achieved after treatment pe-
the Artificial Limb Board, Wellington, 1993) on the nods of 3 to 4 weeks'[9]
basis of below knee, at or above knee procedures. All unit costs relate to the l99l year and are
Amputation of toes (ICD procedure 841l) was ex- exclusive of societal transfer payments such as
cluded from this cosring analysis. It rvas assumed GST (GST is the New Zealand Goods and Ser-
that one-half of rhe patienrs thus identified would vices Tax, a transfer payment from the perspective
be fitted with artificial limbs.ttl of society). Individual items may not add exactly
Production loss (loss of output or productiviry) to the totals shown because of rounding' The mid-
was evaluated using the total average ,,veekly .orn- point exchange rate as at June l99l was $NZ I '00
ings combined for both males and females (15 to = $US0'579'
64 vears of ase inclusive).[8] Estimates of produc-
Results
Ition loss were based on a week otf w'ork for every
lday in hospital. No precise information on time off The data (refined, as in methods) and analysed
lwork was available. However, clinicians and phys- using ICD procedure codes resulted in a total of
liotherapists consulted by the authors considered 6gg records (62g records in rhe public hospital file,
Ithat the method chosen would provide conserva- and 60 in the private hospital file). These records
Itive estimates of the loss of production incurred by were used to estimate hospital costs. Table I shows
Ithose of working age given that the recuperation the total hospital cost of amputarions for critical
ltime is likely to be correlated with the length of leg ischaemia was $NZl2J16 million.
lhospital stay. The incidence of ampurarions for critical legI For the patient with critical leg ischaemia ischaemia was 202 per million. Analysis showed
liloprost is administered as an intravenous infusion that major amputations (involving more than digits
lfor 20 days at a cost of $NZ 185 per day. The dosage only) were almost exclusively undertaken in public
lis adjusted according to indir,idual tolerability hospitals. The analysis of the data with respect to
I
I
I fabn l. Hospital cost for amputations resulting from critical leg ischaemia, determined by procedure code and DRG estimation methods.
I Because of rounding, individual items may not add exactly to the totals shown
(by hospital type) (SNZ) ($NZ million)
Public Pnvate
ICD Procedure code estimation method
841 Amputation lower limb
DRG code estimation method
113 Amputation lower limb except toe
285 Amputation lower limb for endocrine disorders
Amputation lower limb except toe, recorded under
DRG 110, l1'l and l'12
Total DRG method
258
61
34
2
0
0
zco
61
34
18 483
18 483
't4254
18 483
1?.7',t6
4.769
0.869
0.628
6.267351
Abbreviations: DRG = Diagnosis Related Group; ICD = International Classification ol Oiseases.
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gender and age showed that there rvere fewer fe-
male patients both in total and in the workin,s age
group, but little variation existed in average age
between males and females.
Using only DRG I 13 gave a somewhat re-
stricted sample as additional public hospital pa-
tients undergoing leg amputations were also clas-
sified under DRGs I 10, I l l, I l 2 and 285. Patients
classified under DRG 285 rvere included and pa-
tients classified as DRG Il0 to I l2 rvere counted
if they had a lower leg except toe amputation. Thus,
an alternative estimate of hospital costs of
$N26.267 million was obtained. details of which
are shown in table L
Individual patients with critical leg ischaemia
may incur considerable hospital costs. It was found
that one-third of ICD 841 patients in public hospi-
tals were classified as havin_s been readrnitted for
the same condition, although not necessarily
within the same year.
Estimates of the number of patients rvith an'rpu-
tations requiring artificial limbs *'ere selected as
described in methods, and unit costs applied. The
total cost of prostheses was SN20.370 million
when estimated by the ICD procedure method, and
$N20.341 million when estimated by the DRG
method. These costs are detailed in table IL
Production loss for those of working age is de-
tailed in table III. Under the procedure method,
218 patients fell within the rvorking a_se group
( 15 to 64 years inclusive). i.e. 32Vc of the total nunr-
ber of amputations for critical Ieg ischaemia. Males
made up 67Vo (145) and t'emales 33Vc (73) of this
working age group. Lost production amounted to
$N22.764 million.
Under the DRG method. 90 parienrs Q-SVo) of the
total number of patients with critical leg ischaemia
amputations were of working age. Males made up
72Vo (65) and females 28Vo (25) of this group, and
together incurred a production loss of $NZl.90l
million.
Table IV summarises the ICD procedure and
DRG cost estimates. The ICD procedure cost esti-
mates were: hospital costs $NZl2.7 million, pros-
thesis $N20.4 million, lost production $N22.8
million. The DRG estimates were: hospital costs
$N26.3 million, prosthesis $N20.3 million, lost
production SNZl.9 million.
If iloprost is administered for 20 days at a drug
cost of $NZl85 per day in a hospital setting at a
ward (hotel) cost of $N2330 per dayll0l the total
medical cost per patient would be $NZl0 300 com-
pared with a cost of $NZ l9 020 (ICD procedure
method) per critical leg ischaemia patient undergo-
ing amputation. Medical cost savings per amputa-
tion avoided would be $N28720. If the drug treat-
ment fails, the pharmacotherapy cost of $NZl0 300
becomes an additional cost. There have to be 1.2
amputations avoided, that is, 1.2 successful treat-
ments to pay for I failure. In other words, for every
l0 treatment failures there must be 12 successes.
Thus, the success rate must be 0.55 UZI(12 + t0)l
to break even on the costs of iloprost therapy.
If iloprost is administered for 24 days (an aver-
age of the treatment length in European studies) the
treatment cost rises to $NZl2 360 and the savin-es
decrease to $N26660 per amputation avoided. There
have to be 1.9 amputations avoided, that is, 1.9 suc-
cessful treatments to pay for I failure (forevery l0
treatment failures there must be l9 successes).
Thus the success rate must be 0.66 [19(19 + l0)]
to break even on the costs of iloprost therapy with
this longer regimen.
Table ll. Prostheses costs. Because of rounding, individual items may not add exactly to the totals shown
Limb type Unit cost ICD Procedure method DRG method
(sNz) no. total cost (SNZ million) no. total cost ($NZ million)
Leg: below knee
Leg: knee and above knee
Total
1 350
3467
107
172
0.144
0.225
0.370
't10
56
166
0.149
0.192
0.341
Abbreviations; DFIG = Diagnosis Related Group: ICD = International Classification of Diseases.
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Number of oatients
Total number of weeks
otf work
Average weekly eamings
($Nz1
Total cosl (SNZ million)
Table lll. Production loss for those patients of working age (15 to
64 years) undergoing amputation for critical leg ischaemia
ICD procedure DRG method
method
costs, and that the DRG method provided an abso-
lute minimum estimate.
The hospital unit costs used in the paper were
the averages of 4 Area Health Boards. A cross-check
with the reported audited data from I of these
health boardsI I I I corroborated these averages.
The greatest single group of records (23Vo) re-
moved from the data base related to amputations
as a result o[ accidents of all types including med-
ical misadventure. This would indicate that it would
be unwise to measure the incidence of critical leg
ischaemia based solely on total amputation data as
this would result in an overestimation of costs.
The incidence of amputations for critical leg
ischaemia estimated in this study was 202 (ICD
procedure method) per million people. If it is as-
sumed that 257c of critical leg ischaemia patients
have amputations,[ll the estimate of the incidence
of critical leg ischaemia in New Zealand is 808 per
million people, which compares with rates found
in developed countries of between 500 and 1000
per million people.l ll
As one-third of patients are readmitted to hos-
pital, the prevalence of critical leg ischaemia if de-
rived from amputations and./or admissions will be
overestimated. This is because some. but not all.
Table lV. Summary of costs of amputations for critical leg
ischaernia. Because of rounding, individual items may not add
exactly to the totals shown
Total and average costs ICD orocedure DFIG
method method
218
4908
563.22
2.764
90
3375
563.22
1.901
Abbreviations: DFIG = Diagnosis Related Group; ICD =
lnternational Classification of Diseases.
Discussion
This paper presents information. hitherto un-
rvailable, on the incidence and annual economic
:ost of amputations for critical leg ischaemia in
rlew Zealand. Although the paper tocuses on hos-
rital costs for amputations, artificial limb costs.
loprost costs, and production loss tor patients of
vorking age undergoing amputations. other costs
re important in evaluating the cost of illness. but
:ould not be quantified with the data available.
iuch costs include reduced quality of lit'e. mortal-
ty, community care costs. and production losses of
)atients not in the work force.
The estimates of loss of production of those in
he working age group would have been higher had
r separate rate been used for males and females.
)ecause the male earning rate is higher and there
,vere more males in the study. Horvever. the esti-
nates of lost production would have been lorver
rad adjustments been made for unemployment and
.abour force nonparticipation. Lost production of
)atients not in the paid rvorklorce. although of no
less importance to society, was not evaluated.
The ICD procedure method of selecting patient
records gave higher numbers than the DRG
method. This was not unexpected as DRG code I l3
related specifically to amputations for circulatory
disorders, but if a patient had an additional and
more costly procedure they rvould have been
categorised under the more costlv DRG code relat-
ing to that procedure (and. thus. lost to DRG code
113). It was considered that the ICD procedure
method gave the best estimate of incidence and
O Adis Internotionol Limited. All riahts reserved.
Average eost per procedure (SNZ)
Quantified medical costs
Production loss
Total cost
Total costs (SNZ million)
Hospital (all costs)
Proslheses
Subtotal (quantified medical
costs)
Production loss
Total quantilied costs
Number of procedures
12.716
0.370
13.086
2.7&
15.850
688
'19 020
4 017
23 038
6.267
0.341
6.608
1.901
8.509
353
18720
5 385
24 105
Abbreviations: DBG = Diagnosis Related
Intemational Classitication ot Diseases.
Group; ICD =
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patients with readmission indicators will be read-
mitted during the course of a year. However, this
will not result in costs being overestinlated because
costs were calculated on the basis of all admissions
over the period of I year.
There were fewer female patients and little vari-
ation in average age between males and females,
but female patients had longer average hospital
stays. This may indicate possible inadequate early
treatment of female patients.
The costs per amputation represent a weighted
average taking into account the rnix of different
types of amputation and requirements for artificial
limbs, and as such, allow true comparisons to be
made between treatment options. To compare the
treatment costs of iloprost and sur,gery it was as-
sumed that the only difference in usage of medical
resources between each mode of treatment was the
hospital, surgery, prosthesis and iloprost cost. In
other words, it was assumed that costs. up to the
time of intervention either b1' amputation or treat-
ment with iloprost. would have been identical.
Treatment with iloprost has been shown to
lower mortality, reduce amputation rates.[3] heal
ischaemic ulcers and to relieve rest pain.[91 By
avoiding or postponing amputallep[5] iloprost im-
proves quality of life for the patient and reduces
amputation costs. If amputation is simply post-
poned. the patient may have an improved quality
of life and amputation costs will be reduced by be-
ing postponed. These benefits must be offset
against the additional cost of the pharmacothera-
peutic treatment.
If iloprost is administered for 20 days there have
to be 1.2 amputations avoided. that is. l.l success-
ful treatments to pay for I failure. The success rate
must be 55Va to break even on costs. Horvever, if
iloprost is administered for 2-l days there have to
be 1.9 amputations avoided. that is. 1.9 successful
treatments to pay for I failure. The success rate
must be 66Vo to break even on costs. Iloprost has
the potential to either reduce hospital costs or in-
crease them depending on the patients chosen for
treatment. If it is possible to target treatment to
those patients most likely to benefit from it (that is,
@ Adis Internotlonol Limitecl. All rights reserved.
those who can avoid amputation and who will have a
reduction in rest pain) the maximum benefit would
be obtained tiom this pharmacotherapeutic option.
Iloprost as an alternative to amputation would
also become more cost effective if it could be admin-
istered orally or in a lower cost hospital setting such
as a day clinictll or at a time convenient to the
patient. These changes would minimise disruption
to work and loss of production. Additional cost sav-
ings for successful pharmacotherapy would accrue
if production loss avoided was included as a benefit.
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Heart Failure
A Decision Analytic Analysis of New Zealand Data Using
the Published Results of the soLVD Tleatment Thial -
W. Guy Scottt andHelen M. Scott2
1 Wellington Polytechnic, Wellington, New Zealand
2 Health economics consultant, Wellington, New Zealand
Summory This study sought to evaluate the changes in direct medical costs and life-years
gained or lost by adding enalapril to conventional treatment (digoxin and
diuretics) for heart failure (HF).
The published results of the Studies of Left VentricularDysfunction (SOLVD)
Treatment Trial, and a decision analytical model developed by the University of
Pennsylvania, were used in combination with New Zealand data to undertake the
evaluation. All costs were measured in 1993 New Tnaland dollars ($NZy t$NZt
= $US0.5509, September 19931.
Potential net cost savings per patient treated over a 4-year period were $N2652
together with an additional 2 months of life gained. If these individual potential
cost savings are extended to the New Zealand population who have HF (but are
at present not receiving an ACE inhibitor) then $NZ6 517 000 in discounted
health sector costs could be avoided.
The model was sensitive to changes in the price of enalapril, to estimates of
the population with HF, the percentage of the population with HF treated with
enalapril, and to hospital unit costs for nonfatal cases of HF. The study demon-
strated that the addition of enalapril to the conventional treatment of HF was
cost effective when compared with conventional medical therapy alone.
'Increased usage of ACE inhibitors raises the costs
of medication, but on the basis of clinical evidence
it may be expected that lit'e-years will be saved, qual-
ity of lit'e will improve and the frequency of hospi-
tal admissions will decrease.'l I I The purpose of this
study was to evaluate the changes in mortaliry,
direct medical costs and life-years gained or lost
by adding the ACE inhibitor enalapril ro the con-
ventional pharmaceutical regimen (digoxin and di-
uretics) for heart failure (HF).The published results
of the Studies of Left Ventricular Dysfunction
(SOLVD) Treatment Trial,t2l and a decision analyt-
ical model (Version 3.0) developed by Henry Glick
of the University of Pennsylvania in collaboration
@ Adis lnternotionol Limiled. All rights reserved.
with investigators from Merck & Company, were
used in combination with New Zealand data to eval-
uate the possible changes. (Details of the model are
described in an unpublished technical appendix
available from the developers.) lt was appropriate
to apply the model to New Zealand because treat-
ment for HF is similar in both the US and New
Zealand.
HF occurs when the heart muscle is damaged,
overloaded or exhausted by such conditions as hy-
pertension, coronary artery disease, cardiac valve
damage, cardiomyopathy and arrhythmias. About
one-third of those with HF are hospitalised each
year,I2l and the l-year mortality ranges from l5Vo
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among relatively unselected patients to 50Vo among
those in New York Heart Association (NYHA)
functional class IV.t3l HF incurs direct costs asso-
ciated with primary medical care, hospitalisation
and pharmaceutical treatment, and indirect costs
associated with lost production (lost output or pro-
ductivity), a reduced quality of life (intangible costs)
and death. All these costs will increase as the pop-
ulation ages and survival rates for cardiovascular
events continue to improve, thus increasing the
numbers of people likely to die of HF.
The SOLVD investigatorst2l studied the effect
of enalapril on mortality and hospitalisation in pa-
tients with HF. They found that enalapril treatment
substantially reduced morbidity, hospitalisation
and mortality. In the SOLVD Treatment Trial arm
of the study, the 2569 patients with HF were
randomised to receive enalapril or placebo in ad-
dition to conventional treatment with digoxin and
diuretics. 1284 patients were randomised to placebo,
and 1285 were randomised to enalapril (2.5 or 5mg
twice daily initially, to a maximum of IOmg twice
daily). The main aim of the trial was to assess the
effect of enalapril on mortality, but it was also
hoped that additional information would be ob-
tained on hospitalisation and morbidity due to
HF.
Patients with HF who were treated with en-
alapril in addition to conventional therapy showed
a significant reduction in mortality of l6Vo at the
scheduled study end and a 26Vo reduction for the
combined end-point of mortality or hospitalisa-
tion. Although the difference in mortality was still
apparent after 4 years of therapy, the difference
was greatest in the initial 2 years of the study. The
most common cause of death was worsening HF,
which accounted fior about half of the total number
of deaths. More patients in the placebo group re-
quired additional therapy in the form of vasodila-
tors to treat worsening HF, but as this was not taken
into account in the final analysis of the trial, the
benefit of enalapril was conservatively estimated.
The SOLVD investignlql5'[1] trial results were
consistent with other smaller trials of enalapril
such as that conducted by the Co-Operative North
@ Adis lntemollonol Llmited. All rights reserved.
Scandinavian Enalapril Survival Study (CON-
SENSUS) Trial Study Group.tll However, entry to
the CONSENSUS trial and other small studies was
restricted to patients with severe HR whereas the
SOLVD study included a broader range of patients
with clinically stable HF and a longer trial time
period (average 4l months in comparison with an
average of a few months in the other studies). The
greatest benefit seen in both the CONSENSUS and
SOLVD studies was the reduction in mortality from
progressive heart disease. These findings have been
supported by results from the second Veterans Ad-
m i n i strati on Co-Operati ve Vasod i I ator-Heart Fai | -
ure Trial (V-HeFT ll).lal
HF (as defined by tCD-9 primary diagnosis code
428tsl) in New Zealandaccounted for l10Vo of all
deaths,l6l 0.87Vo of all hospital admissions and
l.9lVo of all public hospital bed days in 1992.t71
These public hospital bed days equate to approxi-
mately 23 million New Zealand dollars ($NZ)
U.9l%o of public surgical and medical hospital ex-
pendituretsll. If a broader definition of HF is em-
ployed (additional ICD codes and secondary and
tertiary diagnoses codes, as used by Doughty et al.tll;
the numbers of deaths and hospitalisations, and es-
timated costs, would increase substantially 
- 
in the
order of 50 to 1007o.
ln 1992,456 people aged 60 years and over ( I 68
men and 288 women) died from HF in New Zea-
land, a rate of 86 per 100 000 within this age group
(71 per 100000 for men,98 per 100000 for
women) [table I]. Mortality rates rise rvith increas-
ing age; almost all (88.37o) deaths due to HF occur
in those aged 80 years and over, with only 1.57o of
deaths occurring in people under 60 years of age.
As there are more women than men aged 80 years
and over, there are more deaths recorded for women
than for men (65Vo of all people r.vho died from HF
were women). Although the number of deaths from
HF for those aged 60 years and over has risen by
87o between 1980 and 1992, the rate per 100 000
people in this age group has fallen from 99 to 86.
Figure I shows the rates per 100 000 aged 60 years
and over dying from HF between 1980 and 1992.
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Table l. Mortalaty from heart failure (lCD-9 o26tsl) in New Zealand (1992 numbers and age-specific rates lrom death certificate datal.lot 1" 
"result ol rounding, individual items may not add exacUy lo the totals shown
Age group (years) Rate of dealhs per 100 000 people Number of deaths
G59
60€.1
6S9
70-74
75-79
80€4
>84
>60
All ages
0
4
5
13
41
299
927
71
10
0
1
6
12
22
203
867
98
17
0
3
5
13
30
2
884
86
14
5
3
3
6
13
53
90
t68
173
2
1
4
7
10
trt
20!l
288
290
7
4
7
13
23
116
293
t056
463
Mreviation: ICD-9 = Intemalional Classilication of Diseases, 9th rev. ed.
The statistics show higher age-specific death
'ates from HF for older men than for older women.
ilowever, because of the greater number of women
md of female deaths in the older age groups, the
)revalence rates for all ages and for the aggregated
group aged 60 years and over are higher for women.
lhis apparent anomaly is known as Simpson's para-
Jox.tlol
During 1992, hospital admissions for HF fol-
lowed a similar pattern to that of deaths (as de-
;cribed above), with admission rates rising with age.
Hospital admissions, as would be expected, cover
a younger age group than those dying. The age co-
hort 80 years and over accounts for 367o of hos-
pital admissions for HF, 70 years and over for7 l%o,
and 65 years and over far 82Vo. Table II illustrates
1992 admissions to all New Zealand hospitals
(both public and private), displayed as total num-
bers and age-specific rates. The admission rates
and numbers were calculated at the time of discharge
or death; that is, at time of hospital separation. Be-
tween 1980 and 1992, hospital admissions for HF
120
1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992
Year
Fig. l. The mortality rate from heart failure between 1990 and 1992 among the New Zealand population aged 60 years and 6vgL[61
The sharp dip in 1984 was seen in death rates in generaland is not specitic to heart failure.
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Table ll. Hospital admissions for hearl failure irr 1992 lor all New Zealand hospitals, based on hospital separations (i.e. recorded at time of
death, live discharge or lransler to another hospital).m As a result of rounding, individual items may not add exactly to the totals shown
Age group (years) Rate per 10O 000 peoPleg Number of admissions
iotal
- 
s 7 7 1l e 20
s-sooo000
1G14000000
15-19010011
20-24 1oot01
25-2921',t213
3G346669816
35-39145917623
40-/H 28 15 21 33 18 51
45-49 78 24 51 73 22 95
5G54 105 66 86 84 53 137
55-59 197 149 173 137 1o2 23s
6oa1 u4 198 271 243 139 ffiz
65€9 653 335 487 393 223 616
70-74 1107 694 875 480 n7 867
75-7s 1711 1186 14oO 525 534 1063
80-84 2518 1935 2146 424 576 1000
>84 3881 3oO4 9257 345 659 1004
Alf ages 167 160 163 2781 2738 5518
gender-specificrateSbecause'atthetimeofthestudy,accUratedata
were unavailable for 1992.
increased by 36.7To: from 4038 in 1980 to 5518
in 1992 (128 per 100 000 in l980to 163 per 100 000
in 1992).Itl Figure 2 shows the rates of hospital
admissions for HF.
Methods
The study was performed from a healthcare pro-
vider's perspective, and covers both government
and privately funded goods and services' All trans-
fer payments such as goods and services tax (GST)
were excluded from the analysis. All costs and ben-
efits were estimated incrementally, but the study
did not evaluate indirect and intangible costs. The
most appropriate and up-to-date unit costs avail-
able were used and, where necessary, were adjusted
to September 1993 dollars using the health sector
cost index (HSCI; see appendix). Allunit costs and
prices are in 1993 New Zealand dollars ($NZl =
$US0.5509, September I 993).
The decision analytical model enabled data
from different sources to be used, and allowed key
@ Adis Inlemotionol Limiled. All righfs reseNed.
inputs to be varied in order to evaluate the impact
on costs and to test the assumptions made. Monthly
survival probabilities were derived from the SOLVD
Treatment Trial using parametric failure time sur-
vival models assuming underlying Weibull distri-
butions. The enalapril dosages at the final visit of
the trial were used to estimate the cost of enalapril.
The New Zealand input data for the model were
derived from a variety of sources, as described in
the following paragraphs. A discount rate of 5Vo
was used for both costs and benefits as the baseline,
and the New Zealand Treasury rate of l}Vo for pub-
lic sector project evaluation was used as the high
value for sensitivity analYsis.
The Weibull distribution (an accelerated para-
metric time failure survival method) was used to
estimate the medical effect and economic cost of
extending enalapril treatment to those patients
with HF not currently being treated with an ACE
inhibitor. The Weibull distribution was chosen in
preference to or,linary least squares or numeric in-
PhormocoEconomics 1996 Feb;9 (2)
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100
egration of linear extrapolation estimates (although
rll models gave similar results), because unpub-
ished work by the SOLVD investigarors indicared
hat it provided the besr fir to their data.
There are no reliable data on age-specific rates
br HF or the numbers of HF patients that would
'elate to the NYHA classes. In the absence of this
lata for New Zealand, age-specific rates from the
JS were applied to the New Zealand population.
lhe prevalence rates from Kannel and Belanger,ll ll
vhen applied, gave a prevalence of 24 155 and
hose of Schocken et al.t l2l a prevalence of 35 I 7 I .
fhese figures were rounded to the nearest 1000
vhen applied to the model. lt should be noted that
he rates of Schocken et al.,il2l alrhough giving a
righer prev:rlence, considered only the population
rged 25 to 74 years and thus excluded a large group
rf patients with HF.
Table III shows the applicarion of US age-
pecific prevalence ratesll l.l2l to the New Zealand
ropulation. A baseline and low value of 24 000 and
' 
high value of 35 000 (representi ng lVoof the total
npulation) were used for the number of people
vith HF. A surveytl3l that rnonitors primary care
loctors' prescribing for cardiovascular disease in-
licated that, in New Zealand,,43Vo of the popula-
ion with HF were not being rreated with an ACE
inhibitor. When applied to the population with HF,
this percenrage gave a range of l0 000 to 15 000
people who were untreated with ACE inhibitors to
whom enalapril treatment could theoreticalty be
extended. A baseline value of lOIVo of this poten-
tial treatment group was used, with sensitivity anal-
ysis ranging from a low of 50Vo to ahigh (and base-
line) of I00Vo.
The cost per tablet of enalapril was $N20.5558
for 5mg, $N20.9062 for lOmg and $NZl .7212for
20mg.tl4l As a 2.5mg tablet was unavailable in New
Zealand for the purposes of the model, such a tablet
was assumed to be half the price of the 5mg tablet.
Sensitivity analysis was performed on all tablet
prices by varying them by +2O7o of the baseline
values.
It was assumed that, as enalapril was added to
existing treatment, there would be no extra medical
practitioner consultations. However, an additional
dispensing fee and container charge amounting to
$N22.6009 per 3 months or $N20.87 per monrh
was allocated for enalapril.llal It was also consid-
ered that, as patients with HF would be consulting
their medical practitioners on a regular basis, no
additional monitoring would be required. This prem-
ise was also supported by the published results of
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SOLVD, in which no additional monitoring was
reported.
However, as patients treated with enalapril lived
an average of 2 months longer than those patients
treated with conventional medicines, the incre-
mental routine care costs incurred by enalapril pa-
tients during the additional 2 months were incor-
porated in the model. It was estimated (from
discussions with pharmacists), and subsequently
verified,tl3l that New Zealand patients with HF
routinely visit their medical practitioner on average
once every 3 months for monitoring of their con-
dition and a new prescription for a further 3 months'
supply of conventional medicine. Thus, two-thirds
of the 3-month cost/or 90 days' supply of the fol-
lowing were allocated to the model, to give: medical
practitioner consultation ($NZl 6.09), conventional
therapy [digoxin $N22.91, furosemide (frusemide)
$N22.04J, and dispensing fee and container charge
for each item of conventional therapy ($N23.47).
The total of these additional non-enalapril drug
costs or routine care costs was $N224.51. These
costs were incorporated in the model as a per-month
cost by dividing by the total undiscounted months
of enalapril survival (38 months) to give a value of
$N20.65. This value was added to the nondrug
costs of the model to give a high value ($N20.87
+ $N20.65 = $NZl.52) for sensitivity analysis.
Medical costs for treatment of conditions other than
for HF were not evaluated for these surviving pa-
tients.
The proportion of deaths due to arrhythmia un-
associated with worsening HF, observed in the
treatment arm of the SOLVD trial, was 22.7Vo.121
This proportion of deaths was used for New Zea-
land, as no other data were available. Sensitivity
analysis was applied to the baseline value using
ll%o as the lower limit and 35Vo as the upper limit.
This range was considered to be a reasonable spread
around the baseline value, as the SOLVD investi-
gators noted a divergence of opinion in the medical
literature regarding mortality in patients with HF.
lt was considered that, if a death occurred out-
side hospital, either an ambulance or a general
practitioner (GP), or both, would have been called
to attend to the patient. Thus, the cost of an ambul-
ance and the cost of a medical practitioner call-out
were used for the estimation of the cost of deaths
outside hospital. During the year ending March
1992, the average total cost per patient for the New
7*aland Ambulance Board was $NZ'159.74 (New
7*aland Ambulance Board, personal communica-
tion) and was adjusted to $NZl62 (September
1993 dollars) per call-out.
A typical total call-out fee for certification of
death by a GP as at September 1993 was around
$N250. Rates varied considerably depending on
the day (holiday, weekend, weekday), the time of
day and geographic location. The range of $N230
Table lll. Prevalence ol heart failure in New Zealand (NZ) after application of US age-specific prevalencs 131ssltt't2l to the NZ population. As
a result of rounding, individual items may not add exactly to the tolals shown
50-59 297798
60€9 267 v5
0.8
2.3
4.9
9.1
3.0
2382
6 149
8 578
7 046
24 155
70-79
>79"
Total (>49)
175 053
77 430
817 626
Age group (years) NZ population 1991 Prevalence rates (7o)t121 Estimated prevalence ol heart failure in NZ
25-54
55-tr
65-74
Toral(2$74)
681 081
140 055
I 03 485
924 621
694 704
138 792
122262
955 758
5 449
6 302
4 967
16 718
I 031
4 164
5257
18 452
14 480
10 466
10 225
35 171
0.8
4.5
4.8
1.9
1.3
3.0
4.3
2.0
a US data uses the age group 80 to 89 years, but NZ data includes those aged 90 years and over.
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to $N275 for a total GPfee was used for sensitivity
analysis (informal telephone survey of GPs and
medical centres in Wellington and Auckland, New
7*aland).
Thus, the baseline value (i.e. the cost of an HF
death outside hospital) for September 1993 was
$NZ2l2 (consisting of the ambulance cost of
$NZl62 plus the typical toral GP call-out fee of
$N250). Sensitivity analysis was nor applied ro rhe
ambulance fee, as this was estimated from recorded
data. As an ambulance would not always be called,
the lowest total GP fee of $N230 was used as the
lower limit of the sensitivity analysis. The upper
limit was the ambulance fee of $NZl62 plus the
high total GP fee of $N275, as both an ambulance
and a GP could be called. This gave an upper limit
of $N2240 (rounded to the nearest $NZ5).
Sufficiently detailed data were unavailable to
enable separate costs to be calculated for fatal and
nonfatal hospitalisations. It was therefore assumed
that the hospital costs would be identical whether
or not a patient was discharged alive or dead. The
limited range of diagnosis-related group (DRG)
unit cost data availablell5J were supplemented by
ICD unit cost data from individual cost of illness
studies. As95Vo of all hospital inpatients admitted
for HF during 1992 were admitted to public hospi-
tals,[7] the unit costs applicable to public hospitals
were used for patients in both public and privare
hospitals.
With the exception of costs for stroke, the DRG
and tCD unit costs fully capture rhe hospital costs.
The possibility that some institutional costs asso-
ciated with stroke have not been captured was taken
into account by using data from a cost of illness
study,lr6] which indicated that the DRG unit cost
could be increased by 1007o for sensitivity analy-
sis. The baseline value plus or minus 207o was used
for sensitivity analysis for all hospital unit costs
with the exception of stroke. This variation in range
was chosen because cost data from the public sec-
tor exhibits considerable variation between hospi-
1315.1 l7l
The average length of stay in a public hospital
in 1992 for acute myocardial infarction (ICD-9
410) was 8.6 days formen and 8.5 days forwomen.lTl
An inpatient with myocardial infarction spent on
average 2 days in a coronary care unit and the re-
mainder of their hospitalisation in a cardiology
ward.llEl The cost for a patient's total time in hos-
pital was based on a stay of 2 days in a coronary
care unit at $NZl053 per day, and 6.5 days in a
cardiology ward at a daily rate of $N2592 using
prices relevant to I January 1994 (Green Lane Hos-
pital, Auckland, personal communication). Using
this methodology, the unit cost per patient with a
myocardial infarction for their hospital stay was
$N25954. This cost was deflated using the HSCI
to establish a baseline value of $N25948 in Sep-
tember 1993 dollars.
The public hospital unit costs for cardiac ar-
rhythmia for the year ending June l99ltl5l were
divided into DRG 138, age over 69 years and./or
complicating condition, and DRG 139, age under
70 years without complicating conditions. A
weighted average (by patient numbers) of the unit
costs applicable to each of these DRGs was calcu-
lated and adjusted to give a baseline value of
$N22666. The public hospital DRG 127 unit cost
for HF and shockt l5l waS adjusted to give a baseline
value of $N25030.
The public hospital unit cosr for DRG 0l4,tlsi
specific cerebrovascular disorders except transient
ischaemic attack (TIA), was used for stroke and
adjusted to provide a baseline and low value of
$NZl02l2. For sensitivity analysis this baseline
value was increased by 20Vo andby l00vo to obtain
2 high values. The baseline was increased by l00Vo
to cover the cost of rest home care for stroke, which
is approxinrately equal ro rhe cost of hospital
q41s.ll6l
The category 'other causes' used in the model
represents the average cost for all other non-HF
related hospitalisations. Accordingly, the follow-
ing diagnoses were excluded from the analysis:
heart and chest pain, heart attacks, stroke, and HF
and shock. A weighted average of the 20 most com-
mon kinds of discharge diagnoses for the year end-
ing June lgglttst was calculated and adjusted to a
baseline value of $N22403. The inpur data for the
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Populalion with heart failure to
b€ trealed with enalapril
% Population treated with
enalapdl
Enalaprilco€t per tablet ($NZ)
2.5m9
5mg
1omg
20mg
Monthly nondrug cost ($NZ)
Annual o/" discount rate for
cosls and benefits
% Deaths oulside hospital
Cost of deaths outside
hospital ($NZ)
Hospital unit costs ($NQ
heart failure
myocardial inlarclion
anhylhmia
stroke
other
Low: 10 00O
High: 15 00O
Low: 50
High:100
Low:-2OY"
High: +20olo
Low: 
-20"/o
High: +20%
Low:-2OY"
High: +20olo
Low: 
-20%
High: +20olo
Low: 
-20olo
High: +20"/o and
$N21.52
Low:5
High:10
Low:10
High: 35
Low:30
High:240
Low: 
-20%
High: +20%
Low'.-20"h
High: +20%
Low: 
-20%
High: +20"/o
Low: 
-2Oo/"
High: +20% and
+100%
Low: 
-20%
High: +20"/o
Table lV. Summary of the inpul data for the decision analylical
model used in the study. All costs are in 1993 New Zealand dollars
($NZ; $NZl = $US0.5509, September 1993)
Input data Baseline Range for
value sensitivity analysis
treated with enalapril, there was a total gain of 157
years. The year-by-year breakdown per individual
treated in undiscounted months saved was:0.25 (year
l),0.48 (year 2),0.56 (year 3) and 0.59 (year 4).
Over the 4-year period, 343 of 1000 individuals
treated with enalapril would die, compared with
390 deaths in 1000 individuals treated only with
conventional medicines. In other words, there were
48 fewer deaths for enalapril recipients over the
 -year treatment period. The year-by-year break-
down showed that virtually all the gain in lives
saved were made in the first 2 years of treatment
(year I : 69Vo: yeat 2:Zl%o; a cumulative total of
90Vo). There were 33 lives saved per 1000 treated
patients in the first year, l0 in year 2,4 in year 3,
and I life saved per 1000 patients in year 4.
The model showed that total hospitalisations
were reduced by 347 per 1000 individuals over a
A-year period of treatment with enalapril, compared
with conventional treatment alone. Virtually all
(86Vo) of the 4-year total for hospitalisations
avoided occurred within the first year.
The additional costs of drug treatment and med-
ical practitioner fees ($NZ 1064.5 I ) incurred in the
community setting by a patient treated with en-
alapril were more than offset by hospital costs
avoided and medical costs of death outside hospital
avoided ($NZl 7 16. l6). Over the 4-year period, there
would be total net costs avoided of $N265 1.65 for
each enalapril-treated patient. In addition, a further
2 months of life per patient would be gained.
If enalapril therapy was extended to 1007o ( l0 000
people) of the population with HF who are at pres-
ent untreated with ACE inhibitors, discounted
costs of $NZ6 517 000 could be avoided and, in
addition, 1583 undiscounted life-years could be
gained (19 000 months of life gained). A total of
3465 hospitalisations could be avoided, and 476
deaths could be postponed beyond the 4-year pe-
riod of the study. The baseline estimates for an
individual and for the population to whom en-
alapril treatment could be extended (New Zealand
total) are summarised in table V.
10 000
100
0.2779
0.5558
0.9062
1.7212
0.87
5
2..7
212
5030
5948
2666
10 212
2403
model as described above have been summarised
in table IV.
Results
Boseline Results
Analysis of the baseline case for an individual
patient treated with enalapril in addition to conven-
tional care over the 4-year period showed that an
undiscounted total of 1.88 months of life per in-
dividual was gained. That is, for every 1000 patients
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Table V. Baseline estimales ol the eflects of enalapril for an
individual and for the population in New Zealand to whom enatapril
trealment could be extended lall costs discounted to present values
- 
September 1993 New Zealand dollars ($NZ;gNZ1 
= $US0.S509,
September 1993)1. As a result of rounding, individual items may not
add exactly to lhe totals shown
Eslimate Per individual New Zealand
treated total
Population that could
potentially be treated
Undiscounted months of life
gained
Deaths avoided
Hospitalisations avoided
Coste ($NZ)
Hospital costs avoided and
medical cost of death outside
hospital avoided
Additional drug, dispensing
ancl medical practitioner costs
associated with enalapril
Total net costs avoided
1.9
0.0476
0.3465
1716.16
1064.51
651.65
10 000
19 000
476
3465
17 161 600
10 645 r00
6 516 500
Sensitivity Anolysis
Sensitivity analysis, applied by using the high
and low limits detailed in table [V demonsrrated
that the results, on an individual and on a per pop-
ulation basis, are robust with respect to changes in
the input variables (table VI). Four facrors in par-
ticular were found to be nrajor determinants of the
potential net cost savings:
o the population with HF [o whonr treatment could be ex-
tended
o the percentage of this population treated with en-
alapril
o the price of enalapril
. the hospital costs for nontatal cases oi HF.
If either of the first 2 deterntintnts above is
changed b1, a given percentage fronr the baseline
estimates then the total net costs avoided alter by
the same percentage. If the enalapril price is altered
by 20Vo (holding allother input values at their base-
line levels) then the total costs saved alterby 32Vo.
The price of enalapril could be increased by 63Vo
before the total net costs avoided fall to zero. If the
unit cost for nonfatal cases of HF treated in hospital
is altered by 20Vo, then the total net costs saved
change by 47Vo in the same direction.
Altering the discount rate makes very little dif-
ference to the results, as most of the impact on costs
occurs in the flirst year. It might be argued that a
death outside hospital is cost efficient to a health-
care system, and if all deaths (lO0Vo) occur outside
hospital, the net savings in the model reduce by
25Vo. However, this situation would not occur as
there will always be some patients admitted to
hospital who die from HF.
Although the results are reported using the
Weibull distribution, the model was also run using
ordinary least squares and linear extrapolation,
both of which gave similar results.
Discussion
HF is an important cause of mortality and of
hospital admissions in New Zealand. The growing
number of elderly people (who are most at risk of
cardiovascular disease), in combination with im-
proved survival rates for cardiovascular events,
will increase the number of those who will eventu-
ally have this condition.
The SOLVD decision analytical modelwas used
to simulate changes in key determinants of the
costs of HF in New Zealand when enalapril was
added to conventional treatment. The population with
HF to whom treatment could be extended, the per-
centage of this population treated with enalapril,
the price of enalapril and nonfatal hospital costs
were found to be the key determinants of the net
benefits of the addition of enalapril to conventional
HF therapy.
However, the potentialcost suvings estimated in
dollar terms of adding enalapril ro conventional
treiltment for HF do not include the value to society
of lives saved, any production (productivity or out-
put) gains, or the increase in quality of life of those
patients treated. Changes in productivity could be
considered to be relatively unimportant, as most
patients with HF are not of working age. However,
from the government perspective, prolonging life
could impose additional costs with respect to wel-
fare payments.
It could be considered that enalapril recipients
and their families would have achieved higher
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quality-of-life scores than those patients treated
with conventional medication, this assumption be-
ing based on the difference in usage of healthcare
resources (as indicated in this analysis) between
the 2 groups. The benefit of enalapril was also un-
derestimated, as the SOLVD Treatment Trial did
not take into account the additional cost for the
greater number of patients in the placebo group
who required additional therapy in the form of vaso-
dilators to treat worsening HF.
It is considered unlikely that enalapril treatment
could be extended to all patients untreated with an
ACE inhibitor because, as with any intervention, a
certain proportion of patients will experience ad-
verse effects and will have to be placed on an al-
ternative treatment regimen. In addition, not all
patients (and this may include some patients expe-
riencing adverse effects) will comply with the
treatment regimen. The study was unable to eval-
uate the costs and benefits for men and women
separately, or beyond a time horizon of 4 years as
these factors were not evaluated in the original trial.
The surviving patients will incur medical costs be-
yond the  -year trial period, thereby lowering the
net benefits of enalapril treatment.
The results of the study demonstrate that treat-
ment of patients with HF with enalapril was cost
effective when compared with conventional medi-
cal therapy. Sensitivity analysis indicated that the
results were robust with respect to changes in key
inputs. Within the ranges of the data evaluated,
treatment of such patients with enalapril in addition
to conventional therapy would both reduce mortal-
ity and lower health sector costs.
Application of the model to 3 other countries
has also been reported in the literature. Average net
cost savings per patient were $A I 100 in Australia,
$Can574 in Canada and FF8076 in France (all cur-
rencies March l9921.ttet Although ACE inhibitors
slow the progression of the disease, and treated
patients stay longer in less severe HF categories
and require less hospitalisation,[ll the economic
benefits of treating asymptomatic patients with
enalapril have not yet been assessed.
Table Vl. Results of the sensitivity analyses (see table lV). All costs are in 1993 New Zealand dollars ($NZ; $NZ1 = $US0.5509, September
1993)
Cost savings per
individual($NZ)
Cost savings to New
Zealand ($NZ thousands)
Percentage change
lrom baseline
Baseline
Population wilh heart failure = 15 000
Percent population on enalapril 50%
Drug cosls and nondrug costs plus 20"/"
Drug costs and nondrug costs minus 207"
Drug costs plus 20%, nondrug costs = baseline
Drug costs minus 20olo, nondrug costs = baseline
Drug costs baseline and nondrug costs $NZ1 .52
Discount rate 10o/o
Deaths outside hospital 35o/o
Deaths outside hospital 10%
Cost of deaths outside hospital $N2240
Cosl of deaths outside hospital $N230
651.65
6s1.65
651.65
438.75
8&.55
444.80
858.50
629.04
670.04
625.26
678.89
651.95
649.68
686.38
616.92
9s9.69
343.60
689.89
6516
9775
3258
4387
8645
4448
8585
6290
6700
6253
6789
651 I
6/97
6864
61 69
9597
3436
6899
+50.0
-50.0
-32.7
+32.7
-31.7
+31.8
-3.5
+2.8
--4.0
+4.2
+0.05
-o.3
+5.3
-5.3
+47.3
47.3
+5.9
Fatal hospital cosls plus 20ol"
Fatal hospital costs minus 2070
Nonlalal hospital costs plus 20olo
Nonfatal hospital costs minus 20%
Nonfatal costs for slroke plus '100o/o
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Because healthcare resources are scarce in many
countries, the use of health economic models has
the potential to provide cost-effective information
for policy analysis and decision making. Country-
specilic unit cosrs and epiclenriological duta shoulcl
be used if possible as inputs to such health economic
models. It is inappropriate to apply the results of a
single study to different settings by converting
costs and health effects estimated in one country by
means of exchange rates and crude population
numbers.
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Appendix
ond Prices in 1993
NewZeolqnd Dollors
All hospital prices and unit costs were adjusted
to September 1993 prices by inflating by a health
sector cost index (HSCI). PC INFOS (Personal
Computer Information Network for Official Statis-
tics;t201 statistical series and data manipulation rou-
tines were used to construct a quarterly HSCI.
The following statistical series were used-
Labour wage rates:
o Prevailing Weekly Wage Rates: Central Government
(PWIQ.S4229) December 1977 to June 1993
o l,abour Cost Index, Salary and Ondinary Time Wage
Rates: Central Government Sector (LCIQ SA2IZ9)
December 1992to September 1993.
Prices for nonlabour inputs:
o Producers Price Index: Inputs Central Govern-
ment (PPIQ.SIV), December 1977 to September
1993.
All series were converted to a common base. The
series 'Prevailing Weekly Wage Rates: Central Cov-
ernment' was discontinued and unavailable from Sep
tember 1993, and was replaced by a more appropriate
series 'Salary and Ordinary Time Wage Rates: Central
Government Sector' wh ich commenced i n December
| 992. A wages index was constructed by splicing the
series 'Salary and Ordinary Time Wage Rates: Cen-
tral Government Sector'on to the discontinued series.
Let this series be called 'wages'and the series 'In-
Table A1. Health seclor cost index from the March quarter ol
1990 to the September quangr of 1993
Ouarter Health sector
cost index
March 1990
June 1990
Seplember 1990
December 1990
March 1991
June '1991
September 1991
December 1991
March 1992
June 1992
September 1992
December 1992
March 1993
June 1993
September 1993
938
949
962
976
982
987
987
986
988
990
991
994
997
999
1000
puts: Central Government' be called 'prices'. The
HSCI was constructed by weighting 'prices'as 0.2,
and 'wages'as 0.8. That is: HSCI = (0.8 x wages) +
(0.2 x prices). These weightings were selected be-
cause labour costs make up approximately 807o of
the health industry's and individual hospital's total
costs.
Table VII details the HSCI from the March quar-
ter 1990 to the September quarter of 1993.
_1ry
*i#tii
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Economic Evaluation Applied To Health Policy In New Zealand
CASE 9: ISCHAEMIC STROKE
Discussed in chapter 16
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Abstract
Aim. To quantify and describe the annual cost of ischaemic
stroke to New Zealand society during 1992.
Methods. A prevalence or cross sectional approach
employing incremental estimation was used to ejtimate
costs from the perspective of society. The study used unit
record hospital and mortality data. .
Rcsults. Direct costs ranged from gg3 million to 9140 m
and loss of production was between $6 m and $14 m. Total
quantified costs were estimated to lie between $99 m and
$154 m. Hospital and continuing care costs when combined
make up 907o of all quantified costs.
Conclusion. Ischaemic stroke affects mainly older people
many of whom are discharged into the community and
require costly communiiy support or conlinuing care. The
combination of an ageing population, increasing survival
rates and constant, incidence rates will result in a
substantial rise in the costs of continuing care and
community support. Most of these cosis are at present
obscured because much of the care provided does not
involve money payments and./or data are not recorded and
collated on a national basis. Iqcorrect policy decisions will
be made ifthe nonhospital costs ofstroke are not taken into
account.
NZ Med rl 199{i t0?r 4{:l-o
An economic appraisal was undertaken of the costs of
ischaemic stroke to New Zealand society. Cost of illness
studies of this nature provide the data that enables
different tieatment or management options to be evaluated
in economic terms.
Stroke has been defined by the World Health
Organisation as a rapid onset of disturbances of cerebral
function leading to death or lasting for longer than 24
hours with no apparent cause other than vascular.r It
results from the interruption of the flow of blood to the
brain that can occur with the rupture of an artery wall(cerebral haemorrhage), blood clotting (thrombus), oi when
a clot lodges in an artery (embolus). It is necessary in
clinical practice to differentiate between ischaemic and
haemorrhagic strokes as their parhophysiologies and
treatment differ. The importance of disringuishing between
different trpes of stroke is discusscd bv Friedman2 who
found that 88"i of stroke cases of those iged 60 and above
admitted to hospital in New Zealand were ischaemic in
type. International studies suggest that the proportion of
ischaemic stroke Co all strokes ranged from 617o to 83Vo.3
Patienis with cerebrovascular disease (of which stroke is
a subset) account for the greatest bed day usage in public
hospitals (l.5lo of patients and 8.97o of bed dayl).a In New
Zealand, stroke is the third most common cause of death
and both males and females have similar dealh rates.s In
developed countries, stroke is the third ranking cause of
death and the most common case of long term disability.G
Although there has been no change in the incidence rate ior
stroke over the last 10 years there has been a decline in thedeath rate.? This has important consequences for
rehabilitation, longterm and community care costs.
Ischaemic stroke patients (acute and longstay) aredisproportionately high users of hospital ieso,rr"es,
accounting for 77o of all public hospital patients but 5?o of
hospital patient days. In comparison, data from Scotland
showed that stroke (all forms) accounted for about 4Vo of all
NHS resources and 5.57o of hospital resources.s
Internationally, age adjusted incidence rates for "first in
a lifetime" stroke range between 2 and 7 per thousandpeople for the age groups b5-64 and 6b-24 years. If
recurrent strokes (people who have had a stroke) are
included, the incidence rates rise by between 20c/o andB}Vo.
Prevalence rates (all stroke sufferers) are about 4 to b times
the incidence rates (new strokes per year).6 When data from
a Finnish incidence and prevalence studf were used the
ratio 
-of the prevalence of stroke suryivors dependent onoutside help to the incidence ofall strokes was cilculated tobe 1.74. The Perth Community Stroke Study, f9g9-90,
found that the crude annual event rate for all itrokes was
258 per f00 000, and the rate for first strokes was l?g per
100 000.'g Annual incidence rates per 100 000 puopl"(standardised on the world population lb years and ovlr)
for all strokds were 14l.b in-Auckland 0991) and 14b.6 inPerth (1989-90).10 A 27-country study of stroke rates,
ranked New Zealand l8th highest for men and 15th highesf
for women. Australia was ranked 20 for men and 17 for
women, England and Wales were ranked 15 for men and 14
for women, and USA was 2b for men and 21 for women.u
Methods
A prevalence or cross section study of the cost of ischaemic stroke
from a societal perspective was undertaken. Unit record data for
all_hospitals in both public and private sectors for the year ended
1992, and mor!?ljty data for the year ended 1990 were analysed.r2
The following ICD codes were used to define ischaemic stroke; 434
occlusion of cerebral arteries, and 436 acute and ill defined
cerebrovascular disease. Longer stay stroke patients may be
transferred to another hospital and thus bi recorded is a
readmission within the same year. To minimise the potential for
d.ouble counting all hospital stroke patients with stays of more
than 90 days were cxcludcd from the hospital data. These palients
were not lost to the studv as they rvere captured in the rest home
estimates. All identilr.rl,le rransfer payments, from the perspective
of society, were excluded from the analysis of costs which were
measured in lgg2 New Zealand dollars.
The number of general practitioner consultations (tMS (NZ) Ltd.
Data on prescriptions, consultations and costs ofmedication for the
management of stroke. 1993) in combination with the average fee
chargedB were used to estimate the cost ofsuch consultationi. The
value of medicine prescribed by general practitioners (tMS (NZ)
L.td, f993) had the appropriate dispensing fees, container
allowances, and markupsr{ added to obtain the cost to societv.Transport costs of all ischaemic stroke patients admitted [o
hospital were evaluated using the average iost of transporting a
patient to hospital by ambulance of $159.?4 (NZ Ambulance Board.
lftter, 3l August 1993. Data relating to the financial year lg9V2).Hospital costs were estimated, and then .omp.rud, using two
RcprintcdfronrThcNcwZc:rl;rndlvlcdicalJoumal 9Novcmbcrl994,No9g9.Vtrl l07.pagc.s:-443-6
methods. First, the DRGtn 014 unit costr6 of $10 076 was multiplied
by the number of patients. In the second method hospital patient
days were multiplied by the daily rate ($300/d for public
hospitals.r; and $284.44/d for private hospitalst.rE
The number of ischaemic stroke events occurring annually was
estimated using New Zealand hospital admissions and the
assumption Lhat 701o of stroke cases were admitted to hospital.
This was based on a New Zealand study,ro4 that found that two-
thirds ofall stroke patients entered hospital, and UK findings that
75Va of patients with acute s[roke are admitted to hospital.zt This
paper constructed a flow chart (Figure l) of events using a 507c
survival rate and assuming that 509o of the survivors would
require continuing support. The number of patients requiring
continuing care or support was based on stroke events, survival
rates of 50% (al 3 to 5 years after an acute stroke event, most
dying within the first month),2r and the percentages of survivors
permanently disabled or needing community support. US data
indicated that about half of stroke survi,vors had major motor
problems and up Lo SOVo of stroke survivors may be permanently
disabled.6rr
Figurc 1. 
- 
Annurl incidcncc ischacmic stroke
As the costs of continuing care are unavailable both nationally and
in a disease spegific form the following methods of measurement
were employed. The cost of continuing care In institutions rvas
valued in two ways. The first method evaluated the annual cost of
a caregiver (either unpaid or paid) based on the total average
weekly earnings for males and females combined of $579.90.4 The
second method used $401.34 per week as a proxy for unit cost(Ministry of Health average of stage I and stage 2 rest home
subeidy relating to 1992/3, Personal communication. 1993).
Friedman2 found that 48')i of all ischaemic stroke patients t60
years and overl surviving a stroke were discharged to rest homes
or geriatric hospitals. This percentage (rounded to 507a), with
hospital discharge data (live discharges of patients over 60 )ears)
were used to estimate the number of patients discharged !o rest
homes or geriatric hospitals during 1992.
Calc.ulations using data from Finland3 indicated that the number
of stroke patients dependent on outside help could be estimated by
multiplying the annual incidence of stroke by 1.74. Those
permanently institutionalised accounted for 48.87c of those
dependent on oulside help, and 747c of these permanent institution
residenls were there as a result of the stroke. The incidence data
from Finland were used to estimate the requirements for
physiotherapy and speech therapy sessions within the first year
after stroke. The study found that 52Vo of patients were given on
average 27 physiotherapy sessions thus, the average stroke patient
was given 14 sessions (l x 0.52 x27 = 14.01.In addition the first year after slroke 13.37a of patients were
given on average 14.1 speech therapy sessions thus the average
stroke patient was'given 1.9 sessions (l x 0.133 x 14.1 = 1.9). Our
siudy costed such sessions at a rate of $20 per session based on an
i n formal survey of pri vate physiothe ra py charges.
Loss of production was valued at the total average weekly
earnings for males and females combined over the year ended
December 1992.2' This valuation was made for those in the
sorking age group 15 to 64 years inclusive, using a lower bound of
12 weeks offwork, and an upper bound of26 weeks offwork. lhese
upper and lower bounds were chosen after discussion with health
professionals involved in rehabilitation of stroke patients as there
was no other national information available. No deduction was
made for non-labour force participation or unemployment. It was
considered that non-paid output and leisure time had a value to
society and lacking more precise alternatives could be valued in the
same manner as paid output. Patients discharged dead from
hospital were excluded from the analysis.
Results
The analysis of 1992 unit record data for all hospitalst2
showed that 987c of all ischaemic stroke admissions were to
public hospitals. Routine and self discharges accounted for
most of the discharge types from all hospitals (637o), but
22Vo of ischaemic stroke patients died in hospital.
It was estimated that there were 6 724 ischaemic stroke
events in 1992; 4707 were admitted to hospital (704o), and'
2017 were treated in the community (307o). Table I shows
that the crude hospital admission rate (separations) for all
ages was 135 per 100 000 people. The age specific rates rise
as the age of the cohort increases; 33 for the 40 to 49 age
group to 1764 for the age cohort 80 years and over. Figure 1
describes the survival and future continuing care patterns
of the estimated 6 724 people suffering ischaemic stroke
events in 1992.
Table l. - Hospilsl separations rnd mortalhy 1992: lschaemic stroke
Agc cohon NZ Ilospital scparationsf Dtschrrgcd dcad
Ycars Population Total Ratc Total * of(000) numbcr pcr 100 000 numbcr separations
0tog 551370 6 I
l0 to 19 525 480 4 I
20 tt 29 551 2tt0 30 5
30 to 39 555 370 55 10 4 7 '27'l(
40 to 49 442520 145 33 12 8.28'tt
50 to 59 320 r70 386 l2l 3l 8.03%
60 to 69 2?3 040 925 339 t36 l{.70%
?0 to 79 188 460 1629 864 353 2L.67't
ll0 and ovcr 86 580 L527 1764 477 31.24%
Alf ascs 3 49{ 270 4707 135 l0fg 2l.52qt
Excludcs hospital stays ofmorc than 90 days
f Discharges and deaths
There were 18 000 general practitioner consultations for
stroke at a total cost of $0.49 :n. General practitioners
prescribed medicine valued at $0.+6 m for stroke patients.
TransporL for patienLs is a relatively important aspect of
this disease because of the large number of acute
admissions required for patients, most of whom were
elderly. Acute admissions12 to public hospitals accounted for
3959 or 867r of all admissions for ischaemic stroke, and 17
patients in private hospitals (157n). For the purpbses ofthis
study all admissions to hospital for ischaemic stroke
patients u'ere allotted an ambulance trip estimated to be
$0.75 m in total G707 x $159.74).
Ischaemic stroke patients'hospital costs (based on $300/d
for public hospitals, and $284.44 for private hospitals)
amounted to $27.97 m. Calculation of hospital costs using
the DRG 014 unit cost of $tO OZ0 gave a higher cost of
$+z.aS million. These costs are described in Table 2.
The cost of rehabilitation, that is, physiotherapy and
speech therapy (14 + 1.9 = 15.9 sessions) for each stroke
patient & 7A7 x 15.9 x $20) was calculated to be $1.50
million. If live discharges only are considered this cost falls
to $1.17 m (3.694 x 15.9 x $20). It was estimated that 2958(1.74 x 4.707 x 0.488 x 0.74) ischaemic stroke surwivors
required continuing care in a rest home as a result of the
stroke. The annual cost ofthis continuing care when valued
at the average weekly wage was estimated to be $89.50 m
($579.90/7 x 365.25 x 2958), and when valued using the rest
home subsidy rate was estimated to be $61.94 m ($401.34 /
7x365.25x2958).
Estimsted incidcncc (6724i lfil%)
Hospitll {4707i 70%) Community (2017i,10%l
Aner.l to 5 
-Yc|ni
Surrivc (.3.162:50%l
Supporl rtquir€d ( l68l : 259o)
Indcp€ndcnt ( l68l : 25%)
Tablc 2. 
- 
Hospitrl co!t3 1992: ischaemic strokc malcr and fcmalc: tll ages
ICD number, diagnosis A
434 Occlusion ofcerebral arteries
Public hospital
Private hospital
All hospitals
rt36 Acuter'ill-defi ned cerebmvascular disease
Public hospital
Private hospital
All hospitals
Total
Public hospital
Privatc hospital
All hospitals
Numbcr
4L22
105
422';
, 4597ll0
4707
Average
a8e
years
64.79
78.00
73.55
76.90
72.65
77.00
Average
stay
days
Total
cost @
cost / day
$ million
25.t96
0.397
25.593
27.537
0.436
27.974
Total
cost @
$r0 076
per patient
I million
4.7ffi
0.060
4.836
41.533
1.058
42.591
46.319
l. loE
47.428
475
R
480
Cost
per day
D
Total
sta-t
days
l6.,tl3
28.00
16.55
20.38
13.28
20.20
7804
I'10
7944
83 98?
1394
85 361
9l 79r 19.971534 13.9593325 19.83
300.00
2{14.11
300.00
281.14
2,341
0.0t10
2.381
This table excludes patients with stays ofover 90 daye (4? private patients, average stay 689 days; 307 public patienE, average stay 337 days)
Because of rounding individual items may not add exactly to the totals shown.
Teblc 3. - Lost produstion 1992: icchcemic alrokc mrlts end frmalcs, 15 and undor 65 yearr
ICD number, diagrosis A
434 Occlusion ofccrcbral arteries
Public hospital
Privatc hospital
All hospitals
436 Acutelill-dellncd ccrcbrovascular disease
Public hospital
Private hospitsl
All hospitals
Total
Public hospital
Privata hospitsl
All hospitals
Average
8ge
yeam
50.04
54.62
59.77
53.79
2285
2285
t6 3?l
l7l
16 542
18 656
l?r
l8 827
Average
Btay
daye
14.02
14.02
22.24
13. 15
22.09
Total
stay
days
Lst production valued at
$579.90 per week
@weeks @weekg
t2 26
$ million $ million
1.134 2.458
2.458
5.122 11.09?0.090 0.1965.212 1r.293
'13.555
0. 196
13.751
163
163
6.256
0.090
6.346
20.75
13.r5
20.6d
736
l3
?49
899
l3
912
Cost
Gencral practitiuncr
GP prescribed medicines
Transport to hospital
Hospital
Rehabilitation
Continuing
institutionalised carc
This table ex.iude" patients xho dicd in hospital
Bccause of rounding individual itcms may not add exactly ta the totals shown
Table 3 details lost production for the 912 hospital
patients ofworking age (15 and under 65 years) who had an
ischaemic stroke. Production loss was evaluated at $6.35 m(using 12 weeks offwork), and $13.75 m (using 26 weeks off
work).
Tablc rl. . Cost 3ummary: ischaemic atroka 1992
80 years and over. The crude all ages death rate for
ischaemic stroke was 56 per 100 000 with age specific rat€s
ranging from 3 (40 to 49 years) to 1314 (80 years and over).
Death certificate mortality data is shown in Table 5.
Table 5.-1990 d.rth ccrtiticltr mortrlity: lschaemic atrokc
Mortality
Nunrbur Ratc
pcr l0O 000
r 0-2
12
42
r96
6:15
996
1885
Discussion
As in most health economic studies, difficulties were
encountered in attempting to quantify costs of ischaemic
stroke outside the hospital setting. The cost estimates in
this study are conservative as no measurertrents were made
for a reduction in the quality of life of stroke patients and
their family and friends. Similarly, the costs of home help,
visiting nurses, social workers, of meals on wheels, or the
costs for walking aids and modifications to housing or to
motor vehicles required to assist mobility were not
evaluated. General practitioner consultations and the
medicines they prescribed were the only costs able to be
evaluated for those people who had an ischaemic stroke but
who were not admitted to hospital.
Lls
$ mrllion ',1 of Lotal
0 49 0.{9
0.46 0.46
0,75 0.?6
27.97 28.22
l.l7 l.l8
61.94 62.48
Il iI.lh
$ million 9, of total0.49 0.32
0.46 0.30
0.75 0,49
41.43 30.82
1.50 0.97
89.50 58.16
140.t3 9r.06
r3.?5 8.94
153.88 100.00
Age cohort
'l'cas
0tog
l0 to l9
20ta29
30 to 39
{0 to,l9
50 to 59
60 to 69
70 to 79
80 and over
All ages
NZ
Population
number
521 130
552 800
563 ?30
520 310
414 680
297 2L0
264270
169 3,10
75 780
3 379 250
Total direct medical 92.78 93.59
lnss ofproduction 6.35 6.41
Total direct and indirect costs 99. t3 100.00
3
ld
74
3?5
1314
56
Because of rounding, individual it€ms may not add exactly to the totals shown'
The direct costs of treatment and [he indirect cost of lost
production as discussed above have been summarised in
Table 4. Direct costs ranged from $93 m to $140 m and loss
of production was between $6 m and $14 m. Total
quantified costs were estimated to lie between $99 m and
$154 m. Hospital and continuing care costs when combined
make up 907o of all quantified costs.
For the year ended 1990 (the latest available data)
mortality from ischaemic stroke was 1885. Although some
New Zealanders die at an early age from ischaemic stroke
lhe average age at death was 79 years, wiLh 87Vo of lhose
dying aged 70 years and over, and 63Vo of those dying aged
The level of disability for patients after stroke is
dependent upon the severity of the stroke. Disability
manifests itself as epilepsy, depression, and cognitive losses(for example, in language and perception)23. Studies of
surviving stroke patients have shown reduced social contact
with those outside immediate family and diminished leisure
activity.a Similarly, in an age and sex-matched control
popula[ion it was found that, long term s[roke survivors had
a decreased level of socialisation outside the home. and a
reduced interest in hobbies and activities.zs Some of the
costs associated with these disabilities have been captured
in rehabilitation and continuing care costs but none of the
reduction in quality oflife has been quantified.
Patients admitted to one hospital and subsequen[ly
transferred to another are recorded on separate records and
as such all the hospital costs have been captured but
numbers may have been double counted as discussed in
methods. To minimise double counting, long stay patients(for this study stays of longer than 90 days) were iemoved
from the hospital data and costs for these patients were
captured under continuing care. Hospital costs based on the
DRG 0f4 were higher than estimates based on average bedday costs. The aciual value probably lies some*here
between the upper and lower estimates.
As diagnosis A (the primary diagnosis for which thepatient was admitted) was used to select patient records
from the hospital unit data both the numbers of ischaemic
stroke patients and hospital costs are conservative.
Patients admitted to a public hospitat for an unrelated
diagnosis A but additionally diagnosed ischaemic stroke in
diagnoses B, C or D were not included in the analysis as it
was impossible to separate Lhe additional stroke cost,
c-omponent from the cost of the piimary diagnosis using the
data available. Private hospital data are recorded forprimary diagnosis only. AJthough the Ministry of Health
have quality assurance systems, coding eriors within
hospitals do occur. .lpckson and colleagues26 ftrund that
death certificate coding was accurate to within l07o and the
authors consider that hospital coders are unlikety lo exceed
this error rate.
Finnish prevatence data:t app[ed to New Zealand were
used to evaluate continuing care in institutions and to
estimaie rehabilitation volumes. Limited data rvere
obtained on the breakdown of consultations with private
p_hysiotherapists lOne Day in September Study. Wellington:
New Zealand Private Physiotherapists Assoiiatlon, tgggl
which showed that physiotherapy for hemiplegia formed
1.27o of their workload but lhese could not be applied to thepublic sector in which Lhe majority of stroke patients are
treaied.
It was calculated that in 1992 thcre rl'ere approximatel_v
.1.557 (0.5 x 3 115) patients 60 years and over dischargedlive to rest homes or geriatric hospitals, but as it u'as not
known how long these patients stayed in care this estimate
could not be used to oblain total costs. Although volunre
and case mix data on rest homes were unavailable the cost
of continuing care was estimated to range between $61.94
m and $89.50m based on the esiimated 2gS8 patients
permanently institutionalised. Some stroke patients would
require additional or more intensive care than was
accounted for in the estimates.
, 
Continuing care is an important component of the cost of
ischaemic siroke to society. Further research should be
undertaken to obtain estimates of the case mix and
numbers of patients resident in rest homes and those
requiring similar care in private homes. New Zealand rest
home/continuing care costs were double the acute hospital
costs. USA data2? indicated that nursing home costs were
equivalent in magnitude Lo 757o of inpatient hospital care
costs. This difference between the ratios of continuing care
to acute hospital costs between USA and New Zealand may
be a result ofour decision to exclude longstay patients from[he-New Zealand hospital data and to capture these costs
under rest homes.
It could be argued that for an economy with less Lhan full
employment, loss cif paid output should be omitted from the
analysis as this would not reduce the economy's paid output
and measured GDP. However, this approach ignores the
value of unpaid output and the value of leisure time. Loss
of life could have been evaluated using willingness-to-pay
criteria or the human capital approach but because of the
age of,stroke patients neither method yields satisfactory
nor plausible results. The human capital method
undervalues the lives lost because of the low number of
potential working years lost.
Given the average age of the patients (73 years, and 77
years, for public and private patients respectively) the
willingness-to-pay value of $2 m per life28 would result in a
total cost that may be considered by some readers to be too
high.
This study estimated the costs of ischaemic stroke in
1992 on a prevalence basis. (Prevalence of a disease is the
number of cases in the popula[ion for the period studied.
Incidence ofa disease is the number ofnew cases that occur
within a given time period.) Both those patients having
stroke events during the current year and the survivori
from past events (who still require treatment or support)
contribute to costs and are covered in the prevalince
estimates. Accurate cost and prevalence data are essential
for the economic evaluation of treatment options, policy
changes, and the manner in which an ageing population
may aflect health costs in hospitals and the community.
Although this paper provides more information on cosis
than was previously available, further research is required
to define the non hospital costs of stroke that are a large
proportion of the total costs of stroke.
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4pplication of the Findings of the
Ftgpean Stroke Prevention Study Z(ESPS-2) to a New Zealand Ischaemic
Stroke Cost Analysis
Guy Scottl.2 and Helen M. Scottr
1 W. Guy Scott and Associates Limited, Wellington, New Zealand
2 Department of Business Studies, Wellington Polytechnic, Wellington, New Zealand
Summory The aim of this study was to apply the findings of the European stroke pre-
vention Study 2 (ESPS-2) to a paper that quantified and described rhe annual cosr
of ischaemic stroke in New Zealand, and to compare the cost of alternative drug
regimens in the secondary prevention of ischaemic stroke.
Comparisons were made between the costs of low-dosage aspirin (acetylsali-
cylic acid) monotherapy and a combination of modified-release dipyridamole and
low-dosage aspirin. Differences in undiscounted costs were calculated over a
Z-year period. The New zealand cost per srroke event was multiplied by the
ESPS-2 incremental reduction in stroke events to derive the cost of strokes
avoided. As the focus of the paper wa.q on direct medical costs. the primary
perspective adopted was that of a healthcare provider or funder. but a societal
perspective was also considered by evaluation of direct nonrnedical and indirecr
costs.
Cornpared with aspirin monotherapy.combination therapy generated increnren-
tal net direcr costs of I 8.22 New Zealand dollars ($NZ) per patient or $NZltt 223
per 1000 patients. However. individually, each rreatrnent re girncn resulted
in direct cost savings when compared wirh placebo: conrbination therapy
$N2905.16 per patient: aspirin monorherapy $N2923.-19 per patient (a ditl'erence
between the 2 regirnens ol'$NZl 8.22 per patient). Total direct and indirect incre-
nretttal cost savings were $N240.96 per patient. and $N240 963 per 1000 pa-
tients, tbr the conrbination therapy.
The analysis demonstrates that changing parients t'ronr low-dosage aspirin to
a cQrnbination therapy of modif retl-release dipyridamole plus low-dosage aspirin
would result in a srnall rise in incremental direct costs (using our conservative
assumptions relating to hospital and continuing insritutionat care cost.s). tf less
con'servative unit cost assumptions were adopted, a more likely ourconre woutd
be a saving in direct incremental costs of up to $N2400 per patient rreated.
Scott [t Scotl
Preventive therapy is important for patients who
rve already had a cerebral ischaemic event as they
e at increased risk of further events.lll One study
at assessed this form of preventive medicine was
e European Stroke Prevention Study 2 (ESPS-2).
The ESPS-2 was a multicentre, randomised,
luble-blind, placebo-controlled study with a 2 x
factorial design. Patients were randomised into
re of the following treatment regimens: (i) modi-
cd-release dipyridamole 200mg twice daily com-
ned with low-dosage aspirin (acetylsalicylic
:id) 25mg twice daily; (ii) modified-release di-
lridamole 200mg twice daily; (iii) low-dosage as-
rin 25mg twice daily; or (iv) a matched placebo
rice daily. The study assessed the effects of the
eatment regimens in the secondary prevention of
chaemic cerebrovascular events. Primary end-
rints for the study were stroke (fatal and nonfa-
l), death from all causes, and stroke and/or death
om any cause.tll
The 2-year study (the largest such trial to date)
Lvolved 6602 patients who had experienced either
transient ischaemic attack (TIA) l23.1%oj or an
chaemic stroke (76.3Vo) within the previous 3
onths.tll The age and gerrder distributions in the
udy population reflected both the increase in the
cidence of TIA and stroke with ase and the usual
ter occurrence of strokes and TIAs in women
[mpared with n:en (the mean age of the men was
I years, and the mean age of the women was 69
ears ).121
The results of ESPS-2trlshowcd n greater ben-
lit to the patient (in risk reduction of stroke) if a
ombination therapy (modified-release dipyrida-
role and aspirin) was given rather than either
gent alone. Although each agent was in itsell'ef-
:ctive in reducing stroke risk compared with pla-
ebo, when given in conrbination. their effects
rere additive.
These findings have inrportant cost implications
)r the treatment of ischaemic strokes. ln most de-
eloped countries, strokes are the third most corn-
ron form of death, stroke patients are high users
f hospital resources, and strokes often result in
isability that has important consequences for re-
Tabte l. Results of the European Stroke Prevention Study 2ttl that
are relevant to the cost analysis
Strategy Stroke events avoided
per 10OO patients
(relative to placebo)
DYP +ASP
ASP
Ditference (DYP + ASP 
-ASP)
Abbreviations; ASP = lowdosage aspirin (acetylsalicylic acid);
DYP = modified-release dipyridamole.
habilitation, and for long term community-care
cosm.t3l Friedmanlal observed that 887o of strokes
in patients aged 60 years and above admitted to
hospital in New Zealand were ischaemic in type.
Scott and Scottt3l found that (in 1992) the direct
medical costs of treating patients with ischaemic
stroke ranged from 93 million New Zealand dollars
($NZ) to $NZl40 million.
Therefore, the aim of this study was to apply the
findings of ESPS-2[ll to the paper that quantified
and described the annual cost of ischaemic stroke
in New Zealand,l3l and to compare the cost of al-
ternative drug regimens in the secondary preven-
tion of ischaemic stroke. Differences in undis-
counted direct medical costs were calculated over
a2-year period from the perspective of a healthcare
provider or funder. Asocietal perspective was also
considered by evaluation of direct nonmedical and
indirect costs.
Methods
ESPS-2 Findings
In ESPS-2.1r1 the absolute risk of stroke (fatal
or nonfatal events) was reduced by each treatment
regirnen (compared with placebo): by 26 events
per 1000 patients treated for those receiving modi-
l'ied-release dipyridarnole; by 29 events fbr the as-
pirin group; and by 58 events lbr those receiving
the combination therapy of modified-release di-
pyridamole and aspirin.tll When the combination
(modified-release dipyridarnole and aspirin v.r pla-
cebo) was compared with aspirin (r,.r placebo)
there was r reduction of 29 stroke evenl,s per 1000
58
29
29
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669
pattents treated. These findings are summarised in
table I.
Cost Doto
The original New Z.ealandsrudyt3t used unit re_
cord discharge data for all hospitais in both public
and private sectors for the year ended 1992, and
mortality data for the year ended 1990. It was esti_
mated that there were 6724 ischaemic stroke pa_
tients in 1992, of whom 4707 were admitted to
hospital (70Vo) and 2017 were reated in rhe com_
munity (307d.ttt
The ESPS-I lg5ulmtll obtained from using rreat_
ment with modified-release dipyridamole and aspi_
rin in combination were applied to the New Zealand
data to calculate the net costs (or benefits) of treat_
ing patients who have experienced a TlA/stroke.
The analysis in this currenr paper was conftned to a
that parients would take l50mg of aspirin, but was a
convenient way of arriving at a price proxy. The
cost of modified-release dipyridamole was based on
the average daily dose (200mg twice daily) from
ESPS-2trl and a price ex-supplier of $NZ31.99 per
pack of 60 x 200mg tablets.tst (The cost for 2 years,
supply of medicine was calculated as follows: medi_
cine price ex-pharmacy x daily dose x Z x 365.25).
Unit costs and total costs for primary care,
hospitalisation, rehabilitation, institutional care,
transport to hospital and loss of production are
given, together with their sources, in table IIL The
cost per stroke event was calculated by dividing the
total cost by the number of stroke events estimated
in the arricle by Scott and Scott.tll The nexr step
was to take the New Zealand cost per stroke event
(table tII) and multiply it by rhe ESPS_2 incremen_
tal reduction in stroke events to derive the cost of
strokes avoided (rable IV).
All costs are in New Zealand dollars ($NZl 
=$US0.6846 nrid-rate ar the end of June 1996).
Table ll. Drug unit costs in 1996 New Zeatand doilars (SNZ; $NZ1 =$US0.6846; mid-rate June 1996)
Regimen Unit cost
ex-pharmacy
rug reglmen most Iikely to be replaced by rhe com_
ination therapy, Accordingly, incremental costs for
:combination therapy were compared with those
the aspirin regimen.
As the focus of this study was on incremental
osts, all resource utilisations (tor example, gen-
ral practitioner consultations) prior to drug acqui_
tion are irrelevant and thus not evaluated. Costs
clusive of goods and services tax (GST, 12.5c/o)
ich.is a transfer payment l'rorn the perspective
nn was chosen as the comparator as it is the
society as a whole, and from that oi healthcare
and providersl were estinrated on both apatient and per 1000 patienr basis for a 2_vear
iod with no discounring.
Drug acquisition cosrs (rable ll) were rhe cost.s)r the cornbination therapy (moditied_release
ipyridamole plus aspirin) and the cost for aspi_,HJ.ruqrrrLrrs b i{ t l o n
n n"tonotherapy. As very low_dosa_ee aspirin
ailable in New Zealand,unit costs were basecl onlf a 300mg tabler and a price ex-supplier ot.
omparison of combination therapy with aspirin
ronotherapy, as ESpS-2 found that there was little
ittbrence in outcomes between monotherapy with
ither aspirin or modified-release dipyridamole.
Lowdosage aspirin (acetylsaticytic acid) [ASp]
Pack of tOO0 x 300mg tabtets
(ex-supptier $N226.64)
Average dosage: S0 mg/dayb
Cost for 2 years'supply
Modif ied-release dipyridamole (Dpy)
Pack of 60 x 200mg tablers
(ex-supptier SNZ3 1 .99f
Average dosage: 2OOmg twice daity
Cost ot 2 years'supply
DPY + ASP
Average dosage: dipyridamole 2OOmg twice daily
plus asprrin 25mg twice dailyb
32 61
0 0163
11 91
39 16
1,3053
953 52
l,3216
965.43Cost for 2 years'supply
5mg twice daily), as used in ESpS_2,lrt ii un_ a Ex-pharmacy price = ex-supplier price * 1Oy. *holesaG .irL-
up + 11.28% pharmacy mark-up
b Costed for 150 mg/day, half a 30omg tablel.rsl
c Dipyridamole: price as for .l50mg tablets.26.64 per I000 rablers.t.st This is nor to imply Abbreviation:$NZ 
= 1r1svv Zealand dollars
lnternofionol Umitect Alt rights reserved
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rable lll. costs associated with ischaemic stroke, assuming a total ol 6724 strokes 
in 't 992trl [all costs are in 1996 New Zealand dollars ($NZ1
70
= 
$US0.6846; mid-rate June 1996)l
Quantity (1992) Total cost Cost per strokeCost lactor
Slrokes
Direct costs:
general practitioner consultations
general practitioner prescriplions
hospitalised Patientss
rehabilitation sessionsa
patients continuing to institutional care
patients requiring transport to hospitala
subtotal
lndirec't costs:
lost produclivity
Unit cost
($NZ; 1996) ($NZ; 1996) ($NZ; t
6724
18 oool3l
470131
36g4t3l
295gpl
4707131
10 944 weekst3l
28.89t61
5943.06131
318.OOI3I
26 216.$t4
159.74131
626.9181
520 000
460 oool3l
27 974ono
1 174 692
77 549 393
751 896
108 429 981
6 861 560
115 291 541
77.33
68.41
4160.32
174.70
11 533.22
111.82
16 125.82
1020.46
17146.27
Total (dlrect and indirect) costs
a t-ow estimates used as described in table lV'
Sensitivity AnolYsis
ln order to test the robustness of the results to
in the assumptions used' a sensitivity analy-
sis was performed.
tial care hospital', the direct cost became a cost
saving of $NZ,417.10. Rest home stage [I and resi-
dentiil-care hospital represent higher levels of
government funding for residents requiring higher
ievels of care. Modified-release dipyridamole
prices needed to fall by ZVc to equate the direct
costs of cornbination therapy with that of aspirin
alone. When hospital costs were increased by ZAVo'
the $NZ l8 cost became a cost saving of $N230 per
patient treated. Lower-estimate continuing institu-
iional care unit cosrs caused the cost per parient to
increase to $NZl03, while upper-estimate unrt
costs resulted in cost savings of $NZ4l7'
Sensitivity analysis was also applied to the num-
her of stroke events prevented by the cornbination
therapy. If the cornbination therapy u'as l07c less
effective at reducing stroke events than was mea-
sured in ESPS-2,lll the incretnental baseline direct
cost of $NZ,18.22 increased to SNZ205'28' How-
ever. if combination therapy was l07c nrore effec-
tive at reducing stroke events. there was a cost sav-
ing of $NZlOa.g+. Direct costs tell to zero if the
combination therapy was [7c more effective at re-
ducing strokes.
Discussion
We are aware of concerns relating to problems
with data collection from one centre in ESPS-z'
Results
Table IV summarises the costs on a per patient
and per 1000 patient basis for a 2-year period'
Comtination therapy (modified-release dipyri-
damole plus low-dosage aspirin) generated incre-
mental net direct costs of $NZl8'72 per patient or
$NZ18223 per 1000 patients' However' indivi-
dually, each treatment regimen resulted in direct
cost savings compared with placebo: combinatton
therapy $N2905'16 per patient; aspirin monother-
apy $NZ,923.39 per patient (a difference between
the 2 regimens of $N218.22)' Total direct and in-
direct incremental cost savings were $N240'96 per
patient and $NZ-40 963 per 1000 patients for the
combination therapY'
Table V summarises the results of the sensitivity
analysis. If hospital costs were increased by 20Vo'
the incremental baseline direct cost of $NZl8'22
became a cost saving of $N230.04. tf institutional
care costs were valued at 'rest home stage Il', the
incremental direct cost rose to $NZl03'13, but if
all institutional care costs were valued at 'residen-
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ener et al.,[ll in reporting the results, stated that
data from one centre were considered to be un-
iable and unable to be verified by an audit, they
ve been excluded from the analysis and the sam-
: size has been reduced from 7054 to 6602 pa-
nts.
When reviewing previous reseatch, Diener et
tll comment that the earlier studies did not show
periority of combination therapy over aspirin
rne. These earlier trials had substantially lower
rmbers of patients and 'lacked the power to detect
;mall difference'.Il]
Some allowance should be made for patient
rncompliance when applying the results of this
rdy. Compliance is likely to be higher in a clini-
.l trial than in everyday practice. Estimates of
rncompliance vary considerably and depend not
rly on the individual patient, but also on the na-
re of the disease being treated and the type of
edication prescribed. The ESPS-2 resultstll indi-
rted a noncompliance rate of up to l6vo for pa'
enough for the low dosage of aspirin used and, ac-
cordingly, actual compliance may have been
higher than measured.
Recent studiesle'l0l have investigated the appro-
priate aspirin dosage required to provide efficacy
in stroke prevention. These studies have shown
that aspirin at any dosage above 30 mg/day pre-
vents l37o of vascular events,[l I | lthe UK Transient
lschaemic Attack (UK-TIA) 1tiu1ltol used 300 or
1200 mg/day and the Dutch TIA Group[el com-
pared 283mg with 30mg dailyl. Hart and Harri-
son,[t2l in reviewing these studies, concluded that
according to the Dutch TIA study, aspirin 283
mg/day was unlikely to be more than 5Vo better
than 30 mg/day, and thatthe UK-TIAstudy showed
that l200mg aspirin per day was unlikely to be
more than 25Vo better than 300 mg/day for stroke
prevention. They stated: 'The best existing clinical
evidence supports the concept that 75 mg/d acetyl-
salicylic acid is effective for stroke prevention and
that higher doses may offer no additional protec-
1gon.'[|21
Algra and van Gijntttl undertook a meta-analysis
of 10 randomised triats of aspirin versus a placebo
ts on an aspirin, or aspirin combination, regi-
. In ESPS-2, compliance was evaluated using
ma assays that may not have been sensitive
e tv. Two-year costs [New Zealand dollars ($NZ; $NZ1 = $US0.68a6; mid-rate June 1996)] per patient and per 1000 patients treated
either a combination of modified-release dipyridamole (Dpy) plus low-dosage aspirin (acetylsalicylic acid) [ASP] or AsP monotherapy
prevent ischaemic stroke. Figures in parentheses indicate negative values (a negative cosl = ? cost avoided or a benefit)
Per patient Per 1000 patients
DPY/ASP ASP Incrementala DPY/ASP Incrementala
ol ischaemic stroke events 0.058 0.029
treatment cosl: all palienis in treatment arm:
drug acquisition
)osts generated by ischaemic stroke evenls
primary care
hospital
rehabilitation
continuing institutional care
transport to hospital
subtotal of direct costs
Indirect costs
Lost productivityo
965.43
(16.s 1)
(482.60)
(2O.271
(1337.8s)
(12.97)
(e05.16)
(118.37) (s9.1e) (s9.19)
(40.s6)
965 431
(16 907)
(482 s97)
(20 265)
(1 337 854)
(12 971)
(eos 163)
(118 373)
(1 023 s36)
lr 9ll
(8453)
(241 299)
(10 133)
(668 e27)
(tr86)
(923 386)
(ss 187)
(982 573)
953 521
(84s3)
(241 299)
(10 133)
(668 927)
(6486)
18223
(s9 187)
(40 e63)
11 .9r 953 52
(8.4s) (8.45)
(241.30) (241.30)
(10.13) (10.13)
(668.e3) (668.s3)
(6.4e) (6.49)
(923.39) 18.22
Total (direct medical and indirect) costs (1023.54) (982.57)
a Incremental stroke events and costs = (DPY + ASP) - ASP
b Lo6t produc{iviV was evaluated for trorking-age hospital time{tl work: loss as a result of premature dealh was not evaluatecl
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Baseline
Dipyridamole acquisition costs decreased by
2%
Hospital unit costs increased 20%
Continuing institutional care at rest home
stage ll ($NZ/0.50 per day 
- 
GST 
= $N262.67)
Continuing institutional care at residentialcare
hospital ($N2133.30 per day 
- 
GST =
$N2118.49)
Change in efficary of DPY + ASP in reducing ischaemic stroke
evenls relative to ESPS-2:(11
1O% less effective
1olo rnor€ effective
107o more effeclive
Table V. Results ot a sensitivity analysis on the total incremental
direct cost per patienl [New Zealand dollars ($NZ; $NZt =
$US0.6846; mid-rate June 1996)l of using modified-release dipy-
ridamole IDPYI plus low-dosage aspirin (acetylsalicylic acid) [ASP]
in place ol ASP alone
Parameter and degree ol change lncremental
cost ($N4a
ing, it was not completely free of haemorrhagic
complications. About 8Vo of patients receiving as-
pirin-containing regimens (alone, or in combina-
tion therapy) were affected by bleeding disorders.
The small percentage of patients likety to be unable
to tolerate aspirin, even at low dosages, should also
be taken into account when applying the results of
this study in that not all patients will be able to be
transferred to an aspirin-containing regimen.
In the ESPS-2 trial,tll 22Vo of the placebo group,
22Vo of the aspirin group and 29Vo of those recei-
ving combination therapy discontinued treatment
for medical or nonmedical reasons. Thus, it can be
concluded thatTSVo of the potential candidates for
secondary stroke prevention could be treated with
aspirin and 7l7o could be treated with the combi-
nation therapy of modified-release dipyridamole
and aspirin. This would imply that 9l7o (71l78) of
patients currently treated with aspirin alone, could
be changed to the combination therapy.
In the present study, a sensitivity analysis re-
vealed that the results were responsive to assump-
tions relating to the hospital and continuing insti-
tutional care costs. For example, if patients are
discharged earlier from hospitals to continuing-
care facilities, cost shifting will occur from hospi-
tals to these care facilities. The average cost of pa-
tient care in rest homes will rise i[ the homes are
caring for either increased numbers of patients
and/or the e'ase mix changes to patic'nts u'ho are
more dependent.
To take account of the possible case-mr\
change. the" analysis for contirtuirtg irtstitutiortll
care was also run with 'residential care hospititl'
costs. It is iruportant to note that the Diagnosis Re-
lated Group (DRG) hospital cost for stroke. used
as the upper bound by Scott and Scott,lil has almost
halved since 1991. The costs used by Scott and
Scottlli were actuill hospital costs, while tlte latest
DRG unit costllrl used in this analysis reflects
price.s paid by New Zealand Regional Health Au-
thorities (RHAs), which do not necessarily reflect
the costs of the Crown Health Enterprises (CHEsr.
ACHE is a government-owned public hospital. For
CHEs running deficits, prices are not covering
18,22
0
(30.04)
r03.13
(417.10)
205.28
0
(168.84)
a Figures in parentheses indicate cost savings.
Abbreviations: ESPS-2 = European Stroke Prevention Study 2;
GST = goods and services tax (12.5%).
control involving 6l7l patients who had experienced
a TIA or a nondisabling stroke. Their intention was
to investigate the relative efficacy of iow (less
than 100 mg/day), medium (300 to 325 mg/day),
and high (greater than 900 mg/day) dosages of as-
pirin in secondary prevention of stroke. They con-
cluded that efficacy in secondary prevention after
cerebral ischaemia was similar for any dosage of
aspirin between 30 and 1500 mg/day. The results of
the ESPS-2 trial have also shown that a lower daily
dose of aspirin (25mg twice daily) is clinically el'-
fective at reducing secondary strokes.
An increased risk of adverse effects, such as gas-
trointestinal bleeding, is associated with high dos-
ages of aspirin. The Dutch TIA Grouplql found that
adverse events \\,ere more frequent in the high-
dosage group. For example, nrinor gastrointestinal
bleeding occurred twice as often in patients in the
group taking 283 nrg/day than in the group taking
30 mg/day, However, the ESPS-2 trialtrl found that
although the low aspirin dosage of 25mg twice
daily was associated with a very low incidence of
serious gastrointestinal adverse events and bleed-
O Adis Internolionol Lr.niled All rights reserved Phormocoeconomics 1997 Dec, l2 :))
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)osts. Accordingly, in the sensitivity analysis, we
rncreased hospital costs by 20Vo. If indirect costs
ue evaluated, the cost savings per patient will rise.
Jontinuing unit care costs are more likely to lie
)etween the baseline and the upper-bound values.
ESPS-2tll found differences between treatment
lptions with respect to nonfatal strokes. However,
rone of the treatments significantly reduced the
isk of death alone from all causes or of fatal stroke.
the fatal stroke incidence accounted for about
l2%o of all stroke events. The incremental differ-
:nce in stroke events avoided per thousand patients
)etween aspirin and the combination therapy was
he same for all stroke events as for nonfatal stroke
)vents. At randomisation into ESPS-2,[2] less than
.Vo of patients were classified as severely disabled
rs a result of stroke, and the 4 treatment groups
vere well matched with respect ro the type of quali'
ying event, degree of handicap from stroke and the
listribution of risk factors. The published trial re-
rort,[ll while providing information on stroke se-
'erity, did not give specific information on the de-
Jrees of dependence of patients at the end of the
Fial.
The results of ESPS-2ltl 6srnsnsrrare that with
lombination therapy, although the number of
[eaths remained unchanged, the number of stroke
ivents was reduced. This means that the number of
iatients progressing to a state where either conti-
ruing care, or more intensive care, is required
vould be reduced. However, this assumes that the
listribution of the severity of stroke events is iden-
ical for all treatment groups; if the stroke events
rf one group were more disabling than those of
Lnother group, the costs per stroke event will be
lifferent. Our findings, with respect to potential
;ost savings, are conservative as the weighted
rverage cost for strokesl3] used in this paper cov-
:red the cost of all stroke patients (fatal and non-
'atal and those who recovered with varying de-
Fees of incapacity and dependence), and implicitly
rssumed that there was no change in the proportion
rf patients requiring varying levels of care (over
he trial period).
If it is assumed that there are 8 additional pre-
scriptions per year (based on double the number of
items for combination therapy and a prescription
every 3 months), there will be an additional dis-
pensing cost of $N220.80 over a 2-year period, or
the equivalent of 2To of the drug acquisition cost
of the combination ingredients. However, if
monthly dispensing is assumed, additional dis-
pensing costs will rise to $N262.40, or 6Vo of the
combination drug regimen ingredient cost. As as-
pirin is a very low-cost drug, the incremental direct
medical costs are sensitive to small changes in the
price of dipyridamole.
This analysis demonstrates that changing pa-
tients from aspirin to a combination therapy of
modified-release dipyridamole and aspirin would
result in a small rise in incremental direct costs
(using our conservative assumptions relating to
hospital and continuing institutional care costs). If
less conservative unit cost assumptions were
adopted, a more likely outcome would be a saving
in incremental direct costs of up to $N2400 per
patient treated. Based on ESPS-2 findings,tll ap-
proximately 90Vo of patients being treated with as-
pirin could be switched to the modified-release di-
pyridamole and aspirin combination. Although this
study ibcused on the cost comparisons between the
combination regimen versus aspirin, the combina-
tion regimen could replace monotherapy of either
drug.
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Economic Evaluation Applied To Health Policy In New Zealand
CASE 10: ASTHMA
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Summary
The costs of asthma to New Zealand society were estimated and these costs then used to
develop a decision analytic model. The model was designed for evaluating the economic costs
of treating asthma using different treatment strategies.
Asthma is an important disease for New Tnaland in terms of the number of people affected and
the costs, both direct and indirect. Baseline direct medical costs were $148 million ($451 per
treated asthmatic), direct non-medical costs were $18 million ($54 per treated asthmatic),
indirect costs of lost productivity $95 million ($291 per treated asthmatic), and total costs
amounted to $261 million ($796 per treated asthmatic). Total costs ranged from $251 million to
$340 million, direct medical $142 million to $205 million, direct non-medical $14 million to
$18 million, and productivity loss of $95 million to $ll6 million. These costs allowed us to
validate and develop the model.
A spreadsheet-based deterministic, prevalence decision-analytic model was constructed and
tested. A spreadsheet-based system was used to make the underlying assumptions and
methodology in the model both explicit and transparent.
A user is able to evaluate the tull costs of alternative treatments or, by entering different values
in the input screen, look at asthma-treatment cost from the viewpoint of a patient, a general
practitioner, a hospital or a specific country. The design is sufficiently flexible to take account
Acceptetl for publication: 27 July 1997
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A 1997 Brookwood Medical Publications Ltd. UK - BJME 123' 87
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of changing treatment options and guidelines.
A user is able to calculate total costs,
compare data through benchmarking,
undertake sensitivity analysis, or consider a
defined population, different patient
categories, or appropriate medication use.
The development of the model required the
skills of a number of professionals and thus
mirrors the multidisciplinary nature of health
economics. The model is a tool that allows
the integration of pharmacoeconomic
concepts with clinical decision making and
policy analysis in treatment planning for
populations with a chronic illness.
Introduction
The aim of this research was to first estimate
the societal costs of asthma to New Zealand
and then use this information to develop a
decision analytic model. This model was
designed for evaluating the economic costs
of treating asthma using different treatment
strategies.
The development of this model should be
seen within the broader context of the cost of
asthma to New Zealand society. Asthma is an
important disease fbr New Zealand in terms
of the number of people affected and the
costs, both direct and indirect. It is generally
regarded as a chronic disease requiring
continuing treatment to prevent symptoms.
As such, asthma has considerable associated
morbidity and on-going treatment costs
which include the exacerbation of existing
and other acute illnesses.
Prevalence
Asthma is very common in New Zealand.
Crane et al I found that 26Vo of a sample of
adults aged between 20 and 44 years reported
wheezing within the last year, 87o had
experienced an asthma attack, and 9Vo had
used asthma medication. In 1993, l3%o of
New Zealanders had been diagnosed by their
doctor as having asthma t. A more recent
survey 3 of 2000 adults aged 15 years and
over found that l4%o had been told by their
medical practitioner that they had asthma,
97o had experienced an asthma attack during
the past year and ll%o were currently taking
medication for asthma. Prevalence rates
multiplied by total population 4 indicate that
approximately 500,000 people have been
diagnosed as asthmatics, about 350,000 are
treated with asthma drugs and there are about
150,000 treated asthmatics in the worldorce.
Table I details the prevalence of asthma in
New Zealand in 1996.
Cost
Asthma has important consequences with
respect to health care costs, loss of
productivity and reduction in quality of life.
The costs of asthma may be classified as
follows:
. Drug acquisition cost (ingredients,
markup and dispensing charge)
. PIus General practitioner, specialist and
other health care professional consultations
. Plus Diagnostic tests (e.g. x-ray)
, Plus Secondary care cost (hospital)
= Direct medical (health sector costs)
. Plus Direct non medical cost (non health
sector costs: transport to seek treatment and
other household costs [e.g. special bedding]
of treating or preventing asthma)
= Total direct cost
88
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Plus lndirect cost (Lost productivity and
leisure time activities of patient, family
and friends. That is, time costs of the
illness or its treatment)
Total direct and indirect cost
Where New Zealand information was
unavailable, the authors used Australian and
UK studies, as treatment guidelines for
asthma are similar in all three countries.
All costs quoted in this paper are in 1996
New Zealand dollars exclusive of Goods and
Services Tax (GST) which is a transfer
payment from the perspective of society.
($NZ I = $US 0.6846 mid-rate June 1996.)
Drug Acquisition
In the year ending June 1996, government
spending on asthma preventative medicines,
bronchodilators and respiratory devices was
$ 104. I 6 million (asthma preventative
medicines $72.44 million, bronchodilators
$29.53 million, and respiratory devices $2'19
million). This provided the baseline and low
estimate for drugs. Asthma medicines and
devices accounted for lTVo of total
Pharmaceutical Schedule expenditure on
government subsidised medicines t. A high
estimate of $153.01 million for drug cost was
obtained by taking lTVo of total public and
private expenditure on medicaments u. This
high estimate includes patient co-payments
and premiums (patient out-of-pocket
payments where the government subsidy
does not cover all of the medicine cost) and
over-the-counter (OTC) medicines. As
different therapeutic groups have different
price structures and co-payment amounts and
OTC medicine options this estimate must be
^ 
interpreted with caution.
General Practitioner
Asthma is a frequent reason for general
practitioner consultations 7. Studies indicate
that asthma accounts for between 2.4Vo 8 and
4.5Vo e of general practice encounters. The
latter study found that ZVo of general practice
consultations that included a referral to a
public hospital or to a private specialist were
TABLE l. Prevalence of asthma in,Vc'rv Zealand 1996'
Rate Vo Total number Number in the
of people employed workforce
Diagnosed asthmatics
Baseline
High
Low
Treated asthtnatics
Baseline
High
Lttw
l3Vo
l4o/o
l37o
9o/o
I l%o
97o
413,200
509,600
473,200
327,600
400,400
327.600
218,855
235,690
218,855
l5 l ,515
1 85,1 85
l5l,515
l,683,500
Total population (mean year ending Dec 1996) 3'640,000
Total workforce (June 1996)
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for asthma and that 4.SVo of consultations
that included an admission to a public
hospital were for asthma. During the year
ending September 1996, 791,000 general
practitioner consultations were recorded for
asthma (IMS (NZ) Ltd) at a cost of $23.73
million. Information from (IMS (NZ) Ltd)
indicated that consultations for asthma
represented 4.UVo of the total number of
consultations. The total cost was derived by
multiplying the number of consultations by
the average adult consultation fee of $30
(rounded to the nearest whole dollar)
obtained from the Consumers Price Index r0
(November 1996) and checked against a
consumer survey that gave similar results rr.
A low estimate of $17,63 million for
expenditure on general practitioner
consultations was estimated by multiplying
total expenditure on general practitioner
consultations 't by 3.5Vo (average of the high
and low estimate of encounters).
Specialist consultations
The low and baseline estimate for specialist
consultations was $2.72 million in 1996 (all
specialist consultations $135.88 rnillion rz
multiplied by Z.OVo (using the proportion of
specialist referrals for asthma)) e. e high
estimate of $6.1I million was obtained
($135.88 million multiplied by 4.5Vo, using
the proportion of general practitioner
consultations as a proxy for the proportion of
specialist consultations) n. If it is assumed
that a specialist consultation fee is double
that of a general practitioner, a fee of $60 is
obtained, but if relativity with accident and
emergency consultations is assumed, a fee of
$100 would result. This range of fees was
used to calculate the consultation numbers
from total expenditure, giving numbers of
between 45.000 and 61,000 consultations
(rounded to the nearest thousand). Diagnostic
imaging, and tests associated with diagnosis
and monitoring were unable to be evaluated
because of lack of information.
Emergency medical treatment
A UK study rr found that l3%o of asthmatics
had attended a hospital accident and
emergency department in the last 12 months.
Applying this finding to the number of
treated and diagnosed asthmatics, and
assuming a unit cost of $100 per visit Iu), the
following costs were obtained. Baseline and
low estimate (baseline treated asthmatics x
l3%o x $100) costs were $4.26 million, and
-!righ estimate (baseline diagnosed asthmatics
x l3%o x $ 100) costs were $6. I 5 million.
Hospital inpatient treatment
Asthma is the most common cause of child
admissions to hospital t. In 1994, there were
10,558 (5,171 male and 5,387 female, ICD
(International Classification of Diseases)
493) inpatient discharges from publicly
funded hospitals representing 38,009 days in
hospital 't. The estimated cost was $12.87
million (calculated by applying 1994195
DRG (Diagnostic Related Group) unit prices,
DRG codes bronchitis and asthma 096, 097
and 098 'u to the number of asthma
inpatients). Asthma accounted fot 1.77o of all
inpatient discharges or 0.87o of all public
hospital patient days in 1994. A high
estimate of $16.36 million for hospital costs
was made using 1990/91 DRG prices paid to
hospitals t' 1Z7Vo higher than unit costs in
1994195) to provide a high estimate of
inpatient hospital costs.
Transport cost
It was estimated that transport costs were
between $13,72 and $18.48 million with a
British Joumal of Medical Economics 1997; ll: 87 - l0l
baseline estimate of $ 17.79 million. This
evaluation, at a conservative unit cost of $20
a round trip, was made on the basis of one
round trip per consultation and hospital visit
or admission. An informal survey of
ambulance service providers (conducted by
the authors) indicated a unit cost of about
$100 would be justified if an ambulance was
used for transport.
Indirect costs
Indirect costs attributable to lost productivity
of those in the paid workforce were estimated
to be $95.17 million (this calculation takes
no account of lost school days, unpaid work
or leisure time foregone). The assumptions
were; each treated asthmatic in the workforce
will lose 5 days or I week of work through
asthma 't, the total employed workforce was
1,683,500 (June 1996) a, and the average
weekly wage was $628.11 (June 1996) 4. If
the average weekly wage is applied to the
high estimate of employed treated
asthmatics, a high value of $l 16.32 million is
obtained. Travel and waiting time (at least
one hour per consultation) to attend
consultations was assumed to be included in
the 5 days' lost output.
If productivity loss was evaluated on the
basis of the total labour force (employed and
unemployed) the cost would be 6.3Vo higher
than our estimates. Calculations made using
the working age population (employed,
unemployed and those not seeking paid
employment) would be 62.0Vo greater.
Reduced productivity of asthmatics while at
-work, or asthmatics unable to work, was not
evaluated because of insufficient data.
Similarly, productivity loss by unpaid
caregivers or family members unable to work
because they were caring for a child or other
familv member could not be evaluated.
TABLE 2. Summary of the baseline annual costs of asthnnfrom the perspective
of New Zealand society 1996
Cost Total cost
Nz$(M)
Cost per
treated
asthmatic
NZ$
Drug acquisition (ingredients, markup and dispensing)
Plus primary care-giver (GP and specialist consultations)
Plus secondary care
(hospital inpatient and accident and emergency)
= Direct medical
Plus direct non-rnedicztl (transport)
= 
Total direct
Plus indirect (lost productivity)
= Total direct and indirect
104
26
t7
148
l8
166
95
261
318
81
52
451
54
505
291
796
Because of rounding, individual ilens nlrry not add exactlt,to the totals shov'n.
All costs are itt 1996 Net' Tzaland Dollar.s e.tcltr.rile of GST ( goods and ,ren,iccs ta:r of I2.5Vo)
$N7-l = $U50.6846 nid'rate June 1996
9I
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Figure I. Asthma cost to New Zealand tgg6 Figure 2. Cost per treated asthmatic 1996
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In 1993 there were 126 deaths attributed to
asthma which accounted for O.SVo of all
recorded deaths 
'n. On a willingness-to-pay
basis 20, these lives would be valued ar $Z5Z
million, but considerably less than this if
valued using a human capital and lost
productivity approach.
Tables 2 and J and Figures I and 2
summarise the costs of asthma to New
Zealand society as a total cost, and on the
basis of the cost per treated asthmatic.
Baseline direct medical costs were $l4g
million ($+S t per treated asthmaric), direcr
non-medical costs were $18 million ($54 per
treated asthmatic), indirect costs of lost
productivity $95 million ($2gt per rreated
asthmatic), and total costs amounted to $261
million ($796 per treated asthmatic). Toral
costs ranged from $251 million to $340
million, direct medical $142 million to $205
million, direct non-medical $14 million to
$18 million, and productiviry loss of $95
million to $l l6 million.
The Asthma and Respiratory Foundation of
New Zealand (lnc.) 
'u have higher estimates;
direct costs were $160 million, indirect cosrs
$216 million and total societal costs $376
million per annum in 1996 t'. The primary
difference is that our study took a more
conservative approach in estimating indirect
costs and excluded all transfer payments. We
also focused on treated, rather than
diagnosed, asthmatics in the workforce.
This analysis has quantified the important
consequences of asthma with respect to
resource costs. These costs allowed us to
validate and develop the model.
The Asthma Treatment
Cost Model
Background to modelling
Models are a representation of the relevant
aspects of reality. They help in our
understanding of the real world. Models are
"... an ordered set of assumptions about a
complex system" ". The origins of computer-
based modelling for decision making and
forecasting purposes can be traced to the
work by Forrester 22' 2r and Meadows in the
1960s and 1970s. Models can be constructed
and used without reference to computers but
the process is more difficult and considerably
slower.
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Common criticisms of models and modelling
are that they are imperfect, oversimplify the
real situation, or are incomplete and
unfinished. However, many decisions cannot
be postponed until perfect models are
developed and a full understanding of the
problem is achieved. Models and modelling
assist in the decision-making process by
helping to assemble and analyse relevant
information, but cannot make decisions for
clinicians, managers and policy makers.
The types of models of relevance to
pharmacoeconomics include the following
non mutually exclusive categories.
. Deterministic models give the same
result each time the model is run if the same
input data are used.
. Stochastic models are based on
probabilities and the same inputs will not
give identical results for each run.
. Decision tree models track a sequence of
events and branching options over time. Each
pathway up through the branches of the tree
represents one sequence of events.
. Markov or state transition models allot
members or groups of the study population to
distinct states or categories over time.
. Longitudinal cohort or incidence models
consider expected outcomes for groups of
people over time.
. Cross-sectional population or prevalence
models consider a population at one point in
time.
Models designed for use with digital
computers were originally created using a
general programming language such as
Fortran and may still be constructed in this
way. However, specific modelling software
has been developed and spreadsheets are now
more sophisticated, with the ability to create
multiple work sheets. These changes have
allowed models to be more widely used in a
number of disciplines, such as health
economics.
Whv models are now used in health
e c ono mic s and pharmac o e c onomic s
Although health economics has always
involved the integration of data from a
variety of primary and secondary sources,
this process is made more explicit and
transparent with the assistance of models.
Modelling of costs and health outcomes
enables the assessment of many factors at the
same time and can be used as a tool for 'what
if analysis' decision making. Users are able
to evaluate the effects of changing data and
assumptions about unit costs, risks,
prevalence, and treatment options. As models
may be based on actual clinical practice,
rather than randomised controlled clinical
trials, they are more realistic in that patients
seen in actual clinical practice may differ
quite markedly from the artificial, controlled
environment of a clinical trial. Thus models
are able to utilise evidence-based medicine
and management decisions. While all of the
above can be done without computer-based
models, a modelling system facilitates and
speeds up the process.
Pharmacoeconomic analysis of asthma
treatment options involves comparing the
changes in resource opportunity costs with
the health-related outcomes produced. The
cost effectiveness ratio is the change in the
health related outcome of interest (for
example, controlled or treated asthmatics)
divided by the changes in cost resulting from
the intervention (see Figure 3).
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Figure 3. Pharmacoeconomic analysis of asthma treatment.
Asthma treatment
Cost effectiven€ss ratio =
Models and modelling help explore and
analyse these changes in costs and health-
related outcomes.
Type of model developed
We have constructed and tested a
spreadsheet-based, deterministic, prevalence
decision-analytic model. A spreadsheerbased
system was used to make the underlying
assumptions and methodology used in the
model both explicit and transparent.
Why we developed the model
Asthma is an important disease in New
Zealand in clinical and resource terms.
Clinical decisions have resource implications
and therefore any tool that facilitates
informed, evidence-based decisions
encompassing cost comparisons of treatment
is of value.
The authors wished to provide a tool that
would enable different stakeholders to
evaluate the impact of different unit costs and
policy options from their respective
perspectives. The model will allow them to
focus on overall treatment costs rather than on
one particular aspect or cost item.
Considerations in designing the model
The authors took care in designing the model
to ensure that baseline data were accurate and
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Changes in health related outcomes
Changes in resource opportunity costs
Changes in health related outcomes
Changes in resource opportunity costs
that documentation was provided. The model
mirrors actual asthma treatment as much as
possible and should be able to be used in
evaluating the cost of applying asthma
guidelines to various at-risk groups.
Simplicity, transparency, ability to modify
and change and flexibility of use were of
underlying importance when building the
model. Other design criteria were that the
model should be able to be used easily with
minimal training and be able to run on a wide
range of computing platforms.
Description
The model has a number of different screens
or pages; welcoming pages, instructions for
running, background, pre-loaded baseline
values and assumptions, inputs, calculations,
output tables, chart data and charts. All pre-
loaded values, assumptions and sources have
been documented in the model.
The flow of the Model is as follows:
Inputs 
- 
Calculations -+ Output table -+
Chart data * Output charts
Inputs for the Model:
' Volumes and unit costs
. Drugs and respiratory devices
British Jountal of Medical Economics 1997: ll: 87 - l0l
Table 4. Asthma treatment cost model inputs.
Cost items by annual volumes and unit costs
Drugs Corticosteroid inhalers (assuming no wastage)
Beta-agonist inhalers (assuming no wastage)
Spacers
Other drug I
Other dntg 2
Corticosteroid inhaler over/ under use and test-firing
Beta-agonists over/ under use and test firing
Wholesale/ retail markups and dispensing fees
Primary care General practitioner consultations
Retraining: additional general practitioner consultations
Specialist consultations
Physiotherapist consultations
Nurse consultations
Retraining: additibnal nurse consultations
Diagnostic tests
Secondary care Emergency medical treatment
Hospital outpatient specialist consultations
Hospital admissions for inpatient treatment
Direct non medical Transport to seek treatment
Household costs
Indirect Paid and unpaid production
Education
Leisure time activities
Epidemiological and Population at risk / study population
demographic data 7o of treated asthma patients
Vo of treated patients on each inhaler device
. Prescription markups and
dispensing costs
. Consultations with general practitioner,
specialist, physiotherapist and nurse,
retraining in inhaler technique
. Diagnostic tests
. Emergency medical treatment
. Hospital inpatient treatment volumes
. Transport to seek treatment
. Relevant additional household costs
. Paid and unpaid production, education,
leisure time activities
o Demographic and epidemiological data
These are described in more detail inTable 4.
The model has been pre-loaded with baseline
input data from the perspective of New
Zealand society. These baseline assumptions
and data sources are described within the
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Figure 4. Denngraphic data input to the nrodel
model (pre-loaded baseline values and
assumptions) and any of them may be
changed to reflect a useros needs, enabling
the model to be used from more than one
perspective.
The baseline pre-loaded values were derived
from the burden of illness section of this
paper, the authors' estimates, and from the
Royal New Zealand College of General
Practitioners, Research Unit technical report:
Evaluation of inhalers used in the treatment
of asthma (1997). This report provided
average medicine unit costs and volumes by
inhaler device and numbers of patients
treated by each inhaler device.
Figure 4 shows the pathways the model
follows in assigning the number of
asthmatics treated to each corticosteroid
inhaler device.
Calculations involve multiplying numbers of
patients by the input unit costs and by the
resource volumes for each treatment option.
Output costs in the model are presented (in
both tabular and graph form) by inhaler
device in terms of per treated patient, per
1000 patients, and per study population (see
Table 5 for a listing of the treatment cost
outputs).
Discussion
The model may be used to integrate and
aggregate a range of cost data from a variety
of sources. A user is then able to evaluate the
full costs of alternative treatments. Currently,
there are difficulties in determining costs of
treatment, and comparisons are only readily
available for unit costs of drugs.
Although the model's default settings are
pre-loaded from the perspective of New
Zealand society, the user can, by entering
different values in the input screen, look at
asthma treatment cost from the viewpoint of
a patient, a general practitioner, a hospital, or
a specific country.
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Table 5. Asthma treatment cost rnodel outputs
Asthma annual cost by: Per treated asthma patient, per 1000 members of the
study populations $(000), and by corticosteroid inhaler device
Corticosteroid inhalers
Beta-agonist inhalers
Spacers
Other eg Prednisone
Sub total Ingredients
Wholesale and retail markup
Dispensing
Total Drug acquisition (A)
General practitioner consultations
Specialist consultations
Physiotherapist consultations
Nurse consultations *
Diagnostic tests
Total Primary care consultations plus diagnostic tests (B)
Total Primary care (C 
= A + B)
Emergency medical care
Hospital inpatient
fslq! Secondary care (D)
Total Direct medical (E 
= C + D)
Transport to seek treatment
Household costs
Total Direct non medical (F)
Total Direct medical and non medical (G 
= E + F)
Lost paid and unpaid production
Lost education
Lost leisure tirne activities
Total Indirect (H)
Total Direct and indirect (I 
= G + H)
The design is sufficiently flexible to take
account of changing treatment options and
guidelines. A user is able to calculate total
costs, compare data through benchmarking,
undertake sensitivity analysis, or consider a
defined population, different patient
categories, or appropriate medication use.
The model is able to be used as a planning
tool, to improve decision making in the
clinical management of patients, improve the
allocation of resources in the treatment of
asthma, and minimise costs of providing
high-quality treatment.
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Conclusions
The development of the model required the
skills of a number of professionals (eg
clinicians, pharmacists, health economists,
and operation researchers), and thus mirrors
the multidisciplinary nature of health
economics. Ease of use was of particular
concern to the authors, who wished to
overcome the 'black box syndrome' often
encountered in computer applications. It was
considered that if the model was difficult to
follow it would not be used. The emphasis in
the model's development has been on clarity
and transparency.
The authors hope that this model will be
found to be useful in evaluating the treatment
of asthma in New 7n'aland in particular, and
have application to asthma treatment in other
countries. The model allows the integration
of pharmacoeconomic concepts with clinical
decision making and policy analysis in
treatment planning for populations with a
chronic illness.
Acknowledgements
We are grateful for permission to use data
from the Royal New Zealand College of
General Practitioners, Research Unit
technical report: Evaluation of inhalers used
in the treatment of asthma (1997).
The authors would like to thank those people
who evaluated the model at various stages of
its development and who made many useful
suggestions for its imProvement.
This work was supported by a grant from
New Zealand Limited.
3M
Note: Any inquiries regarding the model
should be directed to 3M New Zealand
Limited with whom copyright exists. 3M
New Zealand Limited, 250 Archers Road,
Glenfield, Auckland, New Zealand.
Postscript
As this paper was going to Press, two
publications were issued that have relevance
to ihis study. Hospital inpatient treatment
costs using the latest prices 2a would increase
by l?o. A recent survey 2s of 25,666 adults
found the prevalence of asthma to be l1%o
rather than the l3%o to 147o discussed in this
paper. The percentage of those surveyed
taking asthma medications was 8.SVo
compared to our baseline value of 97o. This
latest information would have minimal
impact on our results and conclusions.
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Asthma trcatmant +
Cost effectiveness ratio =
The cost effectiveness ratio is the change in
in cost resulting from the intervention
divided by the change in the health related
outcome ofinterest (for example, controlled
or treated asthmatics see figure 3).
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Summsry
Asthma is an important disease for New Zealand in terms of prevalence and costs, both direct
and indirect. The objective of this study was to determine if there were any differences in
primary care medical costs between treatment of asthma with four corticosteroid inhaler drug
delivery systems (AutohalerrM [AUTO], DiskhalerrM [DISK], metered dose inhaler [MDI] and
TurbuhalerrM [TURB]) in a general practice setting.
The retrospective observational data-based research completed for this study involved a large
population and recorded actual general practitioner prescribing practice. The perspective taken
was that of the funder of health care. Data were obtained from the computerised clinical
records of 28 New Zealand general practices. Cost data were on a per year per patient basis'
The largest single cost item identified in this study was that of corticosteroid inhalers which
ranged from 4l% of total primary care cost for MDI to 52Yo for the TURB group. Total drug
acquisition cost (inclusive of dispensing costs and wholesale and retail markups) was highest
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for TURB at $490 and lowest for MDI at
$265, a difference of 85%. There was less
variation in general practitioner consultations
for asthma with total costs ranging from
$104 for AUTO to $127 for DISK. Total
primary care costs were lowest for MDI at
$392 per annum and highest for TURB at
$608, a difference of 55o/o. If the MDI total
primary care costs are used as the base for an
index (MDI total primary care costs set at
100) then AUTO becomes l16, DISK 134
and TURB 155.
The model was robust with respect to
conclusions relating to cost differences
between the treatment groups. In all but one
instance TURB remains the highest cost
group.
Introduction
The objective of this study was to determine
if there were any differences in primary care
medical costs between treatment of asthma
with four corticosteroid inhaler drug delivery
systems (AutohalerrM IAUTO], DiskhalerrM
[DISK], metered dose inhaler [MDI] and
TurbuhalerrM [TURB]) in a general practice
setting.
The International Consensus Report on
Diagnosis and Treatment of Asthma ' defines
asthma as "a chronic inflammatory disorder
of the airways in which many cells play a
role, including mast cells and eosinophils. ln
susceptible individuals this inflammation
causes symptoms which are usually
associated with widespread but variable
airflow obstruction that is often reversible
either spontaneously or with treatment, and
causes an associated increase in airway
responsiveness to a variety of stimuli."
Asthma is an important disease for New
Zealand in terms of prevalence and costs,
both direct and indirect. Crane et al.2 found
that 26Yo of a sample of adults aged between
20 and 44yearsreported wheezing within the
last year, 8% reported an asthma attack and
9% reported using asthma medication. In
1993 l STo of New Zealanders (almost
470,000 people) had been diagnosed by their
doctor as having asthma 3.
Asthrna is a major reason for consulting a
general practitioner and is the most common
cause of child admissions to hospital a.
Studies indicate that asthma accounts for
between 2-4% 5 and 4.5o/o 6 of general
practice encounters. The latter study also
found that2o/o ofgeneral practice encounters
that included a referral to a public hospital or
to a private specialist were for asthma and
that 4.SYo of encounters that included an
admission to a public hospital were for
asthma. In 1993 there were 126 deaths
attributed to asthma which accounted for
0.5o/o of all recorded deaths ?.
The annual cost of asthma to New Zealand
society was estimated to be $261 million in
1996 8. This annual cost consisted of publicly
funded preventer and reliever drugs of $104
million, general practitioner consultations of
$24 million, specialist consultations $3
million, emergency medical treatment at
public hospitals $4 million, public hospital
inpatient costs of $13 million, transport to
' 
" All regi.stered tmtlelrruAr'1M are thc properl'qftheir respectit,e ov,ners
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seek treatment $ l8 million and indirect costs
of lost productivity of $95 million.
The aim of current therapy is to control
asthma, with both the patient and health
professionals managing treatment. The New
Zealand Asthma and Respiratory Foundation
has produced an asthma action plan which
classifies asthma into a number of categories
according to severity e: well-controlled,
worsening, severe and dangerous asthma.
Asthma is treated mainly with preventer
(inhaled corticosteroids) and reliever (inhaled
beta agonist) medicines. The action plan
suggests that patients with established asthma
be treated with an inhaled preventer at an
appropriate dose and use a reliever inhaler
for symptomatic relief. Preventer dosages are
ideally titrated to minimise asthma symptoms
and the need for reliever use while
maintaining patients on clinically acceptable
but low doses of inhaled corticosteroids to
optimise efficacy and avoid unnecessary side
effects. Acute asthma episodes are treated
with increased dosages of preventers and/ or
treatment with oral corticosteroids r0.
There is evidence that the delivery system is
an important factor influencing the efficacy
of inhaled steroids r0-'t. Accordingly, this
study analysed the data by prescribed
corticosteroid inhaler as this is considered the
primary treatment of asthma.
There are two main types of inhaler device:
aerosol (AUTO, MDI), and drY Powder
(DISK and TURB) inhalers. The dry powder
inhalers (DlSK, TURB) deliver active
ingredient as a Powder and require
inspiratory effort for drug delivery. Breath
actuated inhaler devices such as AUTO
overcome the coordination problems
commonly associated with MDI use,
eliminate the need for spacers, and provide
improved medication delivery to the lungs
and improved efficacy for patients unable to
correctly use MDIs lr'lo.
ln New Zealand the general practitioner is
regarded as the gate-keeper to the health care
system, and hence the decisions they make
are major health care cost drivers'
Increasingly, the emphasis is on evidence-
based medicine which encompasses both the
economic and health effects of clinical
practice. The retrospective observational
data-based research completed for this study
jnvolved a large population and recorded
(without altering or influencing) actual
general practitioner prescribing practice'
Methods
The setting for the study was general
practice. The perspective taken was that of
the funder of health care. Regular asthma
medication was considered to be inhaled
corticosteroids for prevention and/or beta
agonists for relief of symptoms' and
additional asthma medication (prednisone
and BetnesolrM) in the event of loss of
asthma control '. Drug information was
classified by preventer, reliever and oral
corticosteroid group.
Utilisation of health care resource volumes
(drugs, general practitioner consultations and
numbers of prescriptions), were obtained
frorn the Royal New Zealand College of
General Practitioners (RNZCGP) Research
Unit, University of Otago.This was a
retrospective population based analysis of
data relating to the year ending 30 June 1995
(described in a technical report: Evaluation of
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inhalers used in the treatment of asthma,
1997). Data were obtained from the
computerised clinical records of 28 general
practices (15 in the North Island and 13 in
the South Island) covering 128,585
consulting patients. The data set is
maintained to a standard suitable for research
and administrative purposes and is
considered to be representative of the nature
of general practice t in New Zealand and a
valid research tool 15'
All prescribing records (from the 128,585
consulting patients) were electronically
searched to identify those patients using
AUTO, DISK, MDI or TURB as the sole
inhaler device for corticosteroids (5,704
patients) over the l2 month study period.
These records for patients prescribed inhaled
corticosteroids were further examined to
identify all beta agonist and oral steroid
prescriptions. The medication key words
searched were: Autohaler, BecloforterM,
beclomethasone, Becotider", Diskhaler,
BetnesolrM, BricanylrM, budesonide,
prednisone, PulmicortrM, RespocortrM,
RespolinrM, salbutamol, terbutaline,
Turbuhaler and VentolinrM. These
medication key words were chosen to
effectively capture the total market for
asthma medication in New Zealand.
Consultations were defined as asthma-related
if a prescription for any of these listed
medicines was generated, an inquiry about
asthma, wheeze or other respiratory condition
was noted, or peak flow was recorded in the
consultation records. Consultations were
actual recorded patient encounters,
Prices for the drugs prescribed, retail and
wholesale markups, and dispensing fees and
charges were obtained from the New Zealand
Pharmaceutical Schedule r6 (Dispensing fee
plus container charge $2.60, wholesale
markup l0%, retail markup 11.28%.) Asthma
inhaler prices in New Zealand are currently
established by reference pricing for
therapeutic groups. These therapeutic
categories are established by grouping the
various inhalers according to their label claim
dose delivery. As a result, the unit costs for
dosing with the different asthma inhalers are
generally equivalent as they are reimbursed
at the same level. General practitioner
consultation fees were obtained from
Statistics New Zealand r71$29.00, May 1996)
aqd checked against a consumer surveytt. All
unit costs and prices were exclusive of Goods
and Services Tax (GST). This tax is a
transfer payment from the perspective of
society, health care providers, government
and patients in aggregate and was therefore
excluded from this analysis.
The average daily dose of inhaled
corticosteroids was calculated from the
prescription information recorded in the
database and was equivalent to analysing the
text of all prescriptions. The average daily
dose of beta agonists used was similarly
calculated and also standardised by calculation
of salbutamol equivalent doses. The dose
relationship used for this estimation of
terbutaline to salbutamol was 250 : 100 re-22.
The data in this analysis did not follow a
normal distribution as it exhibited positive
skewness in all aspects. Accordingly,
Kruskal-Wallis H tests were used to compare
the four samples. The Kruskal-Wallis H test
is a non parametric form of a one-way
ANOVA, much the same as the Mann-
Whitney U test is the non parametric form of
Journal of Medical Economics 1998; l: I - 18
the two sample t-test. The Kruskal-Wallis H
test can be used to test whether two or more
independent samples come from the same
population 23.
Skewness also affects the construction of
confidence intervals as the classical method
is valid only if the data is normally
distributed. Skewness adjusted confidence
intervals were constructed using an estimate
of the skewness of the sample and the
appropriate critical value from the standard
normal distribution to. As a result of the
skewness these confidence intervals are not
symmetric about the mean.
The analysis by age was undertaken as
patterns of asthma treatment differ according
to age. Younger patients are generally treated
with lower doses and patients over 50 years
have a higher prevalence of chronic
obstructive airwaYs disease.
Ethical approval for this study was obtained
from the Otago Ethics Committee of the
Southern Regional Health Authority.
All unit costs and prices used are in 1996
New Zealand dollars ($NZl : $US0.6825,
mid-rate May 1996). 1996 prices were used
as these were the most up to date when the
analysis was undertaken.
FIGURE l: Sample breaMown
All consulting patients
128,585
t00%
Prescribed an asthma drug
12,590
9.79%
Prescribed inhaled corticosteroids
6,582
5.12%
Single type of corticosteroid inhaler
device throughout the study period
5,704
4.44%
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Table 2z General practitioner consultations (mean number per year) by corticosteroid inhaler device
Consultations Corticosteroid inhaler device 
u
AUTO DISK MDI TURB TotalsamPle
Asthma 3.59 44% 3'96 460/o
Kruskal-Wallis test b
All consultations
Kruskal-Watlis test b
Results
From the original 128,585 consulting patients
there were 12,590 patients (9.8%) prescribed
any asthma medication. Of these patients
6,582 received 18,168 prescriptions for
inhaled corticosteroids. From this data subset
5,704 patients (56'7% of patients prescribed
inhaled corticosteroids) were prescribed a
single type of inhaled corticosteroid inhaler
device throughout the one-year study period'
The derivation of the sample is illustrated in
Figure l.
Table 1 describes the sample breakdown by
age and corticosteroid inhaler device' Of the
four inhaled corticosteroid inhaler groups in
this srudy, DISK patients were the youngest
with a mean age of 28 Years and TURB
patients had the oldest mean age of 39 years'
The largest group was MDI with 49.lYo of
the total sample, and AUTO was the smallest
group with 8.6% of the samPle'
Table 2 shows that the MDI group had the
highest average yearly number of asthma
consultations (4.37 per year) while the
8.26100%8.65100%g-72roo%9.97100%9'46r00%
x2 :22 -838, dF3, P<0'00 I
4.37 45% 4.05 4l% 4.15 44%
xz 
:2'1 
.9 | 3, dF3, P<0-00 I
*AUTO group had the lowest average number
of asthma consultations (3.59 per year)' The
TURB group had the highest number of total
consultations (9.97 per year) and the AUTO
group had the lowest average number of total
consultations (8.26 Per Year)'
Table 3 presents the components of primary
care cost by corticosteroid inhaler device'
The average daily dose of prescribed inhaled
corticosteroid was lowest for AUTO (569
mcg) and highest for the TURB group (990
mcg) - a difference of 74o/o. Both DISK and
MDI recorded higher doses than AUTO but
substantially less than TURB. The
salbutamol equivalent average daily dose for
beta agonists for the treatment groups ranged
from AUTO (291 mcg), TURB (332 mcg)'
MDI (358 mcg) to DISK (407mcg) - a
difference between lowest and highest of
40%. The prescribing of a particular
corticosteroid inhaler tended to be matched
with the same type of inhaler device for
inhaled beta agonists.
The largest single cost item identified in this
studv was that of corticosteroid inhalers
a Corticosteroid inhaler device: AWO = Autohaler; DISK = Diskhaler: MDI = metered dose inhaler; TURB = Turbuhaler
bTheKruslcal-Wallistestisanon-paramericequivalentoftheone-wayANovA
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FIGURE 2, Yearlv cost of primaryt care per treated asthma patienl by corticosteroid inhaler device ( |
Corticosteroid inhalers ; ETotal drug acquisition; D General Prat'titioner consultations for asthma;
I Total Primary care)
NZ$
AUTO DISK MDI TURB
Corticosteroid inhaler device
AUTO = Autohaler, DISK = Diskhaler, MDI -- metered dose inhaler. ruRB = Turhuhaler
which ranged from 4l7o of total primary care
cost for MDI to 52Yo for the TURB group.
The acquisition costs for corticosteroid
inhalers (exclusive of wholesale and retail
markups) ranged from $159 for MDI, to
$315 for TURB, a difference of 98%. Beta
agonist acquisition costs (exclusive of
wholesale and retail markups) were lowest
for MDI at $42 and highest for DISK at
$102, a differenceof l43o/o.
Total drug acquisition cost (inclusive of
dispensing costs and wholesale and retail
markups) was highest for TURB at $490 and
lowest for MDI at $265. a difference of 85%.
There was less variation in general
practitioner consultations for asthma with
total costs ranging from $104 for AUTO to
$127 for DISK. Total primary care costs
were lowest for MDI at $392 per annum and
highest for TURB at $608, a difference of
55%. lf the MDI total primary care costs are
used as the base for an index (MDI total
primary care costs set at 100) then AUTO
becomes I16, DISK 134 and TURB 155.
Figure 2 summarises the main cost
components by corticosteroid inhaler device.
The MDI group had the lowest cost for all
major cost components except general
practitioner consultations (which were the
highest of all groups) and the lowest total
primary care costs.
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FIGURE 3. Yearly cost of total pimary care per teated asthma patient by corticosteroid inhaler device(l Lower 95% confidence interval; E Mean; J IJpper 95%o conJ,idence interval)
600
NZ$
300
AUTO DISK MDI TURB
Corticosteroid inhaler device
AUT0 = Autohaler, DISK = Diskhaler, MDI = metered dose inhaler, TURB = Turbuhaler
800
700
500
400
200
r00
Table 4 presents the skewness adjusted 95%
confidence interval upper and lower bounds
for the key cost and volume items described
in Table 3.
Figure 3 displays the skewness-adjusted 95%
confidence intervals and means for total
primary care cost. This visual presentation
clearly shows the statistically significant cost
differences between treatment groups.
Discussion
This study differed from most randomised
controlled clinical trials in that it involved a
large study population and recorded (without
altering or influencing) actual general
practitioner prescribing practice. The
prescribing information does not include
specialist or hospital based prescribing but
information from IMS (N.2,) Limited
suggests that these sources form only a small
part of the cost of the pharmacological
treatment of asthma. The hospital market for
asthma medicines is estimated to be less than
4% by value of the total New Zealand
market.
Not all records in the data base used for our
study allowed clear identification of the
reason for the consultation and thus some
asthma-related consultations may not have
been counted. As data were actual general
practitioner prescribing records and not
I2
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pharmacy dispensing tecords, failure to
present or collect a prescription from the
pharmacist was not measured. Estimates for
non-dispensing vary but Gardner et al. in a
recent study tt found that the non-dispensing
rate for both bronchodilators and
corticosteroids was 10.5%. No information
relating to specific devices was available but
there was no reason to assume different non-
dispensing rates within the study groups.
A number of factors may cause wastage of
asthma drugs; some patients do not comply
with treatment, and inhaler delivery devices
may be test fired and used incorrectly.
Estimates of patient noncompliance with
prescribed medication vary widely.
Noncompliance depends upon the individual
patient, the nahre of the disease being treated,
and the type of medication prescribed. The
study did not attempt to measure
noncompliance but never-the-less the impact
on prescriptions and general practitioner
consultations has been accounted for in the
study. Over-use would have been measured in
additional prescriptions and general
practitioner consultations. Under-use would
have been accounted for by subsequently
fewer prescriptions and fewer general
practitioner consultations. [f under-use resulted
in an asthma attack, additional prescriptions
and additional consultations may have been
generated and measured in the study.
Wastage as a result of test firing, incorrect
activation (poor co-ordination) or incorrect
usage was not specifically measured in the
study but is accounted for as it is included in
the volumes of medication prescribed.
Gebbie 26 reported from a survey of
asthmatics that test firing was an important
cause of wastage of bronchodilator aerosols
in pressurised containers (MDIs). Test firing
is usually a problem associated with MDIs
and is considered to be less of a problem for
breath-actuated inhalers.
King ef a/.27 found that 68% of patients were
unable to use their MDI inhalers
successfully. Errors in use fell into two main
categories; failure to synchronise deep
inspiration with depressing the canister (a
problem of co-ordination), and failure to hold
the breath after inspiration. In a review of
asthma literature 28 Shrestha et al reported
that approximately 20Yo to 40% of asthma
patients used MDIs correctly and this has
important implications for resource usage,
frorbidity and mortality. McFadden 13
reviewed the English language literature (20
papers) and found that the error rate per
patient in the use of MDIs ranged ftom l2o/o
to 89% with an average of 38%. The
proportion of patients misusing MDIs in this
review was 36% (1308 out of 361 I subjects).
A French study of the literature came to
similar conclusioos tt. Faulty inhaler
technique has both clinical and economic
consequences in the treatment of asthma.
Prescribing records are then a different but
more compound impression of asthma
treatment consumption which potentially
accommodates a larger number of variables
compared to dosing in controlled clinical trials.
As explanantory variables for asthma severity
and risk were not sufficiently documented in
the database, further investigation such as
multivariate analysis (a generic term
encompassing multiple regression,
cointegration analysis, principal components
analysis and factor analysis) was not
considered appropriate. However, comment
I3
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Table 5. Patients aged l9 years and over with one or more daily doses of greater than 1500 mcg/day.
Corticosteroid inhaler device "
AUTO DISK MDI TURB
Number
Proportion oftotal patients aged l9
and over in inhaler device group
Statistical significance b
9
2.80/o
102
23J%
t32
6.3%
339
34.2%
y'47o.ro,dF3, p<o.ool
a Corticosteroid inhaler device: ATJTO = Aulohaler, D/S( = Diskhaler, MDI -- metered dose inhaler, TUfuB = Turbuhaler
u 
Th" K*"kol-Ilallis test in a non-parametric equivalent of rhe one-way ANOVA
has been made on differences in age between
heafrnent groups.
Sensitivity analysis was conducted by
referencing or bench marking to MDI costs. If
the largest cost component, corticosteroid
inhalers, were all set to the cost of the MDI
group then total primary care cost would be as
follows: AUTO $416, DISK $464, MDI
unchanged at $392 and TURB $452. The
difference in cost between the highest and
lowest cost groups would fall from 55% to
l8%. The MDI group remains the lowest cost
but the highest cost group changes from
TLIRB to DISK. This change occurs because
the DISK group has the highest cost for beta
agonist treatment.
When the beta agonist cost is set to the cost of
the MDI group the total primary care cost is
as follows': AUTO 5416, DISK $464, MDI
unchanged at $392, and TURB $577. The
MDI group remain the lowest cost and the
TURB group remains the highest cost but the
difference in cost between these groups would
fall from 55o/o to 47o/o. If the cost for general
practitioner consultations is set to the MDI
rate costs rise for the other groups and
become: AUTO $476, DISK $536, MDI
unchanged at $392, and TURB $617. The
MDI and TURB groups remain in their
positions as the lowest and highest groups but
the cost difference increases from 55olo to
58%. The results of the model are robust with
respect to conclusions relating to cost
differences between the treatment groups. In
all but one instance TURB remains the highest
cost group.
Economic ond Therapeutic
Implications
The average daily dose of inhaled
corticosteroids with MDI treatment was
significantly higher (p< 0.001) than with
AUTO treatment. This possibly represents
the effect of high dose treatment with MDI
and spacer on average daily dosing. The
lower volume of inhaled corticosteroid in the
AUTO group may also reflect asthma
severity or lower dose treatment for this
particular group. Possible reasons for this
finding could be: asthma severity was
clinically different, or that different efficacy
was provided by the different inhalers.
Conclusions for the clinical importance of
any differences in outcome between study
groups must consider that patient asthma
severity and treatment was not controlled in
this study. While assessment of asthma
severity for individual patients was not
available, it could be reasonably expected
I4
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that treatment efficacy for the study groups
was similar overall. Treatment in this study
was not conholled and medical practitioners
obviously had an incentive to change
prescribing, as occurs in regular medical
practice, to optimise individual patient
treatment. As a result there are no reasons to
suspect that treatment outcome was any
different for each treatment group.
The higher dose for TURB for inhaled
corticosteroid is difficult to explain as this
group of patients did not display the same
differences with respect to greater numbers of
prescriptions or general practitioner
consultations that may have indicated greater
severity of asthma. It is surprising to have
found patients were being regularly treated
with such high daily doses of inhaled
corticosteroids considering that there is no
evidence to suggest any superior asthma
control at high doses from TURB or DISK
compared to aerosol treatment (AUTO and
MDD ]0.
Additionally, a possible explanation for the
findings from this study is that both the dry
powder inhalers (TURB and DISK) are used
to treat patients with more severe disease,
and so required higher doses of inhaled
corticosteroids. The rather surprising high
average daily dose for inhaled corticosteroids
for the TURB group and the numbers of
patients receiving greater than l500mcg /day
in particular, contrasts with claims for the
efficiency of drug delivery with this inhaler
(see Table 5). It has previously been
suggested that the Turbuhaler has greater
lung deposition than aerosols 3r, atthough the
importance of this for efficacy has not been
clearly established. If greater efficacy were to
be assumed for TURB comparisons with
other inhalers this assumption would require
that the equivalent dose for this inhaler be
increased proportionally.
Definitive conclusions are limited, but
considering the recent proposition of
advanced delivery from the TURB, the
equivalent average daily corticosteroid dose
would have been expected to be
proportionally less than the doses found in
the study for the other inhalers.
AUTO and DISK patients tended to be treated
with the matching beta agonist inhaler device.
Beta agonists are currently recommended for
^intermittent 
or as required use. Volume of beta
agonist usage is also considered to reflect
asthma control '0. The average dose of beta
agonist used in each of the treatment groups
was statistically significantly different
between the treatment groups (p<0.001). As
previously discussed the clinical importance
of any differences could not be determined as
an outcome of this study. However, possible
explanations for this finding could relate to
differences in asthma severity or efficacy
provided by the different inhalers.
Although there were statistically significant
differences between the volumes and costs of
inhaled beta agonists between groups and the
volumes and costs of oral steroids between
groups these differences may not be
clinically significant. The skewness adjusted
confidence intervals for beta agonist volumes
show that DISK had a higher mean dose than
AUTO and TURB. However, in clinical
terms the beta agonist dosages were similar
between groups. A finding may be
statistically significant but too close to zero
to be of clinical relevance tt.
Although treatment with oral steroid was
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found to be of little economic importance in
the cost of asthma treatment, the prescribing
pattern does have some implications as an
indicator of asthma control and asthma
severity.
The skewness adjusted confidence intervals
for oral steroids are very similar for all of the
treatment groups and do not demonstrate
undue differences in the treatment of asthma
or severity between the treatment groups.
While caution is advised for the
interpretation of this information (Betnesol
and prednisone have different potencies and
the analysis is completed on dose), these oral
steroids are used in similar proportions for all
the treatrnent groups in the study.
The lower oral steroid dose range associated
with DISK treatment may be explained in
part by the more comrnon use of this inhaler
treatment for younger patients, who would
more likely be treated with lower doses.
Further analysis and interpretation is difficult
as oral steroids are used infrequently in
treatment and the available data are limited.
The total primary care costs for AUTO and
MDI were less than the total primary care
cost of either of the dry powder inhalers
(DISK or TURB). As spacer costs have not
been included in this analysis the true cost
for MDI would be higher than our estimates.
For those MDI patients requiring two spacers
per year the additional cost would be 535.52.
Although spacers should be replaced at six
monthly intervals some patients may use less
than two per year and others more than this
but we had no information from the database
on spacer usage. It was not possible to obtain
cost data relating to hospital admissions, lost
production or reduction in quality of life.
The database information can be analysed in
several ways, including further sub-group
analysis such as age, gender and dosage
rates. Further analysis would be unlikely to
further ctari$ the conclusions of this study.
Information derived from this research has
also been used to construct a deterministic
decision analytic cost of treatment model 8.
Analysis to determine asthma severity and
treatment efficacy as a result of inhaler or
corticosteroid type was not attempted in this
analysis as separation of the elements of
asthma severity and treatment efficacy was
not possible with the information in the data
base. The importance of this study is that it
-piovides information on total incremental
treatment costs in actual clinical practice.
Most other asthma related research has
compared specific aspects of inhaler devices
and chemical entities rather than difference
in costs associated with treatment with
particular asthma inhalers. This type of study
reported here can provide additional
information for evidence-based decision-
making for clinicians, funders and policy
makers. Prospective randomised controlled
clinical trials would compliment and could
clariff and appropriately further investigate
the importance of the findings of this study.
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